"","study ID","first author","study design","publication date","primary series vaccine","historyofCOVID ","dose_number","dose","timing_of_dose_days","outcome_detail","outcome_category","country","population_detail","population_category","VE","LCL","UCL","variant_sequenced","variant_context","max duration follow-up","dose interval","notes","n_row","country_clean","iso3c","Study_id_f","Country.Code","GNI_per_c_WB","year_GNI","Economy","Region","Income group","q_GNI_per_c_WB","continent","owid_vac_intro","owid_vac_F40","owid_vac_F70","who_vac_intro","min_vac_intro","diff_owid_who_intro","diff_intro_F40","diff_intro_F70","owid_who","V1_date_group","V40_date_group","V40_group","V1_dummy","V40_dummy","V70_dummy","publication_date","outcome_final","semester","clean_vaccine","vac_type","variant_clean","earliest_date","min_pub_date"
"1",1,"Amit","Prospective cohort","18Feb2021","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+","15-28 including some up to day 7 post dose 2","infection ","infection","Israel","HCW","HCW",75,"72",84,NA,"original & alpha",NA,NA,NA,1,"Israel","ISR",1,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-02-18,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-02-18
"2",1,"Amit","Prospective cohort","18Feb2021","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+","15-28 including some up to day 7 post dose 2","symptomatic disease","symptomatic","Israel","HCW","HCW",85,"71",92,NA,"original & alpha",NA,NA,NA,2,"Israel","ISR",1,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-02-18,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-02-18
"3",2,"Immunisation and Countermeasures Division, National Infection Service, PHE","Screening method","22Feb2021","BNT162b2 (Pfizer BioNTech)","included","1","1",">28","symptomatic disease","symptomatic","UK","> 80 years","> 80 years",57,"48",63,NA,"alpha",NA,NA,NA,3,"UK","GBR",2,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-02-22,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-02-22
"4",2,"Immunisation and Countermeasures Division, National Infection Service, PHE","Screening method","22Feb2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7","symptomatic disease","symptomatic","UK","> 80 years","> 80 years",88,"84",90,NA,"alpha",NA,NA,NA,4,"UK","GBR",2,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-02-22,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-02-22
"5",3,"Dagan","Retrospective cohort","24Feb2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-21","infection ","infection","Israel","general pop","general pop",46,"40",51,NA,"original & alpha",NA,NA,NA,5,"Israel","ISR",3,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-02-24,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-02-24
"6",3,"Dagan","Retrospective cohort","24Feb2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","infection ","infection","Israel","general pop","general pop",92,"88",95,NA,"original & alpha",NA,NA,NA,6,"Israel","ISR",3,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-02-24,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-02-24
"7",3,"Dagan","Retrospective cohort","24Feb2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-21","symptomatic disease","symptomatic","Israel","general pop","general pop",57,"50",63,NA,"original & alpha",NA,NA,NA,7,"Israel","ISR",3,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-02-24,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-02-24
"8",3,"Dagan","Retrospective cohort","24Feb2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","symptomatic disease","symptomatic","Israel","general pop","general pop",94,"87",98,NA,"original & alpha",NA,NA,NA,8,"Israel","ISR",3,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-02-24,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-02-24
"9",3,"Dagan","Retrospective cohort","24Feb2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-21","hospitalization","severe","Israel","general pop","general pop",74,"56",86,NA,"original & alpha",NA,NA,NA,9,"Israel","ISR",3,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-02-24,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-02-24
"10",3,"Dagan","Retrospective cohort","24Feb2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","hospitalization","severe","Israel","general pop","general pop",87,"55",100,NA,"original & alpha",NA,NA,NA,10,"Israel","ISR",3,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-02-24,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-02-24
"11",3,"Dagan","Retrospective cohort","24Feb2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-21","severe disease","severe","Israel","general pop","general pop",62,"39",80,NA,"original & alpha",NA,NA,NA,11,"Israel","ISR",3,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-02-24,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-02-24
"12",3,"Dagan","Retrospective cohort","24Feb2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","severe disease","severe","Israel","general pop","general pop",92,"75",100,NA,"original & alpha",NA,NA,NA,12,"Israel","ISR",3,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-02-24,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-02-24
"13",4,"Hyams","Test-negative case-control","01Nov2021","BNT162b2 (Pfizer BioNTech)","included","1","1",">14","hospitalization","severe","UK"," > 80 years"," > 80 years",79,"47",93,NA,"alpha",NA,NA,NA,13,"UK","GBR",4,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-11-01,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-11-01
"14",4,"Hyams","Test-negative case-control","01Nov2021","AZD1222 (AstraZeneca)","included","1","1",">14","hospitalization","severe","UK"," > 80 years"," > 80 years",80,"36",95,NA,"alpha",NA,NA,NA,14,"UK","GBR",4,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-11-01,"severe","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-11-01
"15",5,"Mousten-Helms","Retrospective cohort","09Mar2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1",">14","infection ","infection","Denmark","LTCF residents","LTCF residents",21,"-11",44,NA,"original & alpha",NA,NA,NA,15,"Denmark","DNK",5,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-03-09,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-03-09
"16",5,"Mousten-Helms","Retrospective cohort","09Mar2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","infection ","infection","Denmark","LTCF residents","LTCF residents",64,"14",84,NA,"original & alpha",NA,NA,NA,16,"Denmark","DNK",5,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-03-09,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-03-09
"17",5,"Mousten-Helms","Retrospective cohort","09Mar2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1",">14","infection ","infection","Denmark","LTCF staff","LTCF staff",17,"4",28,NA,"original & alpha",NA,NA,NA,17,"Denmark","DNK",5,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-03-09,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-03-09
"18",5,"Mousten-Helms","Retrospective cohort","09Mar2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","infection ","infection","Denmark","LTCF staff","LTCF staff",90,"82",95,NA,"original & alpha",NA,NA,NA,18,"Denmark","DNK",5,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-03-09,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-03-09
"19",6,"Tande","Retrospective cohort","11Mar2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1+","1+",">10 including some with dose 2","asymptomatic infection","asymptomatic","USA","pre-surgical hospital patients","pre-surgical hospital patients",79,"63",88,NA,"original",NA,NA,NA,19,"USA","USA",6,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-03-11,"infection","2021 (Jan-Jun)","Multiple or heterologous RNA","mRNA","original",NA,2021-03-11
"20",6,"Tande","Retrospective cohort","11Mar2021","BNT162b2 (Pfizer BioNTech)","included","2","final",">0","asymptomatic infection","asymptomatic","USA","pre-surgical hospital patients","pre-surgical hospital patients",80,"56",91,NA,"original",NA,NA,NA,20,"USA","USA",6,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-03-11,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","original",NA,2021-03-11
"21",6,"Tande","Retrospective cohort","11Mar2021","BNT162b2 (Pfizer BioNTech)","included","1","1",">10","asymptomatic infection","asymptomatic","USA","pre-surgical hospital patients","pre-surgical hospital patients",79,"62",89,NA,"original",NA,NA,NA,21,"USA","USA",6,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-03-11,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","original",NA,2021-03-11
"22",6,"Tande","Retrospective cohort","11Mar2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final",">0","asymptomatic infection","asymptomatic","USA","pre-surgical hospital patients","pre-surgical hospital patients",80,"56",91,NA,"original",NA,NA,NA,22,"USA","USA",6,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-03-11,"infection","2021 (Jan-Jun)","Multiple or heterologous RNA","mRNA","original",NA,2021-03-11
"23",7,"Britton","Retrospective cohort","15Mar2021","BNT162b2 (Pfizer BioNTech)","stratified","1+","1+",">14 including some up to day 7 post dose 2","infection ","infection","USA","LTCF residents","LTCF residents",63,"33",79,NA,"original",NA,NA,NA,23,"USA","USA",7,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-03-15,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","original",NA,2021-03-15
"24",7,"Britton","Retrospective cohort","15Mar2021","BNT162b2 (Pfizer BioNTech)","stratified","1+","1+",">14 including some up to day 7 post dose 2","infection ","infection","USA","LTCF residents","LTCF residents",60,"30",77,NA,"original",NA,NA,NA,24,"USA","USA",7,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-03-15,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","original",NA,2021-03-15
"25",8,"Yelin","Retrospective cohort","17Mar2021","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+",">35, most with dose 2","infection ","infection","Israel","general pop","general pop",91,"89",93,NA,"alpha",NA,NA,NA,25,"Israel","ISR",8,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-03-17,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-03-17
"26",8,"Yelin","Retrospective cohort","17Mar2021","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+",">35, most with dose 2","symptomatic disease","symptomatic","Israel","general pop","general pop",99,"95",99,NA,"alpha",NA,NA,NA,26,"Israel","ISR",8,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-03-17,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-03-17
"27",9,"Public Health England","Test-negative case-control","17Mar2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1",">28","symptomatic disease","symptomatic","UK","> 70 years","> 70 years",58,"49",65,NA,"alpha",NA,NA,NA,27,"UK","GBR",9,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-03-17,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-03-17
"28",9,"Public Health England","Test-negative case-control","17Mar2021","AZD1222 (AstraZeneca)","unknown","1","1",">35","symptomatic disease","symptomatic","UK","> 70 years","> 70 years",58,"38",72,NA,"alpha",NA,NA,NA,28,"UK","GBR",9,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-03-17,"symptomatic","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-03-17
"29",9,"Public Health England","Retrospective cohort","17Mar2021","BNT162b2 (Pfizer BioNTech)","included","1","1",">14","hospitalization","severe","UK","> 70 years","> 70 years",42,"32",51,NA,"alpha",NA,NA,NA,29,"UK","GBR",9,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-03-17,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-03-17
"30",9,"Public Health England","Retrospective cohort","17Mar2021","BNT162b2 (Pfizer BioNTech)","included","1","1",">14","death","death","UK","> 70 years","> 70 years",54,"41",64,NA,"alpha",NA,NA,NA,30,"UK","GBR",9,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-03-17,"death","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-03-17
"31",9,"Public Health England","Retrospective cohort","17Mar2021","AZD1222 (AstraZeneca)","included","1","1","14-21","hospitalization","severe","UK","> 70 years","> 70 years",35,"4",56,NA,"alpha",NA,NA,NA,31,"UK","GBR",9,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-03-17,"severe","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-03-17
"32",10,"Shrotri","Prospective cohort","23Jun2021","BNT162b2 (Pfizer BioNTech)","stratified","1","1","35-48","infection ","infection","UK","LTCF residents","LTCF residents",65,"29",83,NA,"original & alpha",NA,NA,NA,32,"UK","GBR",10,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-23,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-06-23
"33",10,"Shrotri","Prospective cohort","23Jun2021","AZD1222 (AstraZeneca)","stratified","1","1","35-48","infection ","infection","UK","LTCF residents","LTCF residents",68,"34",85,NA,"original & alpha",NA,NA,NA,33,"UK","GBR",10,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-23,"infection","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-06-23
"34",11,"Thompson","Prospective cohort","29Mar2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1",">14","infection ","infection","USA","HCW","HCW",80,"59",90,NA,"original",NA,NA,NA,34,"USA","USA",11,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-03-29,"infection","2021 (Jan-Jun)","Multiple or heterologous RNA","mRNA","original",NA,2021-03-29
"35",11,"Thompson","Prospective cohort","29Mar2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final",">14","infection ","infection","USA","HCW","HCW",90,"68",97,NA,"original",NA,NA,NA,35,"USA","USA",11,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-03-29,"infection","2021 (Jan-Jun)","Multiple or heterologous RNA","mRNA","original",NA,2021-03-29
"36",12,"Bouton","Prospective cohort","30Mar2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1+","1+",">14 including some with dose 2","infection ","infection","USA","HCW","HCW",82,"68",90,NA,"original",NA,NA,NA,36,"USA","USA",12,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-03-30,"infection","2021 (Jan-Jun)","Multiple or heterologous RNA","mRNA","original",NA,2021-03-30
"37",13,"Regev-Yochay","Prospective cohort","07Jul2021","BNT162b2 (Pfizer BioNTech)","included","2","final",">11","asymptomatic infection","asymptomatic","Israel","HCW","HCW",65,"45",79,NA,"alpha",NA,NA,NA,37,"Israel","ISR",13,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-07-07,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","09/04/2021",2021-04-09
"38",13,"Regev-Yochay","Prospective cohort","07Jul2021","BNT162b2 (Pfizer BioNTech)","included","2","final",">11","asymptomatic infection (presumed infectious ct<30)","asymptomatic","Israel","HCW","HCW",70,"43",84,NA,"alpha",NA,NA,NA,38,"Israel","ISR",13,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-07-07,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","09/04/2021",2021-04-09
"39",13,"Regev-Yochay","Prospective cohort","07Jul2021","BNT162b2 (Pfizer BioNTech)","included","2","final",">11","symptomatic disease","symptomatic","Israel","HCW","HCW",90,"84",94,NA,"alpha",NA,NA,NA,39,"Israel","ISR",13,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-07-07,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","09/04/2021",2021-04-09
"40",13,"Regev-Yochay","Prospective cohort","07Jul2021","BNT162b2 (Pfizer BioNTech)","included","2","final",">11","symptomatic disease  (presumed infectious ct<30)","symptomatic","Israel","HCW","HCW",88,"80",94,NA,"alpha",NA,NA,NA,40,"Israel","ISR",13,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-07-07,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","09/04/2021",2021-04-09
"41",14,"Andrejko","Test-negative case-control","20Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1",">=15","infection ","infection","USA","general pop","general pop",66.9,"28.7",84.6,NA,"B.1.427/ B.1.429 & alpha",NA,NA,NA,41,"USA","USA",14,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-07-20,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","25/05/2021",2021-05-25
"42",14,"Andrejko","Test-negative case-control","20Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final",">=15","infection ","infection","USA","general pop","general pop",87.4,"77.2",93.1,NA,"B.1.427/ B.1.429 & alpha",NA,NA,NA,42,"USA","USA",14,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-07-20,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","25/05/2021",2021-05-25
"43",14,"Andrejko","Test-negative case-control","20Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final",">=15","asymptomatic infection","asymptomatic","USA","general pop","general pop",68.3,"27.9",85.7,NA,"B.1.427/ B.1.429 & alpha",NA,NA,NA,43,"USA","USA",14,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-07-20,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","25/05/2021",2021-05-25
"44",14,"Andrejko","Test-negative case-control","20Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final",">=15","symptomatic disease","symptomatic","USA","general pop","general pop",91.3,"79.3",96.3,NA,"B.1.427/ B.1.429 & alpha",NA,NA,NA,44,"USA","USA",14,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-07-20,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","25/05/2021",2021-05-25
"45",14,"Andrejko","Test-negative case-control","20Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final",">=15","hospitalization","severe","USA","general pop","general pop",100,NA,NA,NA,"B.1.427/ B.1.429 & alpha",NA,NA,NA,45,"USA","USA",14,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-07-20,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","25/05/2021",2021-05-25
"46",14,"Andrejko","Test-negative case-control","20Jul2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">=15","infection ","infection","USA","general pop","general pop",87,"68.6",94.6,NA,"B.1.427/ B.1.429 & alpha",NA,NA,NA,46,"USA","USA",14,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-07-20,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","25/05/2021",2021-05-25
"47",14,"Andrejko","Test-negative case-control","20Jul2021","mRNA-1273 (Moderna)","excluded","2","final",">=15","infection ","infection","USA","general pop","general pop",86.2,"68.4",93.9,NA,"B.1.427/ B.1.429 & alpha",NA,NA,NA,47,"USA","USA",14,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-07-20,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","25/05/2021",2021-05-25
"48",15,"Glampson","Retrospective cohort","17Sept2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1","22-28","infection ","infection","UK",">= 16 years","general pop",78,"73",82,NA,"alpha",NA,NA,NA,48,"UK","GBR",15,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-09-17,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-17
"49",15,"Glampson","Retrospective cohort","17Sept2021","AZD1222 (AstraZeneca)","unknown","1","1","22-28","infection ","infection","UK",">= 16 years","general pop",74,"65",81,NA,"alpha",NA,NA,NA,49,"UK","GBR",15,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-09-17,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-09-17
"50",16,"Bjork","Retrospective cohort","29Sept2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1",">14","infection ","infection","Sweden","general pop","general pop",42,"14",63,NA,"original & alpha",NA,NA,NA,50,"Sweden","SWE",16,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-29,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","21/04/2021",2021-04-21
"51",16,"Bjork","Retrospective cohort","29Sept2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final",">7","infection ","infection","Sweden","general pop","general pop",86,"72",94,NA,"original & alpha",NA,NA,NA,51,"Sweden","SWE",16,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-29,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","21/04/2021",2021-04-21
"52",17,"Mason","Case-control","18Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21-27","infection ","infection","UK","80-83 years","80-83 years",55,"40",66,NA,"alpha",NA,NA,NA,52,"UK","GBR",17,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-18,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","22/04/2021",2021-04-22
"53",17,"Mason","Case-control","18Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","35-41","infection ","infection","UK","80-83 years","80-83 years",70,"55",80,NA,"alpha",NA,NA,NA,53,"UK","GBR",17,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-18,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","22/04/2021",2021-04-22
"54",17,"Mason","Case-control","18Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21-27","hospitalization","severe","UK","80-83 years","80-83 years",50,"19",69,NA,"alpha",NA,NA,NA,54,"UK","GBR",17,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-18,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","22/04/2021",2021-04-22
"55",17,"Mason","Case-control","18Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","35-41","hospitalization","severe","UK","80-83 years","80-83 years",75,"52",87,NA,"alpha",NA,NA,NA,55,"UK","GBR",17,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-18,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","22/04/2021",2021-04-22
"56",17,"Mason","Case-control","18Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","35-41","ED or UC visit","symptomatic","UK","80-83 years","80-83 years",58,"31",74,NA,"alpha",NA,NA,NA,56,"UK","GBR",17,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-18,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","22/04/2021",2021-04-22
"57",17,"Mason","Case-control","18Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","35-41","ED or UC visit","symptomatic","UK","80-83 years","80-83 years",79,"60",90,NA,"alpha",NA,NA,NA,57,"UK","GBR",17,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-18,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","22/04/2021",2021-04-22
"58",18,"Hall","Prospective cohort","23Apr2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1",">21","infection ","infection","UK","HCW","HCW",72,"58",86,NA,"alpha",NA,NA,NA,58,"UK","GBR",18,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-04-23,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","21/02/2021",2021-02-21
"59",18,"Hall","Prospective cohort","23Apr2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","infection ","infection","UK","HCW","HCW",86,"76",97,NA,"alpha",NA,NA,NA,59,"UK","GBR",18,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-04-23,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","21/02/2021",2021-02-21
"60",19,"Vasileiou","Prospective cohort","23Apr2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","28-34","hospitalization","severe","UK","general pop","general pop",91,"85",94,NA,"original & alpha",NA,NA,NA,60,"UK","GBR",19,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-04-23,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-04-23
"61",19,"Vasileiou","Prospective cohort","23Apr2021","AZD1222 (AstraZeneca)","excluded","1","1","28-34","hospitalization","severe","UK","general pop","general pop",88,"75",94,NA,"original & alpha",NA,NA,NA,61,"UK","GBR",19,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-04-23,"severe","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-04-23
"62",20,"Pritchard","Prospective cohort","09Jun2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1",">21","infection ","infection","UK",">= 16 years","general pop",66,"60",71,NA,"original & alpha",NA,NA,NA,62,"UK","GBR",20,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-09,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/04/2021",2021-04-23
"63",20,"Pritchard","Prospective cohort","09Jun2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">0","infection ","infection","UK",">= 16 years","general pop",80,"74",85,NA,"original & alpha",NA,NA,NA,63,"UK","GBR",20,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-09,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/04/2021",2021-04-23
"64",20,"Pritchard","Prospective cohort","09Jun2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1",">21","symptomatic disease","symptomatic","UK",">= 16 years","general pop",78,"72",83,NA,"original & alpha",NA,NA,NA,64,"UK","GBR",20,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-09,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/04/2021",2021-04-23
"65",20,"Pritchard","Prospective cohort","09Jun2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">0","symptomatic disease","symptomatic","UK",">= 16 years","general pop",95,"91",98,NA,"original & alpha",NA,NA,NA,65,"UK","GBR",20,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-09,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/04/2021",2021-04-23
"66",20,"Pritchard","Prospective cohort","09Jun2021","AZD1222 (AstraZeneca)","excluded","1","1",">21","infection ","infection","UK",">= 16 years","general pop",61,"54",68,NA,"original & alpha",NA,NA,NA,66,"UK","GBR",20,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-09,"infection","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/04/2021",2021-04-23
"67",20,"Pritchard","Prospective cohort","09Jun2021","AZD1222 (AstraZeneca)","excluded","2","final",">0","infection ","infection","UK",">= 16 years","general pop",79,"65",88,NA,"original & alpha",NA,NA,NA,67,"UK","GBR",20,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-09,"infection","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/04/2021",2021-04-23
"68",20,"Pritchard","Prospective cohort","09Jun2021","AZD1222 (AstraZeneca)","excluded","1","1",">21","symptomatic disease","symptomatic","UK",">= 16 years","general pop",71,"62",78,NA,"original & alpha",NA,NA,NA,68,"UK","GBR",20,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-09,"symptomatic","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/04/2021",2021-04-23
"69",20,"Pritchard","Prospective cohort","09Jun2021","AZD1222 (AstraZeneca)","excluded","2","final",">0","symptomatic disease","symptomatic","UK","general pop","general pop",92,"78",97,NA,"original & alpha",NA,NA,NA,69,"UK","GBR",20,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-09,"symptomatic","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/04/2021",2021-04-23
"70",21,"Goldberg","Prospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+",">14 days post dose 1 to <14 days post dose 2","infection ","infection","Israel",">= 16 years","general pop",65.9,"65.4",66.4,NA,"alpha",NA,NA,NA,70,"Israel","ISR",21,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-30,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/04/2021",2021-04-24
"71",21,"Goldberg","Prospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection ","infection","Israel",">= 16 years","general pop",94.5,"94.3",94.7,NA,"alpha","~8 weeks",NA,NA,71,"Israel","ISR",21,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-30,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/04/2021",2021-04-24
"72",21,"Goldberg","Prospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+",">14 days post dose 1 to <14 days post dose 2","hospitalization","severe","Israel",">= 16 years","general pop",74.9,"73.5",76.3,NA,"alpha",NA,NA,NA,72,"Israel","ISR",21,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/04/2021",2021-04-24
"73",21,"Goldberg","Prospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Israel",">= 16 years","general pop",95.8,"95.2",96.2,NA,"alpha","~8 weeks",NA,NA,73,"Israel","ISR",21,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/04/2021",2021-04-24
"74",21,"Goldberg","Prospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+",">14 days post dose 1 to <14 days post dose 2","severe disease","severe","Israel",">= 16 years","general pop",72.1,"69.9",74.1,NA,"alpha",NA,NA,NA,74,"Israel","ISR",21,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/04/2021",2021-04-24
"75",21,"Goldberg","Prospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","severe disease","severe","Israel",">= 16 years","general pop",96.3,"95.7",96.9,NA,"alpha","~8 weeks",NA,NA,75,"Israel","ISR",21,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/04/2021",2021-04-24
"76",21,"Goldberg","Prospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+",">14 days post dose 1 to <14 days post dose 2","death","death","Israel",">= 16 years","general pop",69.1,"65.5",72.3,NA,"alpha",NA,NA,NA,76,"Israel","ISR",21,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-30,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/04/2021",2021-04-24
"77",21,"Goldberg","Prospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","Israel",">= 16 years","general pop",96,"94.9",96.9,NA,"alpha","~8 weeks",NA,NA,77,"Israel","ISR",21,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-30,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/04/2021",2021-04-24
"78",22,"Tenforde","Test-negative case-control","28Apr2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","1+","1+",">14 days post dose 1 to 14 days post dose 2","hospitalization","severe","USA","hospital patients >= 65 years",">= 65 years",64,"28",82,NA,"original & alpha",NA,NA,NA,78,"USA","USA",22,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-04-28,"severe","2021 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-04-28
"79",22,"Tenforde","Test-negative case-control","28Apr2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final",">14","hospitalization","severe","USA","hospital patients >= 65 years",">= 65 years",94,"49",99,NA,"original & alpha",NA,NA,NA,79,"USA","USA",22,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-04-28,"severe","2021 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-04-28
"80",23,"Gras-Valenti","Case-control","29Apr2021","BNT162b2 (Pfizer BioNTech)","included","1","1",">12","infection ","infection","Spain","HCW","HCW",53,"1",77,NA,"original & alpha",NA,NA,NA,80,"Spain","ESP",23,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-04-29,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-04-29
"81",24,"Fabiani","Retrospective cohort","29Apr2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-21","infection ","infection","Italy","HCW","HCW",84,"40",96,NA,"unknown",NA,NA,NA,81,"Italy","ITA",24,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-04-29,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","unknown",NA,2021-04-29
"82",24,"Fabiani","Retrospective cohort","29Apr2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","infection ","infection","Italy","HCW","HCW",95,"62",99,NA,"unknown",NA,NA,NA,82,"Italy","ITA",24,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-04-29,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","unknown",NA,2021-04-29
"83",24,"Fabiani","Retrospective cohort","29Apr2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-21","symptomatic disease","symptomatic","Italy","HCW","HCW",83,"15",97,NA,"unknown",NA,NA,NA,83,"Italy","ITA",24,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-04-29,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","unknown",NA,2021-04-29
"84",24,"Fabiani","Retrospective cohort","29Apr2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","symptomatic disease","symptomatic","Italy","HCW","HCW",94,"51",99,NA,"unknown",NA,NA,NA,84,"Italy","ITA",24,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-04-29,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","unknown",NA,2021-04-29
"85",25,"Corchado-Garcia ","Retrospective cohort","02Nov2021","Ad26.COV2.S (Janssen)","excluded","1","final",">15","infection ","infection","USA","general pop","general pop",74.2,"64.9",81.6,NA,"original & alpha",NA,NA,NA,85,"USA","USA",25,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-11-02,"infection","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","30/04/2021",2021-04-30
"86",26,"Haas","Retrospective cohort","05May2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","infection ","infection","Israel","general pop","general pop",95.3,"94.9",95.7,NA,"alpha",NA,NA,NA,86,"Israel","ISR",26,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-05-05,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/03/2021",2021-03-24
"87",26,"Haas","Retrospective cohort","05May2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","asymptomatic infection","asymptomatic","Israel","general pop","general pop",91.5,"90.7",92.2,NA,"alpha",NA,NA,NA,87,"Israel","ISR",26,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-05-05,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/03/2021",2021-03-24
"88",26,"Haas","Retrospective cohort","05May2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","symptomatic disease","symptomatic","Israel","general pop","general pop",97,"96.7",97.2,NA,"alpha",NA,NA,NA,88,"Israel","ISR",26,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-05-05,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/03/2021",2021-03-24
"89",26,"Haas","Retrospective cohort","05May2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","hospitalization","severe","Israel","general pop","general pop",97.2,"96.8",97.5,NA,"alpha",NA,NA,NA,89,"Israel","ISR",26,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-05-05,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/03/2021",2021-03-24
"90",26,"Haas","Retrospective cohort","05May2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","severe/critical hospitalization","severe","Israel","general pop","general pop",97.5,"97.1",97.8,NA,"alpha",NA,NA,NA,90,"Israel","ISR",26,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-05-05,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/03/2021",2021-03-24
"91",26,"Haas","Retrospective cohort","05May2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","death","death","Israel","general pop","general pop",96.7,"96",97.3,NA,"alpha",NA,NA,NA,91,"Israel","ISR",26,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-05-05,"death","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","24/03/2021",2021-03-24
"92",27,"Abu-Raddad","Test-negative case-control","08Jul2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1","15-21","infection ","infection","Qatar","general pop","general pop",65.5,"58.2",71.5,"alpha","alpha",NA,NA,NA,92,"Qatar","QAT",27,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-08,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-07-08
"93",27,"Abu-Raddad","Test-negative case-control","08Jul2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final",">14","infection ","infection","Qatar","general pop","general pop",90,"86",92,"alpha","alpha",NA,NA,NA,93,"Qatar","QAT",27,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-08,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-07-08
"94",27,"Abu-Raddad","Test-negative case-control","08Jul2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1","15-21","severe/fatal infection","severe","Qatar","general pop","general pop",72,"32",90,"alpha","alpha",NA,NA,NA,94,"Qatar","QAT",27,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-08,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-07-08
"95",27,"Abu-Raddad","Test-negative case-control","08Jul2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final",">14","severe/fatal infection","severe","Qatar","general pop","general pop",100,"82",100,"alpha","alpha",NA,NA,NA,95,"Qatar","QAT",27,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-08,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-07-08
"96",27,"Abu-Raddad","Test-negative case-control","08Jul2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1","15-21","infection ","infection","Qatar","general pop","general pop",46.5,"38.7",53.3,"beta","beta",NA,NA,NA,96,"Qatar","QAT",27,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-08,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta",NA,2021-07-08
"97",27,"Abu-Raddad","Test-negative case-control","08Jul2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final",">14","infection ","infection","Qatar","general pop","general pop",75,"71",79,"beta","beta",NA,NA,NA,97,"Qatar","QAT",27,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-08,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta",NA,2021-07-08
"98",27,"Abu-Raddad","Test-negative case-control","08Jul2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1","15-21","severe/fatal infection","severe","Qatar","general pop","general pop",56.5,"0",82.8,"beta","beta",NA,NA,NA,98,"Qatar","QAT",27,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-08,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta",NA,2021-07-08
"99",27,"Abu-Raddad","Test-negative case-control","08Jul2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final",">14","severe/fatal infection","severe","Qatar","general pop","general pop",100,"74",100,"beta","beta",NA,NA,NA,99,"Qatar","QAT",27,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-08,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta",NA,2021-07-08
"100",27,"Abu-Raddad","Retrospective cohort","08Jul2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final",">14","infection ","infection","Qatar","general pop","general pop",87,"82",91,"alpha","alpha",NA,NA,NA,100,"Qatar","QAT",27,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-08,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-07-08
"101",27,"Abu-Raddad","Retrospective cohort","08Jul2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final",">14","infection ","infection","Qatar","general pop","general pop",72,"66",77,"beta","beta",NA,NA,NA,101,"Qatar","QAT",27,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-08,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta",NA,2021-07-08
"102",28,"Angel","Retrospective cohort","06May2021","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+",">7 days post dose 1 to 7 days post dose 2","symptomatic disease","symptomatic","Israel","HCW","HCW",89,"83",94,NA,"alpha",NA,NA,NA,102,"Israel","ISR",28,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-05-06,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-06
"103",28,"Angel","Retrospective cohort","06May2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","symptomatic disease","symptomatic","Israel","HCW","HCW",97,"94",99,NA,"alpha",NA,NA,NA,103,"Israel","ISR",28,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-05-06,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-06
"104",28,"Angel","Retrospective cohort","06May2021","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+",">7 days post dose 1 to 7 days post dose 2","asymptomatic infection","asymptomatic","Israel","HCW","HCW",36,"-51",69,NA,"alpha",NA,NA,NA,104,"Israel","ISR",28,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-05-06,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-06
"105",28,"Angel","Retrospective cohort","06May2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","asymptomatic infection","asymptomatic","Israel","HCW","HCW",86,"69",97,NA,"alpha",NA,NA,NA,105,"Israel","ISR",28,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-05-06,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-06
"106",29,"Lopez-Bernal","Test-negative case-control","13May2021","BNT162b2 (Pfizer BioNTech)","included","2","final",">=7","symptomatic disease","symptomatic","UK","> 80 years","> 80 years",79,"68",86,NA,"alpha",NA,NA,NA,106,"UK","GBR",29,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-05-13,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","01/03/2021",2021-03-01
"107",29,"Lopez-Bernal","Test-negative case-control","13May2021","BNT162b2 (Pfizer BioNTech)","included","1+","1+","28-34 (includes some with dose 2)","symptomatic disease","symptomatic","UK","> 70 years","> 70 years",61,"51",69,NA,"alpha",NA,NA,NA,107,"UK","GBR",29,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-05-13,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","01/03/2021",2021-03-01
"108",29,"Lopez-Bernal","Test-negative case-control","13May2021","AZD1222 (AstraZeneca)","included","1+","1+","28-34 (includes some with dose 2)","symptomatic disease","symptomatic","UK","> 70 years","> 70 years",60,"41",73,NA,"alpha",NA,NA,NA,108,"UK","GBR",29,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-05-13,"symptomatic","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","01/03/2021",2021-03-01
"109",30,"Pilishvili ","Test-negative case-control","14May2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1+","1+",">14 up to 6 days post dose 2","symptomatic disease","symptomatic","USA","HCW","HCW",82,"74",87,NA,"unknown",NA,NA,NA,109,"USA","USA",30,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-05-14,"symptomatic","2021 (Jan-Jun)","Multiple or heterologous RNA","mRNA","unknown",NA,2021-05-14
"110",30,"Pilishvili ","Test-negative case-control","14May2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final",">7","symptomatic disease","symptomatic","USA","HCW","HCW",94,"87",97,NA,"unknown",NA,NA,NA,110,"USA","USA",30,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-05-14,"symptomatic","2021 (Jan-Jun)","Multiple or heterologous RNA","mRNA","unknown",NA,2021-05-14
"111",31,"Ismail","Screening method","12May2021","AZD1222 (AstraZeneca)","included","1","1","28+","hospitalization","severe","UK","70-79 years","70-79 years",84,"74",89,NA,"alpha",NA,NA,NA,111,"UK","GBR",31,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-05-12,"severe","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-05-12
"112",31,"Ismail","Screening method","12May2021","AZD1222 (AstraZeneca)","included","1","1","28+","hospitalization","severe","UK",">= 80 years",">= 80 years",73,"60",81,NA,"alpha",NA,NA,NA,112,"UK","GBR",31,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-05-12,"severe","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-05-12
"113",31,"Ismail","Screening method","12May2021","BNT162b2 (Pfizer BioNTech)","included","1","1","28+","hospitalization","severe","UK","70-79 years","70-79 years",81,"73",87,NA,"alpha",NA,NA,NA,113,"UK","GBR",31,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-05-12,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-12
"114",31,"Ismail","Screening method","12May2021","BNT162b2 (Pfizer BioNTech)","included","1","1","28+","hospitalization","severe","UK",">= 80 years",">= 80 years",81,"76",85,NA,"alpha",NA,NA,NA,114,"UK","GBR",31,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-05-12,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-12
"115",31,"Ismail","Screening method","12May2021","BNT162b2 (Pfizer BioNTech)","included","2","final",">14","hospitalization","severe","UK",">= 80 years",">= 80 years",93,"89",95,NA,"alpha",NA,NA,NA,115,"UK","GBR",31,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-05-12,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-12
"116",32,"Ranzani","Test-negative case-control","20Aug2021","CoronaVac (Sinovac)","included","1","1",">14","symptomatic disease","symptomatic","Brazil",">= 70 years",">= 70 years",12.5,"3.7",20.6,NA,"gamma",NA,NA,NA,116,"Brazil","BRA",32,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2021-08-20,"symptomatic","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","gamma","21/07/2021",2021-07-21
"117",32,"Ranzani","Test-negative case-control","20Aug2021","CoronaVac (Sinovac)","included","2","final",">14","symptomatic disease","symptomatic","Brazil",">= 70 years",">= 70 years",46.8,"38.7",53.8,NA,"gamma",NA,NA,NA,117,"Brazil","BRA",32,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2021-08-20,"symptomatic","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","gamma","21/07/2021",2021-07-21
"118",32,"Ranzani","Test-negative case-control","20Aug2021","CoronaVac (Sinovac)","included","1","1",">14","hospitalization","severe","Brazil",">= 70 years",">= 70 years",16.9,"5.7",26.8,NA,"gamma",NA,NA,NA,118,"Brazil","BRA",32,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2021-08-20,"severe","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","gamma","21/07/2021",2021-07-21
"119",32,"Ranzani","Test-negative case-control","20Aug2021","CoronaVac (Sinovac)","included","2","final",">14","hospitalization","severe","Brazil",">= 70 years",">= 70 years",55.5,"46.5",62.9,NA,"gamma",NA,NA,NA,119,"Brazil","BRA",32,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2021-08-20,"severe","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","gamma","21/07/2021",2021-07-21
"120",32,"Ranzani","Test-negative case-control","20Aug2021","CoronaVac (Sinovac)","included","1","1",">14","death","death","Brazil",">= 70 years",">= 70 years",31.2,"17.6",42.5,NA,"gamma",NA,NA,NA,120,"Brazil","BRA",32,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2021-08-20,"death","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","gamma","21/07/2021",2021-07-21
"121",32,"Ranzani","Test-negative case-control","20Aug2021","CoronaVac (Sinovac)","included","2","final",">14","death","death","Brazil",">= 70 years",">= 70 years",61.2,"48.9",70.5,NA,"gamma",NA,NA,NA,121,"Brazil","BRA",32,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2021-08-20,"death","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","gamma","21/07/2021",2021-07-21
"122",33,"PHE","Test-negative case-control","20May2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","28+","symptomatic disease","symptomatic","UK",">= 65 years",">= 65 years",54,"50",58,NA,"alpha",NA,NA,NA,122,"UK","GBR",33,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-05-20,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-20
"123",33,"PHE","Test-negative case-control","20May2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">14","symptomatic disease","symptomatic","UK",">= 65 years",">= 65 years",90,"82",95,NA,"alpha",NA,NA,NA,123,"UK","GBR",33,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-05-20,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-20
"124",33,"PHE","Test-negative case-control","20May2021","AZD1222 (AstraZeneca)","excluded","1","1","28+","symptomatic disease","symptomatic","UK",">= 65 years",">= 65 years",53,"49",57,NA,"alpha",NA,NA,NA,124,"UK","GBR",33,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-05-20,"symptomatic","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-05-20
"125",33,"PHE","Test-negative case-control","20May2021","AZD1222 (AstraZeneca)","excluded","2","final",">14","symptomatic disease","symptomatic","UK",">= 65 years",">= 65 years",89,"78",94,NA,"alpha",NA,NA,NA,125,"UK","GBR",33,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-05-20,"symptomatic","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-05-20
"126",34,"Chung","Test-negative case-control","20Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",59,"55",62,NA,"alpha, beta & gamma",NA,NA,NA,126,"Canada","CAN",34,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/07/2021",2021-07-26
"127",34,"Chung","Test-negative case-control","20Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","symptomatic disease","symptomatic","Canada","general pop","general pop",91,"88",93,NA,"alpha, beta & gamma","15 weeks",NA,NA,127,"Canada","CAN",34,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/07/2021",2021-07-26
"128",34,"Chung","Test-negative case-control","20Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",69,"59",77,NA,"alpha, beta & gamma",NA,NA,NA,128,"Canada","CAN",34,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/07/2021",2021-07-26
"129",34,"Chung","Test-negative case-control","20Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","0+","hospitalization or death","severe","Canada","general pop","general pop",96,"82",99,NA,"alpha, beta & gamma","15 weeks",NA,NA,129,"Canada","CAN",34,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/07/2021",2021-07-26
"130",34,"Chung","Test-negative case-control","20Aug2021","mRNA-1273 (Moderna)","excluded","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",72,"63",80,NA,"alpha, beta & gamma",NA,NA,NA,130,"Canada","CAN",34,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","26/07/2021",2021-07-26
"131",34,"Chung","Test-negative case-control","20Aug2021","mRNA-1273 (Moderna)","excluded","2","final","7+","symptomatic disease","symptomatic","Canada","general pop","general pop",94,"86",97,NA,"alpha, beta & gamma","15 weeks",NA,NA,131,"Canada","CAN",34,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","26/07/2021",2021-07-26
"132",34,"Chung","Test-negative case-control","20Aug2021","mRNA-1273 (Moderna)","excluded","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",73,"42",87,NA,"alpha, beta & gamma",NA,NA,NA,132,"Canada","CAN",34,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","26/07/2021",2021-07-26
"133",34,"Chung","Test-negative case-control","20Aug2021","mRNA-1273 (Moderna)","excluded","2","final","0+","hospitalization or death","severe","Canada","general pop","general pop",96,"74",100,NA,"alpha, beta & gamma","15 weeks",NA,NA,133,"Canada","CAN",34,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","26/07/2021",2021-07-26
"134",34,"Chung","Test-negative case-control","20Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",61,"56",66,"alpha","alpha",NA,NA,NA,134,"Canada","CAN",34,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","26/07/2021",2021-07-26
"135",34,"Chung","Test-negative case-control","20Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","symptomatic disease","symptomatic","Canada","general pop","general pop",90,"85",94,"alpha","alpha","15 weeks",NA,NA,135,"Canada","CAN",34,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","26/07/2021",2021-07-26
"136",34,"Chung","Test-negative case-control","20Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",59,"39",73,"alpha","alpha",NA,NA,NA,136,"Canada","CAN",34,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","26/07/2021",2021-07-26
"137",34,"Chung","Test-negative case-control","20Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","0+","hospitalization or death","severe","Canada","general pop","general pop",94,"59",99,"alpha","alpha","15 weeks",NA,NA,137,"Canada","CAN",34,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","26/07/2021",2021-07-26
"138",34,"Chung","Test-negative case-control","20Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",43,"22",59,"beta & gamma","beta & gamma",NA,NA,NA,138,"Canada","CAN",34,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","26/07/2021",2021-07-26
"139",34,"Chung","Test-negative case-control","20Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","symptomatic disease","symptomatic","Canada","general pop","general pop",88,"61",96,"beta & gamma","beta & gamma","15 weeks",NA,NA,139,"Canada","CAN",34,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","26/07/2021",2021-07-26
"140",34,"Chung","Test-negative case-control","20Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",56,"-9",82,"   ","beta & gamma",NA,"15 weeks",NA,140,"Canada","CAN",34,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","26/07/2021",2021-07-26
"141",34,"Chung","Test-negative case-control","20Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","hospitalization or death","severe","Canada","general pop","general pop",100,NA,NA,"   ","beta & gamma","beta & gamma","15 weeks",NA,141,"Canada","CAN",34,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-20,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","26/07/2021",2021-07-26
"142",35,"Martinez-Bas","Prospective cohort","27May2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","infection ","infection","Spain","close contacts","close contacts",21,"3",36,NA,"alpha",NA,NA,NA,142,"Spain","ESP",35,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-05-27,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-27
"143",35,"Martinez-Bas","Prospective cohort","27May2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection ","infection","Spain","close contacts","close contacts",65,"56",73,NA,"alpha","12 weeks",NA,NA,143,"Spain","ESP",35,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-05-27,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-27
"144",35,"Martinez-Bas","Prospective cohort","27May2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","symptomatic disease","symptomatic","Spain","close contacts","close contacts",30,"10",45,NA,"alpha",NA,NA,NA,144,"Spain","ESP",35,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-05-27,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-27
"145",35,"Martinez-Bas","Prospective cohort","27May2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Spain","close contacts","close contacts",82,"73",88,NA,"alpha","12 weeks",NA,NA,145,"Spain","ESP",35,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-05-27,"symptomatic","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-27
"146",35,"Martinez-Bas","Prospective cohort","27May2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","hospitalization","severe","Spain","close contacts","close contacts",65,"25",83,NA,"alpha",NA,NA,NA,146,"Spain","ESP",35,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-05-27,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-27
"147",35,"Martinez-Bas","Prospective cohort","27May2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Spain","close contacts","close contacts",94,"60",99,NA,"alpha","12 weeks",NA,NA,147,"Spain","ESP",35,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-05-27,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-05-27
"148",35,"Martinez-Bas","Prospective cohort","27May2021","AZD1222 (AstraZeneca)","excluded","1","1","14+","infection ","infection","Spain","close contacts","close contacts",44,"31",54,NA,"alpha",NA,NA,NA,148,"Spain","ESP",35,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-05-27,"infection","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-05-27
"149",35,"Martinez-Bas","Prospective cohort","27May2021","AZD1222 (AstraZeneca)","excluded","1","1","14+","symptomatic disease","symptomatic","Spain","close contacts","close contacts",50,"37",61,NA,"alpha",NA,NA,NA,149,"Spain","ESP",35,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-05-27,"symptomatic","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-05-27
"150",35,"Martinez-Bas","Prospective cohort","27May2021","AZD1222 (AstraZeneca)","excluded","1","1","14+","hospitalization","severe","Spain","close contacts","close contacts",92,"46",99,NA,"alpha",NA,NA,NA,150,"Spain","ESP",35,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-05-27,"severe","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-05-27
"151",36,"Khan","Retrospective cohort","31May2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1+","1+","14+ up to 7 days post dose 2","infection ","infection","USA","hospital patients","general pop",-1,"-50",32,NA,"unknown",NA,NA,NA,151,"USA","USA",36,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-05-31,"infection","2021 (Jan-Jun)","Multiple or heterologous RNA","mRNA","unknown",NA,2021-05-31
"152",36,"Khan","Retrospective cohort","31May2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","infection ","infection","USA","hospital patients","general pop",69,"44",83,NA,"unknown","14 weeks",NA,NA,152,"USA","USA",36,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-05-31,"infection","2021 (Jan-Jun)","Multiple or heterologous RNA","mRNA","unknown",NA,2021-05-31
"153",36,"Khan","Retrospective cohort","31May2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1+","1+","14+ up to 7 days post dose 2","hospitalization or death","severe","USA","hospital patients","general pop",9,"-114",61,NA,"unknown",NA,NA,NA,153,"USA","USA",36,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-05-31,"severe","2021 (Jan-Jun)","Multiple or heterologous RNA","mRNA","unknown",NA,2021-05-31
"154",36,"Khan","Retrospective cohort","31May2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","hospitalization or death","severe","USA","hospital patients","general pop",49,"-36",81,NA,"unknown","14 weeks",NA,NA,154,"USA","USA",36,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-05-31,"severe","2021 (Jan-Jun)","Multiple or heterologous RNA","mRNA","unknown",NA,2021-05-31
"155",37,"Salo","Retrospective cohort","04Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","4 weeks","infection ","infection","Finland","HCW","HCW",44.4,"30.4",55.6,NA,"alpha",NA,NA,NA,155,"Finland","FIN",37,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-04,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-03-04
"156",37,"Salo","Retrospective cohort","04Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1+","1+","12 weeks (inlcudes 2 dose recipients)","infection ","infection","Finland","HCW","HCW",63,"56.3",68.7,NA,"alpha",NA,NA,NA,156,"Finland","FIN",37,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-04,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-03-04
"157",38,"Thompson","Cohort","30June2021","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+",">14 up to 13 days post dose 2","infection ","infection","USA","HCW","HCW",80,"60",90,NA,"original",NA,NA,NA,157,"USA","USA",38,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-06-30,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","original","30/06/2021",2021-06-30
"158",38,"Thompson","Cohort","30June2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">14","infection ","infection","USA","HCW","HCW",93,"78",98,NA,"original","13 weeks",NA,NA,158,"USA","USA",38,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-06-30,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","original","30/06/2021",2021-06-30
"159",38,"Thompson","Cohort","30June2021","mRNA-1273 (Moderna)","excluded","1+","1+",">14 up to 13 days post dose 2","infection ","infection","USA","HCW","HCW",83,"40",95,NA,"original",NA,NA,NA,159,"USA","USA",38,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-06-30,"infection","2021 (Jan-Jun)","Moderna mRNA-1273","mRNA","original","30/06/2021",2021-06-30
"160",38,"Thompson","Cohort","30June2021","mRNA-1273 (Moderna)","excluded","2","final",">14","infection ","infection","USA","HCW","HCW",82,"20",96,NA,"original",NA,NA,NA,160,"USA","USA",38,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-06-30,"infection","2021 (Jan-Jun)","Moderna mRNA-1273","mRNA","original","30/06/2021",2021-06-30
"161",39,"Emborg","Cohort","30June2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1",">14","infection ","infection","Denmark","priority groups","priority groups",7,"-1",15,NA,"original & alpha",NA,NA,NA,161,"Denmark","DNK",39,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-06-30,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-06-30
"162",39,"Emborg","Cohort","30June2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","infection ","infection","Denmark","priority groups","priority groups",82,"79",84,NA,"original & alpha","10 weeks",NA,NA,162,"Denmark","DNK",39,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-06-30,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-06-30
"163",39,"Emborg","Cohort","30June2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1",">14","hospitalization","severe","Denmark","priority groups","priority groups",35,"18",49,NA,"original & alpha",NA,NA,NA,163,"Denmark","DNK",39,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-06-30,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-06-30
"164",39,"Emborg","Cohort","30June2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","hospitalization","severe","Denmark","priority groups","priority groups",93,"89",96,NA,"original & alpha","10 weeks",NA,NA,164,"Denmark","DNK",39,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-06-30,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-06-30
"165",39,"Emborg","Cohort","30June2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1",">14","death","death","Denmark","priority groups","priority groups",7,"-15",25,NA,"original & alpha",NA,NA,NA,165,"Denmark","DNK",39,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-06-30,"death","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-06-30
"166",39,"Emborg","Cohort","30June2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">7","death","death","Denmark","priority groups","priority groups",94,"90",96,NA,"original & alpha","10 weeks",NA,NA,166,"Denmark","DNK",39,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-06-30,"death","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-06-30
"167",40,"Skowornski","Test-negative case-control","09Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1","1","21+","infection ","infection","Canada","> 70 years","> 70 years",67,"57",75,"alpha","alpha",NA,NA,NA,167,"Canada","CAN",40,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-07-09,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-07-09
"168",40,"Skowornski","Test-negative case-control","09Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1","1","21+","infection ","infection","Canada","> 70 years","> 70 years",61,"45",72,"gamma","gamma",NA,NA,NA,168,"Canada","CAN",40,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-07-09,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","gamma",NA,2021-07-09
"169",40,"Skowornski","Test-negative case-control","09Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1","1","21+","infection ","infection","Canada","> 70 years","> 70 years",72,"58",81,"non-VOC","non-VOC",NA,NA,NA,169,"Canada","CAN",40,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-07-09,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","original",NA,2021-07-09
"170",40,"Skowornski","Test-negative case-control","09Jul2021","BNT162b2 (Pfizer BioNTech)","included","1","1","21+","infection ","infection","Canada","> 70 years","> 70 years",64,"57",71,NA,"alpha & gamma",NA,NA,NA,170,"Canada","CAN",40,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-07-09,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-07-09
"171",40,"Skowornski","Test-negative case-control","09Jul2021","mRNA-1273 (Moderna)","included","1","1","21+","infection ","infection","Canada","> 70 years","> 70 years",71,"56",81,NA,"alpha & gamma",NA,NA,NA,171,"Canada","CAN",40,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-07-09,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-07-09
"172",41,"Flacco","Retrospective cohort","10June2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","infection ","infection","Italy","general pop","general pop",55,"40",66,NA,"original & alpha",NA,NA,NA,172,"Italy","ITA",41,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-06-10,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-06-10
"173",41,"Flacco","Retrospective cohort","10June2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","infection ","infection","Italy","general pop","general pop",98,"97",99,NA,"original & alpha","~14 weeks",NA,NA,173,"Italy","ITA",41,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-06-10,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-06-10
"174",41,"Flacco","Retrospective cohort","10June2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","hospitalization","severe","Italy","general pop","general pop",99,"96",100,NA,"original & alpha","~14 weeks",NA,NA,174,"Italy","ITA",41,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-06-10,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-06-10
"175",41,"Flacco","Retrospective cohort","10June2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","death","death","Italy","general pop","general pop",98,"87",100,NA,"original & alpha","~14 weeks",NA,NA,175,"Italy","ITA",41,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-06-10,"death","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-06-10
"176",41,"Flacco","Retrospective cohort","10June2021","mRNA-1273 (Moderna)","unknown","1","1","14+","infection ","infection","Italy","general pop","general pop",93,"74",98,NA,"original & alpha",NA,NA,NA,176,"Italy","ITA",41,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-06-10,"infection","2021 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-06-10
"177",41,"Flacco","Retrospective cohort","10June2021","AZD1222 (AstraZeneca)","unknown","1","1","21+","infection ","infection","Italy","general pop","general pop",95,"92",97,NA,"original & alpha",NA,NA,NA,177,"Italy","ITA",41,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-06-10,"infection","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-06-10
"178",42,"Sheikh","Test-negative case-control","14June2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1","28+","infection ","infection","Scotland","general pop","general pop",38,"29",45,"alpha","alpha",NA,NA,NA,178,"UK","GBR",42,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-06-14
"179",42,"Sheikh","Test-negative case-control","14June2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","infection ","infection","Scotland","general pop","general pop",92,"90",93,"alpha","alpha","~20 weeks",NA,NA,179,"UK","GBR",42,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-06-14
"180",42,"Sheikh","Test-negative case-control","14June2021","AZD1222 (AstraZeneca)","unknown","1","1","28+","infection ","infection","Scotland","general pop","general pop",37,"32",42,"alpha","alpha",NA,NA,NA,180,"UK","GBR",42,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"infection","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-06-14
"181",42,"Sheikh","Test-negative case-control","14June2021","AZD1222 (AstraZeneca)","unknown","2","final","14+","infection ","infection","Scotland","general pop","general pop",73,"66",78,"alpha","alpha","~20 weeks",NA,NA,181,"UK","GBR",42,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"infection","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-06-14
"182",42,"Sheikh","Test-negative case-control","14June2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1","28+","infection ","infection","Scotland","general pop","general pop",30,"17",41,"delta","delta",NA,NA,NA,182,"UK","GBR",42,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-06-14
"183",42,"Sheikh","Test-negative case-control","14June2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","infection ","infection","Scotland","general pop","general pop",79,"75",82,"delta","delta","~20 weeks",NA,NA,183,"UK","GBR",42,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-06-14
"184",42,"Sheikh","Test-negative case-control","14June2021","AZD1222 (AstraZeneca)","unknown","1","1","28+","infection ","infection","Scotland","general pop","general pop",18,"9",25,"delta","delta",NA,NA,NA,184,"UK","GBR",42,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"infection","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-06-14
"185",42,"Sheikh","Test-negative case-control","14June2021","AZD1222 (AstraZeneca)","unknown","2","final","14+","infection ","infection","Scotland","general pop","general pop",60,"53",66,"delta","delta","~20 weeks",NA,NA,185,"UK","GBR",42,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"infection","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-06-14
"186",43,"Stowe","Test-negative case-control","14June2021","BNT162b2 (Pfizer BioNTech)","included","1","1","21+","hospitalization","severe","UK","hospital patients","general pop",83,"62",93,"alpha","alpha",NA,NA,NA,186,"UK","GBR",43,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-06-14
"187",43,"Stowe","Test-negative case-control","14June2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","UK","hospital patients","general pop",95,"78",99,"alpha","alpha","~20 weeks",NA,NA,187,"UK","GBR",43,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-06-14
"188",43,"Stowe","Test-negative case-control","14June2021","AZD1222 (AstraZeneca)","included","1","1","21+","hospitalization","severe","UK","hospital patients","general pop",76,"61",85,"alpha","alpha",NA,NA,NA,188,"UK","GBR",43,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"severe","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-06-14
"189",43,"Stowe","Test-negative case-control","14June2021","AZD1222 (AstraZeneca)","included","2","final","14+","hospitalization","severe","UK","hospital patients","general pop",86,"53",96,"alpha","alpha","~20 weeks",NA,NA,189,"UK","GBR",43,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"severe","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-06-14
"190",43,"Stowe","Test-negative case-control","14June2021","BNT162b2 (Pfizer BioNTech)","included","1","1","21+","hospitalization","severe","UK","hospital patients","general pop",94,"46",99,"delta","delta",NA,NA,NA,190,"UK","GBR",43,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-06-14
"191",43,"Stowe","Test-negative case-control","14June2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","UK","hospital patients","general pop",96,"86",99,"delta","delta","~20 weeks",NA,NA,191,"UK","GBR",43,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-06-14
"192",43,"Stowe","Test-negative case-control","14June2021","AZD1222 (AstraZeneca)","included","1","1","21+","hospitalization","severe","UK","hospital patients","general pop",71,"51",83,"delta","delta",NA,NA,NA,192,"UK","GBR",43,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"severe","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-06-14
"193",43,"Stowe","Test-negative case-control","14June2021","AZD1222 (AstraZeneca)","included","2","final","14+","hospitalization","severe","UK","hospital patients","general pop",92,"75",97,"delta","delta","~20 weeks",NA,NA,193,"UK","GBR",43,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"severe","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-06-14
"194",44,"Azamgarhi","Retrospective cohort","17June2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1",">14","infection ","infection","UK","HCW","HCW",70,"6",91,NA,"original & alpha",NA,NA,NA,194,"UK","GBR",44,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-17,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-06-17
"195",45,"Young-Xu","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","7+","infection ","infection","USA","general pop","general pop",58,"54",62,NA,"original & alpha",NA,NA,NA,195,"USA","USA",45,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-06,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/07/2021",2021-07-14
"196",45,"Young-Xu","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","infection ","infection","USA","general pop","general pop",94,"92",95,NA,"original & alpha","~8 weeks",NA,NA,196,"USA","USA",45,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-06,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/07/2021",2021-07-14
"197",45,"Young-Xu","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","7+","hospitalization","severe","USA","general pop","general pop",40,"27",50,NA,"original & alpha",NA,NA,NA,197,"USA","USA",45,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-06,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/07/2021",2021-07-14
"198",45,"Young-Xu","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","hospitalization","severe","USA","general pop","general pop",89,"81",93,NA,"original & alpha","~8 weeks",NA,NA,198,"USA","USA",45,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-06,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/07/2021",2021-07-14
"199",45,"Young-Xu","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","7+","death","death","USA","general pop","general pop",55,"21",74,NA,"original & alpha",NA,NA,NA,199,"USA","USA",45,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-06,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/07/2021",2021-07-14
"200",45,"Young-Xu","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","death","death","USA","general pop","general pop",98.5,"86.6",99.8,NA,"original & alpha","~8 weeks",NA,NA,200,"USA","USA",45,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-06,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/07/2021",2021-07-14
"201",45,"Young-Xu","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","7+","asymptomatic infection","asymptomatic","USA","general pop","general pop",58,"41.7",69.7,NA,"original & alpha",NA,NA,NA,201,"USA","USA",45,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-06,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/07/2021",2021-07-14
"202",45,"Young-Xu","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","asymptomatic infection","asymptomatic","USA","general pop","general pop",69.7,"47.7",82.5,NA,"original & alpha","~8 weeks",NA,NA,202,"USA","USA",45,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-06,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/07/2021",2021-07-14
"203",45,"Young-Xu","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","7+","hospitalization","severe","USA","general pop","general pop",53,"25.7",70.3,NA,"original & alpha",NA,NA,NA,203,"USA","USA",45,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-06,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/07/2021",2021-07-14
"204",45,"Young-Xu","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","hospitalization","severe","USA","general pop","general pop",88.4,"74.9",94.7,NA,"original & alpha","~8 weeks",NA,NA,204,"USA","USA",45,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-06,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/07/2021",2021-07-14
"205",45,"Young-Xu","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","7+","death","death","USA","general pop","general pop",55.6,"26.6",73.2,NA,"original & alpha",NA,NA,NA,205,"USA","USA",45,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-06,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/07/2021",2021-07-14
"206",45,"Young-Xu","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","death","death","USA","general pop","general pop",97,"91.7",98.9,NA,"original & alpha","~8 weeks",NA,NA,206,"USA","USA",45,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-06,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/07/2021",2021-07-14
"207",46,"Pawlowski","Retrospective cohort","17Jun2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1",">14","infection ","infection","USA","general pop","general pop",61,"50.8",69.2,NA,"original & alpha",NA,NA,NA,207,"USA","USA",46,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-06-17,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","18/02/2021",2021-02-18
"208",46,"Pawlowski","Retrospective cohort","17Jun2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">14","infection ","infection","USA","general pop","general pop",88,"84.2",91,NA,"original & alpha","~17 weeks",NA,NA,208,"USA","USA",46,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-06-17,"infection","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","18/02/2021",2021-02-18
"209",46,"Pawlowski","Retrospective cohort","17Jun2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">14","hospitalization","severe","USA","general pop","general pop",88.3,"72.6",95.9,NA,"original & alpha","~17 weeks",NA,NA,209,"USA","USA",46,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-06-17,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","18/02/2021",2021-02-18
"210",46,"Pawlowski","Retrospective cohort","17Jun2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">14","ICU admission","severe","USA","general pop","general pop",100,"18.7",100,NA,"original & alpha","~17 weeks",NA,NA,210,"USA","USA",46,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-06-17,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","18/02/2021",2021-02-18
"211",46,"Pawlowski","Retrospective cohort","17Jun2021","mRNA-1273 (Moderna)","excluded","1","1",">14","infection ","infection","USA","general pop","general pop",66.6,"51.9",77.3,NA,"original & alpha",NA,NA,NA,211,"USA","USA",46,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-06-17,"infection","2021 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","18/02/2021",2021-02-18
"212",46,"Pawlowski","Retrospective cohort","17Jun2021","mRNA-1273 (Moderna)","excluded","2","final",">14","infection ","infection","USA","general pop","general pop",92.3,"82.4",97.3,NA,"original & alpha","~17 weeks",NA,NA,212,"USA","USA",46,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-06-17,"infection","2021 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","18/02/2021",2021-02-18
"213",46,"Pawlowski","Retrospective cohort","17Jun2021","mRNA-1273 (Moderna)","excluded","2","final",">14","hospitalization","severe","USA","general pop","general pop",90.6,"76.5",97.1,NA,"original & alpha","~17 weeks",NA,NA,213,"USA","USA",46,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-06-17,"severe","2021 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","18/02/2021",2021-02-18
"214",46,"Pawlowski","Retrospective cohort","17Jun2021","mRNA-1273 (Moderna)","excluded","2","final",">14","ICU admission","severe","USA","general pop","general pop",100,"17.9",100,NA,"original & alpha","~17 weeks",NA,NA,214,"USA","USA",46,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-06-17,"severe","2021 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","18/02/2021",2021-02-18
"215",47,"Saciuk","Retrospective cohort","30Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","infection ","infection","Israel","general pop","general pop",93,"92.6",93.4,NA,"original & alpha","14 weeks",NA,NA,215,"Israel","ISR",47,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-30,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/06/2021",2021-06-27
"216",47,"Saciuk","Retrospective cohort","30Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","hospitalization","severe","Israel","general pop","general pop",93.4,"91.9",94.7,NA,"original & alpha","14 weeks",NA,NA,216,"Israel","ISR",47,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-30,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/06/2021",2021-06-27
"217",47,"Saciuk","Retrospective cohort","30Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","death","death","Israel","general pop","general pop",91.1,"86.5",94.1,NA,"original & alpha","14 weeks",NA,NA,217,"Israel","ISR",47,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-30,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/06/2021",2021-06-27
"218",48,"Baum","Prospective cohort","18Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","21+","infection ","infection","Finland",">= 70 years",">= 70 years",45,"36",53,NA,"original & alpha",NA,NA,NA,218,"Finland","FIN",48,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-11-18,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","28/06/2021",2021-06-28
"219",48,"Baum","Prospective cohort","18Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","infection ","infection","Finland",">= 70 years",">= 70 years",75,"65",82,NA,"original & alpha","16 weeks",NA,NA,219,"Finland","FIN",48,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-11-18,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","28/06/2021",2021-06-28
"220",48,"Baum","Prospective cohort","18Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","21+","hospitalization","severe","Finland",">= 70 years",">= 70 years",63,"49",74,NA,"original & alpha",NA,NA,NA,220,"Finland","FIN",48,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-11-18,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","28/06/2021",2021-06-28
"221",48,"Baum","Prospective cohort","18Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","hospitalization","severe","Finland",">= 70 years",">= 70 years",93,"70",98,NA,"original & alpha","16 weeks",NA,NA,221,"Finland","FIN",48,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-11-18,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","28/06/2021",2021-06-28
"222",48,"Baum","Prospective cohort","18Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","21+","infection ","infection","Finland","chronically ill","chronically ill",40,"26",51,NA,"original & alpha",NA,NA,NA,222,"Finland","FIN",48,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-11-18,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","28/06/2021",2021-06-28
"223",48,"Baum","Prospective cohort","18Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","infection ","infection","Finland","chronically ill","chronically ill",77,"65",85,NA,"original & alpha","16 weeks",NA,NA,223,"Finland","FIN",48,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-11-18,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","28/06/2021",2021-06-28
"224",48,"Baum","Prospective cohort","18Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","21+","hospitalization","severe","Finland","chronically ill","chronically ill",82,"56",93,NA,"original & alpha",NA,NA,NA,224,"Finland","FIN",48,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-11-18,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","28/06/2021",2021-06-28
"225",48,"Baum","Prospective cohort","18Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","hospitalization","severe","Finland","chronically ill","chronically ill",90,"29",99,NA,"original & alpha","16 weeks",NA,NA,225,"Finland","FIN",48,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-11-18,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","28/06/2021",2021-06-28
"226",48,"Baum","Prospective cohort","18Nov2021","AZD1222 (AstraZeneca)","excluded","1","1","21+","infection ","infection","Finland","chronically ill","chronically ill",42,"32",50,NA,"original & alpha",NA,NA,NA,226,"Finland","FIN",48,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-11-18,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","28/06/2021",2021-06-28
"227",48,"Baum","Prospective cohort","18Nov2021","AZD1222 (AstraZeneca)","excluded","1","1","21+","hospitalization","severe","Finland","chronically ill","chronically ill",62,"42",75,NA,"original & alpha",NA,NA,NA,227,"Finland","FIN",48,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-11-18,"severe","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","28/06/2021",2021-06-28
"228",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",63,"56",68,"non-VOC","non-VOC",NA,NA,NA,228,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","original","30/09/2021",2021-09-30
"229",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",92,"87",95,"non-VOC","non-VOC","18 weeks",NA,NA,229,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","original","30/09/2021",2021-09-30
"230",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",77,"67",84,"non-VOC","non-VOC",NA,NA,NA,230,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","original","30/09/2021",2021-09-30
"231",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",97,"88",99,"non-VOC","non-VOC","18 weeks",NA,NA,231,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","original","30/09/2021",2021-09-30
"232",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",63,"47",74,"non-VOC","non-VOC",NA,NA,NA,232,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","original","30/09/2021",2021-09-30
"233",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",98,"83",100,"non-VOC","non-VOC","18 weeks",NA,NA,233,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","original","30/09/2021",2021-09-30
"234",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",66,"43",80,"non-VOC","non-VOC",NA,NA,NA,234,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","original","30/09/2021",2021-09-30
"235",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",100,NA,NA,"non-VOC","non-VOC","18 weeks",NA,NA,235,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","original","30/09/2021",2021-09-30
"236",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",67,"44",81,"non-VOC","non-VOC",NA,NA,NA,236,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","original","30/09/2021",2021-09-30
"237",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",100,NA,NA,"non-VOC","non-VOC","~3 weeks",NA,NA,237,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","original","30/09/2021",2021-09-30
"238",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",92,"45",99,"non-VOC","non-VOC",NA,NA,NA,238,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","original","30/09/2021",2021-09-30
"239",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",100,NA,NA,"non-VOC","non-VOC","~3 weeks",NA,NA,239,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","original","30/09/2021",2021-09-30
"240",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",67,"65",68,"alpha","alpha",NA,NA,NA,240,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","30/09/2021",2021-09-30
"241",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",88,"86",90,"alpha","alpha","~28 weeks",NA,NA,241,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","30/09/2021",2021-09-30
"242",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",82,"81",84,"alpha","alpha",NA,NA,NA,242,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","30/09/2021",2021-09-30
"243",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",96,"94",97,"alpha","alpha","~28 weeks",NA,NA,243,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","30/09/2021",2021-09-30
"244",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",82,"80",84,"alpha","alpha",NA,NA,NA,244,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","alpha","30/09/2021",2021-09-30
"245",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",92,"87",95,"alpha","alpha","~25 weeks",NA,NA,245,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","alpha","30/09/2021",2021-09-30
"246",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",80,"76",84,"alpha","alpha",NA,NA,NA,246,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","alpha","30/09/2021",2021-09-30
"247",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",95,"92",97,"alpha","alpha","~25 weeks",NA,NA,247,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","alpha","30/09/2021",2021-09-30
"248",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",63,"59",66,"alpha","alpha",NA,NA,NA,248,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","30/09/2021",2021-09-30
"249",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",87,"47",97,"alpha","alpha","~3 weeks",NA,NA,249,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","30/09/2021",2021-09-30
"250",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",87,"83",90,"alpha","alpha",NA,NA,NA,250,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","30/09/2021",2021-09-30
"251",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",92,"41",99,"alpha","alpha","~3 weeks",NA,NA,251,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","30/09/2021",2021-09-30
"252",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",50,"15",70,"beta","beta",NA,NA,NA,252,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","beta","30/09/2021",2021-09-30
"253",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",86,"0",98,"beta","beta","~28 weeks",NA,NA,253,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","beta","30/09/2021",2021-09-30
"254",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",64,"31",82,"beta","beta",NA,NA,NA,254,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","beta","30/09/2021",2021-09-30
"255",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",92,"39",99,"beta","beta","~28 weeks",NA,NA,255,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","beta","30/09/2021",2021-09-30
"256",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",100,NA,NA,"beta","beta","~25 weeks",NA,NA,256,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","beta","30/09/2021",2021-09-30
"257",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",59,"-77",90,"beta","beta",NA,NA,NA,257,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","beta","30/09/2021",2021-09-30
"258",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",100,NA,NA,"beta","beta","~25 weeks",NA,NA,258,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","beta","30/09/2021",2021-09-30
"259",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",84,"-13",98,"beta","beta",NA,NA,NA,259,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","beta","30/09/2021",2021-09-30
"260",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",100,NA,NA,"beta","beta","~3 weeks",NA,NA,260,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","beta","30/09/2021",2021-09-30
"261",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",61,"-64",91,"beta","beta",NA,NA,NA,261,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","beta","30/09/2021",2021-09-30
"262",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",63,"54",70,"gamma","gamma",NA,NA,NA,262,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","gamma","30/09/2021",2021-09-30
"263",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",90,"76",96,"gamma","gamma","~28 weeks",NA,NA,263,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","gamma","30/09/2021",2021-09-30
"264",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",80,"70",87,"gamma","gamma",NA,NA,NA,264,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","gamma","30/09/2021",2021-09-30
"265",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",94,"59",99,"gamma","gamma","~28 weeks",NA,NA,265,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","gamma","30/09/2021",2021-09-30
"266",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",89,"76",95,"gamma","gamma",NA,NA,NA,266,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","gamma","30/09/2021",2021-09-30
"267",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",100,NA,NA,"gamma","gamma","~25 weeks",NA,NA,267,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","gamma","30/09/2021",2021-09-30
"268",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",88,"63",96,"gamma","gamma",NA,NA,NA,268,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","gamma","30/09/2021",2021-09-30
"269",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",100,NA,NA,"gamma","gamma","~25 weeks",NA,NA,269,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","gamma","30/09/2021",2021-09-30
"270",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",41,"12",60,"gamma","gamma",NA,NA,NA,270,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma","30/09/2021",2021-09-30
"271",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",100,NA,NA,"gamma","gamma","~3 weeks",NA,NA,271,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma","30/09/2021",2021-09-30
"272",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",76,"40",90,"gamma","gamma",NA,NA,NA,272,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma","30/09/2021",2021-09-30
"273",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",100,NA,NA,"gamma","gamma","~3 weeks",NA,NA,273,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma","30/09/2021",2021-09-30
"274",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",57,"53",61,"delta","delta",NA,NA,NA,274,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","30/09/2021",2021-09-30
"275",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",92,"89",94,"delta","delta","~28 weeks",NA,NA,275,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","30/09/2021",2021-09-30
"276",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",81,"76",85,"delta","delta",NA,NA,NA,276,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","30/09/2021",2021-09-30
"277",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",98,"96",99,"delta","delta","~28 weeks",NA,NA,277,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","30/09/2021",2021-09-30
"278",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",70,"64",76,"delta","delta",NA,NA,NA,278,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","30/09/2021",2021-09-30
"279",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",94,"90",97,"delta","delta","~25 weeks",NA,NA,279,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","30/09/2021",2021-09-30
"280",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",90,"82",94,"delta","delta",NA,NA,NA,280,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","30/09/2021",2021-09-30
"281",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",98,"93",100,"delta","delta","~25 weeks",NA,NA,281,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","30/09/2021",2021-09-30
"282",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","1","1","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",68,"57",76,"delta","delta",NA,NA,NA,282,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","30/09/2021",2021-09-30
"283",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","2","final","14+","symptomatic disease","symptomatic","Canada","general pop","general pop",88,"68",96,"delta","delta","~ 3 weeks",NA,NA,283,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","30/09/2021",2021-09-30
"284",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","1","1","14+","hospitalization or death","severe","Canada","general pop","general pop",91,"82",96,"delta","delta",NA,NA,NA,284,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","30/09/2021",2021-09-30
"285",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",90,"67",97,"delta","delta","~3 weeks",NA,NA,285,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","30/09/2021",2021-09-30
"286",50,"Jara","Prospective cohort","07Jul2021","CoronaVac (Sinovac)","excluded","1","1","14+","infection ","infection","Chile","general pop","general pop",15.5,"14.2",16.8,NA,"alpha & gamma",NA,NA,NA,286,"Chile","CHL",50,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-07,"infection","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations",NA,2021-07-07
"287",50,"Jara","Prospective cohort","07Jul2021","CoronaVac (Sinovac)","excluded","2","final","14+","infection ","infection","Chile","general pop","general pop",65.9,"65.2",66.6,NA,"alpha & gamma","8 weeks",NA,NA,287,"Chile","CHL",50,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-07,"infection","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations",NA,2021-07-07
"288",50,"Jara","Prospective cohort","07Jul2021","CoronaVac (Sinovac)","excluded","1","1","14+","hospitalization","severe","Chile","general pop","general pop",37.4,"34.9",39.9,NA,"alpha & gamma",NA,NA,NA,288,"Chile","CHL",50,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-07,"severe","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations",NA,2021-07-07
"289",50,"Jara","Prospective cohort","07Jul2021","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Chile","general pop","general pop",87.5,"86.7",88.2,NA,"alpha & gamma","8 weeks",NA,NA,289,"Chile","CHL",50,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-07,"severe","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations",NA,2021-07-07
"290",50,"Jara","Prospective cohort","07Jul2021","CoronaVac (Sinovac)","excluded","1","1","14+","ICU admission","severe","Chile","general pop","general pop",44.7,"40.8",48.3,NA,"alpha & gamma",NA,NA,NA,290,"Chile","CHL",50,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-07,"severe","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations",NA,2021-07-07
"291",50,"Jara","Prospective cohort","07Jul2021","CoronaVac (Sinovac)","excluded","2","final","14+","ICU admission","severe","Chile","general pop","general pop",90.3,"89.1",91.4,NA,"alpha & gamma","8 weeks",NA,NA,291,"Chile","CHL",50,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-07,"severe","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations",NA,2021-07-07
"292",50,"Jara","Prospective cohort","07Jul2021","CoronaVac (Sinovac)","excluded","1","1","14+","death","death","Chile","general pop","general pop",45.7,"40.9",50.2,NA,"alpha & gamma",NA,NA,NA,292,"Chile","CHL",50,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-07,"death","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations",NA,2021-07-07
"293",50,"Jara","Prospective cohort","07Jul2021","CoronaVac (Sinovac)","excluded","2","final","14+","death","death","Chile","general pop","general pop",86.3,"84.5",87.9,NA,"alpha & gamma","8 weeks",NA,NA,293,"Chile","CHL",50,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-07,"death","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations",NA,2021-07-07
"294",51,"Tenforde","Test-negative case-control","06Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1+","1+","14+ up to 14 days post dose 2","hospitalization","severe","USA","hospital patients","general pop",75.4,"60.4",84.7,NA,"original & alpha",NA,NA,NA,294,"USA","USA",51,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-08-06,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","08/07/2021",2021-07-08
"295",51,"Tenforde","Test-negative case-control","06Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","hospital patients","general pop",86.6,"79",91.4,NA,"original & alpha","~2 weeks",NA,NA,295,"USA","USA",51,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-08-06,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","08/07/2021",2021-07-08
"296",51,"Tenforde","Test-negative case-control","06Aug2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA","hospital patients","general pop",84.7,"74.1",91,NA,"original & alpha","~2 weeks",NA,NA,296,"USA","USA",51,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-08-06,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","08/07/2021",2021-07-08
"297",51,"Tenforde","Test-negative case-control","06Aug2021","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","hospital patients","general pop",88.9,"78.7",94,NA,"original & alpha","~2 weeks",NA,NA,297,"USA","USA",51,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-08-06,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","08/07/2021",2021-07-08
"298",51,"Tenforde","Test-negative case-control","06Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","hospital patients","general pop",92.1,"82.3",96.5,"alpha","alpha","~2 weeks",NA,NA,298,"USA","USA",51,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-08-06,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","08/07/2021",2021-07-08
"299",52,"Chemaitelly","Test-negative case-control","09Jul2021","mRNA-1273 (Moderna)","unknown","1","1","14+","infection ","infection","Qatar","general pop","general pop",88.2,"83.8",91.4,"alpha","alpha",NA,NA,NA,299,"Qatar","QAT",52,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-09,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-07-09
"300",52,"Chemaitelly","Test-negative case-control","09Jul2021","mRNA-1273 (Moderna)","unknown","2","final","14+","infection ","infection","Qatar","general pop","general pop",100,NA,NA,"alpha","alpha","13 weeks",NA,NA,300,"Qatar","QAT",52,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-09,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-07-09
"301",52,"Chemaitelly","Test-negative case-control","09Jul2021","mRNA-1273 (Moderna)","unknown","1","1","14+","infection ","infection","Qatar","general pop","general pop",68.2,"64.3",71.7,"beta","beta",NA,NA,NA,301,"Qatar","QAT",52,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-09,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","beta",NA,2021-07-09
"302",52,"Chemaitelly","Test-negative case-control","09Jul2021","mRNA-1273 (Moderna)","unknown","2","final","14+","infection ","infection","Qatar","general pop","general pop",96,"90.9",98.2,"beta","beta","13 weeks",NA,NA,302,"Qatar","QAT",52,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-09,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","beta",NA,2021-07-09
"303",52,"Chemaitelly","Test-negative case-control","09Jul2021","mRNA-1273 (Moderna)","unknown","1","1","14+","severe/fatal infection","severe","Qatar","general pop","general pop",83.7,"74.1",89.7,NA,"alpha & beta",NA,NA,NA,303,"Qatar","QAT",52,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-09,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-07-09
"304",52,"Chemaitelly","Test-negative case-control","09Jul2021","mRNA-1273 (Moderna)","unknown","2","final","14+","severe/fatal infection","severe","Qatar","general pop","general pop",89.5,"18.8",98.7,NA,"alpha & beta","13 weeks",NA,NA,304,"Qatar","QAT",52,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-09,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-07-09
"305",52,"Chemaitelly","Test-negative case-control","09Jul2021","mRNA-1273 (Moderna)","unknown","1","1","14+","symptomatic disease","symptomatic","Qatar","general pop","general pop",66,"60.6",70.7,NA,"alpha & beta",NA,NA,NA,305,"Qatar","QAT",52,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-09,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-07-09
"306",52,"Chemaitelly","Test-negative case-control","09Jul2021","mRNA-1273 (Moderna)","unknown","2","final","14+","symptomatic disease","symptomatic","Qatar","general pop","general pop",98.6,"92",100,NA,"alpha & beta","13 weeks",NA,NA,306,"Qatar","QAT",52,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-09,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-07-09
"307",52,"Chemaitelly","Test-negative case-control","09Jul2021","mRNA-1273 (Moderna)","unknown","1","1","14+","asymptomatic infection","asymptomatic","Qatar","general pop","general pop",47.3,"37.6",55.5,NA,"alpha & beta",NA,NA,NA,307,"Qatar","QAT",52,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-09,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-07-09
"308",52,"Chemaitelly","Test-negative case-control","09Jul2021","mRNA-1273 (Moderna)","unknown","2","final","14+","asymptomatic infection","asymptomatic","Qatar","general pop","general pop",92.5,"84.8",96.9,NA,"alpha & beta","13 weeks",NA,NA,308,"Qatar","QAT",52,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-09,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-07-09
"309",52,"Chemaitelly","Retrospective cohort","09Jul2021","mRNA-1273 (Moderna)","excluded","2","final","14+","infection ","infection","Qatar","general pop","general pop",100,"82.5",100,"alpha","alpha","13 weeks",NA,NA,309,"Qatar","QAT",52,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-09,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-07-09
"310",52,"Chemaitelly","Retrospective cohort","09Jul2021","mRNA-1273 (Moderna)","excluded","2","final","14+","infection ","infection","Qatar","general pop","general pop",87.8,"73.4",95.5,"beta","beta","13 weeks",NA,NA,310,"Qatar","QAT",52,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-09,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","beta",NA,2021-07-09
"311",53,"Goldshtein","Retrospective cohort","12Jul2021","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+","11-27 including some with dose 2","infection ","infection","Israel","pregnant women","pregnant persons",54,"33",69,NA,"original & alpha",NA,NA,NA,311,"Israel","ISR",53,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-07-12,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-07-12
"312",53,"Goldshtein","Retrospective cohort","12Jul2021","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+","28+ including some with dose 2","infection ","infection","Israel","pregnant women","pregnant persons",78,"57",89,NA,"original & alpha",NA,NA,NA,312,"Israel","ISR",53,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-07-12,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-07-12
"313",54,"Bertollini","Prospective cohort","13Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","infection ","infection","Qatar","general pop","general pop",78,"72",83,NA,"original, alpha & beta","~4 weeks",NA,NA,313,"Qatar","QAT",54,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-07-13,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-07-13
"314",55,"John","Retrospective cohort","13Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1+","1+","28+ including some with dose 2","infection ","infection","USA","patients with cirrhosis","patients with cirrhosis",64.8,"10.9",86.1,NA,"original & alpha",NA,NA,NA,314,"USA","USA",55,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-07-13,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-07-13
"315",55,"John","Retrospective cohort","13Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","infection ","infection","USA","patients with cirrhosis","patients with cirrhosis",78.6,"25.5",93.8,NA,"original & alpha","~10 weeks",NA,NA,315,"USA","USA",55,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-07-13,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-07-13
"316",55,"John","Retrospective cohort","13Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1+","1+","28+ including some with dose 2","hospitalization","severe","USA","patients with cirrhosis","patients with cirrhosis",100,"99.3",100,NA,"original & alpha",NA,NA,NA,316,"USA","USA",55,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-07-13,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-07-13
"317",55,"John","Retrospective cohort","13Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","hospitalization","severe","USA","patients with cirrhosis","patients with cirrhosis",100,"99",100,NA,"original & alpha","~10 weeks",NA,NA,317,"USA","USA",55,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-07-13,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-07-13
"318",55,"John","Retrospective cohort","13Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1+","1+","28+ including some with dose 2","death","death","USA","patients with cirrhosis","patients with cirrhosis",100,"99.3",100,NA,"original & alpha",NA,NA,NA,318,"USA","USA",55,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-07-13,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-07-13
"319",55,"John","Retrospective cohort","13Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","death","death","USA","patients with cirrhosis","patients with cirrhosis",100,"99",100,NA,"original & alpha","~10 weeks",NA,NA,319,"USA","USA",55,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-07-13,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-07-13
"320",56,"Whitaker","Prospective cohort","02Jan2022","BNT162b2 (Pfizer BioNTech)","included","1","1","28-90","symptomatic disease","symptomatic","UK","16-64 years","16-64 years",64.1,"50.1",74.1,NA,"original & alpha",NA,NA,NA,320,"UK","GBR",56,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-02,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","09/07/2021",2021-07-09
"321",56,"Whitaker","Prospective cohort","02Jan2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","symptomatic disease","symptomatic","UK","16-64 years","16-64 years",48.6,"-61.5",83.7,NA,"original & alpha","~20 weeks",NA,NA,321,"UK","GBR",56,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-02,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","09/07/2021",2021-07-09
"322",56,"Whitaker","Prospective cohort","02Jan2022","BNT162b2 (Pfizer BioNTech)","included","1","1","28-90","symptomatic disease","symptomatic","UK",">= 65 years",">= 65 years",57.7,"49.7",64.3,NA,"original & alpha",NA,NA,NA,322,"UK","GBR",56,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-02,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","09/07/2021",2021-07-09
"323",56,"Whitaker","Prospective cohort","02Jan2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","symptomatic disease","symptomatic","UK",">= 65 years",">= 65 years",84.7,"77.7",89.5,NA,"original & alpha","~20 weeks",NA,NA,323,"UK","GBR",56,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-02,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","09/07/2021",2021-07-09
"324",56,"Whitaker","Prospective cohort","02Jan2022","BNT162b2 (Pfizer BioNTech)","included","1","1","28-90","symptomatic disease","symptomatic","UK","immunosuprressed","immunocompromised, >= 16 years",24.3,"-5.9",46,NA,"alpha",NA,NA,NA,324,"UK","GBR",56,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-02,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","09/07/2021",2021-07-09
"325",56,"Whitaker","Prospective cohort","02Jan2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","symptomatic disease","symptomatic","UK","immunosuprressed","immunocompromised, >= 16 years",59.6,"-35.5",86.3,NA,"alpha","~8 weeks",NA,NA,325,"UK","GBR",56,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-02,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","09/07/2021",2021-07-09
"326",56,"Whitaker","Prospective cohort","02Jan2022","AZD1222 (AstraZeneca)","included","1","1","28-90","symptomatic disease","symptomatic","UK","16-64 years","16-64 years",65.3,"56.2",72.5,NA,"alpha",NA,NA,NA,326,"UK","GBR",56,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-02,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","09/07/2021",2021-07-09
"327",56,"Whitaker","Prospective cohort","02Jan2022","AZD1222 (AstraZeneca)","included","2","final","14+","symptomatic disease","symptomatic","UK","16-64 years","16-64 years",67.9,"-1.1",89.8,NA,"alpha","~8 weeks",NA,NA,327,"UK","GBR",56,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-02,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","09/07/2021",2021-07-09
"328",56,"Whitaker","Prospective cohort","02Jan2022","AZD1222 (AstraZeneca)","included","1","1","28-90","symptomatic disease","symptomatic","UK",">= 65 years",">= 65 years",59.8,"49.2",68.2,NA,"alpha",NA,NA,NA,328,"UK","GBR",56,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-02,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","09/07/2021",2021-07-09
"329",56,"Whitaker","Prospective cohort","02Jan2022","AZD1222 (AstraZeneca)","included","2","final","14+","symptomatic disease","symptomatic","UK",">= 65 years",">= 65 years",81.7,"59.6",91.7,NA,"alpha","~8 weeks",NA,NA,329,"UK","GBR",56,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-02,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","09/07/2021",2021-07-09
"330",56,"Whitaker","Prospective cohort","02Jan2022","AZD1222 (AstraZeneca)","included","1","1","28-90","symptomatic disease","symptomatic","UK","immunosuprressed","immunocompromised, >= 16 years",22.5,"-15.2",47.9,NA,"alpha",NA,NA,NA,330,"UK","GBR",56,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-02,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","09/07/2021",2021-07-09
"331",56,"Whitaker","Prospective cohort","02Jan2022","AZD1222 (AstraZeneca)","included","2","final","14+","symptomatic disease","symptomatic","UK","immunosuprressed","immunocompromised, >= 16 years",60,"-63.6",90.2,NA,"alpha","~8 weeks",NA,NA,331,"UK","GBR",56,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-02,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","09/07/2021",2021-07-09
"332",57,"Prunas","Retrospective cohort","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1+","1+","10+ including <10 days post dose 2","infection ","infection","Israel","HHC of cases","HHC of cases",62.7,"61.5",63.8,NA,"original & alpha",NA,NA,NA,332,"Israel","ISR",57,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","16/07/2021",2021-07-16
"333",57,"Prunas","Retrospective cohort","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","10-90","infection ","infection","Israel","HHC of cases","HHC of cases",89.4,"88.7",90,NA,"original & alpha","~11 weeks",NA,NA,333,"Israel","ISR",57,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","16/07/2021",2021-07-16
"334",57,"Prunas","Retrospective cohort","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","90+","infection ","infection","Israel","HHC of cases","HHC of cases",58.3,"45.8",67.9,NA,"original & alpha","~26.5 weeks",NA,NA,334,"Israel","ISR",57,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","16/07/2021",2021-07-16
"335",57,"Prunas","Retrospective cohort","27Jan2022","BNT162b2 (Pfizer BioNTech)","1+","1+","1+","10+ including <10 days post dose 2","infection ","infection","Israel","HHC of cases","HHC of cases",72.1,"66.7",75.6,NA,"delta",NA,NA,NA,335,"Israel","ISR",57,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","16/07/2021",2021-07-16
"336",57,"Prunas","Retrospective cohort","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","10-90","infection ","infection","Israel","HHC of cases","HHC of cases",72,"65.9",77,NA,"delta","~11 weeks",NA,NA,336,"Israel","ISR",57,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","16/07/2021",2021-07-16
"337",57,"Prunas","Retrospective cohort","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","90+","infection ","infection","Israel","HHC of cases","HHC of cases",40.2,"37.6",42.6,NA,"delta","~26.5 weeks",NA,NA,337,"Israel","ISR",57,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","16/07/2021",2021-07-16
"338",58,"Butt","Retrospective cohort","07Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection ","infection","Qatar","pregnant women","pregnant persons",87.7,"43.5",97.3,NA,"alpha & beta","~17 weeks",NA,NA,338,"Qatar","QAT",58,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-10-07,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","22/06/2021",2021-06-22
"339",58,"Butt","Retrospective cohort","07Oct2021","mRNA-1273 (Moderna)","excluded","2","final","14+","infection ","infection","Qatar","pregnant women","pregnant persons",100,"0",100,NA,"alpha & beta","~17 weeks",NA,NA,339,"Qatar","QAT",58,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-10-07,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","22/06/2021",2021-06-22
"340",59,"Balicer","Prospective cohort","07Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","infection ","infection","Israel","pregnant women","pregnant persons",67,"40",84,NA,"original & alpha",NA,NA,NA,340,"Israel","ISR",59,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-07,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","12/07/2021",2021-07-12
"341",59,"Balicer","Prospective cohort","07Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-56","infection ","infection","Israel","pregnant women","pregnant persons",96,"89",100,NA,"original & alpha","~18 weeks",NA,NA,341,"Israel","ISR",59,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-07,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","12/07/2021",2021-07-12
"342",59,"Balicer","Prospective cohort","07Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21-27","infection ","infection","Israel","pregnant women","pregnant persons",71,"33",94,NA,"original & alpha",NA,NA,NA,342,"Israel","ISR",59,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-07,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","12/07/2021",2021-07-12
"343",59,"Balicer","Prospective cohort","07Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","symptomatic disease","symptomatic","Israel","pregnant women","pregnant persons",66,"32",86,NA,"original & alpha",NA,NA,NA,343,"Israel","ISR",59,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-07,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","12/07/2021",2021-07-12
"344",59,"Balicer","Prospective cohort","07Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-56","symptomatic disease","symptomatic","Israel","pregnant women","pregnant persons",97,"91",100,NA,"original & alpha","~18 weeks",NA,NA,344,"Israel","ISR",59,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-07,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","12/07/2021",2021-07-12
"345",59,"Balicer","Prospective cohort","07Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21-27","symptomatic disease","symptomatic","Israel","pregnant women","pregnant persons",76,"30",100,NA,"original & alpha",NA,NA,NA,345,"Israel","ISR",59,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-07,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","12/07/2021",2021-07-12
"346",59,"Balicer","Prospective cohort","07Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-56","hospitalization","severe","Israel","pregnant women","pregnant persons",89,"43",100,NA,"original & alpha","~18 weeks",NA,NA,346,"Israel","ISR",59,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-07,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","12/07/2021",2021-07-12
"347",60,"Layan","Prospective cohort","03Mar2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","infection ","infection","Israel","HHC of cases","HHC of cases",79,"56",92,NA,"original & alpha","~12 weeks",NA,NA,347,"Israel","ISR",60,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-03,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","16/07/2021",2021-07-16
"348",61,"Butt","Test-negative case-control","20Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","0+","infection ","infection","USA","general pop","general pop",85,"84.2",85.8,NA,"original & alpha",NA,NA,NA,348,"USA","USA",61,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-07-20,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-07-20
"349",61,"Butt","Test-negative case-control","20Jul2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","infection ","infection","USA","general pop","general pop",97.1,"96.6",97.5,NA,"original & alpha","~6.5 weeks",NA,NA,349,"USA","USA",61,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-07-20,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-07-20
"350",61,"Butt","Test-negative case-control","20Jul2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","0+","infection ","infection","USA","general pop","general pop",84,"82.7",85.1,NA,"original & alpha",NA,NA,NA,350,"USA","USA",61,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-07-20,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-07-20
"351",61,"Butt","Test-negative case-control","20Jul2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","infection ","infection","USA","general pop","general pop",96.2,"95.5",96.9,NA,"original & alpha","~6.5 weeks",NA,NA,351,"USA","USA",61,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-07-20,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-07-20
"352",61,"Butt","Test-negative case-control","20Jul2021","mRNA-1273 (Moderna)","excluded","1","1","0+","infection ","infection","USA","general pop","general pop",85.7,"84.6",86.8,NA,"original & alpha",NA,NA,NA,352,"USA","USA",61,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-07-20,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-07-20
"353",61,"Butt","Test-negative case-control","20Jul2021","mRNA-1273 (Moderna)","excluded","2","final","7+","infection ","infection","USA","general pop","general pop",98.2,"97.5",98.6,NA,"original & alpha","~6.5 weeks",NA,NA,353,"USA","USA",61,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-07-20,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-07-20
"354",62,"Lopez Bernal","Test-negative case-control","21Jul2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21+","symptomatic disease","symptomatic","UK","general pop","general pop",47.5,"41.6",52.8,"alpha","alpha",NA,NA,NA,354,"UK","GBR",62,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-07-21,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-07-21
"355",62,"Lopez Bernal","Test-negative case-control","21Jul2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","UK","general pop","general pop",93.7,"91.6",95.3,"alpha","alpha","~17 weeks",NA,NA,355,"UK","GBR",62,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-07-21,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-07-21
"356",62,"Lopez Bernal","Test-negative case-control","21Jul2021","AZD1222 (AstraZeneca)","excluded","1","1","21+","symptomatic disease","symptomatic","UK","general pop","general pop",48.7,"45.2",51.9,"alpha","alpha",NA,NA,NA,356,"UK","GBR",62,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-07-21,"symptomatic","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-07-21
"357",62,"Lopez Bernal","Test-negative case-control","21Jul2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","symptomatic disease","symptomatic","UK","general pop","general pop",74.5,"68.4",79.4,"alpha","alpha","~17 weeks",NA,NA,357,"UK","GBR",62,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-07-21,"symptomatic","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-07-21
"358",62,"Lopez Bernal","Test-negative case-control","21Jul2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21+","symptomatic disease","symptomatic","UK","general pop","general pop",35.6,"22.7",46.4,"delta","delta",NA,NA,NA,358,"UK","GBR",62,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-07-21,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-07-21
"359",62,"Lopez Bernal","Test-negative case-control","21Jul2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","UK","general pop","general pop",88,"85.3",90.1,"delta","delta","~17 weeks",NA,NA,359,"UK","GBR",62,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-07-21,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-07-21
"360",62,"Lopez Bernal","Test-negative case-control","21Jul2021","AZD1222 (AstraZeneca)","excluded","1","1","21+","symptomatic disease","symptomatic","UK","general pop","general pop",30,"24.3",35.3,"delta","delta",NA,NA,NA,360,"UK","GBR",62,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-07-21,"symptomatic","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-07-21
"361",62,"Lopez Bernal","Test-negative case-control","21Jul2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","symptomatic disease","symptomatic","UK","general pop","general pop",67,"61.3",71.8,"delta","delta","~17 weeks",NA,NA,361,"UK","GBR",62,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-07-21,"symptomatic","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-07-21
"362",63,"Kim","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","1+","1+","14+ up to <14 days post dose 2","symptomatic disease","symptomatic","USA","general pop","general pop",75,"55",87,NA,"non-VOC & alpha",NA,NA,NA,362,"USA","USA",63,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-08,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","22/07/2021",2021-07-22
"363",63,"Kim","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","14+","symptomatic disease","symptomatic","USA","general pop","general pop",91,"83",95,NA,"non-VOC & alpha","~18.5 weeks",NA,NA,363,"USA","USA",63,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-08,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","22/07/2021",2021-07-22
"364",64,"Hitchings","Test-negative case-control","28Oct2021","AZD1222 (AstraZeneca)","included","1","1","28+","symptomatic disease","symptomatic","Brazil","> 60 years","> 60 years",33.4,"26.4",39.7,NA,"gamma",NA,NA,NA,364,"Brazil","BRA",64,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2021-10-28,"symptomatic","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma","22/07/2021",2021-07-22
"365",64,"Hitchings","Test-negative case-control","28Oct2021","AZD1222 (AstraZeneca)","included","2","final","14+","symptomatic disease","symptomatic","Brazil","> 60 years","> 60 years",77.9,"69.2",84.2,NA,"gamma","~9.5 weeks",NA,NA,365,"Brazil","BRA",64,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2021-10-28,"symptomatic","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma","22/07/2021",2021-07-22
"366",64,"Hitchings","Test-negative case-control","28Oct2021","AZD1222 (AstraZeneca)","included","1","1","28+","hospitalization","severe","Brazil","> 60 years","> 60 years",55.1,"46.6",62.2,NA,"gamma",NA,NA,NA,366,"Brazil","BRA",64,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2021-10-28,"severe","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma","22/07/2021",2021-07-22
"367",64,"Hitchings","Test-negative case-control","28Oct2021","AZD1222 (AstraZeneca)","included","2","final","14+","hospitalization","severe","Brazil","> 60 years","> 60 years",87.6,"78.2",92.9,NA,"gamma","~9.5 weeks",NA,NA,367,"Brazil","BRA",64,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2021-10-28,"severe","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma","22/07/2021",2021-07-22
"368",64,"Hitchings","Test-negative case-control","28Oct2021","AZD1222 (AstraZeneca)","included","1","1","28+","death","death","Brazil","> 60 years","> 60 years",61.8,"48.9",71.4,NA,"gamma",NA,NA,NA,368,"Brazil","BRA",64,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2021-10-28,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma","22/07/2021",2021-07-22
"369",64,"Hitchings","Test-negative case-control","28Oct2021","AZD1222 (AstraZeneca)","included","2","final","14+","death","death","Brazil","> 60 years","> 60 years",93.6,"81.9",97.7,NA,"gamma","~9.5 weeks",NA,NA,369,"Brazil","BRA",64,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2021-10-28,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma","22/07/2021",2021-07-22
"370",65,"Carazo","Test-negative case-control","30Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","infection ","infection","Canada","HCW","HCW",70.3,"68.1",72.4,NA,"non-VOC & alpha",NA,NA,NA,370,"Canada","CAN",65,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-30,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","22/07/2021",2021-07-22
"371",65,"Carazo","Test-negative case-control","30Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","infection ","infection","Canada","HCW","HCW",85.5,"80.4",89.3,NA,"non-VOC & alpha","~20 weeks",NA,NA,371,"Canada","CAN",65,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-30,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","22/07/2021",2021-07-22
"372",65,"Carazo","Test-negative case-control","30Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","symptomatic disease","symptomatic","Canada","HCW","HCW",72.8,"70.5",74.9,NA,"non-VOC & alpha",NA,NA,NA,372,"Canada","CAN",65,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-30,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","22/07/2021",2021-07-22
"373",65,"Carazo","Test-negative case-control","30Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","symptomatic disease","symptomatic","Canada","HCW","HCW",92.2,"87.8",95.1,NA,"non-VOC & alpha","~20 weeks",NA,NA,373,"Canada","CAN",65,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-30,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","22/07/2021",2021-07-22
"374",65,"Carazo","Test-negative case-control","30Aug2021","mRNA-1273 (Moderna)","excluded","1","1","14+","infection ","infection","Canada","HCW","HCW",68.7,"59.5",75.9,NA,"non-VOC & alpha",NA,NA,NA,374,"Canada","CAN",65,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-30,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","22/07/2021",2021-07-22
"375",65,"Carazo","Test-negative case-control","30Aug2021","mRNA-1273 (Moderna)","excluded","2","final","7+","infection ","infection","Canada","HCW","HCW",84.1,"34.9",96.1,NA,"non-VOC & alpha","~20 weeks",NA,NA,375,"Canada","CAN",65,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-30,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","22/07/2021",2021-07-22
"376",65,"Carazo","Test-negative case-control","30Aug2021","mRNA-1273 (Moderna)","excluded","1","1","14+","symptomatic disease","symptomatic","Canada","HCW","HCW",80.9,"74.3",85.8,NA,"non-VOC & alpha",NA,NA,NA,376,"Canada","CAN",65,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-30,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","22/07/2021",2021-07-22
"377",65,"Carazo","Test-negative case-control","30Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","hospitalization","severe","Canada","HCW","HCW",97.2,"92.3",99,NA,"non-VOC & alpha",NA,NA,NA,377,"Canada","CAN",65,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-30,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","22/07/2021",2021-07-22
"378",65,"Carazo","Test-negative case-control","30Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","infection ","infection","Canada","HCW","HCW",60,"53.6",65.5,"alpha","alpha",NA,NA,NA,378,"Canada","CAN",65,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-30,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","22/07/2021",2021-07-22
"379",65,"Carazo","Test-negative case-control","30Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","infection ","infection","Canada","HCW","HCW",92.6,"87.1",95.8,"alpha","alpha","~20 weeks",NA,NA,379,"Canada","CAN",65,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-30,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","22/07/2021",2021-07-22
"380",65,"Carazo","Test-negative case-control","30Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","infection ","infection","Canada","HCW","HCW",77,"72.6",80.7,"non-VOC","non-VOC",NA,NA,NA,380,"Canada","CAN",65,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-30,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","original","22/07/2021",2021-07-22
"381",65,"Carazo","Test-negative case-control","30Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","infection ","infection","Canada","HCW","HCW",86.5,"56.8",95.8,"non-VOC","non-VOC","~20 weeks",NA,NA,381,"Canada","CAN",65,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-08-30,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","original","22/07/2021",2021-07-22
"382",67,"Amirthalingam","Test-negative case-control","10Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","28+","infection ","infection","UK","> 80 years","> 80 years",42,"31",52,NA,"alpha",NA,NA,NA,385,"UK","GBR",67,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","28/07/2021",2021-07-28
"383",67,"Amirthalingam","Test-negative case-control","10Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection ","infection","UK","> 80 years","> 80 years",77,"56",88,NA,"alpha","~16 weeks","19-29 days",NA,386,"UK","GBR",67,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","28/07/2021",2021-07-28
"384",67,"Amirthalingam","Test-negative case-control","10Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","1","14+","infection ","infection","UK","> 80 years","> 80 years",90,"83",94,NA,"alpha",NA,"65-84 days",NA,387,"UK","GBR",67,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","28/07/2021",2021-07-28
"385",67,"Amirthalingam","Test-negative case-control","10Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","1","final","28+","infection ","infection","UK","65-79 years","65-79 years",53,"48",58,NA,"alpha","~16 weeks",NA,NA,388,"UK","GBR",67,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","28/07/2021",2021-07-28
"386",67,"Amirthalingam","Test-negative case-control","10Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection ","infection","UK","65-79 years","65-79 years",77,"66",85,NA,"alpha","~16 weeks","19-29 days",NA,389,"UK","GBR",67,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","28/07/2021",2021-07-28
"387",67,"Amirthalingam","Test-negative case-control","10Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection ","infection","UK","65-79 years","65-79 years",89,"86",92,NA,"alpha","~16 weeks","65-84 days",NA,390,"UK","GBR",67,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","28/07/2021",2021-07-28
"388",67,"Amirthalingam","Test-negative case-control","10Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","28+","infection ","infection","UK","50-64 years","50-64 years",51,"47",55,NA,"alpha",NA,NA,NA,391,"UK","GBR",67,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","28/07/2021",2021-07-28
"389",67,"Amirthalingam","Test-negative case-control","10Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection ","infection","UK","50-64 years","50-64 years",88,"67",96,NA,"alpha","~16 weeks","19-29 days",NA,392,"UK","GBR",67,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","28/07/2021",2021-07-28
"390",67,"Amirthalingam","Test-negative case-control","10Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection ","infection","UK","50-64 years","50-64 years",92,"91",94,NA,"alpha","~16 weeks","65-84 days",NA,393,"UK","GBR",67,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","28/07/2021",2021-07-28
"391",67,"Amirthalingam","Test-negative case-control","10Dec2021","AZD1222 (AstraZeneca)","excluded","1","1","28+","infection ","infection","UK","> 80 years","> 80 years",42,"29",53,NA,"alpha",NA,NA,NA,394,"UK","GBR",67,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","28/07/2021",2021-07-28
"392",67,"Amirthalingam","Test-negative case-control","10Dec2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection ","infection","UK","> 80 years","> 80 years",96,"68",99,NA,"alpha","~16 weeks","45-64 days",NA,395,"UK","GBR",67,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","28/07/2021",2021-07-28
"393",67,"Amirthalingam","Test-negative case-control","10Dec2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection ","infection","UK","> 80 years","> 80 years",82,"68",89,NA,"alpha","~16 weeks","65-84 days",NA,396,"UK","GBR",67,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","28/07/2021",2021-07-28
"394",67,"Amirthalingam","Test-negative case-control","10Dec2021","AZD1222 (AstraZeneca)","excluded","1","1","28+","infection ","infection","UK","65-79 years","65-79 years",52,"46",56,NA,"alpha",NA,NA,NA,397,"UK","GBR",67,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","28/07/2021",2021-07-28
"395",67,"Amirthalingam","Test-negative case-control","10Dec2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection ","infection","UK","65-79 years","65-79 years",73,"25",90,NA,"alpha","~16 weeks","30-44 days",NA,398,"UK","GBR",67,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","28/07/2021",2021-07-28
"396",67,"Amirthalingam","Test-negative case-control","10Dec2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection ","infection","UK","65-79 years","65-79 years",74,"69",79,NA,"alpha","~16 weeks","65-84 days",NA,399,"UK","GBR",67,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","28/07/2021",2021-07-28
"397",67,"Amirthalingam","Test-negative case-control","10Dec2021","AZD1222 (AstraZeneca)","excluded","1","1","28+","infection ","infection","UK","50-64 years","50-64 years",42,"39",46,NA,"alpha",NA,NA,NA,400,"UK","GBR",67,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","28/07/2021",2021-07-28
"398",67,"Amirthalingam","Test-negative case-control","10Dec2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection ","infection","UK","50-64 years","50-64 years",55,"34",69,NA,"alpha","~16 weeks","30-44 days",NA,401,"UK","GBR",67,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","28/07/2021",2021-07-28
"399",67,"Amirthalingam","Test-negative case-control","10Dec2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection ","infection","UK","50-64 years","50-64 years",77,"74",79,NA,"alpha","~16 weeks","65-84 days",NA,402,"UK","GBR",67,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-12-10,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","28/07/2021",2021-07-28
"400",68,"Gram","Retrospective cohort","17Dec2021","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","1","1","14-20","infection ","infection","Denmark","general pop","general pop",39,"23",52,NA,"alpha",NA,NA,NA,403,"Denmark","DNK",68,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-17,"infection","2021 (Jul-Dec)","Heterologous platforms","Multiple","alpha","28/07/2021",2021-07-28
"401",68,"Gram","Retrospective cohort","17Dec2021","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14+","infection ","infection","Denmark","general pop","general pop",88,"83",92,NA,"alpha","~20 weeks",NA,NA,404,"Denmark","DNK",68,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-17,"infection","2021 (Jul-Dec)","Heterologous platforms","Multiple","alpha","28/07/2021",2021-07-28
"402",68,"Gram","Retrospective cohort","17Dec2021","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","1","1","105+","infection ","infection","Denmark","general pop","general pop",-47,"-208",30,NA,"alpha",NA,NA,NA,405,"Denmark","DNK",68,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-17,"infection","2021 (Jul-Dec)","Heterologous platforms","Multiple","alpha","28/07/2021",2021-07-28
"403",68,"Gram","Retrospective cohort","17Dec2021","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","1","1","14+","hospitalization","severe","Denmark","general pop","general pop",93,"80",98,NA,"alpha",NA,NA,NA,406,"Denmark","DNK",68,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-17,"severe","2021 (Jul-Dec)","Heterologous platforms","Multiple","alpha","28/07/2021",2021-07-28
"404",69,"Alali","Retrospective cohort","29Jul2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","infection ","infection","Kuwait","HCW","HCW",91.4,"65.1",97.9,NA,"alpha",NA,NA,NA,407,"Kuwait","KWT",69,"KWT",35680,2019,"Kuwait","Middle East & North Africa","High income",4,"Asia",2020-12-28,2021-11-30,2021-11-30,2020-12-28,2020-12-28,0,337,337,"equal","before jan/2021","Sep-Nov/2021","270-359","yes","yes","yes",2021-07-29,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-07-29
"405",69,"Alali","Retrospective cohort","29Jul2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","infection ","infection","Kuwait","HCW","HCW",94.5,"89.4",97.2,NA,"alpha","~18 weeks",NA,NA,408,"Kuwait","KWT",69,"KWT",35680,2019,"Kuwait","Middle East & North Africa","High income",4,"Asia",2020-12-28,2021-11-30,2021-11-30,2020-12-28,2020-12-28,0,337,337,"equal","before jan/2021","Sep-Nov/2021","270-359","yes","yes","yes",2021-07-29,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-07-29
"406",69,"Alali","Retrospective cohort","29Jul2021","AZD1222 (AstraZeneca)","excluded","1","1","28+","infection ","infection","Kuwait","HCW","HCW",75.4,"67.2",81.6,NA,"alpha",NA,NA,NA,409,"Kuwait","KWT",69,"KWT",35680,2019,"Kuwait","Middle East & North Africa","High income",4,"Asia",2020-12-28,2021-11-30,2021-11-30,2020-12-28,2020-12-28,0,337,337,"equal","before jan/2021","Sep-Nov/2021","270-359","yes","yes","yes",2021-07-29,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-07-29
"407",70,"Lefèvre","Retrospective cohort","31Jul2021","BNT162b2 (Pfizer BioNTech)","included","1+","1+","14+ up to t days after 2nd dose","infection ","infection","France","LTCF residents","LTCF residents",55,"13",76,"beta","beta",NA,NA,NA,410,"France","FRA",70,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-07-31,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta",NA,2021-07-31
"408",70,"Lefèvre","Retrospective cohort","31Jul2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","infection ","infection","France","LTCF residents","LTCF residents",49,"14",69,"beta","beta","~16 weeks",NA,NA,411,"France","FRA",70,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-07-31,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta",NA,2021-07-31
"409",70,"Lefèvre","Retrospective cohort","31Jul2021","BNT162b2 (Pfizer BioNTech)","included","1+","1+","14+ up to t days after 2nd dose","hospitalization or death","severe","France","LTCF residents","LTCF residents",86,"32",97,"beta","beta",NA,NA,NA,412,"France","FRA",70,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-07-31,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta",NA,2021-07-31
"410",70,"Lefèvre","Retrospective cohort","31Jul2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","hospitalization or death","severe","France","LTCF residents","LTCF residents",86,"67",94,"beta","beta","~16 weeks",NA,NA,413,"France","FRA",70,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-07-31,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta",NA,2021-07-31
"411",71,"de Gier","Retrospective cohort","05Aug2021","AZD1222 (AstraZeneca)","unknown","1","1","14+","infection ","infection","Netherlands","HHC of cases","HHC of cases",2,"-11",14,NA,"alpha",NA,NA,NA,414,"Netherlands","NLD",71,"NLD",51920,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,198,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2021-08-05,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-08-05
"412",71,"de Gier","Retrospective cohort","05Aug2021","AZD1222 (AstraZeneca)","unknown","2","final","7+","infection ","infection","Netherlands","HHC of cases","HHC of cases",87,"77",93,NA,"alpha","~15 weeks",NA,NA,415,"Netherlands","NLD",71,"NLD",51920,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,198,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2021-08-05,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-08-05
"413",71,"de Gier","Retrospective cohort","05Aug2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","infection ","infection","Netherlands","HHC of cases","HHC of cases",-18,"-43",2,NA,"alpha",NA,NA,NA,416,"Netherlands","NLD",71,"NLD",51920,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,198,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2021-08-05,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-08-05
"414",71,"de Gier","Retrospective cohort","05Aug2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","7+","infection ","infection","Netherlands","HHC of cases","HHC of cases",65,"60",70,NA,"alpha","~15 weeks",NA,NA,417,"Netherlands","NLD",71,"NLD",51920,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,198,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2021-08-05,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-08-05
"415",71,"de Gier","Retrospective cohort","05Aug2021","mRNA-1273 (Moderna)","unknown","1","1","14+","infection ","infection","Netherlands","HHC of cases","HHC of cases",33,"-27",64,NA,"alpha",NA,NA,NA,418,"Netherlands","NLD",71,"NLD",51920,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,198,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2021-08-05,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-08-05
"416",71,"de Gier","Retrospective cohort","05Aug2021","mRNA-1273 (Moderna)","unknown","2","final","7+","infection ","infection","Netherlands","HHC of cases","HHC of cases",91,"79",97,NA,"alpha","~15 weeks",NA,NA,419,"Netherlands","NLD",71,"NLD",51920,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,198,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2021-08-05,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-08-05
"417",71,"de Gier","Retrospective cohort","05Aug2021","Ad26.COV2.S (Janssen)","unknown","1","final","14+","infection ","infection","Netherlands","HHC of cases","HHC of cases",12,"-71",54,NA,"alpha","~15 weeks",NA,NA,420,"Netherlands","NLD",71,"NLD",51920,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,198,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2021-08-05,"infection","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","alpha",NA,2021-08-05
"418",72,"Puranik","Retrospective cohort","09Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","1-7","infection ","infection","USA","general pop","general pop",16,"-20",42,NA,"alpha & delta",NA,NA,NA,421,"USA","USA",72,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-08-09,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-08-09
"419",72,"Puranik","Retrospective cohort","09Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection ","infection","USA","general pop","general pop",76,"69",81,NA,"alpha & delta","~26 weeks",NA,NA,422,"USA","USA",72,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-08-09,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-08-09
"420",72,"Puranik","Retrospective cohort","09Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","1-7","hospitalization","severe","USA","general pop","general pop",75,"-30",97.4,NA,"alpha & delta",NA,NA,NA,423,"USA","USA",72,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-08-09,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-08-09
"421",72,"Puranik","Retrospective cohort","09Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","USA","general pop","general pop",85,"73",93,NA,"alpha & delta","~26 weeks",NA,NA,424,"USA","USA",72,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-08-09,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-08-09
"422",72,"Puranik","Retrospective cohort","09Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","1-7","ICU admission","severe","USA","general pop","general pop",100,"-430",100,NA,"alpha & delta",NA,NA,NA,425,"USA","USA",72,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-08-09,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-08-09
"423",72,"Puranik","Retrospective cohort","09Aug2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","ICU admission","severe","USA","general pop","general pop",87,"46",98.6,NA,"alpha & delta","~26 weeks",NA,NA,426,"USA","USA",72,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-08-09,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-08-09
"424",72,"Puranik","Retrospective cohort","09Aug2021","mRNA-1273 (Moderna)","excluded","1","1","1-7","infection ","infection","USA","general pop","general pop",-10,"-50",24,NA,"alpha & delta",NA,NA,NA,427,"USA","USA",72,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-08-09,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-08-09
"425",72,"Puranik","Retrospective cohort","09Aug2021","mRNA-1273 (Moderna)","excluded","2","final","14+","infection ","infection","USA","general pop","general pop",86,"81",90.6,NA,"alpha & delta","~26 weeks",NA,NA,428,"USA","USA",72,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-08-09,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-08-09
"426",72,"Puranik","Retrospective cohort","09Aug2021","mRNA-1273 (Moderna)","excluded","1","1","1-7","hospitalization","severe","USA","general pop","general pop",25,"-150",79,NA,"alpha & delta",NA,NA,NA,429,"USA","USA",72,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-08-09,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-08-09
"427",72,"Puranik","Retrospective cohort","09Aug2021","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA","general pop","general pop",91.6,"81",97,NA,"alpha & delta","~26 weeks",NA,NA,430,"USA","USA",72,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-08-09,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-08-09
"428",72,"Puranik","Retrospective cohort","09Aug2021","mRNA-1273 (Moderna)","excluded","1","1","1-7","ICU admission","severe","USA","general pop","general pop",100,"-430",100,NA,"alpha & delta",NA,NA,NA,431,"USA","USA",72,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-08-09,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-08-09
"429",72,"Puranik","Retrospective cohort","09Aug2021","mRNA-1273 (Moderna)","excluded","2","final","14+","ICU admission","severe","USA","general pop","general pop",93.3,"57",99.8,NA,"alpha & delta","~26 weeks",NA,NA,432,"USA","USA",72,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-08-09,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-08-09
"430",73,"Chemaitelly","Retrospective cohort","09Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection ","infection","Qatar","transplant patients","transplant patients",46.6,"0",73.7,NA,"alpha & beta","~17 weeks",NA,NA,433,"Qatar","QAT",73,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-08-09,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-08-09
"431",73,"Chemaitelly","Retrospective cohort","09Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","42+","infection ","infection","Qatar","transplant patients","transplant patients",66,"21.3",85.3,NA,"alpha & beta","~17 weeks",NA,NA,434,"Qatar","QAT",73,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-08-09,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-08-09
"432",73,"Chemaitelly","Retrospective cohort","09Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","56+","infection ","infection","Qatar","transplant patients","transplant patients",73.9,"33",89.9,NA,"alpha & beta","~17 weeks",NA,NA,435,"Qatar","QAT",73,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-08-09,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-08-09
"433",73,"Chemaitelly","Retrospective cohort","09Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","severe infection","severe","Qatar","transplant patients","transplant patients",72.3,"0",90.9,NA,"alpha & beta","~17 weeks",NA,NA,436,"Qatar","QAT",73,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-08-09,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-08-09
"434",73,"Chemaitelly","Retrospective cohort","09Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","42+","severe infection","severe","Qatar","transplant patients","transplant patients",85,"35.7",96.5,NA,"alpha & beta","~17 weeks",NA,NA,437,"Qatar","QAT",73,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-08-09,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-08-09
"435",73,"Chemaitelly","Retrospective cohort","09Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","56+","severe infection","severe","Qatar","transplant patients","transplant patients",83.8,"31.3",96.2,NA,"alpha & beta","~17 weeks",NA,NA,438,"Qatar","QAT",73,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-08-09,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-08-09
"436",74,"Tang","Test-negative case-control","02Nov2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","infection ","infection","Qatar","general pop","general pop",42.8,"18.2",60.1,"delta","delta",NA,NA,NA,439,"Qatar","QAT",74,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-11-02,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","11/08/2021",2021-08-11
"437",74,"Tang","Test-negative case-control","02Nov2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection ","infection","Qatar","general pop","general pop",50.6,"45.4",55.3,"delta","delta","~25 weeks",NA,NA,440,"Qatar","QAT",74,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-11-02,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","11/08/2021",2021-08-11
"438",74,"Tang","Test-negative case-control","02Nov2021","mRNA-1273 (Moderna)","included","1","1","14+","infection ","infection","Qatar","general pop","general pop",73.2,"57.3",83.2,"delta","delta",NA,NA,NA,441,"Qatar","QAT",74,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-11-02,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","11/08/2021",2021-08-11
"439",74,"Tang","Test-negative case-control","02Nov2021","mRNA-1273 (Moderna)","included","2","final","14+","infection ","infection","Qatar","general pop","general pop",72,"66.1",76.9,"delta","delta","~25 weeks",NA,NA,442,"Qatar","QAT",74,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-11-02,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","11/08/2021",2021-08-11
"440",74,"Tang","Test-negative case-control","02Nov2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","severe, critical, fatal disease","severe","Qatar","general pop","general pop",84.5,"-25.2",98.1,"delta","delta",NA,NA,NA,443,"Qatar","QAT",74,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-11-02,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","11/08/2021",2021-08-11
"441",74,"Tang","Test-negative case-control","02Nov2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","severe, critical, fatal disease","severe","Qatar","general pop","general pop",94.1,"85.9",97.6,"delta","delta","~25 weeks",NA,NA,444,"Qatar","QAT",74,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-11-02,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","11/08/2021",2021-08-11
"442",74,"Tang","Test-negative case-control","02Nov2021","mRNA-1273 (Moderna)","included","1","1","14+","severe, critical, fatal disease","severe","Qatar","general pop","general pop",87.5,"23.4",95.8,"delta","delta",NA,NA,NA,445,"Qatar","QAT",74,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-11-02,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","11/08/2021",2021-08-11
"443",74,"Tang","Test-negative case-control","02Nov2021","mRNA-1273 (Moderna)","included","2","final","14+","severe, critical, fatal disease","severe","Qatar","general pop","general pop",96.1,"71.4",99.5,"delta","delta","~25 weeks",NA,NA,446,"Qatar","QAT",74,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-11-02,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","11/08/2021",2021-08-11
"444",74,"Tang","Test-negative case-control","02Nov2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","symptomatic disease","symptomatic","Qatar","general pop","general pop",56.2,"30.6",72.4,"delta","delta",NA,NA,NA,447,"Qatar","QAT",74,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-11-02,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","11/08/2021",2021-08-11
"445",74,"Tang","Test-negative case-control","02Nov2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","symptomatic disease","symptomatic","Qatar","general pop","general pop",44.4,"37",50.9,"delta","delta","~25 weeks",NA,NA,448,"Qatar","QAT",74,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-11-02,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","11/08/2021",2021-08-11
"446",74,"Tang","Test-negative case-control","02Nov2021","mRNA-1273 (Moderna)","included","1","1","14+","symptomatic disease","symptomatic","Qatar","general pop","general pop",82.5,"65.2",91.2,"delta","delta",NA,NA,NA,449,"Qatar","QAT",74,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-11-02,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","11/08/2021",2021-08-11
"447",74,"Tang","Test-negative case-control","02Nov2021","mRNA-1273 (Moderna)","included","2","final","14+","symptomatic disease","symptomatic","Qatar","general pop","general pop",73.9,"65.9",79.9,"delta","delta","~25 weeks",NA,NA,450,"Qatar","QAT",74,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-11-02,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","11/08/2021",2021-08-11
"448",74,"Tang","Test-negative case-control","02Nov2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","asymptomatic infection","asymptomatic","Qatar","general pop","general pop",46.7,"-56.2",81.8,"delta","delta",NA,NA,NA,451,"Qatar","QAT",74,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-11-02,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","11/08/2021",2021-08-11
"449",74,"Tang","Test-negative case-control","02Nov2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","asymptomatic infection","asymptomatic","Qatar","general pop","general pop",46,"32.3",56.9,"delta","delta","~25 weeks",NA,NA,452,"Qatar","QAT",74,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-11-02,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","11/08/2021",2021-08-11
"450",74,"Tang","Test-negative case-control","02Nov2021","mRNA-1273 (Moderna)","included","1","1","14+","asymptomatic infection","asymptomatic","Qatar","general pop","general pop",61.8,"-9.6",86.7,"delta","delta",NA,NA,NA,453,"Qatar","QAT",74,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-11-02,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","11/08/2021",2021-08-11
"451",74,"Tang","Test-negative case-control","02Nov2021","mRNA-1273 (Moderna)","included","2","final","14+","asymptomatic infection","asymptomatic","Qatar","general pop","general pop",53.6,"33.4",67.6,"delta","delta","~25 weeks",NA,NA,454,"Qatar","QAT",74,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-11-02,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","11/08/2021",2021-08-11
"452",74,"Tang","Test-negative case-control","02Nov2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","infection ","infection","Qatar","general pop","general pop",18.9,"-1.8",35.4,"beta","beta",NA,NA,NA,455,"Qatar","QAT",74,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-11-02,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta","11/08/2021",2021-08-11
"453",74,"Tang","Test-negative case-control","02Nov2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection ","infection","Qatar","general pop","general pop",74.3,"70.3",77.7,"beta","beta","~25 weeks",NA,NA,456,"Qatar","QAT",74,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-11-02,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta","11/08/2021",2021-08-11
"454",74,"Tang","Test-negative case-control","02Nov2021","mRNA-1273 (Moderna)","included","1","1","14+","infection ","infection","Qatar","general pop","general pop",66.3,"55.8",74.2,"beta","beta",NA,NA,NA,457,"Qatar","QAT",74,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-11-02,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","beta","11/08/2021",2021-08-11
"455",74,"Tang","Test-negative case-control","02Nov2021","mRNA-1273 (Moderna)","included","2","final","14+","infection ","infection","Qatar","general pop","general pop",80.8,"69",88.2,"beta","beta","~25 weeks",NA,NA,458,"Qatar","QAT",74,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-11-02,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","beta","11/08/2021",2021-08-11
"456",74,"Tang","Test-negative case-control","02Nov2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","severe, critical, fatal disease","severe","Qatar","general pop","general pop",74.8,"-7.6",94.1,"beta","beta",NA,NA,NA,459,"Qatar","QAT",74,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-11-02,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta","11/08/2021",2021-08-11
"457",74,"Tang","Test-negative case-control","02Nov2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","severe, critical, fatal disease","severe","Qatar","general pop","general pop",92.7,"81.5",97.1,"beta","beta","~25 weeks",NA,NA,460,"Qatar","QAT",74,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-11-02,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta","11/08/2021",2021-08-11
"458",74,"Tang","Test-negative case-control","02Nov2021","mRNA-1273 (Moderna)","included","1","1","14+","severe, critical, fatal disease","severe","Qatar","general pop","general pop",72.5,"7.7",91.8,"beta","beta",NA,NA,NA,461,"Qatar","QAT",74,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-11-02,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","beta","11/08/2021",2021-08-11
"459",74,"Tang","Test-negative case-control","02Nov2021","mRNA-1273 (Moderna)","included","2","final","14+","severe, critical, fatal disease","severe","Qatar","general pop","general pop",100,NA,NA,"beta","beta","~25 weeks",NA,NA,462,"Qatar","QAT",74,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-11-02,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","beta","11/08/2021",2021-08-11
"460",75,"Nanduri","Retrospective cohort","18Aug2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","infection ","infection","USA","SNF residents","SNF residents",74.2,"69",78.7,NA,"non-VOC & alpha","~16 weeks",NA,NA,463,"USA","USA",75,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-08-18,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-08-18
"461",75,"Nanduri","Retrospective cohort","18Aug2021","mRNA-1273 (Moderna)","unknown","2","final","14+","infection ","infection","USA","SNF residents","SNF residents",74.7,"66.2",81.1,NA,"non-VOC & alpha","~16 weeks",NA,NA,464,"USA","USA",75,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-08-18,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-08-18
"462",75,"Nanduri","Retrospective cohort","18Aug2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","infection ","infection","USA","SNF residents","SNF residents",66.5,"58.3",73.1,NA,"alpha","~22 weeks",NA,NA,465,"USA","USA",75,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-08-18,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-08-18
"463",75,"Nanduri","Retrospective cohort","18Aug2021","mRNA-1273 (Moderna)","unknown","2","final","14+","infection ","infection","USA","SNF residents","SNF residents",70.4,"60.1",78,NA,"alpha","~22 weeks",NA,NA,466,"USA","USA",75,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-08-18,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-08-18
"464",75,"Nanduri","Retrospective cohort","18Aug2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","infection ","infection","USA","SNF residents","SNF residents",52.4,"48",56.4,NA,"delta","~25 weeks",NA,NA,467,"USA","USA",75,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-08-18,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-08-18
"465",75,"Nanduri","Retrospective cohort","18Aug2021","mRNA-1273 (Moderna)","unknown","2","final","14+","infection ","infection","USA","SNF residents","SNF residents",50.6,"45",55.7,NA,"delta","~25 weeks",NA,NA,468,"USA","USA",75,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-08-18,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2021-08-18
"466",76,"Chin","Retrospective cohort","27Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","infection ","infection","USA","incarcerated persons","incarcerated persons",74,"64",82,NA,"non-VOC",NA,NA,NA,469,"USA","USA",76,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-27,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","original","18/08/2021",2021-08-18
"467",76,"Chin","Retrospective cohort","27Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection ","infection","USA","incarcerated persons","incarcerated persons",97,"88",99,NA,"non-VOC","~5 weeks",NA,NA,470,"USA","USA",76,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-27,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","original","18/08/2021",2021-08-18
"468",76,"Chin","Retrospective cohort","27Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","infection ","infection","USA","incarcerated persons, moderate/high risk for severe disease","incarcerated persons, moderate/high risk for severe disease",74,"62",82,NA,"non-VOC",NA,NA,NA,471,"USA","USA",76,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-27,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","original","18/08/2021",2021-08-18
"469",76,"Chin","Retrospective cohort","27Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection ","infection","USA","incarcerated persons, moderate/high risk for severe disease","incarcerated persons, moderate/high risk for severe disease",92,"74",98,NA,"non-VOC","~5 weeks",NA,NA,472,"USA","USA",76,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-27,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","original","18/08/2021",2021-08-18
"470",76,"Chin","Retrospective cohort","27Jan2022","mRNA-1273 (Moderna)","excluded","1","1","14+","infection ","infection","USA","incarcerated persons","incarcerated persons",71,"58",80,NA,"non-VOC",NA,NA,NA,473,"USA","USA",76,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-27,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","original","18/08/2021",2021-08-18
"471",76,"Chin","Retrospective cohort","27Jan2022","mRNA-1273 (Moderna)","excluded","2","final","14+","infection ","infection","USA","incarcerated persons","incarcerated persons",96,"67",99,NA,"non-VOC","~5 weeks",NA,NA,474,"USA","USA",76,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-27,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","original","18/08/2021",2021-08-18
"472",77,"Tenforde","Case-control","04Nov2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA","general pop","general pop",81,"77",84,NA,"alpha & delta","~30 weeks",NA,NA,475,"USA","USA",77,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-11-04,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","18/08/2021",2021-08-18
"473",77,"Tenforde","Case-control","04Nov2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14-120","hospitalization","severe","USA","general pop","general pop",85,"82",88,NA,"alpha & delta",NA,NA,NA,476,"USA","USA",77,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-11-04,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","18/08/2021",2021-08-18
"474",77,"Tenforde","Case-control","04Nov2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","120+","hospitalization","severe","USA","general pop","general pop",64,"51",73,NA,"alpha & delta","~30 weeks",NA,NA,477,"USA","USA",77,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-11-04,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","18/08/2021",2021-08-18
"475",77,"Tenforde","Case-control","04Nov2021","mRNA-1273 (Moderna)","unknown","2","final","14+","hospitalization","severe","USA","general pop","general pop",89,"86",92,NA,"alpha & delta","~30 weeks",NA,NA,478,"USA","USA",77,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-11-04,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","18/08/2021",2021-08-18
"476",77,"Tenforde","Case-control","04Nov2021","mRNA-1273 (Moderna)","unknown","2","final","14-120","hospitalization","severe","USA","general pop","general pop",91,"87",93,NA,"alpha & delta",NA,NA,NA,479,"USA","USA",77,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-11-04,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","18/08/2021",2021-08-18
"477",77,"Tenforde","Case-control","04Nov2021","mRNA-1273 (Moderna)","unknown","2","final","120+","hospitalization","severe","USA","general pop","general pop",85,"77",91,NA,"alpha & delta","~30 weeks",NA,NA,480,"USA","USA",77,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-11-04,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","18/08/2021",2021-08-18
"478",77,"Tenforde","Case-control","04Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","14+","hospitalization","severe","USA","immunocompetent adults","immunocompetent adults",90,"87",91,NA,"alpha & delta","~30 weeks",NA,NA,481,"USA","USA",77,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-11-04,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","18/08/2021",2021-08-18
"479",77,"Tenforde","Case-control","04Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","14+","hospitalization","severe","USA","immucompromised","immunocompromised, >= 16 years",51,"31",65,NA,"alpha & delta","~30 weeks",NA,NA,482,"USA","USA",77,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-11-04,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","18/08/2021",2021-08-18
"480",77,"Tenforde","Case-control","04Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","14+","hospitalization","severe","USA","general pop","general pop",90,"84",94,"alpha","alpha","~30 weeks",NA,NA,483,"USA","USA",77,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-11-04,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","18/08/2021",2021-08-18
"481",77,"Tenforde","Case-control","04Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","14+","hospitalization","severe","USA","general pop","general pop",86,"79",90,"delta","delta","~30 weeks",NA,NA,484,"USA","USA",77,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-11-04,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","18/08/2021",2021-08-18
"482",78,"Pouwels","Prospective cohort","14Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","21+","infection ","infection","UK","general pop","general pop",59,"52",95,NA,"alpha",NA,NA,NA,485,"UK","GBR",78,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","18/08/2021",2021-08-18
"483",78,"Pouwels","Prospective cohort","14Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","21+","infection, ct<30","infection","UK","general pop","general pop",70,"65",74,NA,"alpha",NA,NA,NA,486,"UK","GBR",78,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","18/08/2021",2021-08-18
"484",78,"Pouwels","Prospective cohort","14Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection ","infection","UK","general pop","general pop",78,"68",84,NA,"alpha","~28 weeks",NA,NA,487,"UK","GBR",78,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","18/08/2021",2021-08-18
"485",78,"Pouwels","Prospective cohort","14Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection, ct<30","infection","UK","general pop","general pop",94,"94",96,NA,"alpha","~28 weeks",NA,NA,488,"UK","GBR",78,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","18/08/2021",2021-08-18
"486",78,"Pouwels","Prospective cohort","14Oct2021","AZD1222 (AstraZeneca)","included","1","1","21+","infection ","infection","UK","general pop","general pop",63,"55",69,NA,"alpha",NA,NA,NA,489,"UK","GBR",78,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","18/08/2021",2021-08-18
"487",78,"Pouwels","Prospective cohort","14Oct2021","AZD1222 (AstraZeneca)","included","1","1","21+","infection, ct<30","infection","UK","general pop","general pop",74,"69",79,NA,"alpha",NA,NA,NA,490,"UK","GBR",78,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","18/08/2021",2021-08-18
"488",78,"Pouwels","Prospective cohort","14Oct2021","AZD1222 (AstraZeneca)","included","2","final","14+","infection ","infection","UK","general pop","general pop",79,"56",90,NA,"alpha","~28 weeks",NA,NA,491,"UK","GBR",78,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","18/08/2021",2021-08-18
"489",78,"Pouwels","Prospective cohort","14Oct2021","AZD1222 (AstraZeneca)","included","2","final","14+","infection, ct<30","infection","UK","general pop","general pop",86,"71",93,NA,"alpha","~28 weeks",NA,NA,492,"UK","GBR",78,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","18/08/2021",2021-08-18
"490",78,"Pouwels","Prospective cohort","14Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","21+","infection ","infection","UK","general pop","general pop",57,"50",63,NA,"delta",NA,NA,NA,493,"UK","GBR",78,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/08/2021",2021-08-18
"491",78,"Pouwels","Prospective cohort","14Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","21+","infection, ct<30","infection","UK","general pop","general pop",62,"56",68,NA,"delta",NA,NA,NA,494,"UK","GBR",78,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/08/2021",2021-08-18
"492",78,"Pouwels","Prospective cohort","14Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection ","infection","UK","general pop","general pop",80,"77",83,NA,"delta","~28 weeks",NA,NA,495,"UK","GBR",78,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/08/2021",2021-08-18
"493",78,"Pouwels","Prospective cohort","14Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection, ct<30","infection","UK","general pop","general pop",84,"82",86,NA,"delta","~28 weeks",NA,NA,496,"UK","GBR",78,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/08/2021",2021-08-18
"494",78,"Pouwels","Prospective cohort","14Oct2021","AZD1222 (AstraZeneca)","included","1","1","21+","infection ","infection","UK","general pop","general pop",46,"35",55,NA,"delta",NA,NA,NA,497,"UK","GBR",78,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","18/08/2021",2021-08-18
"495",78,"Pouwels","Prospective cohort","14Oct2021","AZD1222 (AstraZeneca)","included","1","1","21+","infection, ct<30","infection","UK","general pop","general pop",50,"41",59,NA,"delta",NA,NA,NA,498,"UK","GBR",78,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","18/08/2021",2021-08-18
"496",78,"Pouwels","Prospective cohort","14Oct2021","AZD1222 (AstraZeneca)","included","2","final","14+","infection ","infection","UK","general pop","general pop",67,"62",71,NA,"delta","~28 weeks",NA,NA,499,"UK","GBR",78,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","18/08/2021",2021-08-18
"497",78,"Pouwels","Prospective cohort","14Oct2021","AZD1222 (AstraZeneca)","included","2","final","14+","infection, ct<30","infection","UK","general pop","general pop",70,"65",73,NA,"delta","~28 weeks",NA,NA,500,"UK","GBR",78,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-14,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","18/08/2021",2021-08-18
"498",79,"Prasad","Retrospective cohort","19Aug2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","post-operative infection","infection","USA","surgery patients","surgery patients",91,"56",99,NA,"non-VOC","~8 weeks",NA,NA,501,"USA","USA",79,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-08-19,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","original",NA,2021-08-19
"499",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","infection","infection","USA",">= 12 years","general pop",58,"54",61,NA,"epsilon & alpha & delta",NA,NA,NA,502,"USA","USA",80,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"500",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","infection ","infection","USA",">= 12 years","general pop",73,"72",74,NA,"epsilon & alpha & delta","~29 weeks",NA,NA,503,"USA","USA",80,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"501",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7-36","infection","infection","USA",">= 12 years","general pop",88,"86",89,NA,"epsilon & alpha & delta","~3 weeks",NA,NA,504,"USA","USA",80,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"502",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","157+","infection","infection","USA",">= 12 years","general pop",47,"43",51,NA,"epsilon & alpha & delta","~29 weeks",NA,NA,505,"USA","USA",80,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"503",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","hospitalization","severe","USA",">= 12 years","general pop",54,"43",63,NA,"epsilon & alpha & delta",NA,NA,NA,506,"USA","USA",80,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-16,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"504",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","hospitalization","severe","USA",">= 12 years","general pop",90,"89",92,NA,"epsilon & alpha & delta","~29 weeks",NA,NA,507,"USA","USA",80,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-16,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"505",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7-36","hospitalization","severe","USA",">= 12 years","general pop",87,"82",91,NA,"epsilon & alpha & delta","~3 weeks",NA,NA,508,"USA","USA",80,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-16,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"506",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","157+","hospitalization","severe","USA",">= 12 years","general pop",88,"82",92,NA,"epsilon & alpha & delta","~29 weeks",NA,NA,509,"USA","USA",80,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-16,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"507",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","infection ","infection","USA",">= 12 years","general pop",74,"55",85,"delta","delta",NA,NA,NA,510,"USA","USA",80,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","23/08/2021",2021-08-23
"508",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","infection ","infection","USA",">= 12 years","general pop",75,"71",78,"delta","delta","~29 weeks",NA,NA,511,"USA","USA",80,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","23/08/2021",2021-08-23
"509",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7-36","infection","infection","USA",">= 12 years","general pop",93,"85",97,"delta","delta","~3 weeks",NA,NA,512,"USA","USA",80,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","23/08/2021",2021-08-23
"510",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","127+","infection","infection","USA",">= 12 years","general pop",53,"39",65,"delta","delta","~29 weeks",NA,NA,513,"USA","USA",80,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","23/08/2021",2021-08-23
"511",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","hospitalization","severe","USA",">= 12 years","general pop",79,"-49",97,"delta","delta",NA,NA,NA,514,"USA","USA",80,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-16,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","23/08/2021",2021-08-23
"512",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","hospitalization","severe","USA",">= 12 years","general pop",93,"84",96,"delta","delta","~29 weeks",NA,NA,515,"USA","USA",80,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-16,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","23/08/2021",2021-08-23
"513",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","infection ","infection","USA",">= 12 years","general pop",74,"64",81,"non-delta","non-delta",NA,NA,NA,516,"USA","USA",80,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"514",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","infection ","infection","USA",">= 12 years","general pop",91,"88",92,"non-delta","non-delta","~29 weeks",NA,NA,517,"USA","USA",80,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"515",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7-36","infection","infection","USA",">= 12 years","general pop",97,"95",99,"non-delta","non-delta","~3 weeks",NA,NA,518,"USA","USA",80,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"516",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","127+","infection","infection","USA",">= 12 years","general pop",67,"45",80,"non-delta","non-delta","~29 weeks",NA,NA,519,"USA","USA",80,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"517",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","hospitalization","severe","USA",">= 12 years","general pop",75,"21",92,"non-delta","non-delta",NA,NA,NA,520,"USA","USA",80,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-16,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"518",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","hospitalization","severe","USA",">= 12 years","general pop",95,"90",98,"non-delta","non-delta","~29 weeks",NA,NA,521,"USA","USA",80,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-16,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/08/2021",2021-08-23
"519",81,"Golberg","Retrospective cohort","27Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","168-203","infection","infection","Israel","16-39 years","16-39 years",55,"50",60,NA,"delta","28 weeks",NA,NA,522,"Israel","ISR",81,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-27,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/08/2021",2021-08-25
"520",81,"Golberg","Retrospective cohort","27Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","55-98","infection","infection","Israel","16-39 years","16-39 years",80,"75",84,NA,"delta","13 weeks",NA,NA,523,"Israel","ISR",81,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-27,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/08/2021",2021-08-25
"521",81,"Golberg","Retrospective cohort","27Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","168-203","infection","infection","Israel","40-59 years","40-59 years",57,"53",61,NA,"delta","28 weeks",NA,NA,524,"Israel","ISR",81,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-27,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/08/2021",2021-08-25
"522",81,"Golberg","Retrospective cohort","27Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","55-98","infection","infection","Israel","40-59 years","40-59 years",83,"75",88,NA,"delta","13 weeks",NA,NA,525,"Israel","ISR",81,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-27,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/08/2021",2021-08-25
"523",81,"Golberg","Retrospective cohort","27Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","168-203","infection","infection","Israel",">= 60 years",">= 60 years",57,"52",62,NA,"delta","28 weeks",NA,NA,526,"Israel","ISR",81,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-27,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/08/2021",2021-08-25
"524",81,"Golberg","Retrospective cohort","27Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","55-98","infection","infection","Israel",">= 60 years",">= 60 years",82,"70",89,NA,"delta","13 weeks",NA,NA,527,"Israel","ISR",81,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-27,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/08/2021",2021-08-25
"525",81,"Golberg","Retrospective cohort","27Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","168-203","severe disease","severe","Israel","40-59 years","40-59 years",98,"94",99,NA,"delta","28 weeks",NA,NA,528,"Israel","ISR",81,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-27,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/08/2021",2021-08-25
"526",81,"Golberg","Retrospective cohort","27Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","168-203","severe disease","severe","Israel",">= 60 years",">= 60 years",93,"86",97,NA,"delta","13 weeks",NA,NA,529,"Israel","ISR",81,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-27,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/08/2021",2021-08-25
"527",81,"Golberg","Retrospective cohort","27Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","109-159","severe disease","severe","Israel","40-59 years","40-59 years",92,"87",95,NA,"delta","22 weeks",NA,NA,530,"Israel","ISR",81,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-27,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/08/2021",2021-08-25
"528",81,"Golberg","Retrospective cohort","27Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","109-159","severe disease","severe","Israel",">= 60 years",">= 60 years",85,"81",88,NA,"delta","22 weeks",NA,NA,531,"Israel","ISR",81,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-27,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/08/2021",2021-08-25
"529",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","infection","infection","Qatar",">= 12 years","general pop",36.8,"33.2",40.2,NA,"alpha, beta & delta",NA,NA,NA,532,"Qatar","QAT",82,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/08/2021",2021-08-27
"530",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","28-63","infection ","infection","Qatar",">= 12 years","general pop",73.2,"71.3",75,NA,"alpha, beta & delta","7 weeks",NA,NA,533,"Qatar","QAT",82,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/08/2021",2021-08-27
"531",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","175+","infection ","infection","Qatar",">= 12 years","general pop",22.3,"-1.7",40.7,NA,"alpha, beta & delta","~32 weeks",NA,NA,534,"Qatar","QAT",82,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/08/2021",2021-08-27
"532",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","symptomatic disease","symptomatic","Qatar",">= 12 years","general pop",47.9,"43.6",51.9,NA,"alpha, beta & delta",NA,NA,NA,535,"Qatar","QAT",82,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-10-06,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/08/2021",2021-08-27
"533",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","28-63","symptomatic disease","symptomatic","Qatar",">= 12 years","general pop",72.5,"69.6",75.1,NA,"alpha, beta & delta","7 weeks",NA,NA,536,"Qatar","QAT",82,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-10-06,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/08/2021",2021-08-27
"534",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","175+","symptomatic disease","symptomatic","Qatar",">= 12 years","general pop",27.8,"-1.4",48.7,NA,"alpha, beta & delta","~32 weeks",NA,NA,537,"Qatar","QAT",82,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-10-06,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/08/2021",2021-08-27
"535",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","asymptomatic infection","asymptomatic","Qatar",">= 12 years","general pop",22.2,"12.1",31.2,NA,"alpha, beta & delta",NA,NA,NA,538,"Qatar","QAT",82,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/08/2021",2021-08-27
"536",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","28-63","asymptomatic infection","asymptomatic","Qatar",">= 12 years","general pop",66.9,"61.9",71.3,NA,"alpha, beta & delta","7 weeks",NA,NA,539,"Qatar","QAT",82,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/08/2021",2021-08-27
"537",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","175+","asymptomatic infection","asymptomatic","Qatar",">= 12 years","general pop",-33.3,"-181.8",36.9,NA,"alpha, beta & delta","~29 weeks",NA,NA,540,"Qatar","QAT",82,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/08/2021",2021-08-27
"538",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","severe, critical, fatal disease","severe","Qatar",">= 12 years","general pop",66.1,"56.8",73.5,NA,"alpha, beta & delta",NA,NA,NA,541,"Qatar","QAT",82,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-10-06,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/08/2021",2021-08-27
"539",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","28-63","severe, critical, fatal disease","severe","Qatar",">= 12 years","general pop",96.8,"93.9",98.3,NA,"alpha, beta & delta","7 weeks",NA,NA,542,"Qatar","QAT",82,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-10-06,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/08/2021",2021-08-27
"540",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","175+","severe, critical, fatal disease","severe","Qatar",">= 12 years","general pop",55.6,"-44.3",86.3,NA,"alpha, beta & delta","~32 weeks",NA,NA,543,"Qatar","QAT",82,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-10-06,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/08/2021",2021-08-27
"541",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","infection","infection","Qatar",">= 12 years","general pop",47.9,"15.5",67.9,"alpha","alpha",NA,NA,NA,544,"Qatar","QAT",82,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","27/08/2021",2021-08-27
"542",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","28-63","infection","infection","Qatar",">= 12 years","general pop",88.6,"79.2",93.7,"alpha","alpha","7 weeks",NA,NA,545,"Qatar","QAT",82,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","27/08/2021",2021-08-27
"543",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","147+","infection","infection","Qatar",">= 12 years","general pop",80,"-71.2",97.7,"alpha","alpha","~29 weeks",NA,NA,546,"Qatar","QAT",82,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","27/08/2021",2021-08-27
"544",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","infection","infection","Qatar",">= 12 years","general pop",25.8,"-2",46.1,"beta","beta",NA,NA,NA,547,"Qatar","QAT",82,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta","27/08/2021",2021-08-27
"545",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","28-63","infection","infection","Qatar",">= 12 years","general pop",63.9,"52.6",72.5,"beta","beta","7 weeks",NA,NA,548,"Qatar","QAT",82,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta","27/08/2021",2021-08-27
"546",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","147+","infection ","infection","Qatar",">= 12 years","general pop",40,"-151.1",85.7,"beta","beta","~29 weeks",NA,NA,549,"Qatar","QAT",82,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta","27/08/2021",2021-08-27
"547",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","infection","infection","Qatar",">= 12 years","general pop",63.4,"42.6",76.6,"delta","delta",NA,NA,NA,550,"Qatar","QAT",82,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","27/08/2021",2021-08-27
"548",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","28-63","infection","infection","Qatar",">= 12 years","general pop",73.3,"63.6",80.4,"delta","delta","7 weeks",NA,NA,551,"Qatar","QAT",82,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","27/08/2021",2021-08-27
"549",82,"Chemaitelly ","Test-negative case-control","06Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","147+","infection","infection","Qatar",">= 12 years","general pop",17.9,"-12.9",40.3,"delta","delta","~29 weeks",NA,NA,552,"Qatar","QAT",82,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2021-10-06,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","27/08/2021",2021-08-27
"550",83,"Nunes","Retrospective cohort","23Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+ up to <14 post 2nd dose","hospitalization","severe","Portugal","65-79 years","65-79 years",78,"61",87,NA,"alpha & delta",NA,NA,NA,553,"Portugal","PRT",83,"PRT",23180,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,198,247,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-23,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-23
"551",83,"Nunes","Retrospective cohort","23Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","Portugal","65-79 years","65-79 years",94,"88",97,NA,"alpha & delta","~14.5 weeks",NA,NA,554,"Portugal","PRT",83,"PRT",23180,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,198,247,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-23,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-23
"552",83,"Nunes","Retrospective cohort","23Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+ up to <14 post 2nd dose","death","death","Portugal","65-79 years","65-79 years",77,"56",88,NA,"alpha & delta",NA,NA,NA,555,"Portugal","PRT",83,"PRT",23180,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,198,247,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-23,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-23
"553",83,"Nunes","Retrospective cohort","23Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","death","death","Portugal","65-79 years","65-79 years",96,"92",98,NA,"alpha & delta","~14.5 weeks",NA,NA,556,"Portugal","PRT",83,"PRT",23180,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,198,247,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-23,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-23
"554",83,"Nunes","Retrospective cohort","23Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+ up to <14 post 2nd dose","hospitalization","severe","Portugal",">= 80 years",">= 80 years",55,"36",69,NA,"alpha & delta",NA,NA,NA,557,"Portugal","PRT",83,"PRT",23180,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,198,247,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-23,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-23
"555",83,"Nunes","Retrospective cohort","23Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","Portugal",">= 80 years",">= 80 years",82,"72",89,NA,"alpha & delta","~22.5 weeks",NA,NA,558,"Portugal","PRT",83,"PRT",23180,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,198,247,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-23,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-23
"556",83,"Nunes","Retrospective cohort","23Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+ up to <14 post 2nd dose","death","death","Portugal",">= 80 years",">= 80 years",56,"35",70,NA,"alpha & delta",NA,NA,NA,559,"Portugal","PRT",83,"PRT",23180,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,198,247,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-23,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-23
"557",83,"Nunes","Retrospective cohort","23Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","death","death","Portugal",">= 80 years",">= 80 years",81,"74",87,NA,"alpha & delta","~22.5 weeks",NA,NA,560,"Portugal","PRT",83,"PRT",23180,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,198,247,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-23,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-23
"558",84,"Katz","Prospective cohort","10Dec2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","Israel","HCW","HCW",94.5,"82.5",98.2,NA,"alpha","~18 weeks",NA,NA,561,"Israel","ISR",84,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-10,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","02/09/2021",2021-09-02
"559",84,"Katz","Prospective cohort","10Dec2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","symptomatic disease","symptomatic","Israel","HCW","HCW",97,"72",99.7,NA,"alpha","~18 weeks",NA,NA,562,"Israel","ISR",84,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-10,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","02/09/2021",2021-09-02
"560",85,"Giansante","Retrospective cohort","02Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","infection","infection","Italy","HCW and staff","HCW and staff",85.5,"75.9",91.3,NA,"alpha & delta",NA,NA,NA,563,"Italy","ITA",85,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-02,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-02
"561",85,"Giansante","Retrospective cohort","02Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Italy","HCW and staff","HCW and staff",84.8,"73.2",91.4,NA,"alpha & delta","~16 weeks",NA,NA,564,"Italy","ITA",85,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-02,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-02
"562",85,"Giansante","Retrospective cohort","02Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","symptomatic disease","symptomatic","Italy","HCW and staff","HCW and staff",81.7,"62.7",91,NA,"alpha & delta",NA,NA,NA,565,"Italy","ITA",85,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-02,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-02
"563",85,"Giansante","Retrospective cohort","02Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","Italy","HCW and staff","HCW and staff",87.1,"69.3",94.6,NA,"alpha & delta","~16 weeks",NA,NA,566,"Italy","ITA",85,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-02,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-02
"564",85,"Giansante","Retrospective cohort","02Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","infection","infection","Italy","HCW","HCW",87.8,"76.5",93.7,NA,"alpha & delta",NA,NA,NA,567,"Italy","ITA",85,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-02,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-02
"565",85,"Giansante","Retrospective cohort","02Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Italy","HCW","HCW",84.4,"69.7",92,NA,"alpha & delta","~16 weeks",NA,NA,568,"Italy","ITA",85,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-02,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-02
"566",85,"Giansante","Retrospective cohort","02Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","symptomatic disease","symptomatic","Italy","HCW","HCW",83.1,"60",92.9,NA,"alpha & delta",NA,NA,NA,569,"Italy","ITA",85,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-02,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-02
"567",85,"Giansante","Retrospective cohort","02Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","Italy","HCW","HCW",86.5,"62.9",95.1,NA,"alpha & delta","~16 weeks",NA,NA,570,"Italy","ITA",85,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-02,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-02
"568",86,"Bruxvoort","Matched prospective cohort","24Nov2021","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","USA","adults","general pop",87.4,"85.6",89.1,NA,"alpha & delta","~20 weeks",NA,NA,571,"USA","USA",86,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-11-24,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","02/09/2021",2021-09-02
"569",86,"Bruxvoort","Matched prospective cohort","24Nov2021","mRNA-1273 (Moderna)","included","2","final","14+","asymptomatic infection","asymptomatic","USA","adults","general pop",72.7,"57.6",82.4,NA,"alpha & delta","~20 weeks",NA,NA,572,"USA","USA",86,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-11-24,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","02/09/2021",2021-09-02
"570",86,"Bruxvoort","Matched prospective cohort","24Nov2021","mRNA-1273 (Moderna)","included","2","final","14+","symptomatic disease","symptomatic","USA","adults","general pop",88.3,"86.5",89.9,NA,"alpha & delta","~20 weeks",NA,NA,573,"USA","USA",86,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-11-24,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","02/09/2021",2021-09-02
"571",86,"Bruxvoort","Matched prospective cohort","24Nov2021","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","adults","general pop",95.8,"92.5",97.6,NA,"alpha & delta","~20 weeks",NA,NA,574,"USA","USA",86,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-11-24,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","02/09/2021",2021-09-02
"572",86,"Bruxvoort","Matched prospective cohort","24Nov2021","mRNA-1273 (Moderna)","included","2","final","14+","death","death","USA","adults","general pop",97.9,"84.5",99.7,NA,"alpha & delta","~20 weeks",NA,NA,575,"USA","USA",86,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-11-24,"death","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","02/09/2021",2021-09-02
"573",87,"Barlow","Test-negative case-control","03Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA",">= 15 years","general pop",74,"65",82,NA,"delta","~4 weeks",NA,NA,576,"USA","USA",87,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-03,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2021-09-03
"574",87,"Barlow","Test-negative case-control","03Sept2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","infection","infection","USA",">= 15 years","general pop",51,"-2",76,NA,"delta","~4 weeks",NA,NA,577,"USA","USA",87,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-03,"infection","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2021-09-03
"575",88,"Tande","Retrospective cohort","06Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1","1","20+","asymptomatic infection (January-March)","asymptomatic","USA","surgery patients","surgery patients",44,"-6",71,NA,"non-VOC",NA,NA,NA,578,"USA","USA",88,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-06,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","original",NA,2021-09-06
"576",88,"Tande","Retrospective cohort","06Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","asymptomatic infection (January-March)","asymptomatic","USA","surgery patients","surgery patients",91,"72",98,NA,"non-VOC","~10 weeks",NA,NA,579,"USA","USA",88,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-06,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","original",NA,2021-09-06
"577",88,"Tande","Retrospective cohort","06Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1","1","20+","asymptomatic infection (April-May)","asymptomatic","USA","surgery patients","surgery patients",46,"53",83,NA,"alpha",NA,NA,NA,580,"USA","USA",88,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-06,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-09-06
"578",88,"Tande","Retrospective cohort","06Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","asymptomatic infection (April-May)","asymptomatic","USA","surgery patients","surgery patients",71,"53",83,NA,"alpha","~19 weeks",NA,NA,581,"USA","USA",88,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-06,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-09-06
"579",88,"Tande","Retrospective cohort","06Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1","1","20+","asymptomatic infection (June-August)","asymptomatic","USA","surgery patients","surgery patients",63,"44",76,NA,"delta",NA,NA,NA,582,"USA","USA",88,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-06,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2021-09-06
"580",88,"Tande","Retrospective cohort","06Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","asymptomatic infection (June-August)","asymptomatic","USA","surgery patients","surgery patients",63,"44",76,NA,"delta","~32 weeks",NA,NA,583,"USA","USA",88,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-06,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2021-09-06
"581",89,"Iliaki","Retrospective cohort","18Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","infection","infection","USA","HCW","HCW",80.2,"57.5",90.8,NA,"alpha",NA,NA,NA,584,"USA","USA",89,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-18,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","06/09/2021",2021-09-06
"582",89,"Iliaki","Retrospective cohort","18Oct2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","HCW","HCW",95.2,"80",98.8,NA,"alpha","~10 weeks",NA,NA,585,"USA","USA",89,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-18,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","06/09/2021",2021-09-06
"583",90,"Thompson","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","hospitalization","severe","USA",">= 50 years",">= 50 years",33,"18",46,NA,"non-VOC & alpha",NA,NA,NA,586,"USA","USA",90,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-08,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-08
"584",90,"Thompson","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","USA",">= 50 years",">= 50 years",87,"85",90,NA,"non-VOC & alpha","~22 weeks",NA,NA,587,"USA","USA",90,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-08,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-08
"585",90,"Thompson","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","ED or UC visit","symptomatic","USA",">= 50 years",">= 50 years",58,"46",68,NA,"non-VOC & alpha",NA,NA,NA,588,"USA","USA",90,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-08,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-08
"586",90,"Thompson","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","ED or UC visit","symptomatic","USA",">= 50 years",">= 50 years",89,"85",91,NA,"non-VOC & alpha","~22 weeks",NA,NA,589,"USA","USA",90,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-08,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-08
"587",90,"Thompson","Test-negative case-control","08Sept2021","mRNA-1273 (Moderna)","excluded","1","1","14+","hospitalization","severe","USA",">= 50 years",">= 50 years",68,"59",75,NA,"non-VOC & alpha",NA,NA,NA,590,"USA","USA",90,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-08,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-08
"588",90,"Thompson","Test-negative case-control","08Sept2021","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA",">= 50 years",">= 50 years",91,"89",93,NA,"non-VOC & alpha","20 weeks",NA,NA,591,"USA","USA",90,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-08,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-08
"589",90,"Thompson","Test-negative case-control","08Sept2021","mRNA-1273 (Moderna)","excluded","1","1","14+","ED or UC visit","symptomatic","USA",">= 50 years",">= 50 years",73,"64",79,NA,"non-VOC & alpha",NA,NA,NA,592,"USA","USA",90,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-08,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-08
"590",90,"Thompson","Test-negative case-control","08Sept2021","mRNA-1273 (Moderna)","excluded","2","final","14+","ED or UC visit","symptomatic","USA",">= 50 years",">= 50 years",92,"89",94,NA,"non-VOC & alpha","20 weeks",NA,NA,593,"USA","USA",90,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-08,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-08
"591",90,"Thompson","Test-negative case-control","08Sept2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization","severe","USA",">= 50 years",">= 50 years",68,"50",79,NA,"non-VOC & alpha","14 weeks",NA,NA,594,"USA","USA",90,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-08,"severe","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2021-09-08
"592",90,"Thompson","Test-negative case-control","08Sept2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","ED or UC visit","symptomatic","USA",">= 50 years",">= 50 years",73,"59",82,NA,"non-VOC & alpha","14 weeks",NA,NA,595,"USA","USA",90,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-08,"symptomatic","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2021-09-08
"593",90,"Thompson","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","hospitalization","severe","USA",">= 50 years with >= 1 chronic respiratory condition",">= 50 years with >= 1 chronic respiratory condition",56,"47",64,NA,"non-VOC & alpha",NA,NA,NA,596,"USA","USA",90,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-08,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-08
"594",90,"Thompson","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA",">= 50 years with >= 1 chronic respiratory condition",">= 50 years with >= 1 chronic respiratory condition",90,"88",92,NA,"non-VOC & alpha","~22 weeks",NA,NA,597,"USA","USA",90,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-08,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-08
"595",90,"Thompson","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","hospitalization","severe","USA",">= 50 years with >= 1 chronic non-respiratory condition",">= 50 years with >= 1 chronic non-respiratory condition",54,"45",61,NA,"non-VOC & alpha",NA,NA,NA,598,"USA","USA",90,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-08,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-08
"596",90,"Thompson","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA",">= 50 years with >= 1 chronic non-respiratory condition",">= 50 years with >= 1 chronic non-respiratory condition",88,"86",90,NA,"non-VOC & alpha","~22 weeks",NA,NA,599,"USA","USA",90,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-08,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-08
"597",90,"Thompson","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-27","hospitalization","severe","USA",">= 50 years",">= 50 years",88,"84",92,NA,"non-VOC & alpha","~2 weeks",NA,NA,600,"USA","USA",90,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-08,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-08
"598",90,"Thompson","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","112+","hospitalization","severe","USA",">= 50 years",">= 50 years",86,"74",93,NA,"non-VOC & alpha","~22 weeks",NA,NA,601,"USA","USA",90,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-08,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-08
"599",90,"Thompson","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-27","ED or UC visit","symptomatic","USA",">= 50 years",">= 50 years",92,"88",95,NA,"non-VOC & alpha","~2 weeks",NA,NA,602,"USA","USA",90,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-08,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-08
"600",90,"Thompson","Test-negative case-control","08Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","112+","ED or UC visit","symptomatic","USA",">= 50 years",">= 50 years",86,"74",93,NA,"non-VOC & alpha","~22 weeks",NA,NA,603,"USA","USA",90,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-08,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-08
"601",91,"Dagan","Prospective cohort","07Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","21-27","infection","infection","Israel","pregnant women","pregnant persons",71,"33",94,NA,"alpha",NA,NA,NA,604,"Israel","ISR",91,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-07,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-09-07
"602",91,"Dagan","Prospective cohort","07Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-56","infection ","infection","Israel","pregnant women","pregnant persons",96,"89",100,NA,"alpha","~11 weeks",NA,NA,605,"Israel","ISR",91,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-07,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-09-07
"603",91,"Dagan","Prospective cohort","07Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","21-27","symptomatic disease","symptomatic","Israel","pregnant women","pregnant persons",76,"30",100,NA,"alpha",NA,NA,NA,606,"Israel","ISR",91,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-07,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-09-07
"604",91,"Dagan","Prospective cohort","07Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-56","symptomatic disease","symptomatic","Israel","pregnant women","pregnant persons",97,"91",100,NA,"alpha","~11 weeks",NA,NA,607,"Israel","ISR",91,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-07,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-09-07
"605",91,"Dagan","Prospective cohort","07Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-56","hospitalization","severe","Israel","pregnant women","pregnant persons",89,"43",100,NA,"alpha","~11 weeks",NA,NA,608,"Israel","ISR",91,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-07,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-09-07
"606",92,"Grannis","Test-negative case-control","10Sept2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",80,"73",85,NA,"delta","4 weeks",NA,NA,609,"USA","USA",92,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-10,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-09-10
"607",92,"Grannis","Test-negative case-control","10Sept2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","ED or UC visit","symptomatic","USA",">= 18 years","general pop",77,"74",80,NA,"delta","4 weeks",NA,NA,610,"USA","USA",92,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-10,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-09-10
"608",92,"Grannis","Test-negative case-control","10Sept2021","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",95,"92",97,NA,"delta","4 weeks",NA,NA,611,"USA","USA",92,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-10,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2021-09-10
"609",92,"Grannis","Test-negative case-control","10Sept2021","mRNA-1273 (Moderna)","included","2","final","14+","ED or UC visit","symptomatic","USA",">= 18 years","general pop",92,"89",93,NA,"delta","4 weeks",NA,NA,612,"USA","USA",92,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-10,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2021-09-10
"610",92,"Grannis","Test-negative case-control","10Sept2021","Ad26.COV2.S (Janssen)","included","1","final","14+","hospitalization","severe","USA",">= 18 years","general pop",60,"31",77,NA,"delta","4 weeks",NA,NA,613,"USA","USA",92,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-10,"severe","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2021-09-10
"611",92,"Grannis","Test-negative case-control","10Sept2021","Ad26.COV2.S (Janssen)","included","1","final","14+","ED or UC visit","symptomatic","USA",">= 18 years","general pop",65,"56",72,NA,"delta","4 weeks",NA,NA,614,"USA","USA",92,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-10,"symptomatic","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2021-09-10
"612",93,"Polinski","Retrospective cohort","17Mar2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","infection","infection","USA",">= 18 years","general pop",76,"75",77,NA,"alpha","~14 weeks",NA,NA,615,"USA","USA",93,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-17,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","alpha","10/09/2021",2021-09-10
"613",93,"Polinski","Retrospective cohort","17Mar2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization","severe","USA",">= 18 years","general pop",81,"78",82,NA,"alpha","~14 weeks",NA,NA,616,"USA","USA",93,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-17,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","alpha","10/09/2021",2021-09-10
"614",93,"Polinski","Retrospective cohort","17Mar2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","infection","infection","USA","immunocompromised, >= 18 years","immunocompromised adults",64,"59",68,NA,"alpha","~14 weeks",NA,NA,617,"USA","USA",93,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-17,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","alpha","10/09/2021",2021-09-10
"615",93,"Polinski","Retrospective cohort","17Mar2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization","severe","USA","immunocompromised, >= 18 years","immunocompromised adults",67,"57",74,NA,"alpha","~14 weeks",NA,NA,618,"USA","USA",93,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-17,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","alpha","10/09/2021",2021-09-10
"616",93,"Polinski","Retrospective cohort","17Mar2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","infection (June-July)","infection","USA",">= 18 years","general pop",74,"71",77,NA,"delta","~14 weeks",NA,NA,619,"USA","USA",93,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-17,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","10/09/2021",2021-09-10
"617",93,"Polinski","Retrospective cohort","17Mar2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization (June-July)","severe","USA",">= 18 years","general pop",81,"75",86,NA,"delta","~14 weeks",NA,NA,620,"USA","USA",93,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-17,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","10/09/2021",2021-09-10
"618",94,"Bajema","Test-negative case-control","10Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<104 days","hospitalization","severe","USA","hospitalized veterans","hospitalized veterans",86.1,"76.5",91.8,NA,"alpha, delta, non-VOC","~13 weeks",NA,NA,621,"USA","USA",94,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-10,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-10
"619",94,"Bajema","Test-negative case-control","10Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final",">104 days","hospitalization","severe","USA","hospitalized veterans","hospitalized veterans",87.2,"78.2",92.5,NA,"alpha, delta, non-VOC","~28.5 weeks",NA,NA,622,"USA","USA",94,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-10,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-09-10
"620",94,"Bajema","Test-negative case-control","10Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","USA","hospitalized veterans","hospitalized veterans",83.4,"74",89.4,NA,"alpha, delta, non-VOC","~28.5 weeks",NA,NA,623,"USA","USA",94,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-10,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-10
"621",94,"Bajema","Test-negative case-control","10Sept2021","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA","hospitalized veterans","hospitalized veterans",91.6,"83.5",95.7,NA,"alpha, delta, non-VOC","~26.5 weeks",NA,NA,624,"USA","USA",94,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-10,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-10
"622",94,"Bajema","Test-negative case-control","10Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization (February-June)","severe","USA","hospitalized veterans","hospitalized veterans",84.1,"74.1",90.2,NA,"alpha","~23 weeks",NA,NA,625,"USA","USA",94,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-10,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-09-10
"623",94,"Bajema","Test-negative case-control","10Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization (July-August)","severe","USA","hospitalized veterans","hospitalized veterans",89.3,"80.1",94.3,NA,"delta","~28.5 weeks",NA,NA,626,"USA","USA",94,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-10,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2021-09-10
"624",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","28+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",45.9,"44.2",47.6,"alpha","alpha",NA,NA,NA,627,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","14/09/2021",2021-09-14
"625",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",94.9,"93.6",95.9,"alpha","alpha","~33.5 weeks",NA,NA,628,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","14/09/2021",2021-09-14
"626",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","70+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",94.8,"88.4",97.7,"alpha","alpha","~8 weeks",NA,NA,629,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","14/09/2021",2021-09-14
"627",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","28+","hospitalization","severe","UK",">= 16 years","general pop",85.2,"81.6",88.1,"alpha","alpha",NA,NA,NA,630,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","14/09/2021",2021-09-14
"628",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-63","hospitalization","severe","UK",">= 16 years","general pop",97.7,"90.8",99.4,"alpha","alpha","~33.5 weeks",NA,NA,631,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","14/09/2021",2021-09-14
"629",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","28+","death","death","UK",">= 16 years","general pop",73.1,"65",79.3,"alpha","alpha",NA,NA,NA,632,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","14/09/2021",2021-09-14
"630",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","UK",">= 16 years","general pop",96.6,"94.4",96.5,"alpha","alpha","~33.5 weeks",NA,NA,633,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","14/09/2021",2021-09-14
"631",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","28+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",45.1,"43.3",46.7,"alpha","alpha",NA,NA,NA,634,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","14/09/2021",2021-09-14
"632",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",82.1,"79.4",84.5,"alpha","alpha","~20.5 weeks",NA,NA,635,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","14/09/2021",2021-09-14
"633",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14-63","symptomatic disease","symptomatic","UK",">= 16 years","general pop",82.4,"79.6",84.7,"alpha","alpha","~8 weeks",NA,NA,636,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","14/09/2021",2021-09-14
"634",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","70+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",76.2,"49.8",88.7,"alpha","alpha","~20.5 weeks",NA,NA,637,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","14/09/2021",2021-09-14
"635",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","28+","hospitalization","severe","UK",">= 16 years","general pop",82.5,"78.7",85.7,"alpha","alpha",NA,NA,NA,638,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","14/09/2021",2021-09-14
"636",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14-63","hospitalization","severe","UK",">= 16 years","general pop",95.1,"86.7",98.2,"alpha","alpha","~20.5 weeks",NA,NA,639,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","14/09/2021",2021-09-14
"637",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","70+","hospitalization","severe","UK",">= 16 years","general pop",100,NA,NA,"alpha","alpha","~20.5 weeks",NA,NA,640,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","14/09/2021",2021-09-14
"638",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","28+","death","death","UK",">= 16 years","general pop",79.1,"68.8",86,"alpha","alpha",NA,NA,NA,641,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","14/09/2021",2021-09-14
"639",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","death","death","UK",">= 16 years","general pop",100,NA,NA,"alpha","alpha","~20.5 weeks",NA,NA,642,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","14/09/2021",2021-09-14
"640",95,"Andrews","Test-negative case-control","12Jan2022","mRNA-1273 (Moderna)","excluded","1","1","28+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",58.1,"11.7",80.1,"alpha","alpha",NA,NA,NA,643,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","alpha","14/09/2021",2021-09-14
"641",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","28+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",51.2,"50.7",51.7,"delta","delta",NA,NA,NA,644,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/09/2021",2021-09-14
"642",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",83.3,"83.1",83.5,"delta","delta","~33.5 weeks",NA,NA,645,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/09/2021",2021-09-14
"643",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-69","symptomatic disease","symptomatic","UK",">= 16 years","general pop",89.8,"89.6",90,"delta","delta","~8 weeks",NA,NA,646,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/09/2021",2021-09-14
"644",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","140+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",69.7,"68.7",70.5,"delta","delta","~33.5 weeks",NA,NA,647,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/09/2021",2021-09-14
"645",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","28+","hospitalization","severe","UK",">= 16 years","general pop",91.1,"89.7",92.3,"delta","delta",NA,NA,NA,648,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/09/2021",2021-09-14
"646",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","UK",">= 16 years","general pop",96.6,"96.2",96.9,"delta","delta","~33.5 weeks",NA,NA,649,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/09/2021",2021-09-14
"647",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-69","hospitalization","severe","UK",">= 16 years","general pop",98.4,"97.9",98.8,"delta","delta","~8 weeks",NA,NA,650,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/09/2021",2021-09-14
"648",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","140+","hospitalization","severe","UK",">= 16 years","general pop",92.7,"90.3",94.6,"delta","delta","~33.5 weeks",NA,NA,651,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/09/2021",2021-09-14
"649",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","28+","death","death","UK",">= 16 years","general pop",88.6,"78.8",93.9,"delta","delta",NA,NA,NA,652,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/09/2021",2021-09-14
"650",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","UK",">= 16 years","general pop",95.6,"94.4",96.6,"delta","delta","~33.5 weeks",NA,NA,653,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/09/2021",2021-09-14
"651",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-69","death","death","UK",">= 16 years","general pop",98.2,"95.9",99.2,"delta","delta","~8 weeks",NA,NA,654,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/09/2021",2021-09-14
"652",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","140+","death","death","UK",">= 16 years","general pop",90.4,"85.1",93.8,"delta","delta","~33.5 weeks",NA,NA,655,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/09/2021",2021-09-14
"653",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","28+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",45.1,"43.4",46.7,"delta","delta",NA,NA,NA,656,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/09/2021",2021-09-14
"654",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",64.2,"63.9",64.5,"delta","delta","~20.5 weeks",NA,NA,657,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/09/2021",2021-09-14
"655",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14-69","symptomatic disease","symptomatic","UK",">= 16 years","general pop",66.7,"66.3",67,"delta","delta","~8 weeks",NA,NA,658,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/09/2021",2021-09-14
"656",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","140+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",47.3,"45",49.6,"delta","delta","~20.5 weeks",NA,NA,659,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/09/2021",2021-09-14
"657",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","28+","hospitalization","severe","UK",">= 16 years","general pop",80.7,"78",83,"delta","delta",NA,NA,NA,660,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/09/2021",2021-09-14
"658",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","hospitalization","severe","UK",">= 16 years","general pop",92.5,"92",93,"delta","delta","~20.5 weeks",NA,NA,661,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/09/2021",2021-09-14
"659",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14-69","hospitalization","severe","UK",">= 16 years","general pop",95.2,"94.6",95.6,"delta","delta","~8 weeks",NA,NA,662,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/09/2021",2021-09-14
"660",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","140+","hospitalization","severe","UK",">= 16 years","general pop",77,"70.3",82.3,"delta","delta","~20.5 weeks",NA,NA,663,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/09/2021",2021-09-14
"661",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","28+","death","death","UK",">= 16 years","general pop",86.9,"77.5",92.4,"delta","delta",NA,NA,NA,664,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/09/2021",2021-09-14
"662",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","death","death","UK",">= 16 years","general pop",93.2,"91.7",94.5,"delta","delta","~20.5 weeks",NA,NA,665,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/09/2021",2021-09-14
"663",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14-69","death","death","UK",">= 16 years","general pop",94.1,"91.8",95.8,"delta","delta","~8 weeks",NA,NA,666,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/09/2021",2021-09-14
"664",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","140+","death","death","UK",">= 16 years","general pop",78.7,"52.7",90.4,"delta","delta","~20.5 weeks",NA,NA,667,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/09/2021",2021-09-14
"665",95,"Andrews","Test-negative case-control","12Jan2022","mRNA-1273 (Moderna)","excluded","1","1","28+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",64.9,"64",65.7,"delta","delta",NA,NA,NA,668,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","14/09/2021",2021-09-14
"666",95,"Andrews","Test-negative case-control","12Jan2022","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","UK",">= 16 years","general pop",94.8,"94.4",95.2,"delta","delta","~7 weeks",NA,NA,669,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","14/09/2021",2021-09-14
"667",95,"Andrews","Test-negative case-control","12Jan2022","mRNA-1273 (Moderna)","excluded","2","final","14-63","symptomatic disease","symptomatic","UK",">= 16 years","general pop",93.8,"93.4",94.1,"delta","delta","~7 weeks",NA,NA,670,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","14/09/2021",2021-09-14
"668",95,"Andrews","Test-negative case-control","12Jan2022","mRNA-1273 (Moderna)","excluded","2","final","70-104","symptomatic disease","symptomatic","UK",">= 16 years","general pop",85.6,"83.8",87.2,"delta","delta","~7 weeks",NA,NA,671,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","14/09/2021",2021-09-14
"669",95,"Andrews","Test-negative case-control","12Jan2022","mRNA-1273 (Moderna)","excluded","1","1","28+","hospitalization","severe","UK",">= 16 years","general pop",93.7,"89.9",96,"delta","delta",NA,NA,NA,672,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","14/09/2021",2021-09-14
"670",95,"Andrews","Test-negative case-control","12Jan2022","mRNA-1273 (Moderna)","excluded","2","final","14-69","hospitalization","severe","UK",">= 16 years","general pop",100,NA,NA,"delta","delta","~7 weeks",NA,NA,673,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","14/09/2021",2021-09-14
"671",96,"Glatman-Freedman","Retrospective cohort","16Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","infection","infection","Israel",">= 16 years","general pop",54.3,"50.6",57.8,NA,"alpha",NA,NA,NA,674,"Israel","ISR",96,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-16
"672",96,"Glatman-Freedman","Retrospective cohort","16Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","22-28","infection","infection","Israel",">= 16 years","general pop",97.3,"96.7",97.8,NA,"alpha","2 weeks",NA,NA,675,"Israel","ISR",96,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-16,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-16
"673",96,"Glatman-Freedman","Retrospective cohort","16Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","symptomatic disease","symptomatic","Israel",">= 16 years","general pop",58.3,"54.7",61.6,NA,"alpha",NA,NA,NA,676,"Israel","ISR",96,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-16,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-16
"674",96,"Glatman-Freedman","Retrospective cohort","16Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","22-28","symptomatic disease","symptomatic","Israel",">= 16 years","general pop",97.9,"97.4",98.3,NA,"alpha","2 weeks",NA,NA,677,"Israel","ISR",96,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-16,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-16
"675",96,"Glatman-Freedman","Retrospective cohort","16Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","hospitalization","severe","Israel",">= 16 years","general pop",74.5,"69.1",79,NA,"alpha",NA,NA,NA,678,"Israel","ISR",96,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-16,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-16
"676",96,"Glatman-Freedman","Retrospective cohort","16Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","22-28","hospitalization","severe","Israel",">= 16 years","general pop",99,"98.4",99.3,NA,"alpha","2 weeks",NA,NA,679,"Israel","ISR",96,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-16,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-16
"677",96,"Glatman-Freedman","Retrospective cohort","16Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","severe/critical disease","severe","Israel",">= 16 years","general pop",77.3,"71.2",82.1,NA,"alpha",NA,NA,NA,680,"Israel","ISR",96,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-16,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-16
"678",96,"Glatman-Freedman","Retrospective cohort","16Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","22-28","severe/critical disease","severe","Israel",">= 16 years","general pop",99.2,"98.6",99.5,NA,"alpha","2 weeks",NA,NA,681,"Israel","ISR",96,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-16,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-16
"679",96,"Glatman-Freedman","Retrospective cohort","16Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","death","death","Israel",">= 16 years","general pop",71.7,"64.1",77.7,NA,"alpha",NA,NA,NA,682,"Israel","ISR",96,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-16,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-16
"680",96,"Glatman-Freedman","Retrospective cohort","16Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","22-28","death","death","Israel",">= 16 years","general pop",98.6,"97",99.3,NA,"alpha","2 weeks",NA,NA,683,"Israel","ISR",96,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-16,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-16
"681",97,"Self","Test-negative case-control","17Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",88,"85",91,NA,"alpha & delta","~20 weeks",NA,NA,684,"USA","USA",97,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-17,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-17
"682",97,"Self","Test-negative case-control","17Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-120","hospitalization","severe","USA",">= 18 years","general pop",91,"88",93,NA,"alpha & delta","~20 weeks",NA,NA,685,"USA","USA",97,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-17,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-17
"683",97,"Self","Test-negative case-control","17Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">120","hospitalization","severe","USA",">= 18 years","general pop",77,"67",84,NA,"alpha & delta","~20 weeks",NA,NA,686,"USA","USA",97,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-17,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-17
"684",97,"Self","Test-negative case-control","17Sept2021","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",93,"91",95,NA,"alpha & delta","~20 weeks",NA,NA,687,"USA","USA",97,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-17,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-17
"685",97,"Self","Test-negative case-control","17Sept2021","mRNA-1273 (Moderna)","excluded","2","final","14-120","hospitalization","severe","USA",">= 18 years","general pop",93,"90",95,NA,"alpha & delta","~20 weeks",NA,NA,688,"USA","USA",97,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-17,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-17
"686",97,"Self","Test-negative case-control","17Sept2021","mRNA-1273 (Moderna)","excluded","2","final",">120","hospitalization","severe","USA",">= 18 years","general pop",92,"87",96,NA,"alpha & delta","~20 weeks",NA,NA,689,"USA","USA",97,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-17,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-17
"687",97,"Self","Test-negative case-control","17Sept2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization","severe","USA",">= 18 years","general pop",71,"56",81,NA,"alpha & delta","~20 weeks",NA,NA,690,"USA","USA",97,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-17,"severe","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2021-09-17
"688",97,"Self","Test-negative case-control","17Sept2021","Ad26.COV2.S (Janssen)","excluded","1","final",">28","hospitalization","severe","USA",">= 18 years","general pop",68,"49",80,NA,"alpha & delta","~20 weeks",NA,NA,691,"USA","USA",97,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-17,"severe","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2021-09-17
"689",98,"Skowronski","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21+","infection","infection","Canada","50-69 years","50-69 years",70,"68",72,NA,"alpha, gamma & delta",NA,NA,NA,692,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-01-27
"690",98,"Skowronski","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","infection","infection","Canada","50-69 years","50-69 years",55,"48",61,NA,"alpha, gamma & delta",NA,NA,NA,693,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-01-27
"691",98,"Skowronski","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","98+","infection","infection","Canada","50-69 years","50-69 years",65,"57",71,NA,"alpha, gamma & delta",NA,NA,NA,694,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-01-27
"692",98,"Skowronski","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21+","hospitalization","severe","Canada","50-69 years","50-69 years",81,"75",85,NA,"alpha, gamma & delta",NA,NA,NA,695,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-01-27
"693",98,"Skowronski","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","1","1","21+","infection","infection","Canada","50-69 years","50-69 years",75,"71",78,NA,"alpha, gamma & delta",NA,NA,NA,696,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-01-27
"694",98,"Skowronski","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","1","1","14-20","infection","infection","Canada","50-69 years","50-69 years",67,"57",75,NA,"alpha, gamma & delta",NA,NA,NA,697,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-01-27
"695",98,"Skowronski","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","1","1","98+","infection","infection","Canada","50-69 years","50-69 years",54,"38",66,NA,"alpha, gamma & delta",NA,NA,NA,698,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-01-27
"696",98,"Skowronski","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","1","1","21+","hospitalization","severe","Canada","50-69 years","50-69 years",85,"76",91,NA,"alpha, gamma & delta",NA,NA,NA,699,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-01-27
"697",98,"Skowronski","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14-20","hospitalization","severe","Canada","50-69 years","50-69 years",74,"60",83,NA,"alpha, gamma & delta",NA,NA,NA,700,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-01-27
"698",98,"Skowronski","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","98+","hospitalization","severe","Canada","50-69 years","50-69 years",65,"47",77,NA,"alpha, gamma & delta",NA,NA,NA,701,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-01-27
"699",98,"Skowronski","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","21+","infection","infection","Canada","50-69 years","50-69 years",60,"54",65,NA,"alpha, gamma & delta",NA,NA,NA,702,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-01-27
"700",98,"Skowronski","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","14-20","infection","infection","Canada","50-69 years","50-69 years",25,"10",37,NA,"alpha, gamma & delta",NA,NA,NA,703,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-01-27
"701",98,"Skowronski","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","98+","infection","infection","Canada","50-69 years","50-69 years",62,"36",77,NA,"alpha, gamma & delta",NA,NA,NA,704,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-01-27
"702",98,"Skowronski","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","21+","hospitalization","severe","Canada","50-69 years","50-69 years",93,"85",97,NA,"alpha, gamma & delta",NA,NA,NA,705,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-01-27
"703",98,"Skowronski","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","14-20","hospitalization","severe","Canada","50-69 years","50-69 years",67,"30",84,NA,"alpha, gamma & delta",NA,NA,NA,706,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-01-27
"704",98,"Skowronski","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","84+","hospitalization","severe","Canada","50-69 years","50-69 years",74,"-4",94,NA,"alpha, gamma & delta",NA,NA,NA,707,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-01-27
"705",98,"Skowronski","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21+","infection","infection","Canada","50-69 years","50-69 years",77,"73",80,"alpha","alpha",NA,NA,NA,708,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-01-27
"706",98,"Skowronski","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21+","hospitalization","severe","Canada","50-69 years","50-69 years",85,"72",92,"alpha","alpha",NA,NA,NA,709,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-01-27
"707",98,"Skowronski","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","1","1","21+","infection","infection","Canada","50-69 years","50-69 years",84,"77",89,"alpha","alpha",NA,NA,NA,710,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","alpha",NA,2022-01-27
"708",98,"Skowronski","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","1","1","21+","hospitalization","severe","Canada","50-69 years","50-69 years",78,"44",91,"alpha","alpha",NA,NA,NA,711,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","alpha",NA,2022-01-27
"709",98,"Skowronski","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","21+","infection ","infection","Canada","50-69 years","50-69 years",69,"61",75,"alpha","alpha",NA,NA,NA,712,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2022-01-27
"710",98,"Skowronski","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21+","infection ","infection","Canada","50-69 years","50-69 years",77,"72",81,"gamma","gamma",NA,NA,NA,713,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","gamma",NA,2022-01-27
"711",98,"Skowronski","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21+","hospitalization","severe","Canada","50-69 years","50-69 years",89,"79",94,"gamma","gamma",NA,NA,NA,714,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","gamma",NA,2022-01-27
"712",98,"Skowronski","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","1","1","21+","infection","infection","Canada","50-69 years","50-69 years",85,"76",90,"gamma","gamma",NA,NA,NA,715,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","gamma",NA,2022-01-27
"713",98,"Skowronski","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","1","1","21+","hospitalization","severe","Canada","50-69 years","50-69 years",96,"71",99,"gamma","gamma",NA,NA,NA,716,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","gamma",NA,2022-01-27
"714",98,"Skowronski","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","21+","infection","infection","Canada","50-69 years","50-69 years",67,"58",74,"gamma","gamma",NA,NA,NA,717,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma",NA,2022-01-27
"715",98,"Skowronski","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","21+","hospitalization","severe","Canada","50-69 years","50-69 years",93,"78",98,"gamma","gamma",NA,NA,NA,718,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma",NA,2022-01-27
"716",98,"Skowronski","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21+","infection","infection","Canada","50-69 years","50-69 years",58,"52",63,"delta","delta",NA,NA,NA,719,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-27
"717",98,"Skowronski","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21+","hospitalization","severe","Canada","50-69 years","50-69 years",73,"60",82,"delta","delta",NA,NA,NA,720,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-27
"718",98,"Skowronski","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","1","1","21+","infection","infection","Canada","50-69 years","50-69 years",70,"64",76,"delta","delta",NA,NA,NA,721,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-01-27
"719",98,"Skowronski","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","1","1","21+","hospitalization","severe","Canada","50-69 years","50-69 years",86,"72",93,"delta","delta",NA,NA,NA,722,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-01-27
"720",98,"Skowronski","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","21+","infection","infection","Canada","50-69 years","50-69 years",41,"15",59,"delta","delta",NA,NA,NA,723,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-01-27
"721",98,"Skowronski","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","21+","hospitalization","severe","Canada","50-69 years","50-69 years",61,"-8",86,"delta","delta",NA,NA,NA,724,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-01-27
"722",98,"Skowronski","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21+","infection","infection","Canada","50-69 years","50-69 years",88,"75",95,"non-VOC","non-VOC",NA,NA,NA,725,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","original",NA,2022-01-27
"723",98,"Skowronski","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","1","1","21+","infection","infection","Canada","50-69 years","50-69 years",78,"31",93,"non-VOC","non-VOC",NA,NA,NA,726,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","original",NA,2022-01-27
"724",98,"Skowronski","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","21+","infection","infection","Canada","50-69 years","50-69 years",93,"70",98,"non-VOC","non-VOC",NA,NA,NA,727,"Canada","CAN",98,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-27,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","original",NA,2022-01-27
"725",99,"Pilishvili","Test-negative case-control","22Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","USA","HCW","HCW",88.9,"84.7",92,NA,"alpha","~14 weeks",NA,NA,728,"USA","USA",99,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-22,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-09-22
"726",99,"Pilishvili","Test-negative case-control","22Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","15-28","symptomatic disease","symptomatic","USA","HCW","HCW",96.3,"92.5",98.2,NA,"alpha","~14 weeks",NA,NA,729,"USA","USA",99,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-22,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-09-22
"727",99,"Pilishvili","Test-negative case-control","22Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","85-98","symptomatic disease","symptomatic","USA","HCW","HCW",80.7,"61",90.4,NA,"alpha","~14 weeks",NA,NA,730,"USA","USA",99,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-22,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-09-22
"728",99,"Pilishvili","Test-negative case-control","22Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+ through dose 2 or later (at least one dose)","symptomatic disease","symptomatic","USA","immunocompromised HCW","immunocompromised HCW",39.1,"-45",74.4,NA,"alpha",NA,NA,NA,731,"USA","USA",99,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-22,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-09-22
"729",99,"Pilishvili","Test-negative case-control","22Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+ through dose 2 or later (at least one dose)","symptomatic disease","symptomatic","USA","pregnant HCW","pregnant HCW",77.1,"32.2",92.2,NA,"alpha",NA,NA,NA,732,"USA","USA",99,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-22,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2021-09-22
"730",99,"Pilishvili","Test-negative case-control","22Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+ up to <7 days post 2nd dose","symptomatic disease","symptomatic","USA","HCW","HCW",77.6,"70.9",82.7,NA,"alpha",NA,NA,NA,733,"USA","USA",99,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-22,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-22
"731",99,"Pilishvili","Test-negative case-control","22Sept2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","symptomatic disease","symptomatic","USA","HCW","HCW",88.8,"84.6",91.8,NA,"alpha","~14 weeks",NA,NA,734,"USA","USA",99,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-22,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-22
"732",99,"Pilishvili","Test-negative case-control","22Sept2021","mRNA-1273 (Moderna)","excluded","1","1","14+ up to <7 days post 2nd dose","symptomatic disease","symptomatic","USA","HCW","HCW",88.9,"78.7",94.2,NA,"alpha",NA,NA,NA,735,"USA","USA",99,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-22,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-09-22
"733",99,"Pilishvili","Test-negative case-control","22Sept2021","mRNA-1273 (Moderna)","excluded","2","final","7+","symptomatic disease","symptomatic","USA","HCW","HCW",96.3,"91.3",98.4,NA,"alpha","~14 weeks",NA,NA,736,"USA","USA",99,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-22,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-09-22
"734",100,"Meyer","Retrospective cohort","09Sept2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","7+","infection","infection","Germany","LTCF residents and staff","LTCF residents and staff",56,"15",77,NA,"alpha","~11 weeks",NA,NA,737,"Germany","DEU",100,"DEU",49470,2019,"Germany","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-06,2021-12-18,2020-12-23,2020-12-23,4,195,360,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-09,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","23/09/2021",2021-09-09
"735",101,"Glatman-Freedman","Retrospective cohort","27Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","8-28","infection","infection","Israel","12-15 years","12-15 years",91.5,"88.2",93.9,NA,"delta","2 weeks",NA,NA,738,"Israel","ISR",101,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-27,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-09-27
"736",102,"Eyre","Retrospective cohort","05Jan2022","BNT162b2 (Pfizer BioNTech)","included","1","1","0+ up to 13 days post dose 2","infection","infection","UK","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",15,"12",18,"alpha","alpha",NA,NA,NA,739,"UK","GBR",102,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-05,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","29/09/2021",2021-09-29
"737",102,"Eyre","Retrospective cohort","05Jan2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","UK","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",85,"79",89,"alpha","alpha","~20.5 weeks",NA,NA,740,"UK","GBR",102,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-05,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","29/09/2021",2021-09-29
"738",102,"Eyre","Retrospective cohort","05Jan2022","AZD1222 (AstraZeneca)","included","1","1","0+ up to 13 days post dose 2","infection","infection","UK","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",6,"2",9,"alpha","alpha",NA,NA,NA,741,"UK","GBR",102,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-05,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","29/09/2021",2021-09-29
"739",102,"Eyre","Retrospective cohort","05Jan2022","AZD1222 (AstraZeneca)","included","2","final","14+","infection","infection","UK","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",60,"41",73,"alpha","alpha","~8 weeks",NA,NA,742,"UK","GBR",102,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-05,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","29/09/2021",2021-09-29
"740",102,"Eyre","Retrospective cohort","05Jan2022","BNT162b2 (Pfizer BioNTech)","included","1","1","0+ up to 13 days post dose 2","infection","infection","UK","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",33,"31",35,"delta","delta",NA,NA,NA,743,"UK","GBR",102,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-05,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/09/2021",2021-09-29
"741",102,"Eyre","Retrospective cohort","05Jan2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","UK","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",81,"77",84,"delta","delta","~29 weeks",NA,NA,744,"UK","GBR",102,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-05,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/09/2021",2021-09-29
"742",102,"Eyre","Retrospective cohort","05Jan2022","AZD1222 (AstraZeneca)","included","1","1","0+ up to 13 days post dose 2","infection","infection","UK","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",31,"28",34,"delta","delta",NA,NA,NA,745,"UK","GBR",102,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-05,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/09/2021",2021-09-29
"743",102,"Eyre","Retrospective cohort","05Jan2022","AZD1222 (AstraZeneca)","included","2","final","14+","infection","infection","UK","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",58,"55",62,"delta","delta","~16 weeks",NA,NA,746,"UK","GBR",102,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-05,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/09/2021",2021-09-29
"744",103,"Martinez-Baz","Prospective cohort","30Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",57,"52",61,NA,"non-VOC, alpha, & delta",NA,NA,NA,747,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-30
"745",103,"Martinez-Baz","Prospective cohort","30Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",69,"66",72,NA,"non-VOC, alpha, & delta","~31 weeks",NA,NA,748,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-30
"746",103,"Martinez-Baz","Prospective cohort","30Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","<90","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",57,"51",61,NA,"non-VOC, alpha, & delta",NA,NA,NA,749,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-30
"747",103,"Martinez-Baz","Prospective cohort","30Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","<90","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",70,"67",73,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,750,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-30
"748",103,"Martinez-Baz","Prospective cohort","30Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","90+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",63,"58",68,NA,"non-VOC, alpha, & delta","~18 weeks",NA,NA,751,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-30
"749",103,"Martinez-Baz","Prospective cohort","30Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","symptomatic disease","symptomatic","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",66,"60",71,NA,"non-VOC, alpha, & delta",NA,NA,NA,752,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-30
"750",103,"Martinez-Baz","Prospective cohort","30Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",72,"69",75,NA,"non-VOC, alpha, & delta","~31 weeks",NA,NA,753,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-30
"751",103,"Martinez-Baz","Prospective cohort","30Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","hospitalization","severe","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",86,"69",94,NA,"non-VOC, alpha, & delta",NA,NA,NA,754,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-30
"752",103,"Martinez-Baz","Prospective cohort","30Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",93,"88",96,NA,"non-VOC, alpha, & delta","~31 weeks",NA,NA,755,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-09-30
"753",103,"Martinez-Baz","Prospective cohort","30Sep2021","mRNA-1273 (Moderna)","excluded","1","1","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",66,"56",73,NA,"non-VOC, alpha, & delta",NA,NA,NA,756,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-30
"754",103,"Martinez-Baz","Prospective cohort","30Sep2021","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",82,"78",86,NA,"non-VOC, alpha, & delta","~28 weeks",NA,NA,757,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-30
"755",103,"Martinez-Baz","Prospective cohort","30Sep2021","mRNA-1273 (Moderna)","excluded","1","1","<90","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",65,"56",73,NA,"non-VOC, alpha, & delta",NA,NA,NA,758,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-30
"756",103,"Martinez-Baz","Prospective cohort","30Sep2021","mRNA-1273 (Moderna)","excluded","2","final","90+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",67,"50",78,NA,"non-VOC, alpha, & delta","~15 weeks",NA,NA,759,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-30
"757",103,"Martinez-Baz","Prospective cohort","30Sep2021","mRNA-1273 (Moderna)","excluded","1","1","14+","symptomatic disease","symptomatic","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",71,"61",79,NA,"non-VOC, alpha, & delta",NA,NA,NA,760,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-30
"758",103,"Martinez-Baz","Prospective cohort","30Sep2021","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",85,"80",89,NA,"non-VOC, alpha, & delta","~28 weeks",NA,NA,761,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-30
"759",103,"Martinez-Baz","Prospective cohort","30Sep2021","mRNA-1273 (Moderna)","excluded","1","1","14+","hospitalization","severe","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",73,"-10",93,NA,"non-VOC, alpha, & delta",NA,NA,NA,762,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-30
"760",103,"Martinez-Baz","Prospective cohort","30Sep2021","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",98,"82",100,NA,"non-VOC, alpha, & delta","~28 weeks",NA,NA,763,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2021-09-30
"761",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca)","excluded","1","1","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",41,"34",48,NA,"non-VOC, alpha, & delta",NA,NA,NA,764,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-09-30
"762",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",54,"48",60,NA,"non-VOC, alpha, & delta","~16 weeks",NA,NA,765,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-09-30
"763",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca)","excluded","1","1","<90","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",40,"31",47,NA,"non-VOC, alpha, & delta",NA,NA,NA,766,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-09-30
"764",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca)","excluded","2","final","<90","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",54,"47",60,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,767,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-09-30
"765",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca)","excluded","1","1","90+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",52,"37",64,NA,"non-VOC, alpha, & delta",NA,NA,NA,768,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-09-30
"766",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca)","excluded","1","1","14+","symptomatic disease","symptomatic","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",46,"37",54,NA,"non-VOC, alpha, & delta",NA,NA,NA,769,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"symptomatic","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-09-30
"767",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","symptomatic disease","symptomatic","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",56,"48",63,NA,"non-VOC, alpha, & delta","~16 weeks",NA,NA,770,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"symptomatic","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-09-30
"768",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca)","excluded","1","1","14+","hospitalization","severe","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",78,"54",89,NA,"non-VOC, alpha, & delta",NA,NA,NA,771,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"severe","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-09-30
"769",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","hospitalization","severe","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",95,"79",99,NA,"non-VOC, alpha, & delta","~16 weeks",NA,NA,772,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"severe","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-09-30
"770",103,"Martinez-Baz","Prospective cohort","30Sep2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",50,"42",57,NA,"non-VOC, alpha, & delta","~23 weeks",NA,NA,773,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2021-09-30
"771",103,"Martinez-Baz","Prospective cohort","30Sep2021","Ad26.COV2.S (Janssen)","excluded","1","final","<90","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",52,"44",59,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,774,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2021-09-30
"772",103,"Martinez-Baz","Prospective cohort","30Sep2021","Ad26.COV2.S (Janssen)","excluded","1","final","90+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",28,"-8",53,NA,"non-VOC, alpha, & delta","~10 weeks",NA,NA,775,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2021-09-30
"773",103,"Martinez-Baz","Prospective cohort","30Sep2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","symptomatic disease","symptomatic","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",54,"45",62,NA,"non-VOC, alpha, & delta","~23 weeks",NA,NA,776,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"symptomatic","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2021-09-30
"774",103,"Martinez-Baz","Prospective cohort","30Sep2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization","severe","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",74,"43",88,NA,"non-VOC, alpha, & delta","~23 weeks",NA,NA,777,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"severe","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2021-09-30
"775",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca) & BNT162b2 (Pfizer BioNTech) - heterologous","excluded","2","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",86,"70",93,NA,"non-VOC, alpha, & delta","~21 weeks",NA,NA,778,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Heterologous platforms","Multiple","other combinations",NA,2021-09-30
"776",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca) & BNT162b2 (Pfizer BioNTech) - heterologous","excluded","2","final","<90","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",85,"69",93,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,779,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Heterologous platforms","Multiple","other combinations",NA,2021-09-30
"777",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca) & BNT162b2 (Pfizer BioNTech) - heterologous","excluded","2","final","14+","symptomatic disease","symptomatic","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",91,"71",97,NA,"non-VOC, alpha, & delta","~21 weeks",NA,NA,780,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"symptomatic","2021 (Jul-Dec)","Heterologous platforms","Multiple","other combinations",NA,2021-09-30
"778",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca) & BNT162b2 (Pfizer BioNTech) - heterologous","excluded","2","final","14+","hospitalization","severe","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",95,"79",99,NA,"non-VOC, alpha, & delta","~21 weeks",NA,NA,781,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"severe","2021 (Jul-Dec)","Heterologous platforms","Multiple","other combinations",NA,2021-09-30
"779",103,"Martinez-Baz","Prospective cohort","30Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",54,"37",67,"alpha","alpha",NA,NA,NA,782,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-30
"780",103,"Martinez-Baz","Prospective cohort","30Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",71,"61",78,"alpha","alpha","~31 weeks",NA,NA,783,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-09-30
"781",103,"Martinez-Baz","Prospective cohort","30Sep2021","mRNA-1273 (Moderna)","excluded","1","1","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",60,"14",81,"alpha","alpha",NA,NA,NA,784,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-09-30
"782",103,"Martinez-Baz","Prospective cohort","30Sep2021","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",86,"56",95,"alpha","alpha","~28 weeks",NA,NA,785,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-09-30
"783",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca)","excluded","1","1","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",37,"21",50,"alpha","alpha",NA,NA,NA,786,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-09-30
"784",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",38,"-42",73,"alpha","alpha","~16 weeks",NA,NA,787,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-09-30
"785",103,"Martinez-Baz","Prospective cohort","30Sep2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",77,"27",92,"alpha","alpha",NA,NA,NA,788,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","alpha",NA,2021-09-30
"786",103,"Martinez-Baz","Prospective cohort","30Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",63,"51",73,"delta","delta",NA,NA,NA,789,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-09-30
"787",103,"Martinez-Baz","Prospective cohort","30Sep2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",67,"59",74,"delta","delta","~31 weeks",NA,NA,790,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-09-30
"788",103,"Martinez-Baz","Prospective cohort","30Sep2021","mRNA-1273 (Moderna)","excluded","1","1","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",72,"51",84,"delta","delta",NA,NA,NA,791,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2021-09-30
"789",103,"Martinez-Baz","Prospective cohort","30Sep2021","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",77,"64",85,"delta","delta","~28 weeks",NA,NA,792,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2021-09-30
"790",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca)","excluded","1","1","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",53,"26",70,"delta","delta",NA,NA,NA,793,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-09-30
"791",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",55,"39",67,"delta","delta","~16 weeks",NA,NA,794,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-09-30
"792",103,"Martinez-Baz","Prospective cohort","30Sep2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",42,"18",53,"delta","delta",NA,NA,NA,795,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2021-09-30
"793",103,"Martinez-Baz","Prospective cohort","30Sep2021","AZD1222 (AstraZeneca) & BNT162b2 (Pfizer BioNTech) - heterologous","excluded","2","final","14+","infection","infection","Spain","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",86,"45",97,"delta","delta","~21 weeks",NA,NA,796,"Spain","ESP",103,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-30,"infection","2021 (Jul-Dec)","Heterologous platforms","Multiple","delta",NA,2021-09-30
"794",104,"Bruxvoort","Test-negative case-control","15Dec2021","mRNA-1273 (Moderna)","excluded","1","1","14+","infection","infection","USA",">= 18 years","general pop",77,"60.7",86.5,"delta","delta",NA,NA,NA,797,"USA","USA",104,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","01/10/2021",2021-10-01
"795",104,"Bruxvoort","Test-negative case-control","15Dec2021","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA",">= 18 years","general pop",86.7,"84.3",88.7,"delta","delta","~25 weeks",NA,NA,798,"USA","USA",104,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","01/10/2021",2021-10-01
"796",104,"Bruxvoort","Test-negative case-control","15Dec2021","mRNA-1273 (Moderna)","excluded","2","final","14-60","infection","infection","USA",">= 18 years","general pop",94.1,"90.5",96.3,"delta","delta","~6.5 weeks",NA,NA,799,"USA","USA",104,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","01/10/2021",2021-10-01
"797",104,"Bruxvoort","Test-negative case-control","15Dec2021","mRNA-1273 (Moderna)","excluded","2","final","151-180","infection","infection","USA",">= 18 years","general pop",80,"70.2",86.6,"delta","delta","~23.5 weeks",NA,NA,800,"USA","USA",104,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","01/10/2021",2021-10-01
"798",104,"Bruxvoort","Test-negative case-control","15Dec2021","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",97.5,"92.7",99.2,"delta","delta","~25 weeks",NA,NA,801,"USA","USA",104,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-15,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","01/10/2021",2021-10-01
"799",104,"Bruxvoort","Test-negative case-control","15Dec2021","mRNA-1273 (Moderna)","excluded","2","final","14-60","infection","infection","USA",">= 18 years","general pop",98.6,"97.3",99.3,"non-delta","non-delta","~6.5 weeks",NA,NA,802,"USA","USA",104,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","01/10/2021",2021-10-01
"800",104,"Bruxvoort","Test-negative case-control","15Dec2021","mRNA-1273 (Moderna)","excluded","2","final","121-150","infection","infection","USA",">= 18 years","general pop",88.7,"73.2",95.2,"non-delta","non-delta","~19.5 weeks",NA,NA,803,"USA","USA",104,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","01/10/2021",2021-10-01
"801",104,"Bruxvoort","Test-negative case-control","15Dec2021","mRNA-1273 (Moderna)","excluded","1","1","14+","infection","infection","USA",">= 18 years","general pop",90.1,"82.9",94.2,"alpha","alpha",NA,NA,NA,804,"USA","USA",104,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha","01/10/2021",2021-10-01
"802",104,"Bruxvoort","Test-negative case-control","15Dec2021","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA",">= 18 years","general pop",98.4,"96.9",99.1,"alpha","alpha","~25 weeks",NA,NA,805,"USA","USA",104,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha","01/10/2021",2021-10-01
"803",104,"Bruxvoort","Test-negative case-control","15Dec2021","mRNA-1273 (Moderna)","excluded","1","1","14+","infection","infection","USA",">= 18 years","general pop",74.2,"43.8",88.1,"gamma","gamma",NA,NA,NA,806,"USA","USA",104,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","gamma","01/10/2021",2021-10-01
"804",104,"Bruxvoort","Test-negative case-control","15Dec2021","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA",">= 18 years","general pop",95.5,"90.9",97.8,"gamma","gamma","~25 weeks",NA,NA,807,"USA","USA",104,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","gamma","01/10/2021",2021-10-01
"805",105,"Liu","Test-negative case-control","24May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA",">= 18 years","general pop",59,"52",65,NA,"alpha & delta","~35 weeks",NA,NA,808,"USA","USA",105,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-05-24,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","07/10/2021",2021-10-07
"806",105,"Liu","Test-negative case-control","24May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","immunocompromised, >= 18 years","immunocompromised adults",57,"45",66,NA,"alpha & delta","~35 weeks",NA,NA,809,"USA","USA",105,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-05-24,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","07/10/2021",2021-10-07
"807",106,"Ranzani","Test-negative case-control","18Oct2021","Ad26.COV2.S (Janssen)","excluded","1","final","28+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",50.9,"35.5",63,NA,"gamma","~10 weeks",NA,NA,810,"Brazil","BRA",106,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2021-10-18,"symptomatic","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","gamma",NA,2021-10-18
"808",106,"Ranzani","Test-negative case-control","18Oct2021","Ad26.COV2.S (Janssen)","excluded","1","final","28+","hospitalization","severe","Brazil",">= 18 years","general pop",72.9,"35.1",91.1,NA,"gamma","~10 weeks",NA,NA,811,"Brazil","BRA",106,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2021-10-18,"severe","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","gamma",NA,2021-10-18
"809",106,"Ranzani","Test-negative case-control","18Oct2021","Ad26.COV2.S (Janssen)","excluded","1","final","28+","ICU admission","severe","Brazil",">= 18 years","general pop",92.5,"54.9",99.6,NA,"gamma","~10 weeks",NA,NA,812,"Brazil","BRA",106,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2021-10-18,"severe","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","gamma",NA,2021-10-18
"810",106,"Ranzani","Test-negative case-control","18Oct2021","Ad26.COV2.S (Janssen)","excluded","1","final","28+","death","death","Brazil",">= 18 years","general pop",90.5,"31.5",99.6,NA,"gamma","~10 weeks",NA,NA,813,"Brazil","BRA",106,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2021-10-18,"death","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","gamma",NA,2021-10-18
"811",107,"Arregoces","Matched-pair cohort","19Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Colombia",">= 60 years",">= 60 years",90.3,"87.1",92.7,NA,"mu","~9 weeks",NA,NA,814,"Colombia","COL",107,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2021-10-19,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","mu",NA,2021-10-19
"812",107,"Arregoces","Matched-pair cohort","19Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","post-hospitalization death","death","Colombia",">= 60 years",">= 60 years",98.5,"97.8",98.9,NA,"mu","~9 weeks",NA,NA,815,"Colombia","COL",107,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2021-10-19,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","mu",NA,2021-10-19
"813",107,"Arregoces","Matched-pair cohort","19Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death without prior hospitalization","death","Colombia",">= 60 years",">= 60 years",89.2,"85.6",91.9,NA,"mu","~9 weeks",NA,NA,816,"Colombia","COL",107,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2021-10-19,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","mu",NA,2021-10-19
"814",107,"Arregoces","Matched-pair cohort","19Oct2021","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Colombia",">= 60 years",">= 60 years",67.2,"63.7",70.4,NA,"mu","~11 weeks",NA,NA,817,"Colombia","COL",107,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2021-10-19,"severe","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","mu",NA,2021-10-19
"815",107,"Arregoces","Matched-pair cohort","19Oct2021","CoronaVac (Sinovac)","excluded","2","final","14+","post-hospitalization death","death","Colombia",">= 60 years",">= 60 years",77.1,"75.5",78.6,NA,"mu","~11 weeks",NA,NA,818,"Colombia","COL",107,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2021-10-19,"death","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","mu",NA,2021-10-19
"816",107,"Arregoces","Matched-pair cohort","19Oct2021","CoronaVac (Sinovac)","excluded","2","final","14+","death without prior hospitalization","death","Colombia",">= 60 years",">= 60 years",69.8,"66.7",72.6,NA,"mu","~11 weeks",NA,NA,819,"Colombia","COL",107,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2021-10-19,"death","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","mu",NA,2021-10-19
"817",107,"Arregoces","Matched-pair cohort","19Oct2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","hospitalization","severe","Colombia",">= 60 years",">= 60 years",75.4,"48.2",88.3,NA,"mu","~7 weeks",NA,NA,820,"Colombia","COL",107,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2021-10-19,"severe","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","mu",NA,2021-10-19
"818",107,"Arregoces","Matched-pair cohort","19Oct2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","post-hospitalization death","death","Colombia",">= 60 years",">= 60 years",96.3,"88.4",98.8,NA,"mu","~7 weeks",NA,NA,821,"Colombia","COL",107,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2021-10-19,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","mu",NA,2021-10-19
"819",107,"Arregoces","Matched-pair cohort","19Oct2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","death without prior hospitalization","death","Colombia",">= 60 years",">= 60 years",88.7,"64.8",96.4,NA,"mu","~7 weeks",NA,NA,822,"Colombia","COL",107,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2021-10-19,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","mu",NA,2021-10-19
"820",107,"Arregoces","Matched-pair cohort","19Oct2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization","severe","Colombia",">= 60 years",">= 60 years",80,"19.9",95,NA,"mu","~4 weeks",NA,NA,823,"Colombia","COL",107,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2021-10-19,"severe","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","mu",NA,2021-10-19
"821",107,"Arregoces","Matched-pair cohort","19Oct2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","death without prior hospitalization","death","Colombia",">= 60 years",">= 60 years",75,"0",93.8,NA,"mu","~4 weeks",NA,NA,824,"Colombia","COL",107,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2021-10-19,"death","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","mu",NA,2021-10-19
"822",108,"Olson","Test-negative case-control","19Oct2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","hospitalization","severe","USA","12-15 years","12-15 years",91,"74",97,NA,"delta","~12 weeks",NA,NA,825,"USA","USA",108,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-19,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-10-19
"823",108,"Olson","Test-negative case-control","19Oct2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","hospitalization","severe","USA","16-18 years","16-18 years",94,"78",99,NA,"delta","~12 weeks",NA,NA,826,"USA","USA",108,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-19,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-10-19
"824",110,"Chin","Retrospective cohort","20Oct2021","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","USA","incarcerated men","incarcerated men",56.6,"42",67.5,NA,"delta","~27 weeks",NA,NA,866,"USA","USA",110,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-20,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2021-10-20
"825",110,"Chin","Retrospective cohort","20Oct2021","mRNA-1273 (Moderna)","included","2","final","14+","symptomatic disease","symptomatic","USA","incarcerated men","incarcerated men",84.2,"56.4",94.3,NA,"delta","~27 weeks",NA,NA,867,"USA","USA",110,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-20,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2021-10-20
"826",110,"Chin","Retrospective cohort","20Oct2021","mRNA-1273 (Moderna)","previously infected only","2","final","14+","infection","infection","USA","incarcerated men","incarcerated men",80.5,"52.8",92,NA,"delta","~27 weeks",NA,NA,868,"USA","USA",110,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-20,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2021-10-20
"827",110,"Chin","Retrospective cohort","20Oct2021","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","incarcerated men","incarcerated men",49.5,"31.5",62.7,NA,"delta","~27 weeks",NA,NA,869,"USA","USA",110,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-20,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2021-10-20
"828",111,"Ranzani","Test-negative case-control","09Feb2022","AZD1222 (AstraZeneca)","excluded","1","1",">21","infection","infection","Brazil",">= 18 years","general pop",31,"12.7",45.5,NA,"gamma & delta",NA,NA,NA,870,"Brazil","BRA",111,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-09,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","20/10/2021",2021-10-20
"829",111,"Ranzani","Test-negative case-control","09Feb2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection","infection","Brazil",">= 18 years","general pop",59,"33.1",74.8,NA,"gamma & delta","~31 weeks",NA,NA,871,"Brazil","BRA",111,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-09,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","20/10/2021",2021-10-20
"830",111,"Ranzani","Test-negative case-control","09Feb2022","AZD1222 (AstraZeneca)","excluded","1","1",">21","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",31.6,"12",46.8,NA,"gamma & delta",NA,NA,NA,872,"Brazil","BRA",111,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-09,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","20/10/2021",2021-10-20
"831",111,"Ranzani","Test-negative case-control","09Feb2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",65.1,"40.9",79.4,NA,"gamma & delta","~31 weeks",NA,NA,873,"Brazil","BRA",111,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-09,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","20/10/2021",2021-10-20
"832",111,"Ranzani","Test-negative case-control","09Feb2022","AZD1222 (AstraZeneca)","excluded","1","1",">21","asymptomatic infection","asymptomatic","Brazil",">= 18 years","general pop",26.6,"-53.8",65,NA,"gamma & delta",NA,NA,NA,874,"Brazil","BRA",111,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-09,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","20/10/2021",2021-10-20
"833",112,"Nordstrom","Retrospective cohort","04Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","15-30","symptomatic disease","symptomatic","Sweden",">= 18 years","general pop",92,"92",93,NA,"delta","~30 weeks",NA,NA,875,"Sweden","SWE",112,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-04,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/10/2021",2021-10-25
"834",112,"Nordstrom","Retrospective cohort","04Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","210+","symptomatic disease","symptomatic","Sweden",">= 18 years","general pop",23,"-2",41,NA,"delta","~30 weeks",NA,NA,876,"Sweden","SWE",112,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-04,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/10/2021",2021-10-25
"835",112,"Nordstrom","Retrospective cohort","04Feb2022","mRNA-1273 (Moderna)","excluded","2","final","15-30","symptomatic disease","symptomatic","Sweden",">= 18 years","general pop",96,"94",97,NA,"delta","~30 weeks",NA,NA,877,"Sweden","SWE",112,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-04,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","25/10/2021",2021-10-25
"836",112,"Nordstrom","Retrospective cohort","04Feb2022","mRNA-1273 (Moderna)","excluded","2","final","210+","symptomatic disease","symptomatic","Sweden",">= 18 years","general pop",59,"18",79,NA,"delta","~30 weeks",NA,NA,878,"Sweden","SWE",112,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-04,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","25/10/2021",2021-10-25
"837",112,"Nordstrom","Retrospective cohort","04Feb2022","AZD1222 (AstraZeneca)","excluded","2","final","15-30","symptomatic disease","symptomatic","Sweden",">= 18 years","general pop",68,"52",79,NA,"delta","~30 weeks",NA,NA,879,"Sweden","SWE",112,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-04,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","25/10/2021",2021-10-25
"838",112,"Nordstrom","Retrospective cohort","04Feb2022","AZD1222 (AstraZeneca)","excluded","2","final","210+","symptomatic disease","symptomatic","Sweden",">= 18 years","general pop",-19,"-97",28,NA,"delta","~30 weeks",NA,NA,880,"Sweden","SWE",112,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-04,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","25/10/2021",2021-10-25
"839",112,"Nordstrom","Retrospective cohort","04Feb2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","15-30","symptomatic disease","symptomatic","Sweden",">= 18 years","general pop",89,"79",94,NA,"delta","~30 weeks",NA,NA,881,"Sweden","SWE",112,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-04,"symptomatic","2022 (Jan-Jun)","Heterologous platforms","Multiple","delta","25/10/2021",2021-10-25
"840",112,"Nordstrom","Retrospective cohort","04Feb2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","210+","symptomatic disease","symptomatic","Sweden",">= 18 years","general pop",66,"41",80,NA,"delta","~30 weeks",NA,NA,882,"Sweden","SWE",112,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-04,"symptomatic","2022 (Jan-Jun)","Heterologous platforms","Multiple","delta","25/10/2021",2021-10-25
"841",113,"Lin","Retrospective cohort","10Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","1.25 months","symptomatic disease","symptomatic","USA",">= 18 years","general pop",94.5,"94.1",94.9,NA,"alpha & delta","~27 weeks",NA,NA,883,"USA","USA",113,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-10,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/10/2021",2021-10-26
"842",113,"Lin","Retrospective cohort","10Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","7.25 months","symptomatic disease","symptomatic","USA",">= 18 years","general pop",67.8,"65.9",69.7,NA,"alpha & delta","~27 weeks",NA,NA,884,"USA","USA",113,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-10,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/10/2021",2021-10-26
"843",113,"Lin","Retrospective cohort","10Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","1.25 months","hospitalization","severe","USA",">= 18 years","general pop",96.4,"95.1",97.4,NA,"alpha & delta","~27 weeks",NA,NA,885,"USA","USA",113,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-10,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/10/2021",2021-10-26
"844",113,"Lin","Retrospective cohort","10Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","7.25 months","hospitalization","severe","USA",">= 18 years","general pop",92.4,"89.7",94.4,NA,"alpha & delta","~27 weeks",NA,NA,886,"USA","USA",113,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-10,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/10/2021",2021-10-26
"845",113,"Lin","Retrospective cohort","10Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","1.25 months","death","death","USA",">= 18 years","general pop",98,"95.5",99.1,NA,"alpha & delta","~27 weeks",NA,NA,887,"USA","USA",113,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-10,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/10/2021",2021-10-26
"846",113,"Lin","Retrospective cohort","10Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","7.25 months","death","death","USA",">= 18 years","general pop",95.5,"92.2",97.4,NA,"alpha & delta","~32 weeks",NA,NA,888,"USA","USA",113,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-10,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/10/2021",2021-10-26
"847",113,"Lin","Retrospective cohort","10Mar2022","mRNA-1273 (Moderna)","unknown","2","final","1 month","symptomatic disease","symptomatic","USA",">= 18 years","general pop",95.9,"95.5",96.2,NA,"alpha & delta","~32 weeks",NA,NA,889,"USA","USA",113,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-10,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","26/10/2021",2021-10-26
"848",113,"Lin","Retrospective cohort","10Mar2022","mRNA-1273 (Moderna)","unknown","2","final","7 months","symptomatic disease","symptomatic","USA",">= 18 years","general pop",77.8,"75.9",79.6,NA,"alpha & delta","~32 weeks",NA,NA,890,"USA","USA",113,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-10,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","26/10/2021",2021-10-26
"849",113,"Lin","Retrospective cohort","10Mar2022","mRNA-1273 (Moderna)","unknown","2","final","1 month","hospitalization","severe","USA",">= 18 years","general pop",97.2,"96.1",98,NA,"alpha & delta","~32 weeks",NA,NA,891,"USA","USA",113,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-10,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","26/10/2021",2021-10-26
"850",113,"Lin","Retrospective cohort","10Mar2022","mRNA-1273 (Moderna)","unknown","2","final","7 months","hospitalization","severe","USA",">= 18 years","general pop",94.9,"92.4",96.6,NA,"alpha & delta","~32 weeks",NA,NA,892,"USA","USA",113,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-10,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","26/10/2021",2021-10-26
"851",113,"Lin","Retrospective cohort","10Mar2022","mRNA-1273 (Moderna)","unknown","2","final","1 month","death","death","USA",">= 18 years","general pop",98.6,"97.3",99.3,NA,"alpha & delta","~32 weeks",NA,NA,893,"USA","USA",113,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-10,"death","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","26/10/2021",2021-10-26
"852",113,"Lin","Retrospective cohort","10Mar2022","mRNA-1273 (Moderna)","unknown","2","final","7 months","death","death","USA",">= 18 years","general pop",96,"92.8",97.8,NA,"alpha & delta","~22 weeks",NA,NA,894,"USA","USA",113,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-10,"death","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","26/10/2021",2021-10-26
"853",113,"Lin","Retrospective cohort","10Mar2022","Ad26.COV2.S (Janssen)","unknown","1","final","2 months","symptomatic disease","symptomatic","USA",">= 18 years","general pop",71.4,"68.3",74.2,NA,"alpha & delta","~22 weeks",NA,NA,895,"USA","USA",113,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-10,"symptomatic","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","26/10/2021",2021-10-26
"854",113,"Lin","Retrospective cohort","10Mar2022","Ad26.COV2.S (Janssen)","unknown","1","final","6 months","symptomatic disease","symptomatic","USA",">= 18 years","general pop",64,"60.3",67.4,NA,"alpha & delta","~22 weeks",NA,NA,896,"USA","USA",113,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-10,"symptomatic","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","26/10/2021",2021-10-26
"855",113,"Lin","Retrospective cohort","10Mar2022","Ad26.COV2.S (Janssen)","unknown","1","final","2 months","hospitalization","severe","USA",">= 18 years","general pop",85.8,"74.9",91.9,NA,"alpha & delta","~22 weeks",NA,NA,897,"USA","USA",113,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-10,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","26/10/2021",2021-10-26
"856",113,"Lin","Retrospective cohort","10Mar2022","Ad26.COV2.S (Janssen)","unknown","1","final","6 months","hospitalization","severe","USA",">= 18 years","general pop",81.7,"68.6",89.3,NA,"alpha & delta","~22 weeks",NA,NA,898,"USA","USA",113,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-10,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","26/10/2021",2021-10-26
"857",113,"Lin","Retrospective cohort","10Mar2022","Ad26.COV2.S (Janssen)","unknown","1","final","2 months","death","death","USA",">= 18 years","general pop",82.2,"46.3",94.1,NA,"alpha & delta","~22 weeks",NA,NA,899,"USA","USA",113,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-10,"death","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","26/10/2021",2021-10-26
"858",113,"Lin","Retrospective cohort","10Mar2022","Ad26.COV2.S (Janssen)","unknown","1","final","6 months","death","death","USA",">= 18 years","general pop",71.2,"40.8",86,NA,"alpha & delta","~22 weeks",NA,NA,900,"USA","USA",113,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-10,"death","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","26/10/2021",2021-10-26
"859",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",89,"89",89,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,901,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/10/2021",2021-10-26
"860",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-27","Infection","infection","Canada",">= 18 years","general pop",93,"92",94,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,902,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/10/2021",2021-10-26
"861",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","252-279","Infection","infection","Canada",">= 18 years","general pop",80,"75",83,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,903,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/10/2021",2021-10-26
"862",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Hospitalization","severe","Canada",">= 18 years","general pop",97,"97",98,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,904,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/10/2021",2021-10-26
"863",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-27","Hospitalization","severe","Canada",">= 18 years","general pop",98,"96",99,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,905,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/10/2021",2021-10-26
"864",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","252-279","Hospitalization","severe","Canada",">= 18 years","general pop",96,"86",99,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,906,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/10/2021",2021-10-26
"865",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",90,"89",90,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,907,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","26/10/2021",2021-10-26
"866",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14-27","Infection","infection","Canada",">= 18 years","general pop",95,"94",96,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,908,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","26/10/2021",2021-10-26
"867",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","252-279","Infection","infection","Canada",">= 18 years","general pop",55,"40",66,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,909,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","26/10/2021",2021-10-26
"868",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","Hospitalization","severe","Canada",">= 18 years","general pop",97,"97",98,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,910,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","26/10/2021",2021-10-26
"869",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14-27","Hospitalization","severe","Canada",">= 18 years","general pop",99,"95",100,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,911,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","26/10/2021",2021-10-26
"870",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","252-279","Hospitalization","severe","Canada",">= 18 years","general pop",95,"65",99,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,912,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","26/10/2021",2021-10-26
"871",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",74,"72",76,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,913,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","26/10/2021",2021-10-26
"872",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","14-27","Infection","infection","Canada",">= 18 years","general pop",77,"57",87,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,914,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","26/10/2021",2021-10-26
"873",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","168-195","Infection","infection","Canada",">= 18 years","general pop",67,"48",80,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,915,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","26/10/2021",2021-10-26
"874",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","Hospitalization","severe","Canada",">= 18 years","general pop",95,"94",97,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,916,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","26/10/2021",2021-10-26
"875",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","28-55","Hospitalization","severe","Canada",">= 18 years","general pop",97,"71",97,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,917,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","26/10/2021",2021-10-26
"876",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","168-195","Hospitalization","severe","Canada",">= 18 years","general pop",91,"35",99,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,918,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","26/10/2021",2021-10-26
"877",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",90,"89",90,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,919,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","26/10/2021",2021-10-26
"878",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","14-27","Infection","infection","Canada",">= 18 years","general pop",95,"91",97,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,920,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","26/10/2021",2021-10-26
"879",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","168-195","Infection","infection","Canada",">= 18 years","general pop",96,"73",99,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,921,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","26/10/2021",2021-10-26
"880",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","14+","Hospitalization","severe","Canada",">= 18 years","general pop",98,"97",98,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,922,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","26/10/2021",2021-10-26
"881",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","14-27","Hospitalization","severe","Canada",">= 18 years","general pop",96,"75",100,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,923,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","26/10/2021",2021-10-26
"882",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","140-167","Hospitalization","severe","Canada",">= 18 years","general pop",96,"92",98,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,924,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","26/10/2021",2021-10-26
"883",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",89,"88",89,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,925,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations","26/10/2021",2021-10-26
"884",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14-27","Infection","infection","Canada",">= 18 years","general pop",94,"89",97,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,926,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations","26/10/2021",2021-10-26
"885",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","140-167","Infection","infection","Canada",">= 18 years","general pop",82,"78",85,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,927,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations","26/10/2021",2021-10-26
"886",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14+","Hospitalization","severe","Canada",">= 18 years","general pop",99,"99",100,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,928,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations","26/10/2021",2021-10-26
"887",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14-27","Hospitalization","severe","Canada",">= 18 years","general pop",93,"48",99,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,929,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations","26/10/2021",2021-10-26
"888",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","140-167","hospitalization","severe","Canada",">= 18 years","general pop",98,"91",99,NA,"non-VOC, alpha, gamma & delta","~38 weeks",NA,NA,930,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations","26/10/2021",2021-10-26
"889",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",89,"89",89,"delta","delta","~38 weeks",NA,NA,931,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","26/10/2021",2021-10-26
"890",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-27","Infection","infection","Canada",">= 18 years","general pop",93,"93",94,"delta","delta","~38 weeks",NA,NA,932,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","26/10/2021",2021-10-26
"891",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","252-279","Infection","infection","Canada",">= 18 years","general pop",79,"75",83,"delta","delta","~38 weeks",NA,NA,933,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","26/10/2021",2021-10-26
"892",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Canada",">= 18 years","general pop",98,"97",98,"delta","delta","~38 weeks",NA,NA,934,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","26/10/2021",2021-10-26
"893",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-27","hospitalization","severe","Canada",">= 18 years","general pop",98,"95",99,"delta","delta","~38 weeks",NA,NA,935,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","26/10/2021",2021-10-26
"894",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","196-223","hospitalization","severe","Canada",">= 18 years","general pop",94,"87",97,"delta","delta","~38 weeks",NA,NA,936,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","26/10/2021",2021-10-26
"895",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",90,"89",90,"delta","delta","~38 weeks",NA,NA,937,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","26/10/2021",2021-10-26
"896",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14-27","Infection","infection","Canada",">= 18 years","general pop",95,"94",96,"delta","delta","~38 weeks",NA,NA,938,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","26/10/2021",2021-10-26
"897",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","196-223","Infection","infection","Canada",">= 18 years","general pop",55,"41",66,"delta","delta","~38 weeks",NA,NA,939,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","26/10/2021",2021-10-26
"898",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","Canada",">= 18 years","general pop",97,"97",98,"delta","delta","~38 weeks",NA,NA,940,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","26/10/2021",2021-10-26
"899",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14-27","hospitalization","severe","Canada",">= 18 years","general pop",98,"94",100,"delta","delta","~38 weeks",NA,NA,941,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","26/10/2021",2021-10-26
"900",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","196-223","hospitalization","severe","Canada",">= 18 years","general pop",95,"80",99,"delta","delta","~38 weeks",NA,NA,942,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","26/10/2021",2021-10-26
"901",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",73,"72",75,"delta","delta","~38 weeks",NA,NA,943,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","26/10/2021",2021-10-26
"902",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","14-27","Infection","infection","Canada",">= 18 years","general pop",70,"39",86,"delta","delta","~38 weeks",NA,NA,944,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","26/10/2021",2021-10-26
"903",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","168-195","Infection","infection","Canada",">= 18 years","general pop",67,"48",80,"delta","delta","~38 weeks",NA,NA,945,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","26/10/2021",2021-10-26
"904",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","Hospitalization","severe","Canada",">= 18 years","general pop",95,"93",97,"delta","delta","~38 weeks",NA,NA,946,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","26/10/2021",2021-10-26
"905",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","28-55","Hospitalization","severe","Canada",">= 18 years","general pop",89,"67",97,"delta","delta","~38 weeks",NA,NA,947,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","26/10/2021",2021-10-26
"906",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","168-195","Hospitalization","severe","Canada",">= 18 years","general pop",91,"34",99,"delta","delta","~38 weeks",NA,NA,948,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","26/10/2021",2021-10-26
"907",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",90,"89",90,"delta","delta","~38 weeks",NA,NA,949,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","26/10/2021",2021-10-26
"908",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","14-27","Infection","infection","Canada",">= 18 years","general pop",94,"90",97,"delta","delta","~38 weeks",NA,NA,950,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","26/10/2021",2021-10-26
"909",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","168-195","Infection","infection","Canada",">= 18 years","general pop",96,"73",99,"delta","delta","~38 weeks",NA,NA,951,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","26/10/2021",2021-10-26
"910",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","14+","Hospitalization","severe","Canada",">= 18 years","general pop",98,"97",98,"delta","delta","~38 weeks",NA,NA,952,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","26/10/2021",2021-10-26
"911",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","28-55","Hospitalization","severe","Canada",">= 18 years","general pop",97,"93",99,"delta","delta","~38 weeks",NA,NA,953,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","26/10/2021",2021-10-26
"912",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","140-167","Hospitalization","severe","Canada",">= 18 years","general pop",96,"92",98,"delta","delta","~38 weeks",NA,NA,954,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","26/10/2021",2021-10-26
"913",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",88,"88",89,"delta","delta","~38 weeks",NA,NA,955,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","delta","26/10/2021",2021-10-26
"914",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14-27","Infection","infection","Canada",">= 18 years","general pop",94,"88",97,"delta","delta","~38 weeks",NA,NA,956,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","delta","26/10/2021",2021-10-26
"915",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","140-167","Infection","infection","Canada",">= 18 years","general pop",82,"77",85,"delta","delta","~38 weeks",NA,NA,957,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","delta","26/10/2021",2021-10-26
"916",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14+","Hospitalization","severe","Canada",">= 18 years","general pop",99,"99",100,"delta","delta","~38 weeks",NA,NA,958,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Heterologous platforms","Multiple","delta","26/10/2021",2021-10-26
"917",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14-27","Hospitalization","severe","Canada",">= 18 years","general pop",91,"33",99,"delta","delta","~38 weeks",NA,NA,959,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Heterologous platforms","Multiple","delta","26/10/2021",2021-10-26
"918",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","140-167","Hospitalization","severe","Canada",">= 18 years","general pop",98,"91",99,"delta","delta","~38 weeks",NA,NA,960,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Heterologous platforms","Multiple","delta","26/10/2021",2021-10-26
"919",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",96,"92",98,"alpha","alpha","~38 weeks",NA,NA,961,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","26/10/2021",2021-10-26
"920",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Hospitalization","severe","Canada",">= 18 years","general pop",96,"83",99,"alpha","alpha","~38 weeks",NA,NA,962,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","26/10/2021",2021-10-26
"921",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",95,"84",98,"alpha","alpha","~38 weeks",NA,NA,963,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","alpha","26/10/2021",2021-10-26
"922",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",75,"33",91,"alpha","alpha","~38 weeks",NA,NA,964,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha","26/10/2021",2021-10-26
"923",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",96,"73",99,"alpha","alpha","~38 weeks",NA,NA,965,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha","26/10/2021",2021-10-26
"924",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",92,"88",95,"gamma","gamma","~38 weeks",NA,NA,966,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","gamma","26/10/2021",2021-10-26
"925",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Hospitalization","severe","Canada",">= 18 years","general pop",95,"82",98,"gamma","gamma","~38 weeks",NA,NA,967,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","gamma","26/10/2021",2021-10-26
"926",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",95,"85",98,"gamma","gamma","~38 weeks",NA,NA,968,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","gamma","26/10/2021",2021-10-26
"927",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",91,"63",98,"gamma","gamma","~38 weeks",NA,NA,969,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma","26/10/2021",2021-10-26
"928",114,"Skowronski","Test-negative case-control","19Apr2022","Any mRNA - heterologous","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",94,"76",99,"gamma","gamma","~38 weeks",NA,NA,970,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","gamma","26/10/2021",2021-10-26
"929",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14+","Infection","infection","Canada",">= 18 years","general pop",96,"69",99,"gamma","gamma","~38 weeks",NA,NA,971,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","gamma","26/10/2021",2021-10-26
"930",115,"Nordstrom","Retrospective cohort","18Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Sweden",">= 18 years","general pop",78,"78",79,NA,"delta","~11 weeks",NA,NA,972,"Sweden","SWE",115,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-10-18,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-10-18
"931",115,"Nordstrom","Retrospective cohort","18Oct2021","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","Sweden",">= 18 years","general pop",87,"84",88,NA,"delta","~11 weeks",NA,NA,973,"Sweden","SWE",115,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-10-18,"symptomatic","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2021-10-18
"932",115,"Nordstrom","Retrospective cohort","18Oct2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","symptomatic disease","symptomatic","Sweden",">= 18 years","general pop",50,"41",58,NA,"delta","~11 weeks",NA,NA,974,"Sweden","SWE",115,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-10-18,"symptomatic","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-10-18
"933",115,"Nordstrom","Retrospective cohort","18Oct2021","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14+","symptomatic disease","symptomatic","Sweden",">= 18 years","general pop",67,"59",73,NA,"delta","~11 weeks",NA,NA,975,"Sweden","SWE",115,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-10-18,"symptomatic","2021 (Jul-Dec)","Heterologous platforms","Multiple","delta",NA,2021-10-18
"934",115,"Nordstrom","Retrospective cohort","18Oct2021","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14+","symptomatic disease","symptomatic","Sweden",">= 18 years","general pop",79,"62",88,NA,"delta","~11 weeks",NA,NA,976,"Sweden","SWE",115,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-10-18,"symptomatic","2021 (Jul-Dec)","Heterologous platforms","Multiple","delta",NA,2021-10-18
"935",116,"Reis","Retrospective cohort","20Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","infection","infection","Israel","12-18 years","12-18 years",59,"52",65,NA,"delta",NA,NA,NA,977,"Israel","ISR",116,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-20,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-10-20
"936",116,"Reis","Retrospective cohort","20Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-21","infection","infection","Israel","12-18 years","12-18 years",90,"88",92,NA,"delta","~12 weeks",NA,NA,978,"Israel","ISR",116,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-20,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-10-20
"937",116,"Reis","Retrospective cohort","20Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21-27","infection","infection","Israel","12-18 years","12-18 years",66,"59",72,NA,"delta",NA,NA,NA,979,"Israel","ISR",116,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-20,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-10-20
"938",116,"Reis","Retrospective cohort","20Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","symptomatic disease","symptomatic","Israel","12-18 years","12-18 years",57,"39",71,NA,"delta",NA,NA,NA,980,"Israel","ISR",116,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-20,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-10-20
"939",116,"Reis","Retrospective cohort","20Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-21","symptomatic disease","symptomatic","Israel","12-18 years","12-18 years",93,"88",97,NA,"delta","~12 weeks",NA,NA,981,"Israel","ISR",116,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-20,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-10-20
"940",116,"Reis","Retrospective cohort","20Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21-27","symptomatic disease","symptomatic","Israel","12-18 years","12-18 years",82,"73",91,NA,"delta",NA,NA,NA,982,"Israel","ISR",116,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-20,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-10-20
"941",117,"Sheikh","Retrospective cohort","20Oct2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","death","death","Scotland","40-59 years","40-59 years",100,NA,NA,NA,"alpha & delta",NA,NA,NA,983,"UK","GBR",117,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-20,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-10-20
"942",117,"Sheikh","Retrospective cohort","20Oct2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","death","death","Scotland","40-59 years","40-59 years",95,"79",99,NA,"alpha & delta","~25 weeks",NA,NA,984,"UK","GBR",117,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-20,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-10-20
"943",117,"Sheikh","Retrospective cohort","20Oct2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","death","death","Scotland",">= 60 years","60+ years",75,"26",91,NA,"alpha & delta",NA,NA,NA,985,"UK","GBR",117,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-20,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-10-20
"944",117,"Sheikh","Retrospective cohort","20Oct2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","death","death","Scotland",">= 60 years","60+ years",87,"77",93,NA,"alpha & delta","~25 weeks",NA,NA,986,"UK","GBR",117,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-20,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-10-20
"945",117,"Sheikh","Retrospective cohort","20Oct2021","AZD1222 (AstraZeneca)","unknown","1","1","14+","death","death","Scotland","40-59 years","40-59 years",96,"85",99,NA,"alpha & delta",NA,NA,NA,987,"UK","GBR",117,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-20,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-10-20
"946",117,"Sheikh","Retrospective cohort","20Oct2021","AZD1222 (AstraZeneca)","unknown","2","final","14+","death","death","Scotland","40-59 years","40-59 years",88,"76",93,NA,"alpha & delta","~25 weeks",NA,NA,988,"UK","GBR",117,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-20,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-10-20
"947",117,"Sheikh","Retrospective cohort","20Oct2021","AZD1222 (AstraZeneca)","unknown","1","1","14+","death","death","Scotland",">= 60 years","60+ years",97,"86",99,NA,"alpha & delta",NA,NA,NA,989,"UK","GBR",117,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-20,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-10-20
"948",117,"Sheikh","Retrospective cohort","20Oct2021","AZD1222 (AstraZeneca)","unknown","2","final","14+","death","death","Scotland",">= 60 years","60+ years",90,"84",94,NA,"alpha & delta","~25 weeks",NA,NA,990,"UK","GBR",117,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-20,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2021-10-20
"949",117,"Sheikh","Retrospective cohort","20Oct2021","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","death","death","Scotland",">= 18 years","general pop",92,"66",98,"delta","delta",NA,NA,NA,991,"UK","GBR",117,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-20,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-10-20
"950",117,"Sheikh","Retrospective cohort","20Oct2021","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","death","death","Scotland",">= 18 years","general pop",90,"83",94,"delta","delta","~25 weeks",NA,NA,992,"UK","GBR",117,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-20,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-10-20
"951",117,"Sheikh","Retrospective cohort","20Oct2021","AZD1222 (AstraZeneca)","unknown","1","1","14+","death","death","Scotland",">= 18 years","general pop",96,"89",99,"delta","delta",NA,NA,NA,993,"UK","GBR",117,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-20,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-10-20
"952",117,"Sheikh","Retrospective cohort","20Oct2021","AZD1222 (AstraZeneca)","unknown","2","final","14+","death","death","Scotland",">= 18 years","general pop",91,"86",94,"delta","delta","~25 weeks",NA,NA,994,"UK","GBR",117,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-10-20,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-10-20
"953",118,"Embi","Test-negative case-control","30Dec2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA","immunocompromised, >= 18 years","immunocompromised adults",71,"65",76,NA,"non-VOC, alpha, & delta","~33 weeks",NA,NA,995,"USA","USA",118,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-30,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","05/11/2021",2021-11-05
"954",118,"Embi","Test-negative case-control","30Dec2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",88,"86",89,NA,"non-VOC, alpha, & delta","~33 weeks",NA,NA,996,"USA","USA",118,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-30,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","05/11/2021",2021-11-05
"955",118,"Embi","Test-negative case-control","30Dec2021","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","immunocompromised, >= 18 years","immunocompromised adults",81,"76",85,NA,"non-VOC, alpha, & delta","~33 weeks",NA,NA,997,"USA","USA",118,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-30,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","05/11/2021",2021-11-05
"956",118,"Embi","Test-negative case-control","30Dec2021","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",93,"92",94,NA,"non-VOC, alpha, & delta","~33 weeks",NA,NA,998,"USA","USA",118,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-30,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","05/11/2021",2021-11-05
"957",118,"Embi","Test-negative case-control","30Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","immunocompromised, >= 18 years","immunocompromised adults",76,"69",81,NA,"non-VOC & alpha","~33 weeks",NA,NA,999,"USA","USA",118,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-30,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","05/11/2021",2021-11-05
"958",118,"Embi","Test-negative case-control","30Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",91,"90",93,NA,"non-VOC & alpha","~33 weeks",NA,NA,1000,"USA","USA",118,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-30,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","05/11/2021",2021-11-05
"959",118,"Embi","Test-negative case-control","30Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","immunocompromised, >= 18 years","immunocompromised adults",79,"74",83,NA,"delta","~33 weeks",NA,NA,1001,"USA","USA",118,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-30,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","05/11/2021",2021-11-05
"960",118,"Embi","Test-negative case-control","30Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",90,"89",91,NA,"delta","~33 weeks",NA,NA,1002,"USA","USA",118,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-30,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","05/11/2021",2021-11-05
"961",119,"Poukka","Retrospective cohort","31Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","42+","Infection","infection","Finland","HCW","HCW aged 16-69 years",40,"33",46,NA,"non-VOC, alpha, & delta",NA,NA,NA,1003,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","08/11/2021",2021-11-08
"962",119,"Poukka","Retrospective cohort","31Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-90","Infection","infection","Finland","HCW","HCW aged 16-69 years",83,"80",85,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,1004,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","08/11/2021",2021-11-08
"963",119,"Poukka","Retrospective cohort","31Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","181+","Infection","infection","Finland","HCW","HCW aged 16-69 years",55,"45",64,NA,"non-VOC, alpha, & delta","~29.5 weeks",NA,NA,1005,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","08/11/2021",2021-11-08
"964",119,"Poukka","Retrospective cohort","31Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","42+","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",82,"68",90,NA,"non-VOC, alpha, & delta",NA,NA,NA,1006,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","08/11/2021",2021-11-08
"965",119,"Poukka","Retrospective cohort","31Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-90","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",99,"97",100,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,1007,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","08/11/2021",2021-11-08
"966",119,"Poukka","Retrospective cohort","31Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","181+","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",98,"89",100,NA,"non-VOC, alpha, & delta","~38 weeks",NA,NA,1008,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","08/11/2021",2021-11-08
"967",119,"Poukka","Retrospective cohort","31Jan2022","mRNA-1273 (Moderna)","excluded","1","1","42+","Infection","infection","Finland","HCW","HCW aged 16-69 years",61,"45",72,NA,"non-VOC, alpha, & delta",NA,NA,NA,1009,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","08/11/2021",2021-11-08
"968",119,"Poukka","Retrospective cohort","31Jan2022","mRNA-1273 (Moderna)","excluded","2","final","14-90","Infection","infection","Finland","HCW","HCW aged 16-69 years",84,"68",92,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,1010,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","08/11/2021",2021-11-08
"969",119,"Poukka","Retrospective cohort","31Jan2022","mRNA-1273 (Moderna)","excluded","2","final","91-180","Infection","infection","Finland","HCW","HCW aged 16-69 years",69,"-124",96,NA,"non-VOC, alpha, & delta","~24 weeks",NA,NA,1011,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","08/11/2021",2021-11-08
"970",119,"Poukka","Retrospective cohort","31Jan2022","mRNA-1273 (Moderna)","excluded","1","1","42+","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",89,"22",98,NA,"non-VOC, alpha, & delta",NA,NA,NA,1012,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","08/11/2021",2021-11-08
"971",119,"Poukka","Retrospective cohort","31Jan2022","mRNA-1273 (Moderna)","excluded","2","final","14-90","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,1013,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","08/11/2021",2021-11-08
"972",119,"Poukka","Retrospective cohort","31Jan2022","mRNA-1273 (Moderna)","excluded","2","final","181+","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC, alpha, & delta","~34 weeks",NA,NA,1014,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","08/11/2021",2021-11-08
"973",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - heterologous","excluded","2","final","14-90","Infection","infection","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,1015,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","08/11/2021",2021-11-08
"974",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - heterologous","excluded","2","final","181+","Infection","infection","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC, alpha, & delta","~29.5 weeks",NA,NA,1016,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","08/11/2021",2021-11-08
"975",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - heterologous","excluded","2","final","14-90","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,1017,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","08/11/2021",2021-11-08
"976",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - heterologous","excluded","2","final","181+","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC, alpha, & delta","~38 weeks",NA,NA,1018,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","08/11/2021",2021-11-08
"977",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","42+","Infection","infection","Finland","HCW","HCW aged 16-69 years",22,"-3",42,NA,"non-VOC, alpha, & delta",NA,NA,NA,1019,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","08/11/2021",2021-11-08
"978",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14-90","Infection","infection","Finland","HCW","HCW aged 16-69 years",89,"73",95,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,1020,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","08/11/2021",2021-11-08
"979",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","91-180","Infection","infection","Finland","HCW","HCW aged 16-69 years",63,"-166",95,NA,"non-VOC, alpha, & delta","~24 weeks",NA,NA,1021,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","08/11/2021",2021-11-08
"980",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","42+","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",88,"10",98,NA,"non-VOC, alpha, & delta",NA,NA,NA,1022,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","08/11/2021",2021-11-08
"981",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14-90","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,1023,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","08/11/2021",2021-11-08
"982",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","181+","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC, alpha, & delta","~25 weeks",NA,NA,1024,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","08/11/2021",2021-11-08
"983",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14-90","Infection","infection","Finland","HCW","HCW aged 16-69 years",80,"72",86,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,1025,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations","08/11/2021",2021-11-08
"984",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","91-180","Infection","infection","Finland","HCW","HCW aged 16-69 years",62,"30",79,NA,"non-VOC, alpha, & delta","~24 weeks",NA,NA,1026,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations","08/11/2021",2021-11-08
"985",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14-90","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC, alpha, & delta","~11 weeks",NA,NA,1027,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations","08/11/2021",2021-11-08
"986",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","181+","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC, alpha, & delta","~25 weeks",NA,NA,1028,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations","08/11/2021",2021-11-08
"987",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - homologous or heterologous","excluded","1","1","42+","Infection","infection","Finland","HCW","HCW aged 16-69 years",38,"23",50,NA,"non-VOC & alpha",NA,NA,NA,1029,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","08/11/2021",2021-11-08
"988",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - homologous or heterologous","excluded","2","final","14-90","Infection","infection","Finland","HCW","HCW aged 16-69 years",77,"71",82,NA,"non-VOC & alpha","~11 weeks",NA,NA,1030,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","08/11/2021",2021-11-08
"989",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - homologous or heterologous","excluded","2","final","91-180","Infection","infection","Finland","HCW","HCW aged 16-69 years",55,"34",69,NA,"non-VOC & alpha","~24 weeks",NA,NA,1031,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","08/11/2021",2021-11-08
"990",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - homologous or heterologous","excluded","1","1","42+","hospitalization","severe","Finland","HCW","HCW aged 16-69 years",90,"27",99,NA,"non-VOC & alpha",NA,NA,NA,1032,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","08/11/2021",2021-11-08
"991",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - homologous or heterologous","excluded","2","final","14-90","hospitalization","severe","Finland","HCW","HCW aged 16-69 years",95,"64",99,NA,"non-VOC & alpha","~11 weeks",NA,NA,1033,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","08/11/2021",2021-11-08
"992",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - homologous or heterologous","excluded","2","final","91-180","hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC & alpha","~24 weeks",NA,NA,1034,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","08/11/2021",2021-11-08
"993",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","42+","Infection","infection","Finland","HCW","HCW aged 16-69 years",15,"-15",37,NA,"non-VOC & alpha",NA,NA,NA,1035,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","08/11/2021",2021-11-08
"994",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14-90","Infection","infection","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC & alpha","~11 weeks",NA,NA,1036,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","08/11/2021",2021-11-08
"995",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","91-180","Infection","infection","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC & alpha","~24 weeks",NA,NA,1037,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","08/11/2021",2021-11-08
"996",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","42+","hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,"-inf",100,NA,"non-VOC & alpha",NA,NA,NA,1038,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","08/11/2021",2021-11-08
"997",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14-90","hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC & alpha","~11 weeks",NA,NA,1039,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","08/11/2021",2021-11-08
"998",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14-90","Infection","infection","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC & alpha","~11 weeks",NA,NA,1040,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations","08/11/2021",2021-11-08
"999",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","91-180","Infection","infection","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC & alpha","~24 weeks",NA,NA,1041,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations","08/11/2021",2021-11-08
"1000",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14-90","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"non-VOC & alpha","~11 weeks",NA,NA,1042,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations","08/11/2021",2021-11-08
"1001",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - homologous or heterologous","excluded","1","1","42+","Infection","infection","Finland","HCW","HCW aged 16-69 years",45,"37",51,NA,"delta",NA,NA,NA,1043,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","08/11/2021",2021-11-08
"1002",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - homologous or heterologous","excluded","2","final","14-90","Infection","infection","Finland","HCW","HCW aged 16-69 years",85,"81",88,NA,"delta","~11 weeks",NA,NA,1044,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","08/11/2021",2021-11-08
"1003",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - homologous or heterologous","excluded","2","final","181+","Infection","infection","Finland","HCW","HCW aged 16-69 years",56,"46",65,NA,"delta","~29.5 weeks",NA,NA,1045,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","08/11/2021",2021-11-08
"1004",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - homologous or heterologous","excluded","1","1","42+","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",83,"68",91,NA,"delta",NA,NA,NA,1046,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","08/11/2021",2021-11-08
"1005",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - homologous or heterologous","excluded","2","final","14-90","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,"97",100,NA,"delta","~11 weeks",NA,NA,1047,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","08/11/2021",2021-11-08
"1006",119,"Poukka","Retrospective cohort","31Jan2022","Any mRNA - homologous or heterologous","excluded","2","final","181+","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",98,"88",100,NA,"delta","~38 weeks",NA,NA,1048,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","08/11/2021",2021-11-08
"1007",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","42+","Infection","infection","Finland","HCW","HCW aged 16-69 years",49,"-16",77,NA,"delta",NA,NA,NA,1049,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","08/11/2021",2021-11-08
"1008",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14-90","Infection","infection","Finland","HCW","HCW aged 16-69 years",88,"71",95,NA,"delta","~11 weeks",NA,NA,1050,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","08/11/2021",2021-11-08
"1009",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","91-180","Infection","infection","Finland","HCW","HCW aged 16-69 years",62,"-177",95,NA,"delta","~24 weeks",NA,NA,1051,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","08/11/2021",2021-11-08
"1010",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","1","1","42+","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",42,"-330",92,NA,"delta",NA,NA,NA,1052,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","08/11/2021",2021-11-08
"1011",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14-90","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"delta","~11 weeks",NA,NA,1053,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","08/11/2021",2021-11-08
"1012",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","181+","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"delta","~25 weeks",NA,NA,1054,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","08/11/2021",2021-11-08
"1013",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14-90","Infection","infection","Finland","HCW","HCW aged 16-69 years",80,"72",86,NA,"delta","~11 weeks",NA,NA,1055,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","delta","08/11/2021",2021-11-08
"1014",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","91-180","Infection","infection","Finland","HCW","HCW aged 16-69 years",63,"33",80,NA,"delta","~24 weeks",NA,NA,1056,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","delta","08/11/2021",2021-11-08
"1015",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14-90","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"delta","~11 weeks",NA,NA,1057,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Heterologous platforms","Multiple","delta","08/11/2021",2021-11-08
"1016",119,"Poukka","Retrospective cohort","31Jan2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","181+","Hospitalization","severe","Finland","HCW","HCW aged 16-69 years",100,NA,NA,NA,"delta","~25 weeks",NA,NA,1058,"Finland","FIN",119,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-31,"severe","2022 (Jan-Jun)","Heterologous platforms","Multiple","delta","08/11/2021",2021-11-08
"1017",120,"Al Hosani","Retrospective cohort","18Mar2022","BBIBP-CorV (Beijing CNBG)","included","1","1","14+","Hospitalization","severe","United Arab Emirates",">= 15 years",">= 15 years",-20,"-28.6",11.8,NA,"non-VOC & alpha",NA,NA,NA,1059,"United Arab Emirates","ARE",120,"ARE",45070,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,105,191,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-03-18,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations","27/10/2021",2021-10-27
"1018",120,"Al Hosani","Retrospective cohort","18Mar2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","Hospitalization","severe","United Arab Emirates",">= 15 years",">= 15 years",79.8,"78",81.4,NA,"non-VOC & alpha","~34 weeks",NA,NA,1060,"United Arab Emirates","ARE",120,"ARE",45070,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,105,191,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-03-18,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations","27/10/2021",2021-10-27
"1019",120,"Al Hosani","Retrospective cohort","18Mar2022","BBIBP-CorV (Beijing CNBG)","included","1","1","14+","ICU admission","severe","United Arab Emirates",">= 15 years",">= 15 years",3.7,"-12.8",18.1,NA,"non-VOC & alpha",NA,NA,NA,1061,"United Arab Emirates","ARE",120,"ARE",45070,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,105,191,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-03-18,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations","27/10/2021",2021-10-27
"1020",120,"Al Hosani","Retrospective cohort","18Mar2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","ICU admission","severe","United Arab Emirates",">= 15 years",">= 15 years",92.2,"89.7",94.1,NA,"non-VOC & alpha","~34 weeks",NA,NA,1062,"United Arab Emirates","ARE",120,"ARE",45070,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,105,191,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-03-18,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations","27/10/2021",2021-10-27
"1021",120,"Al Hosani","Retrospective cohort","18Mar2022","BBIBP-CorV (Beijing CNBG)","included","1","1","14+","death","death","United Arab Emirates",">= 15 years",">= 15 years",27.9,"-61",72.6,NA,"non-VOC & alpha",NA,NA,NA,1063,"United Arab Emirates","ARE",120,"ARE",45070,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,105,191,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-03-18,"death","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations","27/10/2021",2021-10-27
"1022",120,"Al Hosani","Retrospective cohort","18Mar2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","death","death","United Arab Emirates",">= 15 years",">= 15 years",97.1,"83",99.9,NA,"non-VOC & alpha","~34 weeks",NA,NA,1064,"United Arab Emirates","ARE",120,"ARE",45070,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,105,191,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-03-18,"death","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations","27/10/2021",2021-10-27
"1023",121,"Ng","Retrospective cohort","01Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","15+","Infection","infection","Singapore","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",61.6,"37.5",80.4,"delta","delta","~16.5 weeks",NA,NA,1065,"Singapore","SGP",121,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-11-01,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2021-11-01
"1024",121,"Ng","Retrospective cohort","01Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","15+","symptomatic disease","symptomatic","Singapore","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",67.9,"41.3",87.8,"delta","delta","~16.5 weeks",NA,NA,1066,"Singapore","SGP",121,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-11-01,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2021-11-01
"1025",121,"Ng","Retrospective cohort","01Nov2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","15+","severe disease","severe","Singapore","contacts of SARS-CoV-2 index cases of all ages","contacts of index cases",100,NA,NA,"delta","delta","~16.5 weeks",NA,NA,1067,"Singapore","SGP",121,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-11-01,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2021-11-01
"1026",122,"Paixao","Test-negative case-control","05Apr2022","CoronaVac (Sinovac)","excluded","1","1","14+","symptomatic disease","symptomatic","Brazil","pregnant women","pregnant persons",5,"-18.2",23.7,NA,"gamma & delta",NA,NA,NA,1068,"Brazil","BRA",122,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-04-05,"symptomatic","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","12/11/2021",2021-11-12
"1027",122,"Paixao","Test-negative case-control","05Apr2022","CoronaVac (Sinovac)","excluded","2","final","14+","symptomatic disease","symptomatic","Brazil","pregnant women","pregnant persons",41,"27",52.2,NA,"gamma & delta","~25 weeks",NA,NA,1069,"Brazil","BRA",122,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-04-05,"symptomatic","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","12/11/2021",2021-11-12
"1028",122,"Paixao","Test-negative case-control","05Apr2022","CoronaVac (Sinovac)","excluded","1","1","14+","severe disease","severe","Brazil","pregnant women","pregnant persons",67.7,"20",87,NA,"gamma & delta",NA,NA,NA,1070,"Brazil","BRA",122,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-04-05,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","12/11/2021",2021-11-12
"1029",122,"Paixao","Test-negative case-control","05Apr2022","CoronaVac (Sinovac)","excluded","2","final","14+","severe disease","severe","Brazil","pregnant women","pregnant persons",85.4,"59.4",94.8,NA,"gamma & delta","~25 weeks",NA,NA,1071,"Brazil","BRA",122,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-04-05,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","12/11/2021",2021-11-12
"1030",123,"Desai","Test-negative case-control","23Nov2021","BBV152 (Bharat)","included","1","1","21+","symptomatic disease","symptomatic","India","HCW","HCW",-1,"-51",33,NA,"delta",NA,NA,NA,1072,"India","IND",123,"IND",2070,2019,"India","South Asia","Lower middle income",1,"Asia",2021-01-16,2021-12-24,NA,2021-01-16,2021-01-16,0,342,NA,"equal","jan/2021","Dec/2021 +","270-359","yes","yes","no",2021-11-23,"symptomatic","2021 (Jul-Dec)","Bharat Covaxin/BBV152","Inactivated","delta",NA,2021-11-23
"1031",123,"Desai","Test-negative case-control","23Nov2021","BBV152 (Bharat)","included","2","final","14+","symptomatic disease","symptomatic","India","HCW","HCW",50,"33",62,NA,"delta","~4 weeks",NA,NA,1073,"India","IND",123,"IND",2070,2019,"India","South Asia","Lower middle income",1,"Asia",2021-01-16,2021-12-24,NA,2021-01-16,2021-01-16,0,342,NA,"equal","jan/2021","Dec/2021 +","270-359","yes","yes","no",2021-11-23,"symptomatic","2021 (Jul-Dec)","Bharat Covaxin/BBV152","Inactivated","delta",NA,2021-11-23
"1032",123,"Desai","Test-negative case-control","23Nov2021","BBV152 (Bharat)","included","2","final","28+","symptomatic disease","symptomatic","India","HCW","HCW",46,"22",62,NA,"delta","~4 weeks",NA,NA,1074,"India","IND",123,"IND",2070,2019,"India","South Asia","Lower middle income",1,"Asia",2021-01-16,2021-12-24,NA,2021-01-16,2021-01-16,0,342,NA,"equal","jan/2021","Dec/2021 +","270-359","yes","yes","no",2021-11-23,"symptomatic","2021 (Jul-Dec)","Bharat Covaxin/BBV152","Inactivated","delta",NA,2021-11-23
"1033",123,"Desai","Test-negative case-control","23Nov2021","BBV152 (Bharat)","included","2","final","42+","symptomatic disease","symptomatic","India","HCW","HCW",57,"21",76,NA,"delta","~4 weeks",NA,NA,1075,"India","IND",123,"IND",2070,2019,"India","South Asia","Lower middle income",1,"Asia",2021-01-16,2021-12-24,NA,2021-01-16,2021-01-16,0,342,NA,"equal","jan/2021","Dec/2021 +","270-359","yes","yes","no",2021-11-23,"symptomatic","2021 (Jul-Dec)","Bharat Covaxin/BBV152","Inactivated","delta",NA,2021-11-23
"1034",123,"Desai","Test-negative case-control","23Nov2021","BBV152 (Bharat)","excluded","2","final","14+","symptomatic disease","symptomatic","India","HCW","HCW",47,"29",61,NA,"delta","~4 weeks",NA,NA,1076,"India","IND",123,"IND",2070,2019,"India","South Asia","Lower middle income",1,"Asia",2021-01-16,2021-12-24,NA,2021-01-16,2021-01-16,0,342,NA,"equal","jan/2021","Dec/2021 +","270-359","yes","yes","no",2021-11-23,"symptomatic","2021 (Jul-Dec)","Bharat Covaxin/BBV152","Inactivated","delta",NA,2021-11-23
"1035",124,"Thiruvengadam","Test-negative case-control","25Nov2021","AZD1222 (AstraZeneca)","excluded","1","1","21+","infection","infection","India",">= 18 years","general pop",46.2,"31.6",57.7,NA,"delta",NA,NA,NA,1077,"India","IND",124,"IND",2070,2019,"India","South Asia","Lower middle income",1,"Asia",2021-01-16,2021-12-24,NA,2021-01-16,2021-01-16,0,342,NA,"equal","jan/2021","Dec/2021 +","270-359","yes","yes","no",2021-11-25,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-11-25
"1036",124,"Thiruvengadam","Test-negative case-control","25Nov2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection","infection","India",">= 18 years","general pop",63.1,"51.5",72.1,NA,"delta","~10 weeks",NA,NA,1078,"India","IND",124,"IND",2070,2019,"India","South Asia","Lower middle income",1,"Asia",2021-01-16,2021-12-24,NA,2021-01-16,2021-01-16,0,342,NA,"equal","jan/2021","Dec/2021 +","270-359","yes","yes","no",2021-11-25,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-11-25
"1037",125,"Hall","Prospective cohort","16Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21-27","Infection","infection","UK","HCW","HCW",59,"42",71,NA,"non-VOC, alpha, & delta",NA,NA,NA,1079,"UK","GBR",125,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-02-16,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","01/12/2021",2021-12-01
"1038",125,"Hall","Prospective cohort","16Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-73","Infection","infection","UK","HCW","HCW",89,"78",94,NA,"non-VOC, alpha, & delta","~8 weeks","<6 weeks",NA,1080,"UK","GBR",125,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-02-16,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","01/12/2021",2021-12-01
"1039",125,"Hall","Prospective cohort","16Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","194-265","Infection","infection","UK","HCW","HCW",53,"28",69,NA,"non-VOC, alpha, & delta","36 weeks","<6 weeks",NA,1081,"UK","GBR",125,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-02-16,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","01/12/2021",2021-12-01
"1040",125,"Hall","Prospective cohort","16Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","56-280","Infection","infection","UK","HCW","HCW",63,"46",75,NA,"non-VOC, alpha, & delta",NA,NA,NA,1082,"UK","GBR",125,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-02-16,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","01/12/2021",2021-12-01
"1041",125,"Hall","Prospective cohort","16Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-73","Infection","infection","UK","HCW","HCW",85,"72",92,NA,"non-VOC, alpha, & delta","~8 weeks","6+ weeks",NA,1083,"UK","GBR",125,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-02-16,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","01/12/2021",2021-12-01
"1042",125,"Hall","Prospective cohort","16Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","194-239","Infection","infection","UK","HCW","HCW",51,"22",69,NA,"non-VOC, alpha, & delta","~32 weeks","6+ weeks",NA,1084,"UK","GBR",125,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-02-16,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","01/12/2021",2021-12-01
"1043",125,"Hall","Prospective cohort","16Feb2022","AZD1222 (AstraZeneca)","excluded","1","1","21-27","Infection","infection","UK","HCW","HCW",63,"-80",92,NA,"non-VOC, alpha, & delta",NA,NA,NA,1085,"UK","GBR",125,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-02-16,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","01/12/2021",2021-12-01
"1044",125,"Hall","Prospective cohort","16Feb2022","AZD1222 (AstraZeneca)","excluded","2","final","14-73","Infection","infection","UK","HCW","HCW",58,"23",77,NA,"non-VOC, alpha, & delta","~8 weeks",NA,NA,1086,"UK","GBR",125,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-02-16,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","01/12/2021",2021-12-01
"1045",125,"Hall","Prospective cohort","16Feb2022","AZD1222 (AstraZeneca)","excluded","1","1","56-249","Infection","infection","UK","HCW","HCW",9,"-87",55,NA,"non-VOC, alpha, & delta",NA,NA,NA,1087,"UK","GBR",125,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-02-16,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","01/12/2021",2021-12-01
"1046",125,"Hall","Prospective cohort","16Feb2022","AZD1222 (AstraZeneca)","excluded","2","final","134-220","Infection","infection","UK","HCW","HCW",72,"39",87,NA,"non-VOC, alpha, & delta","~29 weeks",NA,NA,1088,"UK","GBR",125,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-02-16,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","01/12/2021",2021-12-01
"1047",126,"Voko","Retrospective cohort","24Nov2021","BNT162b2 (Pfizer BioNTech)","included","1","1+","0+","Infection","infection","Hungary",">= 16 years","general pop",41,"39.5",42.4,NA,"alpha",NA,NA,NA,1089,"Hungary","HUN",126,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-11-24
"1048",126,"Voko","Retrospective cohort","24Nov2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","Infection","infection","Hungary",">= 16 years","general pop",84,"83.3",84.7,NA,"alpha","~19 weeks",NA,NA,1090,"Hungary","HUN",126,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-11-24
"1049",126,"Voko","Retrospective cohort","24Nov2021","BNT162b2 (Pfizer BioNTech)","included","1","1+","0+","death","death","Hungary",">= 16 years","general pop",64.3,"61.8",66.6,NA,"alpha",NA,NA,NA,1091,"Hungary","HUN",126,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-11-24
"1050",126,"Voko","Retrospective cohort","24Nov2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","death","death","Hungary",">= 16 years","general pop",90.3,"88.9",91.5,NA,"alpha","~19 weeks",NA,NA,1092,"Hungary","HUN",126,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-11-24
"1051",126,"Voko","Retrospective cohort","24Nov2021","BBIBP-CorV (Beijing CNBG)","included","1","1+","0+","Infection","infection","Hungary",">= 16 years","general pop",34,"31.8",36.1,NA,"alpha",NA,NA,NA,1093,"Hungary","HUN",126,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"infection","2021 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","alpha",NA,2021-11-24
"1052",126,"Voko","Retrospective cohort","24Nov2021","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","Infection","infection","Hungary",">= 16 years","general pop",72.8,"71.2",74.4,NA,"alpha","~10.5 weeks",NA,NA,1094,"Hungary","HUN",126,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"infection","2021 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","alpha",NA,2021-11-24
"1053",126,"Voko","Retrospective cohort","24Nov2021","BBIBP-CorV (Beijing CNBG)","included","1","1+","0+","death","death","Hungary",">= 16 years","general pop",39.4,"34.1",44.3,NA,"alpha",NA,NA,NA,1095,"Hungary","HUN",126,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"death","2021 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","alpha",NA,2021-11-24
"1054",126,"Voko","Retrospective cohort","24Nov2021","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","death","death","Hungary",">= 16 years","general pop",86,"83.7",87.9,NA,"alpha","~10.5 weeks",NA,NA,1096,"Hungary","HUN",126,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"death","2021 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","alpha",NA,2021-11-24
"1055",126,"Voko","Retrospective cohort","24Nov2021","Gam-COVID-Vac (Gamaleya)","included","1","1+","0+","Infection","infection","Hungary",">= 16 years","general pop",48.7,"47.1",50.2,NA,"alpha",NA,NA,NA,1097,"Hungary","HUN",126,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"infection","2021 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","alpha",NA,2021-11-24
"1056",126,"Voko","Retrospective cohort","24Nov2021","Gam-COVID-Vac (Gamaleya)","included","2","final","14+","Infection","infection","Hungary",">= 16 years","general pop",88.1,"86.5",89.4,NA,"alpha","~11 weeks",NA,NA,1098,"Hungary","HUN",126,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"infection","2021 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","alpha",NA,2021-11-24
"1057",126,"Voko","Retrospective cohort","24Nov2021","Gam-COVID-Vac (Gamaleya)","included","1","1+","0+","death","death","Hungary",">= 16 years","general pop",78,"74.3",81.2,NA,"alpha",NA,NA,NA,1099,"Hungary","HUN",126,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"death","2021 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","alpha",NA,2021-11-24
"1058",126,"Voko","Retrospective cohort","24Nov2021","Gam-COVID-Vac (Gamaleya)","included","2","final","14+","death","death","Hungary",">= 16 years","general pop",97.8,"95.5",98.9,NA,"alpha","~11 weeks",NA,NA,1100,"Hungary","HUN",126,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"death","2021 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","alpha",NA,2021-11-24
"1059",126,"Voko","Retrospective cohort","24Nov2021","AZD1222 (AstraZeneca)","included","1","1+","0+","Infection","infection","Hungary",">= 16 years","general pop",49.2,"47.7",50.6,NA,"alpha",NA,NA,NA,1101,"Hungary","HUN",126,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-11-24
"1060",126,"Voko","Retrospective cohort","24Nov2021","AZD1222 (AstraZeneca)","included","2","final","14+","Infection","infection","Hungary",">= 16 years","general pop",73.3,"71.1",76,NA,"alpha","~11.5 weeks",NA,NA,1102,"Hungary","HUN",126,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"infection","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-11-24
"1061",126,"Voko","Retrospective cohort","24Nov2021","AZD1222 (AstraZeneca)","included","1","1+","0+","death","death","Hungary",">= 16 years","general pop",71.3,"67.9",74.4,NA,"alpha",NA,NA,NA,1103,"Hungary","HUN",126,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-11-24
"1062",126,"Voko","Retrospective cohort","24Nov2021","AZD1222 (AstraZeneca)","included","2","final","14+","death","death","Hungary",">= 16 years","general pop",85.8,"73.5",92.4,NA,"alpha","~11.5 weeks",NA,NA,1104,"Hungary","HUN",126,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-11-24
"1063",126,"Voko","Retrospective cohort","24Nov2021","mRNA-1273 (Moderna)","included","1","1+","0+","Infection","infection","Hungary",">= 16 years","general pop",60.8,"58.6",63,NA,"alpha",NA,NA,NA,1105,"Hungary","HUN",126,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-11-24
"1064",126,"Voko","Retrospective cohort","24Nov2021","mRNA-1273 (Moderna)","included","2","final","14+","Infection","infection","Hungary",">= 16 years","general pop",88.2,"85.8",90.3,NA,"alpha","~15 weeks",NA,NA,1106,"Hungary","HUN",126,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-11-24
"1065",126,"Voko","Retrospective cohort","24Nov2021","mRNA-1273 (Moderna)","included","1","1+","0+","death","death","Hungary",">= 16 years","general pop",68.7,"62.5",73.8,NA,"alpha",NA,NA,NA,1107,"Hungary","HUN",126,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"death","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-11-24
"1066",126,"Voko","Retrospective cohort","24Nov2021","mRNA-1273 (Moderna)","included","2","final","14+","death","death","Hungary",">= 16 years","general pop",93.8,"90.3",96.1,NA,"alpha","~15 weeks",NA,NA,1108,"Hungary","HUN",126,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2021-11-24,"death","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2021-11-24
"1067",127,"Wu","Retrospective cohort","02Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","Infection","infection","USA","cancer patients","immunocompromised adults",45,"8",66,NA,"non-VOC & alpha",NA,NA,NA,1109,"USA","USA",127,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-02,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-02
"1068",127,"Wu","Retrospective cohort","02Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","Infection","infection","USA","cancer patients","immunocompromised adults",58,"39",73,NA,"non-VOC & alpha","15 weeks",NA,NA,1110,"USA","USA",127,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-02,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-02
"1069",128,"Muhsen","Prospective cohort","28Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Infection","infection","Israel","HCW","HCW",89,"83",93,NA,"alpha","~11 weeks",NA,NA,1111,"Israel","ISR",128,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-28,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-10-28
"1070",129,"Yassi","Retrospective cohort","06Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","7+","Infection","infection","Canada","HCW","HCW",74.1,"62.5",82.1,NA,"non-VOC, alpha, & delta","~40.5 weeks",NA,NA,1112,"Canada","CAN",129,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-06,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-06
"1071",129,"Yassi","Test-negative case-control","06Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","7+","Infection","infection","Canada","HCW","HCW",82.8,"74",88.6,NA,"non-VOC, alpha, & delta","~40.5 weeks",NA,NA,1113,"Canada","CAN",129,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-06,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-06
"1072",130,"UKHSA","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","2-4 weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",65.8,"64.4",67.2,"omicron","omicron","~32 weeks",NA,NA,1114,"UK","GBR",130,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","14/01/2022",2022-01-14
"1073",130,"UKHSA","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","25+ weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",9.4,"7.8",11.1,"omicron","omicron","~32 weeks",NA,NA,1115,"UK","GBR",130,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","14/01/2022",2022-01-14
"1074",130,"UKHSA","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","2-4 weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",49.8,"40.7",57.5,"omicron","omicron","~32 weeks",NA,NA,1116,"UK","GBR",130,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","14/01/2022",2022-01-14
"1075",130,"UKHSA","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","25+ weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",-1,"-2.4",0.3,"omicron","omicron","~32 weeks",NA,NA,1117,"UK","GBR",130,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","14/01/2022",2022-01-14
"1076",130,"UKHSA","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","2","final","2-4 weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",76,"72",79,"omicron","omicron","~32 weeks",NA,NA,1118,"UK","GBR",130,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","14/01/2022",2022-01-14
"1077",130,"UKHSA","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","2","final","25+ weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",13,"3",22,"omicron","omicron","~32 weeks",NA,NA,1119,"UK","GBR",130,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","14/01/2022",2022-01-14
"1078",130,"UKHSA","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","2-4 weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",90.9,"89.6",92,"delta","delta","~32 weeks",NA,NA,1120,"UK","GBR",130,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/01/2022",2022-01-14
"1079",130,"UKHSA","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","25+ weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",62.7,"61.6",63.7,"delta","delta","~32 weeks",NA,NA,1121,"UK","GBR",130,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/01/2022",2022-01-14
"1080",130,"UKHSA","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","2-4 weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",82.8,"74.5",88.4,"delta","delta","~32 weeks",NA,NA,1122,"UK","GBR",130,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/01/2022",2022-01-14
"1081",130,"UKHSA","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","25+ weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",43.5,"42.4",44.5,"delta","delta","~32 weeks",NA,NA,1123,"UK","GBR",130,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/01/2022",2022-01-14
"1082",130,"UKHSA","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","2","final","2-4 weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",94.5,"90.5",96.9,"delta","delta","~32 weeks",NA,NA,1124,"UK","GBR",130,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","14/01/2022",2022-01-14
"1083",130,"UKHSA","Test-negative case-control","27Jan2022","mRNA-1273 (Moderna)","excluded","2","final","25+ weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",80.4,"67.3",88.2,"delta","delta","~32 weeks",NA,NA,1125,"UK","GBR",130,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","14/01/2022",2022-01-14
"1084",130,"UKHSA","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","2-4 weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",73.6,"40.7",88.3,"omicron","omicron","~32 weeks",NA,NA,1126,"UK","GBR",130,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","14/01/2022",2022-01-14
"1085",130,"UKHSA","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","25+ weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",34.9,"17.7",48.4,"omicron","omicron","~32 weeks",NA,NA,1127,"UK","GBR",130,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","14/01/2022",2022-01-14
"1086",130,"UKHSA","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","20-24 weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",55.8,"34.1",70.3,"omicron","omicron","~32 weeks",NA,NA,1128,"UK","GBR",130,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","14/01/2022",2022-01-14
"1087",130,"UKHSA","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","25+ weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",32.7,"19.7",43.6,"omicron","omicron","~32 weeks",NA,NA,1129,"UK","GBR",130,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","14/01/2022",2022-01-14
"1088",130,"UKHSA","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","2-4 weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",94.1,"81.6",98.1,"delta","delta","~32 weeks",NA,NA,1130,"UK","GBR",130,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/01/2022",2022-01-14
"1089",130,"UKHSA","Test-negative case-control","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","25+ weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",95.3,"93.9",96.5,"delta","delta","~32 weeks",NA,NA,1131,"UK","GBR",130,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","14/01/2022",2022-01-14
"1090",130,"UKHSA","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","20-24 weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",92.9,"91.3",94.2,"delta","delta","~32 weeks",NA,NA,1132,"UK","GBR",130,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/01/2022",2022-01-14
"1091",130,"UKHSA","Test-negative case-control","27Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","25+ weeks","symptomatic disease","symptomatic","UK",">= 18 years","general pop",90.6,"89.3",91.8,"delta","delta","~32 weeks",NA,NA,1133,"UK","GBR",130,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-27,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","14/01/2022",2022-01-14
"1092",131,"Bajema","Test-negative case-control","10Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-119","Hospitalization","severe","USA",">= 18 years","general pop",86,"77.6",91.3,NA,"non-VOC, alpha, & delta","~36 weeks",NA,NA,1134,"USA","USA",131,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-10,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","10/09/2021",2021-09-10
"1093",131,"Bajema","Test-negative case-control","10Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","120+","Hospitalization","severe","USA",">= 18 years","general pop",75.1,"64.6",82.4,NA,"non-VOC, alpha, & delta","~36 weeks",NA,NA,1135,"USA","USA",131,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-10,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","10/09/2021",2021-09-10
"1094",131,"Bajema","Test-negative case-control","10Dec2021","mRNA-1273 (Moderna)","excluded","2","final","14-119","Hospitalization","severe","USA",">= 18 years","general pop",89.6,"80.1",94.5,NA,"non-VOC, alpha, & delta","~36 weeks",NA,NA,1136,"USA","USA",131,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-10,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","10/09/2021",2021-09-10
"1095",131,"Bajema","Test-negative case-control","10Dec2021","mRNA-1273 (Moderna)","excluded","2","final","120+","Hospitalization","severe","USA",">= 18 years","general pop",86.1,"77.7",91.3,NA,"non-VOC, alpha, & delta","~36 weeks",NA,NA,1137,"USA","USA",131,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-10,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","10/09/2021",2021-09-10
"1096",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","symptomatic disease","symptomatic","UK","12-15 years","12-15 years",49.6,"43.9",54.8,"omicron","omicron",NA,NA,NA,1138,"UK","GBR",132,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","18/02/2022",2022-02-18
"1097",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","UK","12-15 years","12-15 years",73,"66.4",78.3,"omicron","omicron","~33 weeks",NA,NA,1139,"UK","GBR",132,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","18/02/2022",2022-02-18
"1098",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","84+","symptomatic disease","symptomatic","UK","12-15 years","12-15 years",17.2,"12",22.1,"omicron","omicron",NA,NA,NA,1140,"UK","GBR",132,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","18/02/2022",2022-02-18
"1099",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","symptomatic disease","symptomatic","UK","16-17 years","16-17 years",51.4,"42.7",58.8,"omicron","omicron",NA,NA,NA,1141,"UK","GBR",132,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","18/02/2022",2022-02-18
"1100",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-34","symptomatic disease","symptomatic","UK","16-17 years","16-17 years",71.3,"69.3",73.1,"omicron","omicron","~33 weeks",NA,NA,1142,"UK","GBR",132,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","18/02/2022",2022-02-18
"1101",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","105+","symptomatic disease","symptomatic","UK","16-17 years","16-17 years",12.5,"6.9",17.8,"omicron","omicron",NA,NA,NA,1143,"UK","GBR",132,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","18/02/2022",2022-02-18
"1102",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","70+","symptomatic disease","symptomatic","UK","16-17 years","16-17 years",22.6,"14.5",29.9,"omicron","omicron","~33 weeks",NA,NA,1144,"UK","GBR",132,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","18/02/2022",2022-02-18
"1103",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","symptomatic disease","symptomatic","UK","12-15 years","12-15 years",74.5,"73.2",75.6,"delta","delta",NA,NA,NA,1145,"UK","GBR",132,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/02/2022",2022-02-18
"1104",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","UK","12-15 years","12-15 years",87.2,"73.7",93.8,"delta","delta","~33 weeks",NA,NA,1146,"UK","GBR",132,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/02/2022",2022-02-18
"1105",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","84+","symptomatic disease","symptomatic","UK","12-15 years","12-15 years",53.1,"41.6",62.4,"delta","delta",NA,NA,NA,1147,"UK","GBR",132,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/02/2022",2022-02-18
"1106",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","symptomatic disease","symptomatic","UK","16-17 years","16-17 years",75.9,"74.3",77.3,"delta","delta",NA,NA,NA,1148,"UK","GBR",132,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/02/2022",2022-02-18
"1107",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-34","symptomatic disease","symptomatic","UK","16-17 years","16-17 years",93.1,"91.6",94.4,"delta","delta","~33 weeks",NA,NA,1149,"UK","GBR",132,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/02/2022",2022-02-18
"1108",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","105+","symptomatic disease","symptomatic","UK","16-17 years","16-17 years",30.9,"25.4",36,"delta","delta",NA,NA,NA,1150,"UK","GBR",132,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/02/2022",2022-02-18
"1109",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","70+","symptomatic disease","symptomatic","UK","16-17 years","16-17 years",83.7,"72",90.5,"delta","delta","~33 weeks",NA,NA,1151,"UK","GBR",132,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/02/2022",2022-02-18
"1110",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","28+","hospitalization","severe","UK","12-15 years","12-15 years",83.4,"54",94,"delta","delta",NA,NA,NA,1152,"UK","GBR",132,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/02/2022",2022-02-18
"1111",132,"Powell","Test-negative case-control","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","28+","hospitalization","severe","UK","16-17 years","16-17 years",76.3,"61.1",85.6,"delta","delta",NA,NA,NA,1153,"UK","GBR",132,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-21,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/02/2022",2022-02-18
"1112",133,"Berec","Retrospective cohort","08Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","0-2 months","Infection","infection","Czech Republic",">= 18 years","general pop",87,"86",87,NA,"alpha & delta","~35 weeks",NA,NA,1154,"Czech Republic","CZE",133,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","12/12/2021",2021-12-12
"1113",133,"Berec","Retrospective cohort","08Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7-8 months","Infection","infection","Czech Republic",">= 18 years","general pop",53,"52",54,NA,"alpha & delta","~35 weeks",NA,NA,1155,"Czech Republic","CZE",133,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","12/12/2021",2021-12-12
"1114",133,"Berec","Retrospective cohort","08Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","0-2 months","Hospitalization","severe","Czech Republic",">= 18 years","general pop",90,"89",91,NA,"alpha & delta","~35 weeks",NA,NA,1156,"Czech Republic","CZE",133,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","12/12/2021",2021-12-12
"1115",133,"Berec","Retrospective cohort","08Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7-8 months","Hospitalization","severe","Czech Republic",">= 18 years","general pop",75,"73",76,NA,"alpha & delta","~35 weeks",NA,NA,1157,"Czech Republic","CZE",133,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","12/12/2021",2021-12-12
"1116",133,"Berec","Retrospective cohort","08Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","0-2 months","death","death","Czech Republic",">= 18 years","general pop",92,"90",93,NA,"alpha & delta","~35 weeks",NA,NA,1158,"Czech Republic","CZE",133,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","12/12/2021",2021-12-12
"1117",133,"Berec","Retrospective cohort","08Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7-8 months","death","death","Czech Republic",">= 18 years","general pop",83,"81",86,NA,"alpha & delta","~35 weeks",NA,NA,1159,"Czech Republic","CZE",133,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","12/12/2021",2021-12-12
"1118",133,"Berec","Retrospective cohort","08Jul2022","mRNA-1273 (Moderna)","included","2","final","0-2 months","Infection","infection","Czech Republic",">= 18 years","general pop",90,"89",91,NA,"alpha & delta","~35 weeks",NA,NA,1160,"Czech Republic","CZE",133,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","12/12/2021",2021-12-12
"1119",133,"Berec","Retrospective cohort","08Jul2022","mRNA-1273 (Moderna)","included","2","final","7-8 months","Infection","infection","Czech Republic",">= 18 years","general pop",65,"63",67,NA,"alpha & delta","~35 weeks",NA,NA,1161,"Czech Republic","CZE",133,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","12/12/2021",2021-12-12
"1120",133,"Berec","Retrospective cohort","08Jul2022","mRNA-1273 (Moderna)","included","2","final","0-2 months","Hospitalization","severe","Czech Republic",">= 18 years","general pop",94,"92",96,NA,"alpha & delta","~35 weeks",NA,NA,1162,"Czech Republic","CZE",133,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","12/12/2021",2021-12-12
"1121",133,"Berec","Retrospective cohort","08Jul2022","mRNA-1273 (Moderna)","included","2","final","7-8 months","Hospitalization","severe","Czech Republic",">= 18 years","general pop",81,"78",84,NA,"alpha & delta","~35 weeks",NA,NA,1163,"Czech Republic","CZE",133,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","12/12/2021",2021-12-12
"1122",133,"Berec","Retrospective cohort","08Jul2022","mRNA-1273 (Moderna)","included","2","final","0-2 months","death","death","Czech Republic",">= 18 years","general pop",96,"91",98,NA,"alpha & delta","~35 weeks",NA,NA,1164,"Czech Republic","CZE",133,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"death","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","12/12/2021",2021-12-12
"1123",133,"Berec","Retrospective cohort","08Jul2022","mRNA-1273 (Moderna)","included","2","final","7-8 months","death","death","Czech Republic",">= 18 years","general pop",88,"82",92,NA,"alpha & delta","~35 weeks",NA,NA,1165,"Czech Republic","CZE",133,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"death","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","12/12/2021",2021-12-12
"1124",133,"Berec","Retrospective cohort","08Jul2022","AZD1222 (AstraZeneca)","included","2","final","0-2 months","Infection","infection","Czech Republic",">= 18 years","general pop",83,"80",85,NA,"alpha & delta","~35 weeks",NA,NA,1166,"Czech Republic","CZE",133,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","12/12/2021",2021-12-12
"1125",133,"Berec","Retrospective cohort","08Jul2022","AZD1222 (AstraZeneca)","included","2","final","5-6 months","Infection","infection","Czech Republic",">= 18 years","general pop",55,"54",56,NA,"alpha & delta","~35 weeks",NA,NA,1167,"Czech Republic","CZE",133,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","12/12/2021",2021-12-12
"1126",133,"Berec","Retrospective cohort","08Jul2022","AZD1222 (AstraZeneca)","included","2","final","0-2 months","Hospitalization","severe","Czech Republic",">= 18 years","general pop",87,"81",91,NA,"alpha & delta","~35 weeks",NA,NA,1168,"Czech Republic","CZE",133,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","12/12/2021",2021-12-12
"1127",133,"Berec","Retrospective cohort","08Jul2022","AZD1222 (AstraZeneca)","included","2","final","5-6 months","Hospitalization","severe","Czech Republic",">= 18 years","general pop",70,"68",72,NA,"alpha & delta","~35 weeks",NA,NA,1169,"Czech Republic","CZE",133,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","12/12/2021",2021-12-12
"1128",133,"Berec","Retrospective cohort","08Jul2022","AZD1222 (AstraZeneca)","included","2","final","0-2 months","death","death","Czech Republic",">= 18 years","general pop",93,"77",98,NA,"alpha & delta","~35 weeks",NA,NA,1170,"Czech Republic","CZE",133,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","12/12/2021",2021-12-12
"1129",133,"Berec","Retrospective cohort","08Jul2022","AZD1222 (AstraZeneca)","included","2","final","5-6 months","death","death","Czech Republic",">= 18 years","general pop",82,"78",85,NA,"alpha & delta","~35 weeks",NA,NA,1171,"Czech Republic","CZE",133,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","12/12/2021",2021-12-12
"1130",133,"Berec","Retrospective cohort","08Jul2022","Ad26.COV2.S (Janssen)","included","2","final","0-2 months","Infection","infection","Czech Republic",">= 18 years","general pop",68,"66",70,NA,"alpha & delta","~35 weeks",NA,NA,1172,"Czech Republic","CZE",133,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","12/12/2021",2021-12-12
"1131",133,"Berec","Retrospective cohort","08Jul2022","Ad26.COV2.S (Janssen)","included","2","final","5-6 months","Infection","infection","Czech Republic",">= 18 years","general pop",67,"65",69,NA,"alpha & delta","~35 weeks",NA,NA,1173,"Czech Republic","CZE",133,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","12/12/2021",2021-12-12
"1132",133,"Berec","Retrospective cohort","08Jul2022","Ad26.COV2.S (Janssen)","included","2","final","2 months","Hospitalization","severe","Czech Republic",">= 18 years","general pop",68,"60",75,NA,"alpha & delta","~35 weeks",NA,NA,1174,"Czech Republic","CZE",133,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","12/12/2021",2021-12-12
"1133",133,"Berec","Retrospective cohort","08Jul2022","Ad26.COV2.S (Janssen)","included","2","final","5-6 months","Hospitalization","severe","Czech Republic",">= 18 years","general pop",67,"62",72,NA,"alpha & delta","~35 weeks",NA,NA,1175,"Czech Republic","CZE",133,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","12/12/2021",2021-12-12
"1134",133,"Berec","Retrospective cohort","08Jul2022","Ad26.COV2.S (Janssen)","included","2","final","2 months","death","death","Czech Republic",">= 18 years","general pop",68,"42",82,NA,"alpha & delta","~35 weeks",NA,NA,1176,"Czech Republic","CZE",133,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"death","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","12/12/2021",2021-12-12
"1135",133,"Berec","Retrospective cohort","08Jul2022","Ad26.COV2.S (Janssen)","included","2","final","5-6 months","death","death","Czech Republic",">= 18 years","general pop",68,"53",78,NA,"alpha & delta","~35 weeks",NA,NA,1177,"Czech Republic","CZE",133,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-07-08,"death","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","12/12/2021",2021-12-12
"1136",134,"Machado","Retrospective cohort","13Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-41","symptomatic disease","symptomatic","Portugal","65-79 years","65-79 years",79,"76",83,NA,"alpha & delta","~29 weeks",NA,NA,1178,"Portugal","PRT",134,"PRT",23180,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,198,247,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/12/2021",2021-09-13
"1137",134,"Machado","Retrospective cohort","13Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","98+","symptomatic disease","symptomatic","Portugal","65-79 years","65-79 years",39,"29",48,NA,"alpha & delta","~29 weeks",NA,NA,1179,"Portugal","PRT",134,"PRT",23180,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,198,247,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/12/2021",2021-09-13
"1138",134,"Machado","Retrospective cohort","13Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-41","symptomatic disease","symptomatic","Portugal",">= 80 years",">= 80 years",72,"61",79,NA,"alpha & delta","~29 weeks",NA,NA,1180,"Portugal","PRT",134,"PRT",23180,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,198,247,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/12/2021",2021-09-13
"1139",134,"Machado","Retrospective cohort","13Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","124+","symptomatic disease","symptomatic","Portugal",">= 80 years",">= 80 years",34,"29",48,NA,"alpha & delta","~29 weeks",NA,NA,1181,"Portugal","PRT",134,"PRT",23180,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,198,247,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"symptomatic","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/12/2021",2021-09-13
"1140",134,"Machado","Retrospective cohort","13Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-41","Hospitalization","severe","Portugal","65-79 years","65-79 years",95,"90",97,NA,"alpha & delta","~29 weeks",NA,NA,1182,"Portugal","PRT",134,"PRT",23180,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,198,247,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/12/2021",2021-09-13
"1141",134,"Machado","Retrospective cohort","13Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","70+","Hospitalization","severe","Portugal","65-79 years","65-79 years",93,"86",96,NA,"alpha & delta","~29 weeks",NA,NA,1183,"Portugal","PRT",134,"PRT",23180,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,198,247,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/12/2021",2021-09-13
"1142",134,"Machado","Retrospective cohort","13Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-41","Hospitalization","severe","Portugal",">= 80 years",">= 80 years",83,"68",91,NA,"alpha & delta","~29 weeks",NA,NA,1184,"Portugal","PRT",134,"PRT",23180,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,198,247,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/12/2021",2021-09-13
"1143",134,"Machado","Retrospective cohort","13Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","124+","Hospitalization","severe","Portugal",">= 80 years",">= 80 years",63,"37",78,NA,"alpha & delta","~29 weeks",NA,NA,1185,"Portugal","PRT",134,"PRT",23180,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,198,247,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/12/2021",2021-09-13
"1144",134,"Machado","Retrospective cohort","13Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-41","death","death","Portugal","65-79 years","65-79 years",95,"88",98,NA,"alpha & delta","~29 weeks",NA,NA,1186,"Portugal","PRT",134,"PRT",23180,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,198,247,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/12/2021",2021-09-13
"1145",134,"Machado","Retrospective cohort","13Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","70+","death","death","Portugal","65-79 years","65-79 years",93,"87",96,NA,"alpha & delta","~29 weeks",NA,NA,1187,"Portugal","PRT",134,"PRT",23180,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,198,247,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/12/2021",2021-09-13
"1146",134,"Machado","Retrospective cohort","13Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-41","death","death","Portugal",">= 80 years",">= 80 years",87,"71",93,NA,"alpha & delta","~29 weeks",NA,NA,1188,"Portugal","PRT",134,"PRT",23180,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,198,247,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/12/2021",2021-09-13
"1147",134,"Machado","Retrospective cohort","13Sept2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","124+","death","death","Portugal",">= 80 years",">= 80 years",75,"64",82,NA,"alpha & delta","~29 weeks",NA,NA,1189,"Portugal","PRT",134,"PRT",23180,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,198,247,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","14/12/2021",2021-09-13
"1148",134,"Machado","Retrospective cohort","13Sept2021","AZD1222 (AstraZeneca)","excluded","2","final","14-41","symptomatic disease","symptomatic","Portugal","65-79 years","65-79 years",95,"90",97,NA,"alpha & delta","~29 weeks",NA,NA,1190,"Portugal","PRT",134,"PRT",23180,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,198,247,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"symptomatic","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","14/12/2021",2021-09-13
"1149",134,"Machado","Retrospective cohort","13Sept2021","AZD1222 (AstraZeneca)","excluded","2","final","70+","symptomatic disease","symptomatic","Portugal","65-79 years","65-79 years",93,"86",96,NA,"alpha & delta","~29 weeks",NA,NA,1191,"Portugal","PRT",134,"PRT",23180,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,198,247,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"symptomatic","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","14/12/2021",2021-09-13
"1150",134,"Machado","Retrospective cohort","13Sept2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","Hospitalization","severe","Portugal","65-79 years","65-79 years",89,"52",94,NA,"alpha & delta","~29 weeks",NA,NA,1192,"Portugal","PRT",134,"PRT",23180,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,198,247,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"severe","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","14/12/2021",2021-09-13
"1151",134,"Machado","Retrospective cohort","13Sept2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","death","death","Portugal","65-79 years","65-79 years",95,"90",97,NA,"alpha & delta","~29 weeks",NA,NA,1193,"Portugal","PRT",134,"PRT",23180,2019,"Portugal","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-09,2021-08-27,2020-12-23,2020-12-23,9,198,247,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-09-13,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","14/12/2021",2021-09-13
"1152",135,"Florea","Prospective cohort","28Apr2022","mRNA-1273 (Moderna)","included","2","final","14+","Infection","infection","USA",">= 18 years","general pop",82.8,"82.2",83.3,NA,"non-VOC, alpha, & delta","~35 weeks",NA,NA,1194,"USA","USA",135,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-28,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","24/11/2021",2021-11-24
"1153",135,"Florea","Prospective cohort","28Apr2022","mRNA-1273 (Moderna)","included","2","final","14-60","Infection","infection","USA",">= 18 years","general pop",88,"86.8",89.1,NA,"non-VOC, alpha, & delta","~6.5 weeks",NA,NA,1195,"USA","USA",135,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-28,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","24/11/2021",2021-11-24
"1154",135,"Florea","Prospective cohort","28Apr2022","mRNA-1273 (Moderna)","included","2","final","180-240","Infection","infection","USA",">= 18 years","general pop",75.5,"70.4",79.7,NA,"non-VOC, alpha, & delta","~35 weeks",NA,NA,1196,"USA","USA",135,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-28,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","24/11/2021",2021-11-24
"1155",135,"Florea","Prospective cohort","28Apr2022","mRNA-1273 (Moderna)","included","2","final","14+","Hospitalization","severe","USA",">= 18 years","general pop",96.1,"95.5",96.6,NA,"non-VOC, alpha, & delta","~35 weeks",NA,NA,1197,"USA","USA",135,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-28,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","24/11/2021",2021-11-24
"1156",135,"Florea","Prospective cohort","28Apr2022","mRNA-1273 (Moderna)","included","2","final","14-60","Hospitalization","severe","USA",">= 18 years","general pop",95.9,"93.5",97.4,NA,"non-VOC, alpha, & delta","~6.5 weeks",NA,NA,1198,"USA","USA",135,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-28,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","24/11/2021",2021-11-24
"1157",135,"Florea","Prospective cohort","28Apr2022","mRNA-1273 (Moderna)","included","2","final","180-240","Hospitalization","severe","USA",">= 18 years","general pop",94.5,"90.9",96.7,NA,"non-VOC, alpha, & delta","~35 weeks",NA,NA,1199,"USA","USA",135,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-28,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","24/11/2021",2021-11-24
"1158",135,"Florea","Prospective cohort","28Apr2022","mRNA-1273 (Moderna)","included","2","final","14+","death","death","USA",">= 18 years","general pop",97.2,"94.8",98.4,NA,"non-VOC, alpha, & delta","~35 weeks",NA,NA,1200,"USA","USA",135,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-28,"death","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","24/11/2021",2021-11-24
"1159",135,"Florea","Prospective cohort","28Apr2022","mRNA-1273 (Moderna)","included","2","final","14+","Infection","infection","USA",">= 18 years","general pop",86.5,"84.8",88,NA,"delta","~15 weeks",NA,NA,1201,"USA","USA",135,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-28,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","24/11/2021",2021-11-24
"1160",136,"Young-Xu","Test-negative case-control","15Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-43","Infection","infection","USA","males 65+","males 65+",94.5,"90.7",96.7,NA,"non-VOC & alpha","4 weeks",NA,NA,1202,"USA","USA",136,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","06/10/2021",2021-10-06
"1161",136,"Young-Xu","Test-negative case-control","15Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","74-103","Infection","infection","USA","males 65+","males 65+",87.9,"85.9",89.5,NA,"non-VOC & alpha","12 weeks",NA,NA,1203,"USA","USA",136,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","06/10/2021",2021-10-06
"1162",136,"Young-Xu","Test-negative case-control","15Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-43","Infection","infection","USA","males 65+","males 65+",92.1,"87.2",95.1,NA,"alpha & delta","4 weeks",NA,NA,1204,"USA","USA",136,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","06/10/2021",2021-10-06
"1163",136,"Young-Xu","Test-negative case-control","15Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","134-163","Infection","infection","USA","males 65+","males 65+",67.3,"63.2",70.9,NA,"alpha & delta","20 weeks",NA,NA,1205,"USA","USA",136,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","06/10/2021",2021-10-06
"1164",136,"Young-Xu","Test-negative case-control","15Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-43","Infection","infection","USA","males 65+","males 65+",62,"45.6",73.5,NA,"delta","4 weeks",NA,NA,1206,"USA","USA",136,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","06/10/2021",2021-10-06
"1165",136,"Young-Xu","Test-negative case-control","15Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","224-253","Infection","infection","USA","males 65+","males 65+",24.8,"18.8",30.4,NA,"delta","32 weeks",NA,NA,1207,"USA","USA",136,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-15,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","06/10/2021",2021-10-06
"1166",137,"Castillo-Arregoces","Retrospective matched cohort","16Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Colombia",">= 60 years","60+ years",83,"78.4",86.6,NA,"mu","32 weeks",NA,NA,1208,"Colombia","COL",137,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2021-12-16,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","mu",NA,2021-12-16
"1167",137,"Castillo-Arregoces","Retrospective matched cohort","16Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","post-hospitalization death","death","Colombia",">= 60 years","60+ years",94.8,"93.3",96,NA,"mu","32 weeks",NA,NA,1209,"Colombia","COL",137,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2021-12-16,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","mu",NA,2021-12-16
"1168",137,"Castillo-Arregoces","Retrospective matched cohort","16Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","Colombia",">= 60 years","60+ years",88.3,"84.1",91.4,NA,"mu","32 weeks",NA,NA,1210,"Colombia","COL",137,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2021-12-16,"death","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","mu",NA,2021-12-16
"1169",137,"Castillo-Arregoces","Retrospective matched cohort","16Dec2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","hospitalization","severe","Colombia",">= 60 years","60+ years",90.8,"85.5",94.2,NA,"mu","32 weeks",NA,NA,1211,"Colombia","COL",137,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2021-12-16,"severe","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","mu",NA,2021-12-16
"1170",137,"Castillo-Arregoces","Retrospective matched cohort","16Dec2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","post-hospitalization death","death","Colombia",">= 60 years","60+ years",97.5,"95.8",98.5,NA,"mu","32 weeks",NA,NA,1212,"Colombia","COL",137,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2021-12-16,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","mu",NA,2021-12-16
"1171",137,"Castillo-Arregoces","Retrospective matched cohort","16Dec2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","death","death","Colombia",">= 60 years","60+ years",93.9,"89.3",96.6,NA,"mu","32 weeks",NA,NA,1213,"Colombia","COL",137,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2021-12-16,"death","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","mu",NA,2021-12-16
"1172",137,"Castillo-Arregoces","Retrospective matched cohort","16Dec2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization","severe","Colombia",">= 60 years","60+ years",60.9,"36.8",75.8,NA,"mu","32 weeks",NA,NA,1214,"Colombia","COL",137,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2021-12-16,"severe","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","mu",NA,2021-12-16
"1173",137,"Castillo-Arregoces","Retrospective matched cohort","16Dec2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","post-hospitalization death","death","Colombia",">= 60 years","60+ years",85.8,"77.1",91.2,NA,"mu","32 weeks",NA,NA,1215,"Colombia","COL",137,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2021-12-16,"death","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","mu",NA,2021-12-16
"1174",137,"Castillo-Arregoces","Retrospective matched cohort","16Dec2021","Ad26.COV2.S (Janssen)","excluded","1","final","14+","death","death","Colombia",">= 60 years","60+ years",95.5,"82",98.9,NA,"mu","32 weeks",NA,NA,1216,"Colombia","COL",137,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2021-12-16,"death","2021 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","mu",NA,2021-12-16
"1175",137,"Castillo-Arregoces","Retrospective matched cohort","16Dec2021","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Colombia",">= 60 years",">= 60 years",47.3,"41.9",52.3,NA,"mu","32 weeks",NA,NA,1217,"Colombia","COL",137,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2021-12-16,"severe","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","mu",NA,2021-12-16
"1176",137,"Castillo-Arregoces","Retrospective matched cohort","16Dec2021","CoronaVac (Sinovac)","excluded","2","final","14+","post-hospitalization death","death","Colombia",">= 60 years","60+ years",72.1,"70.1",73.9,NA,"mu","32 weeks",NA,NA,1218,"Colombia","COL",137,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2021-12-16,"death","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","mu",NA,2021-12-16
"1177",137,"Castillo-Arregoces","Retrospective matched cohort","16Dec2021","CoronaVac (Sinovac)","excluded","2","final","14+","death","death","Colombia",">= 60 years","60+ years",64.9,"61.2",68.9,NA,"mu","32 weeks",NA,NA,1219,"Colombia","COL",137,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2021-12-16,"death","2021 (Jul-Dec)","Sinovac CoronaVac","Inactivated","mu",NA,2021-12-16
"1178",138,"McLean","Prospective cohort","18Feb2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA",">= 12 years","general pop",50,"21",69,NA,"non-VOC, alpha, & delta","~52 weeks",NA,NA,1220,"USA","USA",138,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-18,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","16/12/2021",2021-12-16
"1179",138,"McLean","Prospective cohort","18Feb2022","mRNA-1273 (Moderna)","included","2","final","14+","Infection","infection","USA",">= 12 years","general pop",65,"37",81,NA,"non-VOC, alpha, & delta","~52 weeks",NA,NA,1221,"USA","USA",138,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-18,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1180",138,"McLean","Prospective cohort","18Feb2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","symptomatic disease","symptomatic","USA",">= 12 years","general pop",54,"26",71,NA,"non-VOC, alpha, & delta","~52 weeks",NA,NA,1222,"USA","USA",138,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-18,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","16/12/2021",2021-12-16
"1181",138,"McLean","Prospective cohort","18Feb2022","mRNA-1273 (Moderna)","included","2","final","14+","symptomatic disease","symptomatic","USA",">= 12 years","general pop",65,"38",81,NA,"non-VOC, alpha, & delta","~52 weeks",NA,NA,1223,"USA","USA",138,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-18,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1182",138,"McLean","Prospective cohort","18Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Infection","infection","USA",">= 12 years","general pop",51,"22",70,NA,"non-VOC, alpha, & delta","~52 weeks",NA,NA,1224,"USA","USA",138,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-18,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","16/12/2021",2021-12-16
"1183",138,"McLean","Prospective cohort","18Feb2022","mRNA-1273 (Moderna)","excluded","2","final","14+","Infection","infection","USA",">= 12 years","general pop",66,"38",82,NA,"non-VOC, alpha, & delta","~52 weeks",NA,NA,1225,"USA","USA",138,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-18,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1184",138,"McLean","Prospective cohort","18Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Infection","infection","USA",">= 12 years","general pop",52,"20",71,"delta","delta","~52 weeks",NA,NA,1226,"USA","USA",138,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-18,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","16/12/2021",2021-12-16
"1185",138,"McLean","Prospective cohort","18Feb2022","mRNA-1273 (Moderna)","excluded","2","final","14+","Infection","infection","USA",">= 12 years","general pop",59,"24",78,"delta","delta","~52 weeks",NA,NA,1227,"USA","USA",138,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-18,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","16/12/2021",2021-12-16
"1186",139,"Abu-Raddad","Test-negative case-control","21Jan2022","mRNA-1273 (Moderna)","excluded","1","1","14+","Infection","infection","Qatar",">= 18 years","general pop",60.3,"57",63.3,NA,"beta & delta",NA,NA,NA,1228,"Qatar","QAT",139,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-01-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1187",139,"Abu-Raddad","Test-negative case-control","21Jan2022","mRNA-1273 (Moderna)","excluded","2","final","30+","Infection","infection","Qatar",">= 18 years","general pop",85.3,"83.5",86.9,NA,"beta & delta","~35 weeks",NA,NA,1229,"Qatar","QAT",139,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-01-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1188",139,"Abu-Raddad","Test-negative case-control","21Jan2022","mRNA-1273 (Moderna)","excluded","2","final","240+","Infection","infection","Qatar",">= 18 years","general pop",-29.5,"-84",8.8,NA,"beta & delta","~35 weeks",NA,NA,1230,"Qatar","QAT",139,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-01-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1189",139,"Abu-Raddad","Test-negative case-control","21Jan2022","mRNA-1273 (Moderna)","excluded","1","1","14+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",78.3,"75.2",81.1,NA,"beta & delta",NA,NA,NA,1231,"Qatar","QAT",139,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-01-21,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1190",139,"Abu-Raddad","Test-negative case-control","21Jan2022","mRNA-1273 (Moderna)","excluded","2","final","30+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",94.4,"92.8",95.6,NA,"beta & delta","~35 weeks",NA,NA,1232,"Qatar","QAT",139,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-01-21,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1191",139,"Abu-Raddad","Test-negative case-control","21Jan2022","mRNA-1273 (Moderna)","excluded","2","final","240+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",20,"-29",59.3,NA,"beta & delta","~35 weeks",NA,NA,1233,"Qatar","QAT",139,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-01-21,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1192",139,"Abu-Raddad","Test-negative case-control","21Jan2022","mRNA-1273 (Moderna)","excluded","1","1","14+","asymptomatic infection","asymptomatic","Qatar",">= 18 years","general pop",54.6,"47.7",60.6,NA,"beta & delta",NA,NA,NA,1234,"Qatar","QAT",139,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-01-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1193",139,"Abu-Raddad","Test-negative case-control","21Jan2022","mRNA-1273 (Moderna)","excluded","2","final","30+","asymptomatic infection","asymptomatic","Qatar",">= 18 years","general pop",79.9,"75.5",83.4,NA,"beta & delta","~35 weeks",NA,NA,1235,"Qatar","QAT",139,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-01-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1194",139,"Abu-Raddad","Test-negative case-control","21Jan2022","mRNA-1273 (Moderna)","excluded","2","final","240+","asymptomatic infection","asymptomatic","Qatar",">= 18 years","general pop",-28.4,"-129.3",28.1,NA,"beta & delta","~35 weeks",NA,NA,1236,"Qatar","QAT",139,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-01-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1195",139,"Abu-Raddad","Test-negative case-control","21Jan2022","mRNA-1273 (Moderna)","excluded","1","1","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",82.1,"73.1",88.1,NA,"beta & delta",NA,NA,NA,1237,"Qatar","QAT",139,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-01-21,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1196",139,"Abu-Raddad","Test-negative case-control","21Jan2022","mRNA-1273 (Moderna)","excluded","2","final","30+","hospitalization or death","severe","Qatar",">= 18 years","general pop",97.2,"92.4",99,NA,"beta & delta","~35 weeks",NA,NA,1238,"Qatar","QAT",139,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-01-21,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1197",139,"Abu-Raddad","Test-negative case-control","21Jan2022","mRNA-1273 (Moderna)","excluded","2","final","180+","hospitalization or death","severe","Qatar",">= 18 years","general pop",61,"-225.5",95.3,NA,"beta & delta","~35 weeks",NA,NA,1239,"Qatar","QAT",139,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-01-21,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","16/12/2021",2021-12-16
"1198",140,"Bekker","Retrospective matched cohort","19Mar2022","Ad26.COV2.S (Janssen)","included","1","final","28+","hospitalization","severe","South Africa","HCW","HCW",67,"62",71,NA,"beta, delta, & kappa","12 weeks",NA,NA,1240,"South Africa","ZAF",140,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2022-03-19,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","20/12/2021",2021-12-20
"1199",140,"Bekker","Retrospective matched cohort","19Mar2022","Ad26.COV2.S (Janssen)","included","1","final","28+","ICU admission","severe","South Africa","HCW","HCW",75,"69",82,NA,"beta, delta, & kappa","12 weeks",NA,NA,1241,"South Africa","ZAF",140,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2022-03-19,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","20/12/2021",2021-12-20
"1200",140,"Bekker","Retrospective matched cohort","19Mar2022","Ad26.COV2.S (Janssen)","included","1","final","28+","death","death","South Africa","HCW","HCW",83,"75",89,NA,"beta, delta, & kappa","12 weeks",NA,NA,1242,"South Africa","ZAF",140,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2022-03-19,"death","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","20/12/2021",2021-12-20
"1201",140,"Bekker","Retrospective matched cohort","19Mar2022","Ad26.COV2.S (Janssen)","included","1","final","28+","hospitalization","severe","South Africa","HCW","HCW",62,"42",76,"beta","beta","12 weeks",NA,NA,1243,"South Africa","ZAF",140,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2022-03-19,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","beta","20/12/2021",2021-12-20
"1202",140,"Bekker","Retrospective matched cohort","19Mar2022","Ad26.COV2.S (Janssen)","included","1","final","28+","ICU admission","severe","South Africa","HCW","HCW",49,"8",77,"beta","beta","12 weeks",NA,NA,1244,"South Africa","ZAF",140,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2022-03-19,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","beta","20/12/2021",2021-12-20
"1203",140,"Bekker","Retrospective matched cohort","19Mar2022","Ad26.COV2.S (Janssen)","included","1","final","28+","death","death","South Africa","HCW","HCW",86,"57",100,"beta","beta","12 weeks",NA,NA,1245,"South Africa","ZAF",140,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2022-03-19,"death","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","beta","20/12/2021",2021-12-20
"1204",140,"Bekker","Retrospective matched cohort","19Mar2022","Ad26.COV2.S (Janssen)","included","1","final","28+","hospitalization","severe","South Africa","HCW","HCW",67,"62",71,"delta","delta","12 weeks",NA,NA,1246,"South Africa","ZAF",140,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2022-03-19,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","20/12/2021",2021-12-20
"1205",140,"Bekker","Retrospective matched cohort","19Mar2022","Ad26.COV2.S (Janssen)","included","1","final","28+","ICU admission","severe","South Africa","HCW","HCW",78,"71",88,"delta","delta","12 weeks",NA,NA,1247,"South Africa","ZAF",140,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2022-03-19,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","20/12/2021",2021-12-20
"1206",140,"Bekker","Retrospective matched cohort","19Mar2022","Ad26.COV2.S (Janssen)","included","1","final","28+","death","death","South Africa","HCW","HCW",82,"74",89,"delta","delta","12 weeks",NA,NA,1248,"South Africa","ZAF",140,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2022-03-19,"death","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","20/12/2021",2021-12-20
"1207",141,"Tartof","Retrospective matched cohort","14Feb2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7-36","Infection","infection","USA",">= 18 years","general pop",85,"83",86,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1249,"USA","USA",141,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-14,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","21/12/2021",2021-12-21
"1208",141,"Tartof","Retrospective matched cohort","14Feb2022","BNT162b2 (Pfizer BioNTech)","included","2","final","217+","Infection","infection","USA",">= 18 years","general pop",49,"46",51,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1250,"USA","USA",141,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-14,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","21/12/2021",2021-12-21
"1209",141,"Tartof","Retrospective matched cohort","14Feb2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7-36","hospitalization","severe","USA",">= 18 years","general pop",90,"86",92,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1251,"USA","USA",141,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-14,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","21/12/2021",2021-12-21
"1210",141,"Tartof","Retrospective matched cohort","14Feb2022","BNT162b2 (Pfizer BioNTech)","included","2","final","217+","hospitalization","severe","USA",">= 18 years","general pop",88,"85",90,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1252,"USA","USA",141,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-14,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","21/12/2021",2021-12-21
"1211",142,"Lewis","Test-negative case-control","21Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",96,"93",98,NA,"alpha & delta","~30 weeks",NA,NA,1253,"USA","USA",142,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-21,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-21
"1212",142,"Lewis","Test-negative case-control","21Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",93,"89",95,NA,"alpha & delta","~30 weeks",NA,NA,1254,"USA","USA",142,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-21,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-21
"1213",142,"Lewis","Test-negative case-control","21Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",87,"82",91,NA,"alpha & delta","~30 weeks",NA,NA,1255,"USA","USA",142,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-21,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-21
"1214",142,"Lewis","Test-negative case-control","21Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",83,"72",88,NA,"alpha & delta","~30 weeks",NA,NA,1256,"USA","USA",142,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-21,"severe","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-21
"1215",143,"Ioannou","Target trial emulation","21Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","infection (March 31 2021)","infection","USA",">= 18 years","general pop",31,"26",35,NA,"non-VOC & alpha",NA,NA,NA,1257,"USA","USA",143,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-21,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-21
"1216",143,"Ioannou","Target trial emulation","21Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","infection (March 31 2021)","infection","USA",">= 18 years","general pop",65,"63",68,NA,"non-VOC & alpha","~28 weeks",NA,NA,1258,"USA","USA",143,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-21,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-21
"1217",143,"Ioannou","Target trial emulation","21Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","infection (June 30 2021)","infection","USA",">= 18 years","general pop",69,"67",70,NA,"non-VOC & alpha","~28 weeks",NA,NA,1259,"USA","USA",143,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-21,"infection","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-21
"1218",143,"Ioannou","Target trial emulation","21Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","death (March 31 2021)","death","USA",">= 18 years","general pop",55,"42",64,NA,"non-VOC & alpha",NA,NA,NA,1260,"USA","USA",143,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-21,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-21
"1219",143,"Ioannou","Target trial emulation","21Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","death (March 31 2021)","death","USA",">= 18 years","general pop",89,"84",92,NA,"non-VOC & alpha","~28 weeks",NA,NA,1261,"USA","USA",143,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-21,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-21
"1220",143,"Ioannou","Target trial emulation","21Dec2021","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","death (June 30 2021)","death","USA",">= 18 years","general pop",86,"82",89,NA,"non-VOC & alpha","~28 weeks",NA,NA,1262,"USA","USA",143,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-21,"death","2021 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2021-12-21
"1221",144,"Hansen","Retrospective cohort","23Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","15-44","Infection","infection","Denmark",">= 12 years","general pop",55.2,"23.5",73.7,"omicron","omicron","21 weeks",NA,NA,1263,"Denmark","DNK",144,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-23,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2021-12-23
"1222",144,"Hansen","Retrospective cohort","23Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","105-164","Infection","infection","Denmark",">= 12 years","general pop",-76.5,"-95.3",-59.5,"omicron","omicron","22 weeks",NA,NA,1264,"Denmark","DNK",144,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-23,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2021-12-23
"1223",144,"Hansen","Retrospective cohort","23Dec2021","mRNA-1273 (Moderna)","excluded","2","final","15-44","Infection","infection","Denmark",">= 12 years","general pop",36.7,"-69.9",76.4,"omicron","omicron","23 weeks",NA,NA,1265,"Denmark","DNK",144,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-23,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2021-12-23
"1224",144,"Hansen","Retrospective cohort","23Dec2021","mRNA-1273 (Moderna)","excluded","2","final","105-164","Infection","infection","Denmark",">= 12 years","general pop",-39.3,"-61.6",-20,"omicron","omicron","24 weeks",NA,NA,1266,"Denmark","DNK",144,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-23,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2021-12-23
"1225",144,"Hansen","Retrospective cohort","23Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","15-44","Infection","infection","Denmark",">= 12 years","general pop",86.7,"84.6",88.6,"delta","delta","25 weeks",NA,NA,1267,"Denmark","DNK",144,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-23,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-12-23
"1226",144,"Hansen","Retrospective cohort","23Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","105-164","Infection","infection","Denmark",">= 12 years","general pop",53.8,"52.9",54.6,"delta","delta","26 weeks",NA,NA,1268,"Denmark","DNK",144,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-23,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-12-23
"1227",144,"Hansen","Retrospective cohort","23Dec2021","mRNA-1273 (Moderna)","excluded","2","final","15-44","Infection","infection","Denmark",">= 12 years","general pop",88.2,"83.1",91.8,"delta","delta","27 weeks",NA,NA,1269,"Denmark","DNK",144,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-23,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2021-12-23
"1228",144,"Hansen","Retrospective cohort","23Dec2021","mRNA-1273 (Moderna)","excluded","2","final","105-164","Infection","infection","Denmark",">= 12 years","general pop",65,"63.6",66.3,"delta","delta","28 weeks",NA,NA,1270,"Denmark","DNK",144,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-23,"infection","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2021-12-23
"1229",146,"Katikireddi","Retrospective cohort","20Dec2021","AZD1222 (AstraZeneca)","excluded","2","final","14-27","severe disease","severe","Scotland",">= 18 years","general pop",83.7,"79.7",87,NA,"delta","~20 weeks",NA,NA,1281,"UK","GBR",146,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-12-20,"severe","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-12-20
"1230",146,"Katikireddi","Retrospective cohort","20Dec2021","AZD1222 (AstraZeneca)","excluded","2","final","140-153","severe disease","severe","Scotland",">= 18 years","general pop",53.6,"48.4",58.3,NA,"delta","~20 weeks",NA,NA,1282,"UK","GBR",146,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-12-20,"severe","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2021-12-20
"1231",147,"Amir","Quasi-experimental","21Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-60","Infection","infection","Israel","12-14 years","12-14 years",92,"91.1",92.8,NA,"delta","~6.5 weeks",NA,NA,1283,"Israel","ISR",147,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-21,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-12-21
"1232",147,"Amir","Quasi-experimental","21Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-60","Infection","infection","Israel","16-18 years","16-18 years",89.8,"80",93.8,NA,"delta","~6.5 weeks",NA,NA,1284,"Israel","ISR",147,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-21,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-12-21
"1233",148,"Ostropolets","Retrospective cohort","23Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Infection","infection","USA",">= 18 years","general pop",94,"91",95,NA,"non-VOC, alpha, & delta","52 weeks",NA,NA,1285,"USA","USA",148,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-23,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","25/12/2021",2021-12-25
"1234",148,"Ostropolets","Retrospective cohort","23Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Hospitalization","severe","USA",">= 18 years","general pop",95,"92",97,NA,"non-VOC, alpha, & delta","52 weeks",NA,NA,1286,"USA","USA",148,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-23,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","25/12/2021",2021-12-25
"1235",148,"Ostropolets","Retrospective cohort","23Aug2022","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA",">= 18 years","general pop",97,"94",98,NA,"non-VOC, alpha, & delta","52 weeks",NA,NA,1287,"USA","USA",148,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-23,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","25/12/2021",2021-12-25
"1236",148,"Ostropolets","Retrospective cohort","23Aug2022","mRNA-1273 (Moderna)","excluded","2","final","14+","Hospitalization","severe","USA",">= 18 years","general pop",96,"92",99,NA,"non-VOC, alpha, & delta","52 weeks",NA,NA,1288,"USA","USA",148,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-23,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","25/12/2021",2021-12-25
"1237",148,"Ostropolets","Retrospective cohort","23Aug2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","Infection","infection","USA",">= 18 years","general pop",81,"50",94,NA,"non-VOC, alpha, & delta","52 weeks",NA,NA,1289,"USA","USA",148,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-23,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","25/12/2021",2021-12-25
"1238",148,"Ostropolets","Retrospective cohort","23Aug2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization","severe","USA",">= 18 years","general pop",92,"58",100,NA,"non-VOC, alpha, & delta","52 weeks",NA,NA,1290,"USA","USA",148,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-23,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","25/12/2021",2021-12-25
"1239",149,"Alali","Retrospective cohort","07Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","symptomatic disease","symptomatic","Kuwait","HCW","HCW",91.4,"65.1",97.9,NA,"alpha",NA,NA,NA,1291,"Kuwait","KWT",149,"KWT",35680,2019,"Kuwait","Middle East & North Africa","High income",4,"Asia",2020-12-28,2021-11-30,2021-11-30,2020-12-28,2020-12-28,0,337,337,"equal","before jan/2021","Sep-Nov/2021","270-359","yes","yes","yes",2021-12-07,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-12-07
"1240",149,"Alali","Retrospective cohort","07Dec2021","AZD1222 (AstraZeneca)","excluded","1","1","28+","symptomatic disease","symptomatic","Kuwait","HCW","HCW",75.4,"67.2",81.6,NA,"alpha",NA,NA,NA,1292,"Kuwait","KWT",149,"KWT",35680,2019,"Kuwait","Middle East & North Africa","High income",4,"Asia",2020-12-28,2021-11-30,2021-11-30,2020-12-28,2020-12-28,0,337,337,"equal","before jan/2021","Sep-Nov/2021","270-359","yes","yes","yes",2021-12-07,"symptomatic","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-12-07
"1241",149,"Alali","Retrospective cohort","07Dec2021","AZD1222 (AstraZeneca)","excluded","2","final","14+","symptomatic disease","symptomatic","Kuwait","HCW","HCW",94.5,"89.4",97.2,NA,"alpha","~20 weeks",NA,NA,1293,"Kuwait","KWT",149,"KWT",35680,2019,"Kuwait","Middle East & North Africa","High income",4,"Asia",2020-12-28,2021-11-30,2021-11-30,2020-12-28,2020-12-28,0,337,337,"equal","before jan/2021","Sep-Nov/2021","270-359","yes","yes","yes",2021-12-07,"symptomatic","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2021-12-07
"1242",150,"Mendola","Retrospective cohort","23Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","8-98","infection","infection","Italy","HCW","HCW",89,"78",95,NA,"alpha","~12 weeks",NA,NA,1294,"Italy","ITA",150,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2021-12-23,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-12-23
"1243",151,"Collie","Test-negative case-control","29Dec2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","Hospitalization","severe","South Africa",">= 18 years","general pop",70,"62",76,NA,"omicron","~24 weeks",NA,NA,1295,"South Africa","ZAF",151,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2021-12-29,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2021-12-29
"1244",151,"Collie","Test-negative case-control","29Dec2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","Hospitalization","severe","South Africa",">= 18 years","general pop",93,"90",94,NA,"delta","~19 weeks",NA,NA,1296,"South Africa","ZAF",151,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2021-12-29,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-12-29
"1245",152,"Lutrick","Prospective cohort","31Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","USA","12-17 years","12-17 years",92,"79",97,NA,"delta","~17 weeks",NA,NA,1297,"USA","USA",152,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-31,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2021-12-31
"1246",153,"Chung","Test-negative case-control","01Jan2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","symptomatic disease","symptomatic","USA",">= 12 years","general pop",66,"56",73,NA,"non-VOC, alpha, & delta","~34 weeks",NA,NA,1298,"USA","USA",153,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-01,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-01-01
"1247",153,"Chung","Test-negative case-control","01Jan2022","mRNA-1273 (Moderna)","included","2","final","14+","symptomatic disease","symptomatic","USA",">= 12 years","general pop",81,"73",86,NA,"non-VOC, alpha, & delta","~34 weeks",NA,NA,1299,"USA","USA",153,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-01,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-01-01
"1248",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","CoronaVac (Sinovac)","confirmed prior infection","1","1","14+","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",18.8,"10.7",26.1,NA,"non-VOC, gamma, & delta",NA,NA,NA,1300,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","27/12/2021",2021-12-27
"1249",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","CoronaVac (Sinovac)","confirmed prior infection","2","final","14+","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",39.4,"36.1",42.6,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,1301,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","27/12/2021",2021-12-27
"1250",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","CoronaVac (Sinovac)","confirmed prior infection","2","final","14-90","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",40.5,"36.4",44.3,NA,"non-VOC, gamma, & delta","~11 weeks",NA,NA,1302,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","27/12/2021",2021-12-27
"1251",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","CoronaVac (Sinovac)","confirmed prior infection","2","final","90+","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",38,"33.1",42.5,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,1303,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","27/12/2021",2021-12-27
"1252",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","CoronaVac (Sinovac)","confirmed prior infection","1","1","14+","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",35.3,"7.9",54.5,NA,"non-VOC, gamma, & delta",NA,NA,NA,1304,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","27/12/2021",2021-12-27
"1253",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","CoronaVac (Sinovac)","confirmed prior infection","2","final","14+","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",81.3,"75.3",85.8,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,1305,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","27/12/2021",2021-12-27
"1254",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","CoronaVac (Sinovac)","confirmed prior infection","2","final","14-90","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",86.6,"79.8",90.3,NA,"non-VOC, gamma, & delta","~11 weeks",NA,NA,1306,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","27/12/2021",2021-12-27
"1255",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","CoronaVac (Sinovac)","confirmed prior infection","2","final","90+","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",74.4,"63.3",82.2,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,1307,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","27/12/2021",2021-12-27
"1256",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","AZD1222 (AstraZeneca)","confirmed prior infection","1","1","14+","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",34.2,"30.1",38.1,NA,"non-VOC, gamma, & delta",NA,NA,NA,1308,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","27/12/2021",2021-12-27
"1257",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","AZD1222 (AstraZeneca)","confirmed prior infection","2","final","14+","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",56,"51.4",60.2,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,1309,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","27/12/2021",2021-12-27
"1258",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","AZD1222 (AstraZeneca)","confirmed prior infection","2","final","14-90","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",55.5,"50.5",60.1,NA,"non-VOC, gamma, & delta","~11 weeks",NA,NA,1310,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","27/12/2021",2021-12-27
"1259",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","AZD1222 (AstraZeneca)","confirmed prior infection","2","final","90+","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",56.8,"46.6",65.1,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,1311,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","27/12/2021",2021-12-27
"1260",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","AZD1222 (AstraZeneca)","confirmed prior infection","1","1","14+","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",56.9,"45.2",66.1,NA,"non-VOC, gamma, & delta",NA,NA,NA,1312,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","27/12/2021",2021-12-27
"1261",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","AZD1222 (AstraZeneca)","confirmed prior infection","2","final","14+","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",89.9,"83.5",93.8,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,1313,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","27/12/2021",2021-12-27
"1262",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","AZD1222 (AstraZeneca)","confirmed prior infection","2","final","14-90","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",86.6,"77.6",92,NA,"non-VOC, gamma, & delta","~11 weeks",NA,NA,1314,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","27/12/2021",2021-12-27
"1263",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","AZD1222 (AstraZeneca)","confirmed prior infection","2","final","90+","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",95.1,"84.8",98.4,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,1315,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","27/12/2021",2021-12-27
"1264",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","BNT162b2 (Pfizer BioNTech)","confirmed prior infection","1","1","14+","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",45,"39.7",49.9,NA,"non-VOC, gamma, & delta",NA,NA,NA,1316,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/12/2021",2021-12-27
"1265",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","BNT162b2 (Pfizer BioNTech)","confirmed prior infection","2","final","14+","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",64.8,"54.9",72.4,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,1317,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/12/2021",2021-12-27
"1266",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","BNT162b2 (Pfizer BioNTech)","confirmed prior infection","2","final","14-90","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",64.2,"54.2",72,NA,"non-VOC, gamma, & delta","~11 weeks",NA,NA,1318,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/12/2021",2021-12-27
"1267",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","BNT162b2 (Pfizer BioNTech)","confirmed prior infection","2","final","90+","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",100,NA,NA,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,1319,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/12/2021",2021-12-27
"1268",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","BNT162b2 (Pfizer BioNTech)","confirmed prior infection","1","1","14+","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",61.8,"40.8",75.3,NA,"non-VOC, gamma, & delta",NA,NA,NA,1320,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/12/2021",2021-12-27
"1269",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","BNT162b2 (Pfizer BioNTech)","confirmed prior infection","2","final","14+","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",89.7,"54.3",97.7,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,1321,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/12/2021",2021-12-27
"1270",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","BNT162b2 (Pfizer BioNTech)","confirmed prior infection","2","final","14-90","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",88.8,"50",97.5,NA,"non-VOC, gamma, & delta","~11 weeks",NA,NA,1322,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/12/2021",2021-12-27
"1271",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","BNT162b2 (Pfizer BioNTech)","confirmed prior infection","2","final","90+","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",100,NA,NA,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,1323,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","27/12/2021",2021-12-27
"1272",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","Ad26.COV2.S (Janssen)","confirmed prior infection","1","final","14+","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",44,"31.5",54.2,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,1324,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","27/12/2021",2021-12-27
"1273",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","Ad26.COV2.S (Janssen)","confirmed prior infection","1","final","14-90","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",46.1,"32.7",56.7,NA,"non-VOC, gamma, & delta","~11 weeks",NA,NA,1325,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","27/12/2021",2021-12-27
"1274",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","Ad26.COV2.S (Janssen)","confirmed prior infection","1","final","90+","symptomatic reinfection","symptomatic","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",30.6,"-12.4",57.1,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,1326,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"symptomatic","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","27/12/2021",2021-12-27
"1275",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","Ad26.COV2.S (Janssen)","confirmed prior infection","1","final","14+","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",57.7,"-2.6",82.5,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,1327,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","27/12/2021",2021-12-27
"1276",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","Ad26.COV2.S (Janssen)","confirmed prior infection","1","final","14-90","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",60.2,"-10.8",85.7,NA,"non-VOC, gamma, & delta","~11 weeks",NA,NA,1328,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","27/12/2021",2021-12-27
"1277",155,"Cerqueira-Silva ","Test-negative case-control","31Mar2022","Ad26.COV2.S (Janssen)","confirmed prior infection","1","final","90+","hospitalization or death","severe","Brazil",">= 18 years with prior SARS-CoV-2 infection","general pop with prior SARS-CoV-2 infection",41,"-240.9",89.9,NA,"non-VOC, gamma, & delta","~37 weeks",NA,NA,1329,"Brazil","BRA",155,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-31,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","27/12/2021",2021-12-27
"1278",156,"Petraš","Retrospective cohort","22Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","infection","infection","Czech Republic","HCW","HCW",47.7,"19.2",66.2,NA,"alpha & delta",NA,NA,NA,1330,"Czech Republic","CZE",156,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2021-12-22,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-12-22
"1279",156,"Petraš","Retrospective cohort","22Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Infection","infection","Czech Republic","HCW","HCW",88.3,"83.2",91.8,NA,"alpha & delta","~30 weeks",NA,NA,1331,"Czech Republic","CZE",156,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2021-12-22,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-12-22
"1280",156,"Petraš","Retrospective cohort","22Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","symptomatic disease","symptomatic","Czech Republic","HCW","HCW",76.4,"46",89.7,NA,"alpha & delta",NA,NA,NA,1332,"Czech Republic","CZE",156,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2021-12-22,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-12-22
"1281",156,"Petraš","Retrospective cohort","22Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Czech Republic","HCW","HCW",91.7,"85.7",95.2,NA,"alpha & delta","~30 weeks",NA,NA,1333,"Czech Republic","CZE",156,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2021-12-22,"symptomatic","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-12-22
"1282",156,"Petraš","Retrospective cohort","22Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection (February 2021)","infection","Czech Republic","HCW","HCW",96.2,"91.6",98.7,NA,"alpha & delta","4 weeks",NA,NA,1334,"Czech Republic","CZE",156,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2021-12-22,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-12-22
"1283",156,"Petraš","Retrospective cohort","22Dec2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection (June-August 2021)","infection","Czech Republic","HCW","HCW",65,"<0",96.6,NA,"alpha & delta","~30 weeks",NA,NA,1335,"Czech Republic","CZE",156,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2021-12-22,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2021-12-22
"1284",157,"Prunas","Matched case-control","09Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-89","Infection","infection","Israel","12-16 years","12-16 years",85,"84",86,NA,"delta","~25 weeks",NA,NA,1336,"Israel","ISR",157,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-12-09,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","05/01/2022",2022-01-05
"1285",157,"Prunas","Matched case-control","09Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","150-180","Infection","infection","Israel","12-16 years","12-16 years",53,"46",60,NA,"delta","~25 weeks",NA,NA,1337,"Israel","ISR",157,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-12-09,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","05/01/2022",2022-01-05
"1286",157,"Prunas","Matched case-control","09Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-89","symptomatic disease","symptomatic","Israel","12-16 years","12-16 years",90,"89",91,NA,"delta","~25 weeks",NA,NA,1338,"Israel","ISR",157,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-12-09,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","05/01/2022",2022-01-05
"1287",157,"Prunas","Matched case-control","09Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","150-180","symptomatic disease","symptomatic","Israel","12-16 years","12-16 years",66,"59",72,NA,"delta","~25 weeks",NA,NA,1339,"Israel","ISR",157,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-12-09,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","05/01/2022",2022-01-05
"1288",157,"Prunas","Test-negative case-control","09Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-89","Infection","infection","Israel","12-16 years","12-16 years",84,"82",85,NA,"delta","~25 weeks",NA,NA,1340,"Israel","ISR",157,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-12-09,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","05/01/2022",2022-01-05
"1289",157,"Prunas","Test-negative case-control","09Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","150-180","Infection","infection","Israel","12-16 years","12-16 years",50,"43",57,NA,"delta","~25 weeks",NA,NA,1341,"Israel","ISR",157,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-12-09,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","05/01/2022",2022-01-05
"1290",158,"Zambrano","Test-negative case-control","07Jan2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","MIS-C","MIS-C","USA","12-18 years","12-18 years",86,"70",93,NA,"delta","~23 weeks",NA,NA,1342,"USA","USA",158,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-07
"1291",158,"Zambrano","Test-negative case-control","07Jan2022","BNT162b2 (Pfizer BioNTech)","included","2","final","28+","MIS-C","MIS-C","USA","12-18 years","12-18 years",91,"78",97,NA,"delta","~23 weeks",NA,NA,1343,"USA","USA",158,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-07
"1292",158,"Zambrano","Test-negative case-control","07Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","28+","MIS-C","MIS-C","USA","12-18 years","12-18 years",90,"75",96,NA,"delta","~23 weeks",NA,NA,1344,"USA","USA",158,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-07
"1293",159,"Tseng","Test-negative case-control","21Feb2022","mRNA-1273 (Moderna)","included","1","1","14+","Infection","infection","USA",">= 18 years","general pop",20.4,"9.5",30,"omicron","omicron",NA,NA,NA,1345,"USA","USA",159,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","21/01/2022",2022-01-21
"1294",159,"Tseng","Test-negative case-control","21Feb2022","mRNA-1273 (Moderna)","included","2","final","14+","Infection","infection","USA",">= 18 years","general pop",13.9,"10.5",17.1,"omicron","omicron","~47.5 weeks",NA,NA,1346,"USA","USA",159,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","21/01/2022",2022-01-21
"1295",159,"Tseng","Test-negative case-control","21Feb2022","mRNA-1273 (Moderna)","included","2","final","14-90","Infection","infection","USA",">= 18 years","general pop",44,"35.1",51.6,"omicron","omicron","~11 weeks",NA,NA,1347,"USA","USA",159,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","21/01/2022",2022-01-21
"1296",159,"Tseng","Test-negative case-control","21Feb2022","mRNA-1273 (Moderna)","included","2","final","270+","Infection","infection","USA",">= 18 years","general pop",5.9,"0.4",11,"omicron","omicron","~47.5 weeks",NA,NA,1348,"USA","USA",159,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","21/01/2022",2022-01-21
"1297",159,"Tseng","Test-negative case-control","21Feb2022","mRNA-1273 (Moderna)","included","2","final","14+","Hospitalization","severe","USA",">= 18 years","general pop",84.5,"23",96.9,"omicron","omicron","~47.5 weeks",NA,NA,1349,"USA","USA",159,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-21,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","21/01/2022",2022-01-21
"1298",159,"Tseng","Test-negative case-control","21Feb2022","mRNA-1273 (Moderna)","included","1","1","14+","Infection","infection","USA",">= 18 years","general pop",56.7,"40.7",68.4,"delta","delta",NA,NA,NA,1350,"USA","USA",159,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/01/2022",2022-01-21
"1299",159,"Tseng","Test-negative case-control","21Feb2022","mRNA-1273 (Moderna)","included","2","final","14+","Infection","infection","USA",">= 18 years","general pop",63.6,"59.9",66.9,"delta","delta","~47.5 weeks",NA,NA,1351,"USA","USA",159,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/01/2022",2022-01-21
"1300",159,"Tseng","Test-negative case-control","21Feb2022","mRNA-1273 (Moderna)","included","2","final","14-90","Infection","infection","USA",">= 18 years","general pop",80.2,"68.2",87.7,"delta","delta","~11 weeks",NA,NA,1352,"USA","USA",159,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/01/2022",2022-01-21
"1301",159,"Tseng","Test-negative case-control","21Feb2022","mRNA-1273 (Moderna)","included","2","final","270+","Infection","infection","USA",">= 18 years","general pop",61.3,"55",66.7,"delta","delta","~47.5 weeks",NA,NA,1353,"USA","USA",159,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-21,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/01/2022",2022-01-21
"1302",159,"Tseng","Test-negative case-control","21Feb2022","mRNA-1273 (Moderna)","included","1","1","14+","Hospitalization","severe","USA",">= 18 years","general pop",71.2,"-68.7",97.4,"delta","delta",NA,NA,NA,1354,"USA","USA",159,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-21,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/01/2022",2022-01-21
"1303",159,"Tseng","Test-negative case-control","21Feb2022","mRNA-1273 (Moderna)","included","2","final","14+","Hospitalization","severe","USA",">= 18 years","general pop",99,"93.3",99.9,"delta","delta","~47.5 weeks",NA,NA,1355,"USA","USA",159,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-21,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/01/2022",2022-01-21
"1304",160,"Chiew","Retrospective cohort","28Sep2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","8+","Infection","infection","Singapore","12-17 years","12-17 years",25,"21",29,NA,"omicron","~44 weeks",NA,NA,1356,"Singapore","SGP",160,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-28,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","28/09/2022",2022-09-28
"1305",160,"Chiew","Retrospective cohort","28Sep2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","8-59","Infection","infection","Singapore","12-17 years","12-17 years",38,"32",43,NA,"omicron",NA,NA,NA,1357,"Singapore","SGP",160,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-28,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","28/09/2022",2022-09-28
"1306",160,"Chiew","Retrospective cohort","28Sep2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","240+","Infection","infection","Singapore","12-17 years","12-17 years",40,"34",46,NA,"omicron","~44 weeks",NA,NA,1358,"Singapore","SGP",160,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-28,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","28/09/2022",2022-09-28
"1307",160,"Chiew","Retrospective cohort","28Sep2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","8+","Hospitalization","severe","Singapore","12-17 years","12-17 years",75,"56",86,NA,"omicron","~44 weeks",NA,NA,1359,"Singapore","SGP",160,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-28,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","28/09/2022",2022-09-28
"1308",160,"Chiew","Retrospective cohort","28Sep2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","8-59","Hospitalization","severe","Singapore","12-17 years","12-17 years",74,"26",91,NA,"omicron",NA,NA,NA,1360,"Singapore","SGP",160,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-28,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","28/09/2022",2022-09-28
"1309",160,"Chiew","Retrospective cohort","28Sep2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","240+","Hospitalization","severe","Singapore","12-17 years","12-17 years",77,"54",89,NA,"omicron","~44 weeks",NA,NA,1361,"Singapore","SGP",160,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-28,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","28/09/2022",2022-09-28
"1310",160,"Chiew","Retrospective cohort","28Sep2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","8+","Infection","infection","Singapore","12-17 years","12-17 years",66,"63",69,NA,"delta","~24 weeks",NA,NA,1362,"Singapore","SGP",160,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-28,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","28/09/2022",2022-09-28
"1311",160,"Chiew","Retrospective cohort","28Sep2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","8-59","Infection","infection","Singapore","12-17 years","12-17 years",71,"67",74,NA,"delta",NA,NA,NA,1363,"Singapore","SGP",160,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-28,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","28/09/2022",2022-09-28
"1312",160,"Chiew","Retrospective cohort","28Sep2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","240+","Infection","infection","Singapore","12-17 years","12-17 years",57,"27",75,NA,"delta","~24 weeks",NA,NA,1364,"Singapore","SGP",160,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-28,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","28/09/2022",2022-09-28
"1313",160,"Chiew","Retrospective cohort","28Sep2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","8+","Hospitalization","severe","Singapore","12-17 years","12-17 years",83,"74",89,NA,"delta","~24 weeks",NA,NA,1365,"Singapore","SGP",160,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-28,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","28/09/2022",2022-09-28
"1314",160,"Chiew","Retrospective cohort","28Sep2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","8-59","Hospitalization","severe","Singapore","12-17 years","12-17 years",76,"62",85,NA,"delta",NA,NA,NA,1366,"Singapore","SGP",160,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-28,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","28/09/2022",2022-09-28
"1315",160,"Chiew","Retrospective cohort","28Sep2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","240+","Hospitalization","severe","Singapore","12-17 years","12-17 years",89,"64",94,NA,"delta","~24 weeks",NA,NA,1367,"Singapore","SGP",160,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-28,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","28/09/2022",2022-09-28
"1316",161,"Olson","Case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","Hospitalization","severe","USA","12-18 years","12-18 years",97,"86",100,NA,"delta",NA,NA,NA,1368,"USA","USA",161,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-12
"1317",161,"Olson","Case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","Hospitalization","severe","USA","12-18 years","12-18 years",94,"90",96,NA,"delta","~18 weeks",NA,NA,1369,"USA","USA",161,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-12
"1318",161,"Olson","Case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","ICU admission","severe","USA","12-18 years","12-18 years",98,"93",99,NA,"delta","~18 weeks",NA,NA,1370,"USA","USA",161,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-12
"1319",161,"Olson","Case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","life support","severe","USA","12-18 years","12-18 years",98,"92",100,NA,"delta","~18 weeks",NA,NA,1371,"USA","USA",161,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-12
"1320",161,"Olson","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","unknown","1","1","14+","hospitalization","severe","USA","12-18 years","12-18 years",98,"88",100,NA,"delta",NA,NA,NA,1372,"USA","USA",161,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-12
"1321",161,"Olson","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","hospitalization","severe","USA","12-18 years","12-18 years",95,"91",97,NA,"delta","~18 weeks",NA,NA,1373,"USA","USA",161,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-12
"1322",161,"Olson","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","ICU admission","severe","USA","12-18 years","12-18 years",98,"94",100,NA,"delta","~18 weeks",NA,NA,1374,"USA","USA",161,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-12
"1323",161,"Olson","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","life support","severe","USA","12-18 years","12-18 years",99,"93",100,NA,"delta","~18 weeks",NA,NA,1375,"USA","USA",161,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-12
"1324",162,"Gazit","Retrospective cohort","24Nov2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","infection","infection","Israel","adult contacts of SARS-CoV-2 index cases","contacts of index cases",80.3,"73.5",85.4,NA,"alpha","~7.5 weeks",NA,NA,1376,"Israel","ISR",162,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2021-11-24,"infection","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2021-11-24
"1325",163,"Suah","Retrospective cohort","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","9-26 weeks","infection (vaccinated April to June)","infection","Malaysia",">= 15 years","general pop",79.3,"76.1",82.1,NA,"delta","~26 weeks",NA,NA,1377,"Malaysia","MYS",163,"MYS",10750,2019,"Malaysia","East Asia & Pacific","Upper middle income",3,"Asia",2021-02-26,2021-08-24,2021-10-21,2021-02-24,2021-02-24,2,181,239,"who","feb/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-21,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","16/01/2022",2022-01-16
"1326",163,"Suah","Retrospective cohort","21Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","2-13 weeks","infection (vaccinated July to August)","infection","Malaysia",">= 15 years","general pop",90.8,"89.4",92.1,NA,"delta","~26 weeks",NA,NA,1378,"Malaysia","MYS",163,"MYS",10750,2019,"Malaysia","East Asia & Pacific","Upper middle income",3,"Asia",2021-02-26,2021-08-24,2021-10-21,2021-02-24,2021-02-24,2,181,239,"who","feb/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-21,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","16/01/2022",2022-01-16
"1327",163,"Suah","Retrospective cohort","21Mar2022","CoronaVac (Sinovac)","excluded","2","final","9-26 weeks","infection (vaccinated April to June)","infection","Malaysia",">= 15 years","general pop",30.4,"18.8",40.3,NA,"delta","~26 weeks",NA,NA,1379,"Malaysia","MYS",163,"MYS",10750,2019,"Malaysia","East Asia & Pacific","Upper middle income",3,"Asia",2021-02-26,2021-08-24,2021-10-21,2021-02-24,2021-02-24,2,181,239,"who","feb/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-21,"infection","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta","16/01/2022",2022-01-16
"1328",163,"Suah","Retrospective cohort","21Mar2022","CoronaVac (Sinovac)","excluded","2","final","2-13 weeks","infection (vaccinated July to August)","infection","Malaysia",">= 15 years","general pop",74.5,"70.6",78,NA,"delta","~26 weeks",NA,NA,1380,"Malaysia","MYS",163,"MYS",10750,2019,"Malaysia","East Asia & Pacific","Upper middle income",3,"Asia",2021-02-26,2021-08-24,2021-10-21,2021-02-24,2021-02-24,2,181,239,"who","feb/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-21,"infection","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta","16/01/2022",2022-01-16
"1329",164,"Young-Xu","Matched test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","veterans 18+ years","veterans 18+ years",12,"10",15,"omicron","omicron","~48 weeks",NA,NA,1381,"USA","USA",164,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-03,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","13/03/2022",2022-03-13
"1330",164,"Young-Xu","Matched test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA","veterans 18+ years","veterans 18+ years",63,"58",67,"omicron","omicron","~48 weeks",NA,NA,1382,"USA","USA",164,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-03,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","13/03/2022",2022-03-13
"1331",164,"Young-Xu","Matched test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","death","death","USA","veterans 18+ years","veterans 18+ years",77,"67",83,"omicron","omicron","~48 weeks",NA,NA,1383,"USA","USA",164,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-03,"death","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","13/03/2022",2022-03-13
"1332",164,"Young-Xu","Matched test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","veterans 18+ years","veterans 18+ years",54,"50",57,"delta","delta","~48 weeks",NA,NA,1384,"USA","USA",164,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-03,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","13/03/2022",2022-03-13
"1333",164,"Young-Xu","Matched test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA","veterans 18+ years","veterans 18+ years",75,"69",80,"delta","delta","~48 weeks",NA,NA,1385,"USA","USA",164,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-03,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","13/03/2022",2022-03-13
"1334",164,"Young-Xu","Matched test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","death","death","USA","veterans 18+ years","veterans 18+ years",92,"83",96,"delta","delta","~48 weeks",NA,NA,1386,"USA","USA",164,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-03,"death","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","13/03/2022",2022-03-13
"1335",165,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","ED visits","symptomatic","USA","hospital admissions","general pop",47,"40",54,"omicron","omicron","~47 weeks",NA,NA,1387,"USA","USA",165,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-22,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","18/01/2022",2022-01-18
"1336",165,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 to <3 months","ED visits","symptomatic","USA","hospital admissions","general pop",64,"51",73,"omicron","omicron","~47 weeks",NA,NA,1388,"USA","USA",165,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-22,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","18/01/2022",2022-01-18
"1337",165,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">=9 months","ED visits","symptomatic","USA","hospital admissions","general pop",31,"16",43,"omicron","omicron","~47 weeks",NA,NA,1389,"USA","USA",165,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-22,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","18/01/2022",2022-01-18
"1338",165,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","hospitalization","severe","USA","hospital admissions","general pop",62,"53",69,"omicron","omicron","~47 weeks",NA,NA,1390,"USA","USA",165,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","18/01/2022",2022-01-18
"1339",165,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 to <3 months","hospitalization","severe","USA","hospital admissions","general pop",68,"48",80,"omicron","omicron","~47 weeks",NA,NA,1391,"USA","USA",165,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","18/01/2022",2022-01-18
"1340",165,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">=9 months","Hospitalization","severe","USA","hospital admissions","general pop",41,"21",55,"omicron","omicron","~47 weeks",NA,NA,1392,"USA","USA",165,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","18/01/2022",2022-01-18
"1341",165,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","ED visits","symptomatic","USA","hospital admissions","general pop",61,"55",66,"delta","delta","~47 weeks",NA,NA,1393,"USA","USA",165,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-22,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/01/2022",2022-01-18
"1342",165,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 to <3 months","ED visits","symptomatic","USA","hospital admissions","general pop",78,"69",85,"delta","delta","~47 weeks",NA,NA,1394,"USA","USA",165,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-22,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/01/2022",2022-01-18
"1343",165,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">=9 months","ED visits","symptomatic","USA","hospital admissions","general pop",57,"45",66,"delta","delta","~47 weeks",NA,NA,1395,"USA","USA",165,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-22,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/01/2022",2022-01-18
"1344",165,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","hospitalization","severe","USA","hospital admissions","general pop",76,"69",82,"delta","delta","~47 weeks",NA,NA,1396,"USA","USA",165,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/01/2022",2022-01-18
"1345",166,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 to <3 months","hospitalization","severe","USA","hospital admissions","general pop",78,"55",89,"delta","delta","~47 weeks",NA,NA,1397,"USA","USA",165,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/01/2022",2022-01-18
"1346",167,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">=9 months","hospitalization","severe","USA","hospital admissions","general pop",73,"58",83,"delta","delta","~47 weeks",NA,NA,1398,"USA","USA",165,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/01/2022",2022-01-18
"1347",166,"Amodio","Retrospective cohort","11Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","2 months","Infection","infection","Italy",">= 18 years","general pop",81.3,"80.3",82.3,NA,"alpha & delta","~37 weeks",NA,NA,1399,"Italy","ITA",166,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-11,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","13/01/2022",2022-01-13
"1348",166,"Amodio","Retrospective cohort","11Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","8 months","infection","infection","Italy",">= 18 years","general pop",57.8,"55.4",60.2,NA,"alpha & delta","~37 weeks",NA,NA,1400,"Italy","ITA",166,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-11,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","13/01/2022",2022-01-13
"1349",166,"Amodio","Retrospective cohort","11Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","2 months","severe disease","severe","Italy",">= 18 years","general pop",96.1,"94.5",97.7,NA,"alpha & delta","~37 weeks",NA,NA,1401,"Italy","ITA",166,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-11,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","13/01/2022",2022-01-13
"1350",166,"Amodio","Retrospective cohort","11Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","8 months","severe disease","severe","Italy",">= 18 years","general pop",90.3,"86.2",94.4,NA,"alpha & delta","~37 weeks",NA,NA,1402,"Italy","ITA",166,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-11,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","13/01/2022",2022-01-13
"1351",166,"Amodio","Retrospective cohort","11Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","2 months","death or intubation","severe","Italy",">= 18 years","general pop",93.4,"91.2",95.6,NA,"alpha & delta","~37 weeks",NA,NA,1403,"Italy","ITA",166,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-11,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","13/01/2022",2022-01-13
"1352",166,"Amodio","Retrospective cohort","11Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","8 months","death or intubation","severe","Italy",">= 18 years","general pop",83.7,"75.1",92.3,NA,"alpha & delta","~37 weeks",NA,NA,1404,"Italy","ITA",166,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-11,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","13/01/2022",2022-01-13
"1353",167,"Thompson","Test-negative case-control","21Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","14-179","ED or UC visit","symptomatic","USA","ED encounters and hospital admissions","general pop",52,"46",58,NA,"omicron","~50 weeks",NA,NA,1405,"USA","USA",167,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-21,"symptomatic","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-01-21
"1354",167,"Thompson","Test-negative case-control","21Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","180+","ED or UC visit","symptomatic","USA","ED encounters and hospital admissions","general pop",38,"32",43,NA,"omicron","~50 weeks",NA,NA,1406,"USA","USA",167,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-21,"symptomatic","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-01-21
"1355",167,"Thompson","Test-negative case-control","21Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","14-179","hospitalization","severe","USA","ED encounters and hospital admissions","general pop",81,"65",90,NA,"omicron","~50 weeks",NA,NA,1407,"USA","USA",167,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-21,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-01-21
"1356",167,"Thompson","Test-negative case-control","21Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","180+","hospitalization","severe","USA","ED encounters and hospital admissions","general pop",57,"39",70,NA,"omicron","~50 weeks",NA,NA,1408,"USA","USA",167,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-21,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-01-21
"1357",167,"Thompson","Test-negative case-control","21Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","14-179","ED or UC visit","symptomatic","USA","ED encounters and hospital admissions","general pop",86,"85",87,NA,"delta","~32 weeks",NA,NA,1409,"USA","USA",167,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-21,"symptomatic","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-01-21
"1358",167,"Thompson","Test-negative case-control","21Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","180+","ED or UC visit","symptomatic","USA","ED encounters and hospital admissions","general pop",76,"75",77,NA,"delta","~32 weeks",NA,NA,1410,"USA","USA",167,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-21,"symptomatic","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-01-21
"1359",167,"Thompson","Test-negative case-control","21Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","14-179","hospitalization","severe","USA","ED encounters and hospital admissions","general pop",90,"89",90,NA,"delta","~32 weeks",NA,NA,1411,"USA","USA",167,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-21,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-01-21
"1360",167,"Thompson","Test-negative case-control","21Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","180+","hospitalization","severe","USA","ED encounters and hospital admissions","general pop",81,"80",82,NA,"delta","~32 weeks",NA,NA,1412,"USA","USA",167,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-21,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-01-21
"1361",168,"Bedston","Prospective cohort","21Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","3-6 weeks","infection","infection","UK","HCW","HCW",52,"45",58,NA,"alpha",NA,NA,NA,1413,"UK","GBR",168,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-21,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-01-21
"1362",168,"Bedston","Prospective cohort","21Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","2-5 weeks","infection","infection","UK","HCW","HCW",86,"74",91,NA,"alpha","~37 weeks",NA,NA,1414,"UK","GBR",168,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-21,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-01-21
"1363",168,"Bedston","Prospective cohort","21Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","7+ weeks","infection","infection","UK","HCW","HCW",39,"24",50,NA,"alpha",NA,NA,NA,1415,"UK","GBR",168,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-21,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-01-21
"1364",168,"Bedston","Prospective cohort","21Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","26+ weeks","infection","infection","UK","HCW","HCW",45,"39",51,NA,"alpha","~37 weeks",NA,NA,1416,"UK","GBR",168,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-21,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-01-21
"1365",169,"Botton","Retrospective cohort","24Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","1","1","14+","hospitalization","severe","France",">= 75 years",">= 75 years",34,"28",40,NA,"non-VOC & alpha",NA,NA,NA,1417,"France","FRA",169,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-24,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-01-24
"1366",169,"Botton","Retrospective cohort","24Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","7+","hospitalization","severe","France",">= 75 years",">= 75 years",86,"83",89,NA,"non-VOC & alpha","~7 weeks",NA,NA,1418,"France","FRA",169,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-01-24,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-01-24
"1367",170,"Spensley","Prospective cohort","26Jan2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","UK","end stage kidney disease patients","end stage kidney disease patients",17,"-62",57,"omicron","omicron","~52.5 weeks",NA,NA,1419,"UK","GBR",170,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-26,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-01-26
"1368",170,"Spensley","Prospective cohort","26Jan2022","AZD1222 (AstraZeneca)","included","2","final","14+","infection","infection","UK","end stage kidney disease patients","end stage kidney disease patients",-4,"-97",43,"omicron","omicron","~52.5 weeks",NA,NA,1420,"UK","GBR",170,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-26,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2022-01-26
"1369",171,"Willet","Test-negative case-control","26Jan2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","Scotland",">= 18 years","general pop",26,"13.9",36.4,"omicron","omicron","~11 weeks",NA,NA,1421,"UK","GBR",171,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-26,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-01-26
"1370",171,"Willet","Test-negative case-control","26Jan2022","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Scotland",">= 18 years","general pop",23.7,"4.4",39.4,"omicron","omicron","~11 weeks",NA,NA,1422,"UK","GBR",171,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-26,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2022-01-26
"1371",171,"Willet","Test-negative case-control","26Jan2022","AZD1222 (AstraZeneca)","included","2","final","14+","infection","infection","Scotland",">= 18 years","general pop",11.4,"-18.8",34.6,"omicron","omicron","~11 weeks",NA,NA,1423,"UK","GBR",171,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-26,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2022-01-26
"1372",171,"Willet","Test-negative case-control","26Jan2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","Scotland",">= 18 years","general pop",83.5,"78.6",87.3,"delta","delta","~11 weeks",NA,NA,1424,"UK","GBR",171,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-26,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-01-26
"1373",171,"Willet","Test-negative case-control","26Jan2022","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Scotland",">= 18 years","general pop",87.8,"79.8",92.7,"delta","delta","~11 weeks",NA,NA,1425,"UK","GBR",171,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-26,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-01-26
"1374",171,"Willet","Test-negative case-control","26Jan2022","AZD1222 (AstraZeneca)","included","2","final","14+","infection","infection","Scotland",">= 18 years","general pop",78.9,"66.6",86.7,"delta","delta","~11 weeks",NA,NA,1426,"UK","GBR",171,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-26,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-01-26
"1375",172,"Belayachi","Test-negative case-control","07Dec2022","BBIBP-CorV (Beijing CNBG)","included","2","final","1-273","severe hospitalization","severe","Morocco","hospital patients","general pop",73,"71",76,NA,"non-VOC, alpha, & delta","~39 weeks",NA,NA,1427,"Morocco","MAR",172,"MAR",3510,2019,"Morocco","Middle East & North Africa","Lower middle income",2,"Africa",2021-01-30,2021-08-31,NA,2021-01-28,2021-01-28,2,215,NA,"who","jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-12-07,"severe","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations","27/01/2022",2022-01-27
"1376",172,"Belayachi","Test-negative case-control","07Dec2022","BBIBP-CorV (Beijing CNBG)","included","2","final","1-30","severe hospitalization","severe","Morocco","hospital patients","general pop",88,"84",91,NA,"non-VOC, alpha, & delta","~39 weeks",NA,NA,1428,"Morocco","MAR",172,"MAR",3510,2019,"Morocco","Middle East & North Africa","Lower middle income",2,"Africa",2021-01-30,2021-08-31,NA,2021-01-28,2021-01-28,2,215,NA,"who","jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-12-07,"severe","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations","27/01/2022",2022-01-27
"1377",172,"Belayachi","Test-negative case-control","07Dec2022","BBIBP-CorV (Beijing CNBG)","included","2","final","150+","severe hospitalization","severe","Morocco","hospital patients","general pop",64,"59",69,NA,"non-VOC, alpha, & delta","~39 weeks",NA,NA,1429,"Morocco","MAR",172,"MAR",3510,2019,"Morocco","Middle East & North Africa","Lower middle income",2,"Africa",2021-01-30,2021-08-31,NA,2021-01-28,2021-01-28,2,215,NA,"who","jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-12-07,"severe","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations","27/01/2022",2022-01-27
"1378",173,"Tenforde","Test-negative case-control","28Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","hospital patients 18+ years","general pop",69,"57",78,NA,"delta","~47 weeks",NA,NA,1430,"USA","USA",173,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-28,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-01-28
"1379",173,"Tenforde","Test-negative case-control","28Jan2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","hospital patients 18+ years","general pop",82,"77",86,NA,"delta","~47 weeks",NA,NA,1431,"USA","USA",173,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-28,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-01-28
"1380",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","intubation","severe","Greece","15-59 years","15-59 years",98.1,"97.5",98.6,NA,"delta","~48 weeks",NA,NA,1432,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/01/2022",2022-01-29
"1381",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","6 months","intubation","severe","Greece","15-59 years","15-59 years",95.5,"94.3",96.5,NA,"delta","~48 weeks",NA,NA,1433,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/01/2022",2022-01-29
"1382",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","intubation","severe","Greece","60-79 years","60-79 years",96.7,"95.9",97.4,NA,"delta","~48 weeks",NA,NA,1434,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/01/2022",2022-01-29
"1383",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","6 months","intubation","severe","Greece","60-79 years","60-79 years",92,"91",92.9,NA,"delta","~48 weeks",NA,NA,1435,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/01/2022",2022-01-29
"1384",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","intubation","severe","Greece",">= 80 years",">= 80 years",94.2,"92",95.7,NA,"delta","~48 weeks",NA,NA,1436,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/01/2022",2022-01-29
"1385",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","6 months","intubation","severe","Greece",">= 80 years",">= 80 years",85.9,"83.5",88,NA,"delta","~48 weeks",NA,NA,1437,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/01/2022",2022-01-29
"1386",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","death","death","Greece","15-59 years","15-59 years",96.5,"94.8",97.6,NA,"delta","~48 weeks",NA,NA,1438,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/01/2022",2022-01-29
"1387",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","6 months","death","death","Greece","15-59 years","15-59 years",93.8,"91",95.7,NA,"delta","~48 weeks",NA,NA,1439,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/01/2022",2022-01-29
"1388",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","death","death","Greece","60-79 years","60-79 years",94.1,"92.7",95.2,NA,"delta","~48 weeks",NA,NA,1440,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/01/2022",2022-01-29
"1389",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","6 months","death","death","Greece","60-79 years","60-79 years",89.4,"87.9",90.8,NA,"delta","~48 weeks",NA,NA,1441,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/01/2022",2022-01-29
"1390",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","death","death","Greece",">= 80 years",">= 80 years",91,"88.4",93,NA,"delta","~48 weeks",NA,NA,1442,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/01/2022",2022-01-29
"1391",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","6 months","death","death","Greece",">= 80 years",">= 80 years",84,"82.2",85.6,NA,"delta","~48 weeks",NA,NA,1443,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","29/01/2022",2022-01-29
"1392",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","14+","intubation","severe","Greece","15-59 years","15-59 years",99.4,"98.2",99.8,NA,"delta","~48 weeks",NA,NA,1444,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","29/01/2022",2022-01-29
"1393",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","6 months","intubation","severe","Greece","15-59 years","15-59 years",97.3,"93.1",98.9,NA,"delta","~48 weeks",NA,NA,1445,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","29/01/2022",2022-01-29
"1394",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","14+","intubation","severe","Greece","60-79 years","60-79 years",98.9,"97.3",99.5,NA,"delta","~48 weeks",NA,NA,1446,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","29/01/2022",2022-01-29
"1395",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","6 months","intubation","severe","Greece","60-79 years","60-79 years",95.1,"93",96.5,NA,"delta","~48 weeks",NA,NA,1447,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","29/01/2022",2022-01-29
"1396",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","14+","intubation","severe","Greece",">= 80 years",">= 80 years",97.9,"90.2",99.5,NA,"delta","~48 weeks",NA,NA,1448,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","29/01/2022",2022-01-29
"1397",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","6 months","intubation","severe","Greece",">= 80 years",">= 80 years",90.6,"67",97.3,NA,"delta","~48 weeks",NA,NA,1449,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","29/01/2022",2022-01-29
"1398",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","14+","death","death","Greece","15-59 years","15-59 years",99.3,"94.7",99.9,NA,"delta","~48 weeks",NA,NA,1450,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","29/01/2022",2022-01-29
"1399",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","6 months","death","death","Greece","15-59 years","15-59 years",98.3,"88.3",99.8,NA,"delta","~48 weeks",NA,NA,1451,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","29/01/2022",2022-01-29
"1400",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","14+","death","death","Greece","60-79 years","60-79 years",98.4,"95.5",99.5,NA,"delta","~48 weeks",NA,NA,1452,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","29/01/2022",2022-01-29
"1401",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","6 months","death","death","Greece","60-79 years","60-79 years",96.2,"93.6",97.7,NA,"delta","~48 weeks",NA,NA,1453,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","29/01/2022",2022-01-29
"1402",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","14+","death","death","Greece",">= 80 years",">= 80 years",96.7,"87.9",99.1,NA,"delta","~48 weeks",NA,NA,1454,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","29/01/2022",2022-01-29
"1403",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","6 months","death","death","Greece",">= 80 years",">= 80 years",92,"80",96.8,NA,"delta","~48 weeks",NA,NA,1455,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","29/01/2022",2022-01-29
"1404",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","14+","intubation","severe","Greece","15-59 years","15-59 years",97.8,"95.3",99,NA,"delta","~48 weeks",NA,NA,1456,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/01/2022",2022-01-29
"1405",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","6 months","intubation","severe","Greece","15-59 years","15-59 years",92.4,"84",96.4,NA,"delta","~48 weeks",NA,NA,1457,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/01/2022",2022-01-29
"1406",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","14+","intubation","severe","Greece","60-79 years","60-79 years",97.2,"95.3",98.3,NA,"delta","~48 weeks",NA,NA,1458,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/01/2022",2022-01-29
"1407",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","6 months","intubation","severe","Greece","60-79 years","60-79 years",90.3,"87.4",92.5,NA,"delta","~48 weeks",NA,NA,1459,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/01/2022",2022-01-29
"1408",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","14+","intubation","severe","Greece",">= 80 years",">= 80 years",97.8,"91.7",99.4,NA,"delta","~48 weeks",NA,NA,1460,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/01/2022",2022-01-29
"1409",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","6 months","intubation","severe","Greece",">= 80 years",">= 80 years",92.4,"72.7",97.9,NA,"delta","~48 weeks",NA,NA,1461,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/01/2022",2022-01-29
"1410",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","14+","death","death","Greece","15-59 years","15-59 years",97.5,"89.7",99.4,NA,"delta","~48 weeks",NA,NA,1462,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/01/2022",2022-01-29
"1411",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","6 months","death","death","Greece","15-59 years","15-59 years",94.5,"77.2",98.7,NA,"delta","~48 weeks",NA,NA,1463,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/01/2022",2022-01-29
"1412",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","14+","death","death","Greece","60-79 years","60-79 years",95.4,"91.2",97.6,NA,"delta","~48 weeks",NA,NA,1464,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/01/2022",2022-01-29
"1413",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","6 months","death","death","Greece","60-79 years","60-79 years",89.8,"85.2",93,NA,"delta","~48 weeks",NA,NA,1465,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/01/2022",2022-01-29
"1414",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","14+","death","death","Greece",">= 80 years",">= 80 years",92.6,"84.2",96.5,NA,"delta","~48 weeks",NA,NA,1466,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/01/2022",2022-01-29
"1415",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","6 months","death","death","Greece",">= 80 years",">= 80 years",83.4,"69.6",90.9,NA,"delta","~48 weeks",NA,NA,1467,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","29/01/2022",2022-01-29
"1416",174,"Lytras","Retrospective cohort","14Jun2022","Ad26.COV2.S (Janssen)","included","1","final","14+","intubation","severe","Greece","15-59 years","15-59 years",85,"73.9",91.4,NA,"delta","~48 weeks",NA,NA,1468,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","29/01/2022",2022-01-29
"1417",174,"Lytras","Retrospective cohort","14Jun2022","Ad26.COV2.S (Janssen)","included","1","final","6 months","intubation","severe","Greece","15-59 years","15-59 years",91.7,"84.4",95.6,NA,"delta","~48 weeks",NA,NA,1469,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","29/01/2022",2022-01-29
"1418",174,"Lytras","Retrospective cohort","14Jun2022","Ad26.COV2.S (Janssen)","included","1","final","14+","intubation","severe","Greece","60-79 years","60-79 years",79.6,"65.2",88,NA,"delta","~48 weeks",NA,NA,1470,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","29/01/2022",2022-01-29
"1419",174,"Lytras","Retrospective cohort","14Jun2022","Ad26.COV2.S (Janssen)","included","1","final","6 months","intubation","severe","Greece","60-79 years","60-79 years",88.7,"78.7",94,NA,"delta","~48 weeks",NA,NA,1471,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","29/01/2022",2022-01-29
"1420",174,"Lytras","Retrospective cohort","14Jun2022","Ad26.COV2.S (Janssen)","included","1","final","14+","intubation","severe","Greece",">= 80 years",">= 80 years",85,"62.3",94,NA,"delta","~48 weeks",NA,NA,1472,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","29/01/2022",2022-01-29
"1421",174,"Lytras","Retrospective cohort","14Jun2022","Ad26.COV2.S (Janssen)","included","1","final","6 months","intubation","severe","Greece",">= 80 years",">= 80 years",91.7,"75.5",97.2,NA,"delta","~48 weeks",NA,NA,1473,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","29/01/2022",2022-01-29
"1422",174,"Lytras","Retrospective cohort","14Jun2022","Ad26.COV2.S (Janssen)","included","1","final","14+","death","death","Greece","15-59 years","15-59 years",81.7,"57.5",92.1,NA,"delta","~48 weeks",NA,NA,1474,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","29/01/2022",2022-01-29
"1423",174,"Lytras","Retrospective cohort","14Jun2022","Ad26.COV2.S (Janssen)","included","1","final","6 months","death","death","Greece","15-59 years","15-59 years",90.7,"77.2",96.2,NA,"delta","~48 weeks",NA,NA,1475,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","29/01/2022",2022-01-29
"1424",174,"Lytras","Retrospective cohort","14Jun2022","Ad26.COV2.S (Janssen)","included","1","final","14+","death","death","Greece","60-79 years","60-79 years",69.1,"43.2",83.2,NA,"delta","~48 weeks",NA,NA,1476,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","29/01/2022",2022-01-29
"1425",174,"Lytras","Retrospective cohort","14Jun2022","Ad26.COV2.S (Janssen)","included","1","final","6 months","death","death","Greece","60-79 years","60-79 years",84.3,"67.9",92.3,NA,"delta","~48 weeks",NA,NA,1477,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","29/01/2022",2022-01-29
"1426",174,"Lytras","Retrospective cohort","14Jun2022","Ad26.COV2.S (Janssen)","included","1","final","14+","death","death","Greece",">= 80 years",">= 80 years",61.9,"43.2",74.4,NA,"delta","~48 weeks",NA,NA,1478,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","29/01/2022",2022-01-29
"1427",174,"Lytras","Retrospective cohort","14Jun2022","Ad26.COV2.S (Janssen)","included","1","final","6 months","death","death","Greece",">= 80 years",">= 80 years",80.6,"59.7",90.7,NA,"delta","~48 weeks",NA,NA,1479,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"death","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","29/01/2022",2022-01-29
"1428",175,"Roberts","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<3 months","infection","infection","USA",">= 18 years","general pop",83,"81",84,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1480,"USA","USA",175,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-26,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","31/01/2022",2022-01-31
"1429",175,"Roberts","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=3 months","infection","infection","USA",">= 18 years","general pop",60,"58",62,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1481,"USA","USA",175,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-26,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","31/01/2022",2022-01-31
"1430",175,"Roberts","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<3 months","infection (Jan-March)","infection","USA",">= 18 years","general pop",80,"74",85,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1482,"USA","USA",175,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-26,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","31/01/2022",2022-01-31
"1431",175,"Roberts","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=3 months","infection (Jan-March)","infection","USA",">= 18 years","general pop",80.5,"74",86,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1483,"USA","USA",175,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-26,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","31/01/2022",2022-01-31
"1432",175,"Roberts","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<3 months","infection (Oct-Dec)","infection","USA",">= 18 years","general pop",75,"64",81,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1484,"USA","USA",175,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-26,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","31/01/2022",2022-01-31
"1433",175,"Roberts","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=3 months","infection (Oct-Dec)","infection","USA",">= 18 years","general pop",60,"55",62,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1485,"USA","USA",175,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-26,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","31/01/2022",2022-01-31
"1434",175,"Roberts","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<3 months","severe disease","severe","USA",">= 18 years","general pop",88,"80",91,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1486,"USA","USA",175,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","31/01/2022",2022-01-31
"1435",175,"Roberts","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=3 months","severe disease","severe","USA",">= 18 years","general pop",75,"70",80,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1487,"USA","USA",175,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","31/01/2022",2022-01-31
"1436",175,"Roberts","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<3 months","severe disease (Jan-March)","severe","USA",">= 18 years","general pop",90,"49",99,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1488,"USA","USA",175,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","31/01/2022",2022-01-31
"1437",175,"Roberts","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=3 months","severe disease (Jan-March)","severe","USA",">= 18 years","general pop",90,"50",99,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1489,"USA","USA",175,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","31/01/2022",2022-01-31
"1438",175,"Roberts","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<3 months","severe disease (Oct-Dec)","severe","USA",">= 18 years","general pop",69,"22",88,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1490,"USA","USA",175,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","31/01/2022",2022-01-31
"1439",175,"Roberts","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=3 months","severe disease (Oct-Dec)","severe","USA",">= 18 years","general pop",78,"70",82,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1491,"USA","USA",175,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","31/01/2022",2022-01-31
"1440",175,"Roberts","Test-negative case-control","26Jul2022","mRNA-1273 (Moderna)","included","2","final","<3 months","infection","infection","USA",">= 18 years","general pop",88,"85",90,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1492,"USA","USA",175,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-26,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","31/01/2022",2022-01-31
"1441",175,"Roberts","Test-negative case-control","26Jul2022","mRNA-1273 (Moderna)","included","2","final",">=3 months","infection","infection","USA",">= 18 years","general pop",65,"62",68,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1493,"USA","USA",175,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-26,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","31/01/2022",2022-01-31
"1442",175,"Roberts","Test-negative case-control","26Jul2022","mRNA-1273 (Moderna)","included","2","final","<3 months","infection (Jan-March)","infection","USA",">= 18 years","general pop",89,"73",95,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1494,"USA","USA",175,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-26,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","31/01/2022",2022-01-31
"1443",175,"Roberts","Test-negative case-control","26Jul2022","mRNA-1273 (Moderna)","included","2","final",">=3 months","infection (Jan-March)","infection","USA",">= 18 years","general pop",89,"74",93,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1495,"USA","USA",175,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-26,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","31/01/2022",2022-01-31
"1444",175,"Roberts","Test-negative case-control","26Jul2022","mRNA-1273 (Moderna)","included","2","final","<3 months","infection (Oct-Dec)","infection","USA",">= 18 years","general pop",82,"69",91,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1496,"USA","USA",175,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-26,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","31/01/2022",2022-01-31
"1445",175,"Roberts","Test-negative case-control","26Jul2022","mRNA-1273 (Moderna)","included","2","final",">=3 months","infection (Oct-Dec)","infection","USA",">= 18 years","general pop",68,"64",69,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1497,"USA","USA",175,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-26,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","31/01/2022",2022-01-31
"1446",175,"Roberts","Test-negative case-control","26Jul2022","mRNA-1273 (Moderna)","included","2","final","<3 months","severe disease","severe","USA",">= 18 years","general pop",85,"75",90,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1498,"USA","USA",175,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","31/01/2022",2022-01-31
"1447",175,"Roberts","Test-negative case-control","26Jul2022","mRNA-1273 (Moderna)","included","2","final",">=3 months","severe disease","severe","USA",">= 18 years","general pop",72,"65",78,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1499,"USA","USA",175,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","31/01/2022",2022-01-31
"1448",175,"Roberts","Test-negative case-control","26Jul2022","mRNA-1273 (Moderna)","included","2","final","<3 months","severe disease (Jan-March)","severe","USA",">= 18 years","general pop",70,"0",95,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1500,"USA","USA",175,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","31/01/2022",2022-01-31
"1449",175,"Roberts","Test-negative case-control","26Jul2022","mRNA-1273 (Moderna)","included","2","final",">=3 months","severe disease (Jan-March)","severe","USA",">= 18 years","general pop",70,"0",93,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1501,"USA","USA",175,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","31/01/2022",2022-01-31
"1450",175,"Roberts","Test-negative case-control","26Jul2022","mRNA-1273 (Moderna)","included","2","final","<3 months","severe disease (Oct-Dec)","severe","USA",">= 18 years","general pop",91,"5",99,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1502,"USA","USA",175,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","31/01/2022",2022-01-31
"1451",175,"Roberts","Test-negative case-control","26Jul2022","mRNA-1273 (Moderna)","included","2","final",">=3 months","severe disease (Oct-Dec)","severe","USA",">= 18 years","general pop",80,"72",88,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,1503,"USA","USA",175,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","31/01/2022",2022-01-31
"1452",176,"Sritipsukho","Test-negative case-control","03Feb2022","AZD1222 (AstraZeneca)","excluded","1","1","21+","Infection","infection","Thailand",">= 18 years","general pop",49,"36",58,NA,"delta",NA,NA,NA,1504,"Thailand","THA",176,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-03,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-02-03
"1453",176,"Sritipsukho","Test-negative case-control","03Feb2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","Infection","infection","Thailand",">= 18 years","general pop",83,"70",90,NA,"delta","~13 weeks",NA,NA,1505,"Thailand","THA",176,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-03,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-02-03
"1454",176,"Sritipsukho","Test-negative case-control","03Feb2022","CoronaVac (Sinovac)","excluded","1","1","21+","Infection","infection","Thailand",">= 18 years","general pop",-15,"-45",15,NA,"delta",NA,NA,NA,1506,"Thailand","THA",176,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-03,"infection","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta",NA,2022-02-03
"1455",176,"Sritipsukho","Test-negative case-control","03Feb2022","CoronaVac (Sinovac)","excluded","2","final","14+","Infection","infection","Thailand",">= 18 years","general pop",60,"49",69,NA,"delta","~13 weeks",NA,NA,1507,"Thailand","THA",176,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-03,"infection","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta",NA,2022-02-03
"1456",176,"Sritipsukho","Test-negative case-control","03Feb2022","CoronaVac (Sinovac) & AZD1222 (AstraZeneca) - heterologous","excluded","2","final","14+","Infection","infection","Thailand",">= 18 years","general pop",74,"43",88,NA,"delta","~13 weeks",NA,NA,1508,"Thailand","THA",176,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-03,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","delta",NA,2022-02-03
"1457",177,"Suryatma","Test-negative case-control","04Feb2022","CoronaVac (Sinovac)","excluded","1","1","14+","infection","infection","Indonesia",">= 18 years","general pop",10.5,"-12",28.6,NA,"non-VOC & alpha",NA,NA,NA,1509,"Indonesia","IDN",177,"IDN",4020,2019,"Indonesia","East Asia & Pacific","Upper middle income",2,"Asia",2021-01-22,2021-12-25,NA,2021-01-13,2021-01-13,9,346,NA,"who","jan/2021","Dec/2021 +","270-359","yes","yes","no",2022-02-04,"infection","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","03/02/2022",2022-02-03
"1458",177,"Suryatma","Test-negative case-control","04Feb2022","CoronaVac (Sinovac)","excluded","2","final","14+","infection","infection","Indonesia",">= 18 years","general pop",66.7,"58.1",73.5,NA,"non-VOC & alpha","~24 weeks",NA,NA,1510,"Indonesia","IDN",177,"IDN",4020,2019,"Indonesia","East Asia & Pacific","Upper middle income",2,"Asia",2021-01-22,2021-12-25,NA,2021-01-13,2021-01-13,9,346,NA,"who","jan/2021","Dec/2021 +","270-359","yes","yes","no",2022-02-04,"infection","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","03/02/2022",2022-02-03
"1459",177,"Suryatma","Test-negative case-control","04Feb2022","CoronaVac (Sinovac)","excluded","1","1","14+","hospitalization","severe","Indonesia",">= 18 years","general pop",34.1,"16.4",48.1,NA,"non-VOC & alpha",NA,NA,NA,1511,"Indonesia","IDN",177,"IDN",4020,2019,"Indonesia","East Asia & Pacific","Upper middle income",2,"Asia",2021-01-22,2021-12-25,NA,2021-01-13,2021-01-13,9,346,NA,"who","jan/2021","Dec/2021 +","270-359","yes","yes","no",2022-02-04,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","03/02/2022",2022-02-03
"1460",177,"Suryatma","Test-negative case-control","04Feb2022","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Indonesia",">= 18 years","general pop",71.1,"62.9",77.6,NA,"non-VOC & alpha","~24 weeks",NA,NA,1512,"Indonesia","IDN",177,"IDN",4020,2019,"Indonesia","East Asia & Pacific","Upper middle income",2,"Asia",2021-01-22,2021-12-25,NA,2021-01-13,2021-01-13,9,346,NA,"who","jan/2021","Dec/2021 +","270-359","yes","yes","no",2022-02-04,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","03/02/2022",2022-02-03
"1461",177,"Suryatma","Test-negative case-control","04Feb2022","CoronaVac (Sinovac)","excluded","1","1","14+","death","death","Indonesia",">= 18 years","general pop",58.6,"28.3",76.1,NA,"non-VOC & alpha",NA,NA,NA,1513,"Indonesia","IDN",177,"IDN",4020,2019,"Indonesia","East Asia & Pacific","Upper middle income",2,"Asia",2021-01-22,2021-12-25,NA,2021-01-13,2021-01-13,9,346,NA,"who","jan/2021","Dec/2021 +","270-359","yes","yes","no",2022-02-04,"death","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","03/02/2022",2022-02-03
"1462",177,"Suryatma","Test-negative case-control","04Feb2022","CoronaVac (Sinovac)","excluded","2","final","14+","death","death","Indonesia",">= 18 years","general pop",87.4,"65.1",95.4,NA,"non-VOC & alpha","~24 weeks",NA,NA,1514,"Indonesia","IDN",177,"IDN",4020,2019,"Indonesia","East Asia & Pacific","Upper middle income",2,"Asia",2021-01-22,2021-12-25,NA,2021-01-13,2021-01-13,9,346,NA,"who","jan/2021","Dec/2021 +","270-359","yes","yes","no",2022-02-04,"death","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","03/02/2022",2022-02-03
"1463",178,"Lauring","Test-negative case-control","09Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",65,"51",75,"omicron","omicron","~3 weeks",NA,NA,1515,"USA","USA",178,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-09,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","07/02/2022",2022-02-07
"1464",178,"Lauring","Test-negative case-control","09Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","hospitalization","severe","USA",">= 18 years","general pop",85,"83",87,"delta","delta","~27 weeks",NA,NA,1516,"USA","USA",178,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-09,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","07/02/2022",2022-02-07
"1465",178,"Lauring","Test-negative case-control","09Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final",">150","hospitalization","severe","USA",">= 18 years","general pop",90,"85",93,"delta","delta","~27 weeks",NA,NA,1517,"USA","USA",178,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-09,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","07/02/2022",2022-02-07
"1466",178,"Lauring","Test-negative case-control","09Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",82,"80",84,"delta","delta","~27 weeks",NA,NA,1518,"USA","USA",178,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-09,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","07/02/2022",2022-02-07
"1467",178,"Lauring","Test-negative case-control","09Mar2022","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",88,"86",90,"delta","delta","~27 weeks",NA,NA,1519,"USA","USA",178,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-09,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","07/02/2022",2022-02-07
"1468",178,"Lauring","Test-negative case-control","09Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",82,"77",86,"alpha","alpha","~44 weeks",NA,NA,1520,"USA","USA",178,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-09,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha","07/02/2022",2022-02-07
"1469",178,"Lauring","Test-negative case-control","09Mar2022","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",90,"85",93,"alpha","alpha","~44 weeks",NA,NA,1521,"USA","USA",178,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-09,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","alpha","07/02/2022",2022-02-07
"1470",178,"Lauring","Test-negative case-control","09Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","14+","hospitalization","severe","USA",">= 18 years","general pop",77,"71",81,NA,"alpha, delta, & omicron",NA,NA,NA,1522,"USA","USA",178,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-09,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations","07/02/2022",2022-02-07
"1471",179,"Chemaitelly","Test-negative case-control","02Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","1-3 months","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",46.6,"33.4",57.2,"omicron BA.1","omicron BA.1","~58 weeks",NA,NA,1523,"Qatar","QAT",179,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-02,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/03/2022",2022-03-13
"1472",179,"Chemaitelly","Test-negative case-control","02Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7+ months","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",-17.8,"-28.2",-8.2,"omicron BA.1","omicron BA.1","~58 weeks",NA,NA,1524,"Qatar","QAT",179,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-02,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/03/2022",2022-03-13
"1473",179,"Chemaitelly","Test-negative case-control","02Jun2022","mRNA-1273 (Moderna)","included","2","final","1-3 months","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",71,"24",89,"omicron BA.1","omicron BA.1","~58 weeks",NA,NA,1525,"Qatar","QAT",179,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-02,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","13/03/2022",2022-03-13
"1474",179,"Chemaitelly","Test-negative case-control","02Jun2022","mRNA-1273 (Moderna)","included","2","final","7+ months","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",-10.2,"-23.1",1.3,"omicron BA.1","omicron BA.1","~58 weeks",NA,NA,1526,"Qatar","QAT",179,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-02,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","13/03/2022",2022-03-13
"1475",179,"Chemaitelly","Test-negative case-control","02Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","1-3 months","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",51.7,"43.2",58.9,"omicron BA.2","omicron BA.2","~58 weeks",NA,NA,1527,"Qatar","QAT",179,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-02,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/03/2022",2022-03-13
"1476",179,"Chemaitelly","Test-negative case-control","02Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7+ months","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",-12.1,"-19.1",5.5,"omicron BA.2","omicron BA.2","~58 weeks",NA,NA,1528,"Qatar","QAT",179,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-02,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/03/2022",2022-03-13
"1477",179,"Chemaitelly","Test-negative case-control","02Jun2022","mRNA-1273 (Moderna)","included","2","final","1-3 months","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",35.9,"-5.9",61.2,"omicron BA.2","omicron BA.2","~58 weeks",NA,NA,1529,"Qatar","QAT",179,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-02,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","13/03/2022",2022-03-13
"1478",179,"Chemaitelly","Test-negative case-control","02Jun2022","mRNA-1273 (Moderna)","included","2","final","7+ months","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",-20.4,"-30.2",1.2,"omicron BA.2","omicron BA.2","~58 weeks",NA,NA,1530,"Qatar","QAT",179,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-02,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","13/03/2022",2022-03-13
"1479",179,"Chemaitelly","Test-negative case-control","02Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","1-3 months","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",51.7,"43.2",58.9,"omicron","omicron","~58 weeks",NA,NA,1531,"Qatar","QAT",179,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-02,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/03/2022",2022-03-13
"1480",179,"Chemaitelly","Test-negative case-control","02Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7+ months","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",-9,"-14.5",-3.7,"omicron","omicron","~58 weeks",NA,NA,1532,"Qatar","QAT",179,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-02,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/03/2022",2022-03-13
"1481",179,"Chemaitelly","Test-negative case-control","02Jun2022","mRNA-1273 (Moderna)","included","2","final","1-3 months","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",43.2,"15",62.1,"omicron","omicron","~58 weeks",NA,NA,1533,"Qatar","QAT",179,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-02,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","13/03/2022",2022-03-13
"1482",179,"Chemaitelly","Test-negative case-control","02Jun2022","mRNA-1273 (Moderna)","included","2","final","7+ months","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",-13.7,"-21.3",-6.6,"omicron","omicron","~58 weeks",NA,NA,1534,"Qatar","QAT",179,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-02,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","13/03/2022",2022-03-13
"1483",179,"Chemaitelly","Test-negative case-control","02Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","1-6 months","severe, critical or fatal disease","severe","Qatar",">= 18 years","general pop",70.4,"45",85,"omicron","omicron","~58 weeks",NA,NA,1535,"Qatar","QAT",179,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-02,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/03/2022",2022-03-13
"1484",179,"Chemaitelly","Test-negative case-control","02Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=7 months","severe, critical or fatal disease","severe","Qatar",">= 18 years","general pop",77.5,"67.8",84.3,"omicron","omicron","~58 weeks",NA,NA,1536,"Qatar","QAT",179,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-02,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/03/2022",2022-03-13
"1485",179,"Chemaitelly","Test-negative case-control","02Jun2022","mRNA-1273 (Moderna)","included","2","final","1-6 months","severe, critical or fatal disease","severe","Qatar",">= 18 years","general pop",87.1,"40.2",97.2,"omicron","omicron","~58 weeks",NA,NA,1537,"Qatar","QAT",179,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-02,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","13/03/2022",2022-03-13
"1486",179,"Chemaitelly","Test-negative case-control","02Jun2022","mRNA-1273 (Moderna)","included","2","final",">=7 months","severe, critical or fatal disease","severe","Qatar",">= 18 years","general pop",68.4,"46.1",81.5,"omicron","omicron","~58 weeks",NA,NA,1538,"Qatar","QAT",179,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-02,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","13/03/2022",2022-03-13
"1487",180,"Cerqueira-Silva","Test-negative case-control","09Feb2022","CoronaVac (Sinovac)","excluded","2","final","14-30","infection","infection","Brazil",">= 18 years","general pop",55,"54.3",55.7,NA,"gamma & delta","~30 weeks",NA,NA,1539,"Brazil","BRA",180,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-09,"infection","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations",NA,2022-02-09
"1488",180,"Cerqueira-Silva","Test-negative case-control","09Feb2022","CoronaVac (Sinovac)","excluded","2","final","180+","infection","infection","Brazil",">= 18 years","general pop",34.7,"33.1",36.3,NA,"gamma & delta","~30 weeks",NA,NA,1540,"Brazil","BRA",180,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-09,"infection","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations",NA,2022-02-09
"1489",180,"Cerqueira-Silva","Test-negative case-control","09Feb2022","CoronaVac (Sinovac)","excluded","2","final","14-30","severe disease","severe","Brazil",">= 18 years","general pop",82.1,"81.4",82.8,NA,"gamma & delta","~30 weeks",NA,NA,1541,"Brazil","BRA",180,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-09,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations",NA,2022-02-09
"1490",180,"Cerqueira-Silva","Test-negative case-control","09Feb2022","CoronaVac (Sinovac)","excluded","2","final","180+","severe disease","severe","Brazil",">= 18 years","general pop",72.6,"71",74.2,NA,"gamma & delta","~30 weeks",NA,NA,1542,"Brazil","BRA",180,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-09,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations",NA,2022-02-09
"1491",180,"Cerqueira-Silva","Test-negative case-control","09Feb2022","CoronaVac (Sinovac)","excluded","2","final","14-30","hospitalization","severe","Brazil",">= 18 years","general pop",82.1,"81.4",82.8,NA,"gamma & delta","~30 weeks",NA,NA,1543,"Brazil","BRA",180,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-09,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations",NA,2022-02-09
"1492",180,"Cerqueira-Silva","Test-negative case-control","09Feb2022","CoronaVac (Sinovac)","excluded","2","final","180+","hospitalization","severe","Brazil",">= 18 years","general pop",72.4,"70.7",73.9,NA,"gamma & delta","~30 weeks",NA,NA,1544,"Brazil","BRA",180,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-09,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations",NA,2022-02-09
"1493",180,"Cerqueira-Silva","Test-negative case-control","09Feb2022","CoronaVac (Sinovac)","excluded","2","final","14-30","death","death","Brazil",">= 18 years","general pop",82.7,"81.7",83.6,NA,"gamma & delta","~30 weeks",NA,NA,1545,"Brazil","BRA",180,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-09,"death","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations",NA,2022-02-09
"1494",180,"Cerqueira-Silva","Test-negative case-control","09Feb2022","CoronaVac (Sinovac)","excluded","2","final","180+","death","death","Brazil",">= 18 years","general pop",74.8,"72.2",77.2,NA,"gamma & delta","~30 weeks",NA,NA,1546,"Brazil","BRA",180,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-02-09,"death","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations",NA,2022-02-09
"1495",181,"Butt","Test-negative case-control","09Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","infection","infection","USA","haemodialysis patients","haemodialysis patients",60.6,"25.5",79.2,NA,"delta",NA,NA,NA,1547,"USA","USA",181,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-09,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-02-09
"1496",181,"Butt","Test-negative case-control","09Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","USA","haemodialysis patients","haemodialysis patients",68.9,"61.9",74.7,NA,"delta","~31 weeks",NA,NA,1548,"USA","USA",181,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-09,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-02-09
"1497",181,"Butt","Test-negative case-control","09Feb2022","mRNA-1273 (Moderna)","excluded","1","1","14+","infection","infection","USA","haemodialysis patients","haemodialysis patients",37.2,"27.1",69,NA,"delta",NA,NA,NA,1549,"USA","USA",181,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-09,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-02-09
"1498",181,"Butt","Test-negative case-control","09Feb2022","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","haemodialysis patients","haemodialysis patients",66.7,"58.9",73,NA,"delta","~31 weeks",NA,NA,1550,"USA","USA",181,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-09,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-02-09
"1499",183,"Hayek","Retrospective cohort","27Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","infection","infection","Israel","households with children","households with children",94.4,"93.2",95.4,NA,"alpha","~12 weeks",NA,NA,1553,"Israel","ISR",183,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-01-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-01-27
"1500",184,"Goldin","Retrospective cohort","08Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","10+","infection","infection","Israel","LTCF residents","LTCF residents",61.8,"58.2",65.1,NA,"non-VOC & alpha",NA,NA,NA,1554,"Israel","ISR",184,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-08,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-08
"1501",184,"Goldin","Retrospective cohort","08Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","infection","infection","Israel","LTCF residents","LTCF residents",81.2,"78.6",83.5,NA,"non-VOC & alpha","~16.5 weeks",NA,NA,1555,"Israel","ISR",184,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-08,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-08
"1502",184,"Goldin","Retrospective cohort","08Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","10+","death","death","Israel","LTCF residents","LTCF residents",72.3,"66.9",76.8,NA,"non-VOC & alpha",NA,NA,NA,1556,"Israel","ISR",184,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-08,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-08
"1503",184,"Goldin","Retrospective cohort","08Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","death","death","Israel","LTCF residents","LTCF residents",85.3,"80.4",88.9,NA,"non-VOC & alpha","~16.5 weeks",NA,NA,1557,"Israel","ISR",184,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-08,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-08
"1504",185,"Ferdinands","Test-negative case-control","11Feb2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","<2 months","ED or UC visit","symptomatic","USA","ED encounters and hospital admissions","general pop",69,"62",75,NA,"omicron","~53 weeks",NA,NA,1558,"USA","USA",185,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-11,"symptomatic","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-02-11
"1505",185,"Ferdinands","Test-negative case-control","11Feb2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final",">=5 months","ED or UC visit","symptomatic","USA","ED encounters and hospital admissions","general pop",37,"34",40,NA,"omicron","~53 weeks",NA,NA,1559,"USA","USA",185,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-11,"symptomatic","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-02-11
"1506",185,"Ferdinands","Test-negative case-control","11Feb2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","<2 months","hospitalization","severe","USA","ED encounters and hospital admissions","general pop",71,"51",83,NA,"omicron","~53 weeks",NA,NA,1560,"USA","USA",185,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-11,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-02-11
"1507",185,"Ferdinands","Test-negative case-control","11Feb2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final",">=5 months","hospitalization","severe","USA","ED encounters and hospital admissions","general pop",54,"48",59,NA,"omicron","~53 weeks",NA,NA,1561,"USA","USA",185,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-11,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-02-11
"1508",185,"Ferdinands","Test-negative case-control","11Feb2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","<2 months","ED or UC visit","symptomatic","USA","ED encounters and hospital admissions","general pop",92,"91",94,NA,"delta","~25 weeks",NA,NA,1562,"USA","USA",185,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-11,"symptomatic","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-02-11
"1509",185,"Ferdinands","Test-negative case-control","11Feb2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final",">=5 months","ED or UC visit","symptomatic","USA","ED encounters and hospital admissions","general pop",77,"76",78,NA,"delta","~25 weeks",NA,NA,1563,"USA","USA",185,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-11,"symptomatic","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-02-11
"1510",185,"Ferdinands","Test-negative case-control","11Feb2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","<2 months","hospitalization","severe","USA","ED encounters and hospital admissions","general pop",94,"92",96,NA,"delta","~25 weeks",NA,NA,1564,"USA","USA",185,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-11,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-02-11
"1511",185,"Ferdinands","Test-negative case-control","11Feb2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final",">=5 months","hospitalization","severe","USA","ED encounters and hospital admissions","general pop",82,"82",83,NA,"delta","~25 weeks",NA,NA,1565,"USA","USA",185,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-11,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-02-11
"1512",186,"Jara","Prospective cohort","20Apr2023","CoronaVac (Sinovac)","excluded","2","final","14+","infection","infection","Chile","6-16 years","6-16 years",74.8,"74.1",75.5,NA,"delta","~28 weeks",NA,NA,1566,"Chile","CHL",186,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2023-04-20,"infection","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta","15/02/2022",2022-02-15
"1513",186,"Jara","Prospective cohort","20Apr2023","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Chile","6-16 years","6-16 years",91.3,"88.1",93.6,NA,"delta","~28 weeks",NA,NA,1567,"Chile","CHL",186,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2023-04-20,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta","15/02/2022",2022-02-15
"1514",186,"Jara","Prospective cohort","20Apr2023","CoronaVac (Sinovac)","excluded","2","final","14+","ICU admission","severe","Chile","6-16 years","6-16 years",93.8,"85.7",97.3,NA,"delta","~28 weeks",NA,NA,1568,"Chile","CHL",186,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2023-04-20,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta","15/02/2022",2022-02-15
"1515",186,"Jara","Prospective cohort","20Apr2023","CoronaVac (Sinovac)","excluded","2","final","14+","infection","infection","Chile","6-11 years","6-11 years",75.8,"74.8",76.8,NA,"delta","~28 weeks",NA,NA,1569,"Chile","CHL",186,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2023-04-20,"infection","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta","15/02/2022",2022-02-15
"1516",186,"Jara","Prospective cohort","20Apr2023","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Chile","6-11 years","6-11 years",78.5,"62.8",87.6,NA,"delta","~28 weeks",NA,NA,1570,"Chile","CHL",186,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2023-04-20,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta","15/02/2022",2022-02-15
"1517",186,"Jara","Prospective cohort","20Apr2023","CoronaVac (Sinovac)","excluded","2","final","14+","infection","infection","Chile","12-16 years","12-16 years",73.6,"72.5",74.6,NA,"delta","~28 weeks",NA,NA,1571,"Chile","CHL",186,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2023-04-20,"infection","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta","15/02/2022",2022-02-15
"1518",186,"Jara","Prospective cohort","20Apr2023","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Chile","12-16 years","12-16 years",93.4,"90.4",95.5,NA,"delta","~28 weeks",NA,NA,1572,"Chile","CHL",186,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2023-04-20,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta","15/02/2022",2022-02-15
"1519",186,"Jara","Prospective cohort","20Apr2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Chile","12-16 years","12-16 years",84.4,"83.7",85,NA,"delta","~30 weeks",NA,NA,1573,"Chile","CHL",186,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2023-04-20,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","15/02/2022",2022-02-15
"1520",186,"Jara","Prospective cohort","20Apr2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Chile","12-16 years","12-16 years",93.5,"90.4",95.6,NA,"delta","~30 weeks",NA,NA,1574,"Chile","CHL",186,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2023-04-20,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","15/02/2022",2022-02-15
"1521",186,"Jara","Prospective cohort","20Apr2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","ICU admission","severe","Chile","12-16 years","12-16 years",98,"89.9",99.6,NA,"delta","~30 weeks",NA,NA,1575,"Chile","CHL",186,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2023-04-20,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","15/02/2022",2022-02-15
"1522",187,"Halasa","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery","infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery",52,"33",65,NA,"delta & omicron","~33 weeks",NA,NA,1576,"USA","USA",187,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta/omicron","15/02/2022",2022-02-15
"1523",187,"Halasa","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","infants <6 months when timing of maternal vaccination was in first 20 weeks","infants <6 months when timing of maternal vaccination was in first 20 weeks",38,"3",60,NA,"delta & omicron","~33 weeks",NA,NA,1577,"USA","USA",187,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta/omicron","15/02/2022",2022-02-15
"1524",187,"Halasa","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery","infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery",69,"50",80,NA,"delta & omicron","~33 weeks",NA,NA,1578,"USA","USA",187,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta/omicron","15/02/2022",2022-02-15
"1525",187,"Halasa","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery","infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery",38,"8",58,NA,"omicron","~33 weeks",NA,NA,1579,"USA","USA",187,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","15/02/2022",2022-02-15
"1526",187,"Halasa","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","infants <6 months when timing of maternal vaccination was in first 20 weeks","infants <6 months when timing of maternal vaccination was in first 20 weeks",25,"-26",56,NA,"omicron","~33 weeks",NA,NA,1580,"USA","USA",187,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","15/02/2022",2022-02-15
"1527",187,"Halasa","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery","infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery",57,"25",75,NA,"omicron","~33 weeks",NA,NA,1581,"USA","USA",187,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","15/02/2022",2022-02-15
"1528",187,"Halasa","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery","infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery",80,"60",90,NA,"delta","~33 weeks",NA,NA,1582,"USA","USA",187,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","15/02/2022",2022-02-15
"1529",187,"Halasa","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","infants <6 months when timing of maternal vaccination was in first 20 weeks","infants <6 months when timing of maternal vaccination was in first 20 weeks",68,"19",87,NA,"delta","~33 weeks",NA,NA,1583,"USA","USA",187,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","15/02/2022",2022-02-15
"1530",187,"Halasa","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery","infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery",88,"68",96,NA,"delta","~33 weeks",NA,NA,1584,"USA","USA",187,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","15/02/2022",2022-02-15
"1531",188,"Gazit","Retrospective cohort","15Feb2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","Israel",">= 18 years","general pop",82,"80",85,NA,"alpha & delta","~40 weeks",NA,NA,1585,"Israel","ISR",188,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-15,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-15
"1532",188,"Gazit","Retrospective cohort","15Feb2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","symptomatic disease","symptomatic","Israel",">= 18 years","general pop",76,"71",80,NA,"alpha & delta","~40 weeks",NA,NA,1586,"Israel","ISR",188,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-15,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-15
"1533",189,"Filon","Retrospective cohort","15Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection (March)","infection","Italy","HCW","HCW",95,"92",98,NA,"non-VOC & alpha","~16 weeks",NA,NA,1587,"Italy","ITA",189,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-15,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-15
"1534",189,"Filon","Retrospective cohort","15Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection (April)","infection","Italy","HCW","HCW",95,"92",98,NA,"non-VOC & alpha","~16 weeks",NA,NA,1588,"Italy","ITA",189,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-15,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-15
"1535",189,"Filon","Retrospective cohort","15Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection (May)","infection","Italy","HCW","HCW",80,"70",84,NA,"non-VOC & alpha","~16 weeks",NA,NA,1589,"Italy","ITA",189,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-15,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-15
"1536",190,"Wu","Retrospective cohort","10Jan2022","BBIBP-CorV (Beijing CNBG)","excluded","1+","1+","14+","symptomatic disease","symptomatic","China","close contacts","Contacts of index cases",24.7,"-98.8",71.4,NA,"delta",NA,NA,NA,1590,"China","CHN",190,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"symptomatic","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-01-10
"1537",190,"Wu","Retrospective cohort","10Jan2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","14+","symptomatic disease","symptomatic","China","close contacts","Contacts of index cases",50.5,"3.8",74.6,NA,"delta","~24 weeks",NA,NA,1591,"China","CHN",190,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"symptomatic","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-01-10
"1538",190,"Wu","Retrospective cohort","10Jan2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final",">=3 months","symptomatic disease","symptomatic","China","close contacts","Contacts of index cases",39.3,"-20.4",69.4,NA,"delta","~24 weeks",NA,NA,1592,"China","CHN",190,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"symptomatic","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-01-10
"1539",190,"Wu","Retrospective cohort","10Jan2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","4-6 months","symptomatic disease","symptomatic","China","close contacts","Contacts of index cases",82,"-25.7",97.4,NA,"delta","~24 weeks",NA,NA,1593,"China","CHN",190,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"symptomatic","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-01-10
"1540",190,"Wu","Retrospective cohort","10Jan2022","BBIBP-CorV (Beijing CNBG)","excluded","1+","1+","14+","pneumonia","severe","China","close contacts","Contacts of index cases",16.3,"-164.3",73.2,NA,"delta",NA,NA,NA,1594,"China","CHN",190,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-01-10
"1541",190,"Wu","Retrospective cohort","10Jan2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","14+","pneumonia","severe","China","close contacts","Contacts of index cases",54.7,"-3.4",80.2,NA,"delta","~24 weeks",NA,NA,1595,"China","CHN",190,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-01-10
"1542",190,"Wu","Retrospective cohort","10Jan2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final",">=3 months","pneumonia","severe","China","close contacts","Contacts of index cases",39.6,"-35.4",73.1,NA,"delta","~24 weeks",NA,NA,1596,"China","CHN",190,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-01-10
"1543",190,"Wu","Retrospective cohort","10Jan2022","BBIBP-CorV (Beijing CNBG)","excluded","1+","1+","14+","severe disease","severe","China","close contacts","Contacts of index cases",7.5,"-655.6",88.7,NA,"delta",NA,NA,NA,1597,"China","CHN",190,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-01-10
"1544",190,"Wu","Retrospective cohort","10Jan2022","CoronaVac (Sinovac)","excluded","1+","1+","14+","symptomatic disease","symptomatic","China","close contacts","Contacts of index cases",29.9,"-44.3",66,NA,"delta",NA,NA,NA,1598,"China","CHN",190,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"symptomatic","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta",NA,2022-01-10
"1545",190,"Wu","Retrospective cohort","10Jan2022","CoronaVac (Sinovac)","excluded","2","final","14+","symptomatic disease","symptomatic","China","close contacts","Contacts of index cases",39.1,"-0.9",63.3,NA,"delta","~24 weeks",NA,NA,1599,"China","CHN",190,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"symptomatic","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta",NA,2022-01-10
"1546",190,"Wu","Retrospective cohort","10Jan2022","CoronaVac (Sinovac)","excluded","2","final",">=3 months","symptomatic disease","symptomatic","China","close contacts","Contacts of index cases",45.5,"-5.9",71.9,NA,"delta","~24 weeks",NA,NA,1600,"China","CHN",190,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"symptomatic","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta",NA,2022-01-10
"1547",190,"Wu","Retrospective cohort","10Jan2022","CoronaVac (Sinovac)","excluded","2","final","4-6 months","symptomatic disease","symptomatic","China","close contacts","Contacts of index cases",29.8,"-41.1",65.1,NA,"delta","~24 weeks",NA,NA,1601,"China","CHN",190,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"symptomatic","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta",NA,2022-01-10
"1548",190,"Wu","Retrospective cohort","10Jan2022","CoronaVac (Sinovac)","excluded","1","1","14+","pneumonia","severe","China","close contacts","Contacts of index cases",52.6,"-25.2",82.1,NA,"delta",NA,NA,NA,1602,"China","CHN",190,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta",NA,2022-01-10
"1549",190,"Wu","Retrospective cohort","10Jan2022","CoronaVac (Sinovac)","excluded","2","final","14+","pneumonia","severe","China","close contacts","Contacts of index cases",64.9,"22.8",84,NA,"delta","~24 weeks",NA,NA,1603,"China","CHN",190,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta",NA,2022-01-10
"1550",190,"Wu","Retrospective cohort","10Jan2022","CoronaVac (Sinovac)","excluded","2","final",">=3 months","pneumonia","severe","China","close contacts","Contacts of index cases",73.8,"17.9",91.6,NA,"delta","~24 weeks",NA,NA,1604,"China","CHN",190,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta",NA,2022-01-10
"1551",190,"Wu","Retrospective cohort","10Jan2022","CoronaVac (Sinovac)","excluded","2","final","4-6 months","pneumonia","severe","China","close contacts","Contacts of index cases",47.4,"-44.3",80.8,NA,"delta","~24 weeks",NA,NA,1605,"China","CHN",190,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta",NA,2022-01-10
"1552",190,"Wu","Retrospective cohort","10Jan2022","CoronaVac (Sinovac)","excluded","1","1","14+","severe disease","severe","China","close contacts","Contacts of index cases",59.7,"-209.9",94.7,NA,"delta",NA,NA,NA,1606,"China","CHN",190,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2022-01-10,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta",NA,2022-01-10
"1553",191,"Mallow","Test-negative case-control","09Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","ED visits","symptomatic","USA","ED patients (aged 18+)","general pop",73.9,"66.3",79.8,NA,"non-VOC, alpha, & delta","~31 weeks",NA,NA,1607,"USA","USA",191,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-09,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-09
"1554",191,"Mallow","Test-negative case-control","09Feb2022","mRNA-1273 (Moderna)","unknown","2","final","14+","ED visits","symptomatic","USA","ED patients (aged 18+)","general pop",78,"68.1",84.9,NA,"non-VOC, alpha, & delta","~31 weeks",NA,NA,1608,"USA","USA",191,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-09,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-02-09
"1555",192,"Shen","Retrospective cohort","23Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Infection","infection","USA","immunocompromised","immunocompromised adults",41,"9",62,NA,"non-VOC, alpha, & delta","~36 weeks",NA,NA,1609,"USA","USA",192,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-23,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-23
"1556",192,"Shen","Retrospective cohort","23Feb2022","mRNA-1273 (Moderna)","excluded","2","final","14+","Infection","infection","USA","immunocompromised","immunocompromised adults",48,"18",67,NA,"non-VOC, alpha, & delta","~36 weeks",NA,NA,1610,"USA","USA",192,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-23,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-02-23
"1557",192,"Shen","Retrospective cohort","23Feb2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","Infection","infection","USA","immunocompromised","immunocompromised adults",66,"-30",91,NA,"non-VOC, alpha, & delta","~36 weeks",NA,NA,1611,"USA","USA",192,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-23,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-02-23
"1558",193,"Cura-Bilbao","Prospective cohort","02Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","12+","Infection","infection","Spain",">= 18 years","general pop",20.8,"11.6",29,NA,"non-VOC & alpha",NA,NA,NA,1612,"Spain","ESP",193,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-02,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-02
"1559",193,"Cura-Bilbao","Prospective cohort","02Feb2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","Infection","infection","Spain",">= 18 years","general pop",70,"65.3",74.1,NA,"non-VOC & alpha","~16 weeks",NA,NA,1613,"Spain","ESP",193,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-02,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-02
"1560",193,"Cura-Bilbao","Prospective cohort","02Feb2022","mRNA-1273 (Moderna)","excluded","1","1","14+","Infection","infection","Spain",">= 18 years","general pop",52.8,"30.7",67.8,NA,"non-VOC & alpha",NA,NA,NA,1614,"Spain","ESP",193,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-02,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-02-02
"1561",193,"Cura-Bilbao","Prospective cohort","02Feb2022","mRNA-1273 (Moderna)","excluded","2","final","14+","Infection","infection","Spain",">= 18 years","general pop",70.3,"52.2",81.5,NA,"non-VOC & alpha","~16 weeks",NA,NA,1615,"Spain","ESP",193,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-02,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-02-02
"1562",193,"Cura-Bilbao","Prospective cohort","02Feb2022","AZD1222 (AstraZeneca)","excluded","1","1","21+","Infection","infection","Spain",">= 18 years","general pop",40.3,"31.8",47.7,NA,"non-VOC & alpha",NA,NA,NA,1616,"Spain","ESP",193,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-02,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-02-02
"1563",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","1","1","14-74","Infection","infection","Czech Republic","all ages","general pop",31,"28",34,NA,"omicron",NA,NA,NA,1617,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/02/2022",2022-02-25
"1564",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-74","Infection","infection","Czech Republic","all ages","general pop",49,"48",50,NA,"omicron","~54 weeks",NA,NA,1618,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/02/2022",2022-02-25
"1565",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","1","1","75+","Infection","infection","Czech Republic","all ages","general pop",53,"46",59,NA,"omicron",NA,NA,NA,1619,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/02/2022",2022-02-25
"1566",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","135+","Infection","infection","Czech Republic","all ages","general pop",11,"10",12,NA,"omicron","~54 weeks",NA,NA,1620,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/02/2022",2022-02-25
"1567",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","1","1","14-74","hospitalization","severe","Czech Republic","all ages","general pop",41,"-3",66,NA,"omicron",NA,NA,NA,1621,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/02/2022",2022-02-25
"1568",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-74","hospitalization","severe","Czech Republic","all ages","general pop",46,"28",60,NA,"omicron","~54 weeks",NA,NA,1622,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/02/2022",2022-02-25
"1569",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","1","1","75+","hospitalization","severe","Czech Republic","all ages","general pop",4,"-287",76,NA,"omicron",NA,NA,NA,1623,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/02/2022",2022-02-25
"1570",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","135+","hospitalization","severe","Czech Republic","all ages","general pop",34,"24",42,NA,"omicron","~54 weeks",NA,NA,1624,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/02/2022",2022-02-25
"1571",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","1","1","14-74","Infection","infection","Czech Republic","all ages","general pop",49,"42",55,NA,"omicron",NA,NA,NA,1625,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","25/02/2022",2022-02-25
"1572",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","2","final","14-74","Infection","infection","Czech Republic","all ages","general pop",48,"44",52,NA,"omicron","~54 weeks",NA,NA,1626,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","25/02/2022",2022-02-25
"1573",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","1","1","75+","Infection","infection","Czech Republic","all ages","general pop",60,"36",75,NA,"omicron",NA,NA,NA,1627,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","25/02/2022",2022-02-25
"1574",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","2","final","135+","Infection","infection","Czech Republic","all ages","general pop",20,"17",22,NA,"omicron","~54 weeks",NA,NA,1628,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","25/02/2022",2022-02-25
"1575",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","1","1","14-74","hospitalization","severe","Czech Republic","all ages","general pop",56,"-78",89,NA,"omicron",NA,NA,NA,1629,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","25/02/2022",2022-02-25
"1576",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","2","final","14-74","hospitalization","severe","Czech Republic","all ages","general pop",51,"-20",80,NA,"omicron","~54 weeks",NA,NA,1630,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","25/02/2022",2022-02-25
"1577",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","1","1","75+","hospitalization","severe","Czech Republic","all ages","general pop",-160,"-1743",64,NA,"omicron",NA,NA,NA,1631,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","25/02/2022",2022-02-25
"1578",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","2","final","135+","hospitalization","severe","Czech Republic","all ages","general pop",31,"9",49,NA,"omicron","~54 weeks",NA,NA,1632,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","25/02/2022",2022-02-25
"1579",194,"Smid","Retrospective cohort","15Oct2022","AZD1222 (AstraZeneca)","included","2","final","75-135","Infection","infection","Czech Republic","all ages","general pop",51,"23",69,NA,"omicron","~54 weeks",NA,NA,1633,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","25/02/2022",2022-02-25
"1580",194,"Smid","Retrospective cohort","15Oct2022","AZD1222 (AstraZeneca)","included","2","final","135+","Infection","infection","Czech Republic","all ages","general pop",5,"1",9,NA,"omicron","~54 weeks",NA,NA,1634,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","25/02/2022",2022-02-25
"1581",194,"Smid","Retrospective cohort","15Oct2022","AZD1222 (AstraZeneca)","included","2","final","75-135","hospitalization","severe","Czech Republic","all ages","general pop",-139,"-861",41,NA,"omicron","~54 weeks",NA,NA,1635,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","25/02/2022",2022-02-25
"1582",194,"Smid","Retrospective cohort","15Oct2022","AZD1222 (AstraZeneca)","included","2","final","135+","hospitalization","severe","Czech Republic","all ages","general pop",13,"-8",30,NA,"omicron","~54 weeks",NA,NA,1636,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","25/02/2022",2022-02-25
"1583",194,"Smid","Retrospective cohort","15Oct2022","Ad26.COV2.S (Janssen)","included","1","final","14-74","Infection","infection","Czech Republic","all ages","general pop",47,"45",49,NA,"omicron","~54 weeks",NA,NA,1637,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron","25/02/2022",2022-02-25
"1584",194,"Smid","Retrospective cohort","15Oct2022","Ad26.COV2.S (Janssen)","included","1","final","135+","Infection","infection","Czech Republic","all ages","general pop",35,"33",38,NA,"omicron","~54 weeks",NA,NA,1638,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron","25/02/2022",2022-02-25
"1585",194,"Smid","Retrospective cohort","15Oct2022","Ad26.COV2.S (Janssen)","included","1","final","14-74","hospitalization","severe","Czech Republic","all ages","general pop",28,"-22",57,NA,"omicron","~54 weeks",NA,NA,1639,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron","25/02/2022",2022-02-25
"1586",194,"Smid","Retrospective cohort","15Oct2022","Ad26.COV2.S (Janssen)","included","1","final","135+","hospitalization","severe","Czech Republic","all ages","general pop",38,"8",58,NA,"omicron","~54 weeks",NA,NA,1640,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron","25/02/2022",2022-02-25
"1587",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","1","1","14-74","Infection","infection","Czech Republic","all ages","general pop",67,"65",69,NA,"delta",NA,NA,NA,1641,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/02/2022",2022-02-25
"1588",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-74","Infection","infection","Czech Republic","all ages","general pop",82,"81",83,NA,"delta","~54 weeks",NA,NA,1642,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/02/2022",2022-02-25
"1589",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","1","1","75+","Infection","infection","Czech Republic","all ages","general pop",61,"51",69,NA,"delta",NA,NA,NA,1643,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/02/2022",2022-02-25
"1590",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","135+","Infection","infection","Czech Republic","all ages","general pop",54,"53",55,NA,"delta","~54 weeks",NA,NA,1644,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/02/2022",2022-02-25
"1591",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","1","1","14-74","hospitalization","severe","Czech Republic","all ages","general pop",53,"40",63,NA,"delta",NA,NA,NA,1645,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/02/2022",2022-02-25
"1592",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-74","hospitalization","severe","Czech Republic","all ages","general pop",80,"72",85,NA,"delta","~54 weeks",NA,NA,1646,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/02/2022",2022-02-25
"1593",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","1","1","75+","hospitalization","severe","Czech Republic","all ages","general pop",61,"-20",87,NA,"delta",NA,NA,NA,1647,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/02/2022",2022-02-25
"1594",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","135+","hospitalization","severe","Czech Republic","all ages","general pop",82,"77",86,NA,"delta","~54 weeks",NA,NA,1648,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/02/2022",2022-02-25
"1595",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","1","1","14-74","Infection","infection","Czech Republic","all ages","general pop",68,"61",74,NA,"delta",NA,NA,NA,1649,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","25/02/2022",2022-02-25
"1596",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","2","final","14-74","Infection","infection","Czech Republic","all ages","general pop",71,"65",76,NA,"delta","~54 weeks",NA,NA,1650,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","25/02/2022",2022-02-25
"1597",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","1","1","75+","Infection","infection","Czech Republic","all ages","general pop",67,"34",84,NA,"delta",NA,NA,NA,1651,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","25/02/2022",2022-02-25
"1598",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","2","final","135+","Infection","infection","Czech Republic","all ages","general pop",68,"66",69,NA,"delta","~54 weeks",NA,NA,1652,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","25/02/2022",2022-02-25
"1599",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","1","1","14-74","hospitalization","severe","Czech Republic","all ages","general pop",49,"13",71,NA,"delta",NA,NA,NA,1653,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","25/02/2022",2022-02-25
"1600",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","2","final","14-74","hospitalization","severe","Czech Republic","all ages","general pop",100,NA,NA,NA,"delta","~54 weeks",NA,NA,1654,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","25/02/2022",2022-02-25
"1601",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","1","1","75+","hospitalization","severe","Czech Republic","all ages","general pop",100,NA,NA,NA,"delta",NA,NA,NA,1655,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","25/02/2022",2022-02-25
"1602",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","2","final","135+","hospitalization","severe","Czech Republic","all ages","general pop",82,"78",85,NA,"delta","~54 weeks",NA,NA,1656,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","25/02/2022",2022-02-25
"1603",194,"Smid","Retrospective cohort","15Oct2022","AZD1222 (AstraZeneca)","included","2","final","75-135","Infection","infection","Czech Republic","all ages","general pop",65,"57",72,NA,"delta","~54 weeks",NA,NA,1657,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","25/02/2022",2022-02-25
"1604",194,"Smid","Retrospective cohort","15Oct2022","AZD1222 (AstraZeneca)","included","2","final","135+","Infection","infection","Czech Republic","all ages","general pop",45,"43",48,NA,"delta","~54 weeks",NA,NA,1658,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","25/02/2022",2022-02-25
"1605",194,"Smid","Retrospective cohort","15Oct2022","AZD1222 (AstraZeneca)","included","2","final","75-135","hospitalization","severe","Czech Republic","all ages","general pop",80,"62",89,NA,"delta","~54 weeks",NA,NA,1659,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","25/02/2022",2022-02-25
"1606",194,"Smid","Retrospective cohort","15Oct2022","AZD1222 (AstraZeneca)","included","2","final","135+","hospitalization","severe","Czech Republic","all ages","general pop",68,"64",71,NA,"delta","~54 weeks",NA,NA,1660,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","25/02/2022",2022-02-25
"1607",194,"Smid","Retrospective cohort","15Oct2022","Ad26.COV2.S (Janssen)","included","1","final","14-74","Infection","infection","Czech Republic","all ages","general pop",60,"57",63,NA,"delta","~54 weeks",NA,NA,1661,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta","25/02/2022",2022-02-25
"1608",194,"Smid","Retrospective cohort","15Oct2022","Ad26.COV2.S (Janssen)","included","1","final","135+","Infection","infection","Czech Republic","all ages","general pop",54,"50",57,NA,"delta","~54 weeks",NA,NA,1662,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta","25/02/2022",2022-02-25
"1609",194,"Smid","Retrospective cohort","15Oct2022","Ad26.COV2.S (Janssen)","included","1","final","14-74","hospitalization","severe","Czech Republic","all ages","general pop",54,"39",65,NA,"delta","~54 weeks",NA,NA,1663,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta","25/02/2022",2022-02-25
"1610",194,"Smid","Retrospective cohort","15Oct2022","Ad26.COV2.S (Janssen)","included","1","final","135+","hospitalization","severe","Czech Republic","all ages","general pop",61,"51",69,NA,"delta","~54 weeks",NA,NA,1664,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta","25/02/2022",2022-02-25
"1611",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14-67","ED or UC visit","symptomatic","USA","5-11 years","5-11 years",51,"30",65,NA,"omicron","~33 weeks",NA,NA,1665,"USA","USA",195,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-01,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-01
"1612",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14-149","ED or UC visit","symptomatic","USA","12-15 years","12-15 years",45,"30",57,NA,"omicron","~33 weeks",NA,NA,1666,"USA","USA",195,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-01,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-01
"1613",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","150+","ED or UC visit","symptomatic","USA","12-15 years","12-15 years",-2,"-25",17,NA,"omicron","~33 weeks",NA,NA,1667,"USA","USA",195,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-01,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-01
"1614",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14-149","ED or UC visit","symptomatic","USA","16-17 years","16-17 years",34,"8",53,NA,"omicron","~33 weeks",NA,NA,1668,"USA","USA",195,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-01,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-01
"1615",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","150+","ED or UC visit","symptomatic","USA","16-17 years","16-17 years",-3,"-30",18,NA,"omicron","~33 weeks",NA,NA,1669,"USA","USA",195,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-01,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-01
"1616",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14-149","ED or UC visit","symptomatic","USA","12-15 years","12-15 years",92,"89",94,NA,"delta","~33 weeks",NA,NA,1670,"USA","USA",195,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-01,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-01
"1617",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","150+","ED or UC visit","symptomatic","USA","12-15 years","12-15 years",79,"68",86,NA,"delta","~33 weeks",NA,NA,1671,"USA","USA",195,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-01,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-01
"1618",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14-149","ED or UC visit","symptomatic","USA","16-17 years","16-17 years",85,"81",89,NA,"delta","~33 weeks",NA,NA,1672,"USA","USA",195,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-01,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-01
"1619",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","150+","ED or UC visit","symptomatic","USA","16-17 years","16-17 years",77,"67",84,NA,"delta","~33 weeks",NA,NA,1673,"USA","USA",195,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-01,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-01
"1620",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14-67","hospitalization","severe","USA","5-11 years","5-11 years",74,"-35",95,NA,"omicron or delta","~33 weeks",NA,NA,1674,"USA","USA",195,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-01,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-03-01
"1621",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14-149","hospitalization","severe","USA","12-15 years","12-15 years",92,"79",97,NA,"omicron or delta","~33 weeks",NA,NA,1675,"USA","USA",195,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-01,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-03-01
"1622",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","150+","hospitalization","severe","USA","12-15 years","12-15 years",73,"43",88,NA,"omicron or delta","~33 weeks",NA,NA,1676,"USA","USA",195,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-01,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-03-01
"1623",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14-149","hospitalization","severe","USA","16-17 years","16-17 years",94,"87",97,NA,"omicron or delta","~33 weeks",NA,NA,1677,"USA","USA",195,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-01,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-03-01
"1624",195,"Klein","Test-negative case-control","01Mar2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","150+","hospitalization","severe","USA","16-17 years","16-17 years",88,"72",95,NA,"omicron or delta","~33 weeks",NA,NA,1678,"USA","USA",195,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-01,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-03-01
"1625",196,"Wright","Case-control","25Feb2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","severe disease","severe","USA",">= 18 years","general pop",87.9,"86.7",89,NA,"alpha & delta","~40 weeks",NA,NA,1679,"USA","USA",196,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-25,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-02-25
"1626",196,"Wright","Case-control","25Feb2022","mRNA-1273 (Moderna)","included","2","final","14+","severe disease","severe","USA",">= 18 years","general pop",92.9,"92",93.7,NA,"alpha & delta","~40 weeks",NA,NA,1680,"USA","USA",196,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-25,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-02-25
"1627",196,"Wright","Case-control","25Feb2022","Ad26.COV2.S (Janssen)","included","1","final","14+","severe disease","severe","USA",">= 18 years","general pop",73,"68.8",76.6,NA,"alpha & delta","~40 weeks",NA,NA,1681,"USA","USA",196,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-25,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-02-25
"1628",197,"Perry","Retrospective cohort","03Mar2022","BNT162b2 (Pfizer BioNTech)","included","1","1","14-20","infection","infection","UK",">= 50 years",">= 50 years",19,"9",28,NA,"alpha & delta",NA,NA,NA,1682,"UK","GBR",197,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-03,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-03-03
"1629",197,"Perry","Retrospective cohort","03Mar2022","BNT162b2 (Pfizer BioNTech)","included","1","1",">27","infection","infection","UK",">= 50 years",">= 50 years",16,"8",24,NA,"alpha & delta",NA,NA,NA,1683,"UK","GBR",197,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-03,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-03-03
"1630",197,"Perry","Retrospective cohort","03Mar2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">6","infection","infection","UK",">= 50 years",">= 50 years",50,"44",55,NA,"alpha & delta","~26.5 weeks",NA,NA,1684,"UK","GBR",197,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-03,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-03-03
"1631",197,"Perry","Retrospective cohort","03Mar2022","BNT162b2 (Pfizer BioNTech)","included","1","1","14-20","hospitalization","severe","UK",">= 50 years",">= 50 years",69,"43",83,NA,"alpha & delta",NA,NA,NA,1685,"UK","GBR",197,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-03,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-03-03
"1632",197,"Perry","Retrospective cohort","03Mar2022","BNT162b2 (Pfizer BioNTech)","included","1","1",">27","hospitalization","severe","UK",">= 50 years",">= 50 years",75,"56",85,NA,"alpha & delta",NA,NA,NA,1686,"UK","GBR",197,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-03,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-03-03
"1633",197,"Perry","Retrospective cohort","03Mar2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">6","hospitalization","severe","UK",">= 50 years",">= 50 years",88,"81",93,NA,"alpha & delta","~26.5 weeks",NA,NA,1687,"UK","GBR",197,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-03,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-03-03
"1634",197,"Perry","Retrospective cohort","03Mar2022","AZD1222 (AstraZeneca)","included","1","1","14-20","infection","infection","UK",">= 50 years",">= 50 years",7,"-5",19,NA,"alpha & delta",NA,NA,NA,1688,"UK","GBR",197,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-03,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-03
"1635",197,"Perry","Retrospective cohort","03Mar2022","AZD1222 (AstraZeneca)","included","1","1",">27","infection","infection","UK",">= 50 years",">= 50 years",17,"9",25,NA,"alpha & delta",NA,NA,NA,1689,"UK","GBR",197,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-03,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-03
"1636",197,"Perry","Retrospective cohort","03Mar2022","AZD1222 (AstraZeneca)","included","2","final",">6","infection","infection","UK",">= 50 years",">= 50 years",25,"15",33,NA,"alpha & delta","~18 weeks",NA,NA,1690,"UK","GBR",197,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-03,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-03
"1637",197,"Perry","Retrospective cohort","03Mar2022","AZD1222 (AstraZeneca)","included","1","1","14-20","hospitalization","severe","UK",">= 50 years",">= 50 years",48,"26",64,NA,"alpha & delta",NA,NA,NA,1691,"UK","GBR",197,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-03,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-03
"1638",197,"Perry","Retrospective cohort","03Mar2022","AZD1222 (AstraZeneca)","included","1","1",">27","hospitalization","severe","UK",">= 50 years",">= 50 years",72,"62",80,NA,"alpha & delta",NA,NA,NA,1692,"UK","GBR",197,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-03,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-03
"1639",197,"Perry","Retrospective cohort","03Mar2022","AZD1222 (AstraZeneca)","included","2","final",">6","hospitalization","severe","UK",">= 50 years",">= 50 years",81,"71",88,NA,"alpha & delta","~18 weeks",NA,NA,1693,"UK","GBR",197,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-03,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-03
"1640",198,"Oliver","Retrospective cohort","09Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1","1","14+","infection","infection","Canada","hemodialysis patients","hemodialysis patients",41,"24",54,NA,"alpha",NA,NA,NA,1694,"Canada","CAN",198,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-09,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-03-09
"1641",198,"Oliver","Retrospective cohort","09Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","infection","infection","Canada","hemodialysis patients","hemodialysis patients",69,"58",78,NA,"alpha","~22 weeks",NA,NA,1695,"Canada","CAN",198,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-09,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-03-09
"1642",198,"Oliver","Retrospective cohort","09Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1","1","14+","severe disease","severe","Canada","hemodialysis patients","hemodialysis patients",46,"23",63,NA,"alpha",NA,NA,NA,1696,"Canada","CAN",198,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-09,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-03-09
"1643",198,"Oliver","Retrospective cohort","09Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","severe disease","severe","Canada","hemodialysis patients","hemodialysis patients",83,"70",90,NA,"alpha","~22 weeks",NA,NA,1697,"Canada","CAN",198,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-09,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-03-09
"1644",198,"Oliver","Retrospective cohort","09Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1","1","14+","hospitalization","severe","Canada","hemodialysis patients","hemodialysis patients",40,"13",58,NA,"alpha",NA,NA,NA,1698,"Canada","CAN",198,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-09,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-03-09
"1645",198,"Oliver","Retrospective cohort","09Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","hospitalization","severe","Canada","hemodialysis patients","hemodialysis patients",82,"69",90,NA,"alpha","~22 weeks",NA,NA,1699,"Canada","CAN",198,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-09,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-03-09
"1646",198,"Oliver","Retrospective cohort","09Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1","1","14+","death","death","Canada","hemodialysis patients","hemodialysis patients",71,"40",86,NA,"alpha",NA,NA,NA,1700,"Canada","CAN",198,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-09,"death","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-03-09
"1647",198,"Oliver","Retrospective cohort","09Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","death","death","Canada","hemodialysis patients","hemodialysis patients",85,"59",95,NA,"alpha","~22 weeks",NA,NA,1701,"Canada","CAN",198,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-09,"death","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-03-09
"1648",199,"Oliveira","Matched case-control","03Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14+","infection","infection","USA","12-18 years","12-18 years",74,"18",92,NA,"delta",NA,NA,NA,1702,"USA","USA",199,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-03,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-03
"1649",199,"Oliveira","Matched case-control","03Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","1-4 weeks","infection","infection","USA","12-18 years","12-18 years",91,"33",99,NA,"delta","~11 weeks",NA,NA,1703,"USA","USA",199,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-03,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-03
"1650",199,"Oliveira","Matched case-control","03Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","13-17 weeks","infection","infection","USA","12-18 years","12-18 years",83,"34",95,NA,"delta","~11 weeks",NA,NA,1704,"USA","USA",199,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-03,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-03
"1651",199,"Oliveira","Matched case-control","03Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","USA","12-18 years","12-18 years",93,"81",97,NA,"delta","~11 weeks",NA,NA,1705,"USA","USA",199,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-03,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-03
"1652",199,"Oliveira","Matched case-control","03Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","asymptomatic infection","asymptomatic","USA","12-18 years","12-18 years",85,"57",95,NA,"delta","~11 weeks",NA,NA,1706,"USA","USA",199,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-03,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-03
"1653",200,"Ashmawy","Ambispective cohort","24Apr2023","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","symptomatic disease","symptomatic","Egypt","HCW","HCW",67,"43",80,NA,"delta","~29 weeks",NA,NA,1707,"Egypt","EGY",200,"EGY",2640,2019,"Egypt, Arab Rep.","Middle East & North Africa","Lower middle income",2,"Africa",2021-03-27,NA,NA,2021-01-24,2021-01-24,62,NA,NA,"who","jan/2021","not reached","not reached","yes","no","no",2023-04-24,"symptomatic","2023 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta","11/03/2022",2022-03-11
"1654",200,"Ashmawy","Ambispective cohort","24Apr2023","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","infection","infection","Egypt","HCW","HCW",46,"24",62,NA,"delta","~29 weeks",NA,NA,1708,"Egypt","EGY",200,"EGY",2640,2019,"Egypt, Arab Rep.","Middle East & North Africa","Lower middle income",2,"Africa",2021-03-27,NA,NA,2021-01-24,2021-01-24,62,NA,NA,"who","jan/2021","not reached","not reached","yes","no","no",2023-04-24,"infection","2023 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta","11/03/2022",2022-03-11
"1655",200,"Ashmawy","Ambispective cohort","24Apr2023","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","hospitalization","severe","Egypt","HCW","HCW",65,"-8",88,NA,"delta","~29 weeks",NA,NA,1709,"Egypt","EGY",200,"EGY",2640,2019,"Egypt, Arab Rep.","Middle East & North Africa","Lower middle income",2,"Africa",2021-03-27,NA,NA,2021-01-24,2021-01-24,62,NA,NA,"who","jan/2021","not reached","not reached","yes","no","no",2023-04-24,"severe","2023 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta","11/03/2022",2022-03-11
"1656",201,"Fowlkes","Prospective cohort","11Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-82","infection","infection","USA","5-11 years","5-11 years",31,"9",48,"omicron","omicron","~29 weeks",NA,NA,1710,"USA","USA",201,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-11
"1657",201,"Fowlkes","Prospective cohort","11Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","USA","12-15 years","12-15 years",59,"24",78,"omicron","omicron","~29 weeks",NA,NA,1711,"USA","USA",201,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-11
"1658",201,"Fowlkes","Prospective cohort","11Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-149","infection","infection","USA","12-15 years","12-15 years",59,"22",79,"omicron","omicron",NA,NA,NA,1712,"USA","USA",201,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-11
"1659",201,"Fowlkes","Prospective cohort","11Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","150+","infection","infection","USA","12-15 years","12-15 years",62,"-28",29,"omicron","omicron","~29 weeks",NA,NA,1713,"USA","USA",201,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-11
"1660",201,"Fowlkes","Prospective cohort","11Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","USA","12-15 years","12-15 years",81,"51",93,"delta","delta","~29 weeks",NA,NA,1714,"USA","USA",201,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-11
"1661",201,"Fowlkes","Prospective cohort","11Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-149","infection","infection","USA","12-15 years","12-15 years",87,"49",97,"delta","delta",NA,NA,NA,1715,"USA","USA",201,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-11
"1662",201,"Fowlkes","Prospective cohort","11Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","150+","infection","infection","USA","12-15 years","12-15 years",60,"-35",88,"delta","delta","~29 weeks",NA,NA,1716,"USA","USA",201,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-11
"1663",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","28+","infection","infection","UK","LTCF residents","LTCF residents",31.7,"-14.2",59.1,NA,"alpha & delta",NA,NA,NA,1717,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1664",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-83","Infection","infection","UK","LTCF residents","LTCF residents",25.5,"-57.5",64.7,NA,"alpha & delta","45 weeks",NA,NA,1718,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1665",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","84+","Infection","infection","UK","LTCF residents","LTCF residents",26.3,"-21.7",55.4,NA,"alpha & delta","45 weeks",NA,NA,1719,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1666",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","28+","hospitalization","severe","UK","LTCF residents","LTCF residents",40.8,"-16",69.7,NA,"alpha & delta",NA,NA,NA,1720,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1667",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-83","hospitalization","severe","UK","LTCF residents","LTCF residents",88.8,"16.8",98.5,NA,"alpha & delta","45 weeks",NA,NA,1721,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1668",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","84+","hospitalization","severe","UK","LTCF residents","LTCF residents",65.1,"33.6",81.6,NA,"alpha & delta","45 weeks",NA,NA,1722,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1669",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","28+","death","death","UK","LTCF residents","LTCF residents",58.6,"25.3",77,NA,"alpha & delta",NA,NA,NA,1723,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"death","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1670",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-83","death","death","UK","LTCF residents","LTCF residents",100,NA,NA,NA,"alpha & delta","45 weeks",NA,NA,1724,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"death","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1671",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","84+","death","death","UK","LTCF residents","LTCF residents",66.1,"26",84.4,NA,"alpha & delta","45 weeks",NA,NA,1725,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"death","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1672",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","1","1","28+","Infection","infection","UK","LTCF residents","LTCF residents",41.3,"8.8",62.2,NA,"alpha & delta",NA,NA,NA,1726,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1673",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","14-83","Infection","infection","UK","LTCF residents","LTCF residents",62.1,"12.1",83.6,NA,"alpha & delta","45 weeks",NA,NA,1727,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1674",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","84+","Infection","infection","UK","LTCF residents","LTCF residents",13.6,"-33.2",43.9,NA,"alpha & delta","45 weeks",NA,NA,1728,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1675",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","1","1","28+","hospitalization","severe","UK","LTCF residents","LTCF residents",44.9,"7.9",67.1,NA,"alpha & delta",NA,NA,NA,1729,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1676",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","14-83","hospitalization","severe","UK","LTCF residents","LTCF residents",82.7,"46.4",94.4,NA,"alpha & delta","45 weeks",NA,NA,1730,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1677",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","84+","hospitalization","severe","UK","LTCF residents","LTCF residents",48.7,"12.5",70,NA,"alpha & delta","45 weeks",NA,NA,1731,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1678",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","1","1","28+","death","death","UK","LTCF residents","LTCF residents",52.7,"16.4",73.2,NA,"alpha & delta",NA,NA,NA,1732,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1679",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","14-83","death","death","UK","LTCF residents","LTCF residents",91.7,"65.1",98,NA,"alpha & delta","45 weeks",NA,NA,1733,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1680",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","84+","death","death","UK","LTCF residents","LTCF residents",61.1,"26.2",79.5,NA,"alpha & delta","45 weeks",NA,NA,1734,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1681",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","28+","Infection","infection","UK","LTCF staff","LTCF staff",27,"4.4",44.3,NA,"alpha & delta",NA,NA,NA,1735,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1682",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-83","infection","infection","UK","LTCF staff","LTCF staff",60.7,"44.2",72.4,NA,"alpha & delta","45 weeks",NA,NA,1736,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1683",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","84+","Infection","infection","UK","LTCF staff","LTCF staff",45.1,"31.3",56.2,NA,"alpha & delta","45 weeks",NA,NA,1737,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1684",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","1","1","28+","hospitalization","severe","UK","LTCF staff","LTCF staff",100,NA,NA,NA,"alpha & delta",NA,NA,NA,1738,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1685",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-83","hospitalization","severe","UK","LTCF staff","LTCF staff",100,NA,NA,NA,"alpha & delta","45 weeks",NA,NA,1739,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1686",202,"Shrotri","Prospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","84+","hospitalization","severe","UK","LTCF staff","LTCF staff",92.1,"69.3",97.9,NA,"alpha & delta","45 weeks",NA,NA,1740,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-12
"1687",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","1","1","28+","Infection","infection","UK","LTCF staff","LTCF staff",19.6,"-10.7",41.6,NA,"alpha & delta",NA,NA,NA,1741,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1688",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","14-83","Infection","infection","UK","LTCF staff","LTCF staff",29,"-10.3",54.3,NA,"alpha & delta","45 weeks",NA,NA,1742,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1689",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","84+","Infection","infection","UK","LTCF staff","LTCF staff",36.9,"20.6",49.9,NA,"alpha & delta","45 weeks",NA,NA,1743,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1690",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","1","1","28+","hospitalization","severe","UK","LTCF staff","LTCF staff",19.6,"-121.6",70.8,NA,"alpha & delta",NA,NA,NA,1744,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1691",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","14-83","hospitalization","severe","UK","LTCF staff","LTCF staff",100,NA,NA,NA,"alpha & delta","45 weeks",NA,NA,1745,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1692",202,"Shrotri","Prospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","84+","hospitalization","severe","UK","LTCF staff","LTCF staff",89.6,"64.4",96.9,NA,"alpha & delta","45 weeks",NA,NA,1746,"UK","GBR",202,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-12
"1693",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21-83","hospitalization","severe","Finland",">= 70 years",">= 70 years",61,"49",71,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,1747,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","06/07/2022",2022-07-06
"1694",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","84+","hospitalization","severe","Finland",">= 70 years",">= 70 years",64,"49",75,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,1748,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","06/07/2022",2022-07-06
"1695",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-90","hospitalization","severe","Finland",">= 70 years",">= 70 years",93,"89",95,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,1749,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","06/07/2022",2022-07-06
"1696",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","181+","hospitalization","severe","Finland",">= 70 years",">= 70 years",69,"63",74,NA,"non-VOC, alpha, delta, & omicron","~56 weeks",NA,NA,1750,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","06/07/2022",2022-07-06
"1697",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21-83","ICU admission","severe","Finland",">= 70 years",">= 70 years",84,"63",93,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,1751,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","06/07/2022",2022-07-06
"1698",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","84+","ICU admission","severe","Finland",">= 70 years",">= 70 years",69,"15",89,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,1752,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","06/07/2022",2022-07-06
"1699",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-90","ICU admission","severe","Finland",">= 70 years",">= 70 years",98,"92",99,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,1753,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","06/07/2022",2022-07-06
"1700",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","181+","ICU admission","severe","Finland",">= 70 years",">= 70 years",79,"65",87,NA,"non-VOC, alpha, delta, & omicron","~56 weeks",NA,NA,1754,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","06/07/2022",2022-07-06
"1701",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","1","1","21-83","hospitalization","severe","Finland",">= 70 years",">= 70 years",70,"43",84,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,1755,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","06/07/2022",2022-07-06
"1702",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","1","1","84+","hospitalization","severe","Finland",">= 70 years",">= 70 years",63,"26",82,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,1756,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","06/07/2022",2022-07-06
"1703",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","2","final","14-90","hospitalization","severe","Finland",">= 70 years",">= 70 years",93,"82",97,NA,"non-VOC, alpha, delta, & omicron","~56 weeks",NA,NA,1757,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","06/07/2022",2022-07-06
"1704",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","2","final","181+","hospitalization","severe","Finland",">= 70 years",">= 70 years",73,"59",83,NA,"non-VOC, alpha, delta, & omicron","~56 weeks",NA,NA,1758,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","06/07/2022",2022-07-06
"1705",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","1","1","21-83","ICU admission","severe","Finland",">= 70 years",">= 70 years",70,"-29",93,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,1759,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","06/07/2022",2022-07-06
"1706",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","1","1","84+","ICU admission","severe","Finland",">= 70 years",">= 70 years",100,NA,NA,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,1760,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","06/07/2022",2022-07-06
"1707",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","2","final","14-90","ICU admission","severe","Finland",">= 70 years",">= 70 years",100,NA,NA,NA,"non-VOC, alpha, delta, & omicron","~56 weeks",NA,NA,1761,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","06/07/2022",2022-07-06
"1708",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","2","final","181+","ICU admission","severe","Finland",">= 70 years",">= 70 years",93,"46",99,NA,"non-VOC, alpha, delta, & omicron","~56 weeks",NA,NA,1762,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","06/07/2022",2022-07-06
"1709",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","1","1","21-83","hospitalization","severe","Finland",">= 70 years",">= 70 years",68,"-3",90,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,1763,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","06/07/2022",2022-07-06
"1710",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","1","1","84+","hospitalization","severe","Finland",">= 70 years",">= 70 years",37,"-95",80,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,1764,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","06/07/2022",2022-07-06
"1711",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","2","final","14-90","hospitalization","severe","Finland",">= 70 years",">= 70 years",81,"49",93,NA,"non-VOC, alpha, delta, & omicron","~56 weeks",NA,NA,1765,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","06/07/2022",2022-07-06
"1712",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","2","final","181+","hospitalization","severe","Finland",">= 70 years",">= 70 years",48,"17",68,NA,"non-VOC, alpha, delta, & omicron","~56 weeks",NA,NA,1766,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","06/07/2022",2022-07-06
"1713",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","1","1","21-83","ICU admission","severe","Finland",">= 70 years",">= 70 years",68,"-151",96,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,1767,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","06/07/2022",2022-07-06
"1714",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","1","1","84+","ICU admission","severe","Finland",">= 70 years",">= 70 years",100,NA,NA,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,1768,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","06/07/2022",2022-07-06
"1715",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","2","final","14-90","ICU admission","severe","Finland",">= 70 years",">= 70 years",78,"2",95,NA,"non-VOC, alpha, delta, & omicron","~56 weeks",NA,NA,1769,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","06/07/2022",2022-07-06
"1716",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","2","final","181+","ICU admission","severe","Finland",">= 70 years",">= 70 years",64,"-14",89,NA,"non-VOC, alpha, delta, & omicron","~56 weeks",NA,NA,1770,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","06/07/2022",2022-07-06
"1717",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21-83","hospitalization","severe","Finland",">= 70 years",">= 70 years",53,"-16",81,NA,"delta",NA,NA,NA,1771,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","06/07/2022",2022-07-06
"1718",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","84+","hospitalization","severe","Finland",">= 70 years",">= 70 years",68,"45",81,NA,"delta",NA,NA,NA,1772,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","06/07/2022",2022-07-06
"1719",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-90","hospitalization","severe","Finland",">= 70 years",">= 70 years",90,"78",96,NA,"delta","~48.5 weeks",NA,NA,1773,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","06/07/2022",2022-07-06
"1720",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","181+","hospitalization","severe","Finland",">= 70 years",">= 70 years",79,"71",84,NA,"delta","~48.5 weeks",NA,NA,1774,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","06/07/2022",2022-07-06
"1721",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","1","1","21-83","hospitalization","severe","Finland",">= 70 years",">= 70 years",60,"-189",94,NA,"delta",NA,NA,NA,1775,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","06/07/2022",2022-07-06
"1722",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","1","1","84+","hospitalization","severe","Finland",">= 70 years",">= 70 years",91,"35",99,NA,"delta",NA,NA,NA,1776,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","06/07/2022",2022-07-06
"1723",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","2","final","14-90","hospitalization","severe","Finland",">= 70 years",">= 70 years",92,"42",99,NA,"delta","~48.5 weeks",NA,NA,1777,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","06/07/2022",2022-07-06
"1724",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","2","final","181+","hospitalization","severe","Finland",">= 70 years",">= 70 years",87,"70",94,NA,"delta","~48.5 weeks",NA,NA,1778,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","06/07/2022",2022-07-06
"1725",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","1","1","84+","hospitalization","severe","Finland",">= 70 years",">= 70 years",62,"-171",95,NA,"delta",NA,NA,NA,1779,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","06/07/2022",2022-07-06
"1726",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","2","final","91-180","hospitalization","severe","Finland",">= 70 years",">= 70 years",79,"67",87,NA,"delta","~48.5 weeks",NA,NA,1780,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","06/07/2022",2022-07-06
"1727",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","2","final","181+","hospitalization","severe","Finland",">= 70 years",">= 70 years",23,"-76",67,NA,"delta","~48.5 weeks",NA,NA,1781,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","06/07/2022",2022-07-06
"1728",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21-83","hospitalization","severe","Finland",">= 70 years",">= 70 years",22,"-38",56,NA,"omicron",NA,NA,NA,1782,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","06/07/2022",2022-07-06
"1729",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","84+","hospitalization","severe","Finland",">= 70 years",">= 70 years",61,"34",77,NA,"omicron",NA,NA,NA,1783,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","06/07/2022",2022-07-06
"1730",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-90","hospitalization","severe","Finland",">= 70 years",">= 70 years",91,"83",95,NA,"omicron","~56 weeks",NA,NA,1784,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","06/07/2022",2022-07-06
"1731",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","181+","hospitalization","severe","Finland",">= 70 years",">= 70 years",58,"48",66,NA,"omicron","~56 weeks",NA,NA,1785,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","06/07/2022",2022-07-06
"1732",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","1","1","21-83","hospitalization","severe","Finland",">= 70 years",">= 70 years",81,"-33",97,NA,"omicron",NA,NA,NA,1786,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","06/07/2022",2022-07-06
"1733",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","1","1","84+","hospitalization","severe","Finland",">= 70 years",">= 70 years",23,"-63",64,NA,"omicron",NA,NA,NA,1787,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","06/07/2022",2022-07-06
"1734",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","2","final","14-90","hospitalization","severe","Finland",">= 70 years",">= 70 years",79,"43",92,NA,"omicron","~56 weeks",NA,NA,1788,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","06/07/2022",2022-07-06
"1735",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","2","final","181+","hospitalization","severe","Finland",">= 70 years",">= 70 years",60,"34",75,NA,"omicron","~56 weeks",NA,NA,1789,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","06/07/2022",2022-07-06
"1736",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","1","1","84+","hospitalization","severe","Finland",">= 70 years",">= 70 years",100,NA,NA,NA,"omicron",NA,NA,NA,1790,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","06/07/2022",2022-07-06
"1737",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","2","final","91-180","hospitalization","severe","Finland",">= 70 years",">= 70 years",37,"-154",85,NA,"omicron",NA,NA,NA,1791,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","06/07/2022",2022-07-06
"1738",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","2","final","181+","hospitalization","severe","Finland",">= 70 years",">= 70 years",51,"12",73,NA,"omicron","~56 weeks",NA,NA,1792,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","06/07/2022",2022-07-06
"1739",204,"Jara","Retrospective cohort","23May2022","CoronaVac (Sinovac)","excluded","2","final","14+","infection","infection","Chile","3-5 years","3-5 years",37.9,"36.1",39.6,"omicron","omicron","~12 weeks",NA,NA,1793,"Chile","CHL",204,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2022-05-23,"infection","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron","15/03/2022",2022-03-15
"1740",204,"Jara","Retrospective cohort","23May2022","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Chile","3-5 years","3-5 years",65.2,"50.4",75.6,"omicron","omicron","~12 weeks",NA,NA,1794,"Chile","CHL",204,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2022-05-23,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron","15/03/2022",2022-03-15
"1741",204,"Jara","Retrospective cohort","23May2022","CoronaVac (Sinovac)","excluded","2","final","14+","ICU admission","severe","Chile","3-5 years","3-5 years",68.8,"18",88.1,"omicron","omicron","~12 weeks",NA,NA,1795,"Chile","CHL",204,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2022-05-23,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron","15/03/2022",2022-03-15
"1742",205,"Rearte","Test-negative case-control","15Mar2022","AZD1222 (AstraZeneca)","excluded","1","1","21+","infection","infection","Argentina",">= 18 years","general pop",39.9,"39",41,NA,"alpha, gamma, & delta",NA,NA,NA,1796,"Argentina","ARG",205,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-15,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-15
"1743",205,"Rearte","Test-negative case-control","15Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","21+","infection","infection","Argentina",">= 18 years","general pop",68.5,"67",69,NA,"alpha, gamma, & delta","~26 weeks",NA,NA,1797,"Argentina","ARG",205,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-15,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-15
"1744",205,"Rearte","Test-negative case-control","15Mar2022","AZD1222 (AstraZeneca)","excluded","1","1","21+","death","death","Argentina",">= 18 years","general pop",83.1,"82.3",83.9,NA,"alpha, gamma, & delta",NA,NA,NA,1798,"Argentina","ARG",205,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-15,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-15
"1745",205,"Rearte","Test-negative case-control","15Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","21+","death","death","Argentina",">= 18 years","general pop",93.7,"93.2",94.3,NA,"alpha, gamma, & delta","~26 weeks",NA,NA,1799,"Argentina","ARG",205,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-15,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-15
"1746",205,"Rearte","Test-negative case-control","15Mar2022","BBIBP-CorV (Beijing CNBG)","excluded","1","1","21+","infection","infection","Argentina",">= 18 years","general pop",22.6,"20",25,NA,"alpha, gamma, & delta",NA,NA,NA,1800,"Argentina","ARG",205,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-15,"infection","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2022-03-15
"1747",205,"Rearte","Test-negative case-control","15Mar2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","21+","infection","infection","Argentina",">= 18 years","general pop",43.6,"42",45,NA,"alpha, gamma, & delta","~26 weeks",NA,NA,1801,"Argentina","ARG",205,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-15,"infection","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2022-03-15
"1748",205,"Rearte","Test-negative case-control","15Mar2022","BBIBP-CorV (Beijing CNBG)","excluded","1","1","21+","death","death","Argentina",">= 18 years","general pop",70.4,"68.1",72.8,NA,"alpha, gamma, & delta",NA,NA,NA,1802,"Argentina","ARG",205,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-15,"death","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2022-03-15
"1749",205,"Rearte","Test-negative case-control","15Mar2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","21+","death","death","Argentina",">= 18 years","general pop",85,"84",86,NA,"alpha, gamma, & delta","~26 weeks",NA,NA,1803,"Argentina","ARG",205,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-15,"death","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2022-03-15
"1750",205,"Rearte","Test-negative case-control","15Mar2022","Gam-COVID-Vac (Gamaleya)","excluded","1","1","21+","infection","infection","Argentina",">= 18 years","general pop",39.5,"39",40,NA,"alpha, gamma, & delta",NA,NA,NA,1804,"Argentina","ARG",205,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-15,"infection","2022 (Jan-Jun)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-03-15
"1751",205,"Rearte","Test-negative case-control","15Mar2022","Gam-COVID-Vac (Gamaleya)","excluded","2","final","21+","infection","infection","Argentina",">= 18 years","general pop",64,"63",65,NA,"alpha, gamma, & delta","~26 weeks",NA,NA,1805,"Argentina","ARG",205,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-15,"infection","2022 (Jan-Jun)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-03-15
"1752",205,"Rearte","Test-negative case-control","15Mar2022","Gam-COVID-Vac (Gamaleya)","excluded","1","1","21+","death","death","Argentina",">= 18 years","general pop",81.1,"80.5",81.7,NA,"alpha, gamma, & delta",NA,NA,NA,1806,"Argentina","ARG",205,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-15,"death","2022 (Jan-Jun)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-03-15
"1753",205,"Rearte","Test-negative case-control","15Mar2022","Gam-COVID-Vac (Gamaleya)","excluded","2","final","21+","death","death","Argentina",">= 18 years","general pop",93.1,"92.6",93.5,NA,"alpha, gamma, & delta","~26 weeks",NA,NA,1807,"Argentina","ARG",205,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-15,"death","2022 (Jan-Jun)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-03-15
"1754",206,"Can","Retrospective cohort","19Mar2022","CoronaVac (Sinovac)","excluded","2","final","14+","infection","infection","Turkey","HCW","HCW",39,"20",54,NA,"alpha","13 weeks",NA,NA,1808,"Turkey","TUR",206,"TUR",9800,2019,"Türkiye","Europe & Central Asia","Upper middle income",3,"Asia",2021-01-14,2021-08-19,NA,NA,2021-01-14,NA,217,NA,"owid","jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-03-19,"infection","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","alpha",NA,2022-03-19
"1755",207,"Altarawneh","Test-negative case-control","15Jun2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",51.7,"43.5",58.7,"omicron BA.1","omicron BA.1","44 weeks",NA,NA,1809,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","31/03/2022",2022-03-31
"1756",207,"Altarawneh","Test-negative case-control","15Jun2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",96.2,"37.7",99.8,"omicron BA.1","omicron BA.1","44 weeks",NA,NA,1810,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","31/03/2022",2022-03-31
"1757",207,"Altarawneh","Test-negative case-control","15Jun2022","mRNA-1273 (Moderna)","previously infected only","2","final","14+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",44.3,"30.4",55.4,"omicron BA.1","omicron BA.1","44 weeks",NA,NA,1811,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","31/03/2022",2022-03-31
"1758",207,"Altarawneh","Test-negative case-control","15Jun2022","mRNA-1273 (Moderna)","previously infected only","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",100,"-51.5",100,"omicron BA.1","omicron BA.1","44 weeks",NA,NA,1812,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","31/03/2022",2022-03-31
"1759",207,"Altarawneh","Test-negative case-control","15Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",-4.9,"-16.4",5.4,"omicron BA.1","omicron BA.1","44 weeks",NA,NA,1813,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","31/03/2022",2022-03-31
"1760",207,"Altarawneh","Test-negative case-control","15Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",96.8,"71.1",99.6,"omicron BA.1","omicron BA.1","44 weeks",NA,NA,1814,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","31/03/2022",2022-03-31
"1761",207,"Altarawneh","Test-negative case-control","15Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",-2.7,"-16.8",9.7,"omicron BA.1","omicron BA.1","44 weeks",NA,NA,1815,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","31/03/2022",2022-03-31
"1762",207,"Altarawneh","Test-negative case-control","15Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",88.8,"-1.7",98.8,"omicron BA.1","omicron BA.1","44 weeks",NA,NA,1816,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","31/03/2022",2022-03-31
"1763",207,"Altarawneh","Test-negative case-control","15Jun2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",55.1,"50.9",58.9,"omicron BA.2","omicron BA.2","44 weeks",NA,NA,1817,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","31/03/2022",2022-03-31
"1764",207,"Altarawneh","Test-negative case-control","15Jun2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",97.8,"82.6",99.7,"omicron BA.2","omicron BA.2","44 weeks",NA,NA,1818,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","31/03/2022",2022-03-31
"1765",207,"Altarawneh","Test-negative case-control","15Jun2022","mRNA-1273 (Moderna)","previously infected only","2","final","14+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",47.9,"40.8",54.1,"omicron BA.2","omicron BA.2","44 weeks",NA,NA,1819,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","31/03/2022",2022-03-31
"1766",207,"Altarawneh","Test-negative case-control","15Jun2022","mRNA-1273 (Moderna)","previously infected only","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",100,"55.4",100,"omicron BA.2","omicron BA.2","44 weeks",NA,NA,1820,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","31/03/2022",2022-03-31
"1767",207,"Altarawneh","Test-negative case-control","15Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",-1.1,"-7.1",4.6,"omicron BA.2","omicron BA.2","44 weeks",NA,NA,1821,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","31/03/2022",2022-03-31
"1768",207,"Altarawneh","Test-negative case-control","15Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",76.8,"58",87.1,"omicron BA.2","omicron BA.2","44 weeks",NA,NA,1822,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","31/03/2022",2022-03-31
"1769",207,"Altarawneh","Test-negative case-control","15Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",-7.3,"-15.6",0.3,"omicron BA.2","omicron BA.2","44 weeks",NA,NA,1823,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","31/03/2022",2022-03-31
"1770",207,"Altarawneh","Test-negative case-control","15Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",84.8,"47.9",95.6,"omicron BA.2","omicron BA.2","44 weeks",NA,NA,1824,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","31/03/2022",2022-03-31
"1771",207,"Altarawneh","Test-negative case-control","15Jun2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",55.5,"51.8",59,"omicron","omicron","44 weeks",NA,NA,1825,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","31/03/2022",2022-03-31
"1772",207,"Altarawneh","Test-negative case-control","15Jun2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",94.3,"81.3",98.3,"omicron","omicron","44 weeks",NA,NA,1826,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","31/03/2022",2022-03-31
"1773",207,"Altarawneh","Test-negative case-control","15Jun2022","mRNA-1273 (Moderna)","previously infected only","2","final","14+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",52,"45.8",57.4,"omicron","omicron","44 weeks",NA,NA,1827,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","31/03/2022",2022-03-31
"1774",207,"Altarawneh","Test-negative case-control","15Jun2022","mRNA-1273 (Moderna)","previously infected only","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",100,NA,NA,"omicron","omicron","44 weeks",NA,NA,1828,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","31/03/2022",2022-03-31
"1775",207,"Altarawneh","Test-negative case-control","15Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",-0.2,"-5.5",4.9,"omicron","omicron","44 weeks",NA,NA,1829,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","31/03/2022",2022-03-31
"1776",207,"Altarawneh","Test-negative case-control","15Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",73.5,"60.5",82.2,"omicron","omicron","44 weeks",NA,NA,1830,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","31/03/2022",2022-03-31
"1777",207,"Altarawneh","Test-negative case-control","15Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","Qatar",">= 18 years","general pop",2.2,"-4.6",8.5,"omicron","omicron","44 weeks",NA,NA,1831,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","31/03/2022",2022-03-31
"1778",207,"Altarawneh","Test-negative case-control","15Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",66.3,"38.3",81.6,"omicron","omicron","44 weeks",NA,NA,1832,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","31/03/2022",2022-03-31
"1779",208,"Kaura","Retrospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-84","Infection","infection","UK",">= 16 years","general pop",31,"14",45,NA,"alpha",NA,NA,NA,1833,"UK","GBR",208,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-03-12
"1780",208,"Kaura","Retrospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-84","hospitalization","severe","UK",">= 16 years","general pop",75,"45",91,NA,"alpha",NA,NA,NA,1834,"UK","GBR",208,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-03-12
"1781",208,"Kaura","Retrospective cohort","12Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-84","death","death","UK",">= 16 years","general pop",86,"42",98,NA,"alpha",NA,NA,NA,1835,"UK","GBR",208,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-03-12
"1782",208,"Kaura","Retrospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","1","1","14-84","Infection","infection","UK",">= 16 years","general pop",15,"-5",31,NA,"alpha",NA,NA,NA,1836,"UK","GBR",208,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2022-03-12
"1783",208,"Kaura","Retrospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","1","1","14-84","hospitalization","severe","UK",">= 16 years","general pop",75,"45",91,NA,"alpha",NA,NA,NA,1837,"UK","GBR",208,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2022-03-12
"1784",208,"Kaura","Retrospective cohort","12Mar2022","AZD1222 (AstraZeneca)","excluded","1","1","14-84","death","death","UK",">= 16 years","general pop",86,"42",98,NA,"alpha",NA,NA,NA,1838,"UK","GBR",208,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-03-12,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2022-03-12
"1785",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-42","infection","infection","UK","18-39 years","18-39 years",76,"75",77,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1839,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1786",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","161-182","infection","infection","UK","18-39 years","18-39 years",-53,"-118",-7,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1840,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1787",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-42","hospitalization","severe","UK","18-39 years","18-39 years",96,"94",98,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1841,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1788",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","133-154","hospitalization","severe","UK","18-39 years","18-39 years",82,"71",90,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1842,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1789",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-42","infection","infection","UK","40-64 years","40-64 years",73,"69",77,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1843,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1790",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","161-182","infection","infection","UK","40-64 years","40-64 years",-3,"-15",7,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1844,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1791",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","21-42","infection","infection","UK","40-64 years","40-64 years",21,"18",24,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1845,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1792",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","161-182","infection","infection","UK","40-64 years","40-64 years",-99,"-105",-94,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1846,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1793",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","21-42","hospitalization","severe","UK","40-64 years","40-64 years",95,"93",96,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1847,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1794",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","161-182","hospitalization","severe","UK","40-64 years","40-64 years",86,"83",88,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1848,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1795",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","105-126","death","death","UK","40-64 years","40-64 years",55,"-5",81,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1849,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1796",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","161-182","death","death","UK","40-64 years","40-64 years",41,"-7",68,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1850,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1797",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-42","infection","infection","UK","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years",34,"30",39,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1851,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1798",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","161-182","infection","infection","UK","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years",4,"-1",8,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1852,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1799",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","49-70","hospitalization","severe","UK","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years",95,"94",97,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1853,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1800",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","161-182","hospitalization","severe","UK","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years",91,"88",93,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1854,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1801",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","77-98","death","death","UK","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years",96,"91",98,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1855,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1802",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","161-182","death","death","UK","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years",92,"86",96,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1856,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1803",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","21-42","infection","infection","UK","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years",34,"30",39,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1857,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1804",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","161-182","infection","infection","UK","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years",-45,"-50",-40,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1858,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1805",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","21-42","hospitalization","severe","UK","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years",92,"88",95,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1859,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1806",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","161-182","hospitalization","severe","UK","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years",75,"71",78,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1860,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1807",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","77-98","death","death","UK","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years",92,"88",95,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1861,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1808",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","161-182","death","death","UK","clinically vulnerable 16-64 years","clinically vulnerable 16-64 years",87,"81",92,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1862,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1809",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-42","infection","infection","UK",">= 65 years",">= 65 years",81,"74",86,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1863,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1810",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","161-182","infection","infection","UK",">= 65 years",">= 65 years",15,"8",22,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1864,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1811",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-42","hospitalization","severe","UK",">= 65 years",">= 65 years",91,"86",95,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1865,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1812",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","161-182","hospitalization","severe","UK",">= 65 years",">= 65 years",80,"76",82,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1866,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1813",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-42","death","death","UK",">= 65 years",">= 65 years",98,"93",99,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1867,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1814",209,"Horne","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","161-182","death","death","UK",">= 65 years",">= 65 years",88,"84",91,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1868,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","23/03/2022",2022-03-23
"1815",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","21-42","infection","infection","UK",">= 65 years",">= 65 years",53,"41",62,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1869,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1816",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","161-182","infection","infection","UK",">= 65 years",">= 65 years",-21,"-30",-13,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1870,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1817",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","21-42","hospitalization","severe","UK",">= 65 years",">= 65 years",88,"85",90,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1871,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1818",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","161-182","hospitalization","severe","UK",">= 65 years",">= 65 years",75,"71",79,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1872,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1819",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","21-42","death","death","UK",">= 65 years",">= 65 years",90,"84",94,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1873,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1820",209,"Horne","Retrospective cohort","20Jul2022","AZD1222 (AstraZeneca)","excluded","2","final","161-182","death","death","UK",">= 65 years",">= 65 years",83,"77",88,NA,"alpha, delta, & omicron","~30 weeks",NA,NA,1874,"UK","GBR",209,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-20,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","23/03/2022",2022-03-23
"1821",210,"Stowe","Test-negative case-control","30Sep2022","BNT162b2 (Pfizer BioNTech)","included","1","1","28+","hospitalization with ARI","severe","UK","18-64 years","18-64 years",31.7,"-3.1",54.8,NA,"omicron",NA,NA,NA,1875,"UK","GBR",210,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/04/2022",2022-04-01
"1822",210,"Stowe","Test-negative case-control","30Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-174","hospitalization with ARI","severe","UK","18-64 years","18-64 years",73.8,"62.5",81.7,NA,"omicron","~43 weeks",NA,NA,1876,"UK","GBR",210,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/04/2022",2022-04-01
"1823",210,"Stowe","Test-negative case-control","30Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","175+","hospitalization with ARI","severe","UK","18-64 years","18-64 years",65.1,"51.3",74.9,NA,"omicron","~43 weeks",NA,NA,1877,"UK","GBR",210,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/04/2022",2022-04-01
"1824",210,"Stowe","Test-negative case-control","30Sep2022","BNT162b2 (Pfizer BioNTech)","included","1","1","0-27","hospitalization with ARI","severe","UK",">= 65 years",">= 65 years",54.8,"-25.3",83.7,NA,"omicron",NA,NA,NA,1878,"UK","GBR",210,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/04/2022",2022-04-01
"1825",210,"Stowe","Test-negative case-control","30Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-174","hospitalization with ARI","severe","UK",">= 65 years",">= 65 years",87.6,"79.4",92.5,NA,"omicron","~43 weeks",NA,NA,1879,"UK","GBR",210,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/04/2022",2022-04-01
"1826",210,"Stowe","Test-negative case-control","30Sep2022","BNT162b2 (Pfizer BioNTech)","included","1","1","28+","hospitalization with ARI","severe","UK",">= 65 years",">= 65 years",59.5,"35.5",74.6,NA,"omicron",NA,NA,NA,1880,"UK","GBR",210,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/04/2022",2022-04-01
"1827",210,"Stowe","Test-negative case-control","30Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","175+","hospitalization with ARI","severe","UK",">= 65 years",">= 65 years",65.4,"56.6",72.5,NA,"omicron","~43 weeks",NA,NA,1881,"UK","GBR",210,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/04/2022",2022-04-01
"1828",210,"Stowe","Test-negative case-control","30Sep2022","AZD1222 (AstraZeneca)","included","1","1","28+","hospitalization with ARI","severe","UK","18-64 years","18-64 years",48.5,"25.7",64.3,NA,"omicron",NA,NA,NA,1882,"UK","GBR",210,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","01/04/2022",2022-04-01
"1829",210,"Stowe","Test-negative case-control","30Sep2022","AZD1222 (AstraZeneca)","included","2","final","14-174","hospitalization with ARI","severe","UK","18-64 years","18-64 years",59,"31.9",75.3,NA,"omicron","~43 weeks",NA,NA,1883,"UK","GBR",210,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","01/04/2022",2022-04-01
"1830",210,"Stowe","Test-negative case-control","30Sep2022","AZD1222 (AstraZeneca)","included","2","final","175+","hospitalization with ARI","severe","UK","18-64 years","18-64 years",53,"41.7",62,NA,"omicron","~43 weeks",NA,NA,1884,"UK","GBR",210,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","01/04/2022",2022-04-01
"1831",210,"Stowe","Test-negative case-control","30Sep2022","AZD1222 (AstraZeneca)","included","1","1","28+","hospitalization with ARI","severe","UK",">= 65 years",">= 65 years",48.1,"23.5",64.8,NA,"omicron",NA,NA,NA,1885,"UK","GBR",210,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","01/04/2022",2022-04-01
"1832",210,"Stowe","Test-negative case-control","30Sep2022","AZD1222 (AstraZeneca)","included","2","final","14-174","hospitalization with ARI","severe","UK",">= 65 years",">= 65 years",71.2,"50",83.4,NA,"omicron","~43 weeks",NA,NA,1886,"UK","GBR",210,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","01/04/2022",2022-04-01
"1833",210,"Stowe","Test-negative case-control","30Sep2022","AZD1222 (AstraZeneca)","included","2","final","175+","hospitalization with ARI","severe","UK",">= 65 years",">= 65 years",53.1,"43.4",61.2,NA,"omicron","~43 weeks",NA,NA,1887,"UK","GBR",210,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","01/04/2022",2022-04-01
"1834",211,"Tenforde","Case-control","25Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","invasive mechanical ventilation or in-hospital death","severe","USA","hospitalized patients","general pop",79,"66",87,NA,"omicron","~45 weeks",NA,NA,1888,"USA","USA",211,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-25,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-03-25
"1835",211,"Tenforde","Case-control","25Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","invasive mechanical ventilation or in-hospital death","severe","USA","hospitalized patients","general pop",88,"86",90,NA,"delta","~45 weeks",NA,NA,1889,"USA","USA",211,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-25,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-03-25
"1836",211,"Tenforde","Case-control","25Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-150","invasive mechanical ventilation or in-hospital death","severe","USA","hospitalized patients","general pop",92,"90",94,NA,"alpha","~45 weeks",NA,NA,1890,"USA","USA",211,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-25,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-03-25
"1837",211,"Tenforde","Case-control","25Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final",">150","invasive mechanical ventilation or in-hospital death","severe","USA","hospitalized patients","general pop",84,"80",87,NA,"alpha","~45 weeks",NA,NA,1891,"USA","USA",211,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-25,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-03-25
"1838",212,"Veneti","Retrospective cohort","07Mar2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-34","infection","infection","Norway","16-17 years","16-17 years",53.1,"42.6",61.7,NA,"omicron","~12 weeks",NA,NA,1892,"Norway","NOR",212,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/03/2022",2022-03-25
"1839",212,"Veneti","Retrospective cohort","07Mar2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","63+","infection","infection","Norway","16-17 years","16-17 years",23.3,"2.7",39.5,NA,"omicron","~12 weeks",NA,NA,1893,"Norway","NOR",212,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/03/2022",2022-03-25
"1840",212,"Veneti","Retrospective cohort","07Mar2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-34","infection","infection","Norway","16-17 years","16-17 years",90.8,"89.1",92.3,NA,"delta","~12 weeks",NA,NA,1894,"Norway","NOR",212,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/03/2022",2022-03-25
"1841",212,"Veneti","Retrospective cohort","07Mar2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","63+","infection","infection","Norway","16-17 years","16-17 years",83.7,"75.9",89,NA,"delta","~12 weeks",NA,NA,1895,"Norway","NOR",212,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","25/03/2022",2022-03-25
"1842",213,"Wang","Test-negative case-control","23Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-179","infection","infection","USA","patients","general pop",26,"22",30,NA,"omicron","~23.5 weeks",NA,NA,1896,"USA","USA",213,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-11-23,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","25/03/2022",2022-03-25
"1843",213,"Wang","Test-negative case-control","23Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","infection","infection","USA","patients","general pop",7,"4",10,NA,"omicron","54 weeks",NA,NA,1897,"USA","USA",213,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-11-23,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","25/03/2022",2022-03-25
"1844",213,"Wang","Test-negative case-control","23Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-179","infection","infection","USA","patients","general pop",70,"68",72,NA,"delta","~23.5 weeks",NA,NA,1898,"USA","USA",213,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-11-23,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","25/03/2022",2022-03-25
"1845",213,"Wang","Test-negative case-control","23Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","infection","infection","USA","patients","general pop",53,"52",55,NA,"delta","54 weeks",NA,NA,1899,"USA","USA",213,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-11-23,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","25/03/2022",2022-03-25
"1846",214,"Natarajan","Test-negative case-control","29Mar2022","Ad26.COV2.S (Janssen)","included","1","final","14+","ED or UC visit","symptomatic","USA","ED/UC encounters or hospitalization among adults with COVID-19 like illness","ED/UC encounters or hospitalization among adults with COVID-19 like illness",24,"18",29,NA,"omicron","40 weeks",NA,NA,1900,"USA","USA",214,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-29,"symptomatic","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2022-03-29
"1847",214,"Natarajan","Test-negative case-control","29Mar2022","Ad26.COV2.S (Janssen)","included","1","final","14+","hospitalization","severe","USA","ED/UC encounters or hospitalization among adults with COVID-19 like illness","ED/UC encounters or hospitalization among adults with COVID-19 like illness",31,"21",40,NA,"omicron","40 weeks",NA,NA,1901,"USA","USA",214,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-29,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2022-03-29
"1848",215,"Hansen","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-30","infection","infection","Denmark",">= 12 years","general pop",37,"35.6",38.3,NA,"omicron","~2 weeks",NA,NA,1902,"Denmark","DNK",215,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-30
"1849",215,"Hansen","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","121+","infection","infection","Denmark",">= 12 years","general pop",9.8,"9.2",10.4,NA,"omicron","~30 weeks",NA,NA,1903,"Denmark","DNK",215,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-30
"1850",215,"Hansen","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-30","hospitalization","severe","Denmark",">= 12 years","general pop",50.5,"33.9",63,NA,"omicron","~2 weeks",NA,NA,1904,"Denmark","DNK",215,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-30
"1851",215,"Hansen","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","121+","hospitalization","severe","Denmark",">= 12 years","general pop",51.6,"47.2",55.6,NA,"omicron","~30 weeks",NA,NA,1905,"Denmark","DNK",215,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-30
"1852",215,"Hansen","Retrospective cohort","30Mar2022","mRNA-1273 (Moderna)","excluded","2","final","14-30","infection","infection","Denmark",">= 12 years","general pop",37.9,"34.4",41.2,NA,"omicron","~2 weeks",NA,NA,1906,"Denmark","DNK",215,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2022-03-30
"1853",215,"Hansen","Retrospective cohort","30Mar2022","mRNA-1273 (Moderna)","excluded","2","final","121+","infection","infection","Denmark",">= 12 years","general pop",13.2,"12.3",14.2,NA,"omicron","~30 weeks",NA,NA,1907,"Denmark","DNK",215,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2022-03-30
"1854",216,"Price","Test-negative case-control","30Mar2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA","12-18 years","12-18 years",40,"9",60,NA,"omicron","~42 weeks",NA,NA,1908,"USA","USA",216,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-30
"1855",216,"Price","Test-negative case-control","30Mar2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-160","hospitalization","severe","USA","12-18 years","12-18 years",43,"-1",68,NA,"omicron","~20 weeks",NA,NA,1909,"USA","USA",216,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-30
"1856",216,"Price","Test-negative case-control","30Mar2022","BNT162b2 (Pfizer BioNTech)","included","2","final","161-314","hospitalization","severe","USA","12-18 years","12-18 years",38,"-3",62,NA,"omicron","~42 weeks",NA,NA,1910,"USA","USA",216,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-30
"1857",216,"Price","Test-negative case-control","30Mar2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA","5-11 years","5-11 years",68,"42",82,NA,"omicron","~11 weeks",NA,NA,1911,"USA","USA",216,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-03-30
"1858",216,"Price","Test-negative case-control","30Mar2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA","12-18 years","12-18 years",92,"89",95,NA,"delta","~42 weeks",NA,NA,1912,"USA","USA",216,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-30
"1859",216,"Price","Test-negative case-control","30Mar2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-160","hospitalization","severe","USA","12-18 years","12-18 years",93,"89",95,NA,"delta","~20 weeks",NA,NA,1913,"USA","USA",216,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-30
"1860",216,"Price","Test-negative case-control","30Mar2022","BNT162b2 (Pfizer BioNTech)","included","2","final","161-314","hospitalization","severe","USA","12-18 years","12-18 years",92,"80",97,NA,"delta","~42 weeks",NA,NA,1914,"USA","USA",216,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-03-30
"1861",217,"Marra","Retrospective cohort","30Mar2022","CoronaVac (Sinovac)","excluded","2","final","14+","Infection","infection","Brazil","HCW","HCW",51.3,"34.6",63.7,NA,"gamma","~23 weeks",NA,NA,1915,"Brazil","BRA",217,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","gamma",NA,2022-03-30
"1862",217,"Marra","Retrospective cohort","30Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","Infection","infection","Brazil","HCW","HCW",88.1,"82.8",91.7,NA,"gamma","~15 weeks",NA,NA,1916,"Brazil","BRA",217,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma",NA,2022-03-30
"1863",218,"Starrfelt","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21+","Infection","infection","Norway",">= 18 years","general pop",15.5,"12.9",18,NA,"delta",NA,NA,NA,1917,"Norway","NOR",218,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","30/03/2022",2022-03-30
"1864",218,"Starrfelt","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","2-9 weeks","Infection","infection","Norway",">= 18 years","general pop",77.7,"76.8",78.5,NA,"delta","~7 weeks",NA,NA,1918,"Norway","NOR",218,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","30/03/2022",2022-03-30
"1865",218,"Starrfelt","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">33 weeks","Infection","infection","Norway",">= 18 years","general pop",8.2,"3.4",12.8,NA,"delta","~43 weeks",NA,NA,1919,"Norway","NOR",218,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","30/03/2022",2022-03-30
"1866",218,"Starrfelt","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","21+","hospitalization","severe","Norway",">= 18 years","general pop",75.3,"66.4",81.9,NA,"delta",NA,NA,NA,1920,"Norway","NOR",218,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","30/03/2022",2022-03-30
"1867",218,"Starrfelt","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","2-9 weeks","hospitalization","severe","Norway",">= 18 years","general pop",97.5,"95.6",98.6,NA,"delta","~7 weeks",NA,NA,1921,"Norway","NOR",218,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","30/03/2022",2022-03-30
"1868",218,"Starrfelt","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">33 weeks","hospitalization","severe","Norway",">= 18 years","general pop",63.9,"54.3",71.5,NA,"delta","~43 weeks",NA,NA,1922,"Norway","NOR",218,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","30/03/2022",2022-03-30
"1869",218,"Starrfelt","Retrospective cohort","30Mar2022","mRNA-1273 (Moderna)","excluded","1","1","21+","Infection","infection","Norway",">= 18 years","general pop",38.1,"34.7",41.3,NA,"delta",NA,NA,NA,1923,"Norway","NOR",218,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","30/03/2022",2022-03-30
"1870",218,"Starrfelt","Retrospective cohort","30Mar2022","mRNA-1273 (Moderna)","excluded","2","final","2-9 weeks","Infection","infection","Norway",">= 18 years","general pop",86.6,"85.6",87.6,NA,"delta","~7 weeks",NA,NA,1924,"Norway","NOR",218,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","30/03/2022",2022-03-30
"1871",218,"Starrfelt","Retrospective cohort","30Mar2022","mRNA-1273 (Moderna)","excluded","2","final",">33 weeks","Infection","infection","Norway",">= 18 years","general pop",28.6,"9.6",43.6,NA,"delta","~43 weeks",NA,NA,1925,"Norway","NOR",218,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","30/03/2022",2022-03-30
"1872",218,"Starrfelt","Retrospective cohort","30Mar2022","mRNA-1273 (Moderna)","excluded","1","1","21+","hospitalization","severe","Norway",">= 18 years","general pop",77.1,"58.9",87.3,NA,"delta",NA,NA,NA,1926,"Norway","NOR",218,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","30/03/2022",2022-03-30
"1873",218,"Starrfelt","Retrospective cohort","30Mar2022","mRNA-1273 (Moderna)","excluded","2","final","18-25 weeks","hospitalization","severe","Norway",">= 18 years","general pop",95.3,"91.5",97.4,NA,"delta","~23 weeks",NA,NA,1927,"Norway","NOR",218,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","30/03/2022",2022-03-30
"1874",218,"Starrfelt","Retrospective cohort","30Mar2022","mRNA-1273 (Moderna)","excluded","2","final","26-33 weeks","hospitalization","severe","Norway",">= 18 years","general pop",91.1,"84.9",94.8,NA,"delta","~31 weeks",NA,NA,1928,"Norway","NOR",218,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","30/03/2022",2022-03-30
"1875",218,"Starrfelt","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","2-9 weeks","Infection","infection","Norway",">= 18 years","general pop",84.1,"83.2",85,NA,"delta","~7 weeks",NA,NA,1929,"Norway","NOR",218,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","30/03/2022",2022-03-30
"1876",218,"Starrfelt","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","18-25 weeks","Infection","infection","Norway",">= 18 years","general pop",40.7,"23.9",53.8,NA,"delta","~23 weeks",NA,NA,1930,"Norway","NOR",218,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","30/03/2022",2022-03-30
"1877",219,"Pardo-Seco","Test-negative case-control","29Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","14-20","Infection","infection","Spain",">= 18 years","general pop",67.7,"64.6",70.6,NA,"non-VOC & alpha",NA,NA,NA,1931,"Spain","ESP",219,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-29,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-03-29
"1878",219,"Pardo-Seco","Test-negative case-control","29Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","Infection","infection","Spain",">= 18 years","general pop",90.8,"88.6",92.7,NA,"non-VOC & alpha","~7.5 weeks",NA,NA,1932,"Spain","ESP",219,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-29,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-03-29
"1879",220,"Nordstrom","Retrospective cohort","31Mar2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected only","2","final","14+","Infection","infection","Sweden",">= 18 years","general pop",68,"63",72,NA,"non-VOC, alpha, & delta","~38 weeks",NA,NA,1933,"Sweden","SWE",220,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-31,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-03-31
"1880",220,"Nordstrom","Retrospective cohort","31Mar2022","AZD1222 (AstraZeneca)","previously infected only","2","final","14+","Infection","infection","Sweden",">= 18 years","general pop",25,"-37",59,NA,"non-VOC, alpha, & delta","~38 weeks",NA,NA,1934,"Sweden","SWE",220,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-31,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-31
"1881",221,"Ranzani","Test-negative case-control","16Aug2022","CoronaVac (Sinovac)","included","2","final","14-59","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",28.1,"26.5",29.6,NA,"omicron","~10 weeks",NA,NA,1935,"Brazil","BRA",221,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-16,"symptomatic","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","16/08/2022",2022-08-16
"1882",221,"Ranzani","Test-negative case-control","16Aug2022","CoronaVac (Sinovac)","included","2","final","180+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",6.3,"5.3",7.3,NA,"omicron","~59 weeks",NA,NA,1936,"Brazil","BRA",221,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-16,"symptomatic","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","16/08/2022",2022-08-16
"1883",221,"Ranzani","Test-negative case-control","16Aug2022","CoronaVac (Sinovac)","included","2","final","14-59","hospitalization or death","severe","Brazil",">= 18 years","general pop",56.1,"40.6",67.5,NA,"omicron","~10 weeks",NA,NA,1937,"Brazil","BRA",221,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-16,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","16/08/2022",2022-08-16
"1884",221,"Ranzani","Test-negative case-control","16Aug2022","CoronaVac (Sinovac)","included","2","final","180+","hospitalization or death","severe","Brazil",">= 18 years","general pop",57.6,"54.4",60.6,NA,"omicron","~59 weeks",NA,NA,1938,"Brazil","BRA",221,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-16,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","16/08/2022",2022-08-16
"1885",221,"Ranzani","Test-negative case-control","16Aug2022","CoronaVac (Sinovac)","included","2","final","14-59","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",51.3,"49.9",52.7,NA,"delta","~10 weeks",NA,NA,1939,"Brazil","BRA",221,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-16,"symptomatic","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta","16/08/2022",2022-08-16
"1886",221,"Ranzani","Test-negative case-control","16Aug2022","CoronaVac (Sinovac)","included","2","final","180+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",34,"49.9",52.7,NA,"delta","~59 weeks",NA,NA,1940,"Brazil","BRA",221,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-16,"symptomatic","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta","16/08/2022",2022-08-16
"1887",221,"Ranzani","Test-negative case-control","16Aug2022","CoronaVac (Sinovac)","included","2","final","14-59","hospitalization or death","severe","Brazil",">= 18 years","general pop",86.5,"83.4",88.9,NA,"delta","~10 weeks",NA,NA,1941,"Brazil","BRA",221,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-16,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta","16/08/2022",2022-08-16
"1888",221,"Ranzani","Test-negative case-control","16Aug2022","CoronaVac (Sinovac)","included","2","final","180+","hospitalization or death","severe","Brazil",">= 18 years","general pop",60.9,"57.3",64.2,NA,"delta","~59 weeks",NA,NA,1942,"Brazil","BRA",221,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-16,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta","16/08/2022",2022-08-16
"1889",222,"Florentino","Test-negative case-control","08Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-27","symptomatic disease","symptomatic","Brazil","12-17 years","12-17 years",64.7,"63",66.3,NA,"omicron","2 weeks",NA,NA,1943,"Brazil","BRA",222,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-08,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","05/04/2022",2022-04-05
"1890",222,"Florentino","Test-negative case-control","08Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","98+","symptomatic disease","symptomatic","Brazil","12-17 years","12-17 years",5.9,"2.2",9.4,NA,"omicron","~21 weeks",NA,NA,1944,"Brazil","BRA",222,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-08,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","05/04/2022",2022-04-05
"1891",222,"Florentino","Test-negative case-control","08Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-27","severe disease","severe","Brazil","12-17 years","12-17 years",75.6,"58.1",85.8,NA,"omicron","2 weeks",NA,NA,1945,"Brazil","BRA",222,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-08,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","05/04/2022",2022-04-05
"1892",222,"Florentino","Test-negative case-control","08Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","98+","severe disease","severe","Brazil","12-17 years","12-17 years",82.7,"68.8",90.4,NA,"omicron","~21 weeks",NA,NA,1946,"Brazil","BRA",222,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-08,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","05/04/2022",2022-04-05
"1893",222,"Florentino","Test-negative case-control","08Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-27","symptomatic disease","symptomatic","Brazil","12-17 years","12-17 years",80.7,"77.8",83.3,NA,"delta","2 weeks",NA,NA,1947,"Brazil","BRA",222,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-08,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","05/04/2022",2022-04-05
"1894",222,"Florentino","Test-negative case-control","08Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","56-69","symptomatic disease","symptomatic","Brazil","12-17 years","12-17 years",26.6,"4.1",43.9,NA,"delta","~8 weeks",NA,NA,1948,"Brazil","BRA",222,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-08,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","05/04/2022",2022-04-05
"1895",222,"Florentino","Test-negative case-control","08Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-27","symptomatic disease","symptomatic","Scotland","12-17 years","12-17 years",82.6,"80.6",84.5,NA,"omicron","2 weeks",NA,NA,1949,"UK","GBR",501,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-08,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","05/04/2022",2022-04-05
"1896",222,"Florentino","Test-negative case-control","08Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","98+","symptomatic disease","symptomatic","Scotland","12-17 years","12-17 years",50.6,"42.7",57.4,NA,"omicron","~15.5 weeks",NA,NA,1950,"UK","GBR",501,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-08,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","05/04/2022",2022-04-05
"1897",222,"Florentino","Test-negative case-control","08Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-27","symptomatic disease","symptomatic","Scotland","12-17 years","12-17 years",92.8,"85.7",96.4,NA,"delta","2 weeks",NA,NA,1951,"UK","GBR",501,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-08,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","05/04/2022",2022-04-05
"1898",222,"Florentino","Test-negative case-control","08Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","56-69","symptomatic disease","symptomatic","Scotland","12-17 years","12-17 years",86.5,"72.2",93.4,NA,"delta","~8 weeks",NA,NA,1952,"UK","GBR",501,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-08,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","05/04/2022",2022-04-05
"1899",223,"Yoon","Prospective cohort","06Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","HCW","HCW",46,"25",61,"omicron","omicron","~21 weeks",NA,NA,1953,"USA","USA",223,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-06,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-04-06
"1900",223,"Yoon","Prospective cohort","06Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","HCW","HCW",65,"49",76,"delta","delta","~21 weeks",NA,NA,1954,"USA","USA",223,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-06,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-06
"1901",224,"Kwon","Test-negative case-control","06Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","transplant recipients","transplant recipients",29,"-19",58,NA,"alpha & delta","~37 weeks",NA,NA,1955,"USA","USA",224,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-06,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-06
"1902",224,"Kwon","Test-negative case-control","06Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","immunocompromised","immunocompromised adults",72,"64",79,NA,"alpha & delta","~37 weeks",NA,NA,1956,"USA","USA",224,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-06,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-06
"1903",224,"Kwon","Test-negative case-control","06Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","immunocompetent adults","immunocompetent adults",88,"87",90,NA,"alpha & delta","~37 weeks",NA,NA,1957,"USA","USA",224,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-06,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-06
"1904",224,"Kwon","Test-negative case-control","06Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","supplemental oxygen/oxygen support","severe","USA","transplant recipients","transplant recipients",31,"-27",63,NA,"alpha & delta","~37 weeks",NA,NA,1958,"USA","USA",224,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-06,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-06
"1905",224,"Kwon","Test-negative case-control","06Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","supplemental oxygen/oxygen support","severe","USA","immunocompromised","immunocompromised adults",73,"64",80,NA,"alpha & delta","~37 weeks",NA,NA,1959,"USA","USA",224,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-06,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-06
"1906",224,"Kwon","Test-negative case-control","06Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","supplemental oxygen/oxygen support","severe","USA","immunocompetent adults","immunocompetent adults",90,"89",92,NA,"alpha & delta","~37 weeks",NA,NA,1960,"USA","USA",224,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-06,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-06
"1907",225,"Paraguay Ministry of Health and Social Welfare","Test-negative case-control","22Mar2022","BBV152 (Bharat)","excluded","2","final","14+","hospitalization with SARI","severe","Paraguay","patients >=16 years with severe acute respiratory infection","general pop",27.7,"-10.2",52.6,NA,"gamma & delta","~38 weeks",NA,NA,1961,"Paraguay","PRY",225,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2022-03-22,"severe","2022 (Jan-Jun)","Bharat Covaxin/BBV152","Inactivated","other combinations",NA,2022-03-22
"1908",225,"Paraguay Ministry of Health and Social Welfare","Test-negative case-control","22Mar2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","hospitalization with SARI","severe","Paraguay","patients >=16 years with severe acute respiratory infection","general pop",85.8,"70.6",93.1,NA,"gamma & delta","~38 weeks",NA,NA,1962,"Paraguay","PRY",225,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2022-03-22,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-03-22
"1909",225,"Paraguay Ministry of Health and Social Welfare","Test-negative case-control","22Mar2022","Hayat-Vax (Julphar)","excluded","2","final","14+","hospitalization with SARI","severe","Paraguay","patients >=16 years with severe acute respiratory infection","general pop",56.4,"15.5",77.6,NA,"gamma & delta","~38 weeks",NA,NA,1963,"Paraguay","PRY",225,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2022-03-22,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2022-03-22
"1910",225,"Paraguay Ministry of Health and Social Welfare","Test-negative case-control","22Mar2022","Gam-COVID-Vac (Gamaleya)","excluded","2","final","14+","hospitalization with SARI","severe","Paraguay","patients >=16 years with severe acute respiratory infection","general pop",77,"30.8",92.3,NA,"gamma & delta","~38 weeks",NA,NA,1964,"Paraguay","PRY",225,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2022-03-22,"severe","2022 (Jan-Jun)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-03-22
"1911",225,"Paraguay Ministry of Health and Social Welfare","Test-negative case-control","22Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization with SARI","severe","Paraguay","patients >=16 years with severe acute respiratory infection","general pop",95.4,"65.7",99.4,NA,"gamma & delta","~38 weeks",NA,NA,1965,"Paraguay","PRY",225,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2022-03-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-03-22
"1912",226,"Buchan","Test-negative case-control","07Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7-59","symptomatic disease","symptomatic","Canada","12-17 years","12-17 years",51,"38",61,"omicron","omicron","~41 weeks",NA,NA,1966,"Canada","CAN",226,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-04-07
"1913",226,"Buchan","Test-negative case-control","07Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","180+","symptomatic disease","symptomatic","Canada","12-17 years","12-17 years",29,"17",38,"omicron","omicron","~41 weeks",NA,NA,1967,"Canada","CAN",226,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-04-07
"1914",226,"Buchan","Test-negative case-control","07Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7-59","hospitalization or death","severe","Canada","12-17 years","12-17 years",76,"-10",95,"omicron","omicron","~41 weeks",NA,NA,1968,"Canada","CAN",226,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-04-07
"1915",226,"Buchan","Test-negative case-control","07Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","180+","hospitalization or death","severe","Canada","12-17 years","12-17 years",88,"77",94,"omicron","omicron","~32 weeks",NA,NA,1969,"Canada","CAN",226,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-04-07
"1916",226,"Buchan","Test-negative case-control","07Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7-59","symptomatic disease","symptomatic","Canada","12-17 years","12-17 years",97,"94",99,"delta","delta","~32 weeks",NA,NA,1970,"Canada","CAN",226,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-07
"1917",226,"Buchan","Test-negative case-control","07Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","180+","symptomatic disease","symptomatic","Canada","12-17 years","12-17 years",90,"79",95,"delta","delta","~32 weeks",NA,NA,1971,"Canada","CAN",226,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-07,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-07
"1918",227,"Kim","Test-negative case-control","29Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","symptomatic disease","symptomatic","USA",">= 18 years","general pop",45,"14",66,"omicron","omicron","~58 weeks",NA,NA,1972,"USA","USA",227,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-29,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","10/04/2022",2022-04-10
"1919",227,"Kim","Test-negative case-control","29Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","symptomatic disease","symptomatic","USA",">= 18 years","general pop",11,"-21",35,"omicron","omicron","~58 weeks",NA,NA,1973,"USA","USA",227,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-29,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","10/04/2022",2022-04-10
"1920",227,"Kim","Test-negative case-control","29Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","symptomatic disease","symptomatic","USA",">= 18 years","general pop",89,"78",94,"delta","delta","~48 weeks",NA,NA,1974,"USA","USA",227,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-29,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","10/04/2022",2022-04-10
"1921",227,"Kim","Test-negative case-control","29Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","symptomatic disease","symptomatic","USA",">= 18 years","general pop",58,"44",68,"delta","delta","~48 weeks",NA,NA,1975,"USA","USA",227,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-29,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","10/04/2022",2022-04-10
"1922",228,"Kildegard","Retrospective cohort","11Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","1","1","0-20","infection","infection","Denmark","12-17 years","12-17 years",62,"59",65,NA,"delta",NA,NA,NA,1976,"Denmark","DNK",228,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-11
"1923",228,"Kildegard","Retrospective cohort","11Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","0-59","infection","infection","Denmark","12-17 years","12-17 years",93,"93",94,NA,"delta","~13 weeks",NA,NA,1977,"Denmark","DNK",228,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-11
"1924",229,"Institute of Public Health","Test-negative case-control","12Apr2022","BNT162b2 (Pfizer BioNTech)","included","1","1","14+","hospitalization","severe","Chile",">= 18 years","general pop",53.5,"-27.3",83,NA,"gamma & delta",NA,NA,NA,1978,"Chile","CHL",229,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2022-04-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-12
"1925",229,"Institute of Public Health","Test-negative case-control","12Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","Chile",">= 18 years","general pop",85.3,"73.5",91.8,NA,"gamma & delta","~53 weeks",NA,NA,1979,"Chile","CHL",229,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2022-04-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-12
"1926",229,"Institute of Public Health","Test-negative case-control","12Apr2022","CoronaVac (Sinovac)","included","1","1","14+","hospitalization","severe","Chile",">= 18 years","general pop",36.6,"6",57.2,NA,"gamma & delta",NA,NA,NA,1980,"Chile","CHL",229,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2022-04-12,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations",NA,2022-04-12
"1927",229,"Institute of Public Health","Test-negative case-control","12Apr2022","CoronaVac (Sinovac)","included","2","final","14+","hospitalization","severe","Chile",">= 18 years","general pop",59.5,"49",67.9,NA,"gamma & delta","~53 weeks",NA,NA,1981,"Chile","CHL",229,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2022-04-12,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations",NA,2022-04-12
"1928",230,"Plumb","Test-negative case-control","12Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1","1","14+","hospitalization","severe","USA","hospitalized adults","general pop",33,"15",47.2,NA,"omicron",NA,NA,NA,1982,"USA","USA",230,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-12,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-04-12
"1929",230,"Plumb","Test-negative case-control","12Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA","hospitalized adults","general pop",37.3,"25.8",46.9,NA,"omicron","~55 weeks",NA,NA,1983,"USA","USA",230,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-04-12
"1930",230,"Plumb","Test-negative case-control","12Apr2022","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","hospitalized adults","general pop",35.9,"21.7",47.4,NA,"omicron","~55 weeks",NA,NA,1984,"USA","USA",230,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-12,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2022-04-12
"1931",230,"Plumb","Test-negative case-control","12Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","1","1","14+","hospitalization","severe","USA","hospitalized adults","general pop",58.8,"41.3",71.1,NA,"delta",NA,NA,NA,1985,"USA","USA",230,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-12,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-12
"1932",230,"Plumb","Test-negative case-control","12Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA","hospitalized adults","general pop",50,"39",59,NA,"delta","~55 weeks",NA,NA,1986,"USA","USA",230,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-12
"1933",230,"Plumb","Test-negative case-control","12Apr2022","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","hospitalized adults","general pop",44,"29.9",55.2,NA,"delta","~55 weeks",NA,NA,1987,"USA","USA",230,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-12,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-04-12
"1934",231,"Dale","Outbreak investigation","12Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA",">= 18 years","general pop",51,"-27",81,"delta","delta","~25 weeks",NA,NA,1988,"USA","USA",231,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-12,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-12
"1935",231,"Dale","Outbreak investigation","12Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","USA",">= 18 years","general pop",67,"-7",90,"delta","delta","~25 weeks",NA,NA,1989,"USA","USA",231,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-12,"symptomatic","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-12
"1936",231,"Dale","Outbreak investigation","12Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",61,"-59",90,"delta","delta","~25 weeks",NA,NA,1990,"USA","USA",231,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-12,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-12
"1937",231,"Dale","Outbreak investigation","12Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","death","death","USA",">= 18 years","general pop",80,"-10",96,"delta","delta","~25 weeks",NA,NA,1991,"USA","USA",231,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-12,"death","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-12
"1938",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14-69","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",51.9,"50",53.8,NA,"omicron","~59 weeks",NA,NA,1992,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/04/2022",2022-04-13
"1939",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","140+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",26.2,"22.8",29.4,NA,"omicron","~59 weeks",NA,NA,1993,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/04/2022",2022-04-13
"1940",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14-69","hospitalization or death","severe","Brazil",">= 18 years","general pop",59.6,"36.6",74.2,NA,"omicron","~59 weeks",NA,NA,1994,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/04/2022",2022-04-13
"1941",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","140+","hospitalization or death","severe","Brazil",">= 18 years","general pop",53.6,"30.2",69.1,NA,"omicron","~59 weeks",NA,NA,1995,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/04/2022",2022-04-13
"1942",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","AZD1222 (AstraZeneca)","previously infected only","2","final","14-69","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",25.5,"1",29.7,NA,"omicron","~59 weeks",NA,NA,1996,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","13/04/2022",2022-04-13
"1943",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","AZD1222 (AstraZeneca)","previously infected only","2","final","140+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",17,"14.4",19.6,NA,"omicron","~59 weeks",NA,NA,1997,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","13/04/2022",2022-04-13
"1944",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","AZD1222 (AstraZeneca)","previously infected only","2","final","14-69","hospitalization or death","severe","Brazil",">= 18 years","general pop",41,"-8.1",67.8,NA,"omicron","~59 weeks",NA,NA,1998,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","13/04/2022",2022-04-13
"1945",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","AZD1222 (AstraZeneca)","previously infected only","2","final","140+","hospitalization or death","severe","Brazil",">= 18 years","general pop",55.4,"44.6",64.1,NA,"omicron","~59 weeks",NA,NA,1999,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","13/04/2022",2022-04-13
"1946",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","Ad26.COV2.S (Janssen)","previously infected only","1","final","14+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",16.2,"12.4",19.8,NA,"omicron","~59 weeks",NA,NA,2000,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron","13/04/2022",2022-04-13
"1947",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","Ad26.COV2.S (Janssen)","previously infected only","1","final","14+","hospitalization or death","severe","Brazil",">= 18 years","general pop",39.5,"8.3",69,NA,"omicron","~59 weeks",NA,NA,2001,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron","13/04/2022",2022-04-13
"1948",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","CoronaVac (Sinovac)","previously infected only","2","final","14-69","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",23.4,"18.2",28.3,NA,"omicron","~59 weeks",NA,NA,2002,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","13/04/2022",2022-04-13
"1949",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","CoronaVac (Sinovac)","previously infected only","2","final","140+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",12.3,"9.4",15.1,NA,"omicron","~59 weeks",NA,NA,2003,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","13/04/2022",2022-04-13
"1950",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","CoronaVac (Sinovac)","previously infected only","2","final","14-69","hospitalization or death","severe","Brazil",">= 18 years","general pop",34.1,"-28.9",66.3,NA,"omicron","~59 weeks",NA,NA,2004,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","13/04/2022",2022-04-13
"1951",232,"Cerqueira-Silva","Test-negative case-control","01Jul2022","CoronaVac (Sinovac)","previously infected only","2","final","140+","hospitalization or death","severe","Brazil",">= 18 years","general pop",34.4,"18.3",47.3,NA,"omicron","~59 weeks",NA,NA,2005,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","13/04/2022",2022-04-13
"1952",232,"Cerqueira-Silva","Matched case-control","01Jul2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14-69","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",54.1,"52.1",55.9,NA,"omicron","~59 weeks",NA,NA,2006,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/04/2022",2022-04-13
"1953",232,"Cerqueira-Silva","Matched case-control","01Jul2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","140+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",30.6,"27.3",33.7,NA,"omicron","~59 weeks",NA,NA,2007,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/04/2022",2022-04-13
"1954",232,"Cerqueira-Silva","Matched case-control","01Jul2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14-69","hospitalization or death","severe","Brazil",">= 18 years","general pop",53.6,"-6.4",79.8,NA,"omicron","~59 weeks",NA,NA,2008,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/04/2022",2022-04-13
"1955",232,"Cerqueira-Silva","Matched case-control","01Jul2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","140+","hospitalization or death","severe","Brazil",">= 18 years","general pop",55.1,"-1.9",80.2,NA,"omicron","~59 weeks",NA,NA,2009,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","13/04/2022",2022-04-13
"1956",232,"Cerqueira-Silva","Matched case-control","01Jul2022","AZD1222 (AstraZeneca)","previously infected only","2","final","14-69","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",27.2,"22.9",31.3,NA,"omicron","~59 weeks",NA,NA,2010,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","13/04/2022",2022-04-13
"1957",232,"Cerqueira-Silva","Matched case-control","01Jul2022","AZD1222 (AstraZeneca)","previously infected only","2","final","140+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",15.9,"13.2",18.5,NA,"omicron","~59 weeks",NA,NA,2011,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","13/04/2022",2022-04-13
"1958",232,"Cerqueira-Silva","Matched case-control","01Jul2022","AZD1222 (AstraZeneca)","previously infected only","2","final","14-69","hospitalization or death","severe","Brazil",">= 18 years","general pop",67.5,"-7.9",90.2,NA,"omicron","~59 weeks",NA,NA,2012,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","13/04/2022",2022-04-13
"1959",232,"Cerqueira-Silva","Matched case-control","01Jul2022","AZD1222 (AstraZeneca)","previously infected only","2","final","140+","hospitalization or death","severe","Brazil",">= 18 years","general pop",63.2,"39",77.8,NA,"omicron","~59 weeks",NA,NA,2013,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","13/04/2022",2022-04-13
"1960",232,"Cerqueira-Silva","Matched case-control","01Jul2022","Ad26.COV2.S (Janssen)","previously infected only","1","final","14+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",16.9,"13.2",20.5,NA,"omicron","~59 weeks",NA,NA,2014,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron","13/04/2022",2022-04-13
"1961",232,"Cerqueira-Silva","Matched case-control","01Jul2022","Ad26.COV2.S (Janssen)","previously infected only","1","final","14+","hospitalization or death","severe","Brazil",">= 18 years","general pop",45.4,"-19.6",75.1,NA,"omicron","~59 weeks",NA,NA,2015,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron","13/04/2022",2022-04-13
"1962",232,"Cerqueira-Silva","Matched case-control","01Jul2022","CoronaVac (Sinovac)","previously infected only","2","final","14-69","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",27.3,"22.3",31.9,NA,"omicron","~59 weeks",NA,NA,2016,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","13/04/2022",2022-04-13
"1963",232,"Cerqueira-Silva","Matched case-control","01Jul2022","CoronaVac (Sinovac)","previously infected only","2","final","140+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",14.3,"11.4",17,NA,"omicron","~59 weeks",NA,NA,2017,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"symptomatic","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","13/04/2022",2022-04-13
"1964",232,"Cerqueira-Silva","Matched case-control","01Jul2022","CoronaVac (Sinovac)","previously infected only","2","final","14-69","hospitalization or death","severe","Brazil",">= 18 years","general pop",21.4,"-148.4",75.1,NA,"omicron","~59 weeks",NA,NA,2018,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","13/04/2022",2022-04-13
"1965",232,"Cerqueira-Silva","Matched case-control","01Jul2022","CoronaVac (Sinovac)","previously infected only","2","final","140+","hospitalization or death","severe","Brazil",">= 18 years","general pop",66.4,"37.6",81.9,NA,"omicron","~59 weeks",NA,NA,2019,"Brazil","BRA",232,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-01,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","13/04/2022",2022-04-13
"1966",233,"Nasreen","Test-negative case-control","17Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-55","hospitalization or death","severe","Canada",">= 18 years","general pop",98,"95",99,NA,"non-VOC, alpha, beta, gamma, & delta","~32 weeks",NA,NA,2020,"Canada","CAN",233,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-17,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","13/04/2022",2022-04-13
"1967",233,"Nasreen","Test-negative case-control","17Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","112+","hospitalization or death","severe","Canada",">= 18 years","general pop",98,"95",99,NA,"non-VOC, alpha, beta, gamma, & delta","~32 weeks",NA,NA,2021,"Canada","CAN",233,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-17,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","13/04/2022",2022-04-13
"1968",233,"Nasreen","Test-negative case-control","17Aug2022","AZD1222 (AstraZeneca)","excluded","2","final","7-55","hospitalization or death","severe","Canada",">= 18 years","general pop",96,"88",96,NA,"non-VOC, alpha, beta, gamma, & delta","~7 weeks",NA,NA,2022,"Canada","CAN",233,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-17,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","13/04/2022",2022-04-13
"1969",233,"Nasreen","Test-negative case-control","17Aug2022","AZD1222 (AstraZeneca)","excluded","2","final","56+","hospitalization or death","severe","Canada",">= 18 years","general pop",97,"91",99,NA,"non-VOC, alpha, beta, gamma, & delta","~7 weeks",NA,NA,2023,"Canada","CAN",233,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-17,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","13/04/2022",2022-04-13
"1970",233,"Nasreen","Test-negative case-control","17Aug2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","14+","hospitalization or death","severe","Canada",">= 18 years","general pop",99,"98",100,NA,"non-VOC, alpha, beta, gamma, & delta","~7 weeks",NA,NA,2024,"Canada","CAN",233,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-17,"severe","2022 (Jul-Dec)","Heterologous platforms","Multiple","other combinations","13/04/2022",2022-04-13
"1971",234,"Richardson","Prospective cohort","19Jun2022","Ad5-nCOV (CanSino)","excluded","1","final","14-60","infection","infection","Mexico","childcare workers","childcare workers",48,"32",61,NA,"non-VOC, alpha, gamma, & delta","~33 weeks",NA,NA,2025,"Mexico","MEX",234,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2022-06-19,"infection","2022 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","other combinations","17/04/2022",2022-04-17
"1972",234,"Richardson","Prospective cohort","19Jun2022","Ad5-nCOV (CanSino)","excluded","1","final","120+","infection","infection","Mexico","childcare workers","childcare workers",-3,"-26",16,NA,"non-VOC, alpha, gamma, & delta","~33 weeks",NA,NA,2026,"Mexico","MEX",234,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2022-06-19,"infection","2022 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","other combinations","17/04/2022",2022-04-17
"1973",234,"Richardson","Prospective cohort","19Jun2022","Ad5-nCOV (CanSino)","excluded","1","final","14-60","hospitalization","severe","Mexico","childcare workers","childcare workers",92,"23",99,NA,"non-VOC, alpha, gamma, & delta","~33 weeks",NA,NA,2027,"Mexico","MEX",234,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2022-06-19,"severe","2022 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","other combinations","17/04/2022",2022-04-17
"1974",234,"Richardson","Prospective cohort","19Jun2022","Ad5-nCOV (CanSino)","excluded","1","final","120+","hospitalization","severe","Mexico","childcare workers","childcare workers",24,"-263",84,NA,"non-VOC, alpha, gamma, & delta","~33 weeks",NA,NA,2028,"Mexico","MEX",234,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2022-06-19,"severe","2022 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","other combinations","17/04/2022",2022-04-17
"1975",234,"Richardson","Prospective cohort","19Jun2022","Ad5-nCOV (CanSino)","excluded","1","final","61-120","death","death","Mexico","childcare workers","childcare workers",95,"53",100,NA,"non-VOC, alpha, gamma, & delta","~33 weeks",NA,NA,2029,"Mexico","MEX",234,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2022-06-19,"death","2022 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","other combinations","17/04/2022",2022-04-17
"1976",234,"Richardson","Prospective cohort","19Jun2022","Ad5-nCOV (CanSino)","excluded","1","final","120+","death","death","Mexico","childcare workers","childcare workers",93,"22",99,NA,"non-VOC, alpha, gamma, & delta","~33 weeks",NA,NA,2030,"Mexico","MEX",234,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2022-06-19,"death","2022 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","other combinations","17/04/2022",2022-04-17
"1977",234,"Richardson","Prospective cohort","19Jun2022","Ad5-nCOV (CanSino)","excluded","1","final","14+","infection","infection","Mexico","childcare workers","childcare workers",53,"23",71,NA,"alpha & gamma","~33 weeks",NA,NA,2031,"Mexico","MEX",234,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2022-06-19,"infection","2022 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","other combinations","17/04/2022",2022-04-17
"1978",234,"Richardson","Prospective cohort","19Jun2022","Ad5-nCOV (CanSino)","excluded","1","final","14+","infection","infection","Mexico","childcare workers","childcare workers",18,"8",28,NA,"delta","~33 weeks",NA,NA,2032,"Mexico","MEX",234,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2022-06-19,"infection","2022 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","delta","17/04/2022",2022-04-17
"1979",234,"Richardson","Prospective cohort","19Jun2022","Ad5-nCOV (CanSino)","excluded","1","final","14+","hospitalization","severe","Mexico","childcare workers","childcare workers",74,"38",89,NA,"delta","~33 weeks",NA,NA,2033,"Mexico","MEX",234,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2022-06-19,"severe","2022 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","delta","17/04/2022",2022-04-17
"1980",234,"Richardson","Prospective cohort","19Jun2022","Ad5-nCOV (CanSino)","excluded","1","final","14+","death","death","Mexico","childcare workers","childcare workers",94,"67",99,NA,"delta","~33 weeks",NA,NA,2034,"Mexico","MEX",234,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2022-06-19,"death","2022 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","delta","17/04/2022",2022-04-17
"1981",235,"Voko","Retrospective cohort","22Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-120","infection","infection","Hungary","18-64 years","18-64 years",70.3,"69.2",71.3,NA,"delta","~47 weeks",NA,NA,2035,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/04/2022",2022-04-18
"1982",235,"Voko","Retrospective cohort","22Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","240+","infection","infection","Hungary","18-64 years","18-64 years",0.6,"-2.3",3.4,NA,"delta","~47 weeks",NA,NA,2036,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/04/2022",2022-04-18
"1983",235,"Voko","Retrospective cohort","22Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-120","hospitalization","severe","Hungary","18-64 years","18-64 years",82.6,"80.1",84.7,NA,"delta","~47 weeks",NA,NA,2037,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/04/2022",2022-04-18
"1984",235,"Voko","Retrospective cohort","22Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","240+","hospitalization","severe","Hungary","18-64 years","18-64 years",69.6,"64.9",73.6,NA,"delta","~47 weeks",NA,NA,2038,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/04/2022",2022-04-18
"1985",235,"Voko","Retrospective cohort","22Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-120","death","death","Hungary","18-64 years","18-64 years",87.4,"81.5",91.5,NA,"delta","~47 weeks",NA,NA,2039,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/04/2022",2022-04-18
"1986",235,"Voko","Retrospective cohort","22Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","240+","death","death","Hungary","18-64 years","18-64 years",73.6,"61.1",82.1,NA,"delta","~47 weeks",NA,NA,2040,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","18/04/2022",2022-04-18
"1987",235,"Voko","Retrospective cohort","22Jul2022","mRNA-1273 (Moderna)","included","2","final","14-120","infection","infection","Hungary","18-64 years","18-64 years",76.9,"73.3",80,NA,"delta","~47 weeks",NA,NA,2041,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","18/04/2022",2022-04-18
"1988",235,"Voko","Retrospective cohort","22Jul2022","mRNA-1273 (Moderna)","included","2","final","240+","infection","infection","Hungary","18-64 years","18-64 years",22.6,"6.1",36.2,NA,"delta","~47 weeks",NA,NA,2042,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","18/04/2022",2022-04-18
"1989",235,"Voko","Retrospective cohort","22Jul2022","mRNA-1273 (Moderna)","included","2","final","14-120","hospitalization","severe","Hungary","18-64 years","18-64 years",84.9,"75.4",90.8,NA,"delta","~47 weeks",NA,NA,2043,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","18/04/2022",2022-04-18
"1990",235,"Voko","Retrospective cohort","22Jul2022","mRNA-1273 (Moderna)","included","2","final","240+","hospitalization","severe","Hungary","18-64 years","18-64 years",42.5,"-4",68.2,NA,"delta","~47 weeks",NA,NA,2044,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","18/04/2022",2022-04-18
"1991",235,"Voko","Retrospective cohort","22Jul2022","mRNA-1273 (Moderna)","included","2","final","14-120","death","death","Hungary","18-64 years","18-64 years",77.7,"30.7",92.8,NA,"delta","~47 weeks",NA,NA,2045,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"death","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","18/04/2022",2022-04-18
"1992",235,"Voko","Retrospective cohort","22Jul2022","mRNA-1273 (Moderna)","included","2","final","240+","death","death","Hungary","18-64 years","18-64 years",100,NA,NA,NA,"delta","~47 weeks",NA,NA,2046,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"death","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","18/04/2022",2022-04-18
"1993",235,"Voko","Retrospective cohort","22Jul2022","AZD1222 (AstraZeneca)","included","2","final","14-120","infection","infection","Hungary","18-64 years","18-64 years",39.2,"36.4",41.9,NA,"delta","~47 weeks",NA,NA,2047,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","18/04/2022",2022-04-18
"1994",235,"Voko","Retrospective cohort","22Jul2022","AZD1222 (AstraZeneca)","included","2","final","240+","infection","infection","Hungary","18-64 years","18-64 years",-14,"-20.5",-7.9,NA,"delta","~47 weeks",NA,NA,2048,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","18/04/2022",2022-04-18
"1995",235,"Voko","Retrospective cohort","22Jul2022","AZD1222 (AstraZeneca)","included","2","final","14-120","hospitalization","severe","Hungary","18-64 years","18-64 years",76.2,"70.6",80.7,NA,"delta","~47 weeks",NA,NA,2049,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","18/04/2022",2022-04-18
"1996",235,"Voko","Retrospective cohort","22Jul2022","AZD1222 (AstraZeneca)","included","2","final","240+","hospitalization","severe","Hungary","18-64 years","18-64 years",48.8,"38.2",57.6,NA,"delta","~47 weeks",NA,NA,2050,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","18/04/2022",2022-04-18
"1997",235,"Voko","Retrospective cohort","22Jul2022","AZD1222 (AstraZeneca)","included","2","final","14-120","death","death","Hungary","18-64 years","18-64 years",90.1,"73.5",96.3,NA,"delta","~47 weeks",NA,NA,2051,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","18/04/2022",2022-04-18
"1998",235,"Voko","Retrospective cohort","22Jul2022","AZD1222 (AstraZeneca)","included","2","final","240+","death","death","Hungary","18-64 years","18-64 years",57.1,"35.2",71.6,NA,"delta","~47 weeks",NA,NA,2052,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","18/04/2022",2022-04-18
"1999",235,"Voko","Retrospective cohort","22Jul2022","Gam-COVID-Vac (Gamaleya)","included","2","final","14-120","infection","infection","Hungary","18-64 years","18-64 years",38.3,"31.8",44.3,NA,"delta","~47 weeks",NA,NA,2053,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"infection","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta","18/04/2022",2022-04-18
"2000",235,"Voko","Retrospective cohort","22Jul2022","Gam-COVID-Vac (Gamaleya)","included","2","final","240+","infection","infection","Hungary","18-64 years","18-64 years",-4.6,"-12.5",2.9,NA,"delta","~47 weeks",NA,NA,2054,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"infection","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta","18/04/2022",2022-04-18
"2001",235,"Voko","Retrospective cohort","22Jul2022","Gam-COVID-Vac (Gamaleya)","included","2","final","14-120","hospitalization","severe","Hungary","18-64 years","18-64 years",90.4,"78.5",95.7,NA,"delta","~47 weeks",NA,NA,2055,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta","18/04/2022",2022-04-18
"2002",235,"Voko","Retrospective cohort","22Jul2022","Gam-COVID-Vac (Gamaleya)","included","2","final","240+","hospitalization","severe","Hungary","18-64 years","18-64 years",78.7,"69.1",85.4,NA,"delta","~47 weeks",NA,NA,2056,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta","18/04/2022",2022-04-18
"2003",235,"Voko","Retrospective cohort","22Jul2022","Gam-COVID-Vac (Gamaleya)","included","2","final","121-180","death","death","Hungary","18-64 years","18-64 years",89.3,"79.9",94.3,NA,"delta","~47 weeks",NA,NA,2057,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"death","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta","18/04/2022",2022-04-18
"2004",235,"Voko","Retrospective cohort","22Jul2022","Gam-COVID-Vac (Gamaleya)","included","2","final","240+","death","death","Hungary","18-64 years","18-64 years",79.1,"59.8",89.2,NA,"delta","~47 weeks",NA,NA,2058,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"death","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta","18/04/2022",2022-04-18
"2005",235,"Voko","Retrospective cohort","22Jul2022","Ad26.COV2.S (Janssen)","included","1","final","14-120","infection","infection","Hungary","18-64 years","18-64 years",39.3,"36.1",42.4,NA,"delta","~47 weeks",NA,NA,2059,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta","18/04/2022",2022-04-18
"2006",235,"Voko","Retrospective cohort","22Jul2022","Ad26.COV2.S (Janssen)","included","1","final","181-240","infection","infection","Hungary","18-64 years","18-64 years",35.9,"32.5",39.2,NA,"delta","~47 weeks",NA,NA,2060,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta","18/04/2022",2022-04-18
"2007",235,"Voko","Retrospective cohort","22Jul2022","Ad26.COV2.S (Janssen)","included","1","final","14-120","hospitalization","severe","Hungary","18-64 years","18-64 years",43.2,"32.9",52,NA,"delta","~47 weeks",NA,NA,2061,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta","18/04/2022",2022-04-18
"2008",235,"Voko","Retrospective cohort","22Jul2022","Ad26.COV2.S (Janssen)","included","1","final","181-240","hospitalization","severe","Hungary","18-64 years","18-64 years",59.4,"50.1",67,NA,"delta","~47 weeks",NA,NA,2062,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta","18/04/2022",2022-04-18
"2009",235,"Voko","Retrospective cohort","22Jul2022","Ad26.COV2.S (Janssen)","included","1","final","14-120","death","death","Hungary","18-64 years","18-64 years",59.8,"35.2",75.1,NA,"delta","~47 weeks",NA,NA,2063,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"death","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta","18/04/2022",2022-04-18
"2010",235,"Voko","Retrospective cohort","22Jul2022","Ad26.COV2.S (Janssen)","included","1","final","181-240","death","death","Hungary","18-64 years","18-64 years",76.1,"56.7",86.8,NA,"delta","~47 weeks",NA,NA,2064,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"death","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta","18/04/2022",2022-04-18
"2011",235,"Voko","Retrospective cohort","22Jul2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14-120","infection","infection","Hungary","18-64 years","18-64 years",10.9,"6.7",15,NA,"delta","~47 weeks",NA,NA,2065,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"infection","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta","18/04/2022",2022-04-18
"2012",235,"Voko","Retrospective cohort","22Jul2022","BBIBP-CorV (Beijing CNBG)","included","2","final","240+","infection","infection","Hungary","18-64 years","18-64 years",-19.9,"-31.9",-9,NA,"delta","~47 weeks",NA,NA,2066,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"infection","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta","18/04/2022",2022-04-18
"2013",235,"Voko","Retrospective cohort","22Jul2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14-120","hospitalization","severe","Hungary","18-64 years","18-64 years",53.8,"43.9",61.9,NA,"delta","~47 weeks",NA,NA,2067,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta","18/04/2022",2022-04-18
"2014",235,"Voko","Retrospective cohort","22Jul2022","BBIBP-CorV (Beijing CNBG)","included","2","final","240+","hospitalization","severe","Hungary","18-64 years","18-64 years",40.9,"24.4",53.8,NA,"delta","~47 weeks",NA,NA,2068,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta","18/04/2022",2022-04-18
"2015",235,"Voko","Retrospective cohort","22Jul2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14-120","death","death","Hungary","18-64 years","18-64 years",67.4,"39.2",82.5,NA,"delta","~47 weeks",NA,NA,2069,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"death","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta","18/04/2022",2022-04-18
"2016",235,"Voko","Retrospective cohort","22Jul2022","BBIBP-CorV (Beijing CNBG)","included","2","final","240+","death","death","Hungary","18-64 years","18-64 years",50.7,"21.4",69.1,NA,"delta","~47 weeks",NA,NA,2070,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"death","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta","18/04/2022",2022-04-18
"2017",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-30","infection","infection","Denmark","12-59 years","12-59 years",40,"38.6",41.3,NA,"omicron","~56 weeks",NA,NA,2071,"Denmark","DNK",236,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","20/04/2022",2022-04-20
"2018",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","120+","infection","infection","Denmark","12-59 years","12-59 years",12.6,"12",13.3,NA,"omicron","~56 weeks",NA,NA,2072,"Denmark","DNK",236,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","20/04/2022",2022-04-20
"2019",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-30","hospitalization","severe","Denmark","12-59 years","12-59 years",96.2,"72.9",99.5,NA,"omicron","~56 weeks",NA,NA,2073,"Denmark","DNK",236,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","20/04/2022",2022-04-20
"2020",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","120+","hospitalization","severe","Denmark","12-59 years","12-59 years",77.6,"72.6",81.6,NA,"omicron","~56 weeks",NA,NA,2074,"Denmark","DNK",236,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","20/04/2022",2022-04-20
"2021",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-30","infection","infection","Denmark","12-59 years","12-59 years",92.2,"91.8",92.6,NA,"delta","~56 weeks",NA,NA,2075,"Denmark","DNK",236,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","20/04/2022",2022-04-20
"2022",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","120+","infection","infection","Denmark","12-59 years","12-59 years",64.8,"64",65.8,NA,"delta","~56 weeks",NA,NA,2076,"Denmark","DNK",236,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","20/04/2022",2022-04-20
"2023",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-30","hospitalization","severe","Denmark","12-59 years","12-59 years",99.5,"98.4",99.8,NA,"delta","~56 weeks",NA,NA,2077,"Denmark","DNK",236,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","20/04/2022",2022-04-20
"2024",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","120+","hospitalization","severe","Denmark","12-59 years","12-59 years",93.5,"91.6",95,NA,"delta","~56 weeks",NA,NA,2078,"Denmark","DNK",236,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","20/04/2022",2022-04-20
"2025",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-30","infection","infection","Denmark",">= 60 years",">= 60 years",39.9,"26.3",50.9,NA,"omicron","~56 weeks",NA,NA,2079,"Denmark","DNK",236,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","20/04/2022",2022-04-20
"2026",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","120+","infection","infection","Denmark",">= 60 years",">= 60 years",4.4,"-0.1",8.7,NA,"omicron","~56 weeks",NA,NA,2080,"Denmark","DNK",236,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","20/04/2022",2022-04-20
"2027",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-30","infection","infection","Denmark",">= 60 years",">= 60 years",82.3,"75.5",87.2,NA,"delta","~56 weeks",NA,NA,2081,"Denmark","DNK",236,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","20/04/2022",2022-04-20
"2028",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","120+","infection","infection","Denmark",">= 60 years",">= 60 years",50,"46.7",53,NA,"delta","~56 weeks",NA,NA,2082,"Denmark","DNK",236,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","20/04/2022",2022-04-20
"2029",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","31-60","hospitalization","severe","Denmark",">= 60 years",">= 60 years",97.7,"94.8",98.8,NA,"delta","~56 weeks",NA,NA,2083,"Denmark","DNK",236,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","20/04/2022",2022-04-20
"2030",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","120+","hospitalization","severe","Denmark",">= 60 years",">= 60 years",87.5,"85.6",89.2,NA,"delta","~56 weeks",NA,NA,2084,"Denmark","DNK",236,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","20/04/2022",2022-04-20
"2031",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-30","infection","infection","Denmark",">= 60 years",">= 60 years",90.7,"88.2",92.7,NA,"alpha","~56 weeks",NA,NA,2085,"Denmark","DNK",236,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","20/04/2022",2022-04-20
"2032",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","120+","infection","infection","Denmark",">= 60 years",">= 60 years",73.2,"57.1",83.3,NA,"alpha","~56 weeks",NA,NA,2086,"Denmark","DNK",236,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","20/04/2022",2022-04-20
"2033",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-30","hospitalization","severe","Denmark",">= 60 years",">= 60 years",98.1,"94.7",99.3,NA,"alpha","~56 weeks",NA,NA,2087,"Denmark","DNK",236,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","20/04/2022",2022-04-20
"2034",236,"Gram","Retrospective cohort","01Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","120+","hospitalization","severe","Denmark",">= 60 years",">= 60 years",96.5,"73.4",99.5,NA,"alpha","~56 weeks",NA,NA,2088,"Denmark","DNK",236,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-01,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","20/04/2022",2022-04-20
"2035",237,"Lind","Test-negative case-control","25Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-140","infection","infection","USA",">= 18 years","general pop",28.5,"20",36.2,"omicron","omicron","~67 weeks",NA,NA,2089,"USA","USA",237,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-25,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","25/04/2022",2022-04-25
"2036",237,"Lind","Test-negative case-control","25Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","infection","infection","USA",">= 18 years","general pop",15.3,"10.4",20,"omicron","omicron","~67 weeks",NA,NA,2090,"USA","USA",237,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-25,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","25/04/2022",2022-04-25
"2037",237,"Lind","Test-negative case-control","25Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-140","infection","infection","USA",">= 18 years","general pop",36.1,"7.1",56.1,"omicron","omicron","~67 weeks",NA,NA,2091,"USA","USA",237,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-25,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","25/04/2022",2022-04-25
"2038",237,"Lind","Test-negative case-control","25Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","infection","infection","USA",">= 18 years","general pop",34,"18.5",46.5,"omicron","omicron","~67 weeks",NA,NA,2092,"USA","USA",237,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-25,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","25/04/2022",2022-04-25
"2039",237,"Lind","1:1 Matched case control","25Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-140","infection","infection","USA",">= 18 years","general pop",30.7,"20.6",39.6,"omicron","omicron","~67 weeks",NA,NA,2093,"USA","USA",237,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-25,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","25/04/2022",2022-04-25
"2040",237,"Lind","1:1 Matched case control","25Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","infection","infection","USA",">= 18 years","general pop",20,"14",25.6,"omicron","omicron","~67 weeks",NA,NA,2094,"USA","USA",237,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-25,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","25/04/2022",2022-04-25
"2041",237,"Lind","1:1 Matched case control","25Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-140","infection","infection","USA",">= 18 years","general pop",14.3,"-43.1",48.7,"omicron","omicron","~67 weeks",NA,NA,2095,"USA","USA",237,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-25,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","25/04/2022",2022-04-25
"2042",237,"Lind","1:1 Matched case control","25Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","infection","infection","USA",">= 18 years","general pop",18.8,"-9",39.5,"omicron","omicron","~67 weeks",NA,NA,2096,"USA","USA",237,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-25,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","25/04/2022",2022-04-25
"2043",238,"Sanchez Ruiz","Retrospective cohort","01Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","France","LTCF residents","LTCF residents",11.2,"0",61.1,"delta","delta",NA,NA,NA,2097,"France","FRA",238,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-01,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-01
"2044",238,"Sanchez Ruiz","Retrospective cohort","01Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","France","LTCF residents","LTCF residents",88.4,"59.9",96.7,"delta","delta",NA,NA,NA,2098,"France","FRA",238,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-01,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-01
"2045",238,"Sanchez Ruiz","Retrospective cohort","01Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","severe disease","severe","France","LTCF residents","LTCF residents",93.5,"67.2",98.7,"delta","delta",NA,NA,NA,2099,"France","FRA",238,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-01,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-01
"2046",239,"Widdifield","Test-negative case-control","14Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","infection","infection","Canada","individuals with rheumatoid arthritis","individuals with rheumatoid arthritis",82,"78",85,NA,"alpha & delta","~44 weeks",NA,NA,2100,"Canada","CAN",239,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-14
"2047",239,"Widdifield","Test-negative case-control","14Apr2022","mRNA-1273 (Moderna)","included","2","final","7+","infection","infection","Canada","individuals with rheumatoid arthritis","individuals with rheumatoid arthritis",86,"80",90,NA,"alpha & delta","~44 weeks",NA,NA,2101,"Canada","CAN",239,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-04-14
"2048",239,"Widdifield","Test-negative case-control","14Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","infection","infection","Canada","individuals with rheumatoid arthritis","individuals with rheumatoid arthritis",83,"80",86,NA,"alpha & delta","~44 weeks",NA,NA,2102,"Canada","CAN",239,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-14
"2049",239,"Widdifield","Test-negative case-control","14Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","severe disease","severe","Canada","individuals with rheumatoid arthritis","individuals with rheumatoid arthritis",92,"88",95,NA,"alpha & delta","~44 weeks",NA,NA,2103,"Canada","CAN",239,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-14
"2050",239,"Widdifield","Test-negative case-control","14Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","infection","infection","Canada","individuals with ankylosing spondylitis","individuals with ankylosing spondylitis",88,"82",93,NA,"alpha & delta","~44 weeks",NA,NA,2104,"Canada","CAN",239,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-14
"2051",239,"Widdifield","Test-negative case-control","14Apr2022","mRNA-1273 (Moderna)","included","2","final","7+","infection","infection","Canada","individuals with ankylosing spondylitis","individuals with ankylosing spondylitis",93,"83",97,NA,"alpha & delta","~44 weeks",NA,NA,2105,"Canada","CAN",239,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-04-14
"2052",239,"Widdifield","Test-negative case-control","14Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","infection","infection","Canada","individuals with ankylosing spondylitis","individuals with ankylosing spondylitis",89,"83",93,NA,"alpha & delta","~44 weeks",NA,NA,2106,"Canada","CAN",239,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-14
"2053",239,"Widdifield","Test-negative case-control","14Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","severe disease","severe","Canada","individuals with ankylosing spondylitis","individuals with ankylosing spondylitis",97,"83",99,NA,"alpha & delta","~44 weeks",NA,NA,2107,"Canada","CAN",239,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-14
"2054",239,"Widdifield","Test-negative case-control","14Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","infection","infection","Canada","individuals with psoriasis","individuals with psoriasis",82,"79",85,NA,"alpha & delta","~44 weeks",NA,NA,2108,"Canada","CAN",239,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-14
"2055",239,"Widdifield","Test-negative case-control","14Apr2022","mRNA-1273 (Moderna)","included","2","final","7+","infection","infection","Canada","individuals with psoriasis","individuals with psoriasis",87,"82",91,NA,"alpha & delta","~44 weeks",NA,NA,2109,"Canada","CAN",239,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-04-14
"2056",239,"Widdifield","Test-negative case-control","14Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","infection","infection","Canada","individuals with psoriasis","individuals with psoriasis",84,"81",86,NA,"alpha & delta","~44 weeks",NA,NA,2110,"Canada","CAN",239,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-14
"2057",239,"Widdifield","Test-negative case-control","14Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","severe disease","severe","Canada","individuals with psoriasis","individuals with psoriasis",92,"86",95,NA,"alpha & delta","~44 weeks",NA,NA,2111,"Canada","CAN",239,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-14
"2058",239,"Widdifield","Test-negative case-control","14Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","infection","infection","Canada","individuals with inflammatory bowel disease","individuals with inflammatory bowel disease",82,"79",85,NA,"alpha & delta","~44 weeks",NA,NA,2112,"Canada","CAN",239,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-14
"2059",239,"Widdifield","Test-negative case-control","14Apr2022","mRNA-1273 (Moderna)","included","2","final","7+","infection","infection","Canada","individuals with inflammatory bowel disease","individuals with inflammatory bowel disease",87,"82",91,NA,"alpha & delta","~44 weeks",NA,NA,2113,"Canada","CAN",239,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-04-14
"2060",239,"Widdifield","Test-negative case-control","14Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","infection","infection","Canada","individuals with inflammatory bowel disease","individuals with inflammatory bowel disease",79,"74",82,NA,"alpha & delta","~44 weeks",NA,NA,2114,"Canada","CAN",239,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-14
"2061",239,"Widdifield","Test-negative case-control","14Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","severe disease","severe","Canada","individuals with inflammatory bowel disease","individuals with inflammatory bowel disease",94,"88",97,NA,"alpha & delta","~44 weeks",NA,NA,2115,"Canada","CAN",239,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-14,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-14
"2062",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-59","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",49.2,"48.5",49.9,NA,"omicron","~7 weeks",NA,NA,2116,"Brazil","BRA",240,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-11,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","14/04/2022",2022-04-14
"2063",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",9.6,"8.1",11,NA,"omicron","~33 weeks",NA,NA,2117,"Brazil","BRA",240,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-11,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","14/04/2022",2022-04-14
"2064",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-59","severe disease","severe","Brazil",">= 18 years","general pop",82.9,"80.6",85,NA,"omicron","~7 weeks",NA,NA,2118,"Brazil","BRA",240,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-11,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","14/04/2022",2022-04-14
"2065",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","severe disease","severe","Brazil",">= 18 years","general pop",82.6,"80.7",84.3,NA,"omicron","~33 weeks",NA,NA,2119,"Brazil","BRA",240,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-11,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","14/04/2022",2022-04-14
"2066",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","AZD1222 (AstraZeneca)","included","2","final","14-59","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",26.7,"25.2",28.2,NA,"omicron","~7 weeks",NA,NA,2120,"Brazil","BRA",240,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-11,"symptomatic","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","14/04/2022",2022-04-14
"2067",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","AZD1222 (AstraZeneca)","included","2","final","150+","symptomatic disease","symptomatic","Brazil",">= 18 years","general pop",0.9,"0",1.9,NA,"omicron","~36 weeks",NA,NA,2121,"Brazil","BRA",240,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-11,"symptomatic","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","14/04/2022",2022-04-14
"2068",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","AZD1222 (AstraZeneca)","included","2","final","14-59","severe disease","severe","Brazil",">= 18 years","general pop",77.1,"72.9",80.6,NA,"omicron","~7 weeks",NA,NA,2122,"Brazil","BRA",240,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-11,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","14/04/2022",2022-04-14
"2069",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","AZD1222 (AstraZeneca)","included","2","final","150+","severe disease","severe","Brazil",">= 18 years","general pop",67.8,"66.7",69,NA,"omicron","~36 weeks",NA,NA,2123,"Brazil","BRA",240,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-11,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","14/04/2022",2022-04-14
"2070",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-59","symptomatic disease","symptomatic","Scotland",">= 18 years","general pop",57.7,"54.5",60.6,NA,"omicron","~7 weeks",NA,NA,2124,"UK","GBR",500,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-11,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","14/04/2022",2022-04-14
"2071",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","symptomatic disease","symptomatic","Scotland",">= 18 years","general pop",17.8,"15.1",20.5,NA,"omicron","~38.5 weeks",NA,NA,2125,"UK","GBR",500,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-11,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","14/04/2022",2022-04-14
"2072",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-59","severe disease","severe","Scotland",">= 18 years","general pop",90.4,"30.4",98.7,NA,"omicron","~7 weeks",NA,NA,2126,"UK","GBR",500,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-11,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","14/04/2022",2022-04-14
"2073",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","severe disease","severe","Scotland",">= 18 years","general pop",72.9,"57.9",82.5,NA,"omicron","~38.5 weeks",NA,NA,2127,"UK","GBR",500,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-11,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","14/04/2022",2022-04-14
"2074",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","AZD1222 (AstraZeneca)","included","2","final","14-59","symptomatic disease","symptomatic","Scotland",">= 18 years","general pop",40.7,"26.6",52.1,NA,"omicron","~7 weeks",NA,NA,2128,"UK","GBR",500,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-11,"symptomatic","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","14/04/2022",2022-04-14
"2075",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","AZD1222 (AstraZeneca)","included","2","final","150+","symptomatic disease","symptomatic","Scotland",">= 18 years","general pop",9.6,"6.3",12.9,NA,"omicron","~35.5 weeks",NA,NA,2129,"UK","GBR",500,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-11,"symptomatic","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","14/04/2022",2022-04-14
"2076",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","AZD1222 (AstraZeneca)","included","2","final","60-149","severe disease","severe","Scotland",">= 18 years","general pop",78.8,"31.8",93.4,NA,"omicron","~19 weeks",NA,NA,2130,"UK","GBR",500,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-11,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","14/04/2022",2022-04-14
"2077",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","AZD1222 (AstraZeneca)","included","2","final","150+","severe disease","severe","Scotland",">= 18 years","general pop",52.8,"33.3",66.7,NA,"omicron","~35.5 weeks",NA,NA,2131,"UK","GBR",500,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-11,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","14/04/2022",2022-04-14
"2078",241,"Gonzalez","Retrospective cohort","19Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","Argentina","12-17 years","12-17 years",81,"59.9",90.1,NA,"delta & omicron","~17 weeks",NA,NA,2132,"Argentina","ARG",241,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta/omicron","19/04/2022",2022-04-19
"2079",241,"Gonzalez","Retrospective cohort","19Apr2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","hospitalization","severe","Argentina","3-11 years","3-11 years",83.4,"70.9",90.2,NA,"delta & omicron","~9 weeks",NA,NA,2133,"Argentina","ARG",241,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta/omicron","19/04/2022",2022-04-19
"2080",241,"Gonzalez","Retrospective cohort","19Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","Argentina","12-17 years","12-17 years",78.2,"42",90.3,NA,"omicron","~25 weeks",NA,NA,2134,"Argentina","ARG",241,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","19/04/2022",2022-04-19
"2081",241,"Gonzalez","Retrospective cohort","19Apr2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","hospitalization","severe","Argentina","3-11 years","3-11 years",58.6,"4.1",79.7,NA,"omicron","16 weeks",NA,NA,2135,"Argentina","ARG",241,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","omicron","19/04/2022",2022-04-19
"2082",242,"Eick-Cost","Case-control","20Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","USA","military personnel","military personnel",87.6,"86.2",88.9,NA,"pre-delta (non-VOC, alpha)","~19 weeks",NA,NA,2136,"USA","USA",242,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-20,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-20
"2083",242,"Eick-Cost","Case-control","20Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","asymptomatic infection","asymptomatic","USA","military personnel","military personnel",80.3,"76.5",83.5,NA,"pre-delta (non-VOC, alpha)","~19 weeks",NA,NA,2137,"USA","USA",242,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-20,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-20
"2084",242,"Eick-Cost","Case-control","20Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","USA","military personnel","military personnel",89.9,"88.4",91.2,NA,"pre-delta (non-VOC, alpha)","~19 weeks",NA,NA,2138,"USA","USA",242,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-20,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-20
"2085",242,"Eick-Cost","Case-control","20Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","USA","military personnel","military personnel",88,"75.4",94.1,NA,"pre-delta (non-VOC, alpha)","~19 weeks",NA,NA,2139,"USA","USA",242,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-20,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-20
"2086",242,"Eick-Cost","Case-control","20Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","military personnel","military personnel",93.5,"91.9",94.7,NA,"pre-delta (non-VOC, alpha)","~19 weeks",NA,NA,2140,"USA","USA",242,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-20,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-04-20
"2087",242,"Eick-Cost","Case-control","20Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","asymptomatic infection","asymptomatic","USA","military personnel","military personnel",94.7,"91.9",96.6,NA,"pre-delta (non-VOC, alpha)","~19 weeks",NA,NA,2141,"USA","USA",242,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-20,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-04-20
"2088",242,"Eick-Cost","Case-control","20Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","USA","military personnel","military personnel",93.1,"91.2",94.6,NA,"pre-delta (non-VOC, alpha)","~19 weeks",NA,NA,2142,"USA","USA",242,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-20,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-04-20
"2089",242,"Eick-Cost","Case-control","20Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA","military personnel","military personnel",89.6,"57.5",97.4,NA,"pre-delta (non-VOC, alpha)","~19 weeks",NA,NA,2143,"USA","USA",242,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-20,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-04-20
"2090",242,"Eick-Cost","Case-control","20Apr2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","infection","infection","USA","military personnel","military personnel",81.8,"74.2",87.1,NA,"pre-delta (non-VOC, alpha)","~19 weeks",NA,NA,2144,"USA","USA",242,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-20,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-04-20
"2091",242,"Eick-Cost","Case-control","20Apr2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","asymptomatic infection","asymptomatic","USA","military personnel","military personnel",81.4,"62.6",90.8,NA,"pre-delta (non-VOC, alpha)","~19 weeks",NA,NA,2145,"USA","USA",242,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-20,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-04-20
"2092",242,"Eick-Cost","Case-control","20Apr2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","symptomatic disease","symptomatic","USA","military personnel","military personnel",82.4,"73.9",88.2,NA,"pre-delta (non-VOC, alpha)","~19 weeks",NA,NA,2146,"USA","USA",242,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-20,"symptomatic","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-04-20
"2093",242,"Eick-Cost","Case-control","20Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","USA","military personnel","military personnel",69.3,"68.2",70.3,NA,"delta","~35 weeks",NA,NA,2147,"USA","USA",242,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-20,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-20
"2094",242,"Eick-Cost","Case-control","20Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","asymptomatic infection","asymptomatic","USA","military personnel","military personnel",66,"64",67.8,NA,"delta","~35 weeks",NA,NA,2148,"USA","USA",242,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-20,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-20
"2095",242,"Eick-Cost","Case-control","20Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","USA","military personnel","military personnel",71,"69.7",72.1,NA,"delta","~35 weeks",NA,NA,2149,"USA","USA",242,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-20,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-20
"2096",242,"Eick-Cost","Case-control","20Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","USA","military personnel","military personnel",88.4,"82.1",92.5,NA,"delta","~35 weeks",NA,NA,2150,"USA","USA",242,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-20,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-20
"2097",242,"Eick-Cost","Case-control","20Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","military personnel","military personnel",79.4,"78.3",80.4,NA,"delta","~35 weeks",NA,NA,2151,"USA","USA",242,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-20,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-04-20
"2098",242,"Eick-Cost","Case-control","20Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","asymptomatic infection","asymptomatic","USA","military personnel","military personnel",77,"75.1",78.8,NA,"delta","~35 weeks",NA,NA,2152,"USA","USA",242,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-20,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-04-20
"2099",242,"Eick-Cost","Case-control","20Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","USA","military personnel","military personnel",80.6,"79.4",81.8,NA,"delta","~35 weeks",NA,NA,2153,"USA","USA",242,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-20,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-04-20
"2100",242,"Eick-Cost","Case-control","20Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA","military personnel","military personnel",88.1,"75.7",94.2,NA,"delta","~35 weeks",NA,NA,2154,"USA","USA",242,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-20,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-04-20
"2101",242,"Eick-Cost","Case-control","20Apr2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","infection","infection","USA","military personnel","military personnel",38.3,"34.5",41.9,NA,"delta","~35 weeks",NA,NA,2155,"USA","USA",242,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-20,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-04-20
"2102",242,"Eick-Cost","Case-control","20Apr2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","asymptomatic infection","asymptomatic","USA","military personnel","military personnel",19.6,"12.2",26.4,NA,"delta","~35 weeks",NA,NA,2156,"USA","USA",242,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-20,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-04-20
"2103",242,"Eick-Cost","Case-control","20Apr2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","symptomatic disease","symptomatic","USA","military personnel","military personnel",48.9,"45",52.7,NA,"delta","~35 weeks",NA,NA,2157,"USA","USA",242,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-20,"symptomatic","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-04-20
"2104",242,"Eick-Cost","Case-control","20Apr2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization","severe","USA","military personnel","military personnel",57.7,"2.6",81.6,NA,"delta","~35 weeks",NA,NA,2158,"USA","USA",242,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-20,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-04-20
"2105",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0-30","symptomatic disease","symptomatic","France",">= 18 years","general pop",43,"41",45,"omicron","omicron","~48 weeks",NA,NA,2159,"France","FRA",243,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"symptomatic","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-04-21
"2106",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","symptomatic disease","symptomatic","France",">= 18 years","general pop",11,"10",13,"omicron","omicron","~48 weeks",NA,NA,2160,"France","FRA",243,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"symptomatic","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-04-21
"2107",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0-30","hospitalization","severe","France",">= 18 years","general pop",59,"49",70,"omicron","omicron","~48 weeks",NA,NA,2161,"France","FRA",243,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-04-21
"2108",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","hospitalization","severe","France",">= 18 years","general pop",56,"51",62,"omicron","omicron","~48 weeks",NA,NA,2162,"France","FRA",243,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-04-21
"2109",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0-30","ICU admission","severe","France",">= 18 years","general pop",70,"40",97,"omicron","omicron","~48 weeks",NA,NA,2163,"France","FRA",243,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-04-21
"2110",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","ICU admission","severe","France",">= 18 years","general pop",72,"63",81,"omicron","omicron","~48 weeks",NA,NA,2164,"France","FRA",243,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-04-21
"2111",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0-30","death","death","France",">= 18 years","general pop",60,"24",92,"omicron","omicron","~48 weeks",NA,NA,2165,"France","FRA",243,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"death","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-04-21
"2112",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","death","death","France",">= 18 years","general pop",54,"41",69,"omicron","omicron","~48 weeks",NA,NA,2166,"France","FRA",243,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"death","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-04-21
"2113",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0-30","symptomatic disease","symptomatic","France",">= 18 years","general pop",78,"77",80,"delta","delta","~48 weeks",NA,NA,2167,"France","FRA",243,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"symptomatic","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-21
"2114",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","symptomatic disease","symptomatic","France",">= 18 years","general pop",63,"62",64,"delta","delta","~48 weeks",NA,NA,2168,"France","FRA",243,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"symptomatic","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-21
"2115",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0-30","hospitalization","severe","France",">= 18 years","general pop",91,"87",95,"delta","delta","~48 weeks",NA,NA,2169,"France","FRA",243,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-21
"2116",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","hospitalization","severe","France",">= 18 years","general pop",90,"89",91,"delta","delta","~48 weeks",NA,NA,2170,"France","FRA",243,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-21
"2117",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0-30","ICU admission","severe","France",">= 18 years","general pop",93,"86",99,"delta","delta","~48 weeks",NA,NA,2171,"France","FRA",243,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-21
"2118",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","ICU admission","severe","France",">= 18 years","general pop",95,"93",97,"delta","delta","~48 weeks",NA,NA,2172,"France","FRA",243,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-21
"2119",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0-30","death","death","France",">= 18 years","general pop",90,"79",100,"delta","delta","~48 weeks",NA,NA,2173,"France","FRA",243,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"death","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-21
"2120",243,"Castillo","Test-negative case-control","21Apr2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","death","death","France",">= 18 years","general pop",87,"83",91,"delta","delta","~48 weeks",NA,NA,2174,"France","FRA",243,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-21,"death","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-04-21
"2121",244,"Sharma","Matched case-control","27Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","USA","veterans","veterans",25.3,"21.8",28.7,NA,"omicron","~42 weeks",NA,NA,2175,"USA","USA",244,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-27,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-04-27
"2122",244,"Sharma","Matched case-control","27Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","USA","veterans","veterans",52.9,"47.8",57.6,NA,"omicron","~42 weeks",NA,NA,2176,"USA","USA",244,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-27,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-04-27
"2123",244,"Sharma","Matched case-control","27Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","USA","veterans","veterans",50.7,"37.9",61.6,NA,"omicron","~42 weeks",NA,NA,2177,"USA","USA",244,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-27,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-04-27
"2124",244,"Sharma","Matched case-control","27Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","veterans","veterans",39.5,"35.8",43,NA,"omicron","~42 weeks",NA,NA,2178,"USA","USA",244,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-27,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2022-04-27
"2125",244,"Sharma","Matched case-control","27Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA","veterans","veterans",66.7,"61.4",71.6,NA,"omicron","~42 weeks",NA,NA,2179,"USA","USA",244,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-27,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2022-04-27
"2126",244,"Sharma","Matched case-control","27Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","death","death","USA","veterans","veterans",65.6,"52.8",76.3,NA,"omicron","~42 weeks",NA,NA,2180,"USA","USA",244,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-27,"death","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2022-04-27
"2127",246,"Florentino","Test-negative case-control","13Aug2022","CoronaVac (Sinovac)","included","2","final","14+","symptomatic disease","symptomatic","Brazil","6-11 years","6-11 years",39.8,"33.7",45.4,NA,"omicron","~12 weeks",NA,NA,2181,"Brazil","BRA",246,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-13,"symptomatic","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","29/04/2022",2022-04-29
"2128",246,"Florentino","Test-negative case-control","13Aug2022","CoronaVac (Sinovac)","included","2","final","14+","hospitalization","severe","Brazil","6-11 years","6-11 years",59.2,"11.3",84.5,NA,"omicron","~12 weeks",NA,NA,2182,"Brazil","BRA",246,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-13,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","29/04/2022",2022-04-29
"2129",247,"Kirsebom","Test-negative case-control","12Dec2022","AZD1222 (AstraZeneca)","included","2","final","175+","symptomatic disease","symptomatic","UK","40-64 years","40-64 years",8,"6",9.9,"omicron","omicron","~44.5 weeks",NA,NA,2183,"UK","GBR",247,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-12-12,"symptomatic","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","01/05/2022",2022-05-01
"2130",247,"Kirsebom","Test-negative case-control","12Dec2022","AZD1222 (AstraZeneca)","included","2","final","175+","symptomatic disease","symptomatic","UK","40-64 years","40-64 years",19.5,"11.7",26.6,"omicron","omicron","~44.5 weeks",NA,NA,2184,"UK","GBR",247,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-12-12,"symptomatic","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","01/05/2022",2022-05-01
"2131",247,"Kirsebom","Test-negative case-control","12Dec2022","AZD1222 (AstraZeneca)","included","2","final","175+","hospitalization","severe","UK",">= 65 years",">= 65 years",61,"49.8",69.7,"omicron","omicron","~44.5 weeks",NA,NA,2185,"UK","GBR",247,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-12-12,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","01/05/2022",2022-05-01
"2132",247,"Kirsebom","Test-negative case-control","12Dec2022","AZD1222 (AstraZeneca)","included","2","final","175+","hospitalization","severe","UK",">= 65 years",">= 65 years",73.4,"70.4",76.2,"delta","delta","~44.5 weeks",NA,NA,2186,"UK","GBR",247,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-12-12,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","01/05/2022",2022-05-01
"2133",248,"Carazo","Test-negative case-control","14Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","infection","infection","Canada",">= 12 years","general pop",42,"41",44,NA,"omicron","~51 weeks",NA,NA,2187,"Canada","CAN",248,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-10-14,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","03/05/2022",2022-05-03
"2134",248,"Carazo","Test-negative case-control","14Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","hospitalization","severe","Canada",">= 12 years","general pop",76,"74",78,NA,"omicron","~51 weeks",NA,NA,2188,"Canada","CAN",248,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-10-14,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","03/05/2022",2022-05-03
"2135",248,"Carazo","Test-negative case-control","14Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected only","2","final","7+","infection","infection","Canada",">= 12 years","general pop",23.2,"21.2",27.4,NA,"omicron","~51 weeks",NA,NA,2189,"Canada","CAN",248,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-10-14,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","03/05/2022",2022-05-03
"2136",248,"Carazo","Test-negative case-control","14Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected only","2","final","7+","hospitalization","severe","Canada",">= 12 years","general pop",68.4,"63.6",73.5,NA,"omicron","~51 weeks",NA,NA,2190,"Canada","CAN",248,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-10-14,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","03/05/2022",2022-05-03
"2137",249,"Ma","Retrospective cohort/Outbreak investigation","03May2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","symptomatic disease","symptomatic","China","close contacts","close contacts",75.5,"63",93.6,NA,"delta","~8 weeks",NA,NA,2191,"China","CHN",249,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2022-05-03,"symptomatic","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-05-03
"2138",249,"Ma","Retrospective cohort/Outbreak investigation","03May2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","pneumonia","severe","China","close contacts","close contacts",56.5,"-95.9",90.4,NA,"delta","~8 weeks",NA,NA,2192,"China","CHN",249,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2022-05-03,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-05-03
"2139",249,"Ma","Retrospective cohort/Outbreak investigation","03May2022","CoronaVac (Sinovac)","included","2","final","14+","symptomatic disease","symptomatic","China","close contacts","close contacts",73,"22.3",96,NA,"delta","~8 weeks",NA,NA,2193,"China","CHN",249,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2022-05-03,"symptomatic","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta",NA,2022-05-03
"2140",249,"Ma","Retrospective cohort/Outbreak investigation","03May2022","CoronaVac (Sinovac)","included","2","final","14+","pneumonia","severe","China","close contacts","close contacts",84.6,"18.8",97.1,NA,"delta","~8 weeks",NA,NA,2194,"China","CHN",249,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2022-05-03,"severe","2022 (Jan-Jun)","Sinovac CoronaVac","Inactivated","delta",NA,2022-05-03
"2141",249,"Ma","Retrospective cohort/Outbreak investigation","03May2022","Ad5-nCOV (CanSino)","included","1","final","14+","symptomatic disease","symptomatic","China","close contacts","close contacts",61.5,"9.5",83.6,NA,"delta","~8 weeks",NA,NA,2195,"China","CHN",249,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2022-05-03,"symptomatic","2022 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","delta",NA,2022-05-03
"2142",249,"Ma","Retrospective cohort/Outbreak investigation","03May2022","Ad5-nCOV (CanSino)","included","1","final","14+","pneumonia","severe","China","close contacts","close contacts",67.9,"1.7",89.9,NA,"delta","~8 weeks",NA,NA,2196,"China","CHN",249,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2022-05-03,"severe","2022 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","delta",NA,2022-05-03
"2143",249,"Ma","Retrospective cohort/Outbreak investigation","03May2022","Ad5-nCOV (CanSino)","included","1","final","14+","severe disease","severe","China","close contacts","close contacts",100,NA,NA,NA,"delta","~8 weeks",NA,NA,2197,"China","CHN",249,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2022-05-03,"severe","2022 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","delta",NA,2022-05-03
"2144",250,"Rennert","Propensity matched case control","10Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA","students 18-64 years","students 18-64 years",2.1,"-21.2",21,NA,"omicron","~23 weeks",NA,NA,2198,"USA","USA",250,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-10,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","07/05/2022",2022-05-07
"2145",250,"Rennert","Propensity matched case control","10Jan2023","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","USA","students 18-64 years","students 18-64 years",17.3,"-10.8",38.3,NA,"omicron","~23 weeks",NA,NA,2199,"USA","USA",250,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-10,"infection","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","07/05/2022",2022-05-07
"2146",250,"Rennert","Propensity matched case control","10Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA","employees 18-65 years","employees 18-65 years",30.1,"-24.5",60.8,NA,"omicron","~23 weeks",NA,NA,2200,"USA","USA",250,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-10,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","07/05/2022",2022-05-07
"2147",250,"Rennert","Propensity matched case control","10Jan2023","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","USA","employees 18-65 years","employees 18-65 years",14.4,"-64.2",55.4,NA,"omicron","~23 weeks",NA,NA,2201,"USA","USA",250,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-10,"infection","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","07/05/2022",2022-05-07
"2148",251,"Simwanza","Case-control","12Sept2022","Ad26.COV2.S (Janssen)","included","1","final","14+","infection","infection","Zambia",">= 18 years in a correctional facility","18+ years in a correctional facility",63.6,"33.6",80.5,NA,"omicron","~13 weeks",NA,NA,2202,"Zambia","ZMB",251,"ZMB",1380,2019,"Zambia","Sub-Saharan Africa","Lower middle income",1,"Africa",2021-04-18,2022-10-27,NA,2021-04-14,2021-04-14,4,561,NA,"who","march/2021 +","Dec/2021 +","360+","yes","no","no",2022-09-12,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron","08/06/2022",2022-06-08
"2149",251,"Simwanza","Case-control","12Sept2022","Ad26.COV2.S (Janssen)","included","1","final","14+","symptomatic disease","symptomatic","Zambia",">= 18 years in a correctional facility","18+ years in a correctional facility",73,"41.6",87.7,NA,"omicron","~13 weeks",NA,NA,2203,"Zambia","ZMB",251,"ZMB",1380,2019,"Zambia","Sub-Saharan Africa","Lower middle income",1,"Africa",2021-04-18,2022-10-27,NA,2021-04-14,2021-04-14,4,561,NA,"who","march/2021 +","Dec/2021 +","360+","yes","no","no",2022-09-12,"symptomatic","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron","08/06/2022",2022-06-08
"2150",251,"Simwanza","Case-control","12Sept2022","AZD1222 (AstraZeneca)","included","2","final","14+","infection","infection","Zambia",">= 18 years in a correctional facility","18+ years in a correctional facility",89.4,"59.5",97.8,NA,"omicron","~13 weeks",NA,NA,2204,"Zambia","ZMB",251,"ZMB",1380,2019,"Zambia","Sub-Saharan Africa","Lower middle income",1,"Africa",2021-04-18,2022-10-27,NA,2021-04-14,2021-04-14,4,561,NA,"who","march/2021 +","Dec/2021 +","360+","yes","no","no",2022-09-12,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","08/06/2022",2022-06-08
"2151",251,"Simwanza","Case-control","12Sept2022","AZD1222 (AstraZeneca)","included","2","final","14+","symptomatic disease","symptomatic","Zambia",">= 18 years in a correctional facility","18+ years in a correctional facility",85.1,"19.5",98,NA,"omicron","~13 weeks",NA,NA,2205,"Zambia","ZMB",251,"ZMB",1380,2019,"Zambia","Sub-Saharan Africa","Lower middle income",1,"Africa",2021-04-18,2022-10-27,NA,2021-04-14,2021-04-14,4,561,NA,"who","march/2021 +","Dec/2021 +","360+","yes","no","no",2022-09-12,"symptomatic","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","08/06/2022",2022-06-08
"2152",252,"Zahradka","Retrospective cohort","03May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Czech Republic","kidney transplant recipients","transplant recipients",45.6,"12.4",67.6,NA,"alpha","~12.5 weeks",NA,NA,2206,"Czech Republic","CZE",252,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-05-03,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-05-03
"2153",253,"Martellucci","Retrospective cohort","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Italy",">= 18 years","general pop",24,"23",25,NA,"alpha, delta, & omicron","~53 weeks",NA,NA,2207,"Italy","ITA",253,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-22,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-22
"2154",253,"Martellucci","Retrospective cohort","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Italy",">= 18 years","general pop",86,"84",88,NA,"alpha, delta, & omicron","~53 weeks",NA,NA,2208,"Italy","ITA",253,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-22
"2155",253,"Martellucci","Retrospective cohort","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","Italy",">= 18 years","general pop",92,"90",94,NA,"alpha, delta, & omicron","~53 weeks",NA,NA,2209,"Italy","ITA",253,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-22,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-22
"2156",253,"Martellucci","Retrospective cohort","22Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Italy",">= 18 years","general pop",32,"31",34,NA,"alpha, delta, & omicron","~53 weeks",NA,NA,2210,"Italy","ITA",253,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-22,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-04-22
"2157",253,"Martellucci","Retrospective cohort","22Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","Italy",">= 18 years","general pop",90,"86",93,NA,"alpha, delta, & omicron","~53 weeks",NA,NA,2211,"Italy","ITA",253,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-22,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-04-22
"2158",253,"Martellucci","Retrospective cohort","22Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","death","death","Italy",">= 18 years","general pop",96,"92",98,NA,"alpha, delta, & omicron","~53 weeks",NA,NA,2212,"Italy","ITA",253,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-22,"death","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-04-22
"2159",253,"Martellucci","Retrospective cohort","22Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection","infection","Italy",">= 18 years","general pop",4,"1",6,NA,"alpha, delta, & omicron","~53 weeks",NA,NA,2213,"Italy","ITA",253,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-22,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-04-22
"2160",253,"Martellucci","Retrospective cohort","22Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","hospitalization","severe","Italy",">= 18 years","general pop",93,"92",95,NA,"alpha, delta, & omicron","~53 weeks",NA,NA,2214,"Italy","ITA",253,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-22,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-04-22
"2161",253,"Martellucci","Retrospective cohort","22Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","death","death","Italy",">= 18 years","general pop",98,"96",99,NA,"alpha, delta, & omicron","~53 weeks",NA,NA,2215,"Italy","ITA",253,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-22,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-04-22
"2162",253,"Martellucci","Retrospective cohort","22Apr2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","infection","infection","Italy",">= 18 years","general pop",12,"7",17,NA,"alpha, delta, & omicron","~53 weeks",NA,NA,2216,"Italy","ITA",253,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-22,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-04-22
"2163",253,"Martellucci","Retrospective cohort","22Apr2022","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization","severe","Italy",">= 18 years","general pop",87,"73",94,NA,"alpha, delta, & omicron","~53 weeks",NA,NA,2217,"Italy","ITA",253,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-22,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-04-22
"2164",254,"Braeye","Retrospective cohort","11May2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-57","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",72,"70",74,NA,"alpha","~28.5 weeks",NA,NA,2218,"Belgium","BEL",254,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-05-11
"2165",254,"Braeye","Retrospective cohort","11May2022","mRNA-1273 (Moderna)","excluded","2","final","14-64","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",82,"79",84,NA,"alpha","~28.5 weeks",NA,NA,2219,"Belgium","BEL",254,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","alpha",NA,2022-05-11
"2166",254,"Braeye","Retrospective cohort","11May2022","Ad26.COV2.S (Janssen)","excluded","1","final","21-71","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",38,"34",44,NA,"alpha","~28.5 weeks",NA,NA,2220,"Belgium","BEL",254,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","alpha",NA,2022-05-11
"2167",254,"Braeye","Retrospective cohort","11May2022","AZD1222 (AstraZeneca)","excluded","2","final","14-64","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",56,"51",59,NA,"alpha","~28.5 weeks",NA,NA,2221,"Belgium","BEL",254,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","alpha",NA,2022-05-11
"2168",254,"Braeye","Retrospective cohort","11May2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-57","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",64,"63",66,NA,"delta","~28.5 weeks",NA,NA,2222,"Belgium","BEL",254,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-05-11
"2169",254,"Braeye","Retrospective cohort","11May2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","157-207","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",44,"43",44,NA,"delta","~28.5 weeks",NA,NA,2223,"Belgium","BEL",254,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-05-11
"2170",254,"Braeye","Retrospective cohort","11May2022","mRNA-1273 (Moderna)","excluded","2","final","14-64","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",75,"71",77,NA,"delta","~28.5 weeks",NA,NA,2224,"Belgium","BEL",254,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-05-11
"2171",254,"Braeye","Retrospective cohort","11May2022","mRNA-1273 (Moderna)","excluded","2","final","164-214","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",56,"55",58,NA,"delta","~28.5 weeks",NA,NA,2225,"Belgium","BEL",254,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-05-11
"2172",254,"Braeye","Retrospective cohort","11May2022","Ad26.COV2.S (Janssen)","excluded","1","final","21-71","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",33,"28",38,NA,"delta","~28.5 weeks",NA,NA,2226,"Belgium","BEL",254,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-05-11
"2173",254,"Braeye","Retrospective cohort","11May2022","Ad26.COV2.S (Janssen)","excluded","1","final","171-221","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",22,"19",25,NA,"delta","~28.5 weeks",NA,NA,2227,"Belgium","BEL",254,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-05-11
"2174",254,"Braeye","Retrospective cohort","11May2022","AZD1222 (AstraZeneca)","excluded","2","final","14-64","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",49,"45",52,NA,"delta","~28.5 weeks",NA,NA,2228,"Belgium","BEL",254,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-05-11
"2175",254,"Braeye","Retrospective cohort","11May2022","AZD1222 (AstraZeneca)","excluded","2","final","164-214","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",35,"33",37,NA,"delta","~28.5 weeks",NA,NA,2229,"Belgium","BEL",254,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-05-11
"2176",254,"Braeye","Retrospective cohort","11May2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","7-57","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",87,"84",88,NA,"delta","~28.5 weeks",NA,NA,2230,"Belgium","BEL",254,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-05-11
"2177",254,"Braeye","Retrospective cohort","11May2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","157-207","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",82,"81",83,NA,"delta","~28.5 weeks",NA,NA,2231,"Belgium","BEL",254,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-05-11
"2178",254,"Braeye","Retrospective cohort","11May2022","mRNA-1273 (Moderna)","previously infected only","2","final","14-64","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",87,"83",92,NA,"delta","~28.5 weeks",NA,NA,2232,"Belgium","BEL",254,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-05-11
"2179",254,"Braeye","Retrospective cohort","11May2022","mRNA-1273 (Moderna)","previously infected only","2","final","164-214","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",85,"80",89,NA,"delta","~28.5 weeks",NA,NA,2233,"Belgium","BEL",254,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-05-11
"2180",254,"Braeye","Retrospective cohort","11May2022","Ad26.COV2.S (Janssen)","previously infected only","1","final","21-71","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",88,"85",91,NA,"delta","~28.5 weeks",NA,NA,2234,"Belgium","BEL",254,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-05-11
"2181",254,"Braeye","Retrospective cohort","11May2022","Ad26.COV2.S (Janssen)","previously infected only","1","final","171-221","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",87,"84",89,NA,"delta","~28.5 weeks",NA,NA,2235,"Belgium","BEL",254,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-05-11
"2182",254,"Braeye","Retrospective cohort","11May2022","AZD1222 (AstraZeneca)","previously infected only","2","final","14-64","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",88,"84",94,NA,"delta","~28.5 weeks",NA,NA,2236,"Belgium","BEL",254,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-05-11
"2183",254,"Braeye","Retrospective cohort","11May2022","AZD1222 (AstraZeneca)","previously infected only","2","final","164-214","infection","infection","Belgium","contacts of index cases among women aged 45-64","contacts of index cases among women aged 45-64",83,"81",85,NA,"delta","~28.5 weeks",NA,NA,2237,"Belgium","BEL",254,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-11,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-05-11
"2184",255,"Lan","Retrospective cohort","12May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","HCW","HCW",82.3,"75.1",87.4,NA,"non-VOC, alpha, & delta","~36 weeks",NA,NA,2238,"USA","USA",255,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-05-12,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-05-12
"2185",255,"Lan","Retrospective cohort","12May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","HCW","HCW",76.5,"40.9",90.6,NA,"non-VOC, alpha, & delta","~36 weeks",NA,NA,2239,"USA","USA",255,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-05-12,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-05-12
"2186",256,"Tenforde","Case-control","17May2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-179","hospitalization","severe","USA","hospitalized adults","hospitalized adults",88,"86",90,NA,"alpha & delta","~23.5 weeks",NA,NA,2240,"USA","USA",256,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-05-17,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-05-17
"2187",256,"Tenforde","Case-control","17May2022","BNT162b2 (Pfizer BioNTech)","included","2","final","180+","hospitalization","severe","USA","hospitalized adults","hospitalized adults",79,"74",83,NA,"alpha & delta","~47 weeks",NA,NA,2241,"USA","USA",256,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-05-17,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-05-17
"2188",256,"Tenforde","Case-control","17May2022","mRNA-1273 (Moderna)","included","2","final","14-179","hospitalization","severe","USA","hospitalized adults","hospitalized adults",93,"91",94,NA,"alpha & delta","~23.5 weeks",NA,NA,2242,"USA","USA",256,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-05-17,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-05-17
"2189",256,"Tenforde","Case-control","17May2022","mRNA-1273 (Moderna)","included","2","final","180+","hospitalization","severe","USA","hospitalized adults","hospitalized adults",87,"83",90,NA,"alpha & delta","~47 weeks",NA,NA,2243,"USA","USA",256,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-05-17,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-05-17
"2190",256,"Tenforde","Case-control","17May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-179","hospitalization","severe","USA","immunocompetent adults","immunocompetent adults",90,"88",91,NA,"alpha & delta","~23.5 weeks",NA,NA,2244,"USA","USA",256,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-05-17,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-05-17
"2191",256,"Tenforde","Case-control","17May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","hospitalization","severe","USA","immunocompetent adults","immunocompetent adults",82,"79",85,NA,"alpha & delta","~47 weeks",NA,NA,2245,"USA","USA",256,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-05-17,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-05-17
"2192",256,"Tenforde","Case-control","17May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","hospitalized immunocompromised adults","immunocompromised adults",63,"55",69,NA,"alpha & delta","~47 weeks",NA,NA,2246,"USA","USA",256,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-05-17,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-05-17
"2193",256,"Tenforde","Case-control","17May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-179","hospitalization","severe","USA","hospitalized immunocompromised adults","immunocompromised adults",65,"57",72,NA,"alpha & delta","~23.5 weeks",NA,NA,2247,"USA","USA",256,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-05-17,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-05-17
"2194",256,"Tenforde","Case-control","17May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","hospitalization","severe","USA","hospitalized immunocompromised adults","immunocompromised adults",53,"38",65,NA,"alpha & delta","~47 weeks",NA,NA,2248,"USA","USA",256,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-05-17,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-05-17
"2195",256,"Tenforde","Case-control","17May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-179","hospitalization","severe","USA","hospitalized adults","hospitalized adults",90,"88",91,NA,"delta","~23.5 weeks",NA,NA,2249,"USA","USA",256,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-05-17,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-05-17
"2196",256,"Tenforde","Case-control","17May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","hospitalization","severe","USA","hospitalized adults","hospitalized adults",83,"80",86,NA,"delta","~47 weeks",NA,NA,2250,"USA","USA",256,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-05-17,"severe","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-05-17
"2197",257,"Fano","Retrospective cohort","18May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","40-44","infection","infection","Italy",">= 12 years","general pop",70.9,"69.3",72.4,NA,"alpha & delta","~48 weeks",NA,NA,2251,"Italy","ITA",257,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-18,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-05-18
"2198",257,"Fano","Retrospective cohort","18May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","200+","infection","infection","Italy",">= 12 years","general pop",22.7,"18.5",26.8,NA,"alpha & delta","~48 weeks",NA,NA,2252,"Italy","ITA",257,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-18,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-05-18
"2199",257,"Fano","Retrospective cohort","18May2022","AZD1222 (AstraZeneca)","excluded","2","final","40-44","infection","infection","Italy",">= 12 years","general pop",76.3,"71.9",80,NA,"alpha & delta","~48 weeks",NA,NA,2253,"Italy","ITA",257,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-18,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-05-18
"2200",257,"Fano","Retrospective cohort","18May2022","AZD1222 (AstraZeneca)","excluded","2","final","125+","infection","infection","Italy",">= 12 years","general pop",3.8,"0",9.2,NA,"alpha & delta","~48 weeks",NA,NA,2254,"Italy","ITA",257,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-18,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-05-18
"2201",257,"Fano","Retrospective cohort","18May2022","Ad26.COV2.S (Janssen)","excluded","1","final","40-44","infection","infection","Italy",">= 12 years","general pop",39.4,"28.3",48.8,NA,"alpha & delta","~48 weeks",NA,NA,2255,"Italy","ITA",257,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-18,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-05-18
"2202",257,"Fano","Retrospective cohort","18May2022","Ad26.COV2.S (Janssen)","excluded","1","final","150+","infection","infection","Italy",">= 12 years","general pop",2.5,"0",9.1,NA,"alpha & delta","~48 weeks",NA,NA,2256,"Italy","ITA",257,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-18,"infection","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-05-18
"2203",257,"Fano","Retrospective cohort","18May2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","40-44","infection","infection","Italy",">= 12 years","general pop",81.6,"75.3",86.3,NA,"alpha & delta","~48 weeks",NA,NA,2257,"Italy","ITA",257,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-18,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations",NA,2022-05-18
"2204",257,"Fano","Retrospective cohort","18May2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","excluded","2","final","125+","infection","infection","Italy",">= 12 years","general pop",3.1,"0",12,NA,"alpha & delta","~48 weeks",NA,NA,2258,"Italy","ITA",257,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-05-18,"infection","2022 (Jan-Jun)","Heterologous platforms","Multiple","other combinations",NA,2022-05-18
"2205",258,"Paranthaman","Retrospective cohort","20May2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-34","infection","infection","UK","LTCF residents","LTCF residents",62,"46",73,NA,"alpha & delta","~3 weeks",NA,NA,2259,"UK","GBR",258,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-05-20,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-05-20
"2206",258,"Paranthaman","Retrospective cohort","20May2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","147+","infection","infection","UK","LTCF residents","LTCF residents",47,"32",58,NA,"alpha & delta","~37 weeks",NA,NA,2260,"UK","GBR",258,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-05-20,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-05-20
"2207",258,"Paranthaman","Retrospective cohort","20May2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-34","death","death","UK","LTCF residents","LTCF residents",86,"67",94,NA,"alpha & delta","~3 weeks",NA,NA,2261,"UK","GBR",258,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-05-20,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-05-20
"2208",258,"Paranthaman","Retrospective cohort","20May2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","147+","death","death","UK","LTCF residents","LTCF residents",69,"51",80,NA,"alpha & delta","~37 weeks",NA,NA,2262,"UK","GBR",258,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-05-20,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-05-20
"2209",258,"Paranthaman","Retrospective cohort","20May2022","AZD1222 (AstraZeneca)","excluded","2","final","7-34","infection","infection","UK","LTCF residents","LTCF residents",61,"40",74,NA,"alpha & delta","~3 weeks",NA,NA,2263,"UK","GBR",258,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-05-20,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-05-20
"2210",258,"Paranthaman","Retrospective cohort","20May2022","AZD1222 (AstraZeneca)","excluded","2","final","147+","infection","infection","UK","LTCF residents","LTCF residents",29,"10",43,NA,"alpha & delta","~24.5 weeks",NA,NA,2264,"UK","GBR",258,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-05-20,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-05-20
"2211",258,"Paranthaman","Retrospective cohort","20May2022","AZD1222 (AstraZeneca)","excluded","2","final","7-34","death","death","UK","LTCF residents","LTCF residents",83,"58",94,NA,"alpha & delta","~3 weeks",NA,NA,2265,"UK","GBR",258,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-05-20,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-05-20
"2212",258,"Paranthaman","Retrospective cohort","20May2022","AZD1222 (AstraZeneca)","excluded","2","final","147+","death","death","UK","LTCF residents","LTCF residents",56,"33",70,NA,"alpha & delta","~24.5 weeks",NA,NA,2266,"UK","GBR",258,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-05-20,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-05-20
"2213",258,"Paranthaman","Retrospective cohort","20May2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","7-34","infection","infection","UK","LTCF residents","LTCF residents",79,"15",95,NA,"alpha & delta","~3 weeks",NA,NA,2267,"UK","GBR",258,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-05-20,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-05-20
"2214",258,"Paranthaman","Retrospective cohort","20May2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","147+","infection","infection","UK","LTCF residents","LTCF residents",80,"43",93,NA,"alpha & delta","~37 weeks",NA,NA,2268,"UK","GBR",258,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-05-20,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-05-20
"2215",258,"Paranthaman","Retrospective cohort","20May2022","AZD1222 (AstraZeneca)","previously infected only","2","final","7-34","infection","infection","UK","LTCF residents","LTCF residents",37,"-50",73,NA,"alpha & delta","~3 weeks",NA,NA,2269,"UK","GBR",258,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-05-20,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-05-20
"2216",258,"Paranthaman","Retrospective cohort","20May2022","AZD1222 (AstraZeneca)","previously infected only","2","final","147+","infection","infection","UK","LTCF residents","LTCF residents",65,"14",86,NA,"alpha & delta","~24.5 weeks",NA,NA,2270,"UK","GBR",258,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-05-20,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-05-20
"2217",259,"Tsundue","Prospective cohort","24May2022","AZD1222 (Covishield)","included","2","final","14+","infection","infection","India","residents of congregate living facilities","general pop",98,"85",99.8,NA,"delta","13 weeks",NA,NA,2271,"India","IND",259,"IND",2070,2019,"India","South Asia","Lower middle income",1,"Asia",2021-01-16,2021-12-24,NA,2021-01-16,2021-01-16,0,342,NA,"equal","jan/2021","Dec/2021 +","270-359","yes","yes","no",2022-05-24,"infection","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-05-24
"2218",259,"Tsundue","Prospective cohort","24May2022","AZD1222 (Covishield)","included","2","final","14+","shortness of breath/use of supplemental oxygen, hospitalization or death","severe","India","residents of congregate living facilities","general pop",99,"90",99.8,NA,"delta","13 weeks",NA,NA,2272,"India","IND",259,"IND",2070,2019,"India","South Asia","Lower middle income",1,"Asia",2021-01-16,2021-12-24,NA,2021-01-16,2021-01-16,0,342,NA,"equal","jan/2021","Dec/2021 +","270-359","yes","yes","no",2022-05-24,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-05-24
"2219",260,"Amir","Retrospective cohort","09Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-35","infection","infection","Israel","5-10 years","5-10 years",58.3,"54.6",61.5,NA,"omicron","~2 weeks",NA,NA,2273,"Israel","ISR",260,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-09,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/05/2022",2022-05-25
"2220",261,"Chin","Retrospective cohort","26Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","prison residents >= 18 years","prison residents",18.6,"7.7",28.1,NA,"omicron","~65 weeks",NA,NA,2274,"USA","USA",261,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-26,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/05/2022",2022-05-27
"2221",261,"Chin","Retrospective cohort","26Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","prison staff >= 18 years","prison staff",40.1,"34",45.6,NA,"omicron","~65 weeks",NA,NA,2275,"USA","USA",261,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-26,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/05/2022",2022-05-27
"2222",261,"Chin","Retrospective cohort","26Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected before July 1, 2021","2","final","14+","infection","infection","USA","prison residents >= 18 years","prison residents",51.2,"41.5",59.2,NA,"omicron","~65 weeks",NA,NA,2276,"USA","USA",261,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-26,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/05/2022",2022-05-27
"2223",261,"Chin","Retrospective cohort","26Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected before July 1, 2021","2","final","14+","infection","infection","USA","prison staff >= 18 years","prison staff",55.8,"49.6",61.2,NA,"omicron","~65 weeks",NA,NA,2277,"USA","USA",261,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-26,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/05/2022",2022-05-27
"2224",261,"Chin","Retrospective cohort","26Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected between July 1 and November 30, 2021","2","final","14+","infection","infection","USA","prison residents >= 18 years","prison residents",68.7,"38.5",84.1,NA,"omicron","~65 weeks",NA,NA,2278,"USA","USA",261,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-26,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/05/2022",2022-05-27
"2225",261,"Chin","Retrospective cohort","26Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected between July 1 and November 30, 2021","2","final","14+","infection","infection","USA","prison staff >= 18 years","prison staff",83.2,"77.7",87.4,NA,"omicron","~65 weeks",NA,NA,2279,"USA","USA",261,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-26,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/05/2022",2022-05-27
"2226",261,"Chin","Retrospective test-negative case control","26Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","prison residents and staff >= 18 years","prison residents and staff",14.9,"12.3",19.7,NA,"omicron","~65 weeks",NA,NA,2280,"USA","USA",261,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-26,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/05/2022",2022-05-27
"2227",261,"Chin","Retrospective test-negative case control","26Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected before July 1, 2021","2","final","14+","infection","infection","USA","prison residents and staff >= 18 years","prison residents and staff",47.8,"46.6",52.8,NA,"omicron","~65 weeks",NA,NA,2281,"USA","USA",261,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-26,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/05/2022",2022-05-27
"2228",261,"Chin","Retrospective test-negative case control","26Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected between July 1 and November 30, 2021","2","final","14+","infection","infection","USA","prison residents and staff >= 18 years","prison residents and staff",73.1,"69.8",80.1,NA,"omicron","~65 weeks",NA,NA,2282,"USA","USA",261,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-26,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/05/2022",2022-05-27
"2229",262,"Carlsen","Retrospective cohort","01Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection during an infant's first 4 months of life (born to unvaccinated mothers and mothers vaccinated in 2nd or 3rd trimester)","infection during an infant's first 4 months of life","Norway","newborns","newborns",30,"17",41,NA,"omicron","~45 weeks",NA,NA,2283,"Norway","NOR",262,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-01,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-06-01
"2230",262,"Carlsen","Retrospective cohort","01Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection during an infant's first 4 months of life (born to unvaccinated mothers and mothers vaccinated in 2nd or 3rd trimester)","infection during an infant's first 4 months of life","Norway","newborns","newborns",71,"56",81,NA,"delta","~45 weeks",NA,NA,2284,"Norway","NOR",262,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-01,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-06-01
"2231",263,"Grewal","Test-negative case-control","06Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0+","infection","infection","Canada","LTCF residents","LTCF residents",6,"-5",15,"omicron","omicron","~66 weeks",NA,NA,2285,"Canada","CAN",263,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-06,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-07-06
"2232",263,"Grewal","Test-negative case-control","06Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0+","symptomatic disease","symptomatic","Canada","LTCF residents","LTCF residents",23,"1",40,"omicron","omicron","~66 weeks",NA,NA,2286,"Canada","CAN",263,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-06,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-07-06
"2233",263,"Grewal","Test-negative case-control","06Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0+","hospitalization or death","severe","Canada","LTCF residents","LTCF residents",52,"33",65,"omicron","omicron","~66 weeks",NA,NA,2287,"Canada","CAN",263,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-06,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-07-06
"2234",264,"Spicer","Test-negative case-control","26May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","12-17 years","12-17 years",81,"79.7",82.3,NA,"delta","~36.5 weeks",NA,NA,2288,"USA","USA",264,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-05-26,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-05-26
"2235",264,"Spicer","Test-negative case-control","26May2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected only","2","final","14+","infection","infection","USA","12-17 years","12-17 years",78.3,"66.7",86.5,NA,"delta","~36.5 weeks",NA,NA,2289,"USA","USA",264,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-05-26,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2022-05-26
"2236",265,"Richterman","Test-negative case-control","06Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","USA","HCW","HCW",41,"-17",87,NA,"omicron","~63 weeks",NA,NA,2290,"USA","USA",265,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-06,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-06-06
"2237",265,"Richterman","Test-negative case-control","06Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","USA","HCW","HCW",5,"-69",47,NA,"omicron","~63 weeks",NA,NA,2291,"USA","USA",265,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-06,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2022-06-06
"2238",265,"Richterman","Test-negative case-control","06Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","USA","HCW","HCW",75,"52",87,NA,"delta","~63 weeks",NA,NA,2292,"USA","USA",265,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-06,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-06-06
"2239",265,"Richterman","Test-negative case-control","06Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","USA","HCW","HCW",73,"56",84,NA,"delta","~63 weeks",NA,NA,2293,"USA","USA",265,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-06,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-06-06
"2240",266,"Lin","RCT crossover","08Jun2022","mRNA-1273 (Moderna)","excluded","2","final","12 days","symptomatic disease","symptomatic","USA",">= 18 years","general pop",92.6,"80.5",97.2,NA,"original & alpha","~0 weeks",NA,NA,2294,"USA","USA",266,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-08,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-08
"2241",266,"Lin","RCT crossover","08Jun2022","mRNA-1273 (Moderna)","excluded","2","final","172 days","symptomatic disease","symptomatic","USA",">= 18 years","general pop",89.6,"41.7",98.2,NA,"original & alpha","~22.5 weeks",NA,NA,2295,"USA","USA",266,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-08,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-08
"2242",267,"Lewis","Test-negative case-control","08Jun2022","Ad26.COV2.S (Janssen)","included","1","final","14+","hospitalization","severe","USA","hospitalized adults","general pop",70,"63",75,NA,"alpha & delta","~39.5 weeks",NA,NA,2296,"USA","USA",267,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-08,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-06-08
"2243",267,"Lewis","Test-negative case-control","08Jun2022","Ad26.COV2.S (Janssen)","included","1","final","14-90","hospitalization","severe","USA","hospitalized adults","general pop",73,"60",82,NA,"alpha & delta","~39.5 weeks",NA,NA,2297,"USA","USA",267,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-08,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-06-08
"2244",267,"Lewis","Test-negative case-control","08Jun2022","Ad26.COV2.S (Janssen)","included","1","final","180+","hospitalization","severe","USA","hospitalized adults","general pop",70,"54",81,NA,"alpha & delta","~39.5 weeks",NA,NA,2298,"USA","USA",267,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-08,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-06-08
"2245",267,"Lewis","Test-negative case-control","08Jun2022","Ad26.COV2.S (Janssen)","included","1","final","14+","hospitalization","severe","USA","hospitalized immunocompromised adults","immunocompromised adults",55,"31",72,NA,"alpha & delta","~39.5 weeks",NA,NA,2299,"USA","USA",267,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-08,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-06-08
"2246",267,"Lewis","Test-negative case-control","08Jun2022","Ad26.COV2.S (Janssen)","included","1","final","14+","hospitalization","severe","USA","hospitalized adults","general pop",68,"43",83,NA,"alpha","~39.5 weeks",NA,NA,2300,"USA","USA",267,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-08,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","alpha",NA,2022-06-08
"2247",267,"Lewis","Test-negative case-control","08Jun2022","Ad26.COV2.S (Janssen)","included","1","final","14+","hospitalization","severe","USA","hospitalized adults","general pop",72,"64",78,NA,"delta","~39.5 weeks",NA,NA,2301,"USA","USA",267,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-08,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-06-08
"2248",270,"Al Kaabi","Retrospective cohort","09Jun2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","14+","hospitalization","severe","UAE",">= 18 years","general pop",97.3,"95.7",98.3,NA,"non-VOC","~39 weeks",NA,NA,2306,"United Arab Emirates","ARE",270,"ARE",45070,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,105,191,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-09,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","original",NA,2022-06-09
"2249",270,"Al Kaabi","Retrospective cohort","09Jun2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","14+","critical care admission","severe","UAE",">= 18 years","general pop",98.8,"95.3",99.7,NA,"non-VOC","~39 weeks",NA,NA,2307,"United Arab Emirates","ARE",270,"ARE",45070,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,105,191,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-09,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","original",NA,2022-06-09
"2250",270,"Al Kaabi","Retrospective cohort","09Jun2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","14+","death","death","UAE",">= 18 years","general pop",100,"100",100,NA,"non-VOC","~39 weeks",NA,NA,2308,"United Arab Emirates","ARE",270,"ARE",45070,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,105,191,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-09,"death","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","original",NA,2022-06-09
"2251",270,"Al Kaabi","Retrospective cohort","09Jun2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","14+","hospitalization","severe","UAE",">= 18 years","general pop",73.3,"70.6",75.7,NA,"alpha","~39 weeks",NA,NA,2309,"United Arab Emirates","ARE",270,"ARE",45070,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,105,191,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-09,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","alpha",NA,2022-06-09
"2252",270,"Al Kaabi","Retrospective cohort","09Jun2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","14+","critical care admission","severe","UAE",">= 18 years","general pop",79.1,"73.1",83.7,NA,"alpha","~39 weeks",NA,NA,2310,"United Arab Emirates","ARE",270,"ARE",45070,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,105,191,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-09,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","alpha",NA,2022-06-09
"2253",270,"Al Kaabi","Retrospective cohort","09Jun2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","14+","death","death","UAE",">= 18 years","general pop",81.9,"66.9",90.1,NA,"alpha","~39 weeks",NA,NA,2311,"United Arab Emirates","ARE",270,"ARE",45070,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,105,191,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-09,"death","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","alpha",NA,2022-06-09
"2254",270,"Al Kaabi","Retrospective cohort","09Jun2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","14+","hospitalization","severe","UAE",">= 18 years","general pop",34.6,"14.2",50.2,NA,"delta","~39 weeks",NA,NA,2312,"United Arab Emirates","ARE",270,"ARE",45070,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,105,191,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-09,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-06-09
"2255",270,"Al Kaabi","Retrospective cohort","09Jun2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","14+","critical care admission","severe","UAE",">= 18 years","general pop",49.6,"0",76.4,NA,"delta","~39 weeks",NA,NA,2313,"United Arab Emirates","ARE",270,"ARE",45070,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,105,191,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-09,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-06-09
"2256",270,"Al Kaabi","Retrospective cohort","09Jun2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","14+","death","death","UAE",">= 18 years","general pop",62.5,"31.4",79.5,NA,"delta","~39 weeks",NA,NA,2314,"United Arab Emirates","ARE",270,"ARE",45070,2019,"United Arab Emirates","Middle East & North Africa","High income",4,"Asia",2021-01-05,2021-04-20,2021-07-15,NA,2021-01-05,NA,105,191,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-09,"death","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-06-09
"2257",271,"Gray","Test-negative case-control","09Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-27","hospitalization","severe","South Africa","HCW","HCW",88,"62",96,NA,"omicron","~30 weeks",NA,NA,2315,"South Africa","ZAF",271,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2022-06-09,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","29/12/2021",2021-12-29
"2258",271,"Gray","Test-negative case-control","09Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","148-207","hospitalization","severe","South Africa","HCW","HCW",67,"63",71,NA,"omicron","~30 weeks",NA,NA,2316,"South Africa","ZAF",271,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2022-06-09,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","29/12/2021",2021-12-29
"2259",271,"Gray","Test-negative case-control","09Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-27","ICU admission","severe","South Africa","HCW","HCW",69,"56",79,NA,"omicron","~30 weeks",NA,NA,2317,"South Africa","ZAF",271,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2022-06-09,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","29/12/2021",2021-12-29
"2260",271,"Gray","Test-negative case-control","09Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","148-207","ICU admission","severe","South Africa","HCW","HCW",71,"65",76,NA,"omicron","~30 weeks",NA,NA,2318,"South Africa","ZAF",271,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2022-06-09,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","29/12/2021",2021-12-29
"2261",272,"Adams","Prospective test-negative case control","11Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",36,"21",48,"omicron BA.1, BA.2, BA.5","omicron BA.1, BA.2, BA.5","~72 weeks",NA,NA,2319,"USA","USA",272,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-11,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","14/06/2022",2022-06-14
"2262",272,"Adams","Prospective test-negative case control","11Oct2022","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",41,"25",54,"omicron BA.1, BA.2, BA.5","omicron BA.1, BA.2, BA.5","~72 weeks",NA,NA,2320,"USA","USA",272,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-11,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","14/06/2022",2022-06-14
"2263",272,"Adams","Prospective test-negative case control","11Oct2022","Ad26.COV2.S (Janssen)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",32,"9",62,"omicron BA.1, BA.2, BA.5","omicron BA.1, BA.2, BA.5","~72 weeks",NA,NA,2321,"USA","USA",272,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-11,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron","14/06/2022",2022-06-14
"2264",273,"Magro","Matched case-control","22Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","USA","SNF personnel 18+ years","SNF employees",1,"55.9",81.8,NA,"non-VOC & alpha","~10 weeks",NA,NA,2322,"USA","USA",273,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-06-22
"2265",273,"Magro","Matched case-control","22Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","SNF personnel 18+ years","SNF employees",32,"1",54,NA,"non-VOC & alpha","~10 weeks",NA,NA,2323,"USA","USA",273,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-06-22
"2266",274,"Moline","Outbreak investigation","27Jun2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","USA","SNF residents","SNF residents",65,"25",84,NA,"beta","~12 weeks",NA,NA,2324,"USA","USA",274,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-27,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","beta",NA,2022-06-27
"2267",275,"Carazo","Test-negative case-control","21Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Canada","HCW","HCW",35,"27",42,"omicron BA.2","omicron BA.2","~70 weeks",NA,NA,2325,"Canada","CAN",275,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-21,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/06/2022",2022-06-27
"2268",275,"Carazo","Test-negative case-control","21Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","Canada","HCW","HCW",61,"52",69,"omicron BA.2","omicron BA.2","~70 weeks",NA,NA,2326,"Canada","CAN",275,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-21,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/06/2022",2022-06-27
"2269",276,"Cohen-Stavi","Taget trial emulation study","29Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-21","infection","infection","Israel","5-11 years","5-11 years",51,"39",61,NA,"omicron","1 week",NA,NA,2327,"Israel","ISR",276,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-29,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-06-29
"2270",276,"Cohen-Stavi","Taget trial emulation study","29Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-21","symptomatic disease","symptomatic","Israel","5-11 years","5-11 years",48,"29",63,NA,"omicron","1 week",NA,NA,2328,"Israel","ISR",276,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-29,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-06-29
"2271",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Canada (Quebec)","12-17 years","12-17 years",41.9,"37.7",45.8,NA,"omicron","~26 weeks",NA,NA,2329,"Canada","CAN",277,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","28/06/2022",2022-06-28
"2272",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-27","infection","infection","Canada (Quebec)","12-17 years","12-17 years",75.6,"65.8",82.6,NA,"omicron","2 weeks",NA,NA,2330,"Canada","CAN",277,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","28/06/2022",2022-06-28
"2273",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","168-195","infection","infection","Canada (Quebec)","12-17 years","12-17 years",33.9,"27.4",39.9,NA,"omicron","~26 weeks",NA,NA,2331,"Canada","CAN",277,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","28/06/2022",2022-06-28
"2274",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Canada (Quebec)","12-17 years","12-17 years",55.2,"49.5",60.3,NA,"omicron","~26 weeks",NA,NA,2332,"Canada","CAN",277,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","28/06/2022",2022-06-28
"2275",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Canada (Quebec)","12-17 years","12-17 years",82.8,"81",94.4,NA,"delta & omicron","~22 weeks",NA,NA,2333,"Canada","CAN",277,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron","28/06/2022",2022-06-28
"2276",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-27","infection","infection","Canada (Quebec)","12-17 years","12-17 years",83.1,"68.9",90.8,NA,"delta & omicron","2 weeks",NA,NA,2334,"Canada","CAN",277,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron","28/06/2022",2022-06-28
"2277",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","140-167","infection","infection","Canada (Quebec)","12-17 years","12-17 years",75.4,"72.1",78.4,NA,"delta & omicron","~22 weeks",NA,NA,2335,"Canada","CAN",277,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron","28/06/2022",2022-06-28
"2278",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Canada (Quebec)","12-17 years","12-17 years",87.9,"86.1",89.5,NA,"delta & omicron","~22 weeks",NA,NA,2336,"Canada","CAN",277,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron","28/06/2022",2022-06-28
"2279",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Canada (Quebec)","12-17 years","12-17 years",95.5,"95",96,NA,"delta","~18 weeks",NA,NA,2337,"Canada","CAN",277,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","28/06/2022",2022-06-28
"2280",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-27","infection","infection","Canada (Quebec)","12-17 years","12-17 years",97.7,"96.2",98.6,NA,"delta","2 weeks",NA,NA,2338,"Canada","CAN",277,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","28/06/2022",2022-06-28
"2281",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","112-139","infection","infection","Canada (Quebec)","12-17 years","12-17 years",92.4,"90.4",94,NA,"delta","~18 weeks",NA,NA,2339,"Canada","CAN",277,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","28/06/2022",2022-06-28
"2282",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Canada (Quebec)","12-17 years","12-17 years",97.3,"96.8",97.7,NA,"delta","~18 weeks",NA,NA,2340,"Canada","CAN",277,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","28/06/2022",2022-06-28
"2283",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Canada (British Colombia)","12-17 years","12-17 years",33.9,"25.7",41.1,NA,"omicron","~26 weeks",NA,NA,2341,"Canada","CAN",277,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","28/06/2022",2022-06-28
"2284",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-27","infection","infection","Canada (British Colombia)","12-17 years","12-17 years",63.4,"21.4",83,NA,"omicron","2 weeks",NA,NA,2342,"Canada","CAN",277,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","28/06/2022",2022-06-28
"2285",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","168-195","infection","infection","Canada (British Colombia)","12-17 years","12-17 years",22.2,"8.4",33.9,NA,"omicron","~26 weeks",NA,NA,2343,"Canada","CAN",277,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","28/06/2022",2022-06-28
"2286",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Canada (British Colombia)","12-17 years","12-17 years",88,"85.1",90.3,NA,"delta & omicron","~22 weeks",NA,NA,2344,"Canada","CAN",277,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron","28/06/2022",2022-06-28
"2287",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","28-55","infection","infection","Canada (British Colombia)","12-17 years","12-17 years",94.8,"83.7",98.4,NA,"delta & omicron","2 weeks",NA,NA,2345,"Canada","CAN",277,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron","28/06/2022",2022-06-28
"2288",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","140-167","infection","infection","Canada (British Colombia)","12-17 years","12-17 years",84.2,"77.8",88.8,NA,"delta & omicron","~22 weeks",NA,NA,2346,"Canada","CAN",277,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron","28/06/2022",2022-06-28
"2289",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Canada (British Colombia)","12-17 years","12-17 years",95.7,"95.1",96.2,NA,"delta","~18 weeks",NA,NA,2347,"Canada","CAN",277,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","28/06/2022",2022-06-28
"2290",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-27","infection","infection","Canada (British Colombia)","12-17 years","12-17 years",96.8,"94.4",98.2,NA,"delta","2 weeks",NA,NA,2348,"Canada","CAN",277,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","28/06/2022",2022-06-28
"2291",277,"Ionescu","Test-negative case-control","16Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","112-139","infection","infection","Canada (British Colombia)","12-17 years","12-17 years",90.9,"87.7",93.2,NA,"delta","~18 weeks",NA,NA,2349,"Canada","CAN",277,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-16,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","28/06/2022",2022-06-28
"2292",278,"Tartof","Test-negative case-control","07Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<6 months","hospitalization","severe","USA",">= 18 years","general pop",54,"38",65,"omicron BA.1","omicron BA.1","~70 weeks",NA,NA,2350,"USA","USA",278,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-07,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","30/06/2022",2022-06-30
"2293",278,"Tartof","Test-negative case-control","07Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=6 months","hospitalization","severe","USA",">= 18 years","general pop",32,"16",45,"omicron BA.1","omicron BA.1","~70 weeks",NA,NA,2351,"USA","USA",278,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-07,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","30/06/2022",2022-06-30
"2294",278,"Tartof","Test-negative case-control","07Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<6 months","ED admissions","symptomatic","USA",">= 18 years","general pop",42,"31",52,"omicron BA.1","omicron BA.1","~70 weeks",NA,NA,2352,"USA","USA",278,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-07,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","30/06/2022",2022-06-30
"2295",278,"Tartof","Test-negative case-control","07Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=6 months","ED admissions","symptomatic","USA",">= 18 years","general pop",19,"6",31,"omicron BA.1","omicron BA.1","~70 weeks",NA,NA,2353,"USA","USA",278,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-07,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","30/06/2022",2022-06-30
"2296",278,"Tartof","Test-negative case-control","07Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<6 months","hospitalization","severe","USA",">= 18 years","general pop",56,"-2",81,"omicron BA.2","omicron BA.2","~70 weeks",NA,NA,2354,"USA","USA",278,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-07,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","30/06/2022",2022-06-30
"2297",278,"Tartof","Test-negative case-control","07Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=6 months","hospitalization","severe","USA",">= 18 years","general pop",56,"28",73,"omicron BA.2","omicron BA.2","~70 weeks",NA,NA,2355,"USA","USA",278,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-07,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","30/06/2022",2022-06-30
"2298",278,"Tartof","Test-negative case-control","07Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<6 months","ED admissions","symptomatic","USA",">= 18 years","general pop",27,"-11",52,"omicron BA.2","omicron BA.2","~70 weeks",NA,NA,2356,"USA","USA",278,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-07,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","30/06/2022",2022-06-30
"2299",278,"Tartof","Test-negative case-control","07Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=6 months","ED admissions","symptomatic","USA",">= 18 years","general pop",12,"-10",31,"omicron BA.2","omicron BA.2","~70 weeks",NA,NA,2357,"USA","USA",278,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-07,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","30/06/2022",2022-06-30
"2300",279,"Paternina-Caicedo","Retrospective cohort","01Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","symptomatic disease","symptomatic","Colombia",">= 40 years",">= 40 years",13,"5.3",20,NA,"mu","~25 weeks",NA,NA,2358,"Colombia","COL",279,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-07-01,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","mu",NA,2022-07-01
"2301",279,"Paternina-Caicedo","Retrospective cohort","01Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","Colombia",">= 40 years",">= 40 years",45.5,"29.4",58,NA,"mu","~25 weeks",NA,NA,2359,"Colombia","COL",279,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-07-01,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","mu",NA,2022-07-01
"2302",279,"Paternina-Caicedo","Retrospective cohort","01Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","critical care admission","severe","Colombia",">= 40 years",">= 40 years",82.2,"60.1",92.1,NA,"mu","~25 weeks",NA,NA,2360,"Colombia","COL",279,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-07-01,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","mu",NA,2022-07-01
"2303",279,"Paternina-Caicedo","Retrospective cohort","01Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","death","death","Colombia",">= 40 years",">= 40 years",94.1,"76.4",98.5,NA,"mu","~25 weeks",NA,NA,2361,"Colombia","COL",279,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-07-01,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","mu",NA,2022-07-01
"2304",279,"Paternina-Caicedo","Retrospective cohort","01Jul2022","CoronaVac (Sinovac)","included","2","final","14+","symptomatic disease","symptomatic","Colombia",">= 40 years",">= 40 years",-45.1,"-53.6",-37.1,NA,"mu","~25 weeks",NA,NA,2362,"Colombia","COL",279,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-07-01,"symptomatic","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","mu",NA,2022-07-01
"2305",279,"Paternina-Caicedo","Retrospective cohort","01Jul2022","CoronaVac (Sinovac)","included","2","final","14+","hospitalization","severe","Colombia",">= 40 years",">= 40 years",-3,"-18",10.2,NA,"mu","~25 weeks",NA,NA,2363,"Colombia","COL",279,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-07-01,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","mu",NA,2022-07-01
"2306",279,"Paternina-Caicedo","Retrospective cohort","01Jul2022","CoronaVac (Sinovac)","included","2","final","14+","critical care admission","severe","Colombia",">= 40 years",">= 40 years",13.6,"-13.2",34,NA,"mu","~25 weeks",NA,NA,2364,"Colombia","COL",279,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-07-01,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","mu",NA,2022-07-01
"2307",279,"Paternina-Caicedo","Retrospective cohort","01Jul2022","CoronaVac (Sinovac)","included","2","final","14+","death","death","Colombia",">= 40 years",">= 40 years",20.6,"-0.5",37.3,NA,"mu","~25 weeks",NA,NA,2365,"Colombia","COL",279,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-07-01,"death","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","mu",NA,2022-07-01
"2308",280,"Tonnara","Retrospective cohort","04Jul2022","Gam-COVID-Vac (Gamaleya)","excluded","2","final","7-59","infection","infection","Republic of San Marino",">= 18 years","general pop",91.8,"86.3",95.1,NA,"alpha & delta","~27 weeks",NA,NA,2366,"Republic of San Marino","SMR",280,"SMR",43770,2019,"San Marino","Europe & Central Asia","High income",4,"Europe",2021-02-27,2021-05-23,2022-03-20,2021-02-24,2021-02-24,3,88,389,"who","feb/2021","before Jun/2021","<180","yes","yes","yes",2022-07-04,"infection","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-07-04
"2309",280,"Tonnara","Retrospective cohort","04Jul2022","Gam-COVID-Vac (Gamaleya)","excluded","2","final","120+","infection","infection","Republic of San Marino",">= 18 years","general pop",57.8,"42.2",69.2,NA,"alpha & delta","~27 weeks",NA,NA,2367,"Republic of San Marino","SMR",280,"SMR",43770,2019,"San Marino","Europe & Central Asia","High income",4,"Europe",2021-02-27,2021-05-23,2022-03-20,2021-02-24,2021-02-24,3,88,389,"who","feb/2021","before Jun/2021","<180","yes","yes","yes",2022-07-04,"infection","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-07-04
"2310",280,"Tonnara","Retrospective cohort","04Jul2022","Gam-COVID-Vac (Gamaleya)","excluded","2","final","7-59","hospitalization","severe","Republic of San Marino",">= 18 years","general pop",95.2,"79.1",98.9,NA,"alpha & delta","~27 weeks",NA,NA,2368,"Republic of San Marino","SMR",280,"SMR",43770,2019,"San Marino","Europe & Central Asia","High income",4,"Europe",2021-02-27,2021-05-23,2022-03-20,2021-02-24,2021-02-24,3,88,389,"who","feb/2021","before Jun/2021","<180","yes","yes","yes",2022-07-04,"severe","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-07-04
"2311",280,"Tonnara","Retrospective cohort","04Jul2022","Gam-COVID-Vac (Gamaleya)","excluded","2","final","120+","hospitalization","severe","Republic of San Marino",">= 18 years","general pop",89.7,"52.7",97.7,NA,"alpha & delta","~27 weeks",NA,NA,2369,"Republic of San Marino","SMR",280,"SMR",43770,2019,"San Marino","Europe & Central Asia","High income",4,"Europe",2021-02-27,2021-05-23,2022-03-20,2021-02-24,2021-02-24,3,88,389,"who","feb/2021","before Jun/2021","<180","yes","yes","yes",2022-07-04,"severe","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-07-04
"2312",280,"Tonnara","Retrospective cohort","04Jul2022","Gam-COVID-Vac (Gamaleya)","excluded","2","final","7+","infection","infection","Republic of San Marino",">= 18 years","general pop",97.3,"94.2",98.7,NA,"alpha","~15 weeks",NA,NA,2370,"Republic of San Marino","SMR",280,"SMR",43770,2019,"San Marino","Europe & Central Asia","High income",4,"Europe",2021-02-27,2021-05-23,2022-03-20,2021-02-24,2021-02-24,3,88,389,"who","feb/2021","before Jun/2021","<180","yes","yes","yes",2022-07-04,"infection","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","alpha",NA,2022-07-04
"2313",280,"Tonnara","Retrospective cohort","04Jul2022","Gam-COVID-Vac (Gamaleya)","excluded","2","final","7+","hospitalization","severe","Republic of San Marino",">= 18 years","general pop",96.9,"86.5",99.3,NA,"alpha","~15 weeks",NA,NA,2371,"Republic of San Marino","SMR",280,"SMR",43770,2019,"San Marino","Europe & Central Asia","High income",4,"Europe",2021-02-27,2021-05-23,2022-03-20,2021-02-24,2021-02-24,3,88,389,"who","feb/2021","before Jun/2021","<180","yes","yes","yes",2022-07-04,"severe","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","alpha",NA,2022-07-04
"2314",281,"Kerr","Test-negative case-control","09Jul2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","symptomatic disease","symptomatic","Scotland",">= 18 years","general pop",78.7,"69.9",85,NA,"delta & delta plus (AY.4.2)","~38 weeks",NA,NA,2372,"UK","GBR",281,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-09,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-07-09
"2315",281,"Kerr","Test-negative case-control","09Jul2022","mRNA-1273 (Moderna)","unknown","2","final","14+","symptomatic disease","symptomatic","Scotland",">= 18 years","general pop",93.7,"86.4",97.1,NA,"delta & delta plus (AY.4.2)","~38 weeks",NA,NA,2373,"UK","GBR",281,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-09,"symptomatic","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-07-09
"2316",281,"Kerr","Test-negative case-control","09Jul2022","AZD1222 (AstraZeneca)","unknown","2","final","14+","symptomatic disease","symptomatic","Scotland",">= 18 years","general pop",54.5,"35.7",67.8,NA,"delta & delta plus (AY.4.2)","~38 weeks",NA,NA,2374,"UK","GBR",281,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-07-09,"symptomatic","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-07-09
"2317",282,"Stephenson","Retrospective cohort","11Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",85,"81",89,NA,"non-VOC & alpha","~18 weeks",NA,NA,2375,"USA","USA",282,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-11,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-11
"2318",283,"Guedalia","Retrospective cohort","15Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","0+","hospitalization","severe","Israel","pregnant women aged 16+","pregnant persons",-12,"-36",8,NA,"omicron BA.1","~60 weeks",NA,NA,2376,"Israel","ISR",283,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-11-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","11/07/2022",2022-07-11
"2319",283,"Guedalia","Retrospective cohort","15Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","0+","hospitalization with moderate disease","severe","Israel","pregnant women aged 16+","pregnant persons",51,"-47",84,NA,"omicron BA.1","~60 weeks",NA,NA,2377,"Israel","ISR",283,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-11-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","11/07/2022",2022-07-11
"2320",283,"Guedalia","Retrospective cohort","15Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","0+","severe disease","severe","Israel","pregnant women aged 16+","pregnant persons",83,"-47",98,NA,"omicron BA.1","~60 weeks",NA,NA,2378,"Israel","ISR",283,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-11-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","11/07/2022",2022-07-11
"2321",283,"Guedalia","Retrospective cohort","15Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","0+","hospitalization","severe","Israel","pregnant women aged 16+","pregnant persons",61,"51",69,NA,"delta","~44 weeks",NA,NA,2379,"Israel","ISR",283,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-11-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","11/07/2022",2022-07-11
"2322",283,"Guedalia","Retrospective cohort","15Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","0+","hospitalization with moderate disease","severe","Israel","pregnant women aged 16+","pregnant persons",97,"92",99,NA,"delta","~44 weeks",NA,NA,2380,"Israel","ISR",283,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-11-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","11/07/2022",2022-07-11
"2323",283,"Guedalia","Retrospective cohort","15Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","0+","severe disease","severe","Israel","pregnant women aged 16+","pregnant persons",96,"86",99,NA,"delta","~44 weeks",NA,NA,2381,"Israel","ISR",283,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-11-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","11/07/2022",2022-07-11
"2324",284,"Link-Gelles","Test-negative case-control","15Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-140","ED or UC visit","symptomatic","USA",">= 18 years","general pop",47,"44",50,NA,"omicron BA.1","~44 weeks",NA,NA,2382,"USA","USA",284,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-15,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-07-15
"2325",284,"Link-Gelles","Test-negative case-control","15Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","ED or UC visit","symptomatic","USA",">= 18 years","general pop",39,"37",41,NA,"omicron BA.1","~44 weeks",NA,NA,2383,"USA","USA",284,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-15,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-07-15
"2326",284,"Link-Gelles","Test-negative case-control","15Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-140","hospitalization","severe","USA",">= 18 years","general pop",68,"63",73,NA,"omicron BA.1","~44 weeks",NA,NA,2384,"USA","USA",284,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-15,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-07-15
"2327",284,"Link-Gelles","Test-negative case-control","15Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","hospitalization","severe","USA",">= 18 years","general pop",61,"58",63,NA,"omicron BA.1","~44 weeks",NA,NA,2385,"USA","USA",284,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-15,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-07-15
"2328",284,"Link-Gelles","Test-negative case-control","15Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-140","ED or UC visit","symptomatic","USA",">= 18 years","general pop",59,"40",71,NA,"omicron BA.2","~44 weeks",NA,NA,2386,"USA","USA",284,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-15,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-07-15
"2329",284,"Link-Gelles","Test-negative case-control","15Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","ED or UC visit","symptomatic","USA",">= 18 years","general pop",18,"10",26,NA,"omicron BA.2","~44 weeks",NA,NA,2387,"USA","USA",284,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-15,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-07-15
"2330",284,"Link-Gelles","Test-negative case-control","15Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-140","hospitalization","severe","USA",">= 18 years","general pop",57,"19",77,NA,"omicron BA.2","~44 weeks",NA,NA,2388,"USA","USA",284,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-15,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-07-15
"2331",284,"Link-Gelles","Test-negative case-control","15Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","hospitalization","severe","USA",">= 18 years","general pop",24,"12",35,NA,"omicron BA.2","~44 weeks",NA,NA,2389,"USA","USA",284,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-15,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-07-15
"2332",285,"Cerqueira-Silva","Test-negative case-control","18Jul2022","CoronaVac (Sinovac)","included","2","final","14-180","infection","infection","Brazil",">= 18 years","general pop",-0.7,"-1.6",0.2,NA,"omicron","~59 weeks",NA,NA,2390,"Brazil","BRA",285,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-18,"infection","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-07-18
"2333",285,"Cerqueira-Silva","Test-negative case-control","18Jul2022","CoronaVac (Sinovac)","included","2","final","180+","infection","infection","Brazil",">= 18 years","general pop",3.2,"2.1",4.2,NA,"omicron","~59 weeks",NA,NA,2391,"Brazil","BRA",285,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-18,"infection","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-07-18
"2334",285,"Cerqueira-Silva","Test-negative case-control","18Jul2022","CoronaVac (Sinovac)","included","2","final","14-180","hospitalization or death","severe","Brazil",">= 18 years","general pop",64.5,"62.6",66.3,NA,"omicron","~59 weeks",NA,NA,2392,"Brazil","BRA",285,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-18,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-07-18
"2335",285,"Cerqueira-Silva","Test-negative case-control","18Jul2022","CoronaVac (Sinovac)","included","2","final","180+","hospitalization or death","severe","Brazil",">= 18 years","general pop",61.8,"60.3",63.2,NA,"omicron","~59 weeks",NA,NA,2393,"Brazil","BRA",285,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-18,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-07-18
"2336",285,"Cerqueira-Silva","Test-negative case-control","18Jul2022","CoronaVac (Sinovac)","included","2","final","14-180","death","death","Brazil",">= 18 years","general pop",67.8,"64",71.3,NA,"omicron","~59 weeks",NA,NA,2394,"Brazil","BRA",285,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-18,"death","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-07-18
"2337",285,"Cerqueira-Silva","Test-negative case-control","18Jul2022","CoronaVac (Sinovac)","included","2","final","180+","death","death","Brazil",">= 18 years","general pop",63.1,"60.9",65.1,NA,"omicron","~59 weeks",NA,NA,2395,"Brazil","BRA",285,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-18,"death","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-07-18
"2338",286,"Hatfield","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-157","infection","infection","USA","nursing home residents","nursing home residents",67,"40",82,NA,"non-VOC & alpha","~44 weeks",NA,NA,2396,"USA","USA",286,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-07-20
"2339",286,"Hatfield","Retrospective cohort","20Jul2022","mRNA-1273 (Moderna)","excluded","2","final","7-157","infection","infection","USA","nursing home residents","nursing home residents",75,"32",91,NA,"non-VOC & alpha","~44 weeks",NA,NA,2397,"USA","USA",286,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-20,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-07-20
"2340",286,"Hatfield","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","157+","infection","infection","USA","nursing home residents","nursing home residents",33,"-2",56,NA,"delta","~44 weeks",NA,NA,2398,"USA","USA",286,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-07-20
"2341",286,"Hatfield","Retrospective cohort","20Jul2022","mRNA-1273 (Moderna)","excluded","2","final","157+","infection","infection","USA","nursing home residents","nursing home residents",77,"48",91,NA,"delta","~44 weeks",NA,NA,2399,"USA","USA",286,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-20,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-07-20
"2342",287,"Tan","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-14","infection (PCR or antigen)","infection","Singapore","5-11 years","5-11 years",48.8,"46.9",50.8,NA,"omicron","~9 weeks",NA,NA,2400,"Singapore","SGP",287,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-07-20
"2343",287,"Tan","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","60+","infection (PCR or antigen)","infection","Singapore","5-11 years","5-11 years",25.6,"19.3",31.5,NA,"omicron","~9 weeks",NA,NA,2401,"Singapore","SGP",287,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-07-20
"2344",287,"Tan","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-14","infection (PCR only)","infection","Singapore","5-11 years","5-11 years",70.6,"65.9",74.7,NA,"omicron","~9 weeks",NA,NA,2402,"Singapore","SGP",287,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-07-20
"2345",287,"Tan","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","60+","infection (PCR only)","infection","Singapore","5-11 years","5-11 years",42.7,"12",62.7,NA,"omicron","~9 weeks",NA,NA,2403,"Singapore","SGP",287,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-07-20
"2346",287,"Tan","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-14","hospitalization","severe","Singapore","5-11 years","5-11 years",87.8,"72.2",94.7,NA,"omicron","~9 weeks",NA,NA,2404,"Singapore","SGP",287,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-07-20
"2347",287,"Tan","Retrospective cohort","20Jul2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","30-59","hospitalization","severe","Singapore","5-11 years","5-11 years",80.4,"67",88.4,NA,"omicron","~9 weeks",NA,NA,2405,"Singapore","SGP",287,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-20,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-07-20
"2348",288,"Mazagatos","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization with SARI","severe","Spain","20-59 years","20-59 years",92,"78",97,NA,"alpha & delta","~19 weeks",NA,NA,2406,"Spain","ESP",288,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-26
"2349",288,"Mazagatos","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","<90","hospitalization with SARI","severe","Spain","20-59 years","20-59 years",95,"82",98,NA,"alpha & delta","~19 weeks",NA,NA,2407,"Spain","ESP",288,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-26
"2350",288,"Mazagatos","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","152+","hospitalization with SARI","severe","Spain","20-59 years","20-59 years",91,"50",98,NA,"alpha & delta","~19 weeks",NA,NA,2408,"Spain","ESP",288,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-26
"2351",288,"Mazagatos","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization with SARI","severe","Spain","60-69 years","60-69 years",97,"86",99,NA,"alpha & delta","~19 weeks",NA,NA,2409,"Spain","ESP",288,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-26
"2352",288,"Mazagatos","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","<90","hospitalization with SARI","severe","Spain","60-69 years","60-69 years",97,"87",99,NA,"alpha & delta","~19 weeks",NA,NA,2410,"Spain","ESP",288,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-26
"2353",288,"Mazagatos","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","152+","hospitalization with SARI","severe","Spain","60-69 years","60-69 years",96,"47",100,NA,"alpha & delta","~19 weeks",NA,NA,2411,"Spain","ESP",288,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-26
"2354",288,"Mazagatos","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","<90","hospitalization with SARI","severe","Spain","70-79 years","70-79 years",98,"90",100,NA,"alpha & delta","~23 weeks",NA,NA,2412,"Spain","ESP",288,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-26
"2355",288,"Mazagatos","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","152+","hospitalization with SARI","severe","Spain","70-79 years","70-79 years",91,"24",99,NA,"alpha & delta","~23 weeks",NA,NA,2413,"Spain","ESP",288,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-26
"2356",288,"Mazagatos","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","<90","hospitalization with SARI","severe","Spain",">= 80 years",">= 80 years",86,"70",94,NA,"alpha & delta","~33 weeks",NA,NA,2414,"Spain","ESP",288,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-26
"2357",288,"Mazagatos","Test-negative case-control","26Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","152+","hospitalization with SARI","severe","Spain",">= 80 years",">= 80 years",48,"-51",82,NA,"alpha & delta","~33 weeks",NA,NA,2415,"Spain","ESP",288,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-26
"2358",288,"Mazagatos","Test-negative case-control","26Jul2022","Ad26.COV2.S (Janssen)","included","1","final","14+","hospitalization with SARI","severe","Spain","20-59 years","20-59 years",71,"-3",92,NA,"alpha & delta","~19 weeks",NA,NA,2416,"Spain","ESP",288,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-26,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-07-26
"2359",288,"Mazagatos","Test-negative case-control","26Jul2022","Ad26.COV2.S (Janssen)","included","1","final","14+","hospitalization with SARI","severe","Spain","60-69 years","60-69 years",82,"-78",98,NA,"alpha & delta","~19 weeks",NA,NA,2417,"Spain","ESP",288,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-26,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-07-26
"2360",288,"Mazagatos","Test-negative case-control","26Jul2022","AZD1222 (AstraZeneca)","included","2","final","14+","hospitalization with SARI","severe","Spain","60-69 years","60-69 years",89,"25",98,NA,"alpha & delta","~19 weeks",NA,NA,2418,"Spain","ESP",288,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-07-26,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-07-26
"2361",289,"Chemaitelly","Retrospective cohort","02Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Qatar","12-17 years","12-17 years",51.3,"34.9",63.6,NA,"omicron","~68 weeks",NA,NA,2419,"Qatar","QAT",289,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-11-02,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","26/07/2022",2022-07-26
"2362",289,"Chemaitelly","Retrospective cohort","02Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","172+","infection","infection","Qatar","12-17 years","12-17 years",-1.7,"-20",10,NA,"omicron","~68 weeks",NA,NA,2420,"Qatar","QAT",289,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-11-02,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","26/07/2022",2022-07-26
"2363",289,"Chemaitelly","Retrospective cohort","02Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-30","infection","infection","Qatar","5-11 years","5-11 years",49.6,"28.5",64.5,NA,"omicron","~68 weeks",NA,NA,2421,"Qatar","QAT",289,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-11-02,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","26/07/2022",2022-07-26
"2364",289,"Chemaitelly","Retrospective cohort","02Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","120+","infection","infection","Qatar","5-11 years","5-11 years",-9.5,"-30",35,NA,"omicron","~68 weeks",NA,NA,2422,"Qatar","QAT",289,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-11-02,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","26/07/2022",2022-07-26
"2365",289,"Chemaitelly","Retrospective cohort","02Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-30","infection","infection","Qatar","12-17 years","12-17 years",95.3,"92",97.2,NA,"alpha & delta","~68 weeks",NA,NA,2423,"Qatar","QAT",289,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-11-02,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/07/2022",2022-07-26
"2366",289,"Chemaitelly","Retrospective cohort","02Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","152+","infection","infection","Qatar","12-17 years","12-17 years",70.6,"18",92,NA,"alpha & delta","~68 weeks",NA,NA,2424,"Qatar","QAT",289,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-11-02,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","26/07/2022",2022-07-26
"2367",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14 days-1 month","symptomatic disease","symptomatic","USA","veterans","veterans",76.1,"71.1",80.2,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,2425,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2368",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 months","symptomatic disease","symptomatic","USA","veterans","veterans",0.1,"-10.9",10.1,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,2426,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2369",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14 days-1 month","symptomatic disease","symptomatic","USA","veterans < 65 years","veterans < 65 years",81.6,"75.9",85.9,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,2427,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2370",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 months","symptomatic disease","symptomatic","USA","veterans < 65 years","veterans < 65 years",22.5,"7.2",35.2,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,2428,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2371",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14 days-1 month","symptomatic disease","symptomatic","USA","veterans >= 65 years","veterans >= 65 years",66.3,"55.7",74.4,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,2429,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2372",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 months","symptomatic disease","symptomatic","USA","veterans >= 65 years","veterans >= 65 years",-23.3,"-40.5",-8.2,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,2430,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2373",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14 days-1 month","hospitalization","severe","USA","veterans","veterans",72.9,"61.7",80.7,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,2431,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2374",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 months","hospitalization","severe","USA","veterans","veterans",19.8,"2.5",34.1,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,2432,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2375",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14 days-1 month","hospitalization","severe","USA","veterans < 65 years","veterans < 65 years",85.6,"72.6",92.4,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,2433,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2376",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 months","hospitalization","severe","USA","veterans < 65 years","veterans < 65 years",57,"31.2",73.2,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,2434,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2377",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14 days-1 month","hospitalization","severe","USA","veterans >= 65 years","veterans >= 65 years",61,"41.3",74.2,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,2435,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2378",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 months","hospitalization","severe","USA","veterans >= 65 years","veterans >= 65 years",1.7,"-22",20.8,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,2436,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2379",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14 days-1 month","ICU admission or death","severe","USA","veterans","veterans",74.7,"54.2",86,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,2437,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2380",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 months","ICU admission or death","severe","USA","veterans","veterans",39.5,"17.6",55.6,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,2438,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2381",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14 days-1 month","ICU admission or death","severe","USA","veterans < 65 years","veterans < 65 years",87.6,"61",96.1,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,2439,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2382",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 months","ICU admission or death","severe","USA","veterans < 65 years","veterans < 65 years",66.4,"7.7",87.8,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,2440,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2383",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14 days-1 month","ICU admission or death","severe","USA","veterans >= 65 years","veterans >= 65 years",67.4,"32.6",84.3,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,2441,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2384",290,"Mayr","Test-negative case-control","22Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 months","ICU admission or death","severe","USA","veterans >= 65 years","veterans >= 65 years",29.3,"2.3",48.9,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,2442,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-22
"2385",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14 days-1 month","symptomatic disease","symptomatic","USA","veterans","veterans",84.6,"80.5",87.8,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,2443,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2386",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","7 months","symptomatic disease","symptomatic","USA","veterans","veterans",46.6,"40.8",51.9,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,2444,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2387",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14 days-1 month","symptomatic disease","symptomatic","USA","veterans < 65 years","veterans < 65 years",89.7,"84.8",93,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,2445,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2388",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","7 months","symptomatic disease","symptomatic","USA","veterans < 65 years","veterans < 65 years",57.3,"48.4",64.7,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,2446,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2389",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14 days-1 month","symptomatic disease","symptomatic","USA","veterans >= 65 years","veterans >= 65 years",78.4,"71.1",83.9,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,2447,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2390",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","7 months","symptomatic disease","symptomatic","USA","veterans >= 65 years","veterans >= 65 years",36.2,"27.7",43.6,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,2448,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2391",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14 days-1 month","hospitalization","severe","USA","veterans","veterans",76.6,"63.9",84.8,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,2449,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2392",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","7 months","hospitalization","severe","USA","veterans","veterans",71.3,"64",77.1,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,2450,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2393",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14 days-1 month","hospitalization","severe","USA","veterans < 65 years","veterans < 65 years",92,"76.1",97.3,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,2451,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2394",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","7 months","hospitalization","severe","USA","veterans < 65 years","veterans < 65 years",83.1,"66.8",91.4,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,2452,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2395",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14 days-1 month","hospitalization","severe","USA","veterans >= 65 years","veterans >= 65 years",66.1,"45.3",79,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,2453,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2396",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","7 months","hospitalization","severe","USA","veterans >= 65 years","veterans >= 65 years",64.7,"55.2",72.3,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,2454,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2397",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14 days-1 month","ICU admission or death","severe","USA","veterans","veterans",80.5,"64.1",89.4,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,2455,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2398",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","7 months","ICU admission or death","severe","USA","veterans","veterans",77.2,"68.4",83.5,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,2456,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2399",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14 days-1 month","ICU admission or death","severe","USA","veterans < 65 years","veterans < 65 years",89.2,"49.5",97.7,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,2457,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2400",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","7 months","ICU admission or death","severe","USA","veterans < 65 years","veterans < 65 years",84.4,"59",94.1,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,2458,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2401",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14 days-1 month","ICU admission or death","severe","USA","veterans >= 65 years","veterans >= 65 years",75.4,"51.7",87.5,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,2459,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2402",290,"Mayr","Test-negative case-control","22Jun2022","mRNA-1273 (Moderna)","excluded","2","final","7 months","ICU admission or death","severe","USA","veterans >= 65 years","veterans >= 65 years",73.8,"62.9",81.5,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,2460,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-22
"2403",290,"Mayr","Test-negative case-control","22Jun2022","Ad26.COV2.S (Janssen)","excluded","1","final","14 days-1 month","symptomatic disease","symptomatic","USA","veterans","veterans",25.4,"2.9",42.6,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,2461,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-06-22
"2404",290,"Mayr","Test-negative case-control","22Jun2022","Ad26.COV2.S (Janssen)","excluded","1","final","7 months","symptomatic disease","symptomatic","USA","veterans","veterans",25.5,"-2.2",45.6,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,2462,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"symptomatic","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-06-22
"2405",290,"Mayr","Test-negative case-control","22Jun2022","Ad26.COV2.S (Janssen)","excluded","1","final","14 days-1 month","hospitalization","severe","USA","veterans","veterans",55.8,"20.6",75.4,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,2463,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-06-22
"2406",290,"Mayr","Test-negative case-control","22Jun2022","Ad26.COV2.S (Janssen)","excluded","1","final","7 months","hospitalization","severe","USA","veterans","veterans",16.9,"-90.9",63.8,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,2464,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-06-22
"2407",290,"Mayr","Test-negative case-control","22Jun2022","Ad26.COV2.S (Janssen)","excluded","1","final","14 days-1 month","ICU admission or death","severe","USA","veterans","veterans",61.1,"11.9",82.8,NA,"non-VOC, alpha, & delta","2 weeks",NA,NA,2465,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-06-22
"2408",290,"Mayr","Test-negative case-control","22Jun2022","Ad26.COV2.S (Janssen)","excluded","1","final","7 months","ICU admission or death","severe","USA","veterans","veterans",63.3,"-15.5",88.3,NA,"non-VOC, alpha, & delta","~26 weeks",NA,NA,2466,"USA","USA",290,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-06-22,"severe","2022 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-06-22
"2409",291,"Piche-Renaud","Test-negative case-control","03Mar2023","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","symptomatic disease","symptomatic","Canada","5-11 years","5-11 years",49,"43",54,NA,"omicron BA.1, BA.2, BA.4, BA.5","~29 weeks",NA,NA,2467,"Canada","CAN",291,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-03,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/08/2022",2022-08-01
"2410",291,"Piche-Renaud","Test-negative case-control","03Mar2023","BNT162b2 (Pfizer BioNTech)","included","2","final","7-29","symptomatic disease","symptomatic","Canada","5-11 years","5-11 years",66,"60",71,NA,"omicron BA.1, BA.2, BA.4, BA.5","~29 weeks",NA,NA,2468,"Canada","CAN",291,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-03,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/08/2022",2022-08-01
"2411",291,"Piche-Renaud","Test-negative case-control","03Mar2023","BNT162b2 (Pfizer BioNTech)","included","2","final","120+","symptomatic disease","symptomatic","Canada","5-11 years","5-11 years",-4,"-30",46,NA,"omicron BA.1, BA.2, BA.4, BA.5","~29 weeks",NA,NA,2469,"Canada","CAN",291,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-03,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/08/2022",2022-08-01
"2412",291,"Piche-Renaud","Test-negative case-control","03Mar2023","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","hospitalization or death","severe","Canada","5-11 years","5-11 years",79,"63",88,NA,"omicron BA.1, BA.2, BA.4, BA.5","~29 weeks",NA,NA,2470,"Canada","CAN",291,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-03,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/08/2022",2022-08-01
"2413",291,"Piche-Renaud","Test-negative case-control","03Mar2023","BNT162b2 (Pfizer BioNTech)","included","2","final","7-29","hospitalization or death","severe","Canada","5-11 years","5-11 years",94,"57",99,NA,"omicron BA.1, BA.2, BA.4, BA.5","~29 weeks",NA,NA,2471,"Canada","CAN",291,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-03,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/08/2022",2022-08-01
"2414",291,"Piche-Renaud","Test-negative case-control","03Mar2023","BNT162b2 (Pfizer BioNTech)","included","2","final","120+","hospitalization or death","severe","Canada","5-11 years","5-11 years",57,"-20",85,NA,"omicron BA.1, BA.2, BA.4, BA.5","~29 weeks",NA,NA,2472,"Canada","CAN",291,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-03,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/08/2022",2022-08-01
"2415",292,"Arashiro","Case-control","03Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-89","symptomatic disease","symptomatic","Japan",">= 20 years","general pop",55,"34",69,NA,"omicron","~54 weeks",NA,NA,2473,"Japan","JPN",292,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"who","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-03,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-08-03
"2416",292,"Arashiro","Case-control","03Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","symptomatic disease","symptomatic","Japan",">= 20 years","general pop",52,"37",63,NA,"omicron","~54 weeks",NA,NA,2474,"Japan","JPN",292,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"who","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-03,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-08-03
"2417",292,"Arashiro","Case-control","03Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-89","symptomatic disease","symptomatic","Japan",">= 20 years","general pop",88,"80",92,NA,"delta","~54 weeks",NA,NA,2475,"Japan","JPN",292,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"who","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-03,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-08-03
"2418",292,"Arashiro","Case-control","03Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","90-179","symptomatic disease","symptomatic","Japan",">= 20 years","general pop",86,"35",97,NA,"delta","~54 weeks",NA,NA,2476,"Japan","JPN",292,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"who","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-03,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-08-03
"2419",293,"Tartof","Test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<60","ED or UC visit","symptomatic","USA","12-17 years","12-17 years",73,"54",84,"omicron","omicron","~44 weeks",NA,NA,2477,"USA","USA",293,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-03,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-03
"2420",293,"Tartof","Test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","180+","ED or UC visit","symptomatic","USA","12-17 years","12-17 years",16,"-7",34,"omicron","omicron","~44 weeks",NA,NA,2478,"USA","USA",293,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-03,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-03
"2421",293,"Tartof","Test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","<60","ED or UC visit","symptomatic","USA","12-17 years","12-17 years",72,"52",84,"omicron","omicron","~44 weeks",NA,NA,2479,"USA","USA",293,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-03,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-03
"2422",293,"Tartof","Test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","180+","ED or UC visit","symptomatic","USA","12-17 years","12-17 years",18,"-6",36,"omicron","omicron","~44 weeks",NA,NA,2480,"USA","USA",293,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-03,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-03
"2423",293,"Tartof","Test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<60","ED or UC visit","symptomatic","USA","12-17 years","12-17 years",89,"69",96,NA,"delta","~44 weeks",NA,NA,2481,"USA","USA",293,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-03,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-08-03
"2424",293,"Tartof","Test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","180+","ED or UC visit","symptomatic","USA","12-17 years","12-17 years",49,"27",65,NA,"delta","~44 weeks",NA,NA,2482,"USA","USA",293,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-03,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-08-03
"2425",293,"Tartof","Test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","<60","ED or UC visit","symptomatic","USA","12-17 years","12-17 years",88,"68",96,NA,"delta","~44 weeks",NA,NA,2483,"USA","USA",293,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-03,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-08-03
"2426",293,"Tartof","Test-negative case-control","03Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","180+","ED or UC visit","symptomatic","USA","12-17 years","12-17 years",47,"23",63,NA,"delta","~44 weeks",NA,NA,2484,"USA","USA",293,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-03,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-08-03
"2427",294,"Pinto-Alvarez","Nested cohort","13Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","15+","infection","infection","Colombia",">= 16 years","general pop",73.4,"68.6",77.5,NA,"mu, delta, & omicron","~56 weeks",NA,NA,2485,"Colombia","COL",294,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","06/08/2022",2022-08-06
"2428",294,"Pinto-Alvarez","Nested cohort","13Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","15+","hospitalization","severe","Colombia",">= 16 years","general pop",85.4,"80.1",89.3,NA,"mu, delta, & omicron","~56 weeks",NA,NA,2486,"Colombia","COL",294,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","06/08/2022",2022-08-06
"2429",294,"Pinto-Alvarez","Nested cohort","13Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","15+","death","death","Colombia",">= 16 years","general pop",93.4,"89.8",95.7,NA,"mu, delta, & omicron","~56 weeks",NA,NA,2487,"Colombia","COL",294,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","06/08/2022",2022-08-06
"2430",294,"Pinto-Alvarez","Nested cohort","13Oct2022","mRNA-1273 (Moderna)","excluded","2","final","15+","infection","infection","Colombia",">= 16 years","general pop",28.1,"0",48.9,NA,"mu, delta, & omicron","~56 weeks",NA,NA,2488,"Colombia","COL",294,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","06/08/2022",2022-08-06
"2431",294,"Pinto-Alvarez","Nested cohort","13Oct2022","mRNA-1273 (Moderna)","excluded","2","final","15+","hospitalization","severe","Colombia",">= 16 years","general pop",85.2,"64.6",93.8,NA,"mu, delta, & omicron","~56 weeks",NA,NA,2489,"Colombia","COL",294,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","06/08/2022",2022-08-06
"2432",294,"Pinto-Alvarez","Nested cohort","13Oct2022","mRNA-1273 (Moderna)","excluded","2","final","15+","death","death","Colombia",">= 16 years","general pop",96.9,"76.5",99.6,NA,"mu, delta, & omicron","~56 weeks",NA,NA,2490,"Colombia","COL",294,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"death","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","06/08/2022",2022-08-06
"2433",294,"Pinto-Alvarez","Nested cohort","13Oct2022","AZD1222 (AstraZeneca)","excluded","2","final","15+","infection","infection","Colombia",">= 16 years","general pop",67.9,"57.9",75.5,NA,"mu, delta, & omicron","~56 weeks",NA,NA,2491,"Colombia","COL",294,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","06/08/2022",2022-08-06
"2434",294,"Pinto-Alvarez","Nested cohort","13Oct2022","AZD1222 (AstraZeneca)","excluded","2","final","15+","hospitalization","severe","Colombia",">= 16 years","general pop",82.5,"70.9",89.5,NA,"mu, delta, & omicron","~56 weeks",NA,NA,2492,"Colombia","COL",294,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","06/08/2022",2022-08-06
"2435",294,"Pinto-Alvarez","Nested cohort","13Oct2022","AZD1222 (AstraZeneca)","excluded","2","final","15+","death","death","Colombia",">= 16 years","general pop",93.8,"86.4",97.1,NA,"mu, delta, & omicron","~56 weeks",NA,NA,2493,"Colombia","COL",294,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","06/08/2022",2022-08-06
"2436",294,"Pinto-Alvarez","Nested cohort","13Oct2022","CoronaVac (Sinovac)","excluded","2","final","15+","infection","infection","Colombia",">= 16 years","general pop",74.2,"68.3",79.1,NA,"mu, delta, & omicron","~56 weeks",NA,NA,2494,"Colombia","COL",294,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"infection","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations","06/08/2022",2022-08-06
"2437",294,"Pinto-Alvarez","Nested cohort","13Oct2022","CoronaVac (Sinovac)","excluded","2","final","15+","hospitalization","severe","Colombia",">= 16 years","general pop",83.3,"75.3",88.7,NA,"mu, delta, & omicron","~56 weeks",NA,NA,2495,"Colombia","COL",294,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations","06/08/2022",2022-08-06
"2438",294,"Pinto-Alvarez","Nested cohort","13Oct2022","CoronaVac (Sinovac)","excluded","2","final","15+","death","death","Colombia",">= 16 years","general pop",92.6,"87.5",95.6,NA,"mu, delta, & omicron","~56 weeks",NA,NA,2496,"Colombia","COL",294,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"death","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations","06/08/2022",2022-08-06
"2439",294,"Pinto-Alvarez","Nested cohort","13Oct2022","Ad26.COV2.S (Janssen)","excluded","1","final","15+","infection","infection","Colombia",">= 16 years","general pop",73.7,"65.2",80.1,NA,"mu, delta, & omicron","~56 weeks",NA,NA,2497,"Colombia","COL",294,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","06/08/2022",2022-08-06
"2440",294,"Pinto-Alvarez","Nested cohort","13Oct2022","Ad26.COV2.S (Janssen)","excluded","1","final","15+","hospitalization","severe","Colombia",">= 16 years","general pop",88.4,"77.4",94,NA,"mu, delta, & omicron","~56 weeks",NA,NA,2498,"Colombia","COL",294,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","06/08/2022",2022-08-06
"2441",294,"Pinto-Alvarez","Nested cohort","13Oct2022","Ad26.COV2.S (Janssen)","excluded","1","final","15+","death","death","Colombia",">= 16 years","general pop",97.1,"87.9",99.3,NA,"mu, delta, & omicron","~56 weeks",NA,NA,2499,"Colombia","COL",294,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-10-13,"death","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","06/08/2022",2022-08-06
"2442",295,"Zambrano","Test-negative case-control","04Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","28+","hospitalization with MIS-C","hospitalization with MIS-C","USA","12-18 years","12-18 years",92,"71",98,NA,"omicron","~40 weeks",NA,NA,2500,"USA","USA",295,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-04,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-04
"2443",295,"Zambrano","Test-negative case-control","04Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","28+","hospitalization with MIS-C","hospitalization with MIS-C","USA","12-18 years","12-18 years",94,"83",98,NA,"delta","~40 weeks",NA,NA,2501,"USA","USA",295,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-04,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-08-04
"2444",295,"Zambrano","Test-negative case-control","04Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","28-120","hospitalization with MIS-C","hospitalization with MIS-C","USA","12-18 years","12-18 years",90,"75",96,NA,"delta & omicron","~40 weeks",NA,NA,2502,"USA","USA",295,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-04,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-08-04
"2445",295,"Zambrano","Test-negative case-control","04Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","120+","hospitalization with MIS-C","hospitalization with MIS-C","USA","12-18 years","12-18 years",92,"78",97,NA,"delta & omicron","~40 weeks",NA,NA,2503,"USA","USA",295,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-04,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-08-04
"2446",295,"Zambrano","Test-negative case-control","04Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","28+","hospitalization with MIS-C","hospitalization with MIS-C","USA","5-11 years","5-11 years",78,"48",90,NA,"delta & omicron","~16 weeks",NA,NA,2504,"USA","USA",295,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-04,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-08-04
"2447",296,"El Adam","Test-negative case-control","15Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Canada (British Colombia)","HCW","HCW",89,"87",91,NA,"alpha, gamma, & delta","~34 weeks",NA,NA,2505,"Canada","CAN",296,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-15,"infection","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-04-15
"2448",296,"El Adam","Test-negative case-control","15Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Canada (British Colombia)","HCW","HCW",93,"90",95,NA,"alpha, gamma, & delta","~34 weeks",NA,NA,2506,"Canada","CAN",296,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-15,"infection","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-04-15
"2449",296,"El Adam","Test-negative case-control","15Apr2022","Heterologous mRNA","excluded","2","final","14+","infection","infection","Canada (British Colombia)","HCW","HCW",92,"86",95,NA,"alpha, gamma, & delta","~34 weeks",NA,NA,2507,"Canada","CAN",296,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-15,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-15
"2450",296,"El Adam","Test-negative case-control","15Apr2022","Any mRNA","excluded","2","final","14+","infection","infection","Canada (British Colombia)","HCW","HCW",90,"88",92,NA,"alpha, gamma, & delta","~34 weeks",NA,NA,2508,"Canada","CAN",296,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-15,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-15
"2451",296,"El Adam","Test-negative case-control","15Apr2022","Any mRNA","excluded","2","final","14-20","infection","infection","Canada (British Colombia)","HCW","HCW",99,"90",100,NA,"alpha, gamma, & delta","~34 weeks",NA,NA,2509,"Canada","CAN",296,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-15,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-15
"2452",296,"El Adam","Test-negative case-control","15Apr2022","Any mRNA","excluded","2","final","196+","infection","infection","Canada (British Colombia)","HCW","HCW",82,"75",87,NA,"alpha, gamma, & delta","~34 weeks",NA,NA,2510,"Canada","CAN",296,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-15,"infection","2022 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-04-15
"2453",297,"Lewis","Retrospective cohort","27Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected only","2","final","14+","infection","infection","USA",">= 12 years",">= 12 years",64,"58",69,NA,"non-VOC, alpha, & delta","~46 weeks",NA,NA,2511,"USA","USA",297,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-27,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-27
"2454",297,"Lewis","Retrospective cohort","27Jul2022","Ad26.COV2.S (Janssen)","previously infected only","1","final","14+","infection","infection","USA",">= 12 years",">= 12 years",48,"26",63,NA,"non-VOC, alpha, & delta","~46 weeks",NA,NA,2512,"USA","USA",297,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-27,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-07-27
"2455",297,"Lewis","Retrospective cohort","27Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected only","2","final","14+","infection","infection","USA","LTCF residents","LTCF residents",49,"26",65,NA,"non-VOC, alpha, & delta","~46 weeks",NA,NA,2513,"USA","USA",297,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-27,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-27
"2456",297,"Lewis","Retrospective cohort","27Jul2022","Ad26.COV2.S (Janssen)","previously infected only","1","final","14+","infection","infection","USA","LTCF residents","LTCF residents",57,"-211",94,NA,"non-VOC, alpha, & delta","~46 weeks",NA,NA,2514,"USA","USA",297,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-27,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-07-27
"2457",297,"Lewis","Retrospective cohort","27Jul2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected only","2","final","14+","infection","infection","USA","LTCF employees","LTCF employees",52,"26",68,NA,"non-VOC, alpha, & delta","~46 weeks",NA,NA,2515,"USA","USA",297,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-27,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-07-27
"2458",297,"Lewis","Retrospective cohort","27Jul2022","Ad26.COV2.S (Janssen)","previously infected only","1","final","14+","infection","infection","USA","LTCF employees","LTCF employees",-68,"-415",45,NA,"non-VOC, alpha, & delta","~46 weeks",NA,NA,2516,"USA","USA",297,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-07-27,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-07-27
"2459",298,"Cheng","Retrospective cohort","11Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Hong Kong","patients with chronic kidney disease","patients with chronic kidney disease",38,"34",41,NA,"omicron","~51 weeks",NA,NA,2517,"Hong Kong","HKG",298,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-11,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-11
"2460",298,"Cheng","Retrospective cohort","11Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Hong Kong","patients with chronic kidney disease","patients with chronic kidney disease",64,"57",69,NA,"omicron","~51 weeks",NA,NA,2518,"Hong Kong","HKG",298,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-11,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-11
"2461",298,"Cheng","Retrospective cohort","11Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","Hong Kong","patients with chronic kidney disease","patients with chronic kidney disease",86,"80",90,NA,"omicron","~51 weeks",NA,NA,2519,"Hong Kong","HKG",298,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-11,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-11
"2462",298,"Cheng","Retrospective cohort","11Aug2022","CoronaVac (Sinovac)","excluded","2","final","14+","infection","infection","Hong Kong","patients with chronic kidney disease","patients with chronic kidney disease",4,"0",8,NA,"omicron","~51 weeks",NA,NA,2520,"Hong Kong","HKG",298,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-11,"infection","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-08-11
"2463",298,"Cheng","Retrospective cohort","11Aug2022","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Hong Kong","patients with chronic kidney disease","patients with chronic kidney disease",44,"37",91,NA,"omicron","~51 weeks",NA,NA,2521,"Hong Kong","HKG",298,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-11,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-08-11
"2464",298,"Cheng","Retrospective cohort","11Aug2022","CoronaVac (Sinovac)","excluded","2","final","14+","death","death","Hong Kong","patients with chronic kidney disease","patients with chronic kidney disease",70,"64",75,NA,"omicron","~51 weeks",NA,NA,2522,"Hong Kong","HKG",298,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-11,"death","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-08-11
"2465",299,"Risk","Retrospective cohort","16Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA","immunocompromised adults","immunocompromised adults",13,"-23",39,NA,"omicron","~56 weeks",NA,NA,2523,"USA","USA",299,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-16,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-16
"2466",299,"Risk","Retrospective cohort","16Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA","immunocompetent adults","immunocompetent adults",-6,"-16",4,NA,"omicron","~56 weeks",NA,NA,2524,"USA","USA",299,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-16,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-16
"2467",299,"Risk","Retrospective cohort","16Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",67,"51",78,NA,"omicron","~56 weeks",NA,NA,2525,"USA","USA",299,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-16,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-16
"2468",299,"Risk","Retrospective cohort","16Aug2022","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","USA","immunocompromised adults","immunocompromised adults",57,"29",74,NA,"omicron","~56 weeks",NA,NA,2526,"USA","USA",299,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-16,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2022-08-16
"2469",299,"Risk","Retrospective cohort","16Aug2022","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","USA","immunocompetent adults","immunocompetent adults",16,"5",26,NA,"omicron","~56 weeks",NA,NA,2527,"USA","USA",299,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-16,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2022-08-16
"2470",299,"Risk","Retrospective cohort","16Aug2022","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",79,"63",88,NA,"omicron","~56 weeks",NA,NA,2528,"USA","USA",299,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-16,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2022-08-16
"2471",299,"Risk","Retrospective cohort","16Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","immunocompromised adults","immunocompromised adults",85,"62",94,NA,"omicron","~56 weeks",NA,NA,2529,"USA","USA",299,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-16,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-08-16
"2472",299,"Risk","Retrospective cohort","16Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","immunocompetent adults","immunocompetent adults",68,"53",78,NA,"omicron","~56 weeks",NA,NA,2530,"USA","USA",299,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-16,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-08-16
"2473",299,"Risk","Retrospective cohort","16Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","ICU admission","severe","USA",">= 18 years","general pop",92,"66",98,NA,"omicron","~56 weeks",NA,NA,2531,"USA","USA",299,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-16,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-08-16
"2474",300,"Kim","Retrospective cohort","17Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-29","infection","infection","South Korea","12-18 years","12-18 years",76.6,"74.3",78.6,NA,"delta & omicron","~6 weeks",NA,NA,2532,"South Korea","KOR",300,"KOR",33830,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,201,241,"equal","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-17,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-08-17
"2475",300,"Kim","Retrospective cohort","17Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","30-59","infection","infection","South Korea","12-18 years","12-18 years",49.6,"45.9",53.2,NA,"delta & omicron","~6 weeks",NA,NA,2533,"South Korea","KOR",300,"KOR",33830,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,201,241,"equal","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-17,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-08-17
"2476",300,"Kim","Retrospective cohort","17Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-29","infection","infection","South Korea","12-18 years","12-18 years",83.5,"81.3",85.4,NA,"delta & omicron","~11 weeks",NA,NA,2534,"South Korea","KOR",300,"KOR",33830,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,201,241,"equal","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-17,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-08-17
"2477",300,"Kim","Retrospective cohort","17Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","60-89","infection","infection","South Korea","12-18 years","12-18 years",41.8,"35.3",47.6,NA,"delta & omicron","~11 weeks",NA,NA,2535,"South Korea","KOR",300,"KOR",33830,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,201,241,"equal","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-17,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-08-17
"2478",300,"Kim","Retrospective cohort","17Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-29","infection","infection","South Korea","12-18 years","12-18 years",82.8,"75.1",88.1,NA,"delta & omicron","~22 weeks",NA,NA,2536,"South Korea","KOR",300,"KOR",33830,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,201,241,"equal","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-17,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-08-17
"2479",300,"Kim","Retrospective cohort","17Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","90+","infection","infection","South Korea","12-18 years","12-18 years",28.9,"20.6",36.4,NA,"delta & omicron","~22 weeks",NA,NA,2537,"South Korea","KOR",300,"KOR",33830,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,201,241,"equal","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-08-17,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-08-17
"2480",301,"Yan","Case-control","18Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","severe disease","severe","Hong Kong","18-50 years","18-50 years",73.7,"54.2",84.9,NA,"omicron BA.2","~52 weeks",NA,NA,2538,"Hong Kong","HKG",301,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-18,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-18
"2481",301,"Yan","Case-control","18Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","severe disease","severe","Hong Kong","51-64 years","51-64 years",84.5,"72.2",91.4,NA,"omicron BA.2","~52 weeks",NA,NA,2539,"Hong Kong","HKG",301,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-18,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-18
"2482",301,"Yan","Case-control","18Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","severe disease","severe","Hong Kong",">= 65 years",">= 65 years",81.9,"74.4",87.2,NA,"omicron BA.2","~52 weeks",NA,NA,2540,"Hong Kong","HKG",301,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-18,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-18
"2483",301,"Yan","Case-control","18Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","Hong Kong","18-50 years","18-50 years",84.2,"67.3",92.4,NA,"omicron BA.2","~52 weeks",NA,NA,2541,"Hong Kong","HKG",301,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-18,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-18
"2484",301,"Yan","Case-control","18Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","Hong Kong","51-64 years","51-64 years",86.9,"80.3",91.3,NA,"omicron BA.2","~52 weeks",NA,NA,2542,"Hong Kong","HKG",301,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-18,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-18
"2485",301,"Yan","Case-control","18Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","Hong Kong",">= 65 years",">= 65 years",90.6,"88.5",92.4,NA,"omicron BA.2","~52 weeks",NA,NA,2543,"Hong Kong","HKG",301,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-18,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-18
"2486",301,"Yan","Case-control","18Aug2022","CoronaVac (Sinovac)","excluded","2","final","14+","severe disease","severe","Hong Kong","18-50 years","18-50 years",72.6,"40.1",87.5,NA,"omicron BA.2","~52 weeks",NA,NA,2544,"Hong Kong","HKG",301,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-18,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-08-18
"2487",301,"Yan","Case-control","18Aug2022","CoronaVac (Sinovac)","excluded","2","final","14+","severe disease","severe","Hong Kong","51-64 years","51-64 years",67.8,"48.7",79.7,NA,"omicron BA.2","~52 weeks",NA,NA,2545,"Hong Kong","HKG",301,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-18,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-08-18
"2488",301,"Yan","Case-control","18Aug2022","CoronaVac (Sinovac)","excluded","2","final","14+","severe disease","severe","Hong Kong",">= 65 years",">= 65 years",56.7,"47.4",64.4,NA,"omicron BA.2","~52 weeks",NA,NA,2546,"Hong Kong","HKG",301,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-18,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-08-18
"2489",301,"Yan","Case-control","18Aug2022","CoronaVac (Sinovac)","excluded","2","final","14+","death","death","Hong Kong","18-50 years","18-50 years",83.7,"57.9",93.7,NA,"omicron BA.2","~52 weeks",NA,NA,2547,"Hong Kong","HKG",301,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-18,"death","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-08-18
"2490",301,"Yan","Case-control","18Aug2022","CoronaVac (Sinovac)","excluded","2","final","14+","death","death","Hong Kong","51-64 years","51-64 years",78.1,"69.4",84.3,NA,"omicron BA.2","~52 weeks",NA,NA,2548,"Hong Kong","HKG",301,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-18,"death","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-08-18
"2491",301,"Yan","Case-control","18Aug2022","CoronaVac (Sinovac)","excluded","2","final","14+","death","death","Hong Kong",">= 65 years",">= 65 years",72.5,"69.9",74.9,NA,"omicron BA.2","~52 weeks",NA,NA,2549,"Hong Kong","HKG",301,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-18,"death","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-08-18
"2492",302,"Powell","Test-negative case-control","22Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-104","symptomatic disease","symptomatic","UK","11-17 years","11-17 years",64.5,"63.6",65.4,NA,"omicron","~38 weeks",NA,NA,2550,"UK","GBR",302,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-22,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","22/08/2022",2022-08-22
"2493",302,"Powell","Test-negative case-control","22Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","280-286","symptomatic disease","symptomatic","UK","11-17 years","11-17 years",25.7,"-4.2",47,NA,"omicron","~38 weeks",NA,NA,2551,"UK","GBR",302,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-22,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","22/08/2022",2022-08-22
"2494",302,"Powell","Test-negative case-control","22Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-104","symptomatic disease","symptomatic","UK","11-17 years","11-17 years",91.8,"91.2",92.3,NA,"delta","~38 weeks",NA,NA,2552,"UK","GBR",302,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-22,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","22/08/2022",2022-08-22
"2495",302,"Powell","Test-negative case-control","22Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","175-279","symptomatic disease","symptomatic","UK","11-17 years","11-17 years",71.9,"67.9",75.4,NA,"delta","~38 weeks",NA,NA,2553,"UK","GBR",302,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-22,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","22/08/2022",2022-08-22
"2496",303,"Wan","Case-control","17Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Hong Kong",">=12 years with diabetes mellitus",">=12 years with diabetes mellitus",22.1,"20",24.2,NA,"omicron BA.2","~53 weeks",NA,NA,2554,"Hong Kong","HKG",303,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-17,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-17
"2497",303,"Wan","Case-control","17Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Hong Kong",">=12 years with diabetes mellitus",">=12 years with diabetes mellitus",74.2,"71.7",76.4,NA,"omicron BA.2","~53 weeks",NA,NA,2555,"Hong Kong","HKG",303,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-17,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-17
"2498",303,"Wan","Case-control","17Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","ICU admission","severe","Hong Kong",">=12 years with diabetes mellitus",">=12 years with diabetes mellitus",82.3,"72.1",88.8,NA,"omicron BA.2","~53 weeks",NA,NA,2556,"Hong Kong","HKG",303,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-17,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-17
"2499",303,"Wan","Case-control","17Aug2022","CoronaVac (Sinovac)","excluded","2","final","14+","infection","infection","Hong Kong",">=12 years with diabetes mellitus",">=12 years with diabetes mellitus",-0.3,"-2.7",2.1,NA,"omicron BA.2","~53 weeks",NA,NA,2557,"Hong Kong","HKG",303,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-17,"infection","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-08-17
"2500",303,"Wan","Case-control","17Aug2022","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Hong Kong",">=12 years with diabetes mellitus",">=12 years with diabetes mellitus",64.2,"61.8",66.4,NA,"omicron BA.2","~53 weeks",NA,NA,2558,"Hong Kong","HKG",303,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-17,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-08-17
"2501",303,"Wan","Case-control","17Aug2022","CoronaVac (Sinovac)","excluded","2","final","14+","ICU admission","severe","Hong Kong",">=12 years with diabetes mellitus",">=12 years with diabetes mellitus",58.1,"45",68.1,NA,"omicron BA.2","~53 weeks",NA,NA,2559,"Hong Kong","HKG",303,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-17,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-08-17
"2502",304,"Tsang","Prospective cohort","12Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-89","infection","infection","Hong Kong",">=5 years","general pop",27.6,"-6.3",50.7,NA,"omicron BA.2","~55 weeks",NA,NA,2560,"Hong Kong","HKG",304,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-12-12,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/08/2022",2022-08-25
"2503",304,"Tsang","Prospective cohort","12Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","90+","infection","infection","Hong Kong",">=5 years","general pop",1.1,"-22.4",20.1,NA,"omicron BA.2","~55 weeks",NA,NA,2561,"Hong Kong","HKG",304,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-12-12,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/08/2022",2022-08-25
"2504",304,"Tsang","Prospective cohort","12Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-89","symptomatic disease","symptomatic","Hong Kong",">=5 years","general pop",31.6,"-9.3",57.2,NA,"omicron BA.2","~55 weeks",NA,NA,2562,"Hong Kong","HKG",304,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-12-12,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/08/2022",2022-08-25
"2505",304,"Tsang","Prospective cohort","12Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","90+","symptomatic disease","symptomatic","Hong Kong",">=5 years","general pop",4.7,"-23.5",26.6,NA,"omicron BA.2","~55 weeks",NA,NA,2563,"Hong Kong","HKG",304,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-12-12,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","25/08/2022",2022-08-25
"2506",304,"Tsang","Prospective cohort","12Dec2022","CoronaVac (Sinovac)","excluded","2","final","14-89","infection","infection","Hong Kong",">=5 years","general pop",22.7,"-15.2",48.2,NA,"omicron BA.2","~55 weeks",NA,NA,2564,"Hong Kong","HKG",304,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-12-12,"infection","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","25/08/2022",2022-08-25
"2507",304,"Tsang","Prospective cohort","12Dec2022","CoronaVac (Sinovac)","excluded","2","final","90+","infection","infection","Hong Kong",">=5 years","general pop",5.4,"-25.6",28.8,NA,"omicron BA.2","~55 weeks",NA,NA,2565,"Hong Kong","HKG",304,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-12-12,"infection","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","25/08/2022",2022-08-25
"2508",304,"Tsang","Prospective cohort","12Dec2022","CoronaVac (Sinovac)","excluded","2","final","14-89","symptomatic disease","symptomatic","Hong Kong",">=5 years","general pop",12.2,"-40",44.9,NA,"omicron BA.2","~55 weeks",NA,NA,2566,"Hong Kong","HKG",304,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-12-12,"symptomatic","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","25/08/2022",2022-08-25
"2509",304,"Tsang","Prospective cohort","12Dec2022","CoronaVac (Sinovac)","excluded","2","final","90+","symptomatic disease","symptomatic","Hong Kong",">=5 years","general pop",6.4,"-32.1",33.7,NA,"omicron BA.2","~55 weeks",NA,NA,2567,"Hong Kong","HKG",304,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-12-12,"symptomatic","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron","25/08/2022",2022-08-25
"2510",305,"Cocchio","Retrospective cohort","20Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-34","infection","infection","Italy","5-11 years","5-11 years",53,"51",55,NA,"omicron","~16 weeks",NA,NA,2568,"Italy","ITA",305,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-20
"2511",305,"Cocchio","Retrospective cohort","20Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","70+","infection","infection","Italy","5-11 years","5-11 years",23,"20",26,NA,"omicron","~16 weeks",NA,NA,2569,"Italy","ITA",305,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-20
"2512",305,"Cocchio","Retrospective cohort","20Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-34","infection","infection","Italy","12-17 years","12-17 years",59,"55",62,NA,"omicron","~53 weeks",NA,NA,2570,"Italy","ITA",305,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-20
"2513",305,"Cocchio","Retrospective cohort","20Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","70+","infection","infection","Italy","12-17 years","12-17 years",8,"5",11,NA,"omicron","~53 weeks",NA,NA,2571,"Italy","ITA",305,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-08-20
"2514",305,"Cocchio","Retrospective cohort","20Aug2022","mRNA-1273 (Moderna)","excluded","2","final","14-34","infection","infection","Italy","12-17 years","12-17 years",55,"49",61,NA,"omicron","~33 weeks",NA,NA,2572,"Italy","ITA",305,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-20,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2022-08-20
"2515",305,"Cocchio","Retrospective cohort","20Aug2022","mRNA-1273 (Moderna)","excluded","2","final","70+","infection","infection","Italy","12-17 years","12-17 years",20,"15",24,NA,"omicron","~33 weeks",NA,NA,2573,"Italy","ITA",305,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-20,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2022-08-20
"2516",305,"Cocchio","Retrospective cohort","20Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-34","infection","infection","Italy","12-17 years","12-17 years",88,"85",91,NA,"delta","~28 weeks",NA,NA,2574,"Italy","ITA",305,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-08-20
"2517",305,"Cocchio","Retrospective cohort","20Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","70+","infection","infection","Italy","12-17 years","12-17 years",82,"74",88,NA,"delta","~28 weeks",NA,NA,2575,"Italy","ITA",305,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-20,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-08-20
"2518",305,"Cocchio","Retrospective cohort","20Aug2022","mRNA-1273 (Moderna)","excluded","2","final","14-34","infection","infection","Italy","12-17 years","12-17 years",90,"68",97,NA,"delta","~7 weeks",NA,NA,2576,"Italy","ITA",305,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-20,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-08-20
"2519",305,"Cocchio","Retrospective cohort","20Aug2022","mRNA-1273 (Moderna)","excluded","2","final","35-69","infection","infection","Italy","12-17 years","12-17 years",96,"86",99,NA,"delta","~7 weeks",NA,NA,2577,"Italy","ITA",305,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-20,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-08-20
"2520",306,"Lim","Test-negative case-control","24Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-27","infection","infection","Malaysia",">=18 years","general pop",58.9,"40.7",71.9,NA,"alpha & delta","~28 weeks",NA,NA,2578,"Malaysia","MYS",306,"MYS",10750,2019,"Malaysia","East Asia & Pacific","Upper middle income",3,"Asia",2021-02-26,2021-08-24,2021-10-21,2021-02-24,2021-02-24,2,181,239,"who","feb/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-24,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-08-24
"2521",306,"Lim","Test-negative case-control","24Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","98-111","infection","infection","Malaysia",">=18 years","general pop",31.3,"10.8",47.2,NA,"alpha & delta","~28 weeks",NA,NA,2579,"Malaysia","MYS",306,"MYS",10750,2019,"Malaysia","East Asia & Pacific","Upper middle income",3,"Asia",2021-02-26,2021-08-24,2021-10-21,2021-02-24,2021-02-24,2,181,239,"who","feb/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-24,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-08-24
"2522",306,"Lim","Test-negative case-control","24Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","ICU admission","severe","Malaysia",">=18 years","general pop",92.5,"72.3",98.8,NA,"alpha & delta","~28 weeks",NA,NA,2580,"Malaysia","MYS",306,"MYS",10750,2019,"Malaysia","East Asia & Pacific","Upper middle income",3,"Asia",2021-02-26,2021-08-24,2021-10-21,2021-02-24,2021-02-24,2,181,239,"who","feb/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-24,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-08-24
"2523",306,"Lim","Test-negative case-control","24Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","Malaysia",">=18 years","general pop",96.5,"82.3",99.8,NA,"alpha & delta","~28 weeks",NA,NA,2581,"Malaysia","MYS",306,"MYS",10750,2019,"Malaysia","East Asia & Pacific","Upper middle income",3,"Asia",2021-02-26,2021-08-24,2021-10-21,2021-02-24,2021-02-24,2,181,239,"who","feb/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-24,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-08-24
"2524",306,"Lim","Retrospective cohort","24Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Malaysia",">=18 years","general pop",87.9,"86.3",89.4,NA,"alpha & delta","~28 weeks",NA,NA,2582,"Malaysia","MYS",306,"MYS",10750,2019,"Malaysia","East Asia & Pacific","Upper middle income",3,"Asia",2021-02-26,2021-08-24,2021-10-21,2021-02-24,2021-02-24,2,181,239,"who","feb/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-24,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-08-24
"2525",306,"Lim","Retrospective cohort","24Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","ICU admission","severe","Malaysia",">=18 years","general pop",97.5,"81.2",99.6,NA,"alpha & delta","~28 weeks",NA,NA,2583,"Malaysia","MYS",306,"MYS",10750,2019,"Malaysia","East Asia & Pacific","Upper middle income",3,"Asia",2021-02-26,2021-08-24,2021-10-21,2021-02-24,2021-02-24,2,181,239,"who","feb/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-24,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-08-24
"2526",306,"Lim","Retrospective cohort","24Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","Malaysia",">=18 years","general pop",99.3,"96.3",100,NA,"alpha & delta","~28 weeks",NA,NA,2584,"Malaysia","MYS",306,"MYS",10750,2019,"Malaysia","East Asia & Pacific","Upper middle income",3,"Asia",2021-02-26,2021-08-24,2021-10-21,2021-02-24,2021-02-24,2,181,239,"who","feb/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-24,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-08-24
"2527",307,"Lind","Test-negative case-control","21Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-89","infection","infection","USA",">=16 years","general pop",84.4,"75.5",90,NA,"alpha","~29 weeks",NA,NA,2585,"USA","USA",307,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-11-21,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","26/08/2022",2022-08-26
"2528",307,"Lind","Test-negative case-control","21Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","90-149","infection","infection","USA",">=16 years","general pop",96.5,"75.1",99.5,NA,"alpha","~29 weeks",NA,NA,2586,"USA","USA",307,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-11-21,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","26/08/2022",2022-08-26
"2529",307,"Lind","Test-negative case-control","21Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-89","symptomatic disease","symptomatic","USA",">=16 years","general pop",86.6,"75.5",92.7,NA,"alpha","~29 weeks",NA,NA,2587,"USA","USA",307,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-11-21,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","26/08/2022",2022-08-26
"2530",307,"Lind","Test-negative case-control","21Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","90-149","symptomatic disease","symptomatic","USA",">=16 years","general pop",93.8,"55",99.1,NA,"alpha","~29 weeks",NA,NA,2588,"USA","USA",307,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-11-21,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","26/08/2022",2022-08-26
"2531",307,"Lind","Test-negative case-control","21Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-89","hospitalization","severe","USA",">=16 years","general pop",85.5,"65.5",93.9,NA,"alpha","~29 weeks",NA,NA,2589,"USA","USA",307,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-11-21,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","26/08/2022",2022-08-26
"2532",307,"Lind","Test-negative case-control","21Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","90-149","hospitalization","severe","USA",">=16 years","general pop",82.2,"-34.5",97.7,NA,"alpha","~29 weeks",NA,NA,2590,"USA","USA",307,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-11-21,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","26/08/2022",2022-08-26
"2533",307,"Lind","Test-negative case-control","21Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-89","infection","infection","USA",">=16 years","general pop",68.9,"58",77.1,NA,"delta","~29 weeks",NA,NA,2591,"USA","USA",307,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-11-21,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","26/08/2022",2022-08-26
"2534",307,"Lind","Test-negative case-control","21Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","infection","infection","USA",">=16 years","general pop",37.1,"24",48.1,NA,"delta","~29 weeks",NA,NA,2592,"USA","USA",307,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-11-21,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","26/08/2022",2022-08-26
"2535",307,"Lind","Test-negative case-control","21Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-89","symptomatic disease","symptomatic","USA",">=16 years","general pop",74.8,"62.9",82.9,NA,"delta","~29 weeks",NA,NA,2593,"USA","USA",307,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-11-21,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","26/08/2022",2022-08-26
"2536",307,"Lind","Test-negative case-control","21Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","symptomatic disease","symptomatic","USA",">=16 years","general pop",48.4,"32.8",60.4,NA,"delta","~29 weeks",NA,NA,2594,"USA","USA",307,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-11-21,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","26/08/2022",2022-08-26
"2537",307,"Lind","Test-negative case-control","21Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-89","hospitalization","severe","USA",">=16 years","general pop",85.4,"60.2",94.6,NA,"delta","~29 weeks",NA,NA,2595,"USA","USA",307,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-11-21,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","26/08/2022",2022-08-26
"2538",307,"Lind","Test-negative case-control","21Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","hospitalization","severe","USA",">=16 years","general pop",66.2,"42.5",80.1,NA,"delta","~29 weeks",NA,NA,2596,"USA","USA",307,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-11-21,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","26/08/2022",2022-08-26
"2539",308,"Suphanchaimat","Test-negative case-control","05Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","15-29","infection","infection","Thailand",">=18 years","general pop",74.2,"71.8",76.3,NA,"delta","~2 weeks",NA,NA,2597,"Thailand","THA",308,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-05,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-07-05
"2540",308,"Suphanchaimat","Test-negative case-control","05Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","90+","infection","infection","Thailand",">=18 years","general pop",57,"43.6",57.2,NA,"delta","~15 weeks",NA,NA,2598,"Thailand","THA",308,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-05,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-07-05
"2541",308,"Suphanchaimat","Test-negative case-control","05Jul2022","AZD1222 (AstraZeneca)","included","2","final","15-29","infection","infection","Thailand",">=18 years","general pop",61.4,"59.6",63.2,NA,"delta","~2 weeks",NA,NA,2599,"Thailand","THA",308,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-05,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-07-05
"2542",308,"Suphanchaimat","Test-negative case-control","05Jul2022","AZD1222 (AstraZeneca)","included","2","final","90+","infection","infection","Thailand",">=18 years","general pop",25.8,"19.1",31.9,NA,"delta","~31 weeks",NA,NA,2600,"Thailand","THA",308,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-05,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-07-05
"2543",308,"Suphanchaimat","Test-negative case-control","05Jul2022","CoronaVac (Sinovac)","included","2","final","15-29","infection","infection","Thailand",">=18 years","general pop",27.9,"0.3",47.9,NA,"delta","~2 weeks",NA,NA,2601,"Thailand","THA",308,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-05,"infection","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2022-07-05
"2544",308,"Suphanchaimat","Test-negative case-control","05Jul2022","CoronaVac (Sinovac)","included","2","final","90+","infection","infection","Thailand",">=18 years","general pop",49.8,"47.8",51.6,NA,"delta","~40 weeks",NA,NA,2602,"Thailand","THA",308,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-05,"infection","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2022-07-05
"2545",308,"Suphanchaimat","Test-negative case-control","05Jul2022","AZD1222 (AstraZeneca) & BNT162b2 (Pfizer BioNTech) -heterologous","included","2","final","15-29","infection","infection","Thailand",">=18 years","general pop",79.9,"74",84.5,NA,"delta","~2 weeks",NA,NA,2603,"Thailand","THA",308,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-05,"infection","2022 (Jul-Dec)","Heterologous platforms","Multiple","delta",NA,2022-07-05
"2546",308,"Suphanchaimat","Test-negative case-control","05Jul2022","AZD1222 (AstraZeneca) & BNT162b2 (Pfizer BioNTech) -heterologous","included","2","final","90+","infection","infection","Thailand",">=18 years","general pop",77.4,"68.2",84,NA,"delta","~19 weeks",NA,NA,2604,"Thailand","THA",308,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-05,"infection","2022 (Jul-Dec)","Heterologous platforms","Multiple","delta",NA,2022-07-05
"2547",308,"Suphanchaimat","Test-negative case-control","05Jul2022","CoronaVac (Sinovac) & AZD1222 (AstraZeneca) - heterologous","included","2","final","15-29","infection","infection","Thailand",">=18 years","general pop",57.8,"56.3",59.2,NA,"delta","~2 weeks",NA,NA,2605,"Thailand","THA",308,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-05,"infection","2022 (Jul-Dec)","Heterologous platforms","Multiple","delta",NA,2022-07-05
"2548",308,"Suphanchaimat","Test-negative case-control","05Jul2022","CoronaVac (Sinovac) & AZD1222 (AstraZeneca) - heterologous","included","2","final","90+","infection","infection","Thailand",">=18 years","general pop",36.6,"33.6",39.4,NA,"delta","~39 weeks",NA,NA,2606,"Thailand","THA",308,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-05,"infection","2022 (Jul-Dec)","Heterologous platforms","Multiple","delta",NA,2022-07-05
"2549",308,"Suphanchaimat","Test-negative case-control","05Jul2022","CoronaVac (Sinovac) & BNT162b2 (Pfizer BioNTech) - heterologous","included","2","final","15-29","infection","infection","Thailand",">=18 years","general pop",74.7,"62.8",82.8,NA,"delta","~2 weeks",NA,NA,2607,"Thailand","THA",308,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-05,"infection","2022 (Jul-Dec)","Heterologous platforms","Multiple","delta",NA,2022-07-05
"2550",308,"Suphanchaimat","Test-negative case-control","05Jul2022","CoronaVac (Sinovac) & BNT162b2 (Pfizer BioNTech) - heterologous","included","2","final","90+","infection","infection","Thailand",">=18 years","general pop",84.6,"64.9",89.3,NA,"delta","~19 weeks",NA,NA,2608,"Thailand","THA",308,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-07-05,"infection","2022 (Jul-Dec)","Heterologous platforms","Multiple","delta",NA,2022-07-05
"2551",309,"Barraza","Retrospective cohort","05Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization with SARI","severe","Chile",">=18 years","general pop",80.3,"68.9",87.5,NA,"gamma, delta & omicron","~77 weeks",NA,NA,2609,"Chile","CHL",309,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2022-08-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-08-05
"2552",309,"Barraza","Retrospective cohort","05Aug2022","AZD1222 (AstraZeneca)","included","2","final","14+","hospitalization with SARI","severe","Chile",">=18 years","general pop",72.4,"32.8",88.6,NA,"gamma, delta & omicron","~71 weeks",NA,NA,2610,"Chile","CHL",309,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2022-08-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-08-05
"2553",309,"Barraza","Retrospective cohort","05Aug2022","CoronaVac (Sinovac)","included","2","final","14+","hospitalization with SARI","severe","Chile",">=18 years","general pop",54.5,"45.2",62.3,NA,"gamma, delta & omicron","~72 weeks",NA,NA,2611,"Chile","CHL",309,"CHL",14690,2019,"Chile","Latin America & Caribbean","High income",3,"South America",2020-12-25,2021-05-25,2021-09-02,2020-12-21,2020-12-21,4,155,255,"who","before jan/2021","before Jun/2021","<180","yes","yes","yes",2022-08-05,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations",NA,2022-08-05
"2554",310,"Penayo","Test-negative case-control","01Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",91.9,"72.2",97.6,NA,"delta","~38 weeks",NA,NA,2612,"Paraguay","PRY",310,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-06-01
"2555",310,"Penayo","Test-negative case-control","01Jun2022","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",76.1,"-127.4",97.5,NA,"delta","~37 weeks",NA,NA,2613,"Paraguay","PRY",310,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-06-01
"2556",310,"Penayo","Test-negative case-control","01Jun2022","AZD1222 (AstraZeneca)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",83,"66.3",91.5,NA,"delta","~33 weeks",NA,NA,2614,"Paraguay","PRY",310,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-06-01
"2557",310,"Penayo","Test-negative case-control","01Jun2022","Gam-COVID-Vac (Gamaleya)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",83.2,"48.9",94.5,NA,"delta","~38 weeks",NA,NA,2615,"Paraguay","PRY",310,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta",NA,2022-06-01
"2558",310,"Penayo","Test-negative case-control","01Jun2022","Hayat-Vax (Julphar)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",31.8,"-41.2",67.1,NA,"delta","~39 weeks",NA,NA,2616,"Paraguay","PRY",310,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-06-01
"2559",310,"Penayo","Test-negative case-control","01Jun2022","BBV152 (Bharat)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",25.8,"-37.1",59.9,NA,"delta","~37 weeks",NA,NA,2617,"Paraguay","PRY",310,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","Bharat Covaxin/BBV152","Inactivated","delta",NA,2022-06-01
"2560",310,"Penayo","Test-negative case-control","01Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",49.5,"9.9",71.7,NA,"omicron","~53 weeks",NA,NA,2618,"Paraguay","PRY",310,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-06-01
"2561",310,"Penayo","Test-negative case-control","01Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-89","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",78,"-97",97.5,NA,"omicron","~11 weeks",NA,NA,2619,"Paraguay","PRY",310,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-06-01
"2562",310,"Penayo","Test-negative case-control","01Jun2022","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",42.1,"-105.4",83.7,NA,"omicron","~52 weeks",NA,NA,2620,"Paraguay","PRY",310,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2022-06-01
"2563",310,"Penayo","Test-negative case-control","01Jun2022","AZD1222 (AstraZeneca)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",10.1,"-31",38.3,NA,"omicron","~48 weeks",NA,NA,2621,"Paraguay","PRY",310,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2022-06-01
"2564",310,"Penayo","Test-negative case-control","01Jun2022","Gam-COVID-Vac (Gamaleya)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",25.7,"-29.9",57.5,NA,"omicron","~53 weeks",NA,NA,2622,"Paraguay","PRY",310,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","omicron",NA,2022-06-01
"2565",310,"Penayo","Test-negative case-control","01Jun2022","Gam-COVID-Vac (Gamaleya)","included","2","final","14-89","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",64.4,"-44.6",92.2,NA,"omicron","~11 weeks",NA,NA,2623,"Paraguay","PRY",310,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","omicron",NA,2022-06-01
"2566",310,"Penayo","Test-negative case-control","01Jun2022","Hayat-Vax (Julphar)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",40.4,"-5.1",66.2,NA,"omicron","~54 weeks",NA,NA,2624,"Paraguay","PRY",310,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","omicron",NA,2022-06-01
"2567",310,"Penayo","Test-negative case-control","01Jun2022","BBV152 (Bharat)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",13,"-45.8",48,NA,"omicron","~52 weeks",NA,NA,2625,"Paraguay","PRY",310,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","Bharat Covaxin/BBV152","Inactivated","omicron",NA,2022-06-01
"2568",311,"Monge","Case cohort","02Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","Spain","50-59 years","50-59 years",77,"76",77,NA,"delta","~21 weeks",NA,NA,2626,"Spain","ESP",311,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-02
"2569",311,"Monge","Case cohort","02Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","symptomatic disease","symptomatic","Spain","50-59 years","50-59 years",77,"76",78,NA,"delta","~21 weeks",NA,NA,2627,"Spain","ESP",311,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-02
"2570",311,"Monge","Case cohort","02Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","Spain","50-59 years","50-59 years",97,"97",98,NA,"delta","~21 weeks",NA,NA,2628,"Spain","ESP",311,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-02
"2571",311,"Monge","Case cohort","02Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","death","death","Spain","50-59 years","50-59 years",97,"93",99,NA,"delta","~21 weeks",NA,NA,2629,"Spain","ESP",311,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-02
"2572",311,"Monge","Case cohort","02Sept2022","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Spain","50-59 years","50-59 years",87,"86",87,NA,"delta","~21 weeks",NA,NA,2630,"Spain","ESP",311,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-09-02
"2573",311,"Monge","Case cohort","02Sept2022","mRNA-1273 (Moderna)","included","2","final","14+","symptomatic disease","symptomatic","Spain","50-59 years","50-59 years",89,"88",90,NA,"delta","~21 weeks",NA,NA,2631,"Spain","ESP",311,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"symptomatic","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-09-02
"2574",311,"Monge","Case cohort","02Sept2022","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","Spain","50-59 years","50-59 years",98,"97",99,NA,"delta","~21 weeks",NA,NA,2632,"Spain","ESP",311,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-09-02
"2575",311,"Monge","Case cohort","02Sept2022","mRNA-1273 (Moderna)","included","2","final","14+","death","death","Spain","50-59 years","50-59 years",94,"75",99,NA,"delta","~21 weeks",NA,NA,2633,"Spain","ESP",311,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"death","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-09-02
"2576",311,"Monge","Case cohort","02Sept2022","AZD1222 (AstraZeneca)","included","2","final","14+","infection","infection","Spain","50-59 years","50-59 years",59,"56",61,NA,"delta","~21 weeks",NA,NA,2634,"Spain","ESP",311,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-09-02
"2577",311,"Monge","Case cohort","02Sept2022","AZD1222 (AstraZeneca)","included","2","final","14+","symptomatic disease","symptomatic","Spain","50-59 years","50-59 years",59,"55",62,NA,"delta","~21 weeks",NA,NA,2635,"Spain","ESP",311,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"symptomatic","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-09-02
"2578",311,"Monge","Case cohort","02Sept2022","AZD1222 (AstraZeneca)","included","2","final","14+","hospitalization","severe","Spain","50-59 years","50-59 years",96,"93",98,NA,"delta","~21 weeks",NA,NA,2636,"Spain","ESP",311,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-09-02
"2579",311,"Monge","Case cohort","02Sept2022","Ad26.COV2.S (Janssen)","included","1","final","14+","infection","infection","Spain","50-59 years","50-59 years",64,"62",66,NA,"delta","~21 weeks",NA,NA,2637,"Spain","ESP",311,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-09-02
"2580",311,"Monge","Case cohort","02Sept2022","Ad26.COV2.S (Janssen)","included","1","final","14+","symptomatic disease","symptomatic","Spain","50-59 years","50-59 years",56,"53",59,NA,"delta","~21 weeks",NA,NA,2638,"Spain","ESP",311,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"symptomatic","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-09-02
"2581",311,"Monge","Case cohort","02Sept2022","Ad26.COV2.S (Janssen)","included","1","final","14+","hospitalization","severe","Spain","50-59 years","50-59 years",86,"83",89,NA,"delta","~21 weeks",NA,NA,2639,"Spain","ESP",311,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-09-02
"2582",311,"Monge","Case cohort","02Sept2022","Ad26.COV2.S (Janssen)","included","1","final","14+","death","death","Spain","50-59 years","50-59 years",89,"64",97,NA,"delta","~21 weeks",NA,NA,2640,"Spain","ESP",311,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"death","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-09-02
"2583",311,"Monge","Case cohort","02Sept2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","included","2","final","14+","infection","infection","Spain","50-59 years","50-59 years",88,"85",91,NA,"delta","~21 weeks",NA,NA,2641,"Spain","ESP",311,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"infection","2022 (Jul-Dec)","Heterologous platforms","Multiple","delta",NA,2022-09-02
"2584",311,"Monge","Case cohort","02Sept2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","included","2","final","14+","symptomatic disease","symptomatic","Spain","50-59 years","50-59 years",82,"75",87,NA,"delta","~21 weeks",NA,NA,2642,"Spain","ESP",311,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"symptomatic","2022 (Jul-Dec)","Heterologous platforms","Multiple","delta",NA,2022-09-02
"2585",311,"Monge","Case cohort","02Sept2022","AZD1222 (AstraZeneca) & any mRNA - heterologous","included","2","final","14+","hospitalization","severe","Spain","50-59 years","50-59 years",98,"84",100,NA,"delta","~21 weeks",NA,NA,2643,"Spain","ESP",311,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"severe","2022 (Jul-Dec)","Heterologous platforms","Multiple","delta",NA,2022-09-02
"2586",312,"Huang","Matched case-control","20Oct2022","Ad5-nCOV (CanSino)","excluded","1","final","14+","infection","infection","China",">=3 years","general pop",13.2,"10.9",15.5,NA,"omicron","~62 weeks",NA,NA,2644,"China","CHN",312,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2022-10-20,"infection","2022 (Jul-Dec)","Cansino Ad5-nCoV","Vectored","omicron","09/09/2022",2022-09-09
"2587",312,"Huang","Matched case-control","20Oct2022","Ad5-nCOV (CanSino)","excluded","1","final","14+","severe/critical illness","severe","China",">=3 years","general pop",77.9,"15.6",94.2,NA,"omicron","~62 weeks",NA,NA,2645,"China","CHN",312,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2022-10-20,"severe","2022 (Jul-Dec)","Cansino Ad5-nCoV","Vectored","omicron","09/09/2022",2022-09-09
"2588",313,"Chico-Sanchez","Test-negative case-control","31Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","12-120","infection","infection","Spain","HCW","HCW",91.6,"89.6",93.2,NA,"non-VOC & alpha","~22 weeks",NA,NA,2646,"Spain","ESP",313,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-31,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-08-31
"2589",313,"Chico-Sanchez","Test-negative case-control","31Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","120+","infection","infection","Spain","HCW","HCW",71.5,"67",75.5,NA,"non-VOC & alpha","~22 weeks",NA,NA,2647,"Spain","ESP",313,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-31,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-08-31
"2590",313,"Chico-Sanchez","Test-negative case-control","31Aug2022","mRNA-1273 (Moderna)","included","2","final","12-120","infection","infection","Spain","HCW","HCW",95.2,"88.3",98.1,NA,"non-VOC & alpha","~22 weeks",NA,NA,2648,"Spain","ESP",313,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-31,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-08-31
"2591",313,"Chico-Sanchez","Test-negative case-control","31Aug2022","mRNA-1273 (Moderna)","included","2","final","120+","infection","infection","Spain","HCW","HCW",88.3,"75.7",94.4,NA,"non-VOC & alpha","~22 weeks",NA,NA,2649,"Spain","ESP",313,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-31,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-08-31
"2592",313,"Chico-Sanchez","Test-negative case-control","31Aug2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","12+","hospitalization","severe","Spain","HCW","HCW",96.8,"76.1",99.6,NA,"non-VOC & alpha","~22 weeks",NA,NA,2650,"Spain","ESP",313,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-08-31,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-08-31
"2593",314,"Mallah","Test-negative case-control","10Sept2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","infection","infection","Spain",">=11 years","general pop",72,"71",73,NA,"alpha & delta","~42 weeks",NA,NA,2651,"Spain","ESP",314,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-10,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-09-10
"2594",314,"Mallah","Test-negative case-control","10Sept2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","hospitalization","severe","Spain",">=11 years","general pop",74,"70",77,NA,"alpha & delta","~42 weeks",NA,NA,2652,"Spain","ESP",314,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-10,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-09-10
"2595",315,"Chatzilena","Test-negative case-control","07Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","hospitalization","severe","UK",">=18 years","general pop",82.5,"76.2",87.2,NA,"delta","~56 weeks",NA,NA,2653,"UK","GBR",315,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-12-07,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","12/09/2022",2022-09-12
"2596",315,"Chatzilena","Test-negative case-control","07Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">=3 months","hospitalization","severe","UK",">=18 years","general pop",91.5,"83.1",96.2,NA,"delta","~56 weeks",NA,NA,2654,"UK","GBR",315,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-12-07,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","12/09/2022",2022-09-12
"2597",315,"Chatzilena","Test-negative case-control","07Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">3 months","hospitalization","severe","UK",">=18 years","general pop",79.5,"71.5",85.3,NA,"delta","~56 weeks",NA,NA,2655,"UK","GBR",315,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-12-07,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","12/09/2022",2022-09-12
"2598",316,"Collie","Test-negative case-control","14Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-27","hospitalization","severe","South Africa",">=18 years","general pop",80.3,"62.8",89.5,NA,"omicron BA.1 or BA.2","~36 weeks",NA,NA,2656,"South Africa","ZAF",316,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2022-09-14,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-14
"2599",316,"Collie","Test-negative case-control","14Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7-8 months","hospitalization","severe","South Africa",">=18 years","general pop",38.4,"16.9",54.4,NA,"omicron BA.1 or BA.2","~36 weeks",NA,NA,2657,"South Africa","ZAF",316,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2022-09-14,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-14
"2600",316,"Collie","Test-negative case-control","14Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","3-4 months","hospitalization","severe","South Africa",">=18 years","general pop",47.4,"19.9",65.5,NA,"omicron BA.4 or BA.5","~53 weeks",NA,NA,2658,"South Africa","ZAF",316,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2022-09-14,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-14
"2601",316,"Collie","Test-negative case-control","14Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","9+ months","hospitalization","severe","South Africa",">=18 years","general pop",19.3,"6.3",30.5,NA,"omicron BA.4 or BA.5","~53 weeks",NA,NA,2659,"South Africa","ZAF",316,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2022-09-14,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-14
"2602",317,"Martin","Prospective cohort","10Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","UK","patients with end-stage kidney disease undergoing hemodialysis","immunocompromised adults",62,"18",82,NA,"non-VOC, alpha, & delta","~46 weeks",NA,NA,2660,"UK","GBR",317,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-10,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-09-10
"2603",317,"Martin","Prospective cohort","10Sep2022","AZD1222 (AstraZeneca)","included","2","final","14+","infection","infection","UK","patients with end-stage kidney disease undergoing hemodialysis","immunocompromised adults",42,"-22",70,NA,"non-VOC, alpha, & delta","~46 weeks",NA,NA,2661,"UK","GBR",317,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-10,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-09-10
"2604",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-59","infection","infection","Canada",">=16 years","general pop",89,"88",90,NA,"non-VOC & alpha","~6 weeks",NA,NA,2662,"Canada","CAN",318,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-09-07
"2605",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","60-119","infection","infection","Canada",">=16 years","general pop",80,"75",85,NA,"non-VOC & alpha","~15 weeks",NA,NA,2663,"Canada","CAN",318,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-09-07
"2606",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-59","symptomatic disease","symptomatic","Canada",">=16 years","general pop",94,"91",96,NA,"non-VOC & alpha","~6 weeks",NA,NA,2664,"Canada","CAN",318,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-09-07
"2607",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","60-119","symptomatic disease","symptomatic","Canada",">=16 years","general pop",93,"79",98,NA,"non-VOC & alpha","~15 weeks",NA,NA,2665,"Canada","CAN",318,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-09-07
"2608",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-59","severe disease","severe","Canada",">=16 years","general pop",95,"90",97,NA,"non-VOC & alpha","~6 weeks",NA,NA,2666,"Canada","CAN",318,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-09-07
"2609",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-59","infection","infection","Canada",">=16 years","general pop",92,"91",93,NA,"alpha","~6 weeks",NA,NA,2667,"Canada","CAN",318,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-09-07
"2610",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","120-179","infection","infection","Canada",">=16 years","general pop",82,"79",85,NA,"alpha","~24 weeks",NA,NA,2668,"Canada","CAN",318,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-09-07
"2611",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-59","symptomatic disease","symptomatic","Canada",">=16 years","general pop",92,"91",94,NA,"alpha","~6 weeks",NA,NA,2669,"Canada","CAN",318,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-09-07
"2612",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","120-179","symptomatic disease","symptomatic","Canada",">=16 years","general pop",86,"78",91,NA,"alpha","~24 weeks",NA,NA,2670,"Canada","CAN",318,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-09-07
"2613",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-59","severe disease","severe","Canada",">=16 years","general pop",94,"92",95,NA,"alpha","~6 weeks",NA,NA,2671,"Canada","CAN",318,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-09-07
"2614",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","120-179","severe disease","severe","Canada",">=16 years","general pop",97,"95",98,NA,"alpha","~24 weeks",NA,NA,2672,"Canada","CAN",318,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-09-07
"2615",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-59","infection","infection","Canada",">=16 years","general pop",90,"90",90,NA,"delta","~6 weeks",NA,NA,2673,"Canada","CAN",318,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-07
"2616",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","240+","infection","infection","Canada",">=16 years","general pop",78,"76",80,NA,"delta","~42 weeks",NA,NA,2674,"Canada","CAN",318,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-07
"2617",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-59","symptomatic disease","symptomatic","Canada",">=16 years","general pop",94,"94",95,NA,"delta","~6 weeks",NA,NA,2675,"Canada","CAN",318,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-07
"2618",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","240+","symptomatic disease","symptomatic","Canada",">=16 years","general pop",88,"86",90,NA,"delta","~42 weeks",NA,NA,2676,"Canada","CAN",318,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-07
"2619",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-59","severe disease","severe","Canada",">=16 years","general pop",98,"98",99,NA,"delta","~6 weeks",NA,NA,2677,"Canada","CAN",318,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-07
"2620",318,"Chung","Test-negative case-control","07Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","240+","severe disease","severe","Canada",">=16 years","general pop",98,"95",99,NA,"delta","~42 weeks",NA,NA,2678,"Canada","CAN",318,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-07,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-07
"2621",319,"Xu","Retrospective cohort","05Dec2022","BNT162b2 (Pfizer BioNTech)","included","2","final","28+","infection","infection","Sweden",">=65 years",">=65 years",85.8,"83.8",88.2,NA,"non-VOC, alpha, delta, & omicron","~51 weeks",NA,NA,2679,"Sweden","SWE",319,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-05,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","20/09/2022",2022-09-20
"2622",319,"Xu","Retrospective cohort","05Dec2022","BNT162b2 (Pfizer BioNTech)","included","2","final","350-371","infection","infection","Sweden",">=65 years",">=65 years",18.2,"2.2",31.6,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,2680,"Sweden","SWE",319,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-05,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","20/09/2022",2022-09-20
"2623",319,"Xu","Retrospective cohort","05Dec2022","BNT162b2 (Pfizer BioNTech)","included","2","final","28+","hospitalization","severe","Sweden",">=65 years",">=65 years",87.2,"83.6",90,NA,"non-VOC, alpha, delta, & omicron","~51 weeks",NA,NA,2681,"Sweden","SWE",319,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","20/09/2022",2022-09-20
"2624",319,"Xu","Retrospective cohort","05Dec2022","BNT162b2 (Pfizer BioNTech)","included","2","final","350-371","hospitalization","severe","Sweden",">=65 years",">=65 years",68.5,"45.5",81.8,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,2682,"Sweden","SWE",319,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","20/09/2022",2022-09-20
"2625",319,"Xu","Retrospective cohort","05Dec2022","mRNA-1273 (Moderna)","included","2","final","28+","infection","infection","Sweden",">=65 years",">=65 years",94.6,"89.6",97.2,NA,"non-VOC, alpha, delta, & omicron","~51 weeks",NA,NA,2683,"Sweden","SWE",319,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-05,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","20/09/2022",2022-09-20
"2626",319,"Xu","Retrospective cohort","05Dec2022","mRNA-1273 (Moderna)","included","2","final","350-371","infection","infection","Sweden",">=65 years",">=65 years",11.8,"-55.5",50,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,2684,"Sweden","SWE",319,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-05,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","20/09/2022",2022-09-20
"2627",319,"Xu","Retrospective cohort","05Dec2022","mRNA-1273 (Moderna)","included","2","final","28+","hospitalization","severe","Sweden",">=65 years",">=65 years",96,"89.5",98.5,NA,"non-VOC, alpha, delta, & omicron","~51 weeks",NA,NA,2685,"Sweden","SWE",319,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","20/09/2022",2022-09-20
"2628",319,"Xu","Retrospective cohort","05Dec2022","mRNA-1273 (Moderna)","included","2","final","350-371","hospitalization","severe","Sweden",">=65 years",">=65 years",21.5,"-89.2",67.4,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,2686,"Sweden","SWE",319,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","20/09/2022",2022-09-20
"2629",319,"Xu","Retrospective cohort","05Dec2022","AZD1222 (AstraZeneca)","included","2","final","28+","infection","infection","Sweden",">=65 years",">=65 years",43.6,"1.9",67.6,NA,"non-VOC, alpha, delta, & omicron","~39 weeks",NA,NA,2687,"Sweden","SWE",319,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-05,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","20/09/2022",2022-09-20
"2630",319,"Xu","Retrospective cohort","05Dec2022","AZD1222 (AstraZeneca)","included","2","final","266-287","infection","infection","Sweden",">=65 years",">=65 years",-2.3,"-627.9",85.6,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,2688,"Sweden","SWE",319,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-05,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","20/09/2022",2022-09-20
"2631",319,"Xu","Retrospective cohort","05Dec2022","AZD1222 (AstraZeneca)","included","2","final","28+","hospitalization","severe","Sweden",">=65 years",">=65 years",74.6,"-5",93.9,NA,"non-VOC, alpha, delta, & omicron","~39 weeks",NA,NA,2689,"Sweden","SWE",319,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","20/09/2022",2022-09-20
"2632",319,"Xu","Retrospective cohort","05Dec2022","AZD1222 (AstraZeneca)","included","2","final","238-259","hospitalization","severe","Sweden",">=65 years",">=65 years",28.7,"-37.6",63,NA,"non-VOC, alpha, delta, & omicron",NA,NA,NA,2690,"Sweden","SWE",319,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","20/09/2022",2022-09-20
"2633",320,"Mas-Bermejo","Retrospective cohort","28Sep2022","Abdala (CIBG)","excluded","3","final","14+","severe disease","severe","Cuba",">=19 years","general pop",98.2,"97.9",98.5,NA,"delta","~20 weeks",NA,NA,2691,"Cuba","CUB",320,"CUB",9010,2019,"Cuba","Latin America & Caribbean","Upper middle income",3,"North America",2021-05-31,2021-09-18,2021-11-09,NA,2021-05-31,NA,110,162,"owid","march/2021 +","Sep-Nov/2021","<180","yes","yes","yes",2022-09-28,"severe","2022 (Jul-Dec)","Abdala (CIBG)","Protein subunit","delta",NA,2022-09-28
"2634",320,"Mas-Bermejo","Retrospective cohort","28Sep2022","Abdala (CIBG)","excluded","3","final","14+","death","death","Cuba",">=19 years","general pop",98.7,"98.3",99,NA,"delta","~20 weeks",NA,NA,2692,"Cuba","CUB",320,"CUB",9010,2019,"Cuba","Latin America & Caribbean","Upper middle income",3,"North America",2021-05-31,2021-09-18,2021-11-09,NA,2021-05-31,NA,110,162,"owid","march/2021 +","Sep-Nov/2021","<180","yes","yes","yes",2022-09-28,"death","2022 (Jul-Dec)","Abdala (CIBG)","Protein subunit","delta",NA,2022-09-28
"2635",321,"Copur","Retrospective cohort","28Sep2022","CoronaVac (Sinovac)","excluded","2","final","14+","infection","infection","Turkey","HCW","HCW",65,"50",75,NA,"alpha","~15 weeks",NA,NA,2693,"Turkey","TUR",321,"TUR",9800,2019,"Türkiye","Europe & Central Asia","Upper middle income",3,"Asia",2021-01-14,2021-08-19,NA,NA,2021-01-14,NA,217,NA,"owid","jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-09-28,"infection","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","alpha",NA,2022-09-28
"2636",322,"Schrag","Test-negative case-control","26Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","ED or UC visit","symptomatic","USA","pregnant persons 18-49 years","pregnant persons",16,"-22",42,NA,"omicron","~55 weeks",NA,NA,2694,"USA","USA",322,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-09-26
"2637",322,"Schrag","Test-negative case-control","26Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","ED or UC visit","symptomatic","USA","pregnant persons 18-49 years","pregnant persons",3,"-49",37,NA,"omicron",NA,NA,NA,2695,"USA","USA",322,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-09-26
"2638",322,"Schrag","Test-negative case-control","26Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","ED or UC visit","symptomatic","USA","pregnant persons 18-49 years","pregnant persons",42,"-16",72,NA,"omicron","~55 weeks",NA,NA,2696,"USA","USA",322,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-09-26
"2639",322,"Schrag","Test-negative case-control","26Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","pregnant persons 18-49 years","pregnant persons",77,"28",93,NA,"omicron","~55 weeks",NA,NA,2697,"USA","USA",322,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-09-26
"2640",322,"Schrag","Test-negative case-control","26Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","hospitalization","severe","USA","pregnant persons 18-49 years","pregnant persons",86,"41",97,NA,"omicron",NA,NA,NA,2698,"USA","USA",322,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-09-26
"2641",322,"Schrag","Test-negative case-control","26Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization","severe","USA","pregnant persons 18-49 years","pregnant persons",64,"-102",93,NA,"omicron","~55 weeks",NA,NA,2699,"USA","USA",322,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-09-26
"2642",322,"Schrag","Test-negative case-control","26Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","ED or UC visit","symptomatic","USA","pregnant persons 18-49 years","pregnant persons",83,"68",91,NA,"delta","~55 weeks",NA,NA,2700,"USA","USA",322,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-26
"2643",322,"Schrag","Test-negative case-control","26Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","ED or UC visit","symptomatic","USA","pregnant persons 18-49 years","pregnant persons",84,"69",92,NA,"delta",NA,NA,NA,2701,"USA","USA",322,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-26
"2644",322,"Schrag","Test-negative case-control","26Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","ED or UC visit","symptomatic","USA","pregnant persons 18-49 years","pregnant persons",75,"5",93,NA,"delta","~55 weeks",NA,NA,2702,"USA","USA",322,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-26
"2645",322,"Schrag","Test-negative case-control","26Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","pregnant persons 18-49 years","pregnant persons",98,"96",99,NA,"delta",NA,NA,NA,2703,"USA","USA",322,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-26
"2646",322,"Schrag","Test-negative case-control","26Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","hospitalization","severe","USA","pregnant persons 18-49 years","pregnant persons",99,"96",100,NA,"delta",NA,NA,NA,2704,"USA","USA",322,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-26
"2647",322,"Schrag","Test-negative case-control","26Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization","severe","USA","pregnant persons 18-49 years","pregnant persons",96,"86",99,NA,"delta","~55 weeks",NA,NA,2705,"USA","USA",322,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-26
"2648",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<2 months","ED or UC visit","symptomatic","USA",">=18 years","general pop",63,"57",68,NA,"omicron",NA,NA,NA,2706,"USA","USA",323,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-03,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-03
"2649",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","16-<18 months","ED or UC visit","symptomatic","USA",">=18 years","general pop",22,"5",36,NA,"omicron",NA,NA,NA,2707,"USA","USA",323,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-03,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-03
"2650",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<2 months","hospitalization","severe","USA",">=18 years","general pop",73,"63",80,NA,"omicron",NA,NA,NA,2708,"USA","USA",323,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-03,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-03
"2651",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+ months","hospitalization","severe","USA",">=18 years","general pop",19,"6",30,NA,"omicron","~67 weeks",NA,NA,2709,"USA","USA",323,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-03,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-03
"2652",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<4 months","hospitalization","severe","USA","immunocompromised, >=18 years","immunocompromised adults",34,"13",51,NA,"omicron",NA,NA,NA,2710,"USA","USA",323,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-03,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-03
"2653",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","6+ months","hospitalization","severe","USA","immunocompromised, >=18 years","immunocompromised adults",20,"1",36,NA,"omicron","~67 weeks",NA,NA,2711,"USA","USA",323,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-03,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-03
"2654",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<2 months","ED or UC visit","symptomatic","USA",">=18 years","general pop",93,"92",94,NA,"delta",NA,NA,NA,2712,"USA","USA",323,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-03,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-10-03
"2655",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","10-<12 months","ED or UC visit","symptomatic","USA",">=18 years","general pop",66,"60",72,NA,"delta",NA,NA,NA,2713,"USA","USA",323,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-03,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-10-03
"2656",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<2 months","hospitalization","severe","USA",">=18 years","general pop",96,"95",97,NA,"delta",NA,NA,NA,2714,"USA","USA",323,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-03,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-10-03
"2657",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","10-<12 months","hospitalization","severe","USA",">=18 years","general pop",68,"59",75,NA,"delta",NA,NA,NA,2715,"USA","USA",323,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-03,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-10-03
"2658",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<2 months","ED or UC visit","symptomatic","USA",">=18 years","general pop",95,"94",96,NA,"alpha","~19 weeks",NA,NA,2716,"USA","USA",323,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-03,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-10-03
"2659",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","4-<6 months","ED or UC visit","symptomatic","USA",">=18 years","general pop",86,"78",91,NA,"alpha","~19 weeks",NA,NA,2717,"USA","USA",323,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-03,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-10-03
"2660",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<2 months","hospitalization","severe","USA",">=18 years","general pop",94,"93",95,NA,"alpha","~19 weeks",NA,NA,2718,"USA","USA",323,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-03,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-10-03
"2661",323,"Ferdinands","Test-negative case-control","03Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","4-<6 months","hospitalization","severe","USA",">=18 years","general pop",87,"77",93,NA,"alpha","~19 weeks",NA,NA,2719,"USA","USA",323,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-03,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha",NA,2022-10-03
"2662",324,"Link-Gelles","Test-negative case-control","05Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-159","ED or UC visit","symptomatic","USA",">=18 years","general pop",45,"27",59,NA,"omicron BA.4 or BA.5",NA,NA,NA,2720,"USA","USA",324,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-05,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","05/10/2022",2022-10-05
"2663",324,"Link-Gelles","Test-negative case-control","05Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","ED or UC visit","symptomatic","USA",">=18 years","general pop",24,"19",27,NA,"omicron BA.4 or BA.5","~82 weeks",NA,NA,2721,"USA","USA",324,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-05,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","05/10/2022",2022-10-05
"2664",324,"Link-Gelles","Test-negative case-control","05Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","hospitalization","severe","USA",">=18 years","general pop",17,"7",27,NA,"omicron BA.4 or BA.5","~82 weeks",NA,NA,2722,"USA","USA",324,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","05/10/2022",2022-10-05
"2665",324,"Link-Gelles","Test-negative case-control","05Oct2022","mRNA-1273 (Moderna)","included","2","final","14-159","ED or UC visit","symptomatic","USA",">=18 years","general pop",51,"30",66,NA,"omicron BA.4 or BA.5",NA,NA,NA,2723,"USA","USA",324,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-05,"symptomatic","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","05/10/2022",2022-10-05
"2666",324,"Link-Gelles","Test-negative case-control","05Oct2022","mRNA-1273 (Moderna)","included","2","final","150+","ED or UC visit","symptomatic","USA",">=18 years","general pop",30,"25",34,NA,"omicron BA.4 or BA.5","~82 weeks",NA,NA,2724,"USA","USA",324,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-05,"symptomatic","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","05/10/2022",2022-10-05
"2667",324,"Link-Gelles","Test-negative case-control","05Oct2022","mRNA-1273 (Moderna)","included","2","final","150+","hospitalization","severe","USA",">=18 years","general pop",28,"17",38,NA,"omicron BA.4 or BA.5","~82 weeks",NA,NA,2725,"USA","USA",324,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","05/10/2022",2022-10-05
"2668",324,"Link-Gelles","Test-negative case-control","05Oct2022","Any mRNA - heterologous","included","2","final","14-159","ED or UC visit","symptomatic","USA",">=18 years","general pop",70,"52",81,NA,"omicron BA.4 or BA.5",NA,NA,NA,2726,"USA","USA",324,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-05,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","05/10/2022",2022-10-05
"2669",324,"Link-Gelles","Test-negative case-control","05Oct2022","Any mRNA - heterologous","included","2","final","150+","ED or UC visit","symptomatic","USA",">=18 years","general pop",38,"29",46,NA,"omicron BA.4 or BA.5","~82 weeks",NA,NA,2727,"USA","USA",324,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-05,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","05/10/2022",2022-10-05
"2670",325,"Grewal","Test-negative case-control","03Dec2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0+","infection","infection","Canada","LTCF residents, >=60 years","LTCF residents",3,"-7",12,NA,"omicron BA.1 or BA.2 or BA.4 or BA.5","~80 weeks",NA,NA,2728,"Canada","CAN",325,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-03,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","30/09/2022",2022-09-30
"2671",325,"Grewal","Test-negative case-control","03Dec2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0+","symptomatic disease","symptomatic","Canada","LTCF residents, >=60 years","LTCF residents",21,"1",38,NA,"omicron BA.1 or BA.2 or BA.4 or BA.5","~80 weeks",NA,NA,2729,"Canada","CAN",325,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-03,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","30/09/2022",2022-09-30
"2672",325,"Grewal","Test-negative case-control","03Dec2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0+","severe disease","severe","Canada","LTCF residents, >=60 years","LTCF residents",43,"24",58,NA,"omicron BA.1 or BA.2 or BA.4 or BA.5","~80 weeks",NA,NA,2730,"Canada","CAN",325,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-12-03,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","30/09/2022",2022-09-30
"2673",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~47 weeks","infection ","infection ","USA",">=5 years","general pop",37.5,"36",39,NA,"omicron","~47 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2731,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-26
"2674",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~60 weeks","infection ","infection ","USA",">=5 years","general pop",0.8,"-1.5",3,NA,"omicron","~60 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2732,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-26
"2675",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~47 weeks","hospitalization","severe","USA",">=5 years","general pop",58.8,"49.3",66.5,NA,"omicron","~47 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2733,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-26
"2676",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~60 weeks","hospitalization","severe","USA",">=5 years","general pop",29.4,"50.4",76.9,NA,"omicron","~60 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2734,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-26
"2677",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~47 weeks","death ","death ","USA",">=5 years","general pop",75.2,"67.7",81,NA,"omicron","~47 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2735,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-26
"2678",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~60 weeks","death ","death ","USA",">=5 years","general pop",59.1,"27.2",77,NA,"omicron","~60 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2736,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-26
"2679",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~46 weeks","infection ","infection ","USA",">=5 years","general pop",47.2,"45.8",48.5,NA,"omicron","~46 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2737,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2022-09-26
"2680",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~59 weeks","infection ","infection ","USA",">=5 years","general pop",30.3,"28.9",32.9,NA,"omicron","~59 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2738,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2022-09-26
"2681",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~46 weeks","hospitalization","severe","USA",">=5 years","general pop",64.7,"57.2",70.9,NA,"omicron","~46 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2739,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2022-09-26
"2682",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~59 weeks","hospitalization","severe","USA",">=5 years","general pop",61.5,"49.6",70.6,NA,"omicron","~59 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2740,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2022-09-26
"2683",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~46 weeks","death ","death ","USA",">=5 years","general pop",69.6,"62.3",75.5,NA,"omicron","~46 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2741,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2022-09-26
"2684",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~59 weeks","death ","death ","USA",">=5 years","general pop",48.3,"22.6",65.4,NA,"omicron","~59 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2742,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2022-09-26
"2685",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~41 weeks","infection ","infection ","USA",">=5 years","general pop",48.8,"47.2",50.4,NA,"omicron","~41 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2743,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2022-09-26
"2686",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~54 weeks","infection ","infection ","USA",">=5 years","general pop",49,"46.4",51.4,NA,"omicron","~54 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2744,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2022-09-26
"2687",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~41 weeks","hospitalization","severe","USA",">=5 years","general pop",65.3,"58.3",71.1,NA,"omicron","~41 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2745,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2022-09-26
"2688",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~54 weeks","hospitalization","severe","USA",">=5 years","general pop",53.3,"26.7",70.2,NA,"omicron","~54 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2746,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2022-09-26
"2689",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~41 weeks","death ","death ","USA",">=5 years","general pop",76.1,"69.2",81.4,NA,"omicron","~41 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2747,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2022-09-26
"2690",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~54 weeks","death ","death ","USA",">=5 years","general pop",77.5,"19.6",93.7,NA,"omicron","~54 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2748,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2022-09-26
"2691",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~25 weeks","infection ","infection ","USA",">=5 years","general pop",54.3,"53.6",55,NA,"delta","~25 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2749,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-26
"2692",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~38 weeks","infection ","infection ","USA",">=5 years","general pop",47.4,"46.6",48.2,NA,"delta","~38 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2750,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-26
"2693",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~25 weeks","hospitalization","severe","USA",">=5 years","general pop",85.8,"83.4",87.8,NA,"delta","~25 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2751,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-26
"2694",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~38 weeks","hospitalization","severe","USA",">=5 years","general pop",70.9,"65.3",75.6,NA,"delta","~38 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2752,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-26
"2695",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~25 weeks","death ","death ","USA",">=5 years","general pop",89.6,"87",91.6,NA,"delta","~25 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2753,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-26
"2696",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~38 weeks","death ","death ","USA",">=5 years","general pop",77.4,"70.6",82.6,NA,"delta","~38 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2754,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-26
"2697",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~24 weeks","infection ","infection ","USA",">=5 years","general pop",69.2,"68.5",69.9,NA,"delta","~24 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2755,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-09-26
"2698",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~37 weeks","infection ","infection ","USA",">=5 years","general pop",48.4,"47.5",49.3,NA,"delta","~37 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2756,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-09-26
"2699",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~24 weeks","hospitalization","severe","USA",">=5 years","general pop",89.8,"88.1",91.3,NA,"delta","~24 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2757,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-09-26
"2700",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~37 weeks","hospitalization","severe","USA",">=5 years","general pop",72.7,"67.8",77,NA,"delta","~37 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2758,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-09-26
"2701",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~24 weeks","death ","death ","USA",">=5 years","general pop",93,"91.1",94.5,NA,"delta","~24 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2759,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-09-26
"2702",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~37 weeks","death ","death ","USA",">=5 years","general pop",85.1,"80.1",88.8,NA,"delta","~37 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2760,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-09-26
"2703",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~20 weeks","infection ","infection ","USA",">=5 years","general pop",59.2,"57.7",60.7,NA,"delta","~20 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2761,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-09-26
"2704",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~33 weeks","infection ","infection ","USA",">=5 years","general pop",60.5,"58.9",62.1,NA,"delta","~33 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2762,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-09-26
"2705",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~20 weeks","hospitalization","severe","USA",">=5 years","general pop",77.9,"72.2",82.4,NA,"delta","~20 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2763,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-09-26
"2706",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~33 weeks","hospitalization","severe","USA",">=5 years","general pop",70,"64.8",74.5,NA,"delta","~33 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2764,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-09-26
"2707",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~20 weeks","death ","death ","USA",">=5 years","general pop",83.8,"76.1",89,NA,"delta","~20 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2765,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-09-26
"2708",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~33 weeks","death ","death ","USA",">=5 years","general pop",79.2,"73.1",84,NA,"delta","~33 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2766,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-09-26
"2709",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~3 weeks","infection ","infection ","USA",">=5 years","general pop",67.6,"66.9",68.3,NA,"alpha","~3 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2767,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-09-26
"2710",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~21 weeks","infection ","infection ","USA",">=5 years","general pop",58.6,"58",59.2,NA,"alpha","~21 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2768,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-09-26
"2711",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~3 weeks","hospitalization","severe","USA",">=5 years","general pop",94.1,"92.2",95.5,NA,"alpha","~3 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2769,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-09-26
"2712",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~21 weeks","hospitalization","severe","USA",">=5 years","general pop",87.1,"85",88.9,NA,"alpha","~21 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2770,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-09-26
"2713",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~3 weeks","death ","death ","USA",">=5 years","general pop",97.1,"94.7",98.4,NA,"alpha","~3 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2771,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-09-26
"2714",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~21 weeks","death ","death ","USA",">=5 years","general pop",91.9,"89.4",93.8,NA,"alpha","~21 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2772,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2022-09-26
"2715",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~2 weeks","infection ","infection ","USA",">=5 years","general pop",90.1,"89.6",90.7,NA,"alpha","~2 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2773,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2022-09-26
"2716",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~20 weeks","infection ","infection ","USA",">=5 years","general pop",71.9,"71.3",72.6,NA,"alpha","~20 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2774,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2022-09-26
"2717",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~2 weeks","hospitalization","severe","USA",">=5 years","general pop",96.5,"95.1",97.6,NA,"alpha","~2 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2775,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2022-09-26
"2718",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~20 weeks","hospitalization","severe","USA",">=5 years","general pop",90.4,"88.6",91.9,NA,"alpha","~20 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2776,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2022-09-26
"2719",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~2 weeks","death ","death ","USA",">=5 years","general pop",97.2,"95.1",98.4,NA,"alpha","~2 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2777,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2022-09-26
"2720",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~20 weeks","death ","death ","USA",">=5 years","general pop",92.8,"90.3",94.6,NA,"alpha","~20 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2778,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","alpha",NA,2022-09-26
"2721",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~2 weeks","infection ","infection ","USA",">=5 years","general pop",70.6,"68.8",72.3,NA,"alpha","~2 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2779,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","alpha",NA,2022-09-26
"2722",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~10 weeks","infection ","infection ","USA",">=5 years","general pop",63,"60.8",65,NA,"alpha","~10 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2780,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","alpha",NA,2022-09-26
"2723",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~2 weeks","hospitalization","severe","USA",">=5 years","general pop",67.9,"56.5",76.3,NA,"alpha","~2 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2781,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","alpha",NA,2022-09-26
"2724",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~10 weeks","hospitalization","severe","USA",">=5 years","general pop",79.3,"71.7",84.8,NA,"alpha","~10 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2782,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","alpha",NA,2022-09-26
"2725",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~2 weeks","death ","death ","USA",">=5 years","general pop",85.7,"74.6",91.9,NA,"alpha","~2 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2783,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","alpha",NA,2022-09-26
"2726",326,"Lin","Retrospective cohort","26Sep2022","Ad26.COV2.S (Janssen)","included","2","final","~10 weeks","death ","death ","USA",">=5 years","general pop",80.5,"75.7",84.4,NA,"alpha","~10 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2784,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"death","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","alpha",NA,2022-09-26
"2727",327,"Rudan","Test-negative case-control","28Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-35","symptomatic disease","symptomatic","UK (Scotland)","12-15 years","12-15 years",81.2,"77.7",84.2,"omicron","omicron",NA,NA,NA,2785,"UK","GBR",327,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-28,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-28
"2728",327,"Rudan","Test-negative case-control","28Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","98+","symptomatic disease","symptomatic","UK (Scotland)","12-15 years","12-15 years",48.7,"22",66.3,"omicron","omicron","~21 weeks",NA,NA,2786,"UK","GBR",327,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-28,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-28
"2729",327,"Rudan","Test-negative case-control","28Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-35","symptomatic disease","symptomatic","UK (Scotland)","12-15 years","12-15 years",100,"-∞",100,"delta","delta",NA,NA,NA,2787,"UK","GBR",327,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-28,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-28
"2730",327,"Rudan","Test-negative case-control","28Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","42-63","symptomatic disease","symptomatic","UK (Scotland)","12-15 years","12-15 years",92.9,"42.5",99.1,"delta","delta","~10 weeks",NA,NA,2788,"UK","GBR",327,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-28,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-28
"2731",327,"Rudan","Test-negative case-control","28Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-35","symptomatic disease","symptomatic","UK (Scotland)","16-17 years","16-17 years",65.5,"56",73,"omicron","omicron",NA,NA,NA,2789,"UK","GBR",327,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-28,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-28
"2732",327,"Rudan","Test-negative case-control","28Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","98+","symptomatic disease","symptomatic","UK (Scotland)","16-17 years","16-17 years",1.2,"-49.3",34.6,"omicron","omicron","~27 weeks",NA,NA,2790,"UK","GBR",327,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-28,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-28
"2733",327,"Rudan","Test-negative case-control","28Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-35","symptomatic disease","symptomatic","UK (Scotland)","16-17 years","16-17 years",95.6,"77",99.1,"delta","delta",NA,NA,NA,2791,"UK","GBR",327,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-28,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-28
"2734",327,"Rudan","Test-negative case-control","28Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","42-63","symptomatic disease","symptomatic","UK (Scotland)","16-17 years","16-17 years",96.7,"51.3",99.8,"delta","delta","~17 weeks",NA,NA,2792,"UK","GBR",327,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-28,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-28
"2735",328,"Lewis","Outbreak investigation","28Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","unknown","2","final","14+","infection","infection","USA",">=60 years",">=60 years",80,"46.4",92.6,"gamma","gamma","~14 weeks",NA,NA,2793,"USA","USA",328,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-28,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","gamma",NA,2022-09-28
"2736",329,"Buchan","Test-negative case-control","22Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7-59 ","symptomatic disease","symptomatic","Canada",">=18 years","general pop",36,"24",45,"omicron","omicron",NA,NA,NA,2794,"Canada","CAN",329,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-22,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-09-22
"2737",329,"Buchan","Test-negative case-control","22Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","240+ ","symptomatic disease","symptomatic","Canada",">=18 years","general pop",2,"-17",17,"omicron","omicron","~49 weeks",NA,NA,2795,"Canada","CAN",329,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-22,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-09-22
"2738",329,"Buchan","Test-negative case-control","22Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","120-179 ","severe disease","severe","Canada",">=18 years","general pop",75,"51",87,"omicron","omicron",NA,NA,NA,2796,"Canada","CAN",329,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-22,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-09-22
"2739",329,"Buchan","Test-negative case-control","22Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180-239 ","severe disease","severe","Canada",">=18 years","general pop",82,"62",91,"omicron","omicron","~32 weeks",NA,NA,2797,"Canada","CAN",329,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-22,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-09-22
"2740",329,"Buchan","Test-negative case-control","22Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7-59 ","symptomatic disease","symptomatic","Canada",">=18 years","general pop",89,"86",92,"delta","delta",NA,NA,NA,2798,"Canada","CAN",329,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-22,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-22
"2741",329,"Buchan","Test-negative case-control","22Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","240+ ","symptomatic disease","symptomatic","Canada",">=18 years","general pop",80,"74",84,"delta","delta","~49 weeks",NA,NA,2799,"Canada","CAN",329,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-22,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-22
"2742",329,"Buchan","Test-negative case-control","22Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7-59 ","severe disease","severe","Canada",">=18 years","general pop",94,"84",98,"delta","delta",NA,NA,NA,2800,"Canada","CAN",329,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-22,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-22
"2743",329,"Buchan","Test-negative case-control","22Sep2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","240+","severe disease","severe","Canada",">=18 years","general pop",95,"85",99,"delta","delta","~49 weeks",NA,NA,2801,"Canada","CAN",329,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-22,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-09-22
"2744",330,"Risk","Test-negative case-control","08Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","0-3 months","infection","infection","USA","12-17 years","12-17 years",54.5,"17.8",76.9,"omicron","omicron",NA,NA,"This study does not adjust for calendar time",2802,"USA","USA",330,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-08,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-08
"2745",330,"Risk","Test-negative case-control","08Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=6 months","infection","infection","USA","12-17 years","12-17 years",4.2,"-20.2",23.6,"omicron","omicron","~58 weeks",NA,"This study does not adjust for calendar time",2803,"USA","USA",330,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-08,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-08
"2746",330,"Risk","Test-negative case-control","08Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","0-3 months","infection","infection","USA","12-17 years","12-17 years",81.9,"67.9",90.8,"delta","delta",NA,NA,"This study does not adjust for calendar time",2804,"USA","USA",330,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-08,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-10-08
"2747",330,"Risk","Test-negative case-control","08Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=6 months","infection","infection","USA","12-17 years","12-17 years",65.3,"34.6",83.8,"delta","delta","~44 weeks",NA,"This study does not adjust for calendar time",2805,"USA","USA",330,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-08,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-10-08
"2748",331,"Mimura","Retrospective cohort","08Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+ (includes up to 13 days post booster dose)","infection","infection","Japan","16-64 years","16-64 years",15.8,"7.9",23.1,"omicron","omicron","~43 weeks",NA,NA,2806,"Japan","JPN",331,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"who","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-10-08,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-08
"2749",331,"Mimura","Retrospective cohort","08Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+ (includes up to 13 days post booster dose)","symptomatic disease","symptomatic","Japan","16-64 years","16-64 years",21.2,"11",30.3,"omicron","omicron","~43 weeks",NA,NA,2807,"Japan","JPN",331,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"who","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-10-08,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-08
"2750",331,"Mimura","Retrospective cohort","08Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+ (includes up to 13 days post booster dose)","infection","infection","Japan","16-64 years","16-64 years",82.9,"69.4",90.4,"delta","delta","~31 weeks",NA,NA,2808,"Japan","JPN",331,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"who","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-10-08,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-10-08
"2751",331,"Mimura","Retrospective cohort","08Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+ (includes up to 13 days post booster dose)","symptomatic disease","symptomatic","Japan","16-64 years","16-64 years",95.7,"82.5",98.9,"delta","delta","~31 weeks",NA,NA,2809,"Japan","JPN",331,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"who","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-10-08,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-10-08
"2752",332,"Wan","Case-control","17Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-180","infection","infection","Hong Kong","60-79 years","60-79 years",17.3,"15.2",19.3,NA,"omicron BA.2","~24 weeks",NA,NA,2810,"Hong Kong","HKG",332,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-17
"2753",332,"Wan","Case-control","17Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-180","hospitalization","severe","Hong Kong","60-79 years","60-79 years",74.6,"72.1",76.8,NA,"omicron BA.2","~24 weeks",NA,NA,2811,"Hong Kong","HKG",332,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-17
"2754",332,"Wan","Case-control","17Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-180","severe disease","severe","Hong Kong","60-79 years","60-79 years",77.5,"65.7",85.2,NA,"omicron BA.2","~24 weeks",NA,NA,2812,"Hong Kong","HKG",332,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-17
"2755",332,"Wan","Case-control","17Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-180","death","death","Hong Kong","60-79 years","60-79 years",92.1,"88.7",94.5,NA,"omicron BA.2","~24 weeks",NA,NA,2813,"Hong Kong","HKG",332,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-17
"2756",332,"Wan","Case-control","17Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-180","infection","infection","Hong Kong",">=80 years",">=80 years",54.2,"51.4",56.9,NA,"omicron BA.2","~24 weeks",NA,NA,2814,"Hong Kong","HKG",332,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-17
"2757",332,"Wan","Case-control","17Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-180","hospitalization","severe","Hong Kong",">=80 years",">=80 years",81,"78.2",83.5,NA,"omicron BA.2","~24 weeks",NA,NA,2815,"Hong Kong","HKG",332,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-17
"2758",332,"Wan","Case-control","17Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-180","severe disease","severe","Hong Kong",">=80 years",">=80 years",82.7,"62.7",92,NA,"omicron BA.2","~24 weeks",NA,NA,2816,"Hong Kong","HKG",332,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-17
"2759",332,"Wan","Case-control","17Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-180","death","death","Hong Kong",">=80 years",">=80 years",92.5,"89.3",94.8,NA,"omicron BA.2","~24 weeks",NA,NA,2817,"Hong Kong","HKG",332,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"death","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-17
"2760",332,"Wan","Case-control","17Oct2022","CoronaVac (Sinovac)","excluded","2","final","14-180","infection","infection","Hong Kong","60-79 years","60-79 years",-23.1,"-25.8",-20.5,NA,"omicron BA.2","~24 weeks",NA,NA,2818,"Hong Kong","HKG",332,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"infection","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-10-17
"2761",332,"Wan","Case-control","17Oct2022","CoronaVac (Sinovac)","excluded","2","final","14-180","hospitalization","severe","Hong Kong","60-79 years","60-79 years",59.4,"56.6",62,NA,"omicron BA.2","~24 weeks",NA,NA,2819,"Hong Kong","HKG",332,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-10-17
"2762",332,"Wan","Case-control","17Oct2022","CoronaVac (Sinovac)","excluded","2","final","14-180","severe disease","severe","Hong Kong","60-79 years","60-79 years",57.7,"43.8",68.2,NA,"omicron BA.2","~24 weeks",NA,NA,2820,"Hong Kong","HKG",332,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-10-17
"2763",332,"Wan","Case-control","17Oct2022","CoronaVac (Sinovac)","excluded","2","final","14-180","death","death","Hong Kong","60-79 years","60-79 years",79.6,"75",83.3,NA,"omicron BA.2","~24 weeks",NA,NA,2821,"Hong Kong","HKG",332,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"death","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-10-17
"2764",332,"Wan","Case-control","17Oct2022","CoronaVac (Sinovac)","excluded","2","final","14-180","infection","infection","Hong Kong",">=80 years",">=80 years",31.2,"28.7",33.6,NA,"omicron BA.2","~24 weeks",NA,NA,2822,"Hong Kong","HKG",332,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"infection","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-10-17
"2765",332,"Wan","Case-control","17Oct2022","CoronaVac (Sinovac)","excluded","2","final","14-180","hospitalization","severe","Hong Kong",">=80 years",">=80 years",58.4,"55.8",60.9,NA,"omicron BA.2","~24 weeks",NA,NA,2823,"Hong Kong","HKG",332,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-10-17
"2766",332,"Wan","Case-control","17Oct2022","CoronaVac (Sinovac)","excluded","2","final","14-180","severe disease","severe","Hong Kong",">=80 years",">=80 years",55,"38.6",67,NA,"omicron BA.2","~24 weeks",NA,NA,2824,"Hong Kong","HKG",332,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"severe","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-10-17
"2767",332,"Wan","Case-control","17Oct2022","CoronaVac (Sinovac)","excluded","2","final","14-180","death","death","Hong Kong",">=80 years",">=80 years",69.4,"65.6",72.8,NA,"omicron BA.2","~24 weeks",NA,NA,2825,"Hong Kong","HKG",332,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"death","2022 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2022-10-17
"2768",333,"Chambers","Test-negative case-control","19Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","infection","infection","Canada",">=19 years","general pop",82,"74",88,NA,"alpha & delta","~44 weeks",NA,NA,2826,"Canada","CAN",333,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-10-19,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-10-19
"2769",333,"Chambers","Test-negative case-control","19Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","symptomatic disease","symptomatic","Canada",">=19 years","general pop",93,"79",98,NA,"alpha & delta","~44 weeks",NA,NA,2827,"Canada","CAN",333,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-10-19,"symptomatic","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-10-19
"2770",333,"Chambers","Test-negative case-control","19Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","severe disease","severe","Canada",">=19 years","general pop",97,"80",99,NA,"alpha & delta","~44 weeks",NA,NA,2828,"Canada","CAN",333,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-10-19,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-10-19
"2771",333,"Chambers","Test-negative case-control","19Oct2022","AZD1222 (AstraZeneca)","excluded","2","final","7+","infection","infection","Canada",">=19 years","general pop",77,"34",92,NA,"alpha & delta","~44 weeks",NA,NA,2829,"Canada","CAN",333,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-10-19,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-10-19
"2772",333,"Chambers","Test-negative case-control","19Oct2022","AZD1222 (AstraZeneca) + any mRNA - heterologous","excluded","2","final","7+","infection","infection","Canada",">=19 years","general pop",80,"49",92,NA,"alpha & delta","~44 weeks",NA,NA,2830,"Canada","CAN",333,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-10-19,"infection","2022 (Jul-Dec)","Heterologous platforms","Multiple","other combinations",NA,2022-10-19
"2773",334,"Consonni","Retrospective cohort","19Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-119","infection","infection","Italy","HCW","HCW",70,"54",80,NA,"omicron","~67 weeks",NA,"88.3% of cases were during the Omicron period; 8.2% and 3.5% of cases were during Alpha, and Delta periods, respectively",2831,"Italy","ITA",334,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-10-19,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-19
"2774",334,"Consonni","Retrospective cohort","19Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","120+","infection","infection","Italy","HCW","HCW",16,"0",43,NA,"omicron","~67 weeks",NA,"88.3% of cases were during the Omicron period; 8.2% and 3.5% of cases were during Alpha, and Delta periods, respectively",2832,"Italy","ITA",334,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-10-19,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-19
"2775",334,"Consonni","Retrospective cohort","19Oct2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","7-119","infection","infection","Italy","HCW","HCW",25,"0",69,NA,"omicron","~67 weeks",NA,"88.3% of cases were during the Omicron period; 8.2% and 3.5% of cases were during Alpha, and Delta periods, respectively",2833,"Italy","ITA",334,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-10-19,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-19
"2776",334,"Consonni","Retrospective cohort","19Oct2022","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","120+","infection","infection","Italy","HCW","HCW",88,"66",96,NA,"omicron","~67 weeks",NA,"88.3% of cases were during the Omicron period; 8.2% and 3.5% of cases were during Alpha, and Delta periods, respectively",2834,"Italy","ITA",334,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-10-19,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-19
"2777",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in first trimester","excluded","2","final","7+","infection in the first 2 months of life","infection in the first 2 months of life","USA","infants born to mothers 16-50 years of age","infants",26,"-22",56,NA,"omicron","~11 months",NA,NA,2835,"USA","USA",335,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","18/10/2022",2022-10-18
"2778",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in first trimester","excluded","2","final","7+","infection in the first 4 months of life","infection in the first 4 months of life","USA","infants born to mothers 16-50 years of age","infants",23,"-6",44,NA,"omicron","~13 months",NA,NA,2836,"USA","USA",335,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","18/10/2022",2022-10-18
"2779",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in first trimester","excluded","2","final","7+","infection in the first 6 months of life","infection in the first 6 months of life","USA","infants born to mothers 16-50 years of age","infants",19,"-3",37,NA,"omicron","~15 months",NA,NA,2837,"USA","USA",335,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","18/10/2022",2022-10-18
"2780",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in second trimester","excluded","2","final","7+","infection in the first 2 months of life","infection in the first 2 months of life","USA","infants born to mothers 16-50 years of age","infants",37,"-21",67,NA,"omicron","~8 months",NA,NA,2838,"USA","USA",335,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","18/10/2022",2022-10-18
"2781",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in second trimester","excluded","2","final","7+","infection in the first 4 months of life","infection in the first 4 months of life","USA","infants born to mothers 16-50 years of age","infants",5,"-28",29,NA,"omicron","~10 months",NA,NA,2839,"USA","USA",335,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","18/10/2022",2022-10-18
"2782",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in second trimester","excluded","2","final","7+","infection in the first 6 months of life","infection in the first 6 months of life","USA","infants born to mothers 16-50 years of age","infants",3,"-19",21,NA,"omicron","~12 months",NA,NA,2840,"USA","USA",335,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","18/10/2022",2022-10-18
"2783",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in third trimester","excluded","2","final","7+","infection in the first 2 months of life","infection in the first 2 months of life","USA","infants born to mothers 16-50 years of age","infants",-4,"-84",41,NA,"omicron","~5 months",NA,NA,2841,"USA","USA",335,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","18/10/2022",2022-10-18
"2784",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in third trimester","excluded","2","final","7+","infection in the first 4 months of life","infection in the first 4 months of life","USA","infants born to mothers 16-50 years of age","infants",12,"-23",37,NA,"omicron","~7 months",NA,NA,2842,"USA","USA",335,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","18/10/2022",2022-10-18
"2785",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in third trimester","excluded","2","final","7+","infection in the first 6 months of life","infection in the first 6 months of life","USA","infants born to mothers 16-50 years of age","infants",18,"-4",36,NA,"omicron","~9 months",NA,NA,2843,"USA","USA",335,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","18/10/2022",2022-10-18
"2786",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in first trimester","excluded","2","final","7+","infection in the first 2 months of life","infection in the first 2 months of life","USA","infants born to mothers 16-50 years of age","infants",61,"-31",89,NA,"delta","~11 months",NA,NA,2844,"USA","USA",335,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","18/10/2022",2022-10-18
"2787",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in first trimester","excluded","2","final","7+","infection in the first 4 months of life","infection in the first 4 months of life","USA","infants born to mothers 16-50 years of age","infants",48,"-54",82,NA,"delta","~13 months",NA,NA,2845,"USA","USA",335,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","18/10/2022",2022-10-18
"2788",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in first trimester","excluded","2","final","7+","infection in the first 6 months of life","infection in the first 6 months of life","USA","infants born to mothers 16-50 years of age","infants",49,"-46",82,NA,"delta","~15 months",NA,NA,2846,"USA","USA",335,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","18/10/2022",2022-10-18
"2789",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in second trimester","excluded","2","final","7+","infection in the first 2 months of life","infection in the first 2 months of life","USA","infants born to mothers 16-50 years of age","infants",91,"63",98,NA,"delta","~8 months",NA,NA,2847,"USA","USA",335,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","18/10/2022",2022-10-18
"2790",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in second trimester","excluded","2","final","7+","infection in the first 4 months of life","infection in the first 4 months of life","USA","infants born to mothers 16-50 years of age","infants",60,"23",79,NA,"delta","~10 months",NA,NA,2848,"USA","USA",335,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","18/10/2022",2022-10-18
"2791",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in second trimester","excluded","2","final","7+","infection in the first 6 months of life","infection in the first 6 months of life","USA","infants born to mothers 16-50 years of age","infants",65,"33",81,NA,"delta","~12 months",NA,NA,2849,"USA","USA",335,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","18/10/2022",2022-10-18
"2792",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in third trimester","excluded","2","final","7+","infection in the first 2 months of life","infection in the first 2 months of life","USA","infants born to mothers 16-50 years of age","infants",87,"55",96,NA,"delta","~5 months",NA,NA,2850,"USA","USA",335,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","18/10/2022",2022-10-18
"2793",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in third trimester","excluded","2","final","7+","infection in the first 4 months of life","infection in the first 4 months of life","USA","infants born to mothers 16-50 years of age","infants",70,"43",84,NA,"delta","~7 months",NA,NA,2851,"USA","USA",335,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","18/10/2022",2022-10-18
"2794",335,"Zerbo","Cohort study","28Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) received in third trimester","excluded","2","final","7+","infection in the first 6 months of life","infection in the first 6 months of life","USA","infants born to mothers 16-50 years of age","infants",54,"27",71,NA,"delta","~9 months",NA,NA,2852,"USA","USA",335,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-28,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","18/10/2022",2022-10-18
"2795",336,"Embi","Test-negative case-control","22May2023","mRNA-1273 (Moderna)","included","2","final","14-149","ED or UC visits with COVID-like illness","symptomatic","USA","immunocompetent adults >=18 years","immunocompetent adults",90,"89",91,NA,"delta","~46 weeks",NA,NA,2853,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"symptomatic","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/10/2022",2022-10-21
"2796",336,"Embi","Test-negative case-control","22May2023","mRNA-1273 (Moderna)","included","2","final","150+","ED or UC visits with COVID-like illness","symptomatic","USA","immunocompetent adults >=18 years","immunocompetent adults",84,"83",85,NA,"delta","~46 weeks",NA,NA,2854,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"symptomatic","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/10/2022",2022-10-21
"2797",336,"Embi","Test-negative case-control","22May2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-149","ED or UC visits with COVID-like illness","symptomatic","USA","immunocompetent adults >=18 years","immunocompetent adults",85,"84",86,NA,"delta","~46 weeks",NA,NA,2855,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","21/10/2022",2022-10-21
"2798",336,"Embi","Test-negative case-control","22May2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","ED or UC visits with COVID-like illness","symptomatic","USA","immunocompetent adults >=18 years","immunocompetent adults",73,"72",74,NA,"delta","~46 weeks",NA,NA,2856,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","21/10/2022",2022-10-21
"2799",336,"Embi","Test-negative case-control","22May2023","mRNA-1273 (Moderna)","included","2","final","14-149","hospitalization with COVID-like illness","severe","USA","immunocompetent adults >=18 years","immunocompetent adults",95,"92",95,NA,"delta","~46 weeks",NA,NA,2857,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/10/2022",2022-10-21
"2800",336,"Embi","Test-negative case-control","22May2023","mRNA-1273 (Moderna)","included","2","final","150+","hospitalization with COVID-like illness","severe","USA","immunocompetent adults >=18 years","immunocompetent adults",89,"88",90,NA,"delta","~46 weeks",NA,NA,2858,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/10/2022",2022-10-21
"2801",336,"Embi","Test-negative case-control","22May2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-149","hospitalization with COVID-like illness","severe","USA","immunocompetent adults >=18 years","immunocompetent adults",90,"88",91,NA,"delta","~46 weeks",NA,NA,2859,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","21/10/2022",2022-10-21
"2802",336,"Embi","Test-negative case-control","22May2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","hospitalization with COVID-like illness","severe","USA","immunocompetent adults >=18 years","immunocompetent adults",80,"79",82,NA,"delta","~46 weeks",NA,NA,2860,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","21/10/2022",2022-10-21
"2803",336,"Embi","Test-negative case-control","22May2023","mRNA-1273 (Moderna)","included","2","final","14-149","ED or UC visits with COVID-like illness","symptomatic","USA","immunocompromised adults >=18 years","immunocompromised adults",79,"64",88,NA,"delta","~46 weeks",NA,NA,2861,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"symptomatic","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/10/2022",2022-10-21
"2804",336,"Embi","Test-negative case-control","22May2023","mRNA-1273 (Moderna)","included","2","final","150+","ED or UC visits with COVID-like illness","symptomatic","USA","immunocompromised adults >=18 years","immunocompromised adults",64,"54",72,NA,"delta","~46 weeks",NA,NA,2862,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"symptomatic","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/10/2022",2022-10-21
"2805",336,"Embi","Test-negative case-control","22May2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-149","ED or UC visits with COVID-like illness","symptomatic","USA","immunocompromised adults >=18 years","immunocompromised adults",62,"45",73,NA,"delta","~46 weeks",NA,NA,2863,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","21/10/2022",2022-10-21
"2806",336,"Embi","Test-negative case-control","22May2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","ED or UC visits with COVID-like illness","symptomatic","USA","immunocompromised adults >=18 years","immunocompromised adults",56,"46",64,NA,"delta","~46 weeks",NA,NA,2864,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","21/10/2022",2022-10-21
"2807",336,"Embi","Test-negative case-control","22May2023","mRNA-1273 (Moderna)","included","2","final","14-149","hospitalization with COVID-like illness","severe","USA","immunocompromised adults >=18 years","immunocompromised adults",81,"69",88,NA,"delta","~46 weeks",NA,NA,2865,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/10/2022",2022-10-21
"2808",336,"Embi","Test-negative case-control","22May2023","mRNA-1273 (Moderna)","included","2","final","150+","hospitalization with COVID-like illness","severe","USA","immunocompromised adults >=18 years","immunocompromised adults",73,"68",77,NA,"delta","~46 weeks",NA,NA,2866,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","21/10/2022",2022-10-21
"2809",336,"Embi","Test-negative case-control","22May2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-149","hospitalization with COVID-like illness","severe","USA","immunocompromised adults >=18 years","immunocompromised adults",68,"58",75,NA,"delta","~46 weeks",NA,NA,2867,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","21/10/2022",2022-10-21
"2810",336,"Embi","Test-negative case-control","22May2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","hospitalization with COVID-like illness","severe","USA","immunocompromised adults >=18 years","immunocompromised adults",64,"58",69,NA,"delta","~46 weeks",NA,NA,2868,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","21/10/2022",2022-10-21
"2811",336,"Embi","Test-negative case-control","22May2023","Ad26.COV2.S (Janssen)","included","1","final","14-149","ED or UC visits with COVID-like illness","symptomatic","USA","immunocompetent adults >=18 years","immunocompetent adults",67,"63",71,NA,"delta","~46 weeks",NA,NA,2869,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"symptomatic","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","21/10/2022",2022-10-21
"2812",336,"Embi","Test-negative case-control","22May2023","Ad26.COV2.S (Janssen)","included","1","final","150+","ED or UC visits with COVID-like illness","symptomatic","USA","immunocompetent adults >=18 years","immunocompetent adults",62,"58",65,NA,"delta","~46 weeks",NA,NA,2870,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"symptomatic","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","21/10/2022",2022-10-21
"2813",336,"Embi","Test-negative case-control","22May2023","Ad26.COV2.S (Janssen)","included","1","final","14-149","hospitalization with COVID-like illness","severe","USA","immunocompetent adults >=18 years","immunocompetent adults",77,"71",82,NA,"delta","~46 weeks",NA,NA,2871,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","21/10/2022",2022-10-21
"2814",336,"Embi","Test-negative case-control","22May2023","Ad26.COV2.S (Janssen)","included","1","final","150+","hospitalization with COVID-like illness","severe","USA","immunocompetent adults >=18 years","immunocompetent adults",69,"65",73,NA,"delta","~46 weeks",NA,NA,2872,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","21/10/2022",2022-10-21
"2815",336,"Embi","Test-negative case-control","22May2023","Ad26.COV2.S (Janssen)","included","1","final","14-149","ED or UC visits with COVID-like illness","symptomatic","USA","immunocompromised adults >=18 years","immunocompromised adults",9,"-66",50,NA,"delta","~46 weeks",NA,NA,2873,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"symptomatic","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","21/10/2022",2022-10-21
"2816",336,"Embi","Test-negative case-control","22May2023","Ad26.COV2.S (Janssen)","included","1","final","150+","ED or UC visits with COVID-like illness","symptomatic","USA","immunocompromised adults >=18 years","immunocompromised adults",-6,"-49",25,NA,"delta","~46 weeks",NA,NA,2874,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"symptomatic","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","21/10/2022",2022-10-21
"2817",336,"Embi","Test-negative case-control","22May2023","Ad26.COV2.S (Janssen)","included","1","final","14-149","hospitalization with COVID-like illness","severe","USA","immunocompromised adults >=18 years","immunocompromised adults",35,"-3",60,NA,"delta","~46 weeks",NA,NA,2875,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","21/10/2022",2022-10-21
"2818",336,"Embi","Test-negative case-control","22May2023","Ad26.COV2.S (Janssen)","included","1","final","150+","hospitalization with COVID-like illness","severe","USA","immunocompromised adults >=18 years","immunocompromised adults",43,"23",58,NA,"delta","~46 weeks",NA,NA,2876,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta","21/10/2022",2022-10-21
"2819",337,"Britton","Test-negative case-control","21Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization with COVID-like illness","severe","USA","immunocompromised adults >=18 years","immunocompromised adults",40,"34",46,NA,"omicron BA.1","~56 weeks",NA,NA,2877,"USA","USA",337,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-21,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-21
"2820",337,"Britton","Test-negative case-control","21Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization with COVID-like illness","severe","USA","immunocompromised adults >=18 years","immunocompromised adults",7,"-16",25,NA,"omicron BA.2/BA.2.12.1","~69 weeks",NA,NA,2878,"USA","USA",337,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-21,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-21
"2821",337,"Britton","Test-negative case-control","21Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization with COVID-like illness","severe","USA","immunocompromised adults >=18 years","immunocompromised adults",38,"23",50,NA,"omicron BA.4/BA.5","~77 weeks",NA,NA,2879,"USA","USA",337,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-21,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-21
"2822",337,"Britton","Test-negative case-control","21Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization with COVID-like illness","severe","USA","immunocompromised adults >=18 years","immunocompromised adults",22,"10",33,NA,"omicron BA.2/BA.2.12.1/BA.4/BA.5","~77 weeks",NA,NA,2880,"USA","USA",337,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-21,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-21
"2823",338,"Surie","Test-negative case-control","21Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-150","hospitalization with COVID-like illness","severe","USA",">=18 years","general pop",63,"46",75,NA,"omicron BA.1/BA.2","~74 weeks",NA,NA,2881,"USA","USA",338,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-21,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-21
"2824",338,"Surie","Test-negative case-control","21Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization with COVID-like illness","severe","USA",">=18 years","general pop",34,"20",46,NA,"omicron BA.1/BA.2","~74 weeks",NA,NA,2882,"USA","USA",338,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-21,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-21
"2825",338,"Surie","Test-negative case-control","21Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-150","hospitalization with COVID-like illness","severe","USA",">=18 years","general pop",83,"35",96,NA,"omicron BA.4/BA.5","~82 weeks",NA,NA,2883,"USA","USA",338,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-21,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-21
"2826",338,"Surie","Test-negative case-control","21Oct2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization with COVID-like illness","severe","USA",">=18 years","general pop",37,"12",55,NA,"omicron BA.4/BA.5","~82 weeks",NA,NA,2884,"USA","USA",338,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-21,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-10-21
"2827",339,"Collie","Test-negative case-control","24Oct2022","Ad26.COV2.S (Janssen)","included","1","final","14-20","infection","infection","South Africa","HCW >=18 years with low physical activity","HCW with low physical activity",48,"9.7",70.1,NA,"beta & delta","~34 weeks",NA,NA,2885,"South Africa","ZAF",339,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2022-10-24,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-10-24
"2828",339,"Collie","Test-negative case-control","24Oct2022","Ad26.COV2.S (Janssen)","included","1","final","28+","infection","infection","South Africa","HCW >=18 years with low physical activity","HCW with low physical activity",39.8,"34",45.1,NA,"beta & delta","~34 weeks",NA,NA,2886,"South Africa","ZAF",339,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2022-10-24,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-10-24
"2829",339,"Collie","Test-negative case-control","24Oct2022","Ad26.COV2.S (Janssen)","included","1","final","28+","hospitalization","severe","South Africa","HCW >=18 years with low physical activity","HCW with low physical activity",60,"39",73.8,NA,"beta & delta","~34 weeks",NA,NA,2887,"South Africa","ZAF",339,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2022-10-24,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-10-24
"2830",339,"Collie","Test-negative case-control","24Oct2022","Ad26.COV2.S (Janssen)","included","1","final","14-20","infection","infection","South Africa","HCW >=18 years with moderate physical activity","HCW years with moderate physical activity",39,"-4.9",64.5,NA,"beta & delta","~34 weeks",NA,NA,2888,"South Africa","ZAF",339,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2022-10-24,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-10-24
"2831",339,"Collie","Test-negative case-control","24Oct2022","Ad26.COV2.S (Janssen)","included","1","final","28+","infection","infection","South Africa","HCW >=18 years with moderate physical activity","HCW years with moderate physical activity",36.3,"31.3",41,NA,"beta & delta","~34 weeks",NA,NA,2889,"South Africa","ZAF",339,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2022-10-24,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-10-24
"2832",339,"Collie","Test-negative case-control","24Oct2022","Ad26.COV2.S (Janssen)","included","1","final","28+","hospitalization","severe","South Africa","HCW >=18 years with moderate physical activity","HCW years with moderate physical activity",72.1,"55.2",82.6,NA,"beta & delta","~34 weeks",NA,NA,2890,"South Africa","ZAF",339,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2022-10-24,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-10-24
"2833",339,"Collie","Test-negative case-control","24Oct2022","Ad26.COV2.S (Janssen)","included","1","final","14-20","infection","infection","South Africa","HCW >=18 years with high physical activity","HCW years with high physical activity",51,"16.8",71.1,NA,"beta & delta","~34 weeks",NA,NA,2891,"South Africa","ZAF",339,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2022-10-24,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-10-24
"2834",339,"Collie","Test-negative case-control","24Oct2022","Ad26.COV2.S (Janssen)","included","1","final","28+","infection","infection","South Africa","HCW >=18 years with high physical activity","HCW years with high physical activity",41.2,"37.5",44.7,NA,"beta & delta","~34 weeks",NA,NA,2892,"South Africa","ZAF",339,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2022-10-24,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-10-24
"2835",339,"Collie","Test-negative case-control","24Oct2022","Ad26.COV2.S (Janssen)","included","1","final","28+","hospitalization","severe","South Africa","HCW >=18 years with high physical activity","HCW years with high physical activity",85.8,"74.1",92.2,NA,"beta & delta","~34 weeks",NA,NA,2893,"South Africa","ZAF",339,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"who","feb/2021","not reached","not reached","yes","no","no",2022-10-24,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations",NA,2022-10-24
"2836",340,"Nordstrom","Case-control","21Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","infection","infection","Sweden","adolescents vaccinated on or after January 1, 2022","adolescents",51,"48",55,NA,"omicron","~6 weeks",NA,NA,2894,"Sweden","SWE",340,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-21,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","24/10/2022",2022-10-24
"2837",340,"Nordstrom","Case-control","21Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","infection","infection","Sweden","adolescents vaccinated on or after September 1, 2021","adolescents",12,"10",13,NA,"omicron BA.1/BA.2","~24 weeks",NA,NA,2895,"Sweden","SWE",340,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-21,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","24/10/2022",2022-10-24
"2838",340,"Nordstrom","Case-control","21Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","hospitalization with COVID-19 as the main diagnosis","severe","Sweden","adolescents vaccinated on or after November 15, 2021","adolescents",87,"66",95,NA,"omicron BA.1/BA.2","~27 weeks",NA,NA,2896,"Sweden","SWE",340,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-21,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","24/10/2022",2022-10-24
"2839",340,"Nordstrom","Case-control","21Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","48+","hospitalization with COVID-19 as the main diagnosis","severe","Sweden","adolescents vaccinated before November 15, 2021","adolescents",69,"29",87,NA,"omicron BA.1/BA.2","~45 weeks",NA,NA,2897,"Sweden","SWE",340,"SWE",56230,2019,"Sweden","Europe & Central Asia","High income",4,"Europe",2021-01-03,2021-08-08,2022-01-23,2020-12-23,2020-12-23,11,228,396,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-21,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","24/10/2022",2022-10-24
"2840",341,"Tartof","Test-negative case-control","25Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<6 months","ED visit for ARI","symptomatic","USA",">=18 years","general pop",30,"-86",74,"omicron BA.4/BA.5","omicron BA.4/BA.5","~84 weeks",NA,NA,2898,"USA","USA",341,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-25,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-25
"2841",341,"Tartof","Test-negative case-control","25Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=6 months","ED visit for ARI","symptomatic","USA",">=18 years","general pop",44,"20",61,"omicron BA.4/BA.5","omicron BA.4/BA.5","~84 weeks",NA,NA,2899,"USA","USA",341,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-25,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-25
"2842",341,"Tartof","Test-negative case-control","25Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<6 months","UC visit for ARI","symptomatic","USA",">=18 years","general pop",50,"10",72,"omicron BA.4/BA.5","omicron BA.4/BA.5","~84 weeks",NA,NA,2900,"USA","USA",341,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-25,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-25
"2843",341,"Tartof","Test-negative case-control","25Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=6 months","UC visit for ARI","symptomatic","USA",">=18 years","general pop",7,"-11",22,"omicron BA.4/BA.5","omicron BA.4/BA.5","~84 weeks",NA,NA,2901,"USA","USA",341,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-25,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-25
"2844",341,"Tartof","Test-negative case-control","25Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<6 months","outpatient care visit for ARI","symptomatic","USA",">=18 years","general pop",30,"4",49,"omicron BA.4/BA.5","omicron BA.4/BA.5","~84 weeks",NA,NA,2902,"USA","USA",341,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-25,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-25
"2845",341,"Tartof","Test-negative case-control","25Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=6 months","outpatient care visit for ARI","symptomatic","USA",">=18 years","general pop",19,"9",29,"omicron BA.4/BA.5","omicron BA.4/BA.5","~84 weeks",NA,NA,2903,"USA","USA",341,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-25,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-25
"2846",341,"Tartof","Test-negative case-control","25Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=6 months","hospitalization for ARI","severe","USA",">=18 years","general pop",-4,"-118",50,"omicron BA.4/BA.5","omicron BA.4/BA.5","~84 weeks",NA,NA,2904,"USA","USA",341,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-25,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-10-25
"2847",342,"Moghnieh","Retrospective cohort","22Sept2022","Gam-COVID-Vac (Gamaleya)","included","2","final","3-5 months","infection","infection","Lebanon",">=18 years","general pop",52.3,"-27.4",78.7,"delta","delta","~30 weeks",NA,NA,2905,"Lebanon","LBN",342,"LBN",8630,2019,"Lebanon","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-15,2022-03-24,NA,2021-02-14,2021-02-14,1,403,NA,"who","feb/2021","Dec/2021 +","360+","yes","no","no",2022-09-22,"infection","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta",NA,2022-09-22
"2848",342,"Moghnieh","Retrospective cohort","22Sept2022","Gam-COVID-Vac (Gamaleya)","included","2","final","7-9 months","infection","infection","Lebanon",">=18 years","general pop",23.7,"-84.7",62.8,"delta","delta","~30 weeks",NA,NA,2906,"Lebanon","LBN",342,"LBN",8630,2019,"Lebanon","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-15,2022-03-24,NA,2021-02-14,2021-02-14,1,403,NA,"who","feb/2021","Dec/2021 +","360+","yes","no","no",2022-09-22,"infection","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta",NA,2022-09-22
"2849",342,"Moghnieh","Retrospective cohort","22Sept2022","Gam-COVID-Vac (Gamaleya)","excluded","2","final","7-9 months","infection","infection","Lebanon",">=18 years","general pop",20.1,"-94.7",61.6,"delta","delta","~30 weeks",NA,NA,2907,"Lebanon","LBN",342,"LBN",8630,2019,"Lebanon","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-15,2022-03-24,NA,2021-02-14,2021-02-14,1,403,NA,"who","feb/2021","Dec/2021 +","360+","yes","no","no",2022-09-22,"infection","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta",NA,2022-09-22
"2850",342,"Moghnieh","Retrospective cohort","22Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<3 months","infection","infection","Lebanon",">=18 years","general pop",95.1,"78.4",99.3,"delta","delta","~30 weeks",NA,NA,2908,"Lebanon","LBN",342,"LBN",8630,2019,"Lebanon","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-15,2022-03-24,NA,2021-02-14,2021-02-14,1,403,NA,"who","feb/2021","Dec/2021 +","360+","yes","no","no",2022-09-22,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-22
"2851",342,"Moghnieh","Retrospective cohort","22Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<7 months","infection","infection","Lebanon",">=18 years","general pop",67.5,"12.8",87.2,"delta","delta","~30 weeks",NA,NA,2909,"Lebanon","LBN",342,"LBN",8630,2019,"Lebanon","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-15,2022-03-24,NA,2021-02-14,2021-02-14,1,403,NA,"who","feb/2021","Dec/2021 +","360+","yes","no","no",2022-09-22,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-22
"2852",342,"Moghnieh","Retrospective cohort","22Sept2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","<7 months","infection","infection","Lebanon",">=18 years","general pop",71.8,"22.3",89.1,"delta","delta","~30 weeks",NA,NA,2910,"Lebanon","LBN",342,"LBN",8630,2019,"Lebanon","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-15,2022-03-24,NA,2021-02-14,2021-02-14,1,403,NA,"who","feb/2021","Dec/2021 +","360+","yes","no","no",2022-09-22,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-09-22
"2853",342,"Moghnieh","Retrospective cohort","22Sept2022","Gam-COVID-Vac (Gamaleya)","included","2","final",">6 months","infection","infection","Lebanon",">=18 years","general pop",-54.1,"-151",0.84,"omicron","omicron","~43 weeks",NA,NA,2911,"Lebanon","LBN",342,"LBN",8630,2019,"Lebanon","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-15,2022-03-24,NA,2021-02-14,2021-02-14,1,403,NA,"who","feb/2021","Dec/2021 +","360+","yes","no","no",2022-09-22,"infection","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","omicron",NA,2022-09-22
"2854",342,"Moghnieh","Retrospective cohort","22Sept2022","Gam-COVID-Vac (Gamaleya)","excluded","2","final",">6 months","infection","infection","Lebanon",">=18 years","general pop",-46,"-149.7",10.1,"omicron","omicron","~43 weeks",NA,NA,2912,"Lebanon","LBN",342,"LBN",8630,2019,"Lebanon","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-15,2022-03-24,NA,2021-02-14,2021-02-14,1,403,NA,"who","feb/2021","Dec/2021 +","360+","yes","no","no",2022-09-22,"infection","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","omicron",NA,2022-09-22
"2855",342,"Moghnieh","Retrospective cohort","22Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","3-5 months","infection","infection","Lebanon",">=18 years","general pop",23.1,"-28.7",52.1,"omicron","omicron","~43 weeks",NA,NA,2913,"Lebanon","LBN",342,"LBN",8630,2019,"Lebanon","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-15,2022-03-24,NA,2021-02-14,2021-02-14,1,403,NA,"who","feb/2021","Dec/2021 +","360+","yes","no","no",2022-09-22,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-22
"2856",342,"Moghnieh","Retrospective cohort","22Sept2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","3-5 months","infection","infection","Lebanon",">=18 years","general pop",21.9,"-38.9",54.1,"omicron","omicron","~43 weeks",NA,NA,2914,"Lebanon","LBN",342,"LBN",8630,2019,"Lebanon","Middle East & North Africa","Lower middle income",3,"Asia",2021-02-15,2022-03-24,NA,2021-02-14,2021-02-14,1,403,NA,"who","feb/2021","Dec/2021 +","360+","yes","no","no",2022-09-22,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-09-22
"2857",343,"Grewal","Test-negative case-control","07Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","240-299","severe disease","severe","Canada","50-59 years","50-59 years",83,"76",88,"omicron BA.1/BA.2","omicron BA.1/BA.2","~74 weeks",NA,NA,2915,"Canada","CAN",343,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","01/11/2022",2022-11-01
"2858",343,"Grewal","Test-negative case-control","07Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","300+","severe disease","severe","Canada","50-59 years","50-59 years",83,"74",89,"omicron BA.1/BA.2","omicron BA.1/BA.2","~74 weeks",NA,NA,2916,"Canada","CAN",343,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","01/11/2022",2022-11-01
"2859",343,"Grewal","Test-negative case-control","07Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","300+","severe disease","severe","Canada","60-69 years","60-69 years",79,"71",86,"omicron BA.1/BA.2","omicron BA.1/BA.2","~74 weeks",NA,NA,2917,"Canada","CAN",343,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","01/11/2022",2022-11-01
"2860",343,"Grewal","Test-negative case-control","07Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","300+","severe disease","severe","Canada","70-79 years","70-79 years",80,"72",86,"omicron BA.1/BA.2","omicron BA.1/BA.2","~74 weeks",NA,NA,2918,"Canada","CAN",343,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","01/11/2022",2022-11-01
"2861",343,"Grewal","Test-negative case-control","07Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","300+","severe disease","severe","Canada",">=80 years",">=80 years",72,"62",79,"omicron BA.1/BA.2","omicron BA.1/BA.2","~74 weeks",NA,NA,2919,"Canada","CAN",343,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","01/11/2022",2022-11-01
"2862",343,"Grewal","Test-negative case-control","07Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","240-299","severe disease","severe","Canada","50-59 years","50-59 years",87,"43",97,"omicron BA.4/BA.5","omicron BA.4/BA.5","~86 weeks",NA,NA,2920,"Canada","CAN",343,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","01/11/2022",2022-11-01
"2863",343,"Grewal","Test-negative case-control","07Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","300+","severe disease","severe","Canada","50-59 years","50-59 years",56,"30",72,"omicron BA.4/BA.5","omicron BA.4/BA.5","~86 weeks",NA,NA,2921,"Canada","CAN",343,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","01/11/2022",2022-11-01
"2864",343,"Grewal","Test-negative case-control","07Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","300+","severe disease","severe","Canada","60-69 years","60-69 years",43,"16",61,"omicron BA.4/BA.5","omicron BA.4/BA.5","~86 weeks",NA,NA,2922,"Canada","CAN",343,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","01/11/2022",2022-11-01
"2865",343,"Grewal","Test-negative case-control","07Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","300+","severe disease","severe","Canada","70-79 years","70-79 years",48,"25",64,"omicron BA.4/BA.5","omicron BA.4/BA.5","~86 weeks",NA,NA,2923,"Canada","CAN",343,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","01/11/2022",2022-11-01
"2866",343,"Grewal","Test-negative case-control","07Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","300+","severe disease","severe","Canada",">=80 years",">=80 years",40,"18",56,"omicron BA.4/BA.5","omicron BA.4/BA.5","~86 weeks",NA,NA,2924,"Canada","CAN",343,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-03-07,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","01/11/2022",2022-11-01
"2867",344,"Chemaitelly","Retrospective cohort","07Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected only","2","final","91+ (90+ days post primary Omicron infection)","reinfection","reinfection","Qatar",">=18 years with prior breakthrough Omicron infection",">=18 years with prior breakthrough Omicron infection",57,"52",62,NA,"omicron","~85 weeks",NA,NA,2925,"Qatar","QAT",344,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-03-07,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-03-07
"2868",345,"Clemens","Test-negative case-control","13Oct2022","AZD1222 (AstraZeneca)","included","2","final","14+","infection","infection","Brazil","18-60 years","18-60 years",76,"49.5",87.8,"delta","delta","~12.5 weeks",NA,NA,2926,"Brazil","BRA",345,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-10-13,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-10-13
"2869",345,"Clemens","Test-negative case-control","13Oct2022","AZD1222 (AstraZeneca)","included","2","final","14+","severe disease","severe","Brazil","18-60 years","18-60 years",100,"44.3",100,NA,"delta","~12.5 weeks",NA,NA,2927,"Brazil","BRA",345,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-10-13,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-10-13
"2870",345,"Clemens","Test-negative case-control","13Oct2022","AZD1222 (AstraZeneca)","included","2","final","14+","infection","infection","Brazil","18-60 years","18-60 years",81.3,"-298",97.9,"gamma","gamma","~12.5 weeks",NA,NA,2928,"Brazil","BRA",345,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-10-13,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","gamma",NA,2022-10-13
"2871",346,"Jorgensen","Test-negative case-control","08Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Canada","infants < 6 months","mothers of infants < 6 months",45,"37",53,NA,"omicron","~66 weeks",NA,NA,2929,"Canada","CAN",346,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-08,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","08/11/2022",2022-11-08
"2872",346,"Jorgensen","Test-negative case-control","08Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Canada","infants < 6 months of mothers receiving second dose in first trimester","infants < 6 months of mothers receiving second dose in first trimester",47,"31",59,NA,"omicron","~66 weeks",NA,NA,2930,"Canada","CAN",346,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-08,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","08/11/2022",2022-11-08
"2873",346,"Jorgensen","Test-negative case-control","08Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Canada","infants < 6 months of mothers receiving second dose in second trimester","infants < 6 months of mothers receiving second dose in second trimester",37,"24",47,NA,"omicron","~66 weeks",NA,NA,2931,"Canada","CAN",346,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-08,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","08/11/2022",2022-11-08
"2874",346,"Jorgensen","Test-negative case-control","08Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Canada","infants < 6 months of mothers receiving second dose in third trimester","infants < 6 months of mothers receiving second dose in third trimester",53,"42",62,NA,"omicron","~66 weeks",NA,NA,2932,"Canada","CAN",346,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-08,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","08/11/2022",2022-11-08
"2875",346,"Jorgensen","Test-negative case-control","08Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Canada","infants 0-8 weeks","infants 0-8 weeks",57,"44",66,NA,"omicron","~66 weeks",NA,NA,2933,"Canada","CAN",346,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-08,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","08/11/2022",2022-11-08
"2876",346,"Jorgensen","Test-negative case-control","08Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Canada","infants 9-16 weeks","infants 9-16 weeks",47,"31",60,NA,"omicron","~66 weeks",NA,NA,2934,"Canada","CAN",346,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-08,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","08/11/2022",2022-11-08
"2877",346,"Jorgensen","Test-negative case-control","08Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Canada","infants >16 weeks and < 6 months","infants >16 weeks and < 6 months",40,"21",54,NA,"omicron","~66 weeks",NA,NA,2935,"Canada","CAN",346,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-08,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","08/11/2022",2022-11-08
"2878",346,"Jorgensen","Test-negative case-control","08Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","Canada","infants < 6 months","infants < 6 months",58,"44",69,NA,"omicron","~66 weeks",NA,NA,2936,"Canada","CAN",346,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-08,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","08/11/2022",2022-11-08
"2879",346,"Jorgensen","Test-negative case-control","08Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Canada","infants < 6 months","infants < 6 months",95,"88",98,NA,"delta","~28 weeks",NA,NA,2937,"Canada","CAN",346,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-08,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","08/11/2022",2022-11-08
"2880",346,"Jorgensen","Test-negative case-control","08Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","Canada","infants < 6 months","infants < 6 months",97,"74",100,NA,"delta","~28 weeks",NA,NA,2938,"Canada","CAN",346,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-08,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta","08/11/2022",2022-11-08
"2881",347,"Van Ewijk","Test-negative case-control","10Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Netherlands",">=18 years","general pop",64,"51",74,NA,"delta","~41 weeks",NA,NA,2939,"Netherlands","NLD",347,"NLD",51920,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,198,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-11-10
"2882",347,"Van Ewijk","Test-negative case-control","10Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Netherlands",">=18 years","general pop",64,"49",75,NA,"delta","~41 weeks",NA,NA,2940,"Netherlands","NLD",347,"NLD",51920,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,198,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"symptomatic","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-11-10
"2883",347,"Van Ewijk","Test-negative case-control","10Nov2022","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Netherlands",">=18 years","general pop",76,"62",85,NA,"delta","~41 weeks",NA,NA,2941,"Netherlands","NLD",347,"NLD",51920,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,198,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-11-10
"2884",347,"Van Ewijk","Test-negative case-control","10Nov2022","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","Netherlands",">=18 years","general pop",75,"58",85,NA,"delta","~41 weeks",NA,NA,2942,"Netherlands","NLD",347,"NLD",51920,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,198,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"symptomatic","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-11-10
"2885",347,"Van Ewijk","Test-negative case-control","10Nov2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection","infection","Netherlands",">=18 years","general pop",53,"37",68,NA,"delta","~41 weeks",NA,NA,2943,"Netherlands","NLD",347,"NLD",51920,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,198,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-11-10
"2886",347,"Van Ewijk","Test-negative case-control","10Nov2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","symptomatic disease","symptomatic","Netherlands",">=18 years","general pop",52,"26",69,NA,"delta","~41 weeks",NA,NA,2944,"Netherlands","NLD",347,"NLD",51920,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,198,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"symptomatic","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-11-10
"2887",347,"Van Ewijk","Test-negative case-control","10Nov2022","Ad26.COV2.S (Janssen)","excluded","1","final","28+","infection","infection","Netherlands",">=18 years","general pop",55,"32",70,NA,"delta","~36 weeks",NA,NA,2945,"Netherlands","NLD",347,"NLD",51920,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,198,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-11-10
"2888",347,"Van Ewijk","Test-negative case-control","10Nov2022","Ad26.COV2.S (Janssen)","excluded","1","final","28+","symptomatic disease","symptomatic","Netherlands",">=18 years","general pop",59,"35",74,NA,"delta","~36 weeks",NA,NA,2946,"Netherlands","NLD",347,"NLD",51920,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,198,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"symptomatic","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-11-10
"2889",347,"Van Ewijk","Test-negative case-control","10Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<120","infection","infection","Netherlands",">=18 years","general pop",74,"63",81,NA,"delta",NA,NA,NA,2947,"Netherlands","NLD",347,"NLD",51920,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,198,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-11-10
"2890",347,"Van Ewijk","Test-negative case-control","10Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final",">120","infection","infection","Netherlands",">=18 years","general pop",56,"36",69,NA,"delta","~41 weeks",NA,NA,2948,"Netherlands","NLD",347,"NLD",51920,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,198,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-11-10
"2891",347,"Van Ewijk","Test-negative case-control","10Nov2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","Netherlands",">=18 years","general pop",59,"25",70,NA,"delta","~41 weeks",NA,NA,2949,"Netherlands","NLD",347,"NLD",51920,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,198,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-11-10
"2892",347,"Van Ewijk","Test-negative case-control","10Nov2022","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Netherlands",">=18 years","general pop",73,"59",83,NA,"delta","~41 weeks",NA,NA,2950,"Netherlands","NLD",347,"NLD",51920,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,198,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-11-10
"2893",347,"Van Ewijk","Test-negative case-control","10Nov2022","AZD1222 (AstraZeneca)","included","2","final","14+","infection","infection","Netherlands",">=18 years","general pop",48,"25",64,NA,"delta","~36 weeks",NA,NA,2951,"Netherlands","NLD",347,"NLD",51920,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,198,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"infection","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-11-10
"2894",347,"Van Ewijk","Test-negative case-control","10Nov2022","Ad26.COV2.S (Janssen)","included","1","final","14+","infection","infection","Netherlands",">=18 years","general pop",50,"24",66,NA,"delta","~36 weeks",NA,NA,2952,"Netherlands","NLD",347,"NLD",51920,2019,"Netherlands","Europe & Central Asia","High income",4,"Europe",2021-01-08,2021-07-16,NA,2020-12-30,2020-12-30,9,198,NA,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-11-10,"infection","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2022-11-10
"2895",348,"Turbyfill","Test-negative case-control","15Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","immunocompetent adults >=18 years","immunocompetent adults",91,"88",93,NA,"alpha & delta","~30 weeks",NA,NA,2953,"USA","USA",348,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-11-15,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-11-15
"2896",348,"Turbyfill","Test-negative case-control","15Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","immunocompetent adults >=18 years","immunocompetent adults",84,"80",88,NA,"alpha & delta","~30 weeks",NA,NA,2954,"USA","USA",348,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-11-15,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-11-15
"2897",348,"Turbyfill","Test-negative case-control","15Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","immunocompromised, >=18 years","immunocompromised adults",64,"48",75,NA,"alpha & delta","~30 weeks",NA,NA,2955,"USA","USA",348,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-11-15,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-11-15
"2898",348,"Turbyfill","Test-negative case-control","15Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","immunocompromised, >=18 years","immunocompromised adults",53,"22",72,NA,"alpha & delta","~30 weeks",NA,NA,2956,"USA","USA",348,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-11-15,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations",NA,2022-11-15
"2899",349,"Castelli","Test-negative case-control","30Nov2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","Argentina","12-17 years","12-17 years",28.1,"25.2",30.8,NA,"omicron","~32.5 weeks",NA,NA,2957,"Argentina","ARG",349,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2022-11-30
"2900",349,"Castelli","Test-negative case-control","30Nov2022","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Argentina","12-17 years","12-17 years",17.9,"14",21.5,NA,"omicron","~32.5 weeks",NA,NA,2958,"Argentina","ARG",349,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2022-11-30
"2901",349,"Castelli","Test-negative case-control","30Nov2022","BNT162b2 (Pfizer BioNTech) & mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Argentina","12-17 years","12-17 years",40.6,"29.4",50,NA,"omicron","~32.5 weeks",NA,NA,2959,"Argentina","ARG",349,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-11-30
"2902",349,"Castelli","Test-negative case-control","30Nov2022","BNT162b2 (Pfizer BioNTech) & mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Argentina","12-17 years","12-17 years",31.5,"26.3",36.4,NA,"omicron","~32.5 weeks",NA,NA,2960,"Argentina","ARG",349,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-11-30
"2903",349,"Castelli","Test-negative case-control","30Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","15-30","infection","infection","Argentina","12-17 years","12-17 years",55.8,"52.4",59,NA,"omicron","~32.5 weeks",NA,NA,2961,"Argentina","ARG",349,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-11-30
"2904",349,"Castelli","Test-negative case-control","30Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","61+","infection","infection","Argentina","12-17 years","12-17 years",12.4,"8.6",16.1,NA,"omicron","~32.5 weeks",NA,NA,2962,"Argentina","ARG",349,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-11-30
"2905",349,"Castelli","Test-negative case-control","30Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","death","death","Argentina","12-17 years","12-17 years",97.6,"81",99.7,NA,"omicron","~32.5 weeks",NA,NA,2963,"Argentina","ARG",349,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"death","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-11-30
"2906",349,"Castelli","Test-negative case-control","30Nov2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","infection","infection","Argentina","3-11 years","3-11 years",26,"23.2",28.8,NA,"omicron","~22.5 weeks",NA,NA,2964,"Argentina","ARG",349,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","omicron",NA,2022-11-30
"2907",349,"Castelli","Test-negative case-control","30Nov2022","BBIBP-CorV (Beijing CNBG)","included","2","final","15-30","infection","infection","Argentina","3-11 years","3-11 years",37.6,"34.2",40.8,NA,"omicron","~22.5 weeks",NA,NA,2965,"Argentina","ARG",349,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","omicron",NA,2022-11-30
"2908",349,"Castelli","Test-negative case-control","30Nov2022","BBIBP-CorV (Beijing CNBG)","included","2","final","61+","infection","infection","Argentina","3-11 years","3-11 years",2,"1.8",5.6,NA,"omicron","~22.5 weeks",NA,NA,2966,"Argentina","ARG",349,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","omicron",NA,2022-11-30
"2909",349,"Castelli","Test-negative case-control","30Nov2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","death","death","Argentina","3-11 years","3-11 years",66.9,"6.4",89.8,NA,"omicron","~22.5 weeks",NA,NA,2967,"Argentina","ARG",349,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"death","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","omicron",NA,2022-11-30
"2910",349,"Castelli","Test-negative case-control","30Nov2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","Argentina","12-17 years","12-17 years",64.1,"60.5",67.3,NA,"delta","~15.5 weeks",NA,NA,2968,"Argentina","ARG",349,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-11-30
"2911",349,"Castelli","Test-negative case-control","30Nov2022","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Argentina","12-17 years","12-17 years",70.2,"66.8",73.1,NA,"delta","~15.5 weeks",NA,NA,2969,"Argentina","ARG",349,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-11-30
"2912",349,"Castelli","Test-negative case-control","30Nov2022","BNT162b2 (Pfizer BioNTech) & mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Argentina","12-17 years","12-17 years",88.9,"66.1",96.4,NA,"delta","~15.5 weeks",NA,NA,2970,"Argentina","ARG",349,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-11-30
"2913",349,"Castelli","Test-negative case-control","30Nov2022","BNT162b2 (Pfizer BioNTech) & mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Argentina","12-17 years","12-17 years",66.3,"54",75.4,NA,"delta","~15.5 weeks",NA,NA,2971,"Argentina","ARG",349,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-11-30
"2914",349,"Castelli","Test-negative case-control","30Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","15-30","infection","infection","Argentina","12-17 years","12-17 years",74.8,"71.3",77.9,NA,"delta","~15.5 weeks",NA,NA,2972,"Argentina","ARG",349,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-11-30
"2915",349,"Castelli","Test-negative case-control","30Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","61+","infection","infection","Argentina","12-17 years","12-17 years",56.3,"50.2",61.7,NA,"delta","~15.5 weeks",NA,NA,2973,"Argentina","ARG",349,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2022-11-30
"2916",349,"Castelli","Test-negative case-control","30Nov2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","infection","infection","Argentina","3-11 years","3-11 years",61.2,"56.4",65.5,NA,"delta","~5.5 weeks",NA,NA,2974,"Argentina","ARG",349,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-11-30
"2917",349,"Castelli","Test-negative case-control","30Nov2022","BBIBP-CorV (Beijing CNBG)","included","2","final","15-30","infection","infection","Argentina","3-11 years","3-11 years",68.4,"64.1",72.2,NA,"delta","~5.5 weeks",NA,NA,2975,"Argentina","ARG",349,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-11-30
"2918",349,"Castelli","Test-negative case-control","30Nov2022","BBIBP-CorV (Beijing CNBG)","included","2","final","61+","infection","infection","Argentina","3-11 years","3-11 years",65.2,"44",78.4,NA,"delta","~5.5 weeks",NA,NA,2976,"Argentina","ARG",349,"ARG",11210,2019,"Argentina","Latin America & Caribbean","Upper middle income",3,"South America",2020-12-29,2021-09-18,2022-01-14,2020-12-29,2020-12-29,0,263,381,"equal","before jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-11-30
"2919",350,"Fu","Retrospective cohort","22Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA",">=18 years","general pop",-122.3,"-124.2",120.3,NA,"omicron BA.1, BA.2","~75.5 weeks",NA,NA,2977,"USA","USA",350,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","10/12/2022",2022-12-10
"2920",350,"Fu","Retrospective cohort","22Sep2023","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","USA",">=18 years","general pop",-163.5,"-166.6",-160.5,NA,"omicron BA.1, BA.2","~73.5 weeks",NA,NA,2978,"USA","USA",350,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","10/12/2022",2022-12-10
"2921",350,"Fu","Retrospective cohort","22Sep2023","mRNA (heterologous)","included","2","final","14+","infection","infection","USA",">=18 years","general pop",-19,"-27.4",-11,NA,"omicron BA.1, BA.2","~75.5 weeks",NA,NA,2979,"USA","USA",350,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","10/12/2022",2022-12-10
"2922",350,"Fu","Retrospective cohort","22Sep2023","Ad26.COV2.S (Janssen)","included","1","final","14+","infection","infection","USA",">=18 years","general pop",-38.1,"-44.2",32.2,NA,"omicron BA.1, BA.2","~69.5 weeks",NA,NA,2980,"USA","USA",350,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron","10/12/2022",2022-12-10
"2923",350,"Fu","Retrospective cohort","22Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA",">=18 years","general pop",-25,"-26.2",-23.8,NA,"delta","~48.5 weeks",NA,NA,2981,"USA","USA",350,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","10/12/2022",2022-12-10
"2924",350,"Fu","Retrospective cohort","22Sep2023","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","USA",">=18 years","general pop",-11.3,"-12.9",-9.8,NA,"delta","~46.5 weeks",NA,NA,2982,"USA","USA",350,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","10/12/2022",2022-12-10
"2925",350,"Fu","Retrospective cohort","22Sep2023","mRNA (heterologous)","included","2","final","14+","infection","infection","USA",">=18 years","general pop",-13.6,"-22.7",-5.2,NA,"delta","~48.5 weeks",NA,NA,2983,"USA","USA",350,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","10/12/2022",2022-12-10
"2926",350,"Fu","Retrospective cohort","22Sep2023","Ad26.COV2.S (Janssen)","included","1","final","14+","infection","infection","USA",">=18 years","general pop",33,"29.2",36.5,NA,"delta","~42.5 weeks",NA,NA,2984,"USA","USA",350,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta","10/12/2022",2022-12-10
"2927",350,"Fu","Retrospective cohort","22Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA",">=18 years","general pop",77.9,"77.2",78.5,NA,"pre-delta (non-VOC, alpha)","~23 weeks",NA,NA,2985,"USA","USA",350,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","10/12/2022",2022-12-10
"2928",350,"Fu","Retrospective cohort","22Sep2023","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","USA",">=18 years","general pop",85.9,"85.1",86.5,NA,"pre-delta (non-VOC, alpha)","~21 weeks",NA,NA,2986,"USA","USA",350,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","10/12/2022",2022-12-10
"2929",350,"Fu","Retrospective cohort","22Sep2023","mRNA (heterologous)","included","2","final","14+","infection","infection","USA",">=18 years","general pop",78.9,"66.6",87.7,NA,"pre-delta (non-VOC, alpha)","~23 weeks",NA,NA,2987,"USA","USA",350,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","10/12/2022",2022-12-10
"2930",350,"Fu","Retrospective cohort","22Sep2023","Ad26.COV2.S (Janssen)","included","1","final","14+","infection","infection","USA",">=18 years","general pop",81.4,"78.4",84.2,NA,"pre-delta (non-VOC, alpha)","~17 weeks",NA,NA,2988,"USA","USA",350,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","10/12/2022",2022-12-10
"2931",350,"Fu","Retrospective cohort","22Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","1st month","infection","infection","USA",">=18 years","general pop",47.3,"46",48.5,NA,"pre-delta & delta & omicron BA.1, BA.2",NA,NA,NA,2989,"USA","USA",350,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","10/12/2022",2022-12-10
"2932",350,"Fu","Retrospective cohort","22Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","6th month","infection","infection","USA",">=18 years","general pop",-77,"-80.6",-73.5,NA,"pre-delta & delta & omicron BA.1, BA.2","~50 weeks",NA,NA,2990,"USA","USA",350,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","10/12/2022",2022-12-10
"2933",350,"Fu","Retrospective cohort","22Sep2023","mRNA-1273 (Moderna)","included","2","final","1st month","infection","infection","USA",">=18 years","general pop",64.7,"63.3",66,NA,"pre-delta & delta & omicron BA.1, BA.2",NA,NA,NA,2991,"USA","USA",350,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","10/12/2022",2022-12-10
"2934",350,"Fu","Retrospective cohort","22Sep2023","mRNA-1273 (Moderna)","included","2","final","6th month","infection","infection","USA",">=18 years","general pop",-62.6,"-67.2",-58.1,NA,"pre-delta & delta & omicron BA.1, BA.2","~50 weeks",NA,NA,2992,"USA","USA",350,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","10/12/2022",2022-12-10
"2935",350,"Fu","Retrospective cohort","22Sep2023","mRNA (heterologous)","included","2","final","1st month","infection","infection","USA",">=18 years","general pop",-35.5,"-48.6",-23.6,NA,"pre-delta & delta & omicron BA.1, BA.2",NA,NA,NA,2993,"USA","USA",350,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","10/12/2022",2022-12-10
"2936",350,"Fu","Retrospective cohort","22Sep2023","mRNA (heterologous)","included","2","final","6th month","infection","infection","USA",">=18 years","general pop",-4.2,"-27.4",14.8,NA,"pre-delta & delta & omicron BA.1, BA.2","~34 weeks",NA,NA,2994,"USA","USA",350,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","10/12/2022",2022-12-10
"2937",350,"Fu","Retrospective cohort","22Sep2023","Ad26.COV2.S (Janssen)","included","1","final","1st month","infection","infection","USA",">=18 years","general pop",30.8,"23.5",37.4,NA,"pre-delta & delta & omicron BA.1, BA.2",NA,NA,NA,2995,"USA","USA",350,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","10/12/2022",2022-12-10
"2938",350,"Fu","Retrospective cohort","22Sep2023","Ad26.COV2.S (Janssen)","included","1","final","6th month","infection","infection","USA",">=18 years","general pop",-1.2,"-13.2",9.5,NA,"pre-delta & delta & omicron BA.1, BA.2","~50 weeks",NA,NA,2996,"USA","USA",350,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-22,"infection","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","10/12/2022",2022-12-10
"2939",351,"Cegolon","Retrospective cohort","30Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","infection","infection","Italy","HCW","HCW",41,"-49",77,NA,"omicron BA.1, BA.2, BA.4/BA.5","~69 weeks",NA,NA,2997,"Italy","ITA",351,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-11-30
"2940",351,"Cegolon","Retrospective cohort","30Nov2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected only","2","final","7+","infection","infection","Italy","HCW","HCW",-4,"-43",24,NA,"omicron BA.1, BA.2, BA.4/BA.5","~69 weeks",NA,NA,2998,"Italy","ITA",351,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-30,"infection","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-11-30
"2941",352,"Khanam","Test-negative case-control","02Dec2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","symptomatic disease","symptomatic","Bangladesh",">=18 years","general pop",-45,"-119",4,NA,"delta","~36 weeks",NA,NA,2999,"Bangladesh","BGD",352,"BGD",2220,2019,"Bangladesh","South Asia","Lower middle income",2,"Asia",2021-02-07,2022-02-18,2022-07-16,2021-01-27,2021-01-27,11,387,535,"who","jan/2021","Dec/2021 +","360+","yes","no","no",2022-12-02,"symptomatic","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-12-02
"2942",352,"Khanam","Test-negative case-control","02Dec2022","AZD1222 (AstraZeneca)","excluded","2","final","<19 weeks","symptomatic disease","symptomatic","Bangladesh",">=18 years","general pop",3,"-129",59,NA,"delta","~36 weeks",NA,NA,3000,"Bangladesh","BGD",352,"BGD",2220,2019,"Bangladesh","South Asia","Lower middle income",2,"Asia",2021-02-07,2022-02-18,2022-07-16,2021-01-27,2021-01-27,11,387,535,"who","jan/2021","Dec/2021 +","360+","yes","no","no",2022-12-02,"symptomatic","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-12-02
"2943",352,"Khanam","Test-negative case-control","02Dec2022","AZD1222 (AstraZeneca)","excluded","2","final",">19 weeks","symptomatic disease","symptomatic","Bangladesh",">=18 years","general pop",-35,"-112",14,NA,"delta","~36 weeks",NA,NA,3001,"Bangladesh","BGD",352,"BGD",2220,2019,"Bangladesh","South Asia","Lower middle income",2,"Asia",2021-02-07,2022-02-18,2022-07-16,2021-01-27,2021-01-27,11,387,535,"who","jan/2021","Dec/2021 +","360+","yes","no","no",2022-12-02,"symptomatic","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-12-02
"2944",352,"Khanam","Test-negative case-control","02Dec2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","death","death","Bangladesh",">=18 years","general pop",86,"-23",98,NA,"delta","~36 weeks",NA,NA,3002,"Bangladesh","BGD",352,"BGD",2220,2019,"Bangladesh","South Asia","Lower middle income",2,"Asia",2021-02-07,2022-02-18,2022-07-16,2021-01-27,2021-01-27,11,387,535,"who","jan/2021","Dec/2021 +","360+","yes","no","no",2022-12-02,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2022-12-02
"2945",352,"Khanam","Test-negative case-control","02Dec2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","14+","symptomatic disease","symptomatic","Bangladesh",">=18 years","general pop",29,"-22",58,NA,"delta","~36 weeks",NA,NA,3003,"Bangladesh","BGD",352,"BGD",2220,2019,"Bangladesh","South Asia","Lower middle income",2,"Asia",2021-02-07,2022-02-18,2022-07-16,2021-01-27,2021-01-27,11,387,535,"who","jan/2021","Dec/2021 +","360+","yes","no","no",2022-12-02,"symptomatic","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-12-02
"2946",352,"Khanam","Test-negative case-control","02Dec2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","<19 weeks","symptomatic disease","symptomatic","Bangladesh",">=18 years","general pop",34,"-16",62,NA,"delta","~36 weeks",NA,NA,3004,"Bangladesh","BGD",352,"BGD",2220,2019,"Bangladesh","South Asia","Lower middle income",2,"Asia",2021-02-07,2022-02-18,2022-07-16,2021-01-27,2021-01-27,11,387,535,"who","jan/2021","Dec/2021 +","360+","yes","no","no",2022-12-02,"symptomatic","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-12-02
"2947",352,"Khanam","Test-negative case-control","02Dec2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final",">19 weeks","symptomatic disease","symptomatic","Bangladesh",">=18 years","general pop",-36,"-886",81,NA,"delta","~36 weeks",NA,NA,3005,"Bangladesh","BGD",352,"BGD",2220,2019,"Bangladesh","South Asia","Lower middle income",2,"Asia",2021-02-07,2022-02-18,2022-07-16,2021-01-27,2021-01-27,11,387,535,"who","jan/2021","Dec/2021 +","360+","yes","no","no",2022-12-02,"symptomatic","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-12-02
"2948",352,"Khanam","Test-negative case-control","02Dec2022","BBIBP-CorV (Beijing CNBG)","excluded","2","final","14+","death","death","Bangladesh",">=18 years","general pop",75,"-124",97,NA,"delta","~36 weeks",NA,NA,3006,"Bangladesh","BGD",352,"BGD",2220,2019,"Bangladesh","South Asia","Lower middle income",2,"Asia",2021-02-07,2022-02-18,2022-07-16,2021-01-27,2021-01-27,11,387,535,"who","jan/2021","Dec/2021 +","360+","yes","no","no",2022-12-02,"death","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2022-12-02
"2949",352,"Khanam","Test-negative case-control","02Dec2022","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","Bangladesh",">=18 years","general pop",64,"10",86,NA,"delta","~36 weeks",NA,NA,3007,"Bangladesh","BGD",352,"BGD",2220,2019,"Bangladesh","South Asia","Lower middle income",2,"Asia",2021-02-07,2022-02-18,2022-07-16,2021-01-27,2021-01-27,11,387,535,"who","jan/2021","Dec/2021 +","360+","yes","no","no",2022-12-02,"symptomatic","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2022-12-02
"2950",353,"Nittayasoot","Test-negative case-control","12Dec2022","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","pneumonia requiring invasive ventilation","severe","Thailand",">=18 years","general pop",65.8,"39.4",80.7,NA,"delta & omicron BA.1, BA.2","~54 weeks",NA,NA,3008,"Thailand","THA",353,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-12-12,"severe","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta/omicron",NA,2022-12-12
"2951",353,"Nittayasoot","Test-negative case-control","12Dec2022","AZD1222 (AstraZeneca)","included","2","final","14+","pneumonia requiring invasive ventilation","severe","Thailand",">=18 years","general pop",58.4,"39.9",71.2,NA,"delta & omicron BA.1, BA.3","~54 weeks",NA,NA,3009,"Thailand","THA",353,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-12-12,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta/omicron",NA,2022-12-12
"2952",353,"Nittayasoot","Test-negative case-control","12Dec2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","pneumonia requiring invasive ventilation","severe","Thailand",">=18 years","general pop",71.7,"49.7",84.1,NA,"delta & omicron BA.1, BA.4","~54 weeks",NA,NA,3010,"Thailand","THA",353,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-12-12,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2022-12-12
"2953",353,"Nittayasoot","Test-negative case-control","12Dec2022","CoronaVac (Sinovac) & AZD1222 (AstraZeneca) - heterologous","included","2","final","14+","pneumonia requiring invasive ventilation","severe","Thailand",">=18 years","general pop",71.7,"63.2",78.2,NA,"delta & omicron BA.1, BA.5","~54 weeks",NA,NA,3011,"Thailand","THA",353,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-12-12,"severe","2022 (Jul-Dec)","Heterologous platforms","Multiple","delta/omicron",NA,2022-12-12
"2954",353,"Nittayasoot","Test-negative case-control","12Dec2022","CoronaVac (Sinovac) & BNT162b2 (Pfizer BioNTech) - heterologous","included","2","final","14+","pneumonia requiring invasive ventilation","severe","Thailand",">=18 years","general pop",79.7,"7.3",95.6,NA,"delta & omicron BA.1, BA.6","~54 weeks",NA,NA,3012,"Thailand","THA",353,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-12-12,"severe","2022 (Jul-Dec)","Heterologous platforms","Multiple","delta/omicron",NA,2022-12-12
"2955",353,"Nittayasoot","Test-negative case-control","12Dec2022","AZD1222 (AstraZeneca) & BNT162b2 (Pfizer BioNTech) - heterologous","included","2","final","14+","pneumonia requiring invasive ventilation","severe","Thailand",">=18 years","general pop",83.1,"62.3",92.4,NA,"delta & omicron BA.1, BA.7","~54 weeks",NA,NA,3013,"Thailand","THA",353,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-12-12,"severe","2022 (Jul-Dec)","Heterologous platforms","Multiple","delta/omicron",NA,2022-12-12
"2956",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","hospitalization","severe","Canada",">=60 years",">=60 years",78,"75",80,NA,"omicron BA.1","~60 weeks",NA,NA,3014,"Canada","CAN",354,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2957",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-90","hospitalization","severe","Canada",">=60 years",">=60 years",86,"78",91,NA,"omicron BA.1","~60 weeks",NA,NA,3015,"Canada","CAN",354,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2958",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","270-359","hospitalization","severe","Canada",">=60 years",">=60 years",68,"37",84,NA,"omicron BA.1","~60 weeks",NA,NA,3016,"Canada","CAN",354,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2959",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","hospitalization","severe","Canada",">=60 years",">=60 years",60,"50",67,NA,"omicron BA.2","~73 weeks",NA,NA,3017,"Canada","CAN",354,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2960",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-90","hospitalization","severe","Canada",">=60 years",">=60 years",66,"28",84,NA,"omicron BA.2","~73 weeks",NA,NA,3018,"Canada","CAN",354,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2961",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","360-449","hospitalization","severe","Canada",">=60 years",">=60 years",73,"-13",94,NA,"omicron BA.2","~73 weeks",NA,NA,3019,"Canada","CAN",354,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2962",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7+","hospitalization","severe","Canada",">=60 years",">=60 years",40,"30",49,NA,"omicron BA.4/BA.5","~94 weeks",NA,NA,3020,"Canada","CAN",354,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2963",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","7-90","hospitalization","severe","Canada",">=60 years",">=60 years",55,"-95",89,NA,"omicron BA.4/BA.5","~94 weeks",NA,NA,3021,"Canada","CAN",354,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2964",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","360-449","hospitalization","severe","Canada",">=60 years",">=60 years",47,"35",57,NA,"omicron BA.4/BA.5","~94 weeks",NA,NA,3022,"Canada","CAN",354,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2965",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","pre-Omicron prior infection","2","final","7+","hospitalization","severe","Canada",">=60 years",">=60 years",97,"96",99,NA,"omicron BA.1","~60 weeks",NA,NA,3023,"Canada","CAN",354,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2966",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","pre-Omicron prior infection","2","final","7+","hospitalization","severe","Canada",">=60 years",">=60 years",92,"86",96,NA,"omicron BA.2","~73 weeks",NA,NA,3024,"Canada","CAN",354,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2967",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","Omicron prior infection","2","final","7+","hospitalization","severe","Canada",">=60 years",">=60 years",99,"94",100,NA,"omicron BA.2","~73 weeks",NA,NA,3025,"Canada","CAN",354,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2968",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","pre-Omicron prior infection","2","final","7+","hospitalization","severe","Canada",">=60 years",">=60 years",92,"80",97,NA,"omicron BA.4/BA.5","~94 weeks",NA,NA,3026,"Canada","CAN",354,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2969",354,"Carazo","Test-negative case-control","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","Omicron prior infection","2","final","7+","hospitalization","severe","Canada",">=60 years",">=60 years",91,"85",95,NA,"omicron BA.4/BA.5","~94 weeks",NA,NA,3027,"Canada","CAN",354,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","27/12/2022",2022-12-27
"2970",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-48","infection","infection","UK","18-39 years","18-39 years",75,"74",76,NA,"alpha, delta, & omicron","~45 weeks",NA,NA,3028,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2971",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","245-272","infection","infection","UK","18-39 years","18-39 years",-83,"-294",15,NA,"alpha, delta, & omicron","~45 weeks",NA,NA,3029,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2972",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-48","hospitalization","severe","UK","18-39 years","18-39 years",96,"93",97,NA,"alpha, delta, & omicron","~45 weeks",NA,NA,3030,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2973",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","245-272","hospitalization","severe","UK","18-39 years","18-39 years",-48,"-217",31,NA,"alpha, delta, & omicron","~45 weeks",NA,NA,3031,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2974",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","21-48","infection","infection","UK","40-64 years","40-64 years",22,"19",25,NA,"alpha, delta, & omicron","~36 weeks",NA,NA,3032,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2975",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","301-328","infection","infection","UK","40-64 years","40-64 years",41,"-47",77,NA,"alpha, delta, & omicron","~36 weeks",NA,NA,3033,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2976",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","21-48","hospitalization","severe","UK","40-64 years","40-64 years",95,"93",96,NA,"alpha, delta, & omicron","~36 weeks",NA,NA,3034,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2977",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","301-328","hospitalization","severe","UK","40-64 years","40-64 years",44,"-41",78,NA,"alpha, delta, & omicron","~36 weeks",NA,NA,3035,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2978",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","77-104","death","death","UK","40-64 years","40-64 years",99,"96",100,NA,"alpha, delta, & omicron","~36 weeks",NA,NA,3036,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"death","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2979",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","217-244","death","death","UK","40-64 years","40-64 years",74,"36",89,NA,"alpha, delta, & omicron","~36 weeks",NA,NA,3037,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"death","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2980",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-48","infection","infection","UK","18-64 years clinically vulnerable","18-64 years clinically vulnerable",78,"73",82,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,3038,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2981",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","329-356","infection","infection","UK","18-64 years clinically vulnerable","18-64 years clinically vulnerable",28,"-41",63,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,3039,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2982",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-48","hospitalization","severe","UK","18-64 years clinically vulnerable","18-64 years clinically vulnerable",97,"92",99,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,3040,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2983",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","329-356","hospitalization","severe","UK","18-64 years clinically vulnerable","18-64 years clinically vulnerable",28,"-38",62,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,3041,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2984",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","105-132","death","death","UK","18-64 years clinically vulnerable","18-64 years clinically vulnerable",96,"92",98,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,3042,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"death","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2985",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","245-272","death","death","UK","18-64 years clinically vulnerable","18-64 years clinically vulnerable",37,"-36",70,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,3043,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"death","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2986",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","21-48","infection","infection","UK","18-64 years clinically vulnerable","18-64 years clinically vulnerable",26,"20",33,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,3044,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2987",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","329-356","infection","infection","UK","18-64 years clinically vulnerable","18-64 years clinically vulnerable",14,"-42",48,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,3045,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2988",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","21-48","hospitalization","severe","UK","18-64 years clinically vulnerable","18-64 years clinically vulnerable",93,"89",96,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,3046,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2989",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","329-356","hospitalization","severe","UK","18-64 years clinically vulnerable","18-64 years clinically vulnerable",21,"-30",52,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,3047,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2990",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","49-76","death","death","UK","18-64 years clinically vulnerable","18-64 years clinically vulnerable",96,"87",99,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,3048,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"death","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2991",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","301-328","death","death","UK","18-64 years clinically vulnerable","18-64 years clinically vulnerable",50,"-125",89,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,3049,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"death","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2992",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-48","infection","infection","UK",">=65 years",">=65 years",77,"67",84,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,3050,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2993",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","329-356","infection","infection","UK",">=65 years",">=65 years",4,"-30",29,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,3051,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2994",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-48","hospitalization","severe","UK",">=65 years",">=65 years",92,"86",95,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,3052,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2995",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","329-356","hospitalization","severe","UK",">=65 years",">=65 years",2,"-34",27,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,3053,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2996",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","21-48","death","death","UK",">=65 years",">=65 years",97,"92",99,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,3054,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"death","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2997",356,"Horne","Retrospective cohort","05Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","329-356","death","death","UK",">=65 years",">=65 years",33,"-49",70,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,3055,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"death","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-05
"2998",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","21-48","infection","infection","UK",">=65 years",">=65 years",47,"29",61,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,3056,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"2999",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","329-356","infection","infection","UK",">=65 years",">=65 years",-12,"-54",18,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,3057,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"3000",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","21-48","hospitalization","severe","UK",">=65 years",">=65 years",86,"75",92,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,3058,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"3001",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","329-356","hospitalization","severe","UK",">=65 years",">=65 years",-12,"-53",18,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,3059,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"3002",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","49-76","death","death","UK",">=65 years",">=65 years",93,"84",97,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,3060,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"death","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"3003",356,"Horne","Retrospective cohort","05Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","329-356","death","death","UK",">=65 years",">=65 years",23,"-82",68,NA,"alpha, delta, & omicron","~48 weeks",NA,NA,3061,"UK","GBR",356,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-05,"death","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-01-05
"3004",357,"Lewis","Test-negative case-control","31Dec2022","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization","severe","USA",">=18 years","general pop",46,"30",58,NA,"omicron BA.1/BA.2","~63 weeks",NA,NA,3062,"USA","USA",357,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-12-31,"severe","2022 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2022-12-31
"3005",357,"Lewis","Test-negative case-control","31Dec2022","Ad26.COV2.S (Janssen)","included","1","final","60+","hospitalization","severe","USA",">=18 years","general pop",36,"-4",60,NA,"omicron BA.1/BA.2","~55 weeks",NA,NA,3063,"USA","USA",357,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-12-31,"severe","2022 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2022-12-31
"3006",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 1",">=18 years, Social Vulnerability Index Quartile 1",47,"40",53,NA,"omicron BA.1","~62 weeks",NA,NA,3064,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3007",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 1",">=18 years, Social Vulnerability Index Quartile 1",35,"31",40,NA,"omicron BA.1","~62 weeks",NA,NA,3065,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3008",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 1",">=18 years, Social Vulnerability Index Quartile 1",59,"39",72,NA,"omicron BA.1","~62 weeks",NA,NA,3066,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3009",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 1",">=18 years, Social Vulnerability Index Quartile 1",58,"51",65,NA,"omicron BA.1","~62 weeks",NA,NA,3067,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3010",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 2",">=18 years, Social Vulnerability Index Quartile 2",42,"33",49,NA,"omicron BA.1","~62 weeks",NA,NA,3068,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3011",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 2",">=18 years, Social Vulnerability Index Quartile 2",37,"32",41,NA,"omicron BA.1","~62 weeks",NA,NA,3069,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3012",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 2",">=18 years, Social Vulnerability Index Quartile 2",65,"48",76,NA,"omicron BA.1","~62 weeks",NA,NA,3070,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3013",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 2",">=18 years, Social Vulnerability Index Quartile 2",57,"49",64,NA,"omicron BA.1","~62 weeks",NA,NA,3071,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3014",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 3",">=18 years, Social Vulnerability Index Quartile 3",54,"47",61,NA,"omicron BA.1","~62 weeks",NA,NA,3072,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3015",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 3",">=18 years, Social Vulnerability Index Quartile 3",31,"25",36,NA,"omicron BA.1","~62 weeks",NA,NA,3073,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3016",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 3",">=18 years, Social Vulnerability Index Quartile 3",62,"45",74,NA,"omicron BA.1","~62 weeks",NA,NA,3074,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3017",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 3",">=18 years, Social Vulnerability Index Quartile 3",55,"47",63,NA,"omicron BA.1","~62 weeks",NA,NA,3075,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3018",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 4",">=18 years, Social Vulnerability Index Quartile 4",51,"43",58,NA,"omicron BA.1","~62 weeks",NA,NA,3076,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3019",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 4",">=18 years, Social Vulnerability Index Quartile 4",27,"20",33,NA,"omicron BA.1","~62 weeks",NA,NA,3077,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3020",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 4",">=18 years, Social Vulnerability Index Quartile 4",63,"43",75,NA,"omicron BA.1","~62 weeks",NA,NA,3078,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3021",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 4",">=18 years, Social Vulnerability Index Quartile 4",43,"32",52,NA,"omicron BA.1","~62 weeks",NA,NA,3079,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-06
"3022",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 1",">=18 years, Social Vulnerability Index Quartile 1",87,"84",89,NA,"delta","~48.5 weeks",NA,NA,3080,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3023",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 1",">=18 years, Social Vulnerability Index Quartile 1",81,"79",82,NA,"delta","~48.5 weeks",NA,NA,3081,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3024",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 1",">=18 years, Social Vulnerability Index Quartile 1",90,"84",94,NA,"delta","~48.5 weeks",NA,NA,3082,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3025",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 1",">=18 years, Social Vulnerability Index Quartile 1",85,"82",87,NA,"delta","~48.5 weeks",NA,NA,3083,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3026",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 2",">=18 years, Social Vulnerability Index Quartile 2",85,"81",88,NA,"delta","~48.5 weeks",NA,NA,3084,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3027",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 2",">=18 years, Social Vulnerability Index Quartile 2",80,"77",81,NA,"delta","~48.5 weeks",NA,NA,3085,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3028",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 2",">=18 years, Social Vulnerability Index Quartile 2",91,"85",95,NA,"delta","~48.5 weeks",NA,NA,3086,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3029",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 2",">=18 years, Social Vulnerability Index Quartile 2",86,"83",88,NA,"delta","~48.5 weeks",NA,NA,3087,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3030",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 3",">=18 years, Social Vulnerability Index Quartile 3",89,"85",91,NA,"delta","~48.5 weeks",NA,NA,3088,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3031",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 3",">=18 years, Social Vulnerability Index Quartile 3",74,"71",77,NA,"delta","~48.5 weeks",NA,NA,3089,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3032",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 3",">=18 years, Social Vulnerability Index Quartile 3",94,"88",97,NA,"delta","~48.5 weeks",NA,NA,3090,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3033",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 3",">=18 years, Social Vulnerability Index Quartile 3",82,"78",85,NA,"delta","~48.5 weeks",NA,NA,3091,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3034",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 4",">=18 years, Social Vulnerability Index Quartile 4",84,"79",87,NA,"delta","~48.5 weeks",NA,NA,3092,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3035",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","ED or UC visit","symptomatic","USA",">=18 years, Social Vulnerability Index Quartile 4",">=18 years, Social Vulnerability Index Quartile 4",75,"72",78,NA,"delta","~48.5 weeks",NA,NA,3093,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3036",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 4",">=18 years, Social Vulnerability Index Quartile 4",90,"83",94,NA,"delta","~48.5 weeks",NA,NA,3094,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3037",358,"Dalton","Test-negative case-control","06Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization","severe","USA",">=18 years, Social Vulnerability Index Quartile 4",">=18 years, Social Vulnerability Index Quartile 4",84,"80",87,NA,"delta","~48.5 weeks",NA,NA,3095,"USA","USA",358,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-06
"3038",359,"Jang","Retrospective cohort","09Jan2023","BNT162b2 (Pfizer BioNTech)","unknown","2","final","15-30","infection","infection","South Korea","5-11 years","5-11 years",57.6,"51.6",62.8,NA,"omicron","~11 weeks",NA,NA,3096,"South Korea","KOR",359,"KOR",33830,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,201,241,"equal","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-09,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-01-09
"3039",359,"Jang","Retrospective cohort","09Jan2023","BNT162b2 (Pfizer BioNTech)","unknown","2","final","31-60","infection","infection","South Korea","5-11 years","5-11 years",46.9,"43.7",49.9,NA,"omicron","~11 weeks",NA,NA,3097,"South Korea","KOR",359,"KOR",33830,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,201,241,"equal","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-09,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-01-09
"3040",359,"Jang","Retrospective cohort","09Jan2023","BNT162b2 (Pfizer BioNTech)","unknown","2","final","61-90","infection","infection","South Korea","5-11 years","5-11 years",41.2,"34.3",47.4,NA,"omicron","~11 weeks",NA,NA,3098,"South Korea","KOR",359,"KOR",33830,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,201,241,"equal","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-09,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-01-09
"3041",359,"Jang","Retrospective cohort","09Jan2023","BNT162b2 (Pfizer BioNTech)","unknown","2","final","15-30","ICU admission or death","severe","South Korea","5-11 years","5-11 years",100,"100",100,NA,"omicron","~11 weeks",NA,NA,3099,"South Korea","KOR",359,"KOR",33830,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,201,241,"equal","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-09,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-01-09
"3042",359,"Jang","Retrospective cohort","09Jan2023","BNT162b2 (Pfizer BioNTech)","unknown","2","final","31-60","ICU admission or death","severe","South Korea","5-11 years","5-11 years",100,"100",100,NA,"omicron","~11 weeks",NA,NA,3100,"South Korea","KOR",359,"KOR",33830,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,201,241,"equal","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-09,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-01-09
"3043",359,"Jang","Retrospective cohort","09Jan2023","BNT162b2 (Pfizer BioNTech)","unknown","2","final","61-90","ICU admission or death","severe","South Korea","5-11 years","5-11 years",100,"100",100,NA,"omicron","~11 weeks",NA,NA,3101,"South Korea","KOR",359,"KOR",33830,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,201,241,"equal","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-09,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-01-09
"3044",360,"Peebles","Retrospective cohort","10Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","USA","LTCF staff <65 years","LTCF staff <65 years",80,"67.6",87.7,NA,"non-VOC & alpha","~17 weeks",NA,NA,3102,"USA","USA",360,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-10,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-10
"3045",360,"Peebles","Retrospective cohort","10Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","USA","LTCF staff <65 years","LTCF staff <65 years",87.5,"69.4",94.9,NA,"non-VOC & alpha","~17 weeks",NA,NA,3103,"USA","USA",360,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-10,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-10
"3046",360,"Peebles","Retrospective cohort","10Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","asymptomatic infection","asymptomatic","USA","LTCF staff <65 years","LTCF staff <65 years",68.9,"36",84.9,NA,"non-VOC & alpha","~17 weeks",NA,NA,3104,"USA","USA",360,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-10,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-01-10
"3047",361,"Tartof","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","USA",">=18 years","general pop",-53,"-205",23,NA,"omicron","~64.5 weeks",NA,NA,3105,"USA","USA",361,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-11,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-11
"3048",361,"Tartof","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","prior infection only","2","final","14+","symptomatic disease","symptomatic","USA",">=18 years","general pop",45,"-4",70,NA,"omicron","~64.5 weeks",NA,NA,3106,"USA","USA",361,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-11,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-11
"3049",361,"Tartof","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","USA",">=18 years","general pop",70,"11",90,NA,"delta","~46.5 weeks",NA,NA,3107,"USA","USA",361,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-11,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-11
"3050",361,"Tartof","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","prior infection only","2","final","14+","symptomatic disease","symptomatic","USA",">=18 years","general pop",23,"-225",82,NA,"delta","~46.5 weeks",NA,NA,3108,"USA","USA",361,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-11,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-01-11
"3051",361,"Tartof","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","USA",">=18 years","general pop",17,"-40",51,NA,"omicron or delta","~64.5 weeks",NA,NA,3109,"USA","USA",361,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-11,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta/omicron",NA,2023-01-11
"3052",361,"Tartof","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","prior infection only","2","final","14+","symptomatic disease","symptomatic","USA",">=18 years","general pop",42,"-1",66,NA,"omicron or delta","~64.5 weeks",NA,NA,3110,"USA","USA",361,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-11,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta/omicron",NA,2023-01-11
"3053",363,"Alkadi","Test-negative case-control","26Dec2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","infection","infection","Qatar",">=18 years on chronic hemodialysis",">=18 years on chronic hemodialysis",94.3,"89",97,NA,"non-VOC, alpha, & delta","~48 weeks",NA,NA,3114,"Qatar","QAT",363,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-12-26,"infection","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-12-26
"3054",363,"Alkadi","Test-negative case-control","26Dec2022","mRNA-1273 (Moderna)","unknown","2","final","14+","infection","infection","Qatar",">=18 years on chronic hemodialysis",">=18 years on chronic hemodialysis",98.2,"88.6",99.9,NA,"non-VOC, alpha, & delta","~40 weeks",NA,NA,3115,"Qatar","QAT",363,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2022-12-26,"infection","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-12-26
"3055",364,"Heidarzadeh","Test-negative case-control","23Dec2022","AZD1222 (AstraZeneca)","included","2","final","31-60","hospitalization (moderate)","severe","Iran",">=5 years","general pop",97,"75",99.5,NA,"alpha & delta","~23 weeks",NA,NA,3116,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-12-23
"3056",364,"Heidarzadeh","Test-negative case-control","23Dec2022","AZD1222 (AstraZeneca)","included","2","final","91-120","hospitalization (moderate)","severe","Iran",">=5 years","general pop",93,"69",99,NA,"alpha & delta","~23 weeks",NA,NA,3117,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-12-23
"3057",364,"Heidarzadeh","Test-negative case-control","23Dec2022","AZD1222 (AstraZeneca)","included","2","final","31-60","hospitalization (severe)","severe","Iran",">=5 years","general pop",87,"80",92,NA,"alpha & delta","~23 weeks",NA,NA,3118,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-12-23
"3058",364,"Heidarzadeh","Test-negative case-control","23Dec2022","AZD1222 (AstraZeneca)","included","2","final","151+","hospitalization (severe)","severe","Iran",">=5 years","general pop",90,"51",98,NA,"alpha & delta","~23 weeks",NA,NA,3119,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-12-23
"3059",364,"Heidarzadeh","Test-negative case-control","23Dec2022","AZD1222 (AstraZeneca)","included","2","final","31-60","ICU admission","severe","Iran",">=5 years","general pop",57,"-41",87,NA,"alpha & delta","~23 weeks",NA,NA,3120,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-12-23
"3060",364,"Heidarzadeh","Test-negative case-control","23Dec2022","AZD1222 (AstraZeneca)","included","2","final","91-120","ICU admission","severe","Iran",">=5 years","general pop",12,"-113",63,NA,"alpha & delta","~23 weeks",NA,NA,3121,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-12-23
"3061",364,"Heidarzadeh","Test-negative case-control","23Dec2022","AZD1222 (AstraZeneca)","included","2","final","31-60","death","death","Iran",">=5 years","general pop",80,"48",92,NA,"alpha & delta","~23 weeks",NA,NA,3122,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-12-23
"3062",364,"Heidarzadeh","Test-negative case-control","23Dec2022","AZD1222 (AstraZeneca)","included","2","final","121-150","death","death","Iran",">=5 years","general pop",92,"48",99,NA,"alpha & delta","~23 weeks",NA,NA,3123,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"death","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-12-23
"3063",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BBIBP-CorV (Beijing CNBG)","included","2","final","31-60","hospitalization (moderate)","severe","Iran",">=5 years","general pop",78,"69",84,NA,"alpha & delta","~36 weeks",NA,NA,3124,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2022-12-23
"3064",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BBIBP-CorV (Beijing CNBG)","included","2","final","151+","hospitalization (moderate)","severe","Iran",">=5 years","general pop",95,"67",99.4,NA,"alpha & delta","~36 weeks",NA,NA,3125,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2022-12-23
"3065",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BBIBP-CorV (Beijing CNBG)","included","2","final","31-60","hospitalization (severe)","severe","Iran",">=5 years","general pop",71,"68",75,NA,"alpha & delta","~36 weeks",NA,NA,3126,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2022-12-23
"3066",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BBIBP-CorV (Beijing CNBG)","included","2","final","151+","hospitalization (severe)","severe","Iran",">=5 years","general pop",85,"77",91,NA,"alpha & delta","~36 weeks",NA,NA,3127,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2022-12-23
"3067",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BBIBP-CorV (Beijing CNBG)","included","2","final","31-60","ICU admission","severe","Iran",">=5 years","general pop",25,"-9",48,NA,"alpha & delta","~36 weeks",NA,NA,3128,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2022-12-23
"3068",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BBIBP-CorV (Beijing CNBG)","included","2","final","151+","ICU admission","severe","Iran",">=5 years","general pop",26,"-77",69,NA,"alpha & delta","~36 weeks",NA,NA,3129,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2022-12-23
"3069",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BBIBP-CorV (Beijing CNBG)","included","2","final","31-60","death","death","Iran",">=5 years","general pop",41,"23",55,NA,"alpha & delta","~36 weeks",NA,NA,3130,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"death","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2022-12-23
"3070",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BBIBP-CorV (Beijing CNBG)","included","2","final","151+","death","death","Iran",">=5 years","general pop",33,"-40",69,NA,"alpha & delta","~36 weeks",NA,NA,3131,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"death","2022 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2022-12-23
"3071",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BIV1-CovIran","included","2","final","31-60","hospitalization (moderate)","severe","Iran",">=5 years","general pop",96,"68",99.4,NA,"alpha & delta","~21 weeks",NA,NA,3132,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Shifa Pharmed COVIran","Inactivated","other combinations",NA,2022-12-23
"3072",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BIV1-CovIran","included","2","final","61-90","hospitalization (moderate)","severe","Iran",">=5 years","general pop",97,"76",99.6,NA,"alpha & delta","~21 weeks",NA,NA,3133,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Shifa Pharmed COVIran","Inactivated","other combinations",NA,2022-12-23
"3073",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BIV1-CovIran","included","2","final","31-60","hospitalization (severe)","severe","Iran",">=5 years","general pop",82,"73",88,NA,"alpha & delta","~21 weeks",NA,NA,3134,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Shifa Pharmed COVIran","Inactivated","other combinations",NA,2022-12-23
"3074",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BIV1-CovIran","included","2","final","91-120","hospitalization (severe)","severe","Iran",">=5 years","general pop",92,"86",96,NA,"alpha & delta","~21 weeks",NA,NA,3135,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Shifa Pharmed COVIran","Inactivated","other combinations",NA,2022-12-23
"3075",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BIV1-CovIran","included","2","final","31-60","ICU admission","severe","Iran",">=5 years","general pop",61,"-61",91,NA,"alpha & delta","~21 weeks",NA,NA,3136,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Shifa Pharmed COVIran","Inactivated","other combinations",NA,2022-12-23
"3076",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BIV1-CovIran","included","2","final","91-120","ICU admission","severe","Iran",">=5 years","general pop",35,"-116",80,NA,"alpha & delta","~21 weeks",NA,NA,3137,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Shifa Pharmed COVIran","Inactivated","other combinations",NA,2022-12-23
"3077",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BIV1-CovIran","included","2","final","31-60","death","death","Iran",">=5 years","general pop",88,"48",97,NA,"alpha & delta","~21 weeks",NA,NA,3138,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"death","2022 (Jul-Dec)","Shifa Pharmed COVIran","Inactivated","other combinations",NA,2022-12-23
"3078",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BIV1-CovIran","included","2","final","91-120","death","death","Iran",">=5 years","general pop",93,"46",99,NA,"alpha & delta","~21 weeks",NA,NA,3139,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"death","2022 (Jul-Dec)","Shifa Pharmed COVIran","Inactivated","other combinations",NA,2022-12-23
"3079",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BBV152 (Bharat)","included","2","final","61-90","hospitalization (severe)","severe","Iran",">=5 years","general pop",55,"-33",85,NA,"alpha & delta","~35 weeks",NA,NA,3140,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Bharat Covaxin/BBV152","Inactivated","other combinations",NA,2022-12-23
"3080",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BBV152 (Bharat)","included","2","final","151+","hospitalization (severe)","severe","Iran",">=5 years","general pop",96,"68",99.5,NA,"alpha & delta","~35 weeks",NA,NA,3141,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Bharat Covaxin/BBV152","Inactivated","other combinations",NA,2022-12-23
"3081",364,"Heidarzadeh","Test-negative case-control","23Dec2022","BBV152 (Bharat)","included","2","final","91-120","death","death","Iran",">=5 years","general pop",4,"-671",79,NA,"alpha & delta","~35 weeks",NA,NA,3142,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"death","2022 (Jul-Dec)","Bharat Covaxin/BBV152","Inactivated","other combinations",NA,2022-12-23
"3082",364,"Heidarzadeh","Test-negative case-control","23Dec2022","Gam-COVID-Vac (Gamaleya)","included","2","final","31-60","hospitalization (moderate)","severe","Iran",">=5 years","general pop",74,"-9",94,NA,"alpha & delta","~40 weeks",NA,NA,3143,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-12-23
"3083",364,"Heidarzadeh","Test-negative case-control","23Dec2022","Gam-COVID-Vac (Gamaleya)","included","2","final","151+","hospitalization (moderate)","severe","Iran",">=5 years","general pop",95,"79",99,NA,"alpha & delta","~40 weeks",NA,NA,3144,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-12-23
"3084",364,"Heidarzadeh","Test-negative case-control","23Dec2022","Gam-COVID-Vac (Gamaleya)","included","2","final","31-60","hospitalization (severe)","severe","Iran",">=5 years","general pop",62,"32",78,NA,"alpha & delta","~40 weeks",NA,NA,3145,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-12-23
"3085",364,"Heidarzadeh","Test-negative case-control","23Dec2022","Gam-COVID-Vac (Gamaleya)","included","2","final","151+","hospitalization (severe)","severe","Iran",">=5 years","general pop",93,"88",96,NA,"alpha & delta","~40 weeks",NA,NA,3146,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-12-23
"3086",364,"Heidarzadeh","Test-negative case-control","23Dec2022","Gam-COVID-Vac (Gamaleya)","included","2","final","91-120","ICU admission","severe","Iran",">=5 years","general pop",51,"-258",94,NA,"alpha & delta","~40 weeks",NA,NA,3147,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-12-23
"3087",364,"Heidarzadeh","Test-negative case-control","23Dec2022","Gam-COVID-Vac (Gamaleya)","included","2","final","151+","ICU admission","severe","Iran",">=5 years","general pop",18,"-136",71,NA,"alpha & delta","~40 weeks",NA,NA,3148,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"severe","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-12-23
"3088",364,"Heidarzadeh","Test-negative case-control","23Dec2022","Gam-COVID-Vac (Gamaleya)","included","2","final","31-60","death","death","Iran",">=5 years","general pop",25,"-149",78,NA,"alpha & delta","~40 weeks",NA,NA,3149,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"death","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-12-23
"3089",364,"Heidarzadeh","Test-negative case-control","23Dec2022","Gam-COVID-Vac (Gamaleya)","included","2","final","151+","death","death","Iran",">=5 years","general pop",93,"47",99.1,NA,"alpha & delta","~40 weeks",NA,NA,3150,"Iran","IRN",364,"IRN",4530,2019,"Iran, Islamic Rep.","Middle East & North Africa","Lower middle income",2,"Asia",2021-02-17,2021-11-02,NA,2021-02-09,2021-02-09,8,266,NA,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2022-12-23,"death","2022 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations",NA,2022-12-23
"3090",365,"Lin","Retrospective cohort","16Jun2023","mRNA-1273 (Moderna)","included","2","final","0 to ~4 weeks","infection","infection","USA","0-4 years","0-4 years",58,"47.5",66.5,NA,"omicron (all lineages)","~23 weeks",NA,NA,3151,"USA","USA",365,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-06-16,"infection","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","19/01/2023",2023-01-19
"3091",365,"Lin","Retrospective cohort","16Jun2023","mRNA-1273 (Moderna)","included","2","final","~16-21 weeks","infection","infection","USA","0-4 years","0-4 years",47.6,"27.7",62,NA,"omicron (all lineages)","~23 weeks",NA,NA,3152,"USA","USA",365,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-06-16,"infection","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","19/01/2023",2023-01-19
"3092",365,"Lin","Retrospective cohort","16Jun2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0 to ~5 weeks","hospitalization or death","severe","USA","5-11 years","5-11 years",73.3,"8.3",92.3,NA,"omicron (all lineages)","~57 weeks",NA,NA,3153,"USA","USA",365,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-06-16,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","19/01/2023",2023-01-19
"3093",365,"Lin","Retrospective cohort","16Jun2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","~20-25 weeks","hospitalization or death","severe","USA","5-11 years","5-11 years",2.9,"-50.8",37.4,NA,"omicron (all lineages)","~57 weeks",NA,NA,3154,"USA","USA",365,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-06-16,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","19/01/2023",2023-01-19
"3094",365,"Lin","Retrospective cohort","16Jun2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","prior infection only","2","final","0 to ~5 weeks","infection","infection","USA","0-4 years","0-4 years",37.5,"21.2",50.4,NA,"omicron (all lineages)","~24 weeks",NA,NA,3155,"USA","USA",365,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-06-16,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","19/01/2023",2023-01-19
"3095",365,"Lin","Retrospective cohort","16Jun2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","prior infection only","2","final","~16-21 weeks","infection","infection","USA","0-4 years","0-4 years",46.8,"-0.3",71.8,NA,"omicron (all lineages)","~24 weeks",NA,NA,3156,"USA","USA",365,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-06-16,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","19/01/2023",2023-01-19
"3096",365,"Lin","Retrospective cohort","16Jun2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","prior infection only","2","final","0 to ~5 weeks","infection","infection","USA","5-11 years","5-11 years",65.3,"58.1",71.2,NA,"omicron (all lineages)","~57 weeks",NA,NA,3157,"USA","USA",365,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-06-16,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","19/01/2023",2023-01-19
"3097",365,"Lin","Retrospective cohort","16Jun2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","prior infection only","2","final","~24-29 weeks","infection","infection","USA","5-11 years","5-11 years",4.6,"-2.1",10.9,NA,"omicron (all lineages)","~57 weeks",NA,NA,3158,"USA","USA",365,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-06-16,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","19/01/2023",2023-01-19
"3098",365,"Lin","Retrospective cohort","16Jun2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","0 to ~5 weeks","infection","infection","USA","0-4 years","0-4 years",55.7,"49.1",61.5,NA,"omicron (all lineages)","~24 weeks",NA,NA,3159,"USA","USA",365,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-06-16,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","19/01/2023",2023-01-19
"3099",365,"Lin","Retrospective cohort","16Jun2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","~16-21 weeks","infection","infection","USA","0-4 years","0-4 years",58.6,"48.3",66.9,NA,"omicron (all lineages)","~24 weeks",NA,NA,3160,"USA","USA",365,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-06-16,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","19/01/2023",2023-01-19
"3100",365,"Lin","Retrospective cohort","16Jun2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","0 to ~5 weeks","infection","infection","USA","5-11 years","5-11 years",59.7,"58.3",61,NA,"omicron (all lineages)","~57 weeks",NA,NA,3161,"USA","USA",365,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-06-16,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","19/01/2023",2023-01-19
"3101",365,"Lin","Retrospective cohort","16Jun2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","~36-41 weeks","infection","infection","USA","5-11 years","5-11 years",16,"13.1",18.7,NA,"omicron (all lineages)","~57 weeks",NA,NA,3162,"USA","USA",365,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-06-16,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","19/01/2023",2023-01-19
"3102",366,"Battacharya","Test-negative case-control","06Jan2023","BBV152 (Bharat)","included","2","final","7+","hospitalization with symptoms of pulmonary disease","severe","India",">=18 years","general pop",74,"50.5",86,NA,"delta","~22 weeks",NA,NA,3163,"India","IND",366,"IND",2070,2019,"India","South Asia","Lower middle income",1,"Asia",2021-01-16,2021-12-24,NA,2021-01-16,2021-01-16,0,342,NA,"equal","jan/2021","Dec/2021 +","270-359","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Bharat Covaxin/BBV152","Inactivated","delta",NA,2023-01-06
"3103",366,"Battacharya","Test-negative case-control","06Jan2023","AZD1222 (Covishield)","included","2","final","7+","hospitalization with symptoms of pulmonary disease","severe","India",">=18 years","general pop",79,"53.1",81,NA,"delta","~22 weeks",NA,NA,3164,"India","IND",366,"IND",2070,2019,"India","South Asia","Lower middle income",1,"Asia",2021-01-16,2021-12-24,NA,2021-01-16,2021-01-16,0,342,NA,"equal","jan/2021","Dec/2021 +","270-359","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-01-06
"3104",367,"Ellingson","Prospective cohort","26Jan2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","prior infection only","2","final","14+","infection","infection","USA","frontline workers","general pop",43,"35",57,NA,"omicron","~63 weeks",NA,NA,3165,"USA","USA",367,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-26,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-01-26
"3105",368,"Niesen","Test-negative case-control","28Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-73","symptomatic disease","symptomatic","USA",">=18 years","general pop",80.6,"76.9",83.7,NA,"delta","~54 weeks",NA,NA,3166,"USA","USA",368,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-28,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-28
"3106",368,"Niesen","Test-negative case-control","28Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","314-355","symptomatic disease","symptomatic","USA",">=18 years","general pop",43.3,"28.8",54.7,NA,"delta","~54 weeks",NA,NA,3167,"USA","USA",368,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-28,"symptomatic","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2022-04-28
"3107",368,"Niesen","Test-negative case-control","28Apr2022","mRNA-1273 (Moderna)","excluded","2","final","7-13","symptomatic disease","symptomatic","USA",">=18 years","general pop",94.8,"88",97.8,NA,"delta","~54 weeks",NA,NA,3168,"USA","USA",368,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-28,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-04-28
"3108",368,"Niesen","Test-negative case-control","28Apr2022","mRNA-1273 (Moderna)","excluded","2","final","254-313","symptomatic disease","symptomatic","USA",">=18 years","general pop",63.2,"53.7",70.7,NA,"delta","~54 weeks",NA,NA,3169,"USA","USA",368,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-28,"symptomatic","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2022-04-28
"3109",369,"Toh","Test-negative case-control","27Jan2023","CoronaVac (Sinovac)","included","2","final","15+","hospitalization","severe","Malaysia",">=18 years","general pop",76.5,"45.6",89.8,NA,"non-VOC & delta","~24 weeks",NA,NA,3170,"Malaysia","MYS",369,"MYS",10750,2019,"Malaysia","East Asia & Pacific","Upper middle income",3,"Asia",2021-02-26,2021-08-24,2021-10-21,2021-02-24,2021-02-24,2,181,239,"who","feb/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-01-27,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations",NA,2023-01-27
"3110",370,"Tartof","Test-negative case-control","28Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-89","ED or UC visit","symptomatic","USA","5-11 years","5-11 years",60,"47",69,NA,"omicron BA.1, BA.2, BA.4/BA.5","~39 weeks",NA,NA,3171,"USA","USA",370,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-28,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-01-28
"3111",370,"Tartof","Test-negative case-control","28Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","90+","ED or UC visit","symptomatic","USA","5-11 years","5-11 years",28,"8",43,NA,"omicron BA.1, BA.2, BA.4/BA.5","~39 weeks",NA,NA,3172,"USA","USA",370,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-28,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-01-28
"3112",370,"Tartof","Test-negative case-control","28Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","90+","ED or UC visit","symptomatic","USA","5-11 years","5-11 years",85,"59",95,NA,"delta","~5 weeks",NA,NA,3173,"USA","USA",370,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-01-28,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-01-28
"3113",371,"Sritipsukho","Test-negative case-control","30Jan2023","CoronaVac (Sinovac)","excluded","2","final","14+","infection","infection","Thailand",">=18 years","general pop",26,"-9",50,NA,"omicron BA.1/BA.2","~67 weeks",NA,NA,3174,"Thailand","THA",371,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-30,"infection","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-01-30
"3114",371,"Sritipsukho","Test-negative case-control","30Jan2023","CoronaVac (Sinovac)","excluded","2","final","<90 days","infection","infection","Thailand",">=18 years","general pop",47,"7",70,NA,"omicron BA.1/BA.2","~67 weeks",NA,NA,3175,"Thailand","THA",371,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-30,"infection","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-01-30
"3115",371,"Sritipsukho","Test-negative case-control","30Jan2023","CoronaVac (Sinovac)","excluded","2","final",">90 days","infection","infection","Thailand",">=18 years","general pop",21,"-15",47,NA,"omicron BA.1/BA.2","~67 weeks",NA,NA,3176,"Thailand","THA",371,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-30,"infection","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-01-30
"3116",371,"Sritipsukho","Test-negative case-control","30Jan2023","CoronaVac (Sinovac)","excluded","2","final","14+","moderate to critical disease","symptomatic","Thailand",">=18 years","general pop",-4,"-50",45,NA,"omicron BA.1/BA.2","~67 weeks",NA,NA,3177,"Thailand","THA",371,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-30,"symptomatic","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-01-30
"3117",371,"Sritipsukho","Test-negative case-control","30Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection","infection","Thailand",">=18 years","general pop",38,"13",56,NA,"omicron BA.1/BA.2","~67 weeks",NA,NA,3178,"Thailand","THA",371,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-30,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2023-01-30
"3118",371,"Sritipsukho","Test-negative case-control","30Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","<90 days","infection","infection","Thailand",">=18 years","general pop",61,"41",74,NA,"omicron BA.1/BA.2","~67 weeks",NA,NA,3179,"Thailand","THA",371,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-30,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2023-01-30
"3119",371,"Sritipsukho","Test-negative case-control","30Jan2023","AZD1222 (AstraZeneca)","excluded","2","final",">90 days","infection","infection","Thailand",">=18 years","general pop",30,"0",51,NA,"omicron BA.1/BA.2","~67 weeks",NA,NA,3180,"Thailand","THA",371,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-30,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2023-01-30
"3120",371,"Sritipsukho","Test-negative case-control","30Jan2023","AZD1222 (AstraZeneca)","excluded","2","final","14+","moderate to critical disease","symptomatic","Thailand",">=18 years","general pop",56,"25",74,NA,"omicron BA.1/BA.2","~67 weeks",NA,NA,3181,"Thailand","THA",371,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-30,"symptomatic","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2023-01-30
"3121",371,"Sritipsukho","Test-negative case-control","30Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Thailand",">=18 years","general pop",23,"-13",49,NA,"omicron BA.1/BA.2","~67 weeks",NA,NA,3182,"Thailand","THA",371,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-30,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-01-30
"3122",371,"Sritipsukho","Test-negative case-control","30Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","<90 days","infection","infection","Thailand",">=18 years","general pop",38,"4",60,NA,"omicron BA.1/BA.2","~67 weeks",NA,NA,3183,"Thailand","THA",371,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-30,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-01-30
"3123",371,"Sritipsukho","Test-negative case-control","30Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">90 days","infection","infection","Thailand",">=18 years","general pop",-38,"-60",24,NA,"omicron BA.1/BA.2","~67 weeks",NA,NA,3184,"Thailand","THA",371,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-30,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-01-30
"3124",371,"Sritipsukho","Test-negative case-control","30Jan2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","moderate to critical disease","infection","Thailand",">=18 years","general pop",30,"-37",69,NA,"omicron BA.1/BA.2","~67 weeks",NA,NA,3185,"Thailand","THA",371,"THA",7060,2019,"Thailand","East Asia & Pacific","Upper middle income",3,"Asia",2021-03-02,2021-10-26,2022-03-30,2021-02-28,2021-02-28,2,240,395,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-30,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-01-30
"3125",372,"Weng","Retrospective cohort","01Feb2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA",">=12 years","general pop",94.6,"83.4",98.3,NA,"alpha","~48 weeks",NA,NA,3186,"USA","USA",372,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-01,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","alpha",NA,2023-02-01
"3126",372,"Weng","Retrospective cohort","01Feb2023","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","USA",">=12 years","general pop",97.5,"82.5",99.7,NA,"alpha","~48 weeks",NA,NA,3187,"USA","USA",372,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-01,"infection","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","alpha",NA,2023-02-01
"3127",372,"Weng","Retrospective cohort","01Feb2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA",">=12 years","general pop",64.8,"54.2",73,NA,"delta","~48 weeks",NA,NA,3188,"USA","USA",372,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-01,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-02-01
"3128",372,"Weng","Retrospective cohort","01Feb2023","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","USA",">=12 years","general pop",65,"52.9",74.1,NA,"delta","~48 weeks",NA,NA,3189,"USA","USA",372,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-01,"infection","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2023-02-01
"3129",372,"Weng","Retrospective cohort","01Feb2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA",">=12 years","general pop",31.6,"19.6",42.5,NA,"omicron BA.1","~48 weeks",NA,NA,3190,"USA","USA",372,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-01,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-02-01
"3130",372,"Weng","Retrospective cohort","01Feb2023","mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","USA",">=12 years","general pop",25.6,"10.7",39,NA,"omicron BA.1","~48 weeks",NA,NA,3191,"USA","USA",372,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-01,"infection","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2023-02-01
"3131",374,"Bello Chavolla","Test-negative case-control","02Feb2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Mexico",">=18 years","general pop",80.3,"80.1",80.6,NA,"alpha & delta","~35 weeks",NA,NA,3194,"Mexico","MEX",374,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","02/02/2023",2023-02-02
"3132",374,"Bello Chavolla","Test-negative case-control","02Feb2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Mexico",">=18 years","general pop",84.3,"83.6",84.9,NA,"alpha & delta","~35 weeks",NA,NA,3195,"Mexico","MEX",374,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","02/02/2023",2023-02-02
"3133",374,"Bello Chavolla","Test-negative case-control","02Feb2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","Mexico",">=18 years","general pop",89.8,"89.1",90.4,NA,"alpha & delta","~35 weeks",NA,NA,3196,"Mexico","MEX",374,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"death","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","02/02/2023",2023-02-02
"3134",374,"Bello Chavolla","Test-negative case-control","02Feb2023","mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Mexico",">=18 years","general pop",91.5,"90.3",92.4,NA,"alpha & delta","~1 week",NA,NA,3197,"Mexico","MEX",374,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"infection","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","02/02/2023",2023-02-02
"3135",374,"Bello Chavolla","Test-negative case-control","02Feb2023","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","Mexico",">=18 years","general pop",78,"69",84.4,NA,"alpha & delta","~1 week",NA,NA,3198,"Mexico","MEX",374,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"severe","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","02/02/2023",2023-02-02
"3136",374,"Bello Chavolla","Test-negative case-control","02Feb2023","mRNA-1273 (Moderna)","excluded","2","final","14+","death","death","Mexico",">=18 years","general pop",93.5,"85.9",96.9,NA,"alpha & delta","~1 week",NA,NA,3199,"Mexico","MEX",374,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"death","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations","02/02/2023",2023-02-02
"3137",374,"Bello Chavolla","Test-negative case-control","02Feb2023","AZD1222 (AstraZeneca)","excluded","2","final","14+","infection","infection","Mexico",">=18 years","general pop",80.8,"80.4",81.1,NA,"alpha & delta","~32 weeks",NA,NA,3200,"Mexico","MEX",374,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","02/02/2023",2023-02-02
"3138",374,"Bello Chavolla","Test-negative case-control","02Feb2023","AZD1222 (AstraZeneca)","excluded","2","final","14+","hospitalization","severe","Mexico",">=18 years","general pop",80.2,"79.3",81.1,NA,"alpha & delta","~32 weeks",NA,NA,3201,"Mexico","MEX",374,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","02/02/2023",2023-02-02
"3139",374,"Bello Chavolla","Test-negative case-control","02Feb2023","AZD1222 (AstraZeneca)","excluded","2","final","14+","death","death","Mexico",">=18 years","general pop",86.8,"85.9",87.7,NA,"alpha & delta","~32 weeks",NA,NA,3202,"Mexico","MEX",374,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"death","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","02/02/2023",2023-02-02
"3140",374,"Bello Chavolla","Test-negative case-control","02Feb2023","Ad26.COV2.S (Janssen)","excluded","1","final","14+","infection","infection","Mexico",">=18 years","general pop",82.2,"81.4",82.9,NA,"alpha & delta","~11 weeks",NA,NA,3203,"Mexico","MEX",374,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"infection","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","02/02/2023",2023-02-02
"3141",374,"Bello Chavolla","Test-negative case-control","02Feb2023","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization","severe","Mexico",">=18 years","general pop",77.3,"72.9",81,NA,"alpha & delta","~11 weeks",NA,NA,3204,"Mexico","MEX",374,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"severe","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","02/02/2023",2023-02-02
"3142",374,"Bello Chavolla","Test-negative case-control","02Feb2023","Ad26.COV2.S (Janssen)","excluded","1","final","14+","death","death","Mexico",">=18 years","general pop",85.8,"80.1",89.9,NA,"alpha & delta","~11 weeks",NA,NA,3205,"Mexico","MEX",374,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"death","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","other combinations","02/02/2023",2023-02-02
"3143",374,"Bello Chavolla","Test-negative case-control","02Feb2023","Ad5-nCOV (CanSino)","excluded","1","final","14+","infection","infection","Mexico",">=18 years","general pop",70.5,"70.1",70.9,NA,"alpha & delta","~27 weeks",NA,NA,3206,"Mexico","MEX",374,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"infection","2023 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","other combinations","02/02/2023",2023-02-02
"3144",374,"Bello Chavolla","Test-negative case-control","02Feb2023","Ad5-nCOV (CanSino)","excluded","1","final","14+","hospitalization","severe","Mexico",">=18 years","general pop",72.3,"71.1",73.5,NA,"alpha & delta","~27 weeks",NA,NA,3207,"Mexico","MEX",374,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"severe","2023 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","other combinations","02/02/2023",2023-02-02
"3145",374,"Bello Chavolla","Test-negative case-control","02Feb2023","Ad5-nCOV (CanSino)","excluded","1","final","14+","death","death","Mexico",">=18 years","general pop",79.9,"78.5",81.2,NA,"alpha & delta","~27 weeks",NA,NA,3208,"Mexico","MEX",374,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"death","2023 (Jan-Jun)","Cansino Ad5-nCoV","Vectored","other combinations","02/02/2023",2023-02-02
"3146",374,"Bello Chavolla","Test-negative case-control","02Feb2023","CoronaVac (Sinovac)","excluded","2","final","14+","infection","infection","Mexico",">=18 years","general pop",71.9,"71.4",72.5,NA,"alpha & delta","~27 weeks",NA,NA,3209,"Mexico","MEX",374,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"infection","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","02/02/2023",2023-02-02
"3147",374,"Bello Chavolla","Test-negative case-control","02Feb2023","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Mexico",">=18 years","general pop",73.8,"72.5",75,NA,"alpha & delta","~27 weeks",NA,NA,3210,"Mexico","MEX",374,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","02/02/2023",2023-02-02
"3148",374,"Bello Chavolla","Test-negative case-control","02Feb2023","CoronaVac (Sinovac)","excluded","2","final","14+","death","death","Mexico",">=18 years","general pop",80.4,"79",81.6,NA,"alpha & delta","~27 weeks",NA,NA,3211,"Mexico","MEX",374,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"death","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations","02/02/2023",2023-02-02
"3149",374,"Bello Chavolla","Test-negative case-control","02Feb2023","Gam-COVID-Vac (Gamaleya)","excluded","2","final","14+","infection","infection","Mexico",">=18 years","general pop",78.8,"78.2",79.3,NA,"alpha & delta","~26 weeks",NA,NA,3212,"Mexico","MEX",374,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"infection","2023 (Jan-Jun)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations","02/02/2023",2023-02-02
"3150",374,"Bello Chavolla","Test-negative case-control","02Feb2023","Gam-COVID-Vac (Gamaleya)","excluded","2","final","14+","hospitalization","severe","Mexico",">=18 years","general pop",81.4,"79.5",83.1,NA,"alpha & delta","~26 weeks",NA,NA,3213,"Mexico","MEX",374,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"severe","2023 (Jan-Jun)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations","02/02/2023",2023-02-02
"3151",374,"Bello Chavolla","Test-negative case-control","02Feb2023","Gam-COVID-Vac (Gamaleya)","excluded","2","final","14+","death","death","Mexico",">=18 years","general pop",87.7,"85.8",89.3,NA,"alpha & delta","~26 weeks",NA,NA,3214,"Mexico","MEX",374,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-02-02,"death","2023 (Jan-Jun)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","other combinations","02/02/2023",2023-02-02
"3152",375,"Jorgensen","Test-negative case-control","27Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Canada","infants of mothers vaccinated post-partum","infants of mothers vaccinated post-partum",13,"-14",33,NA,"omicron BA.5","~66 weeks",NA,NA,3215,"Canada","CAN",375,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-27,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-02-27
"3153",375,"Jorgensen","Test-negative case-control","27Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","Canada","infants of mothers vaccinated post-partum","infants of mothers vaccinated post-partum",36,"-21",66,NA,"omicron BA.5","~66 weeks",NA,NA,3216,"Canada","CAN",375,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-27,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-02-27
"3154",375,"Jorgensen","Test-negative case-control","27Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","infection","infection","Canada","infants of mothers vaccinated post-partum","infants of mothers vaccinated post-partum",73,"72",87,NA,"omicron BA.5","~66 weeks",NA,NA,3217,"Canada","CAN",375,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-27,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-02-27
"3155",376,"Yan","Case-control","28Feb2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-60","infection","infection","Hong Kong","3-17 years","3-17 years",39.7,"29",48.7,NA,"omicron BA.1, BA.2, BA.4, BA.5","~68 weeks",NA,NA,3218,"Hong Kong","HKG",376,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-02-28,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-02-28
"3156",376,"Yan","Case-control","28Feb2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","180+","infection","infection","Hong Kong","3-17 years","3-17 years",16.5,"8.7",23.6,NA,"omicron BA.1, BA.2, BA.4, BA.5","~68 weeks",NA,NA,3219,"Hong Kong","HKG",376,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-02-28,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-02-28
"3157",376,"Yan","Case-control","28Feb2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-60","hospitalization","severe","Hong Kong","3-17 years","3-17 years",45.5,"-0.2",70.3,NA,"omicron BA.1, BA.2, BA.4, BA.5","~68 weeks",NA,NA,3220,"Hong Kong","HKG",376,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-02-28,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-02-28
"3158",376,"Yan","Case-control","28Feb2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","180+","hospitalization","severe","Hong Kong","3-17 years","3-17 years",33.6,"5.5",53.3,NA,"omicron BA.1, BA.2, BA.4, BA.5","~68 weeks",NA,NA,3221,"Hong Kong","HKG",376,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-02-28,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-02-28
"3159",376,"Yan","Case-control","28Feb2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-60","severe disease","severe","Hong Kong","3-17 years","3-17 years",67.3,"34.1",83.8,NA,"omicron BA.1, BA.2, BA.4, BA.5","~68 weeks",NA,NA,3222,"Hong Kong","HKG",376,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-02-28,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-02-28
"3160",376,"Yan","Case-control","28Feb2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","180+","severe disease","severe","Hong Kong","3-17 years","3-17 years",29.2,"-4.9",52.2,NA,"omicron BA.1, BA.2, BA.4, BA.5","~68 weeks",NA,NA,3223,"Hong Kong","HKG",376,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-02-28,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-02-28
"3161",376,"Yan","Case-control","28Feb2023","CoronaVac (Sinovac)","excluded","2","final","14-60","infection","infection","Hong Kong","3-17 years","3-17 years",29.5,"20.1",37.7,NA,"omicron BA.1, BA.2, BA.4, BA.5","~68 weeks",NA,NA,3224,"Hong Kong","HKG",376,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-02-28,"infection","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-02-28
"3162",376,"Yan","Case-control","28Feb2023","CoronaVac (Sinovac)","excluded","2","final","121-179","infection","infection","Hong Kong","3-17 years","3-17 years",-35.2,"-63.3",-12,NA,"omicron BA.1, BA.2, BA.4, BA.5","~68 weeks",NA,NA,3225,"Hong Kong","HKG",376,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-02-28,"infection","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-02-28
"3163",376,"Yan","Case-control","28Feb2023","CoronaVac (Sinovac)","excluded","2","final","14-60","hospitalization","severe","Hong Kong","3-17 years","3-17 years",55.8,"34.9",70,NA,"omicron BA.1, BA.2, BA.4, BA.5","~68 weeks",NA,NA,3226,"Hong Kong","HKG",376,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-02-28,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-02-28
"3164",376,"Yan","Case-control","28Feb2023","CoronaVac (Sinovac)","excluded","2","final","121-179","hospitalization","severe","Hong Kong","3-17 years","3-17 years",-66.9,"-137.3",17.3,NA,"omicron BA.1, BA.2, BA.4, BA.5","~68 weeks",NA,NA,3227,"Hong Kong","HKG",376,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-02-28,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-02-28
"3165",376,"Yan","Case-control","28Feb2023","CoronaVac (Sinovac)","excluded","2","final","14-60","severe disease","severe","Hong Kong","3-17 years","3-17 years",57.6,"32.8",73.2,NA,"omicron BA.1, BA.2, BA.4, BA.5","~68 weeks",NA,NA,3228,"Hong Kong","HKG",376,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-02-28,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-02-28
"3166",376,"Yan","Case-control","28Feb2023","CoronaVac (Sinovac)","excluded","2","final","121-179","severe disease","severe","Hong Kong","3-17 years","3-17 years",-48.8,"-120",0.7,NA,"omicron BA.1, BA.2, BA.4, BA.5","~68 weeks",NA,NA,3229,"Hong Kong","HKG",376,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-02-28,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-02-28
"3167",378,"Glatman-Freedman","Test-negative case-control","02Mar2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","8-14","infection","infection","Israel","5-11 years","5-11 years",58.1,"55.5",60.6,NA,"omicron BA.1","4 weeks",NA,NA,3230,"Israel","ISR",378,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-03-02,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-03-02
"3168",378,"Glatman-Freedman","Test-negative case-control","02Mar2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","36-42","infection","infection","Israel","5-11 years","5-11 years",39.5,"36.1",42.8,NA,"omicron BA.1","4 weeks",NA,NA,3231,"Israel","ISR",378,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-03-02,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-03-02
"3169",380,"Tamandjou Tchuem","Test-negative case-control","27Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","8-30","symptomatic disease","symptomatic","France",">=50 years",">=50 years",69.8,"58.3",79.3,NA,"omicron BA.1","~54 weeks",NA,NA,3232,"France","FRA",380,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-27,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-02-27
"3170",380,"Tamandjou Tchuem","Test-negative case-control","27Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final",">120","symptomatic disease","symptomatic","France",">=50 years",">=50 years",19.9,"16.3",24.1,NA,"omicron BA.1","~54 weeks",NA,NA,3233,"France","FRA",380,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-27,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-02-27
"3171",380,"Tamandjou Tchuem","Test-negative case-control","27Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","8-30","symptomatic disease","symptomatic","France",">=50 years",">=50 years",85.9,"75.2",92.4,NA,"delta","~45 weeks",NA,NA,3234,"France","FRA",380,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-27,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-02-27
"3172",380,"Tamandjou Tchuem","Test-negative case-control","27Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final",">120","symptomatic disease","symptomatic","France",">=50 years",">=50 years",60.1,"57.2",63,NA,"delta","~45 weeks",NA,NA,3235,"France","FRA",380,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-02-27,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-02-27
"3173",381,"Rojas-Botero","Retrospective cohort","08Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","15+","hospitalization","severe","Colombia",">=18 years","general pop",90.5,"89.8",91.2,NA,"mu, delta, & omicron","~64 weeks",NA,NA,3236,"Colombia","COL",381,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-08,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","22/03/2023",2023-03-22
"3174",381,"Rojas-Botero","Retrospective cohort","08Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","15+","death","death","Colombia",">=18 years","general pop",93.5,"92.8",94.2,NA,"mu, delta, & omicron","~64 weeks",NA,NA,3237,"Colombia","COL",381,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-08,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations","22/03/2023",2023-03-22
"3175",381,"Rojas-Botero","Retrospective cohort","08Sep2023","mRNA-1273 (Moderna)","included","2","final","15+","hospitalization","severe","Colombia",">=18 years","general pop",93.7,"91.8",95.2,NA,"mu, delta, & omicron","~41 weeks",NA,NA,3238,"Colombia","COL",381,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-08,"severe","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","22/03/2023",2023-03-22
"3176",381,"Rojas-Botero","Retrospective cohort","08Sep2023","mRNA-1273 (Moderna)","included","2","final","15+","death","death","Colombia",">=18 years","general pop",95.7,"93.5",97.2,NA,"mu, delta, & omicron","~41 weeks",NA,NA,3239,"Colombia","COL",381,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-08,"death","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","other combinations","22/03/2023",2023-03-22
"3177",381,"Rojas-Botero","Retrospective cohort","08Sep2023","AZD1222 (AstraZeneca)","included","2","final","15+","hospitalization","severe","Colombia",">=18 years","general pop",88,"86.8",89.1,NA,"mu, delta, & omicron","~57 weeks",NA,NA,3240,"Colombia","COL",381,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-08,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","22/03/2023",2023-03-22
"3178",381,"Rojas-Botero","Retrospective cohort","08Sep2023","AZD1222 (AstraZeneca)","included","2","final","15+","death","death","Colombia",">=18 years","general pop",92.6,"91.5",93.6,NA,"mu, delta, & omicron","~57 weeks",NA,NA,3241,"Colombia","COL",381,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-08,"death","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations","22/03/2023",2023-03-22
"3179",381,"Rojas-Botero","Retrospective cohort","08Sep2023","CoronaVac (Sinovac)","included","2","final","15+","hospitalization","severe","Colombia",">=18 years","general pop",77.4,"76.5",78.2,NA,"mu, delta, & omicron","~64 weeks",NA,NA,3242,"Colombia","COL",381,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-08,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations","22/03/2023",2023-03-22
"3180",381,"Rojas-Botero","Retrospective cohort","08Sep2023","CoronaVac (Sinovac)","included","2","final","15+","death","death","Colombia",">=18 years","general pop",81.9,"81.2",82.7,NA,"mu, delta, & omicron","~64 weeks",NA,NA,3243,"Colombia","COL",381,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-08,"death","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","other combinations","22/03/2023",2023-03-22
"3181",381,"Rojas-Botero","Retrospective cohort","08Sep2023","Ad26.COV2.S (Janssen)","included","1","final","15+","hospitalization","severe","Colombia",">=18 years","general pop",85.4,"83.8",86.9,NA,"mu, delta, & omicron","~51 weeks",NA,NA,3244,"Colombia","COL",381,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-08,"severe","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","22/03/2023",2023-03-22
"3182",381,"Rojas-Botero","Retrospective cohort","08Sep2023","Ad26.COV2.S (Janssen)","included","1","final","15+","death","death","Colombia",">=18 years","general pop",90.5,"88.8",91.9,NA,"mu, delta, & omicron","~51 weeks",NA,NA,3245,"Colombia","COL",381,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-08,"death","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","other combinations","22/03/2023",2023-03-22
"3183",382,"Bouillon","Retrospective cohort","13Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-30","hospitalization","severe","France",">=50 years",">=50 years",90,"88",91,NA,"alpha & delta","~28 weeks",NA,NA,3246,"France","FRA",382,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-13,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-13
"3184",382,"Bouillon","Retrospective cohort","13Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","152-180","hospitalization","severe","France",">=50 years",">=50 years",94,"92",94,NA,"alpha & delta","~28 weeks",NA,NA,3247,"France","FRA",382,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-13,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-13
"3185",382,"Bouillon","Retrospective cohort","13Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","death","death","France",">=50 years",">=50 years",91,"90",93,NA,"alpha & delta","~28 weeks",NA,NA,3248,"France","FRA",382,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-13,"death","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2022-06-13
"3186",382,"Bouillon","Retrospective cohort","13Jun2022","mRNA-1273 (Moderna)","included","2","final","14-30","hospitalization","severe","France",">=50 years",">=50 years",92,"85",95,NA,"alpha & delta","~28 weeks",NA,NA,3249,"France","FRA",382,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-13,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-13
"3187",382,"Bouillon","Retrospective cohort","13Jun2022","mRNA-1273 (Moderna)","included","2","final","152-180","hospitalization","severe","France",">=50 years",">=50 years",98,"93",100,NA,"alpha & delta","~28 weeks",NA,NA,3250,"France","FRA",382,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-13,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-13
"3188",382,"Bouillon","Retrospective cohort","13Jun2022","mRNA-1273 (Moderna)","included","2","final","14+","death","death","France",">=50 years",">=50 years",96,"92",98,NA,"alpha & delta","~28 weeks",NA,NA,3251,"France","FRA",382,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-13,"death","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2022-06-13
"3189",382,"Bouillon","Retrospective cohort","13Jun2022","AZD1222 (AstraZeneca)","included","2","final","14-30","hospitalization","severe","France",">=50 years",">=50 years",94,"88",97,NA,"alpha & delta","~23 weeks",NA,NA,3252,"France","FRA",382,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-13,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-06-13
"3190",382,"Bouillon","Retrospective cohort","13Jun2022","AZD1222 (AstraZeneca)","included","2","final","90-120","hospitalization","severe","France",">=50 years",">=50 years",90,"63",97,NA,"alpha & delta","~23 weeks",NA,NA,3253,"France","FRA",382,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-13,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-06-13
"3191",382,"Bouillon","Retrospective cohort","13Jun2022","AZD1222 (AstraZeneca)","included","2","final","14+","death","death","France",">=50 years",">=50 years",88,"68",95,NA,"alpha & delta","~23 weeks",NA,NA,3254,"France","FRA",382,"FRA",42470,2019,"France","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-15,2021-12-03,2020-12-23,2020-12-23,9,204,345,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-13,"death","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2022-06-13
"3192",383,"Lipshuetz","Retrospective cohort","23Mar2023","BNT162b2 (Pfizer BioNTech) in mothers during pregnancy","excluded","2","final","120 days after birth","hospitalization up to 120 days after birth","severe","Israel","infants 0-120 days of unvaccinated mothers and mothers vaccinated during pregnancy at least 5 months prior","infants",-16,"-56",14,NA,"delta & omicron BA.1","~59 weeks",NA,NA,3255,"Israel","ISR",383,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"who","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-03-23,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2023-03-23
"3193",384,"Lutz","Test-negative case-control","27Mar2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA",">=12 years","general pop",93.9,"85.7",97.4,NA,"alpha & delta","~45 weeks",NA,NA,3256,"USA","USA",384,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-03-27,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-03-27
"3194",384,"Lutz","Test-negative case-control","27Mar2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","outpatient clinic and emergency visits","symptomatic","USA",">=12 years","general pop",85.9,"60",95,NA,"alpha & delta","~45 weeks",NA,NA,3257,"USA","USA",384,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-03-27,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-03-27
"3195",384,"Lutz","Test-negative case-control","27Mar2023","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">=12 years","general pop",97.3,"88.3",99.4,NA,"alpha & delta","~45 weeks",NA,NA,3258,"USA","USA",384,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-03-27,"severe","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2023-03-27
"3196",384,"Lutz","Test-negative case-control","27Mar2023","mRNA-1273 (Moderna)","included","2","final","14+","outpatient clinic and emergency visits","symptomatic","USA",">=12 years","general pop",85.4,"39.3",96.5,NA,"alpha & delta","~45 weeks",NA,NA,3259,"USA","USA",384,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-03-27,"symptomatic","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","other combinations",NA,2023-03-27
"3197",384,"Lutz","Test-negative case-control","27Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","hospitalization","severe","USA",">=12 years","general pop",96.2,"94",99.4,NA,"alpha & delta","~45 weeks",NA,NA,3260,"USA","USA",384,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-03-27,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2023-03-27
"3198",384,"Lutz","Test-negative case-control","27Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","hospitalization","severe","USA",">=12 years","general pop",87.7,"69.4",95,NA,"alpha & delta","~45 weeks",NA,NA,3261,"USA","USA",384,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-03-27,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2023-03-27
"3199",384,"Lutz","Test-negative case-control","27Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-149","outpatient clinic and emergency visits","symptomatic","USA",">=12 years","general pop",87.7,"60.5",96.2,NA,"alpha & delta","~45 weeks",NA,NA,3262,"USA","USA",384,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-03-27,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2023-03-27
"3200",384,"Lutz","Test-negative case-control","27Mar2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","150+","outpatient clinic and emergency visits","symptomatic","USA",">=12 years","general pop",87,"55.6",96.2,NA,"alpha & delta","~45 weeks",NA,NA,3263,"USA","USA",384,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-03-27,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","other combinations",NA,2023-03-27
"3201",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-59","ED or UC visit","symptomatic","USA","5-11 years","5-11 years",49,"33",61,NA,"omicron BA.1, BA.2, BA.4/BA.5","~6 weeks",NA,NA,3264,"USA","USA",385,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-04-07,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-04-07
"3202",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","ED or UC visit","symptomatic","USA","5-11 years","5-11 years",41,"29",51,NA,"omicron BA.1, BA.2, BA.4/BA.5","~31 weeks",NA,NA,3265,"USA","USA",385,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-04-07,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-04-07
"3203",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-59","ED or UC visit","symptomatic","USA","12-15 years","12-15 years",64,"44",77,NA,"omicron BA.1, BA.2, BA.4/BA.5","~6 weeks",NA,NA,3266,"USA","USA",385,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-04-07,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-04-07
"3204",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","ED or UC visit","symptomatic","USA","12-15 years","12-15 years",13,"3",23,NA,"omicron BA.1, BA.2, BA.4/BA.5","~62 weeks",NA,NA,3267,"USA","USA",385,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-04-07,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-04-07
"3205",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","60-149","ED or UC visit","symptomatic","USA","16-17 years","16-17 years",31,"10",47,NA,"omicron BA.1, BA.2, BA.4/BA.5","~19 weeks",NA,NA,3268,"USA","USA",385,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-04-07,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-04-07
"3206",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","ED or UC visit","symptomatic","USA","16-17 years","16-17 years",7,"-8",20,NA,"omicron BA.1, BA.2, BA.4/BA.5","~72 weeks",NA,NA,3269,"USA","USA",385,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-04-07,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-04-07
"3207",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-59","ED or UC visit","symptomatic","USA","12-15 years","12-15 years",93,"89",95,NA,"delta","~6 weeks",NA,NA,3270,"USA","USA",385,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-04-07,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-04-07
"3208",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","ED or UC visit","symptomatic","USA","12-15 years","12-15 years",77,"69",84,NA,"delta","~22 weeks",NA,NA,3271,"USA","USA",385,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-04-07,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-04-07
"3209",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-59","ED or UC visit","symptomatic","USA","16-17 years","16-17 years",93,"86",97,NA,"delta","~ 6 weeks",NA,NA,3272,"USA","USA",385,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-04-07,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-04-07
"3210",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","ED or UC visit","symptomatic","USA","16-17 years","16-17 years",72,"63",79,NA,"delta","~32 weeks",NA,NA,3273,"USA","USA",385,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-04-07,"symptomatic","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-04-07
"3211",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-59","hospitalization","severe","USA","12-15 years","12-15 years",98,"21",100,NA,"delta","~6 weeks",NA,NA,3274,"USA","USA",385,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-04-07,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-04-07
"3212",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","60-149","hospitalization","severe","USA","12-15 years","12-15 years",97,"74",100,NA,"delta","~19 weeks",NA,NA,3275,"USA","USA",385,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-04-07,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-04-07
"3213",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","60-149","hospitalization","severe","USA","16-17 years","16-17 years",99,"90",100,NA,"delta","~19 weeks",NA,NA,3276,"USA","USA",385,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-04-07,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-04-07
"3214",385,"Klein","Test-negative case-control","07Apr2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","hospitalization","severe","USA","16-17 years","16-17 years",98,"73",100,NA,"delta","~32 weeks",NA,NA,3277,"USA","USA",385,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-04-07,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-04-07
"3215",386,"Huang","Retrospective cohort","12Apr2023","CoronaVac (Sinovac)","Partially excluded (excluded if prior infection prior to study start)","2","final","8+","severe disease","severe","China",">=60 years",">=60 years",65.5,"50.9",75.7,NA,"alpha & delta & omicron BA.1, BA.2","~66 weeks",NA,NA,3278,"China","CHN",386,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2023-04-12,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations",NA,2023-04-12
"3216",386,"Huang","Retrospective cohort","12Apr2023","CoronaVac (Sinovac)","Partially excluded (excluded if prior infection prior to study start)","2","final","8+","death","death","China",">=60 years",">=60 years",80.4,"55.8",91.3,NA,"alpha & delta & omicron BA.1, BA.2","~66 weeks",NA,NA,3279,"China","CHN",386,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2023-04-12,"death","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","other combinations",NA,2023-04-12
"3217",386,"Huang","Retrospective cohort","12Apr2023","BBIBP-CorV (Beijing CNBG)","Partially excluded (excluded if prior infection prior to study start)","2","final","8+","severe disease","severe","China",">=60 years",">=60 years",76.4,"61.8",85.4,NA,"alpha & delta & omicron BA.1, BA.2","~66 weeks",NA,NA,3280,"China","CHN",386,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2023-04-12,"severe","2023 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2023-04-12
"3218",386,"Huang","Retrospective cohort","12Apr2023","BBIBP-CorV (Beijing CNBG)","Partially excluded (excluded if prior infection prior to study start)","2","final","8+","death","death","China",">=60 years",">=60 years",82.7,"53.4",93.6,NA,"alpha & delta & omicron BA.1, BA.2","~66 weeks",NA,NA,3281,"China","CHN",386,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2023-04-12,"death","2023 (Jan-Jun)","Beijing/Sinopharm BBIBP-CorV","Inactivated","other combinations",NA,2023-04-12
"3219",387,"Altarawneh","Test-negative case-control","27Jul2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Qatar","all ages","general pop",90.5,"83.9",94.4,NA,"alpha","~8 weeks",NA,NA,3282,"Qatar","QAT",387,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-27,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","22/04/2023",2023-04-22
"3220",387,"Altarawneh","Test-negative case-control","27Jul2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","severe, critical or fatal disease","severe","Qatar","all ages","general pop",96.1,"71.2",99.5,NA,"alpha","~8 weeks",NA,NA,3283,"Qatar","QAT",387,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-27,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","alpha","22/04/2023",2023-04-22
"3221",387,"Altarawneh","Test-negative case-control","27Jul2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Qatar","all ages","general pop",80.5,"79",82,NA,"beta","~17 weeks",NA,NA,3284,"Qatar","QAT",387,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-27,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta","22/04/2023",2023-04-22
"3222",387,"Altarawneh","Test-negative case-control","27Jul2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","severe, critical or fatal disease","severe","Qatar","all ages","general pop",97.4,"95.8",98.4,NA,"beta","~17 weeks",NA,NA,3285,"Qatar","QAT",387,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-27,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","beta","22/04/2023",2023-04-22
"3223",387,"Altarawneh","Test-negative case-control","27Jul2023","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","Qatar","all ages","general pop",96,"91.6",98.1,NA,"beta","~17 weeks",NA,NA,3286,"Qatar","QAT",387,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-27,"symptomatic","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","beta","22/04/2023",2023-04-22
"3224",387,"Altarawneh","Test-negative case-control","27Jul2023","mRNA-1273 (Moderna)","excluded","2","final","14+","severe, critical or fatal disease","severe","Qatar","all ages","general pop",100,"92.2",100,NA,"beta","~17 weeks",NA,NA,3287,"Qatar","QAT",387,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-27,"severe","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","beta","22/04/2023",2023-04-22
"3225",387,"Altarawneh","Test-negative case-control","27Jul2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease","symptomatic","Qatar","all ages","general pop",58.1,"54.6",61.3,NA,"delta","~48 weeks",NA,NA,3288,"Qatar","QAT",387,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-27,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","22/04/2023",2023-04-22
"3226",387,"Altarawneh","Test-negative case-control","27Jul2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","severe, critical or fatal disease","severe","Qatar","all ages","general pop",91.1,"86.3",94.2,NA,"delta","~48 weeks",NA,NA,3289,"Qatar","QAT",387,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-27,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","22/04/2023",2023-04-22
"3227",387,"Altarawneh","Test-negative case-control","27Jul2023","mRNA-1273 (Moderna)","excluded","2","final","14+","symptomatic disease","symptomatic","Qatar","all ages","general pop",71,"66.4",74.9,NA,"delta","~48 weeks",NA,NA,3290,"Qatar","QAT",387,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-27,"symptomatic","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","22/04/2023",2023-04-22
"3228",387,"Altarawneh","Test-negative case-control","27Jul2023","mRNA-1273 (Moderna)","excluded","2","final","14+","severe, critical or fatal disease","severe","Qatar","all ages","general pop",97.9,"91.2",99.5,NA,"delta","~48 weeks",NA,NA,3291,"Qatar","QAT",387,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-27,"severe","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","22/04/2023",2023-04-22
"3229",388,"Braeye","Retrospective cohort","05Apr2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-57","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",3,"1",5,NA,"omicron BA.1","~28.5 weeks",NA,NA,3292,"Belgium","BEL",388,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-04-05
"3230",388,"Braeye","Retrospective cohort","05Apr2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","157-207","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",2,"0",3,NA,"omicron BA.1","~28.5 weeks",NA,NA,3293,"Belgium","BEL",388,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-04-05
"3231",388,"Braeye","Retrospective cohort","05Apr2023","mRNA-1273 (Moderna)","excluded","2","final","14-64","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",4,"1",7,NA,"omicron BA.1","~28.5 weeks",NA,NA,3294,"Belgium","BEL",388,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2023-04-05
"3232",388,"Braeye","Retrospective cohort","05Apr2023","mRNA-1273 (Moderna)","excluded","2","final","164-214","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",3,"0",4,NA,"omicron BA.1","~28.5 weeks",NA,NA,3295,"Belgium","BEL",388,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2023-04-05
"3233",388,"Braeye","Retrospective cohort","05Apr2023","AZD1222 (AstraZeneca)","excluded","2","final","14-64","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",2,"0",4,NA,"omicron BA.1","~28.5 weeks",NA,NA,3296,"Belgium","BEL",388,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2023-04-05
"3234",388,"Braeye","Retrospective cohort","05Apr2023","AZD1222 (AstraZeneca)","excluded","2","final","164-214","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",1,"0",2,NA,"omicron BA.1","~28.5 weeks",NA,NA,3297,"Belgium","BEL",388,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2023-04-05
"3235",388,"Braeye","Retrospective cohort","05Apr2023","Ad26.COV2.S (Janssen)","excluded","1","final","21-71","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",1,"0",2,NA,"omicron BA.1","~28.5 weeks",NA,NA,3298,"Belgium","BEL",388,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2023-04-05
"3236",388,"Braeye","Retrospective cohort","05Apr2023","Ad26.COV2.S (Janssen)","excluded","1","final","171-221","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",1,"0",2,NA,"omicron BA.1","~28.5 weeks",NA,NA,3299,"Belgium","BEL",388,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2023-04-05
"3237",388,"Braeye","Retrospective cohort","05Apr2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7-57","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",62,"56",66,NA,"delta","~28.5 weeks",NA,NA,3300,"Belgium","BEL",388,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-04-05
"3238",388,"Braeye","Retrospective cohort","05Apr2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","157-207","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",43,"41",45,NA,"delta","~28.5 weeks",NA,NA,3301,"Belgium","BEL",388,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-04-05
"3239",388,"Braeye","Retrospective cohort","05Apr2023","mRNA-1273 (Moderna)","excluded","2","final","14-64","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",75,"70",77,NA,"delta","~28.5 weeks",NA,NA,3302,"Belgium","BEL",388,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2023-04-05
"3240",388,"Braeye","Retrospective cohort","05Apr2023","mRNA-1273 (Moderna)","excluded","2","final","164-214","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",56,"54",58,NA,"delta","~28.5 weeks",NA,NA,3303,"Belgium","BEL",388,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta",NA,2023-04-05
"3241",388,"Braeye","Retrospective cohort","05Apr2023","AZD1222 (AstraZeneca)","excluded","2","final","14-64","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",48,"43",55,NA,"delta","~28.5 weeks",NA,NA,3304,"Belgium","BEL",388,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-04-05
"3242",388,"Braeye","Retrospective cohort","05Apr2023","AZD1222 (AstraZeneca)","excluded","2","final","164-214","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",35,"34",38,NA,"delta","~28.5 weeks",NA,NA,3305,"Belgium","BEL",388,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-04-05
"3243",388,"Braeye","Retrospective cohort","05Apr2023","Ad26.COV2.S (Janssen)","excluded","1","final","21-71","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",28,"26",31,NA,"delta","~28.5 weeks",NA,NA,3306,"Belgium","BEL",388,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta",NA,2023-04-05
"3244",388,"Braeye","Retrospective cohort","05Apr2023","Ad26.COV2.S (Janssen)","excluded","1","final","171-221","infection","infection","Belgium","close contacts of unvaccinated index cases, females 45-64 years","close contacts of unvaccinated index cases, females 45-64 years",27,"23",30,NA,"delta","~28.5 weeks",NA,NA,3307,"Belgium","BEL",388,"BEL",48050,2019,"Belgium","Europe & Central Asia","High income",4,"Europe",2020-12-30,2021-07-08,2021-08-30,2020-12-30,2020-12-30,0,190,243,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-04-05,"infection","2023 (Jan-Jun)","Janssen Ad26.COV2.S","Vectored","delta",NA,2023-04-05
"3245",389,"DeCuir","Test-negative case-control","28Apr2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7+","invasive mechanical ventilation or death","severe","USA",">=18 years","general pop",53,"37",65,NA,"omicron BA.1, BA.2, BA.4/BA.5, BQ.1","62 weeks",NA,NA,3308,"USA","USA",389,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-04-28,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-04-28
"3246",389,"DeCuir","Test-negative case-control","28Apr2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+","invasive mechanical ventilation or death","severe","USA",">=18 years","general pop",50,"32",64,NA,"omicron BA.1, BA.2, BA.4/BA.5, BQ.1","62 weeks",NA,NA,3309,"USA","USA",389,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-04-28,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-04-28
"3247",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 459)","infection, September 2022","infection","Qatar","all ages","general pop",-5.8,"-11.1",-0.3,NA,"omicron BA.2.75, XBB","~87 weeks",NA,NA,3310,"Qatar","QAT",390,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-19,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","29/04/2023",2023-04-29
"3248",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 541)","infection, November 2022","infection","Qatar","all ages","general pop",-2.1,"-10.5",6.7,NA,"omicron BA.2.75, XBB","~96 weeks",NA,NA,3311,"Qatar","QAT",390,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-19,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","29/04/2023",2023-04-29
"3249",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 453)","severe critical, or fatal disease, August-November 2022","severe","Qatar","all ages","general pop",53.1,"-41.3",87.1,NA,"omicron BA.4/BA.5, BA.2.75, XBB","~96 weeks",NA,NA,3312,"Qatar","QAT",390,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","29/04/2023",2023-04-29
"3250",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 389)","infection, June 2022","infection","Qatar","all ages","general pop",-20.7,"-26.7",-14.2,NA,"omicron BA.4/BA.5","~74 weeks",NA,NA,3313,"Qatar","QAT",390,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-19,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","29/04/2023",2023-04-29
"3251",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 432)","infection, August 2022","infection","Qatar","all ages","general pop",-1.1,"-7.1",5.1,NA,"omicron BA.4/BA.5","~83 weeks",NA,NA,3314,"Qatar","QAT",390,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-19,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","29/04/2023",2023-04-29
"3252",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 425)","severe critical, or fatal disease, May-July 2022","severe","Qatar","all ages","general pop",83.8,"14.1",96.9,NA,"omicron BA.1, BA.2, BA.4/BA.5","~78.5 weeks",NA,NA,3315,"Qatar","QAT",390,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","29/04/2023",2023-04-29
"3253",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 228)","infection, December 2021","infection","Qatar","all ages","general pop",-3.9,"-7.8",0,NA,"omicron BA.1, BA.2","~48 weeks",NA,NA,3316,"Qatar","QAT",390,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-19,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","29/04/2023",2023-04-29
"3254",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 364)","infection, May 2022","infection","Qatar","all ages","general pop",-1.6,"-14.7",11.9,NA,"omicron BA.1, BA.2","~70 weeks",NA,NA,3317,"Qatar","QAT",390,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-19,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","29/04/2023",2023-04-29
"3255",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 254)","severe critical, or fatal disease, February-April 2022","severe","Qatar","all ages","general pop",81.4,"48.5",93.3,NA,"omicron BA.1, BA.2","~65 weeks",NA,NA,3318,"Qatar","QAT",390,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","29/04/2023",2023-04-29
"3256",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 64)","infection, June 2021","infection","Qatar","all ages","general pop",80.7,"77.2",83.7,NA,"delta","~22 weeks",NA,NA,3319,"Qatar","QAT",390,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-19,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","29/04/2023",2023-04-29
"3257",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 209)","infection, November 2021","infection","Qatar","all ages","general pop",52.7,"46.5",58.2,NA,"delta","~44 weeks",NA,NA,3320,"Qatar","QAT",390,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-19,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","29/04/2023",2023-04-29
"3258",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 189)","severe critical, or fatal disease, August-October 2021","severe","Qatar","all ages","general pop",91.4,"86.6",94.5,NA,"delta","~39.5 weeks",NA,NA,3321,"Qatar","QAT",390,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta","29/04/2023",2023-04-29
"3259",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 34)","infection, March 2021","infection","Qatar","all ages","general pop",81.8,"79.8",83.6,NA,"beta","~9 weeks",NA,NA,3322,"Qatar","QAT",390,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-19,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","beta","29/04/2023",2023-04-29
"3260",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 48)","infection, May 2021","infection","Qatar","all ages","general pop",80.9,"78.4",83.1,NA,"beta","~17.5 weeks",NA,NA,3323,"Qatar","QAT",390,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-19,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","beta","29/04/2023",2023-04-29
"3261",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 50)","severe critical, or fatal disease, February-April 2021","severe","Qatar","all ages","general pop",95.4,"93.6",96.7,NA,"alpha & beta","~13 weeks",NA,NA,3324,"Qatar","QAT",390,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","other combinations","29/04/2023",2023-04-29
"3262",390,"Qassim","Test-negative case-control","19Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+ (median 24)","infection, February 2021","infection","Qatar","all ages","general pop",84.5,"77.8",89.2,NA,"alpha","~4.5 weeks",NA,NA,3325,"Qatar","QAT",390,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-19,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","alpha","29/04/2023",2023-04-29
"3263",391,"Huang","Case-control","01May2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-180","infection","infection","Hong Kong",">=18 years with substance abuse disorders",">=18 years with substance abuse disorders",20.7,"14",27,NA,"omicron BA.1, BA.2","~24 weeks",NA,NA,3326,"Hong Kong","HKG",391,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-05-01,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-01
"3264",391,"Huang","Case-control","01May2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Hong Kong",">=18 years with substance abuse disorders",">=18 years with substance abuse disorders",73.3,"64.3",80,NA,"omicron BA.1, BA.2","~60.5 weeks",NA,NA,3327,"Hong Kong","HKG",391,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-05-01,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-01
"3265",391,"Huang","Case-control","01May2023","CoronaVac (Sinovac)","excluded","2","final","14-180","infection","infection","Hong Kong",">=18 years with substance abuse disorders",">=18 years with substance abuse disorders",6.1,"-0.5",12.3,NA,"omicron BA.1, BA.2","~24 weeks",NA,NA,3328,"Hong Kong","HKG",391,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-05-01,"infection","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-05-01
"3266",391,"Huang","Case-control","01May2023","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Hong Kong",">=18 years with substance abuse disorders",">=18 years with substance abuse disorders",59.9,"50.2",67.7,NA,"omicron BA.1, BA.2","~59.5 weeks",NA,NA,3329,"Hong Kong","HKG",391,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-05-01,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-05-01
"3267",392,"Yan","Case-control","03May2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-30","hospitalization","severe","Hong Kong",">=18 years","general pop",73,"69.2",76.3,NA,"omicron BA.2","~32 weeks",NA,NA,3330,"Hong Kong","HKG",392,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-03
"3268",392,"Yan","Case-control","03May2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","211-240","hospitalization","severe","Hong Kong",">=18 years","general pop",46.6,"40.7",51.8,NA,"omicron BA.2","~32 weeks",NA,NA,3331,"Hong Kong","HKG",392,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-03
"3269",392,"Yan","Case-control","03May2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-30","severe disease","severe","Hong Kong",">=18 years","general pop",69.7,"50",81.6,NA,"omicron BA.2","~32 weeks",NA,NA,3332,"Hong Kong","HKG",392,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-03
"3270",392,"Yan","Case-control","03May2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","211-240","severe disease","severe","Hong Kong",">=18 years","general pop",71.8,"47.2",84.9,NA,"omicron BA.2","~32 weeks",NA,NA,3333,"Hong Kong","HKG",392,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-03
"3271",392,"Yan","Case-control","03May2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-30","death","death","Hong Kong",">=18 years","general pop",89.8,"83.7",93.6,NA,"omicron BA.2","~32 weeks",NA,NA,3334,"Hong Kong","HKG",392,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"death","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-03
"3272",392,"Yan","Case-control","03May2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","211-240","death","death","Hong Kong",">=18 years","general pop",73.8,"55.9",84.4,NA,"omicron BA.2","~32 weeks",NA,NA,3335,"Hong Kong","HKG",392,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"death","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-03
"3273",392,"Yan","Case-control","03May2023","CoronaVac (Sinovac)","excluded","2","final","14-30","hospitalization","severe","Hong Kong",">=18 years","general pop",66,"63.5",68.3,NA,"omicron BA.2","~32 weeks",NA,NA,3336,"Hong Kong","HKG",392,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-05-03
"3274",392,"Yan","Case-control","03May2023","CoronaVac (Sinovac)","excluded","2","final","211-240","hospitalization","severe","Hong Kong",">=18 years","general pop",36.2,"28",43.4,NA,"omicron BA.2","~32 weeks",NA,NA,3337,"Hong Kong","HKG",392,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-05-03
"3275",392,"Yan","Case-control","03May2023","CoronaVac (Sinovac)","excluded","2","final","14-30","severe disease","severe","Hong Kong",">=18 years","general pop",54.5,"40.6",65.1,NA,"omicron BA.2","~32 weeks",NA,NA,3338,"Hong Kong","HKG",392,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-05-03
"3276",392,"Yan","Case-control","03May2023","CoronaVac (Sinovac)","excluded","2","final","211-240","severe disease","severe","Hong Kong",">=18 years","general pop",67.1,"34",83.6,NA,"omicron BA.2","~32 weeks",NA,NA,3339,"Hong Kong","HKG",392,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"severe","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-05-03
"3277",392,"Yan","Case-control","03May2023","CoronaVac (Sinovac)","excluded","2","final","14-30","death","death","Hong Kong",">=18 years","general pop",81.1,"77.4",84.2,NA,"omicron BA.2","~32 weeks",NA,NA,3340,"Hong Kong","HKG",392,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"death","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-05-03
"3278",392,"Yan","Case-control","03May2023","CoronaVac (Sinovac)","excluded","2","final","211-240","death","death","Hong Kong",">=18 years","general pop",76.6,"60.8",86,NA,"omicron BA.2","~32 weeks",NA,NA,3341,"Hong Kong","HKG",392,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"death","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-05-03
"3279",393,"Finci","Test-negative case-control","12Oct2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","Albania","HCW >=20 years","HCW",17,"-38",50,NA,"omicron BA.1, BA.2","~65 weeks",NA,NA,3342,"Albania","ALB",393,"ALB",5280,2019,"Albania","Europe & Central Asia","Upper middle income",2,"Europe",2021-01-13,2022-02-01,NA,2021-01-13,2021-01-13,0,384,NA,"equal","jan/2021","Dec/2021 +","360+","yes","no","no",2023-10-12,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","05/05/2023",2023-05-05
"3280",393,"Finci","Test-negative case-control","12Oct2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","symptomatic disease (PCR only)","symptomatic","Albania","HCW >=20 years","HCW",26,"-53",64,NA,"omicron BA.1, BA.2","~65 weeks",NA,NA,3343,"Albania","ALB",393,"ALB",5280,2019,"Albania","Europe & Central Asia","Upper middle income",2,"Europe",2021-01-13,2022-02-01,NA,2021-01-13,2021-01-13,0,384,NA,"equal","jan/2021","Dec/2021 +","360+","yes","no","no",2023-10-12,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","05/05/2023",2023-05-05
"3281",393,"Finci","Test-negative case-control","12Oct2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","symptomatic disease (PCR or RAT)","symptomatic","Albania","HCW >=20 years","HCW",33,"-32",66,NA,"omicron BA.1, BA.2","~65 weeks",NA,NA,3344,"Albania","ALB",393,"ALB",5280,2019,"Albania","Europe & Central Asia","Upper middle income",2,"Europe",2021-01-13,2022-02-01,NA,2021-01-13,2021-01-13,0,384,NA,"equal","jan/2021","Dec/2021 +","360+","yes","no","no",2023-10-12,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","05/05/2023",2023-05-05
"3282",394,"Surie","Test-negative case-control","29Jun2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) (ascertained by electronic medical records)","included","2","final","14+","hospitalization","severe","USA",">=18 years","general pop",20,"3",34,NA,"omicron BA.1, BA.2, BA.4/BA.5","~82 weeks",NA,NA,3345,"USA","USA",394,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-06-29,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","05/05/2023",2023-05-05
"3283",394,"Surie","Test-negative case-control","29Jun2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) (ascertained by immunization information system)","included","2","final","14+","hospitalization","severe","USA",">=18 years","general pop",32,"16",45,NA,"omicron BA.1, BA.2, BA.4/BA.5","~82 weeks",NA,NA,3346,"USA","USA",394,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-06-29,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron","05/05/2023",2023-05-05
"3284",395,"Langlete","Retrospective cohort","10May2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7-112","infection","infection","Norway","HCW 18-66 years","HCW",73.3,"70.6",75.8,NA,"delta","~43 weeks",NA,NA,3347,"Norway","NOR",395,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-10,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-05-10
"3285",395,"Langlete","Retrospective cohort","10May2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","225-336","infection","infection","Norway","HCW 18-66 years","HCW",8.9,"-2.1",18.7,NA,"delta","~43 weeks",NA,NA,3348,"Norway","NOR",395,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-10,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-05-10
"3286",395,"Langlete","Retrospective cohort","10May2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7-112","infection","infection","Norway","18-66 years","18-66 years",68.7,"67.7",69.7,NA,"delta","~43 weeks",NA,NA,3349,"Norway","NOR",395,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-10,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-05-10
"3287",395,"Langlete","Retrospective cohort","10May2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","225-336","infection","infection","Norway","18-66 years","18-66 years",10.6,"-15.4",30.8,NA,"delta","~43 weeks",NA,NA,3350,"Norway","NOR",395,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-10,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-05-10
"3288",395,"Langlete","Retrospective cohort","10May2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7-112","infection","infection","Norway","HCW 18-66 years","HCW",16.7,"10.5",22.4,NA,"omicron BA.1","~54 weeks",NA,NA,3351,"Norway","NOR",395,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-10,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-05-10
"3289",395,"Langlete","Retrospective cohort","10May2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","225-336","infection","infection","Norway","HCW 18-66 years","HCW",9.7,"2.3",16.6,NA,"omicron BA.1","~54 weeks",NA,NA,3352,"Norway","NOR",395,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-10,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-05-10
"3290",395,"Langlete","Retrospective cohort","10May2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","7-112","infection","infection","Norway","18-66 years","18-66 years",-32.6,"-35.6",-29.7,NA,"omicron BA.1","~54 weeks",NA,NA,3353,"Norway","NOR",395,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-10,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-05-10
"3291",395,"Langlete","Retrospective cohort","10May2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","225-336","infection","infection","Norway","18-66 years","18-66 years",-29.8,"-37.9",-22.2,NA,"omicron BA.1","~54 weeks",NA,NA,3354,"Norway","NOR",395,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-10,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-05-10
"3292",396,"Park","Retrospective cohort","15May2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","death","death","South Korea",">=60 years",">=60 years",72,"70",74,NA,"omicron BA.1, BA.2, BA.4/BA.5","~80 weeks",NA,NA,3355,"South Korea","KOR",396,"KOR",33830,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,201,241,"equal","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-05-15,"death","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-05-15
"3293",396,"Park","Retrospective cohort","15May2023","AZD1222 (AstraZeneca)","included","2","final","14+","death","death","South Korea",">=60 years",">=60 years",65,"62",68,NA,"omicron BA.1, BA.2, BA.4/BA.5","~80 weeks",NA,NA,3356,"South Korea","KOR",396,"KOR",33830,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,201,241,"equal","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-05-15,"death","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2023-05-15
"3294",396,"Park","Retrospective cohort","15May2023","AZD1222 (AstraZeneca) + any mRNA - heterologous","included","2","final","14+","death","death","South Korea",">=60 years",">=60 years",55,"44",60,NA,"omicron BA.1, BA.2, BA.4/BA.5","~80 weeks",NA,NA,3357,"South Korea","KOR",396,"KOR",33830,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,201,241,"equal","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-05-15,"death","2023 (Jan-Jun)","Heterologous platforms","Multiple","omicron",NA,2023-05-15
"3295",396,"Park","Retrospective cohort","15May2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","critical infection","severe","South Korea",">=60 years",">=60 years",68,"67",69,NA,"omicron BA.1, BA.2, BA.4/BA.5","~80 weeks",NA,NA,3358,"South Korea","KOR",396,"KOR",33830,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,201,241,"equal","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-05-15,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-05-15
"3296",396,"Park","Retrospective cohort","15May2023","AZD1222 (AstraZeneca)","included","2","final","14+","critical infection","severe","South Korea",">=60 years",">=60 years",72,"70",74,NA,"omicron BA.1, BA.2, BA.4/BA.5","~80 weeks",NA,NA,3359,"South Korea","KOR",396,"KOR",33830,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,201,241,"equal","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-05-15,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2023-05-15
"3297",396,"Park","Retrospective cohort","15May2023","AZD1222 (AstraZeneca) + any mRNA - heterologous","included","2","final","14+","critical infection","severe","South Korea",">=60 years",">=60 years",61,"55",67,NA,"omicron BA.1, BA.2, BA.4/BA.5","~80 weeks",NA,NA,3360,"South Korea","KOR",396,"KOR",33830,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,201,241,"equal","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-05-15,"severe","2023 (Jan-Jun)","Heterologous platforms","Multiple","omicron",NA,2023-05-15
"3298",397,"Yung","Retrospective cohort","15May2023","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14+","infection","infection","Singapore","5-11 years","5-11 years",74,"67.7",79.1,NA,"omicron BA.4/BA.5","~34 weeks",NA,NA,3361,"Singapore","SGP",397,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-15,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-15
"3299",397,"Yung","Retrospective cohort","15May2023","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14-119","infection","infection","Singapore","5-11 years","5-11 years",67.9,"58.5",75.2,NA,"omicron BA.4/BA.5","~34 weeks",NA,NA,3362,"Singapore","SGP",397,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-15,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-15
"3300",397,"Yung","Retrospective cohort","15May2023","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","180+","infection","infection","Singapore","5-11 years","5-11 years",78.7,"70.4",84.7,NA,"omicron BA.4/BA.5","~34 weeks",NA,NA,3363,"Singapore","SGP",397,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-15,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-15
"3301",397,"Yung","Retrospective cohort","15May2023","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14+","infection","infection","Singapore","12-17 years","12-17 years",84.9,"77",90.1,NA,"omicron BA.4/BA.5","~68 weeks",NA,NA,3364,"Singapore","SGP",397,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-15,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-15
"3302",397,"Yung","Retrospective cohort","15May2023","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14+","infection","infection","Singapore","5-11 years","5-11 years",62.8,"42.3",76,NA,"omicron XBB","~47 weeks",NA,NA,3365,"Singapore","SGP",397,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-15,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-15
"3303",397,"Yung","Retrospective cohort","15May2023","BNT162b2 (Pfizer BioNTech)","previously infected only","2","final","14+","infection","infection","Singapore","12-17 years","12-17 years",57.9,"33.6",73.3,NA,"omicron XBB","~82 weeks",NA,NA,3366,"Singapore","SGP",397,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-05-15,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-15
"3304",398,"Ng","Test-negative case-control","26May2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","<180","infection","infection","Hong Kong","3-105 years","general pop",27,"4.2",44.5,NA,"omicron BA.2","~63 weeks",NA,NA,3367,"Hong Kong","HKG",398,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-05-26,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-26
"3305",398,"Ng","Test-negative case-control","26May2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","180+","infection","infection","Hong Kong","3-105 years","general pop",20.9,"-4.3",39.9,NA,"omicron BA.2","~63 weeks",NA,NA,3368,"Hong Kong","HKG",398,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-05-26,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-05-26
"3306",398,"Ng","Test-negative case-control","26May2023","CoronaVac (Sinovac)","excluded","2","final","<180","infection","infection","Hong Kong","3-105 years","general pop",22.9,"1.3",39.7,NA,"omicron BA.2","~63 weeks",NA,NA,3369,"Hong Kong","HKG",398,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-05-26,"infection","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-05-26
"3307",398,"Ng","Test-negative case-control","26May2023","CoronaVac (Sinovac)","excluded","2","final","180+","infection","infection","Hong Kong","3-105 years","general pop",16.8,"-15.4",39.9,NA,"omicron BA.2","~63 weeks",NA,NA,3370,"Hong Kong","HKG",398,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-05-26,"infection","2023 (Jan-Jun)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-05-26
"3308",399,"Monteiro","Target trial emulation","10Aug2023","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Brazil",">=60 years",">=60 years",55.8,"42.7",68.3,NA,"gamma","~30 weeks",NA,NA,3371,"Brazil","BRA",399,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-08-10,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","gamma","07/06/2023",2023-06-07
"3309",399,"Monteiro","Target trial emulation","10Aug2023","CoronaVac (Sinovac)","excluded","2","final","14+","ICU admission","severe","Brazil",">=60 years",">=60 years",68.4,"425.3",86.4,NA,"gamma","~30 weeks",NA,NA,3372,"Brazil","BRA",399,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-08-10,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","gamma","07/06/2023",2023-06-07
"3310",399,"Monteiro","Target trial emulation","10Aug2023","CoronaVac (Sinovac)","excluded","2","final","14+","death","death","Brazil",">=60 years",">=60 years",82.3,"66.3",93.9,NA,"gamma","~30 weeks",NA,NA,3373,"Brazil","BRA",399,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-08-10,"death","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","gamma","07/06/2023",2023-06-07
"3311",401,"Bozio","Retrospective cohort","18Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","ED or UC visit","symptomatic","USA",">=18 years","general pop",18,"14",22,NA,"omicron BA.1, BA.2","~73 weeks",NA,NA,3374,"USA","USA",401,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-18,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-02-18
"3312",401,"Bozio","Retrospective cohort","18Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-149","ED or UC visit","symptomatic","USA",">=18 years","general pop",21,"12",28,NA,"omicron BA.1, BA.2","~73 weeks",NA,NA,3375,"USA","USA",401,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-18,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-02-18
"3313",401,"Bozio","Retrospective cohort","18Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","ED or UC visit","symptomatic","USA",">=18 years","general pop",18,"14",22,NA,"omicron BA.1, BA.2","~73 weeks",NA,NA,3376,"USA","USA",401,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-18,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-02-18
"3314",401,"Bozio","Retrospective cohort","18Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA",">=18 years","general pop",39,"33",44,NA,"omicron BA.1, BA.2","~73 weeks",NA,NA,3377,"USA","USA",401,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-18,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-02-18
"3315",401,"Bozio","Retrospective cohort","18Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-149","hospitalization","severe","USA",">=18 years","general pop",39,"24",51,NA,"omicron BA.1, BA.2","~73 weeks",NA,NA,3378,"USA","USA",401,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-18,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-02-18
"3316",401,"Bozio","Retrospective cohort","18Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","hospitalization","severe","USA",">=18 years","general pop",39,"33",44,NA,"omicron BA.1, BA.2","~73 weeks",NA,NA,3379,"USA","USA",401,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-18,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-02-18
"3317",401,"Bozio","Retrospective cohort","18Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","ED or UC visit","symptomatic","USA",">=18 years","general pop",72,"70",74,NA,"delta","~49 weeks",NA,NA,3380,"USA","USA",401,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-18,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-02-18
"3318",401,"Bozio","Retrospective cohort","18Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-149","ED or UC visit","symptomatic","USA",">=18 years","general pop",82,"79",84,NA,"delta","~49 weeks",NA,NA,3381,"USA","USA",401,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-18,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-02-18
"3319",401,"Bozio","Retrospective cohort","18Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","ED or UC visit","symptomatic","USA",">=18 years","general pop",68,"65",70,NA,"delta","~49 weeks",NA,NA,3382,"USA","USA",401,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-18,"symptomatic","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-02-18
"3320",401,"Bozio","Retrospective cohort","18Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA",">=18 years","general pop",73,"70",75,NA,"delta","~49 weeks",NA,NA,3383,"USA","USA",401,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-18,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-02-18
"3321",401,"Bozio","Retrospective cohort","18Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-149","hospitalization","severe","USA",">=18 years","general pop",85,"81",88,NA,"delta","~49 weeks",NA,NA,3384,"USA","USA",401,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-18,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-02-18
"3322",401,"Bozio","Retrospective cohort","18Feb2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","hospitalization","severe","USA",">=18 years","general pop",69,"65",72,NA,"delta","~49 weeks",NA,NA,3385,"USA","USA",401,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-02-18,"severe","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta",NA,2023-02-18
"3323",403,"Wu","Target trial emulation","09Jan2024","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","USA","5-11 years","5-11 years",74.3,"72.2",76.2,NA,"omicron BA.1, BA.2, BA.2.12.1, BA.5","~48 weeks",NA,NA,3421,"USA","USA",403,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2024-01-09,"infection","2024 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/06/2023",2023-06-01
"3324",403,"Wu","Target trial emulation","09Jan2024","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","mild disease","symptomatic","USA","5-11 years","5-11 years",73.5,"69.2",77.1,NA,"omicron BA.1, BA.2, BA.2.12.1, BA.5","~48 weeks",NA,NA,3422,"USA","USA",403,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2024-01-09,"symptomatic","2024 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/06/2023",2023-06-01
"3325",403,"Wu","Target trial emulation","09Jan2024","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","moderate or severe disease","symptomatic","USA","5-11 years","5-11 years",75.5,"69",81,NA,"omicron BA.1, BA.2, BA.2.12.1, BA.5","~48 weeks",NA,NA,3423,"USA","USA",403,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2024-01-09,"symptomatic","2024 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/06/2023",2023-06-01
"3326",403,"Wu","Target trial emulation","09Jan2024","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","ICU admission","severe","USA","5-11 years","5-11 years",84.9,"64.8",93.5,NA,"omicron BA.1, BA.2, BA.2.12.1, BA.5","~48 weeks",NA,NA,3424,"USA","USA",403,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2024-01-09,"severe","2024 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/06/2023",2023-06-01
"3327",403,"Wu","Target trial emulation","09Jan2024","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","USA","12-20 years","12-20 years",85.5,"83.8",87.1,NA,"omicron BA.1, BA.2, BA.2.12.1, BA.5","~52 weeks",NA,NA,3425,"USA","USA",403,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2024-01-09,"infection","2024 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/06/2023",2023-06-01
"3328",403,"Wu","Target trial emulation","09Jan2024","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","mild disease","symptomatic","USA","12-20 years","12-20 years",87,"83.5",89.8,NA,"omicron BA.1, BA.2, BA.2.12.1, BA.5","~52 weeks",NA,NA,3426,"USA","USA",403,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2024-01-09,"symptomatic","2024 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/06/2023",2023-06-01
"3329",403,"Wu","Target trial emulation","09Jan2024","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","moderate or severe disease","symptomatic","USA","12-20 years","12-20 years",84.8,"77.3",89.9,NA,"omicron BA.1, BA.2, BA.2.12.1, BA.5","~52 weeks",NA,NA,3427,"USA","USA",403,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2024-01-09,"symptomatic","2024 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/06/2023",2023-06-01
"3330",403,"Wu","Target trial emulation","09Jan2024","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","ICU admission","severe","USA","12-20 years","12-20 years",91.5,"69.5",97.6,NA,"omicron BA.1, BA.2, BA.2.12.1, BA.5","~52 weeks",NA,NA,3428,"USA","USA",403,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2024-01-09,"severe","2024 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","01/06/2023",2023-06-01
"3331",403,"Wu","Target trial emulation","09Jan2024","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","USA","12-20 years","12-20 years",98.4,"98.1",98.7,NA,"delta","~22 weeks",NA,NA,3429,"USA","USA",403,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2024-01-09,"infection","2024 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","01/06/2023",2023-06-01
"3332",403,"Wu","Target trial emulation","09Jan2024","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","mild disease","symptomatic","USA","12-20 years","12-20 years",99,"98.5",99.3,NA,"delta","~22 weeks",NA,NA,3430,"USA","USA",403,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2024-01-09,"symptomatic","2024 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","01/06/2023",2023-06-01
"3333",403,"Wu","Target trial emulation","09Jan2024","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","moderate or severe disease","symptomatic","USA","12-20 years","12-20 years",98.7,"97.4",99.3,NA,"delta","~22 weeks",NA,NA,3431,"USA","USA",403,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2024-01-09,"symptomatic","2024 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","01/06/2023",2023-06-01
"3334",403,"Wu","Target trial emulation","09Jan2024","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","ICU admission","severe","USA","12-20 years","12-20 years",99,"92.5",99.9,NA,"delta","~22 weeks",NA,NA,3432,"USA","USA",403,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2024-01-09,"severe","2024 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","01/06/2023",2023-06-01
"3335",404,"Spicer","Retrospective cohort","12May2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-90","infection","infection","USA","12-17 years","12-17 years",31.5,"24.6",37.7,NA,"omicron BA.1","~35 weeks",NA,NA,3433,"USA","USA",404,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-12,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-05-12
"3336",404,"Spicer","Retrospective cohort","12May2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","151+","infection","infection","USA","12-17 years","12-17 years",1.3,"-2.4",4.9,NA,"omicron BA.1","~35 weeks",NA,NA,3434,"USA","USA",404,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-12,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-05-12
"3337",405,"Lowthian","Retrospective cohort","22Jun2023","BNT162b2 (Pfizer BioNTech)","included","2","final","0+","infection","infection","UK","4-11 years","4-11 years",87,"83",90,NA,"omicron BA.1, BA.2","~13 weeks",NA,NA,3435,"UK","GBR",405,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-06-22,"infection","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-06-22
"3338",405,"Lowthian","Retrospective cohort","22Jun2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","0+","infection","infection","UK","11-16 years","11-16 years",64,"62",65,NA,"delta & omicron BA.1, BA.2","~35 weeks",NA,NA,3436,"UK","GBR",405,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-06-22,"infection","2023 (Jan-Jun)","Multiple or heterologous RNA","mRNA","delta/omicron",NA,2023-06-22
"3339",406,"Aglipay","Test-negative case-control","28Jun2023","mRNA-1273 (Moderna)","included","2","final","7+","symptomatic disease","symptomatic","Canada","6m-5 years","6m-5 years",90,"53",99,NA,"omicron BA.5, BQ.1","~12 weeks",NA,NA,3437,"Canada","CAN",406,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-06-28,"symptomatic","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2023-06-28
"3340",406,"Aglipay","Test-negative case-control","28Jun2023","mRNA-1273 (Moderna)","included","2","final","7+","hospitalization","severe","Canada","6m-5 years","6m-5 years",82,"4",99,NA,"omicron BA.5, BQ.1","~12 weeks",NA,NA,3438,"Canada","CAN",406,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-06-28,"severe","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron",NA,2023-06-28
"3341",408,"Cegolon","Retrospective cohort","14Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected only","2","final","8+","infection","infection","Italy","HCW","HCW",51,"37",62,NA,"omicron BA.1, BA.2, BA.5, BQ.1","~104 weeks",NA,NA,3447,"Italy","ITA",408,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-07-14,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-07-14
"3342",409,"Tamada","Test-negative case-control","22Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14-34","infection","infection","Japan",">=20 years","general pop",89.1,"80.5",93.9,NA,"delta","~27 weeks",NA,NA,3448,"Japan","JPN",409,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"who","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-07-22,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-07-22
"3343",409,"Tamada","Test-negative case-control","22Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","56+","infection","infection","Japan",">=20 years","general pop",73.1,"59.7",82,NA,"delta","~27 weeks",NA,NA,3449,"Japan","JPN",409,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"who","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-07-22,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-07-22
"3344",409,"Tamada","Test-negative case-control","22Jul2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","Japan",">=20 years","general pop",81.8,"58.2",92.1,NA,"delta","~27 weeks",NA,NA,3450,"Japan","JPN",409,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"who","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-07-22,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-07-22
"3345",409,"Tamada","Test-negative case-control","22Jul2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Japan",">=20 years","general pop",78.2,"70.5",83.8,NA,"delta","~27 weeks",NA,NA,3451,"Japan","JPN",409,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"who","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-07-22,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-07-22
"3346",410,"Liu","Retrospective cohort","29Jul2023","mRNA-1273 (Moderna) vs. BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-63","infection","infection","Australia",">=18 years","general pop",-3,"-30",18,NA,"omicron BA.1, BA.2","~7 weeks",NA,"Note this estimate is comparative VE (reference group = receipt of BNT162b2 primary series 14-63 days prior rather than unvaccinated persons)",3452,"Australia","AUS",410,"AUS",54890,2019,"Australia","East Asia & Pacific","High income",4,"Oceania",2021-02-22,2021-09-24,2021-11-21,2021-02-21,2021-02-21,1,215,273,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-29,"infection","2023 (Jul-Dec)","Comparative","mRNA","omicron",NA,2023-07-29
"3347",410,"Liu","Retrospective cohort","29Jul2023","AZD1222 (AstraZeneca) vs. BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-63","infection","infection","Australia",">=18 years","general pop",-19,"-49",5,NA,"omicron BA.1, BA.2","~7 weeks",NA,"Note this estimate is comparative VE (reference group = receipt of BNT162b2 primary series 14-63 days prior rather than unvaccinated persons)",3453,"Australia","AUS",410,"AUS",54890,2019,"Australia","East Asia & Pacific","High income",4,"Oceania",2021-02-22,2021-09-24,2021-11-21,2021-02-21,2021-02-21,1,215,273,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-29,"infection","2023 (Jul-Dec)","Comparative","Multiple","omicron",NA,2023-07-29
"3348",410,"Liu","Retrospective cohort","29Jul2023","NVX-CoV2373 (Novavax) vs. BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-63","infection","infection","Australia",">=18 years","general pop",-70,"-97",-46,NA,"omicron BA.1, BA.2","~7 weeks",NA,"Note this estimate is comparative VE (reference group = receipt of BNT162b2 primary series 14-63 days prior rather than unvaccinated persons)",3454,"Australia","AUS",410,"AUS",54890,2019,"Australia","East Asia & Pacific","High income",4,"Oceania",2021-02-22,2021-09-24,2021-11-21,2021-02-21,2021-02-21,1,215,273,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-29,"infection","2023 (Jul-Dec)","Comparative","Multiple","omicron",NA,2023-07-29
"3349",410,"Liu","Retrospective cohort","29Jul2023","mRNA-1273 (Moderna) vs. BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-63","infection","infection","Australia",">=18 years","general pop",-15,"-62",18,NA,"omicron BA.2","~7 weeks",NA,"Note this estimate is comparative VE (reference group = receipt of BNT162b2 primary series 14-63 days prior rather than unvaccinated persons)",3455,"Australia","AUS",410,"AUS",54890,2019,"Australia","East Asia & Pacific","High income",4,"Oceania",2021-02-22,2021-09-24,2021-11-21,2021-02-21,2021-02-21,1,215,273,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-29,"infection","2023 (Jul-Dec)","Comparative","mRNA","omicron",NA,2023-07-29
"3350",410,"Liu","Retrospective cohort","29Jul2023","AZD1222 (AstraZeneca) vs. BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-63","infection","infection","Australia",">=18 years","general pop",1,"-51",35,NA,"omicron BA.2","~7 weeks",NA,"Note this estimate is comparative VE (reference group = receipt of BNT162b2 primary series 14-63 days prior rather than unvaccinated persons)",3456,"Australia","AUS",410,"AUS",54890,2019,"Australia","East Asia & Pacific","High income",4,"Oceania",2021-02-22,2021-09-24,2021-11-21,2021-02-21,2021-02-21,1,215,273,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-29,"infection","2023 (Jul-Dec)","Comparative","Multiple","omicron",NA,2023-07-29
"3351",410,"Liu","Retrospective cohort","29Jul2023","NVX-CoV2373 (Novavax) vs. BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-63","infection","infection","Australia",">=18 years","general pop",-71,"-105",-43,NA,"omicron BA.2","~7 weeks",NA,"Note this estimate is comparative VE (reference group = receipt of BNT162b2 primary series 14-63 days prior rather than unvaccinated persons)",3457,"Australia","AUS",410,"AUS",54890,2019,"Australia","East Asia & Pacific","High income",4,"Oceania",2021-02-22,2021-09-24,2021-11-21,2021-02-21,2021-02-21,1,215,273,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-29,"infection","2023 (Jul-Dec)","Comparative","Multiple","omicron",NA,2023-07-29
"3352",411,"Rosa","Test-negative case-control","26Jul2023","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","symptomatic disease","symptomatic","Brazil",">=12 years","general pop",46.7,"19.9",64.6,NA,"omicron BA.1, BA.2","~70 weeks",NA,NA,3458,"Brazil","BRA",411,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-26,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-07-26
"3353",411,"Rosa","Test-negative case-control","26Jul2023","BNT162b2 (Pfizer BioNTech)","included","2","final","7-29","symptomatic disease","symptomatic","Brazil",">=12 years","general pop",77.7,"54.8",89.4,NA,"omicron BA.1, BA.2","~70 weeks",NA,NA,3459,"Brazil","BRA",411,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-26,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-07-26
"3354",411,"Rosa","Test-negative case-control","26Jul2023","BNT162b2 (Pfizer BioNTech)","included","2","final","180+","symptomatic disease","symptomatic","Brazil",">=12 years","general pop",22.5,"-55.2",61.3,NA,"omicron BA.1, BA.2","~70 weeks",NA,NA,3460,"Brazil","BRA",411,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-26,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-07-26
"3355",411,"Rosa","Test-negative case-control","26Jul2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","symptomatic disease","symptomatic","Brazil",">=12 years","general pop",58.2,"27.7",76,NA,"omicron BA.1","~70 weeks",NA,NA,3461,"Brazil","BRA",411,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-26,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-07-26
"3356",411,"Rosa","Test-negative case-control","26Jul2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","symptomatic disease","symptomatic","Brazil",">=12 years","general pop",51.5,"-82.5",69.4,NA,"omicron BA.2","~70 weeks",NA,NA,3462,"Brazil","BRA",411,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-26,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-07-26
"3357",411,"Rosa","Test-negative case-control","26Jul2023","BNT162b2 (Pfizer BioNTech) vs. AZD1222 (AstraZeneca)","included","2","final","14+","symptomatic disease","symptomatic","Brazil",">=12 years","general pop",25,"5",41,NA,"omicron BA.1, BA.2","~70 weeks",NA,"Note this estimate is comparative VE (reference group = receipt of BNT162b2 primary series rather than unvaccinated persons)",3463,"Brazil","BRA",411,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-26,"symptomatic","2023 (Jul-Dec)","Comparative","Multiple","omicron",NA,2023-07-26
"3358",411,"Rosa","Test-negative case-control","26Jul2023","BNT162b2 (Pfizer BioNTech) vs. CoronaVac (Sinovac)","included","2","final","14+","symptomatic disease","symptomatic","Brazil",">=12 years","general pop",33,"8",51,NA,"omicron BA.1, BA.2","~70 weeks",NA,"Note this estimate is comparative VE (reference group = receipt of BNT162b2 primary series rather than unvaccinated persons)",3464,"Brazil","BRA",411,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-26,"symptomatic","2023 (Jul-Dec)","Comparative","Multiple","omicron",NA,2023-07-26
"3359",411,"Rosa","Test-negative case-control","26Jul2023","BNT162b2 (Pfizer BioNTech) vs. Ad26.COV2.S (Janssen)","included","2","final","14+","symptomatic disease","symptomatic","Brazil",">=12 years","general pop",14,"-52",51,NA,"omicron BA.1, BA.2","~70 weeks",NA,"Note this estimate is comparative VE (reference group = receipt of BNT162b2 primary series rather than unvaccinated persons)",3465,"Brazil","BRA",411,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"who","jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-07-26,"symptomatic","2023 (Jul-Dec)","Comparative","Multiple","omicron",NA,2023-07-26
"3360",412,"Franchi","Nested case-control","01Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Italy",">=12 years","general pop",18,"13",23,NA,"omicron BA.1, BA.2","~72 weeks",NA,NA,3466,"Italy","ITA",412,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-08-01,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-08-01
"3361",412,"Franchi","Nested case-control","01Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","14+","infection","infection","Italy",">=12 years","general pop",81,"65",89,NA,"delta","~43 weeks",NA,NA,3467,"Italy","ITA",412,"ITA",34890,2019,"Italy","Europe & Central Asia","High income",4,"Europe",2020-12-27,2021-07-12,2021-10-04,2020-12-23,2020-12-23,4,201,285,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-08-01,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-08-01
"3362",413,"Whitaker","Retrospective cohort","12Aug2023","AZD1222 (AstraZeneca)","included","2","final","14-69","death","death","UK","general pop with overrepsentation of clinical risk groups (30%)","general pop with overrepsentation of clinical risk groups (30%)",89.9,"86.1",92.6,NA,"delta","~44 weeks",NA,NA,3468,"UK","GBR",413,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-08-12,"death","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-08-12
"3363",413,"Whitaker","Retrospective cohort","12Aug2023","AZD1222 (AstraZeneca)","included","2","final","182+","death","death","UK","general pop with overrepsentation of clinical risk groups (30%)","general pop with overrepsentation of clinical risk groups (30%)",72.3,"67.6",76.4,NA,"delta","~44 weeks",NA,NA,3469,"UK","GBR",413,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-08-12,"death","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-08-12
"3364",413,"Whitaker","Retrospective cohort","12Aug2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-69","death","death","UK","general pop with overrepsentation of clinical risk groups (30%)","general pop with overrepsentation of clinical risk groups (30%)",95.5,"91.8",97.5,NA,"delta","~47 weeks",NA,NA,3470,"UK","GBR",413,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-08-12,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-08-12
"3365",413,"Whitaker","Retrospective cohort","12Aug2023","BNT162b2 (Pfizer BioNTech)","included","2","final","182+","death","death","UK","general pop with overrepsentation of clinical risk groups (30%)","general pop with overrepsentation of clinical risk groups (30%)",81.7,"78.7",84.3,NA,"delta","~47 weeks",NA,NA,3471,"UK","GBR",413,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-08-12,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-08-12
"3366",413,"Whitaker","Retrospective cohort","12Aug2023","AZD1222 (AstraZeneca)","included","2","final","14-69","hospitalization","hospitalization","UK","general pop with overrepsentation of clinical risk groups (30%)","general pop with overrepsentation of clinical risk groups (30%)",92.5,"91.7",93.2,NA,"delta","~44 weeks",NA,NA,3472,"UK","GBR",413,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-08-12,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-08-12
"3367",413,"Whitaker","Retrospective cohort","12Aug2023","AZD1222 (AstraZeneca)","included","2","final","182+","hospitalization","hospitalization","UK","general pop with overrepsentation of clinical risk groups (30%)","general pop with overrepsentation of clinical risk groups (30%)",68.7,"66.3",71,NA,"delta","~44 weeks",NA,NA,3473,"UK","GBR",413,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-08-12,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-08-12
"3368",413,"Whitaker","Retrospective cohort","12Aug2023","AZD1222 (AstraZeneca)","included","2","final","14-69","hospitalization","hospitalization","UK","Immunocompromised","Immunocompromised",76.6,"66.9",83.4,NA,"delta","~44 weeks",NA,NA,3474,"UK","GBR",413,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-08-12,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-08-12
"3369",413,"Whitaker","Retrospective cohort","12Aug2023","AZD1222 (AstraZeneca)","included","2","final","182+","hospitalization","hospitalization","UK","Immunocompromised","Immunocompromised",62.1,"51.4",70.5,NA,"delta","~44 weeks",NA,NA,3475,"UK","GBR",413,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-08-12,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-08-12
"3370",413,"Whitaker","Retrospective cohort","12Aug2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-69","hospitalization","hospitalization","UK","general pop with overrepsentation of clinical risk groups (30%)","general pop with overrepsentation of clinical risk groups (30%)",96,"95.1",96.7,NA,"delta","~47 weeks",NA,NA,3476,"UK","GBR",413,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-08-12,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-08-12
"3371",413,"Whitaker","Retrospective cohort","12Aug2023","BNT162b2 (Pfizer BioNTech)","included","2","final","182+","hospitalization","hospitalization","UK","general pop with overrepsentation of clinical risk groups (30%)","general pop with overrepsentation of clinical risk groups (30%)",82.9,"81.4",84.2,NA,"delta","~47 weeks",NA,NA,3477,"UK","GBR",413,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-08-12,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-08-12
"3372",413,"Whitaker","Retrospective cohort","12Aug2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-69","hospitalization","hospitalization","UK","Immunocompromised","Immunocompromised",86.7,"76.8",92.4,NA,"delta","~47 weeks",NA,NA,3478,"UK","GBR",413,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-08-12,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-08-12
"3373",413,"Whitaker","Retrospective cohort","12Aug2023","BNT162b2 (Pfizer BioNTech)","included","2","final","182+","hospitalization","hospitalization","UK","Immunocompromised","Immunocompromised",72.1,"64.1",78.3,NA,"delta","~47 weeks",NA,NA,3479,"UK","GBR",413,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-08-12,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-08-12
"3374",414,"Link-Gelles","Test-negative case-control","17Aug2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","ED or UC visit","symptomatic","USA","6 months - 5 years","6 months - 5 years",37,"19",51,NA,"omicron BA.4, BA.5","~44 weeks",NA,NA,3480,"USA","USA",414,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-08-17,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-08-17
"3375",414,"Link-Gelles","Test-negative case-control","17Aug2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-59","ED or UC visit","symptomatic","USA","6 months - 5 years","6 months - 5 years",46,"22",62,NA,"omicron BA.4, BA.5","~44 weeks",NA,NA,3481,"USA","USA",414,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-08-17,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-08-17
"3376",414,"Link-Gelles","Test-negative case-control","17Aug2023","BNT162b2 (Pfizer BioNTech)","included","2","final","60+","ED or UC visit","symptomatic","USA","6 months - 5 years","6 months - 5 years",27,"-2",47,NA,"omicron BA.4, BA.5","~44 weeks",NA,NA,3482,"USA","USA",414,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-08-17,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-08-17
"3377",414,"Link-Gelles","Test-negative case-control","17Aug2023","mRNA-1273 (Moderna)","included","2","final","14+","ED or UC visit","symptomatic","USA","6 months - 4 years","6 months - 4 years",29,"12",42,NA,"omicron BA.4, BA.5","~44 weeks",NA,NA,3483,"USA","USA",414,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-08-17,"symptomatic","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2023-08-17
"3378",414,"Link-Gelles","Test-negative case-control","17Aug2023","mRNA-1273 (Moderna)","included","2","final","14-59","ED or UC visit","symptomatic","USA","6 months - 4 years","6 months - 4 years",46,"17",64,NA,"omicron BA.4, BA.5","~44 weeks",NA,NA,3484,"USA","USA",414,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-08-17,"symptomatic","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2023-08-17
"3379",414,"Link-Gelles","Test-negative case-control","17Aug2023","mRNA-1273 (Moderna)","included","2","final","60+","ED or UC visit","symptomatic","USA","6 months - 4 years","6 months - 4 years",21,"-1",38,NA,"omicron BA.4, BA.5","~44 weeks",NA,NA,3485,"USA","USA",414,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-08-17,"symptomatic","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2023-08-17
"3380",415,"Zerbo","Test-negative case-control","25Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<150","infection","infection","USA","16-49 years","16-49 years",22,"-7",44,NA,"omicron BA.1","~80 weeks",NA,NA,3486,"USA","USA",415,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-08-25,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-08-25
"3381",415,"Zerbo","Test-negative case-control","25Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","infection","infection","USA","16-49 years","16-49 years",19,"-2",50,NA,"omicron BA.1","~80 weeks",NA,NA,3487,"USA","USA",415,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-08-25,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-08-25
"3382",415,"Zerbo","Test-negative case-control","25Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<150","infection","infection","USA","16-49 years","16-49 years",12,"-48",59,NA,"omicron BA.2, BA.4/BA.5","~55 weeks",NA,NA,3488,"USA","USA",415,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-08-25,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-08-25
"3383",415,"Zerbo","Test-negative case-control","25Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","infection","infection","USA","16-49 years","16-49 years",-55,"-79",-6,NA,"omicron BA.2, BA.4/BA.5","~55 weeks",NA,NA,3489,"USA","USA",415,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-08-25,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-08-25
"3384",415,"Zerbo","Test-negative case-control","25Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<150","infection","infection","USA","16-49 years","16-49 years",77,"69",82,NA,"delta","~42 weeks",NA,NA,3490,"USA","USA",415,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-08-25,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-08-25
"3385",415,"Zerbo","Test-negative case-control","25Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","infection","infection","USA","16-49 years","16-49 years",66,"49",77,NA,"delta","~42 weeks",NA,NA,3491,"USA","USA",415,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-08-25,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-08-25
"3386",415,"Zerbo","Retrospective cohort","25Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<150","infection","infection","USA","16-49 years","16-49 years",14,"-5",30,NA,"omicron BA.1","~80 weeks",NA,NA,3492,"USA","USA",415,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-08-25,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-08-25
"3387",415,"Zerbo","Retrospective cohort","25Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","infection","infection","USA","16-49 years","16-49 years",10,"-17",33,NA,"omicron BA.1","~80 weeks",NA,NA,3493,"USA","USA",415,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-08-25,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-08-25
"3388",415,"Zerbo","Retrospective cohort","25Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<150","infection","infection","USA","16-49 years","16-49 years",-16,"-60",43,NA,"omicron BA.2, BA.4/BA.5","~55 weeks",NA,NA,3494,"USA","USA",415,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-08-25,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-08-25
"3389",415,"Zerbo","Retrospective cohort","25Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","infection","infection","USA","16-49 years","16-49 years",-33,"-65",24,NA,"omicron BA.2, BA.4/BA.5","~55 weeks",NA,NA,3495,"USA","USA",415,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-08-25,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-08-25
"3390",415,"Zerbo","Retrospective cohort","25Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","<150","infection","infection","USA","16-49 years","16-49 years",78,"72",83,NA,"delta","~42 weeks",NA,NA,3496,"USA","USA",415,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-08-25,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-08-25
"3391",415,"Zerbo","Retrospective cohort","25Aug2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","150+","infection","infection","USA","16-49 years","16-49 years",68,"52",78,NA,"delta","~42 weeks",NA,NA,3497,"USA","USA",415,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-08-25,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-08-25
"3392",416,"Ogilvie","Retrospective cohort","08Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA","5-17 years","5-17 years",9,"-1",19,NA,"omicron BA.1, BA.2","~69 weeks",NA,NA,3498,"USA","USA",416,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-08,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-09-08
"3393",416,"Ogilvie","Retrospective cohort","08Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization or ED visit","symptomatic or severe","USA","5-17 years","5-17 years",13,"-39",46,NA,"omicron BA.1, BA.2","~69 weeks",NA,NA,3499,"USA","USA",416,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-08,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-09-08
"3394",416,"Ogilvie","Retrospective cohort","08Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA","5-17 years","5-17 years",61,"59",64,NA,"delta","~47 weeks",NA,NA,3500,"USA","USA",416,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-08,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-09-08
"3395",416,"Ogilvie","Retrospective cohort","08Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization or ED visit","symptomatic or severe","USA","5-17 years","5-17 years",78,"71",83,NA,"delta","~47 weeks",NA,NA,3501,"USA","USA",416,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-08,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-09-08
"3396",416,"Ogilvie","Retrospective cohort","08Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","infection","infection","USA","5-17 years","5-17 years",61,"52",68,NA,"non-VOC & alpha","~17 weeks",NA,NA,3502,"USA","USA",416,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-08,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-09-08
"3397",416,"Ogilvie","Retrospective cohort","08Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization or ED visit","symptomatic or severe","USA","5-17 years","5-17 years",65,"4",87,NA,"non-VOC & alpha","~17 weeks",NA,NA,3503,"USA","USA",416,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-08,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-09-08
"3398",417,"Copland","Nested case-control","07Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-41","hospitalization","severe","UK",">=12 years with blood cancer",">=12 years with blood cancer",72,"18",89,NA,"alpha, delta, & omicron BA.1","~65 weeks",NA,NA,3504,"UK","GBR",417,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-09-07
"3399",417,"Copland","Nested case-control","07Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","182+","hospitalization","severe","UK",">=12 years with blood cancer",">=12 years with blood cancer",-46,"-130",7,NA,"alpha, delta, & omicron BA.1","~65 weeks",NA,NA,3505,"UK","GBR",417,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-09-07
"3400",417,"Copland","Nested case-control","07Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","42-97","death","death","UK",">=12 years with blood cancer",">=12 years with blood cancer",64,"-3",87,NA,"alpha, delta, & omicron BA.1","~65 weeks",NA,NA,3506,"UK","GBR",417,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-09-07
"3401",417,"Copland","Nested case-control","07Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","182+","death","death","UK",">=12 years with blood cancer",">=12 years with blood cancer",-52,"-176",17,NA,"alpha, delta, & omicron BA.1","~65 weeks",NA,NA,3507,"UK","GBR",417,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-09-07
"3402",417,"Copland","Nested case-control","07Sep2023","AZD1222 (AstraZeneca)","included","2","final","14-41","hospitalization","severe","UK",">=12 years with blood cancer",">=12 years with blood cancer",15,"-77",59,NA,"alpha, delta, & omicron BA.1","~56 weeks",NA,NA,3508,"UK","GBR",417,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-09-07
"3403",417,"Copland","Nested case-control","07Sep2023","AZD1222 (AstraZeneca)","included","2","final","182+","hospitalization","severe","UK",">=12 years with blood cancer",">=12 years with blood cancer",6,"-47",39,NA,"alpha, delta, & omicron BA.1","~56 weeks",NA,NA,3509,"UK","GBR",417,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-09-07
"3404",417,"Copland","Nested case-control","07Sep2023","AZD1222 (AstraZeneca)","included","2","final","42-97","death","death","UK",">=12 years with blood cancer",">=12 years with blood cancer",-13,"-188",55,NA,"alpha, delta, & omicron BA.1","~56 weeks",NA,NA,3510,"UK","GBR",417,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"death","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-09-07
"3405",417,"Copland","Nested case-control","07Sep2023","AZD1222 (AstraZeneca)","included","2","final","182+","death","death","UK",">=12 years with blood cancer",">=12 years with blood cancer",-100,"-283",-4,NA,"alpha, delta, & omicron BA.1","~56 weeks",NA,NA,3511,"UK","GBR",417,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"death","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-09-07
"3406",417,"Copland","Nested case-control","07Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-41","hospitalization","severe","UK",">=12 years","general pop",61,"56",66,NA,"alpha, delta, & omicron BA.1","~65 weeks",NA,NA,3512,"UK","GBR",417,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-09-07
"3407",417,"Copland","Nested case-control","07Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","182+","hospitalization","severe","UK",">=12 years","general pop",-38,"-48",-29,NA,"alpha, delta, & omicron BA.1","~65 weeks",NA,NA,3513,"UK","GBR",417,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-09-07
"3408",417,"Copland","Nested case-control","07Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-41","death","death","UK",">=12 years","general pop",80,"73",85,NA,"alpha, delta, & omicron BA.1","~65 weeks",NA,NA,3514,"UK","GBR",417,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-09-07
"3409",417,"Copland","Nested case-control","07Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","182+","death","death","UK",">=12 years","general pop",-97,"-127",-72,NA,"alpha, delta, & omicron BA.1","~65 weeks",NA,NA,3515,"UK","GBR",417,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-09-07
"3410",417,"Copland","Nested case-control","07Sep2023","AZD1222 (AstraZeneca)","included","2","final","14-41","hospitalization","severe","UK",">=12 years","general pop",66,"61",70,NA,"alpha, delta, & omicron BA.1","~56 weeks",NA,NA,3516,"UK","GBR",417,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-09-07
"3411",417,"Copland","Nested case-control","07Sep2023","AZD1222 (AstraZeneca)","included","2","final","182+","hospitalization","severe","UK",">=12 years","general pop",-22,"-31",-13,NA,"alpha, delta, & omicron BA.1","~56 weeks",NA,NA,3517,"UK","GBR",417,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-09-07
"3412",417,"Copland","Nested case-control","07Sep2023","AZD1222 (AstraZeneca)","included","2","final","14-41","death","death","UK",">=12 years","general pop",62,"43",75,NA,"alpha, delta, & omicron BA.1","~56 weeks",NA,NA,3518,"UK","GBR",417,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"death","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-09-07
"3413",417,"Copland","Nested case-control","07Sep2023","AZD1222 (AstraZeneca)","included","2","final","182+","death","death","UK",">=12 years","general pop",-74,"-101",-50,NA,"alpha, delta, & omicron BA.1","~56 weeks",NA,NA,3519,"UK","GBR",417,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-09-07,"death","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-09-07
"3414",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","AZD1222 (AstraZeneca)","excluded","2","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",36,"24",47,NA,"omicron BA.1","~43 weeks",NA,NA,3520,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2023-09-09
"3415",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","AZD1222 (AstraZeneca)","excluded","2","final","165+","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",-8,"-34",13,NA,"omicron BA.1","~43 weeks",NA,NA,3521,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2023-09-09
"3416",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","AZD1222 (AstraZeneca)","excluded","2","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",10,"-78",55,NA,"omicron BA.1","~43 weeks",NA,NA,3522,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2023-09-09
"3417",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","CoronaVac (Sinovac)","excluded","2","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",37,"8",56,NA,"omicron BA.1","~46 weeks",NA,NA,3523,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-09-09
"3418",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","CoronaVac (Sinovac)","excluded","2","final","165+","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",-36,"-48",24,NA,"omicron BA.1","~46 weeks",NA,NA,3524,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-09-09
"3419",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",7,"-41",38,NA,"omicron BA.1","~46 weeks",NA,NA,3525,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-09-09
"3420",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",59,"45",70,NA,"omicron BA.1","~47 weeks",NA,NA,3526,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-09-09
"3421",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","165+","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",4,"-2",11,NA,"omicron BA.1","~47 weeks",NA,NA,3527,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-09-09
"3422",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",45,"1",70,NA,"omicron BA.1","~47 weeks",NA,NA,3528,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-09-09
"3423",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","mRNA-1273 (Moderna)","excluded","2","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",65,"54",74,NA,"omicron BA.1","~25 weeks",NA,NA,3529,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2023-09-09
"3424",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","mRNA-1273 (Moderna)","excluded","2","final","165+","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",-22,"-639",80,NA,"omicron BA.1","~25 weeks",NA,NA,3530,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2023-09-09
"3425",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",95,"54",99,NA,"omicron BA.1","~25 weeks",NA,NA,3531,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron",NA,2023-09-09
"3426",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","Ad26.COV2.S (Janssen)","excluded","1","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",34,"11",51,NA,"omicron BA.1","~33 weeks",NA,NA,3532,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2023-09-09
"3427",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","Ad26.COV2.S (Janssen)","excluded","1","final","165+","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",-29,"-43",17,NA,"omicron BA.1","~33 weeks",NA,NA,3533,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2023-09-09
"3428",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",-5,"-158",57,NA,"omicron BA.1","~33 weeks",NA,NA,3534,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","omicron",NA,2023-09-09
"3429",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","AZD1222 (AstraZeneca)","excluded","2","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",-2,"-32",21,NA,"delta","~32 weeks",NA,NA,3535,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-09-09
"3430",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","AZD1222 (AstraZeneca)","excluded","2","final","165+","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",54,"-177",92,NA,"delta","~32 weeks",NA,NA,3536,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-09-09
"3431",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","AZD1222 (AstraZeneca)","excluded","2","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",71,"27",89,NA,"delta","~32 weeks",NA,NA,3537,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-09-09
"3432",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","CoronaVac (Sinovac)","excluded","2","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",31,"10",47,NA,"delta","~35 weeks",NA,NA,3538,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2023-09-09
"3433",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","CoronaVac (Sinovac)","excluded","2","final","165+","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",34,"18",47,NA,"delta","~35 weeks",NA,NA,3539,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2023-09-09
"3434",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",63,"35",79,NA,"delta","~35 weeks",NA,NA,3540,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2023-09-09
"3435",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",10,"-20",33,NA,"delta","~36 weeks",NA,NA,3541,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-09-09
"3436",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","165+","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",62,"57",67,NA,"delta","~36 weeks",NA,NA,3542,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-09-09
"3437",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",91,"79",96,NA,"delta","~36 weeks",NA,NA,3543,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-09-09
"3438",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","mRNA-1273 (Moderna)","excluded","2","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",52,"41",61,NA,"delta","~14 weeks",NA,NA,3544,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2023-09-09
"3439",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","mRNA-1273 (Moderna)","excluded","2","final","105-134","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",89,"-8",99,NA,"delta","~14 weeks",NA,NA,3545,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta",NA,2023-09-09
"3440",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","Ad26.COV2.S (Janssen)","excluded","1","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",7,"-19",27,NA,"delta","~22 weeks",NA,NA,3546,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2023-09-09
"3441",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","Ad26.COV2.S (Janssen)","excluded","1","final","165+","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",70,"-5",92,NA,"delta","~22 weeks",NA,NA,3547,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2023-09-09
"3442",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","Ad26.COV2.S (Janssen)","excluded","1","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",73,"23",91,NA,"delta","~22 weeks",NA,NA,3548,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","delta",NA,2023-09-09
"3443",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","AZD1222 (AstraZeneca)","excluded","2","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",62,"26",81,NA,"mu","~14 weeks",NA,NA,3549,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","mu",NA,2023-09-09
"3444",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","AZD1222 (AstraZeneca)","excluded","2","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",-57,"-1646",86,NA,"mu","~14 weeks",NA,NA,3550,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","mu",NA,2023-09-09
"3445",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","CoronaVac (Sinovac)","excluded","2","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",56,"46",65,NA,"mu","~18 weeks",NA,NA,3551,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","mu",NA,2023-09-09
"3446",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","CoronaVac (Sinovac)","excluded","2","final","165+","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",59,"-385",97,NA,"mu","~18 weeks",NA,NA,3552,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","mu",NA,2023-09-09
"3447",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",68,"24",86,NA,"mu","~18 weeks",NA,NA,3553,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","mu",NA,2023-09-09
"3448",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",67,"61",72,NA,"mu","~19 weeks",NA,NA,3554,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","mu",NA,2023-09-09
"3449",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","165+","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",77,"53",89,NA,"mu","~19 weeks",NA,NA,3555,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","mu",NA,2023-09-09
"3450",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",88,"59",96,NA,"mu","~19 weeks",NA,NA,3556,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","mu",NA,2023-09-09
"3451",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","Ad26.COV2.S (Janssen)","excluded","1","final","14-44","symptomatic disease","symptomatic","Colombia",">=5 years","general pop",50,"33",63,NA,"mu","~5 weeks",NA,NA,3557,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"who","feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"symptomatic","2023 (Jul-Dec)","Janssen Ad26.COV2.S","Vectored","mu",NA,2023-09-09
"3452",419,"Chen","Nested test-negative case-control","14Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-41","hospitalization","severe","UK","Immunocompromised","immunocompromised",77,"63",86,NA,"alpha, delta, & omicron BA.1","~50 weeks",NA,NA,3558,"UK","GBR",419,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-09-14,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-09-14
"3453",419,"Chen","Nested test-negative case-control","14Sep2023","BNT162b2 (Pfizer BioNTech)","included","2","final","182-272","hospitalization","severe","UK","Immunocompromised","immunocompromised",49,"13",70,NA,"alpha, delta, & omicron BA.1","~50 weeks",NA,NA,3559,"UK","GBR",419,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-09-14,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","other combinations",NA,2023-09-14
"3454",419,"Chen","Nested test-negative case-control","14Sep2023","AZD1222 (AstraZeneca)","included","2","final","14-41","hospitalization","severe","UK","Immunocompromised","immunocompromised",43,"-9",70,NA,"alpha, delta, & omicron BA.1","~50 weeks",NA,NA,3560,"UK","GBR",419,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-09-14,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-09-14
"3455",419,"Chen","Nested test-negative case-control","14Sep2023","AZD1222 (AstraZeneca)","included","2","final","42-97","hospitalization","severe","UK","Immunocompromised","immunocompromised",31,"-33",64,NA,"alpha, delta, & omicron BA.1","~50 weeks",NA,NA,3561,"UK","GBR",419,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-09-14,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","other combinations",NA,2023-09-14
"3456",420,"Irala","Test-negative case-control","15Sep2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization due to SARI","severe","Paraguay",">=5 years","general pop",45.3,"5.8",68.7,NA,"omicron BA.1","~52 weeks",NA,NA,3562,"Paraguay","PRY",420,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2023-09-15,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-09-15
"3457",420,"Irala","Test-negative case-control","15Sep2023","AZD1222 (AstraZeneca)","included","2","final","14+","hospitalization due to SARI","severe","Paraguay",">=5 years","general pop",10,"-31.3",38.2,NA,"omicron BA.1","~52 weeks",NA,NA,3563,"Paraguay","PRY",420,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2023-09-15,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron",NA,2023-09-15
"3458",420,"Irala","Test-negative case-control","15Sep2023","Gam-COVID-Vac (Gamaleya)","included","2","final","14+","hospitalization due to SARI","severe","Paraguay",">=5 years","general pop",25.4,"-30.2",57.5,NA,"omicron BA.1","~52 weeks",NA,NA,3564,"Paraguay","PRY",420,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2023-09-15,"severe","2023 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","omicron",NA,2023-09-15
"3459",420,"Irala","Test-negative case-control","15Sep2023","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","hospitalization due to SARI","severe","Paraguay",">=5 years","general pop",42.3,"-2",67.6,NA,"omicron BA.1","~52 weeks",NA,NA,3565,"Paraguay","PRY",420,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2023-09-15,"severe","2023 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","omicron",NA,2023-09-15
"3460",420,"Irala","Test-negative case-control","15Sep2023","BBV152 (Bharat)","included","2","final","14+","hospitalization due to SARI","severe","Paraguay",">=5 years","general pop",13,"-46.1",48,NA,"omicron BA.1","~52 weeks",NA,NA,3566,"Paraguay","PRY",420,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2023-09-15,"severe","2023 (Jul-Dec)","Bharat Covaxin/BBV152","Inactivated","omicron",NA,2023-09-15
"3461",420,"Irala","Test-negative case-control","15Sep2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization due to SARI","severe","Paraguay",">=5 years","general pop",90.4,"74.3",97.3,NA,"delta","~37 weeks",NA,NA,3567,"Paraguay","PRY",420,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2023-09-15,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-09-15
"3462",420,"Irala","Test-negative case-control","15Sep2023","AZD1222 (AstraZeneca)","included","2","final","14+","hospitalization due to SARI","severe","Paraguay",">=5 years","general pop",83.2,"67.8",91.9,NA,"delta","~37 weeks",NA,NA,3568,"Paraguay","PRY",420,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2023-09-15,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-09-15
"3463",420,"Irala","Test-negative case-control","15Sep2023","Gam-COVID-Vac (Gamaleya)","included","2","final","14+","hospitalization due to SARI","severe","Paraguay",">=5 years","general pop",82.9,"53",95.2,NA,"delta","~37 weeks",NA,NA,3569,"Paraguay","PRY",420,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2023-09-15,"severe","2023 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta",NA,2023-09-15
"3464",420,"Irala","Test-negative case-control","15Sep2023","BBIBP-CorV (Beijing CNBG)","included","2","final","14+","hospitalization due to SARI","severe","Paraguay",">=5 years","general pop",29.7,"-42.6",67.3,NA,"delta","~37 weeks",NA,NA,3570,"Paraguay","PRY",420,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2023-09-15,"severe","2023 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","delta",NA,2023-09-15
"3465",420,"Irala","Test-negative case-control","15Sep2023","BBV152 (Bharat)","included","2","final","14+","hospitalization due to SARI","severe","Paraguay",">=5 years","general pop",24.9,"-36.9",59.8,NA,"delta","~37 weeks",NA,NA,3571,"Paraguay","PRY",420,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"who","feb/2021","Dec/2021 +","270-359","yes","yes","no",2023-09-15,"severe","2023 (Jul-Dec)","Bharat Covaxin/BBV152","Inactivated","delta",NA,2023-09-15
"3466",421,"Tartof","Test-negative case-control","15Sep2023","BNT162b2 (Pfizer BioNTech)","included","3 (pediatric dose)","final","14+","ED or UC visit due to ARI","symptomatic","USA","6 months - 4 years","6 months - 4 years",10,"-40",42,NA,"omicron BA.4/BA.5, BQ.1, XBB","~35 weeks",NA,NA,3572,"USA","USA",421,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-15,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-09-15
"3467",421,"Tartof","Test-negative case-control","15Sep2023","BNT162b2 (Pfizer BioNTech)","included","3 (pediatric dose)","final","14+","other outpatient encounter due to ARI","symptomatic","USA","6 months - 4 years","6 months - 4 years",21,"-41",56,NA,"omicron BA.4/BA.5, BQ.1, XBB","~35 weeks",NA,NA,3573,"USA","USA",421,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-15,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-09-15
"3468",422,"Mimura","Retrospective cohort","23Sep2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","infection","infection","Japan",">=65 years",">=65 years",78.1,"65.2",87.8,NA,"delta","~22 weeks",NA,NA,3574,"Japan","JPN",422,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"who","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-09-23,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-09-23
"3469",422,"Mimura","Retrospective cohort","23Sep2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","symptomatic disease","symptomatic","Japan",">=65 years",">=65 years",79.1,"64.6",88.9,NA,"delta","~22 weeks",NA,NA,3575,"Japan","JPN",422,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"who","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-09-23,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-09-23
"3470",422,"Mimura","Retrospective cohort","23Sep2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","hospitalization","severe","Japan",">=65 years",">=65 years",93.5,"83.7",100,NA,"delta","~22 weeks",NA,NA,3576,"Japan","JPN",422,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"who","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-09-23,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-09-23
"3471",423,"Patel","Test-negative case-control","29Sep2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","ED/UC visit","symptomatic","USA",">=18 years with any disability",">=18 years with any disability",45,"36",52,NA,"omicron BA.1, BA.2, BA.5","~82 weeks",NA,NA,3577,"USA","USA",423,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-29,"symptomatic","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-09-29
"3472",423,"Patel","Test-negative case-control","29Sep2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">=18 years with any disability",">=18 years with any disability",45,"38",52,NA,"omicron BA.1, BA.2, BA.5","~82 weeks",NA,NA,3578,"USA","USA",423,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-29,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-09-29
"3473",423,"Patel","Test-negative case-control","29Sep2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","ED/UC visit","symptomatic","USA",">=18 years with no disability",">=18 years with no disability",31,"29",32,NA,"omicron BA.1, BA.2, BA.5","~82 weeks",NA,NA,3579,"USA","USA",423,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-29,"symptomatic","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-09-29
"3474",423,"Patel","Test-negative case-control","29Sep2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">=18 years with no disability",">=18 years with no disability",45,"43",48,NA,"omicron BA.1, BA.2, BA.5","~82 weeks",NA,NA,3580,"USA","USA",423,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-29,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-09-29
"3475",423,"Patel","Test-negative case-control","29Sep2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","ED/UC visit","symptomatic","USA",">=18 years with any disability",">=18 years with any disability",79,"75",83,NA,"delta","~42 weeks",NA,NA,3581,"USA","USA",423,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-29,"symptomatic","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-09-29
"3476",423,"Patel","Test-negative case-control","29Sep2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">=18 years with any disability",">=18 years with any disability",79,"76",83,NA,"delta","~42 weeks",NA,NA,3582,"USA","USA",423,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-29,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-09-29
"3477",423,"Patel","Test-negative case-control","29Sep2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","ED/UC visit","symptomatic","USA",">=18 years with no disability",">=18 years with no disability",82,"82",83,NA,"delta","~42 weeks",NA,NA,3583,"USA","USA",423,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-29,"symptomatic","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-09-29
"3478",423,"Patel","Test-negative case-control","29Sep2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">=18 years with no disability",">=18 years with no disability",87,"86",87,NA,"delta","~42 weeks",NA,NA,3584,"USA","USA",423,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-09-29,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-09-29
"3479",424,"Chemaitelly","Retrospective cohort","04Oct2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","previously infected with Omicron only","2","final","90+","infection","infection","Qatar","all ages","all ages",57,"51",61,NA,"omicron BA.2, BA.2.75, BA.4/BA.5","~85 weeks",NA,NA,3585,"Qatar","QAT",424,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"owid","jan/2021","before Jun/2021","<180","yes","yes","yes",2023-10-04,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-10-04
"3480",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","<91","symptomatic disease","symptomatic","Mexico",">=65 years",">=65 years",74.3,"70.5",77.6,NA,"delta","~33 weeks",NA,NA,3586,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-10-19
"3481",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","141+","symptomatic disease","symptomatic","Mexico",">=65 years",">=65 years",66.9,"62.7",70.7,NA,"delta","~33 weeks",NA,NA,3587,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-10-19
"3482",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","<91","hospitalization with ARI","severe","Mexico",">=65 years",">=65 years",87.5,"84.9",89.7,NA,"delta","~33 weeks",NA,NA,3588,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-10-19
"3483",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","141+","hospitalization with ARI","severe","Mexico",">=65 years",">=65 years",80.5,"77.4",83.2,NA,"delta","~33 weeks",NA,NA,3589,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-10-19
"3484",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","<91","severe disease","severe","Mexico",">=65 years",">=65 years",90.4,"87.8",92.4,NA,"delta","~33 weeks",NA,NA,3590,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-10-19
"3485",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","141+","severe disease","severe","Mexico",">=65 years",">=65 years",85.3,"82.3",87.8,NA,"delta","~33 weeks",NA,NA,3591,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-10-19
"3486",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","<91","death","death","Mexico",">=65 years",">=65 years",90.3,"87.7",92.4,NA,"delta","~33 weeks",NA,NA,3592,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-10-19
"3487",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","141+","death","death","Mexico",">=65 years",">=65 years",85.7,"82.8",88.2,NA,"delta","~33 weeks",NA,NA,3593,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-10-19
"3488",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","AZD1222 (AstraZeneca)","excluded","2","final","<91","symptomatic disease","symptomatic","Mexico",">=65 years",">=65 years",61.2,"56.9",65.1,NA,"delta","~33 weeks",NA,NA,3594,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"symptomatic","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-10-19
"3489",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","AZD1222 (AstraZeneca)","excluded","2","final","141+","symptomatic disease","symptomatic","Mexico",">=65 years",">=65 years",51.8,"43.5",58.8,NA,"delta","~33 weeks",NA,NA,3595,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"symptomatic","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-10-19
"3490",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","AZD1222 (AstraZeneca)","excluded","2","final","<91","hospitalization with ARI","severe","Mexico",">=65 years",">=65 years",81.1,"78.4",83.5,NA,"delta","~33 weeks",NA,NA,3596,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-10-19
"3491",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","AZD1222 (AstraZeneca)","excluded","2","final","141+","hospitalization with ARI","severe","Mexico",">=65 years",">=65 years",70.5,"64.2",75.8,NA,"delta","~33 weeks",NA,NA,3597,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-10-19
"3492",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","AZD1222 (AstraZeneca)","excluded","2","final","<91","severe disease","severe","Mexico",">=65 years",">=65 years",85.3,"82.8",87.5,NA,"delta","~33 weeks",NA,NA,3598,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-10-19
"3493",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","AZD1222 (AstraZeneca)","excluded","2","final","141+","severe disease","severe","Mexico",">=65 years",">=65 years",73.5,"66.5",79.1,NA,"delta","~33 weeks",NA,NA,3599,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-10-19
"3494",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","AZD1222 (AstraZeneca)","excluded","2","final","<91","death","death","Mexico",">=65 years",">=65 years",85.4,"82.9",87.6,NA,"delta","~33 weeks",NA,NA,3600,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"death","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-10-19
"3495",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","AZD1222 (AstraZeneca)","excluded","2","final","141+","death","death","Mexico",">=65 years",">=65 years",73.6,"66.6",79.2,NA,"delta","~33 weeks",NA,NA,3601,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"death","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta",NA,2023-10-19
"3496",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","CoronaVac (Sinovac)","excluded","2","final","<91","symptomatic disease","symptomatic","Mexico",">=65 years",">=65 years",47,"39.6",53.5,NA,"delta","~33 weeks",NA,NA,3602,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"symptomatic","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2023-10-19
"3497",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","CoronaVac (Sinovac)","excluded","2","final","141+","symptomatic disease","symptomatic","Mexico",">=65 years",">=65 years",34.9,"26.2",42.6,NA,"delta","~33 weeks",NA,NA,3603,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"symptomatic","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2023-10-19
"3498",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","CoronaVac (Sinovac)","excluded","2","final","<91","hospitalization with ARI","severe","Mexico",">=65 years",">=65 years",69.8,"64.5",74.2,NA,"delta","~33 weeks",NA,NA,3604,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2023-10-19
"3499",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","CoronaVac (Sinovac)","excluded","2","final","141+","hospitalization with ARI","severe","Mexico",">=65 years",">=65 years",57.8,"51",63.6,NA,"delta","~33 weeks",NA,NA,3605,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2023-10-19
"3500",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","CoronaVac (Sinovac)","excluded","2","final","<91","severe disease","severe","Mexico",">=65 years",">=65 years",75.4,"70.3",79.7,NA,"delta","~33 weeks",NA,NA,3606,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2023-10-19
"3501",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","CoronaVac (Sinovac)","excluded","2","final","141+","severe disease","severe","Mexico",">=65 years",">=65 years",59.2,"51.6",65.5,NA,"delta","~33 weeks",NA,NA,3607,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2023-10-19
"3502",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","CoronaVac (Sinovac)","excluded","2","final","<91","death","death","Mexico",">=65 years",">=65 years",75.6,"70.5",79.8,NA,"delta","~33 weeks",NA,NA,3608,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"death","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2023-10-19
"3503",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","CoronaVac (Sinovac)","excluded","2","final","141+","death","death","Mexico",">=65 years",">=65 years",59.2,"51.6",65.5,NA,"delta","~33 weeks",NA,NA,3609,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"death","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2023-10-19
"3504",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Ad5-nCOV (CanSino)","excluded","1","final","<91","symptomatic disease","symptomatic","Mexico",">=65 years",">=65 years",29,"5.3",46.7,NA,"delta","~33 weeks",NA,NA,3610,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"symptomatic","2023 (Jul-Dec)","Cansino Ad5-nCoV","Vectored","delta",NA,2023-10-19
"3505",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Ad5-nCOV (CanSino)","excluded","1","final","141+","symptomatic disease","symptomatic","Mexico",">=65 years",">=65 years",43.6,"32.1",53.1,NA,"delta","~33 weeks",NA,NA,3611,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"symptomatic","2023 (Jul-Dec)","Cansino Ad5-nCoV","Vectored","delta",NA,2023-10-19
"3506",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Ad5-nCOV (CanSino)","excluded","1","final","<91","hospitalization with ARI","severe","Mexico",">=65 years",">=65 years",58.2,"39",71.3,NA,"delta","~33 weeks",NA,NA,3612,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Cansino Ad5-nCoV","Vectored","delta",NA,2023-10-19
"3507",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Ad5-nCOV (CanSino)","excluded","1","final","141+","hospitalization with ARI","severe","Mexico",">=65 years",">=65 years",58.8,"48.7",66.9,NA,"delta","~33 weeks",NA,NA,3613,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Cansino Ad5-nCoV","Vectored","delta",NA,2023-10-19
"3508",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Ad5-nCOV (CanSino)","excluded","1","final","<91","severe disease","severe","Mexico",">=65 years",">=65 years",69.4,"50.6",81,NA,"delta","~33 weeks",NA,NA,3614,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Cansino Ad5-nCoV","Vectored","delta",NA,2023-10-19
"3509",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Ad5-nCOV (CanSino)","excluded","1","final","141+","severe disease","severe","Mexico",">=65 years",">=65 years",63.8,"53.2",72,NA,"delta","~33 weeks",NA,NA,3615,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Cansino Ad5-nCoV","Vectored","delta",NA,2023-10-19
"3510",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Ad5-nCOV (CanSino)","excluded","1","final","<91","death","death","Mexico",">=65 years",">=65 years",69.1,"50",80.8,NA,"delta","~33 weeks",NA,NA,3616,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"death","2023 (Jul-Dec)","Cansino Ad5-nCoV","Vectored","delta",NA,2023-10-19
"3511",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Ad5-nCOV (CanSino)","excluded","1","final","141+","death","death","Mexico",">=65 years",">=65 years",64.1,"53.6",72.3,NA,"delta","~33 weeks",NA,NA,3617,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"death","2023 (Jul-Dec)","Cansino Ad5-nCoV","Vectored","delta",NA,2023-10-19
"3512",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Gam-COVID-Vac (Gamaleya)","excluded","2","final","<91","symptomatic disease","symptomatic","Mexico",">=65 years",">=65 years",68.5,"59.5",75.5,NA,"delta","~33 weeks",NA,NA,3618,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"symptomatic","2023 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta",NA,2023-10-19
"3513",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Gam-COVID-Vac (Gamaleya)","excluded","2","final","141+","symptomatic disease","symptomatic","Mexico",">=65 years",">=65 years",75.5,"69.1",80.6,NA,"delta","~33 weeks",NA,NA,3619,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"symptomatic","2023 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta",NA,2023-10-19
"3514",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Gam-COVID-Vac (Gamaleya)","excluded","2","final","<91","hospitalization with ARI","severe","Mexico",">=65 years",">=65 years",90.4,"85.5",93.7,NA,"delta","~33 weeks",NA,NA,3620,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta",NA,2023-10-19
"3515",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Gam-COVID-Vac (Gamaleya)","excluded","2","final","141+","hospitalization with ARI","severe","Mexico",">=65 years",">=65 years",87.1,"82.2",90.6,NA,"delta","~33 weeks",NA,NA,3621,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta",NA,2023-10-19
"3516",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Gam-COVID-Vac (Gamaleya)","excluded","2","final","<91","severe disease","severe","Mexico",">=65 years",">=65 years",94.8,"90.5",97.2,NA,"delta","~33 weeks",NA,NA,3622,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta",NA,2023-10-19
"3517",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Gam-COVID-Vac (Gamaleya)","excluded","2","final","141+","severe disease","severe","Mexico",">=65 years",">=65 years",91.8,"87.3",94.7,NA,"delta","~33 weeks",NA,NA,3623,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta",NA,2023-10-19
"3518",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Gam-COVID-Vac (Gamaleya)","excluded","2","final","<91","death","death","Mexico",">=65 years",">=65 years",95.2,"91",94.7,NA,"delta","~33 weeks",NA,NA,3624,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"death","2023 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta",NA,2023-10-19
"3519",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","Gam-COVID-Vac (Gamaleya)","excluded","2","final","141+","death","death","Mexico",">=65 years",">=65 years",91.8,"87.3",94.7,NA,"delta","~33 weeks",NA,NA,3625,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"who","before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"death","2023 (Jul-Dec)","Gamaleya Gam-COVID-Vac/Sputnik V","Vectored","delta",NA,2023-10-19
"3520",427,"Lee","Test-negative case-control","24Nov2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","3 months","severe disease","severe","Canada",">=50 years",">=50 years",80,"78",83,NA,"omicron BA.1, BA.2","~63 weeks",NA,"Note 3.2% of participants received AZ+mRNA as their primary series  ",3626,"Canada","CAN",427,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-11-24,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","25/08/2023",2023-08-25
"3521",427,"Lee","Test-negative case-control","24Nov2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","15 months","severe disease","severe","Canada",">=50 years",">=50 years",80,"77",82,NA,"omicron BA.1, BA.2","~63 weeks",NA,"Note 3.2% of participants received AZ+mRNA as their primary series  ",3627,"Canada","CAN",427,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-11-24,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","25/08/2023",2023-08-25
"3522",427,"Lee","Test-negative case-control","24Nov2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","3 months","severe disease","severe","Canada",">=50 years",">=50 years",43,"19",60,NA,"omicron BA.4, BA.5","~63 weeks",NA,"Note 3.2% of participants received AZ+mRNA as their primary series  ",3628,"Canada","CAN",427,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-11-24,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","25/08/2023",2023-08-25
"3523",427,"Lee","Test-negative case-control","24Nov2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","15 months","severe disease","severe","Canada",">=50 years",">=50 years",49,"41",56,NA,"omicron BA.4, BA.5","~63 weeks",NA,"Note 3.2% of participants received AZ+mRNA as their primary series  ",3629,"Canada","CAN",427,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-11-24,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","25/08/2023",2023-08-25
"3524",427,"Lee","Test-negative case-control","24Nov2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","3 months","severe disease","severe","Canada",">=50 years",">=50 years",25,"-61",65,NA,"omicron BQ, XBB","~63 weeks",NA,"Note 3.2% of participants received AZ+mRNA as their primary series  ",3630,"Canada","CAN",427,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-11-24,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","25/08/2023",2023-08-25
"3525",427,"Lee","Test-negative case-control","24Nov2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","excluded","2","final","15 months","severe disease","severe","Canada",">=50 years",">=50 years",31,"17",43,NA,"omicron BQ, XBB","~63 weeks",NA,"Note 3.2% of participants received AZ+mRNA as their primary series  ",3631,"Canada","CAN",427,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-11-24,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron","25/08/2023",2023-08-25
"3526",428,"Yiu","Case-control","10Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization due to COVID-19","severe","Hong Kong",">=18 years with a mental disorder",">=18 years with a mental disorder",71.1,"68",73.9,NA,"omicron BA.2","~70 weeks",NA,NA,3632,"Hong Kong","HKG",428,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-10-10,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-10
"3527",428,"Yiu","Case-control","10Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","death","death","Hong Kong",">=18 years with a mental disorder",">=18 years with a mental disorder",86.1,"80.5",90.1,NA,"omicron BA.2","~70 weeks",NA,NA,3633,"Hong Kong","HKG",428,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-10-10,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-10
"3528",428,"Yiu","Case-control","10Oct2023","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization due to COVID-19","severe","Hong Kong",">=18 years with a mental disorder",">=18 years with a mental disorder",46.1,"42.7",49.3,NA,"omicron BA.2","~71 weeks",NA,NA,3634,"Hong Kong","HKG",428,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-10-10,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-10-10
"3529",428,"Yiu","Case-control","10Oct2023","CoronaVac (Sinovac)","excluded","2","final","14+","death","death","Hong Kong",">=18 years with a mental disorder",">=18 years with a mental disorder",59.5,"53.7",64.6,NA,"omicron BA.2","~71 weeks",NA,NA,3635,"Hong Kong","HKG",428,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-10-10,"death","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-10-10
"3530",429,"Tartof","Test-negative case-control","25Oct2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","severe disease","severe","USA",">=18 years","general pop",29,"-7",53,NA,"omicron BA.4, BA.5, XBB, XBB.1.5, XBB.1.16","~116 weeks",NA,NA,3636,"USA","USA",429,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-10-25,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-10-25
"3531",429,"Tartof","Test-negative case-control","25Oct2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">=18 years","general pop",27,"13",39,NA,"omicron BA.4, BA.5, XBB, XBB.1.5, XBB.1.16","~116 weeks",NA,NA,3637,"USA","USA",429,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-10-25,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-10-25
"3532",429,"Tartof","Test-negative case-control","25Oct2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","ED/UC visit","symptomatic","USA",">=18 years","general pop",18,"12",24,NA,"omicron BA.4, BA.5, XBB, XBB.1.5, XBB.1.16","~116 weeks",NA,NA,3638,"USA","USA",429,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-10-25,"symptomatic","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-10-25
"3533",429,"Tartof","Test-negative case-control","25Oct2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14+","outpatient visit","symptomatic","USA",">=18 years","general pop",14,"6",21,NA,"omicron BA.4, BA.5, XBB, XBB.1.5, XBB.1.16","~116 weeks",NA,NA,3639,"USA","USA",429,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"owid","before jan/2021","before Jun/2021","<180","yes","yes","no",2023-10-25,"symptomatic","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-10-25
"3534",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Canada","5-11 years","5-11 years",20,"13",26,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks",NA,NA,3640,"Canada","CAN",430,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3535",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-55","infection","infection","Canada","5-11 years","5-11 years",42,"35",49,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks",NA,NA,3641,"Canada","CAN",430,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3536",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","56-385","infection","infection","Canada","5-11 years","5-11 years",2,"-7",11,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks",NA,NA,3642,"Canada","CAN",430,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3537",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Canada","5-11 years","5-11 years",10,"-2",21,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks","21-55 days",NA,3643,"Canada","CAN",430,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3538",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Canada","5-11 years","5-11 years",39,"20",55,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks","84-362 days",NA,3644,"Canada","CAN",430,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3539",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease (ambulatory centers)","symptomatic","Canada","5-11 years","5-11 years",47,"40",54,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks",NA,NA,3645,"Canada","CAN",430,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3540",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-55","symptomatic disease (ambulatory centers)","symptomatic","Canada","5-11 years","5-11 years",68,"62",74,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks",NA,NA,3646,"Canada","CAN",430,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3541",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","56-385","symptomatic disease (ambulatory centers)","symptomatic","Canada","5-11 years","5-11 years",25,"11",36,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks",NA,NA,3647,"Canada","CAN",430,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3542",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease (ambulatory centers)","symptomatic","Canada","5-11 years","5-11 years",48,"36",57,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks","21-55 days",NA,3648,"Canada","CAN",430,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3543",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease (ambulatory centers)","symptomatic","Canada","5-11 years","5-11 years",45,"10",68,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks","84-362 days",NA,3649,"Canada","CAN",430,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3544",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease (acute care hospital)","symptomatic","Canada","5-11 years","5-11 years",42,"30",52,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks",NA,NA,3650,"Canada","CAN",430,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3545",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-55","symptomatic disease (acute care hospital)","symptomatic","Canada","5-11 years","5-11 years",41,"17",59,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks",NA,NA,3651,"Canada","CAN",430,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3546",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","56-385","symptomatic disease (acute care hospital)","symptomatic","Canada","5-11 years","5-11 years",42,"29",53,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks",NA,NA,3652,"Canada","CAN",430,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3547",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease (acute care hospital)","symptomatic","Canada","5-11 years","5-11 years",18,"-17",44,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks","21-55 days",NA,3653,"Canada","CAN",430,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3548",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease (acute care hospital)","symptomatic","Canada","5-11 years","5-11 years",69,"43",86,NA,"omicron BA.1, BA.2, BA.4/BA.5","~54 weeks","84-362 days",NA,3654,"Canada","CAN",430,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3549",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Canada","5-11 years","5-11 years",40,"31",47,NA,"omicron BA.1","~13 weeks",NA,NA,3655,"Canada","CAN",430,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3550",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease (ambulatory centers)","symptomatic","Canada","5-11 years","5-11 years",70,"63",76,NA,"omicron BA.1","~13 weeks",NA,NA,3656,"Canada","CAN",430,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3551",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease (acute care hospital)","symptomatic","Canada","5-11 years","5-11 years",27,"-13",53,NA,"omicron BA.1","~13 weeks",NA,NA,3657,"Canada","CAN",430,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3552",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Canada","5-11 years","5-11 years",14,"0",26,NA,"omicron BA.2","~25 weeks",NA,NA,3658,"Canada","CAN",430,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3553",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease (ambulatory centers)","symptomatic","Canada","5-11 years","5-11 years",32,"13",47,NA,"omicron BA.2","~25 weeks",NA,NA,3659,"Canada","CAN",430,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3554",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease (acute care hospital)","symptomatic","Canada","5-11 years","5-11 years",47,"26",62,NA,"omicron BA.2","~25 weeks",NA,NA,3660,"Canada","CAN",430,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3555",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Canada","5-11 years","5-11 years",-5,"-22",9,NA,"omicron BA.4/BA.5","~54 weeks",NA,NA,3661,"Canada","CAN",430,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3556",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease (ambulatory centers)","symptomatic","Canada","5-11 years","5-11 years",-15,"-55",14,NA,"omicron BA.4/BA.5","~54 weeks",NA,NA,3662,"Canada","CAN",430,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3557",430,"Razafimandimby","Test-negative case-control","30Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","symptomatic disease (acute care hospital)","symptomatic","Canada","5-11 years","5-11 years",38,"18",54,NA,"omicron BA.4/BA.5","~54 weeks",NA,NA,3663,"Canada","CAN",430,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-10-30,"symptomatic","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-10-30
"3558",431,"Goh","Retrospective cohort","10Nov2023","any mRNA in mothers before pregnancy","included (refers to mothers)","2","final","14+","infection","infection","Singapore","infants 0-6 months","infants 0-6 months",60.7,"-56.6",90.1,NA,"omicron XBB, XBB.1.5","~126 weeks",NA,NA,3664,"Singapore","SGP",431,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-11-10,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-11-10
"3559",431,"Goh","Retrospective cohort","10Nov2023","any mRNA in mothers during pregnancy","included (refers to mothers)","2","final","14+","infection","infection","Singapore","infants 0-6 months","infants 0-6 months",73,"-30.6",94.4,NA,"omicron XBB, XBB.1.5","~63 weeks",NA,NA,3665,"Singapore","SGP",431,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-11-10,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-11-10
"3560",431,"Goh","Retrospective cohort","10Nov2023","any mRNA in mothers before pregnancy","included (refers to mothers)","2","final","14+","infection","infection","Singapore","infants 0-6 months","infants 0-6 months",18.3,"-14.6",41.8,NA,"omicron BA.2, BA.5, XBB, XBB.1.5","~126 weeks",NA,NA,3666,"Singapore","SGP",431,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-11-10,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-11-10
"3561",431,"Goh","Retrospective cohort","10Nov2023","any mRNA in mothers during pregnancy","included (refers to mothers)","2","final","14+","infection","infection","Singapore","infants 0-6 months","infants 0-6 months",37.6,"17.2",53.1,NA,"omicron BA.2, BA.5, XBB, XBB.1.5","~63 weeks",NA,NA,3667,"Singapore","SGP",431,"SGP",58810,2019,"Singapore","East Asia & Pacific","High income",4,"Asia",2020-12-30,2021-07-10,2021-08-14,2020-12-30,2020-12-30,0,192,227,"equal","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-11-10,"infection","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-11-10
"3562",432,"Culpan","Retrospective cohort","15Nov2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Turkey","HCW","HCW",82.3,"68",90.2,NA,"delta","~30 weeks",NA,NA,3668,"Turkey","TUR",432,"TUR",9800,2019,"Türkiye","Europe & Central Asia","Upper middle income",3,"Asia",2021-01-14,2021-08-19,NA,NA,2021-01-14,NA,217,NA,"owid","jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2023-11-15,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-11-15
"3563",432,"Culpan","Retrospective cohort","15Nov2023","CoronaVac (Sinovac)","excluded","2","final","14+","infection","infection","Turkey","HCW","HCW",21,"-20.7",48.3,NA,"delta","~42 weeks",NA,NA,3669,"Turkey","TUR",432,"TUR",9800,2019,"Türkiye","Europe & Central Asia","Upper middle income",3,"Asia",2021-01-14,2021-08-19,NA,NA,2021-01-14,NA,217,NA,"owid","jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2023-11-15,"infection","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta",NA,2023-11-15
"3564",433,"Szekanecz","Retrospective cohort","02Nov2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-120","infection","infection","Hungary","immunocompromised adults 18-84 years","immunocompromised",73,"68.8",76.7,NA,"delta","~32 weeks",NA,NA,3670,"Hungary","HUN",433,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2023-11-02,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-11-02
"3565",433,"Szekanecz","Retrospective cohort","02Nov2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","181-240","infection","infection","Hungary","immunocompromised adults 18-84 years","immunocompromised",38.7,"35.1",42.1,NA,"delta","~32 weeks",NA,NA,3671,"Hungary","HUN",433,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2023-11-02,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-11-02
"3566",433,"Szekanecz","Retrospective cohort","02Nov2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-120","death","death","Hungary","immunocompromised adults 18-84 years","immunocompromised",53,"7.7",76.1,NA,"delta","~32 weeks",NA,NA,3672,"Hungary","HUN",433,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2023-11-02,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-11-02
"3567",433,"Szekanecz","Retrospective cohort","02Nov2023","BNT162b2 (Pfizer BioNTech)","included","2","final","181-240","death","death","Hungary","immunocompromised adults 18-84 years","immunocompromised",51.1,"33.3",64.1,NA,"delta","~32 weeks",NA,NA,3673,"Hungary","HUN",433,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2023-11-02,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-11-02
"3568",433,"Szekanecz","Retrospective cohort","02Nov2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-120","infection","infection","Hungary","non-immunocompromised adults 18-84 years","immunocompetent adults",68.1,"66.8",69.3,NA,"delta","~32 weeks",NA,NA,3674,"Hungary","HUN",433,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2023-11-02,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-11-02
"3569",433,"Szekanecz","Retrospective cohort","02Nov2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","181-240","infection","infection","Hungary","non-immunocompromised adults 18-84 years","immunocompetent adults",16.1,"14.2",17.9,NA,"delta","~32 weeks",NA,NA,3675,"Hungary","HUN",433,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2023-11-02,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-11-02
"3570",433,"Szekanecz","Retrospective cohort","02Nov2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-120","death","death","Hungary","non-immunocompromised adults 18-84 years","immunocompetent adults",74.9,"64.6",82.2,NA,"delta","~32 weeks",NA,NA,3676,"Hungary","HUN",433,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2023-11-02,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-11-02
"3571",433,"Szekanecz","Retrospective cohort","02Nov2023","BNT162b2 (Pfizer BioNTech)","included","2","final","181-240","death","death","Hungary","non-immunocompromised adults 18-84 years","immunocompetent adults",80.8,"76.6",84.2,NA,"delta","~32 weeks",NA,NA,3677,"Hungary","HUN",433,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"who","before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2023-11-02,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta",NA,2023-11-02
"3572",436,"Qin","Retrospective cohort","12Dec2023","CoronaVac (Sinovac)","excluded","2","final","0+","hospitalization","severe","Hong Kong",">=18 years","general pop",18,"6",23,NA,"delta & omicron BA.2, BA.5","~88 weeks",NA,NA,3687,"Hong Kong","HKG",436,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-12-12,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta/omicron",NA,2023-12-12
"3573",436,"Qin","Retrospective cohort","12Dec2023","CoronaVac (Sinovac)","excluded","2","final","0+","severe disease","severe","Hong Kong",">=18 years","general pop",29,"12",43,NA,"delta & omicron BA.2, BA.5","~88 weeks",NA,NA,3688,"Hong Kong","HKG",436,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-12-12,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta/omicron",NA,2023-12-12
"3574",436,"Qin","Retrospective cohort","12Dec2023","CoronaVac (Sinovac)","excluded","2","final","0+","death","death","Hong Kong",">=18 years","general pop",77,"74",80,NA,"delta & omicron BA.2, BA.5","~88 weeks",NA,NA,3689,"Hong Kong","HKG",436,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-12-12,"death","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","delta/omicron",NA,2023-12-12
"3575",436,"Qin","Retrospective cohort","12Dec2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","0+","hospitalization","severe","Hong Kong",">=18 years","general pop",33,"30",37,NA,"delta & omicron BA.2, BA.5","~87 weeks",NA,NA,3690,"Hong Kong","HKG",436,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-12-12,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2023-12-12
"3576",436,"Qin","Retrospective cohort","12Dec2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","0+","severe disease","severe","Hong Kong",">=18 years","general pop",57,"45",66,NA,"delta & omicron BA.2, BA.5","~87 weeks",NA,NA,3691,"Hong Kong","HKG",436,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-12-12,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2023-12-12
"3577",436,"Qin","Retrospective cohort","12Dec2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","0+","death","death","Hong Kong",">=18 years","general pop",92,"91",94,NA,"delta & omicron BA.2, BA.5","~87 weeks",NA,NA,3692,"Hong Kong","HKG",436,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-12-12,"death","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2023-12-12
"3578",437,"Arashiro","Retrospective cohort","19Dec2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-180 (median 76)","severe disease requiring oxygen therapy","severe","Japan",">=16 years","general pop",95.2,"88.7",98,NA,"delta","24 weeks",NA,NA,3693,"Japan","JPN",437,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"who","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-12-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-12-19
"3579",437,"Arashiro","Retrospective cohort","19Dec2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-180 (median 83)","severe disease requiring mechanical ventilation","severe","Japan",">=16 years","general pop",99.6,"97.3",99.9,NA,"delta","24 weeks",NA,NA,3694,"Japan","JPN",437,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"who","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-12-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-12-19
"3580",437,"Arashiro","Retrospective cohort","19Dec2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-180 (median 83)","death","death","Japan",">=16 years","general pop",98.6,"92.3",99.7,NA,"delta","24 weeks",NA,NA,3695,"Japan","JPN",437,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"who","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-12-19,"death","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-12-19
"3581",437,"Arashiro","Retrospective cohort","19Dec2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-180 (median 79)","severe disease requiring oxygen therapy with respiratory failure","severe","Japan",">=16 years","general pop",65.5,"89.3",98.1,NA,"delta","24 weeks",NA,NA,3696,"Japan","JPN",437,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"who","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-12-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","delta",NA,2023-12-19
"3582",437,"Arashiro","Retrospective cohort","19Dec2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-180 (median 155)","severe disease requiring oxygen therapy","severe","Japan",">=16 years","general pop",37,"-50.9",73.7,NA,"omicron BA.1, BA.2","~65 weeks",NA,NA,3697,"Japan","JPN",437,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"who","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-12-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-12-19
"3583",437,"Arashiro","Retrospective cohort","19Dec2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+ (median 218)","severe disease requiring oxygen therapy","severe","Japan",">=16 years","general pop",47.9,"-2.1",73.4,NA,"omicron BA.1, BA.2","~65 weeks",NA,NA,3698,"Japan","JPN",437,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"who","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-12-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-12-19
"3584",437,"Arashiro","Retrospective cohort","19Dec2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-180 (median 149)","severe disease requiring mechanical ventilation","severe","Japan",">=16 years","general pop",73.7,"-30.6",94.7,NA,"omicron BA.1, BA.2","~65 weeks",NA,NA,3699,"Japan","JPN",437,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"who","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-12-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-12-19
"3585",437,"Arashiro","Retrospective cohort","19Dec2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+ (median 215)","severe disease requiring mechanical ventilation","severe","Japan",">=16 years","general pop",82.7,"37.1",95.3,NA,"omicron BA.1, BA.2","~65 weeks",NA,NA,3700,"Japan","JPN",437,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"who","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-12-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-12-19
"3586",437,"Arashiro","Retrospective cohort","19Dec2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-180 (median 139)","death","death","Japan",">=16 years","general pop",43.1,"-213.4",89.7,NA,"omicron BA.1, BA.2","~65 weeks",NA,NA,3701,"Japan","JPN",437,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"who","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-12-19,"death","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-12-19
"3587",437,"Arashiro","Retrospective cohort","19Dec2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+ (median 216)","death","death","Japan",">=16 years","general pop",59.5,"-41.9",216,NA,"omicron BA.1, BA.2","~65 weeks",NA,NA,3702,"Japan","JPN",437,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"who","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-12-19,"death","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-12-19
"3588",437,"Arashiro","Retrospective cohort","19Dec2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","14-180 (median 155)","severe disease requiring oxygen therapy with respiratory failure","severe","Japan",">=16 years","general pop",41.1,"-43.9",155,NA,"omicron BA.1, BA.2","~65 weeks",NA,NA,3703,"Japan","JPN",437,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"who","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-12-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-12-19
"3589",437,"Arashiro","Retrospective cohort","19Dec2023","BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna)","included","2","final","180+ (median 218)","severe disease requiring oxygen therapy with respiratory failure","severe","Japan",">=16 years","general pop",50.2,"1.1",218,NA,"omicron BA.1, BA.2","~65 weeks",NA,NA,3704,"Japan","JPN",437,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"who","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-12-19,"severe","2023 (Jul-Dec)","Multiple or heterologous RNA","mRNA","omicron",NA,2023-12-19
"3590",438,"Cheng","Retrospective cohort","26Dec2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","infection","infection","Hong Kong",">=18 years with chronic kidney disease",">=18 years with chronic kidney disease",35,"31",39,NA,"omicron BA.2","~51 weeks",NA,NA,3705,"Hong Kong","HKG",438,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-12-26,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-12-26
"3591",438,"Cheng","Retrospective cohort","26Dec2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Hong Kong",">=18 years with chronic kidney disease",">=18 years with chronic kidney disease",66,"62",80,NA,"omicron BA.2","~51 weeks",NA,NA,3706,"Hong Kong","HKG",438,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-12-26,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron",NA,2023-12-26
"3592",438,"Cheng","Retrospective cohort","26Dec2023","CoronaVac (Sinovac)","excluded","2","final","14+","infection","infection","Hong Kong",">=18 years with chronic kidney disease",">=18 years with chronic kidney disease",29,"26",32,NA,"omicron BA.2","~51 weeks",NA,NA,3707,"Hong Kong","HKG",438,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-12-26,"infection","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-12-26
"3593",438,"Cheng","Retrospective cohort","26Dec2023","CoronaVac (Sinovac)","excluded","2","final","14+","hospitalization","severe","Hong Kong",">=18 years with chronic kidney disease",">=18 years with chronic kidney disease",63,"60",66,NA,"omicron BA.2","~51 weeks",NA,NA,3708,"Hong Kong","HKG",438,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"owid","feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-12-26,"severe","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-12-26
"3594",439,"Birk","Retrospective cohort","29Dec2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","0-56","infection","infection","Denmark","12-15 years","12-15 years",96.2,"95.4",96.9,NA,"delta & omicron BA.1","~24 weeks",NA,NA,3709,"Denmark","DNK",439,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-12-29,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2023-12-29
"3595",439,"Birk","Retrospective cohort","29Dec2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","57-182","infection","infection","Denmark","12-15 years","12-15 years",5.8,"4.6",7,NA,"delta & omicron BA.1","~24 weeks",NA,NA,3710,"Denmark","DNK",439,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-12-29,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2023-12-29
"3596",439,"Birk","Retrospective cohort","29Dec2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","0-56","infection","infection","Denmark","16-18 years","16-18 years",95.5,"94.8",96.1,NA,"delta & omicron BA.1","~24 weeks",NA,NA,3711,"Denmark","DNK",439,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-12-29,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2023-12-29
"3597",439,"Birk","Retrospective cohort","29Dec2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","57-182","infection","infection","Denmark","16-18 years","16-18 years",9.2,"7.7",10.6,NA,"delta & omicron BA.1","~24 weeks",NA,NA,3712,"Denmark","DNK",439,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"who","before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2023-12-29,"infection","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta/omicron",NA,2023-12-29
"3598",440,"Ye","Test-negative case-control","14Dec2023","CoronaVac (Sinovac)","included","2","final","28+","symptomatic disease","symptomatic","China",">=3 years",">=3 years",14,"-11",33,NA,"omicron BA.2","~61 weeks",NA,"Note: this study was conucted in an outbreak setting.",3713,"China","CHN",440,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2023-12-14,"symptomatic","2023 (Jul-Dec)","Sinovac CoronaVac","Inactivated","omicron",NA,2023-12-14
"3599",440,"Ye","Test-negative case-control","14Dec2023","BBIBP-CorV (Beijing CNBG)","included","2","final","28+","symptomatic disease","symptomatic","China",">=3 years",">=3 years",20,"-10",43,NA,"omicron BA.2","~66 weeks",NA,"Note: this study was conucted in an outbreak setting.",3714,"China","CHN",440,"CHN",10310,2019,"China","East Asia & Pacific","Upper middle income",3,"Asia",2020-12-15,2021-08-12,2021-09-15,2020-07-22,2020-07-22,146,386,420,"who","before jan/2021","Jun-Aug/2021","360+","yes","yes","yes",2023-12-14,"symptomatic","2023 (Jul-Dec)","Beijing/Sinopharm BBIBP-CorV","Inactivated","omicron",NA,2023-12-14
